<SEC-DOCUMENT>0001178913-16-004924.txt : 20160330
<SEC-HEADER>0001178913-16-004924.hdr.sgml : 20160330
<ACCEPTANCE-DATETIME>20160330134445
ACCESSION NUMBER:		0001178913-16-004924
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20151231
FILED AS OF DATE:		20160330
DATE AS OF CHANGE:		20160330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Integrity Applications, Inc.
		CENTRAL INDEX KEY:			0001506983
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				980668934
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54785
		FILM NUMBER:		161538484

	BUSINESS ADDRESS:	
		STREET 1:		19 HA'YAHALOMIM ST
		STREET 2:		P.O. BOX 12163
		CITY:			ASHDOD
		STATE:			L3
		ZIP:			7760049
		BUSINESS PHONE:		972 (8) 675-7878

	MAIL ADDRESS:	
		STREET 1:		19 HA'YAHALOMIM ST
		STREET 2:		P.O. BOX 12163
		CITY:			ASHDOD
		STATE:			L3
		ZIP:			7760049
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>zk1618280.htm
<DESCRIPTION>10-K
<TEXT>
<html>
<head>
    <title>zk1618280.htm</title>
    <!--Licensed to: ZKG-->
    <!--Document Created using EDGARizer 2020 5.5.2.0-->
    <!--Copyright 1995 - 2015 Summit Financial Printing. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">FORM 10-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Mark One)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt; FONT-WEIGHT: bold">x</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the fiscal year ended <font style="DISPLAY: inline; TEXT-DECORATION: underline">December 31, 2015</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt; FONT-WEIGHT: bold">o</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">For the transition period from _________________________ to _________________________</font></font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission file number <font style="DISPLAY: inline; TEXT-DECORATION: underline">000-54785</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="3" valign="top" width="90%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></div>
</td>
</tr><tr>
<td colspan="3" valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>
</td>
</tr><tr>
<td colspan="3" valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="40%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Delaware</font></div>
</td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="40%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">98-0668934</font></div>
</td>
</tr><tr>
<td valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">incorporation or organization)</font></div>
</td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(I.R.S. Employer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="40%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19 Ha'Yahalomim Street</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">P.O. Box 12163</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Ashdod, Israel</font></div>
</td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="40%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">L3 7760049</font></div>
</td>
</tr><tr>
<td valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address of principal executive offices)</font></div>
</td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Zip Code)</font></div>
</td>
</tr><tr>
<td colspan="3" valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td colspan="3" valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Registrant&#8217;s telephone number, including area code <font style="DISPLAY: inline; TEXT-DECORATION: underline">972 (8) 675-7878</font></font></div>
</td>
</tr><tr>
<td colspan="3" valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td colspan="3" valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Securities registered pursuant to Section 12(b) of the Act:&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">None</font></font></div>
</td>
</tr><tr>
<td colspan="3" valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td colspan="3" valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Securities registered pursuant to Section 12(g) of the Act:&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Common stock, par value $0.001 per share</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes <font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;No <font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline;" face="Wingdings">x</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes <font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;No <font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline;" face="Wingdings">x</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes <font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;No <font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes <font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;No <font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K <font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline;" face="Wingdings">x</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Large accelerated filer <font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td valign="top" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accelerated filer <font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
</tr><tr>
<td valign="top" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-accelerated filer <font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Do not check if a smaller reporting company)</font></div>
</td>
<td valign="top" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Smaller Reporting Company <font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The aggregate market value of the voting stock held by non-affiliates is $21,931,012, based on the closing price of $4.50 per share of the registrant&#8217;s common stock, as reported on the OTCQB on June 30, 2015, the last business day of the registrant&#8217;s most recently completed second fiscal quarter of 2015.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March 30, 2016, 5,690,097 shares of the registrant&#8217;s common stock, par value $0.001 per share, were outstanding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DOCUMENTS INCORPORATED BY REFERENCE:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A for the 2016 Annual Meeting of Stockholders is incorporated by reference in Part III of this Form 10-K to the extent stated herein.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TABLE OF CONTENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="left">
<table cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#general">GENERAL</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></div>
</td>
</tr><tr>
<td valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#lookingstatements">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></div>
</td>
</tr><tr>
<td valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#parti">PART I </a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item1business">Item 1. Business.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item1ariskfactors">Item 1A. Risk Factors.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item1bunresolvedstaffcomments">Item 1B. Unresolved Staff Comments.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item2">Item 2. Properties.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item3">Item 3. Legal Proceedings.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#partii">Part II</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item5">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item6">Item 6. Selected Financial Data</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">44</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item7">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">44</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item7a">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item8">Item 8. Financial Statements and Supplementary Data.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item9">Item 9. Change in and Disagreements With Accountants on Accounting and Financial Disclosure.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item9a">Item 9A. Controls and Procedures.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item9b">Item 9B. Other Information.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">54</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#partiii">PART III</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">55</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item10">Item 10. Directors, Executive Officers and Corporate Governance.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">55</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item11">Item 11. Executive Compensation.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">55</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item12">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">55</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item13">Item 13. Certain Relationships and Related Transactions, and Director Independence.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">55</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item14">Item 14. Principal Accounting Fees and Services.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">55</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#partiv">PART IV</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">56</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item15">Item 15. Exhibits, Financial Statement Schedules.</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">56</font></div>
</td>
</tr><tr>
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#signatures">SIGNATURES</a></font></div>
</td>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">58</font></div>
</td>
</tr></table>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="GENERAL">GENERAL</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Unless the context otherwise requires, the terms &#8220;we&#8221;, &#8220;our&#8221;, &#8220;ours&#8221; &#8220;us&#8221; and &#8220;Integrity&#8221;, refer to A.D. Integrity Applications, Ltd., an Israeli corporation (&#8220;Integrity Israel&#8221;), for all periods prior to July 15, 2010 and to Integrity Israel and Integrity Applications, Inc., a Delaware corporation, on a combined basis, for all periods from and including July 15, 2010.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CAU<a name="LOOKINGSTATEMENTS">TIONA</a>RY NOTE REGARDING FORWARD LOOKING STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This Annual Report on Form 10-K includes forward-looking statements. These forward looking statements include statements about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies or prospects. All statements other than statements of historical fact included in this Annual Report on Form 10-K, including statements regarding our future activities, events or developments, including such things as future revenues, product development, clinical trials, regulatory approval, market acceptance, responses from competitors, capital expenditures (including the amount and nature thereof), business strategy and measures to implement strategy, competitive strengths, goals, expansion and growth of our business and operations, plans, references to future success, projected performance and trends, and other such matters, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and other similar words and phrases or the negative of such terms, are intended to identify forward-looking statements. The forward-looking statements made in this Annual Report on Form 10-K are based on certain historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. These statements relate only to events as of the date on which the statements are made and we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this Annual Report on Form 10-K are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Whether actual results will conform to our expectations and predictions is subject to a number of risks and uncertainties that may cause actual results to differ materially. Risks and uncertainties, the occurrence of which could adversely affect our business, include the risks identified in this Annual Report on Form 10-K under the caption &#8220;Risk Factors,&#8221; beginning on page 25. We undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this report unless required by law.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="PARTI">PART I</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item1Business">Item 1. Business</a>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Overview</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Integrity is a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Integrity Israel was founded in 2001 with a mission to develop, produce and market non-invasive glucose monitors for home use by diabetics. We have developed a non-invasive blood glucose monitor, the GlucoTrack&#174; model DF-F glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The GlucoTrack&#174; model DF-F utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain blood glucose measurements in less than one minute via a small sensor that is clipped onto one&#8217;s earlobe and connected to a small, handheld control and display unit, all without drawing blood.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On June 4, 2013, we received initial CE Mark approval for the GlucoTrack&#174; model DF-F non-invasive glucose monitoring device from DEKRA Certification B.V., our European notified body (the &#8220;Notified Body&#8221;). In March 2014 we received CE Mark approval for six months calibration validity of the same device. Receipt of the CE Mark allows us to market and sell the GlucoTrack&#174; model DF-F glucose monitoring device in European Union (&#8220;EU&#8221;) member countries that have adopted the European Medical Device Directive (the &#8220;MDD&#8221;) without being subject to additional national regulations with regard to demonstration of performance and safety. However, although the MDD is applicable throughout the EU, in practice it does not ensure uniform regulation throughout the EU.&#160;&#160;Accordingly, member countries may apply and enforce the MDD&#8217;s terms differently, and certain EU member countries may request or require performance and/or safety data additional to the MDD&#8217;s requirements from time to time, on a case-by-case basis. The CE Mark also permits the sale in countries that have an MDD Mutual Recognition Agreement with the EU.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 31, 2015, we received approval from the Notified Body for improvements to the GlucoTrack&#174; model DF-F which simplify and shorten (from approximately 2.5 hours to approximately half an hour) the initial calibration process for the device. These improvements are intended to reduce the backlog created as purchasers of the device await calibration. In addition, we received approval from the Notified Body on the updated intended use for the device, which expands the intended user population to include not only Type 2 diabetics, but persons suffering from pre-diabetes conditions as well, which we believe represents a material expansion of the potential market for the device. In December 2015, we received approval from the Notified Body for further improvements to the GlucoTrack&#174; model DF-F that increase the accuracy and efficacy of the device. On February 19, 2016, we received an extension of our ISO 13485:2003 certificate and Annex II certification from the EU.&#160;&#160;The ISO 13485:2003 certification signifies that we have met the standards required for company-wide implementation of device quality management system(s).&#160;&#160;The scope of the certification is design, development, manufacture and service of non-invasive glucose monitoring systems for home use.&#160;&#160;Annex II also addresses quality control systems. The certification allows us to self-certify certain modifications and changes and simplifies some of the reporting to and review by the relevant Notified Body.&#160;&#160;This can shorten CE-mark review process of future GlucoTrack&#174; model DF-F enhancements or revisions. Without an Annex II certification, each new device enhancement or modified version would be subject to the full EU CE-mark review process.&#160;&#160;The ISO 13485:2003 and Annex II certifications enable us to potentially improve the time to market for product sales on new,&#160;&#160;enhanced or modified GlucoTrack&#174;&#160;model DF-F devices.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The GlucoTrack&#174; model DF-F has not yet been approved for commercial sale in the United States. On August 10, 2015, we submitted pre-submission documents to the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in connection with our proposed future application for FDA approval of our U.S. clinical trial protocol.&#160;&#160;The pre-submission documentation was submitted to the FDA in order to obtain the FDA&#8217;s guidance regarding the U.S. regulatory pathway for the GlucoTrack&#174; model DF-F, the proper approach to refining the trial protocol, and preparing the pre-marketing application. On October 19, 2015, we met with the FDA to discuss the pre-submission documents, including the approach to and details of the clinical trial protocol for the GlucoTrack&#174;&#160;model DF-F.&#160;We are in the process of amending our proposed clinical trial protocol to reflect the feedback received from the FDA at the meeting. If our clinical trial protocol is approved by the FDA, and subject to our raising sufficient funds to do so, we expect to begin clinical trials in the United States in the first half of 2016.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are continuing to work on improvements of certain features of the GlucoTrack&#174; model DF-F, such as further simplifying the calibration process and improving the accuracy of the device.&#160;&#160;In addition, we have begun developing a module which we expect will enable transmission of measurement data captured by the GlucoTrack&#174; model DF-F to a cloud based server as well as a related smartphone application.&#160;&#160;We expect this module and the related application, if successfully developed, to enable easy sharing and analysis of GlucoTrack&#174; blood glucose measurements to clinicians and others.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Since receiving CE Mark approval for our GlucoTrack&#174; model DF-F glucose monitoring device, we have expanded our primary focus to include, in addition to research and development activities, preparation for anticipated future mass-production and distribution of the GlucoTrack&#174; model DF-F in EU member countries and other countries that have an MDD Mutual Recognition Agreement with the EU.&#160;&#160;We have entered into exclusive distribution agreements with distribution firms in more than 15 countries, the effectiveness of which in many cases is subject to the receipt of local regulatory approval or registration, if required, for the commencement of sales of the GlucoTrack&#174; model DF-F in the subject territory.&#160;&#160;We cannot provide any assurance that we will receive the required local regulatory approvals in any of the countries in which such approvals are required, and therefore we may never be permitted to commence commercial sales of our products in such territories. Further discussions with other potential distributors are in different stages. Among other jurisdictions, we are in the process of seeking regulatory approval for the GlucoTrack&#174; model DF-F in China (where we have a distribution agreement in place), South Korea (where we have a distribution agreement in place) and Japan (where we do not yet have a distribution agreement in place), and are awaiting local regulatory approval in each of those countries.&#160;&#160;Although we expected to&#160;receive local regulatory approval in South Korea by February 2016, we recently received and responded to additional inquiries from the South Korean regulatory body (KFDA).&#160;&#160;We expect that it will take at least two more months to receive a response from the South Korean regulatory body, and potentially longer to receive regulatory approval if they ask additional questions or impose additional requirements for such approval.&#160;&#160;Based on input from our local distributors and regulatory consultants, we estimated that we would complete the local regulatory approval review process in Japan and China by February 2017 and August 2016, respectively. However, we have been informed that the local regulatory bodies in Japan and China (PMDA and CFDA, respectively) have now requested that we conduct additional clinical trials in their respective countries before they determine whether or not to approve the device to be marketed in such countries. Due to these developments, we now anticipate that the regulatory review process in Japan and China will take an additional 18 to 24 months, and potentially longer if the results of the additional clinical trials are not satisfactory to the local regulatory bodies or such regulatory bodies impose additional requirements for approval.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In support of our sales and distribution efforts, we are continuing to seek to expand our sales and customer support capabilities by increasing our sales and customer support teams, by adding new members to our advisory board, as well as by raising market awareness of our GlucoTrack&#174; model DF-F device and its benefits.&#160;&#160;In February 2015, we held the first meeting of our new Scientific Advisory Board, comprised of the following well-known leaders in the fields of Diabetes research, monitoring and treatment: Professor Lutz Heinemann, CEO and Head, Business Development of Profil Institute for Metabolic Research, Ltd. in Neuss, Germany; Professor Michael Heise, University of Applied Science of South-Westphalia, Iserlohn, Germany; Professor Mark A. Arnold, Professor and Edwin B. Green Chair Professor in Laser Chemistry at the University of Iowa; and Professor Jan Bolinder, Professor of Clinical Diabetes Research at the department of Medicine, Huddinge,&#160;&#160;Sweden.&#160;&#160;Members of the Scientific Advisory Board will receive a per meeting fee of 2,000 Euros each, plus reimbursement of expenses.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In October 2015, we held our first international distributors&#8217; conference in which we provided our distributors with current diabetes scientific information and an overview of market conditions and presented them with new global branding and marketing and sales materials for the GlucoTrack&#174; model DF-F. In addition we presented the advantages of the recent approval from the European Union to market the GlucoTrack&#174; model DF-F for pre-diabetic usage.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not have commercial manufacturing facilities and do not intend to build commercial manufacturing facilities of our own in the foreseeable future. We currently utilize a third party manufacturer in Israel to manufacture the GlucoTrack&#174; model DF-F.&#160;&#160;In July 2014, we entered into a manufacturing agreement with Wistron Corp. (&#8220;Wistron&#8221;), a Taiwanese entity and the manufacturing arm of Acer Inc.&#160;&#160;Pursuant to such agreement, Wistron has agreed to mass produce and service, on a non-exclusive basis, the GlucoTrack<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#174;</font> model DF-F and any future products, if any, introduced by us. Pursuant to such agreement, Wistron has also agreed to provide full turn-key manufacturing services for the GlucoTrack<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#174;</font> model DF-F, including components procurement, unit assembly, device integration, testing, packaging and delivery to customers (distributors).&#160;&#160;In November 2015, we sent a delegation to Wistron&#8217;s main production facility in Taiwan<font style="DISPLAY: inline; TEXT-DECORATION: line-through">&#160;</font>to, among other things, inspect the readiness<font style="DISPLAY: inline; TEXT-DECORATION: line-through">&#160;</font>of Wistron&#8217;s production line for the GlucoTrack&#174; model DF-F.&#160;&#160;Wistron has produced a small pilot batch and is in the process of producing a second pilot batch of the GlucoTrack&#174; model DF-F device. Subject to satisfactory completion of a GMP (Good Manufacturing Practice) audit by the local regulatory authorities in Taiwan, we now anticipate that the production line for the GlucoTrack&#174; model DF-F will be operational during the second or third quarter of 2016.&#160;&#160;Following the completion of Wistron&#8217;s production line, we intend to utilize the services of both Wistron and the Israeli third-party manufacturer to produce the GlucoTrack&#174; model DF-F.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have not yet generated any material revenues from our operations and, as of December 31, 2015, have incurred an accumulated deficit of $29,376,515, stockholders&#8217; deficit of $6,970,914<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>and negative operating cash flows. We currently have no material sources of recurring revenue and therefore are dependent upon external sources for financing our operations. There can be no assurance that we will succeed in obtaining the necessary financing to continue our operations. As a result, our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We were incorporated in Delaware in May 2010. On July 15, 2010, we completed a reverse triangular merger with Integrity Israel and Integrity Acquisition Corp. Ltd., an Israeli corporation and a wholly owned subsidiary of ours, pursuant to which Integrity Acquisition Corp. Ltd. merged with and into Integrity Israel and all of the stockholders and option holders of Integrity Israel became entitled to receive shares and options in us in exchange for their shares and options in Integrity Israel (the &#8220;Reorganization&#8221;). Following the Reorganization, the former equity holders of Integrity Israel were entitled to the same proportional ownership in us as they had in Integrity Israel prior to the Reorganization. As a result of the Reorganization, Integrity Israel became a wholly owned subsidiary of ours. We operate primarily through Integrity Israel.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our principal offices are located at 19 Ha'Yahalomim St., Ashdod, Israel 7760049 and our telephone number is 972-8-675-7878. Our website address is http://www.integrity-app.com; the reference to such website address does not constitute incorporation by reference of the information contained on the website and such information should not be considered part of this report. There is no relationship between us and Integrity Applications, Incorporated, the engineering and software services company based in Chantilly, Virginia.</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Corporate Developments</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Resolution of Dimri Arbitration</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 11, 2015 the arbitrator in the previously disclosed arbitration proceeding among Integrity Israel, Avner Gal, David Malka, Zvi Cohen, Ilana Freger and Alexander Raykhman, as defendants, and Y.H. Dimri Holdings (2001) Ltd. (&#8220;Dimri&#8221;), as plaintiff, issued a binding arbitration decision (the &#8220;Arbitration Decision&#8221;) which documents the parties&#8217; negotiated settlement of such arbitration.&#160;&#160;Pursuant to the terms of the Arbitration Decision, (1) Avner Gal, David Malka, Zvi Cohen, Ilana Freger and Alexander Raykhman transferred to Dimri, on March 18, 2015, an aggregate of 440,652 shares of the Company&#8217;s outstanding common stock par value $0.001 per share (the &#8220;Common Stock&#8221;) held collectively by such shareholders, (2) Integrity Israel (A) paid to Dimri on March 23, 2015, NIS 1,767,674 ($439,939 based on the exchange rate of 4.018 NIS:$1 as of March 23, 2015), as repayment in full of the outstanding principal amount under the Investment Agreement dated February 18, 2003 (the &#8220;Investment Agreement&#8221;), among Integrity Israel, Avner Gal, Zvi Cohen, David Malka, David Freger and Yigal Dimri, as adjusted for changes in the Israeli consumer price index since the date on which the loan was made, and (B) paid to Dimri on April 30, 2015, NIS 316,100 ($81,870 based on the exchange rate of 3.861 NIS:$1 as of April 30, 2015), as partial reimbursement of Dimri&#8217;s attorney&#8217;s fees in the arbitration. The Company accrued for the fee reimbursement obligation as part of professional fees within selling, marketing and general and administrative expenses included in its results of operations for the fiscal year ended December 31, 2014. As of December 31, 2015 such amount was fully paid.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Following the completion of the abovementioned transfers and payments, pursuant to the Arbitration Decision, Integrity Israel, the Company and the other defendants in the arbitration were released from any legal claim by Yigal Dimri, the principal shareholder of Dimri, and any other companies under his control in respect of the subject matter of the arbitration, including the shareholder loan granted under and any claim of anti-dilution rights under the Investment Agreement, and Mr. Dimri and all companies under his control were released from any legal claim by Integrity Israel, the Company and the other defendants in the arbitration in respect of the subject matter of the arbitration.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exchange of Series A Unit for Series B Units</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As more fully described in Note 10 to the Company's financial statements included in this Annual Report on Form 10-K, on March 13, 2013, the Company entered into a Securities Purchase Agreement (&#8220;Series A Purchase Agreement&#8221;) with certain accredited investors (the &#8220;Series A Unit Purchasers&#8221;) pursuant to which the Company issued to the Series A Unit Purchasers an aggregate of 6,300 Series A Units, at a price of $1,000 per unit, each consisting of (i) one share of Series A 5.0% Convertible Preferred Stock, par value $0.001 per share (&#8220;Series A Preferred Stock&#8221;), convertible into shares of Common Stock at an initial conversion price of $5.80 per share, and (b) a Warrant to purchase, at an exercise price of $6.96 per share, up to 100% of the shares of Common Stock issuable upon conversion of such share of Series A Preferred Stock (the &#8220;Series A Warrant&#8221; and, together with the Series A Preferred Stock, the &#8220;Series A Units&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The issuance and sale of the Series A Units constituted the second and final closing of an offering under the terms of the Series A Purchase Agreement. On November 19, 2012, the Company completed the first closing of the offering (the &#8220;First Closing&#8221;), pursuant to which the Company issued and sold an aggregate of 165,057 shares of Common Stock at a price of $7.00 per share to certain accredited investors (the &#8220;First Closing Purchasers&#8221;). As a result of the conversion of the offering from an offering of Common Stock to an offering of Series A Units, the Company agreed with Andrew Garrett, Inc., the placement agent for the offering (the &#8220;Placement Agent&#8221;), that, following the closing of the sale of the Series A Units, the Company would exchange the shares of Common Stock acquired by each First Closing Purchaser in the First Closing for such number of Series A Units equal to the aggregate purchase price paid by such First Closing Purchaser in the First Closing, divided by $1,000, in each case subject to the execution by the First Closing Purchasers of a consent to such modification. Pursuant to this agreement, on May 13, 2013, the Company cancelled 162,907 of the 165,057 shares of Common Stock issued to the First Closing Purchasers and issued to such First Closing Purchasers an aggregate of 1,140.35 Series A Units. Such Series A Units include Series A Preferred Stock convertible into an aggregate of 196,597 shares of Common Stock at a conversion price of $5.80 per share and Series A Warrants exercisable for 196,597 shares of Common Stock at an exercise price of $6.96 per share.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on the terms the Purchase Agreement, so long as any initial Series A Unit Purchaser holds any shares of Series A Preferred Stock, if (1) the Company sells any shares of Common Stock or other securities convertible into, or rights to acquire, Common Stock and (2) a Series A Unit Purchaser then holding Series A Preferred Stock, Series A Warrants, conversion shares or warrant shares reasonably believes that any of the terms and conditions appurtenant to such issuance or sale are more favorable to the purchaser in such subsequent sale of securities than are the terms and conditions granted to such Series A Unit Purchaser, then the Series A Unit Purchaser will be permitted to require the Company to amend the terms of the Series A Unit Sale transaction (only with respect to such Series A Unit Purchaser) so as to match the terms of the subsequent issuance (including, for the avoidance of doubt, any terms and provisions that are or may be less favorable to such Purchaser).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Between August and December of 2014, we received aggregate net proceeds of approximately $7.3 million (net of related cash expenses) from the issuance and sale in a private placement transaction, at a price of $1,000 per unit, of 8,500 Series B units (the &#8220;Series B Units&#8221;), each consisting of (a) one share of our newly designated Series B 5.5% Convertible Preferred Stock, par value $0.001 per share (the &#8220;Series B Preferred Stock&#8221;), convertible into shares of our common stock, par value $0.001 per share, at an initial conversion price of $5.80 per share, (b) a five year warrant to purchase, at an exercise price of $5.80 per share, up to such number of shares of our common stock issuable upon conversion of such share of Series B Preferred Stock (each a &#8220;Series B-1 Warrant&#8221;) and (c) a five year warrant to purchase, at an exercise price of $10.00 per share, up to such number of shares of our common stock issuable upon conversion of such share of Series B Preferred Stock (each a &#8220;Series B-2 Warrant&#8221; and, together with the Series B-1 Warrants, collectively, the &#8220;Series B Warrants&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the Series A Purchase Agreement, the Company was required to and did notify the holders of the Series A Preferred Stock of the closing of the sale of the Series B Units, and following receipt thereof such holders of Series A Preferred Stock were entitled, pursuant to the &#8220;most favored nation&#8221; provisions contained in the Purchase Agreement (as described above), to elect to amend the terms of their purchase of Series A Units to match the terms of the Series B Units. The Company was obligated to amend the terms of any Series A Units held by a Series A Purchaser who timely made such election and tendered its Series A Units for exchange.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December 31, 2015, the holders of approximately 6,931 Series A Units have elected, pursuant to the &#8220;most favored nation&#8221; provision in the Series A Purchase Agreement, to amend the terms of their Series A Units to match the terms of the Series B Units. Accordingly, the Company has exchange 6,931 share of Series A Preferred Stock into 6,931 shares of Series B Stock and 1,440,880 Series A Warrants into 1,200,710 Series B-1 Warrants and 1,200,710 Series B-2 Warrants. Due to the differences in the contractual terms of each of the financial instruments exchanged management determined that the exchange constitutes an extinguishment of the existing instruments and an issuance of new financial instruments. As a result of the exchange elections, the Company recorded during the year ended December 31, 2015 a non-cash loss on extinguishment of Series A Preferred Stock and Series A Warrants in the amount of $1,284,354, resulting from the differences between the fair market value estimate of the new Series B Units less the net book value of the exchanged Series A Preferred Stock and less the fair value of the exchanged Warrants with down-round protection.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Market Opportunity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Diabetes</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Diabetes is a chronic, life-threatening disease for which there is no known cure. Diabetes is caused by the body&#8217;s inability to produce or effectively utilize the hormone insulin. This inability prevents the body from adequately regulating blood glucose levels. Glucose, the primary source of energy for cells, must be maintained at certain concentrations in the blood in order to permit optimal cell function and health. Normally, the pancreas provides control of blood glucose levels by secreting the hormone insulin to decrease blood glucose levels when concentrations are too high. In people with diabetes, blood glucose levels fluctuate between very high levels, a condition known as hyperglycemia, and very low levels, a condition known as hypoglycemia. Hyperglycemia can lead to serious long-term complications, such as blindness, kidney disease, nervous system disease, amputations, stroke and cardiovascular disease. Hypoglycemia can lead to confusion, loss of consciousness or death.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Diabetes is typically classified into two major groups: Type 1 and Type 2. Type 1 diabetes is characterized by the body&#8217;s inability to produce insulin, resulting from destruction of the insulin producing cells of the pancreas. Individuals with Type 1 diabetes must rely on frequent insulin injections in order to regulate and maintain blood glucose levels. Type 1 diabetes is frequently diagnosed during childhood or adolescence, although disease onset can occur at any age. Type 2 diabetes, the more common form of diabetes, is characterized by the body&#8217;s inability to either properly utilize insulin or produce enough insulin. Type 2 diabetes is associated with older age, obesity, family history of diabetes, history of gestational diabetes, impaired glucose metabolism, physical inactivity and race or ethnicity. Depending on the severity of Type 2 diabetes, individuals may require diet and nutrition management, exercise, oral medications or insulin injections to regulate blood glucose levels.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">According to the Diabetes Atlas (Sixth Edition) published by the International Diabetes Federation in 2013, an estimated 382 million adults worldwide, between the ages of 20 and 79, or approximately 8.4% of the world&#8217;s adult population, were estimated to suffer from diabetes in 2013 (not including those persons who suffer from impaired glucose tolerance or gestational diabetes, diabetic conditions first arising during pregnancy). The International Diabetes Federation estimates that this number will grow to approximately 592 million adults worldwide by 2035, a 55% increase from 2013. By 2035, the number of adults suffering from diabetes is estimated to increase by 109.1% in Africa, 96.2% in the Middle East and North Africa, 70.6% in Southeast Asia, 59.8% in South and Central America, 46.0% in the Western Pacific, 37.3% in North America and the Caribbean and 22.4% in Europe, over such regions&#8217; respective 2013 levels.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="v232648_s1_htm_page39"><!--EFPlaceholder--></a>Glucose Monitoring</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Blood glucose levels can be affected by many factors, including the carbohydrate and fat content of meals, exercise, stress, illness or impending illness, hormonal releases, variability in insulin absorption and changes in the effects of insulin in the body. Given the many factors that affect blood glucose levels, maintaining glucose within a normal range can be difficult. Diabetics generally manage their blood glucose levels by administering insulin or ingesting carbohydrates throughout the day to maintain blood glucose within normal ranges. Normal ranges in diabetics vary from person to person. In order to maintain blood glucose levels within normal ranges, diabetics must first measure their blood glucose levels so that they can make the proper therapeutic adjustments. As adjustments are made, additional blood glucose measurements may be necessary to gauge the individual&#8217;s response to the adjustments. More frequent testing of blood glucose levels provides patients with information that can be used to better understand and manage their diabetes. Testing of blood glucose levels is usually done before meals, after meals and before going to sleep. Diabetics who take insulin usually need to test more often than those who do not take insulin.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Clinical data supports the recommendation that frequent monitoring of blood glucose levels is an important component of effective diabetes management. The Diabetes Control and Complications Trial, consisting of patients with Type 1 diabetes, and the 1998 UK Prospective Diabetes Study, consisting of patients with Type 2 diabetes, demonstrated that patients who intensely managed blood glucose levels delayed the onset and slowed the progression of diabetes-related complications. In the Diabetes Control and Complications Trial, a major component of intensive management was monitoring blood glucose levels at least four times per day using conventional spot finger stick blood glucose meters. The Diabetes Control and Complications Trial demonstrated that intensive management reduced the risk of complications by 76% for eye disease, 60% for nerve disease and 50% for kidney disease. However, the Diabetes Control and Complications Trial also found that intensive management led to a two- to three-fold increase in the frequency of hypoglycemic events. In the December 2005 edition of the New England Journal of Medicine, the authors of a peer-reviewed study concluded that intensive diabetes therapy has long-term beneficial effects on the risk of cardiovascular disease in patients with Type 1 diabetes. The study showed that intensive diabetes therapy reduced the risk of cardiovascular disease by 42% and the risk of non-fatal heart attack, stroke or death from cardiovascular disease by 57%. However, despite evidence that intensive glucose management reduces the long-term complications associated with diabetes, the American Diabetes Association reported in a 2001 issue of its publication Diabetes Care that up to 67% of patients with diabetes fail to routinely monitor their glucose levels.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Spot finger stick devices are the most prevalent devices for blood glucose monitoring. These devices require users to insert a strip into a glucose meter, take a blood sample with a finger stick and place a drop of blood on a test strip that yields a single point in time blood glucose measurement. Despite continued developments in the field of blood glucose monitors, the routine measurement of glucose levels remains invasive, painful, inconvenient, difficult and costly. This has resulted in a sub-optimal measurement regimen for many diabetics.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The FDA has approved continuous glucose monitoring system (&#8220;CGMS&#8221;) devices for blood glucose monitoring, when prescribed by a doctor. CGMS devices use sensors inserted under the skin to check glucose levels in interstitial fluid. The sensor stays in place for several days to a week and then must be replaced. A transmitter sends information about glucose levels via radio waves from the sensor to a pager-like wireless monitor. According to the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health, CGMS device users must check blood samples with a conventional glucose meter to calibrate the CGMS devices, and because currently approved CGMS devices are not as accurate as standard blood glucose meters, users should confirm glucose levels with a conventional glucose meter when making treatment decisions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To our knowledge, only one device other than the GlucoTrack&#174; model DF-F is currently approved for use in the EU for spot non-invasive blood glucose measurement. The FDA has previously approved a single non-invasive product for glucose trend analysis, the GlucoWatch&#174;, so long as the device was used with conventional finger stick glucose monitoring devices. However, the device is no longer available commercially.<a name="v232648_s1_htm_page40"><!--EFPlaceholder--></a>&#160;&#160;We are not aware of any other devices that have been approved for use in either the United Stated or the EU for spot or continuous non-invasive blood glucose measurement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe that a significant market opportunity exists for a reliable, inexpensive, non-invasive blood glucose measurement device and that such a device could greatly increase compliance with blood glucose measurement recommendations and help many diabetics better manage their disease, providing significant benefits to both patients and payors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The Product</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our non-invasive blood glucose monitor, the GlucoTrack&#174; model DF-F, utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain blood glucose measurements in less than one minute via a small sensor that is clipped onto one&#8217;s earlobe and connected to a handheld control and display unit. See Figure A, below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Figure A</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><img src="img.jpg" alt=""></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe that the GlucoTrack&#174; model DF-F addresses the expressed, currently unmet needs of the diabetic market as it removes or diminishes two of the most significant barriers to the recommended frequent monitoring of blood glucose by diabetics:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">pain, as the GlucoTrack&#174; model DF-F is a truly non-invasive device; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">cost, as, despite the relatively high upfront cost of purchasing a GlucoTrack&#174; model DF-F, we anticipate that the total cost of purchasing a device and purchasing replacement ear clips every six months (anticipated to be the only recurring cost, other than calibration costs, which are expected to be minimal) over the useful life of the device will be significantly lower than the cost of purchasing single use glucose sticks over that same period.&#160;&#160;See Figure B and the accompanying footnotes for a direct cost comparison of the GlucoTrack&#174; model DF-F and conventional (invasive) spot finger stick devices.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We estimate that, over a five-year period, a GlucoTrack&#174; model DF-F user could save an average of $6,405 when compared to the cost of a conventional invasive blood glucose monitoring system, while also taking advantage of the benefits of more frequent blood glucose testing. See Figure B, below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Figure B</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><img src="img2.jpg" alt=""></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The direct cost comparison assumes (i) a single invasive measurement costs $1.00; (ii) the average user of an invasive device takes five measurements daily; (iii) the average retail price for the GlucoTrack&#174; model DF-F is $2,000 (including one personal ear-clip); and (iv) the personal ear-clip is replaced every six months at a cost of $100. The direct cost comparison excludes calibration costs, which are expected to be approximately $70, in total, over a five year period.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Despite the fact that the overall costs associated with owning and using a GlucoTrack&#174; model DF-F device are expected to be substantially lower than the cost of purchasing and using single use invasive devices over an extended period of time, as demonstrated in Figure B above, the significant initial purchase price of a GlucoTrack&#174; model DF-F might present a barrier to adoption of the GlucoTrack&#174; system by patients. In light of this fact, we are suggesting to distributors of the GlucoTrack&#174; model DF-F that they consider offering end users financing and/or leasing options to lessen the initial financial burden associated with purchasing a GlucoTrack&#174; model DF-F.&#160;&#160;There can be no assurance that any such alternatives will be made available to end users. In addition, we intend to seek reimbursement approval for the GlucoTrack&#174; model DF-F from third-party payors, including government payors (such as the Medicare and Medicaid programs in the United States, in the event the GlucoTrack&#174; model DF-F is approved for commercial sale in the United States), managed care organizations and other third-party payors. There can be no assurance that such third party-payors will provide reimbursement coverage for the GlucoTrack&#174; model DF-F or, if so, whether such reimbursement coverage will be adequate. See &#8220;Risk Factors - If the GlucoTrack&#174; model DF-F or our future product candidates, if any, fail to achieve market acceptance, we may not be able to generate significant revenue or achieve or sustain profitability&#8221;.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Instead of directly measuring the glucose level of a user&#8217;s blood, as conventional spot finger stick devices do, the GlucoTrack&#174; model DF-F uses a small, non-invasive sensor that is clipped onto a user&#8217;s earlobe to obtain certain body measurements using three technologies, which are then analyzed using a proprietary algorithm on a small, handheld control and display unit. Within one minute, the GlucoTrack&#174; model DF-F will produce a blood glucose measurement that can be simultaneously audibly announced and displayed on the control unit, as well as recorded on internal flash memory. The two units of the device (main unit and personal ear-clip) are connected through a multi-wire flexible cable. When and if we develop a continuous measurement model, we plan for this connection to be wireless.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Since the GlucoTrack&#174; model DF-F non-invasive measurement does not directly measure glucose levels in the blood, but rather measures a series of physiological characteristics that correlate with glucose levels, each patient must be calibrated by using a reference to a measurement obtained from an invasive device. Calibration consists of comparing an individual patient&#8217;s physiological measurements obtained using the GlucoTrack&#174; model DF-F to measurements obtained from an invasive device under different circumstances over a defined period (such as fasting and after eating).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The three different technologies used by GlucoTrack&#174; model DF-F, ultrasound, electromagnetic and thermal, simultaneously measure three independent criteria. These three measurements (criteria) are combined together by a unique (on line) algorithm to produce an acceptable measurement of a user&#8217;s blood glucose level.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The technologies operate as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Ultrasound</font>: The GlucoTrack&#174; model DF-F uses ultrasound technology to measure the change of speed of sound through the earlobe, which is impacted by the glucose concentration in the capillary blood vessels.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Electromagnetic</font>: The GlucoTrack&#174; model DF-F&#8217;s electromagnetic technology uses a measurement of conductivity to measure the change in tissue impedance, which is a function of glucose concentration.&#160;&#160;The GlucoTrack&#174; model DF-F&#8217;s electromagnetic technology analyzes criteria similar to those analyzed by conventional invasive devices, such as spot finger stick devices, but does so in a non-invasive manner.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Thermal</font>: The GlucoTrack&#174; model DF-F&#8217;s thermal technology uses a measurement of heat capacity characteristics of the tissue, which are influenced by glucose concentration.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The GlucoTrack&#174; model DF-F does not directly measure the glucose level concentration in the blood. Rather, it measures several physiological phenomena that are correlated with the glucose level. In order to correlate between the measured signal and the glucose level, a translation is needed. This translation is accomplished through the individual calibration of the device by reference to a measurement obtained from an invasive device.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Non-invasive devices (under different stages of development) generally require frequent recalibration. For example, GlucoWatch, a single non-invasive product for glucose trend analysis that was previously approved for sale by the FDA, but which is no longer available commercially, required recalibrations approximately every 13 hours. The main reasons for calibration are that tissue parameters generally fluctuate in the area of the measurement, and are sensitive to the location of the sensor and the impact of potential disturbances. Disturbances are less frequent in the earlobes, where the GlucoTrack&#174; model DF-F takes its measurements. Utilizing three channels simultaneously reduces the noise contribution in the measurement. In addition, the personal ear-clip contains sensors to help users attach the device to the proper part of the ear lobe.&#160;&#160;The Notified Body for our CE Mark approval has determined that the initial calibration of the GlucoTrack&#174; model DF-F device is valid for a period of six months, while to our knowledge, competing products require recalibration significantly more frequently. Therefore, the GlucoTrack&#174; model DF-F will require only an initial calibration upon use of a new personal ear-clip (to be replaced every six months) and will not require recalibration.&#160;&#160;However, to date, in informal discussions with the FDA, the FDA has indicated that initially it would require recalibration of the GlucoTrack&#174; model DF-F every month, but has not yet indicated what standards will be used for clearance.&#160;&#160;Thus, if and when we receive FDA approval to market the GlucoTrack&#174; model DF-F in the United States, we may be required to provide for calibration on at least a monthly basis.&#160;&#160;Recalibration of the device would be accomplished in the same manner as the initial calibration of the device, by comparing the readings obtained from the GlucoTrack&#174; model DF-F against measurements obtained using an invasive device. We expect that the initial calibration and the first one or two recalibrations would be completed by experienced clinicians in a clinical setting, and all other recalibrations after the initial one or two recalibrations would be completed by the patient in a location of his or her choosing.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The GlucoTrack&#174; model DF-F does not use any optical method (either Infra Red (IR) or Near Infra Red (NIR) technology), which we understand are being used by other developers of non-invasive blood glucose measurement devices. We believe that optical technologies are less reliable than the GlucoTrack&#174; model DF-F&#8217;s combination of ultrasound, electromagnetic and thermal technologies due to inherent physiological limitations with optical technology. More specifically, optical technology is based on dispersion of a beam that is analyzed by spectrometric methods. As such devices are non-invasive, the beam passes through other components in the finger tip, such as skin, bone, muscle and fat tissue, which interfere with the measurements. Generally, most of these interferences have been overcome, but not the epidermis, primarily due to roughness, pigmentation and perspiration, which act like lenses in optical wavelengths.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Unlike conventional spot finger stick devices, which require single-use glucose test strips, the GlucoTrack&#174; model DF-F requires no short-term disposables. We believe that the personal ear-clip that accompanies each GlucoTrack&#174; model</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;DF-F will need to be replaced only once every six months, although regulatory authorities may require that replacement occur more frequently. Since there is no additional cost or pain involved with each blood glucose measurement using the GlucoTrack&#174; model DF-F, we believe that users of our device would be encouraged to take multiple blood glucose measurements per day, significantly increasing compliance with blood glucose measurement recommendations and helping diabetics better manage their disease. More frequent testing of blood glucose levels may provide a patient with information that can be used to determine optimal timing and dosage for corrective treatments such as insulin, and can also direct a patient to seek a clinical analysis or detailed testing and diagnosis. We believe that the GlucoTrack&#174; model DF-F&#8217;s non-invasive advantages will hold particular appeal for classes of users that require special care, including premature infants (through a separate GlucoTrack&#174; device which we may develop in the future), children and the elderly.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We intend to eventually develop a family of GlucoTrack&#174; devices, including a device for nighttime usage (which would provide advance warnings of potential hypoglycemic episodes); a continuous measurement device; a driver alert device; a basic model to be used in poorer countries; a device for use in pediatric incubators; and a device for people with pre-diabetes. The current GlucoTrack&#174; model DF-F, measures glucose levels at discrete times as desired by the user, known as spot measurement. We intend that next generation models of GlucoTrack&#174; will include both spot and continuous measurements of glucose levels. We also intend to develop accessories for GlucoTrack&#174;, and software applications for data processing and analysis. Certain models of the device will include a USB port to allow offline analysis of downloaded data. All of the above models will be derivative of the technologies currently used by the DF-F model. The modifications involve mostly engineering changes as opposed to development. Notwithstanding the foregoing, there is no assurance that we will be successful in developing or engineering any of these models or accessories.<a name="v232648_s1_htm_page50"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The GlucoTrack&#174; model DF-F has received CE Mark approval, which allows us to market and sell the GlucoTrack&#174; model DF-F glucose monitoring device in EU member countries that have adopted the MDD without being subject to additional national regulations with regard to demonstration of performance and safety. While the MDD is applicable throughout the EU, it requires only a minimum level of harmonization among member countries.&#160;&#160;Accordingly, member countries may apply and enforce the MDD&#8217;s terms differently, and certain EU member countries may request or require performance and/or safety data additional to the MDD&#8217;s requirements from time to time, on a case-by-case basis.&#160;&#160;Moreover, the MDD notwithstanding, because the regulatory regimes of the EU member countries are significantly diverse, it is difficult to predict future regulatory developments and risks. The GlucoTrack&#174; model DF-F has not yet been cleared or approved for commercial sale in any other jurisdiction, including the United States.&#160;&#160;See &#8220;Government Regulation - Regulation of the Design, Manufacture and Distribution of Medical Devices&#8221; below for a discussion of the approval process for commercial sale in the United States. There can be no assurance that approval for commercial sale in any additional jurisdiction will be obtained on a timely basis or at all.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacturing</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not have commercial manufacturing facilities and do not intend to build commercial manufacturing facilities of our own in the foreseeable future. We currently utilize a third party manufacturer in Israel to manufacture the GlucoTrack&#174; model DF-F. In July 2014, we entered into a manufacturing agreement with Wistron, the manufacturing arm of Acer Inc. Wistron has agreed to mass produce and service, on a non-exclusive basis, the GlucoTrack<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#174;</font> model DF-F and any future products, if any, introduced by us. Pursuant to such agreement, Wistron has agreed to provide full turn-key manufacturing services for the GlucoTrack<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#174;</font> model DF-F, including components procurement, unit assembly, device integration, testing and packaging. Wistron is in the process of preparing a production line for the GlucoTrack&#174; model DF-F.&#160;&#160;Wistron has produced a small pilot batch and is in the process of producing a second pilot batch of the GlucoTrack&#174; model DF-F device. Subject to satisfactory completion of a GMP (Good Manufacturing Practice) audit by the local regulatory authorities in Taiwan, we now anticipate that the production line for the GlucoTrack&#174; model DF-F will be operational during the second or third quarter of 2016.&#160;&#160;&#160;&#160;Following the completion of Wistron&#8217;s production line, we intend to utilize the services of both Wistron and the Israeli third-party manufacturer to produce the GlucoTrack<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#174;</font> model DF-F. Our suppliers and their manufacturing facilities must comply with applicable regulations in the jurisdictions in which the GlucoTrack&#174; model DF-F is being marketed (including ISO 13485 in the EU), current quality system regulations, which include current good manufacturing practices, and to the extent laboratory analysis is involved, current good laboratory practices. There can be no assurance that we will be able to enter into agreements with qualified manufacturers on terms acceptable to us, or at all, or that, once contracted, such manufacturers will perform as expected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Furthermore, the manufacturing of the GlucoTrack&#174; model DF-F may be impacted by the Recast Directive on the Restriction of Hazardous Substances in Electrical and Electronic Equipment, 2011/65/EU (&#8220;RoHS 2&#8221;). RoHS 2 is a new EU directive that came into force on July 22, 2014.&#160;&#160;Like the MDD, RoHS 2, a recast of Directive 2002/95/EC that will cover electrical and electronic medical devices, is relevant in order to obtain CE Marking for certain products.&#160;&#160;RoHS 2 compliance requires medical device manufacturers to:&#160;&#160;draw up required technical documentation; conduct an internal control procedure in accordance with Module A of Annex II to Decision No. 768/2008/EC; prepare a Declaration of Conformity; and affix CE Marking to a finished product.&#160;&#160;Although these requirements are similar to those of the MDD, RoHS 2 does not require a Notified Body assessment of compliance. However, if they are not compliant with RoHS 2, medical device manufacturers face the risk of being barred from selling medical devices in the EU after July 22, 2014.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Sales &amp; Marketing</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have a limited number of dedicated sales and marketing personnel, as we intend to collaborate with third parties with established sales and marketing operations in the medical device industry (such as the distributors described below) to market and sell the GlucoTrack&#174; model DF-F to point of sale end users and/or local distributors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have entered into agreements with distributors to sell the GlucoTrack&#174; model DF-F device in more than 15 countries, subject in certain cases to the receipt of local regulatory approval or registration, if required, for the commencement of sales of the GlucoTrack&#174; model DF-F in the subject territory. We cannot provide any assurance that we will receive the required local regulatory approvals in any of the countries in which such approvals are required, and therefore we may never be permitted to commence commercial sales of our products in such territories. Further discussions with other potential distributors are in different stages.&#160;&#160;However, there can be no assurance that we will be able to enter into additional distribution agreements on terms acceptable to us or at all or that, once contracted, our distributors will perform as expected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our distribution agreements entered into to date generally appoint the counterparty as the exclusive distributor of the GlucoTrack&#174; model DF-F in a stated territory.&#160;&#160;Where local regulatory approval of the device is required, such appointment is generally conditioned upon receipt of such approval.&#160;&#160;Our distributions agreements generally have a term of 18 months to three years, subject to renewal for additional terms, each of one year, unless either party provides notice of non-renewal at least 90 days prior to the end of the then current term.&#160;&#160;The distribution agreements provide minimum purchase quotas for the first contract year.&#160;&#160;If a distributor fails to reach a specified quota, we may either terminate the distributor&#8217;s appointment upon 30 days prior written notice to the distributor, or, by notice to the distributor, provide that its distribution rights in the applicable territory shall no longer be exclusive.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research &amp; Development</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We focus significant time and resources on research and development in connection with our efforts to continue to develop, improve and commercialize the GlucoTrack&#174; model DF-F, as well as in connection with our development of other GlucoTrack<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#174;</font> models. Our continuing research and development activities are primarily focused on software and algorithm improvements intended to improve the accuracy of the device, clinical trials to test the performance of the GlucoTrack<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#174;</font> device when used by children and teenagers between the ages of six and 18, preparation for future FDA trials, testing new characteristics of the device, development of a new device in the GlucoTrack<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#174;</font> family and seeking to streamline and continue to simplify the calibration process.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Government Regulatory</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Healthcare is heavily regulated by federal, state and local governments in the United States, and by similar authorities in other countries.&#160;&#160;Any product that we develop must receive all relevant regulatory approvals or clearances, as the case may be, before it may be marketed in a particular country. The laws and regulations affecting healthcare change regularly, thereby increasing the uncertainty and risk associated with any healthcare-related venture. The United States government has in the past considered, is currently considering and may in the future consider healthcare policies and proposals intended to curb rising healthcare costs, including those that could significantly and adversely affect reimbursement for healthcare products such as GlucoTrack&#174; devices. These policies have included, and may in the future include: basing reimbursement policies and rates on clinical outcomes, the comparative effectiveness and costs of different treatment technologies and modalities; imposing price controls and taxes on medical device providers; and other measures. Future significant changes in the healthcare systems in any jurisdiction in which the GlucoTrack&#174; model DF-F or our future products, if any, may be cleared for sale could also have a negative impact on the demand for the GlucoTrack&#174; model DF-F or our future products, if any. These include changes that may reduce reimbursement or payment rates for such products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the United States, the federal government regulates healthcare through various agencies, including but not limited to the following: (i) the FDA, which administers the Food, Drug, and Cosmetic Act, as well as other relevant laws; (ii) the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), which administers the Medicare and Medicaid programs; (iii) the Office of Inspector General, which enforces various laws aimed at curtailing fraudulent or abusive practices including, by way of example, the Anti-Kickback Law, the Anti-Physician Referral Law, commonly referred to as the Stark Law, the Anti-Inducement Law, the Civil Money Penalty Law, and the laws that authorize the Office of Inspector General to exclude health care providers and others from participating in federal healthcare programs; and (iv) the Office of Civil Rights which administers the privacy and security aspects of the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;). All of the aforementioned are agencies within the Department of Health and Human Services. Healthcare is also provided or regulated, as the case may be, by the Department of Defense through its TriCare program, the Department of Veterans Affairs under, among other laws, the Veterans Health Care Act of 1992, the Public Health Service within the Department of Health and Human Services under the Public Health Service Act, the Department of Justice through the Federal False Claims Act and various criminal statutes, and state governments under the Medicaid program and their internal laws regulating all healthcare activities.&#160;&#160;If and when we receive FDA approval to market the GlucoTrack&#174; DF-F in the United States, we will be subject to regulation by some or all of the foregoing agencies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The applicable regulatory schemes in the EU are significantly more diverse than those in the United States and do not lend themselves to similar summary.&#160;&#160;Although the CE Mark system and the MDD require a minimum level of harmonization in the EU, each EU member country may impose additional regulatory requirements.&#160;&#160;Because there are numerous EU member countries with distinct legal systems, the scope of potential regulatory requirements in each of the EU countries (additional to the harmonized EU requirements) is difficult to summarize or predict.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Regulation of the Design, Manufacture and Distribution of Medical Devices</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any product that we develop must receive all relevant regulatory clearances or approvals, as the case may be, before it may be marketed in a particular country.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sales of medical devices outside the United States are subject to foreign regulatory requirements that vary widely from country to country.&#160;&#160;These laws and regulations range from simple product registration requirements in some countries to complex clearance and production controls in others. As a result, the processes and time periods required to obtain foreign marketing approval may be longer or shorter than those necessary to obtain FDA approval (as described below). These differences may affect the efficiency and timeliness of international market introduction of GlucoTrack&#174; model DF-F. For countries in the EU, medical devices must display a CE Mark before they may be imported or sold and must comply with the requirements of the MDD or the Active Implantable Medical Device Directive. On June 4, 2013, we received our CE Mark approval for the GlucoTrack&#174; model DF-F non-invasive glucose monitoring device from the Notified Body. Receipt of the CE Mark allows us to market and sell the GlucoTrack&#174; model DF-F glucose monitoring device in EU member countries that have adopted the MDD without being subject to additional national regulations with regard to demonstration of performance and safety. However, although the MDD is applicable throughout the EU, in practice it does not ensure uniform regulation throughout the EU.&#160;&#160;Rather, the MDD requires only a minimum level of harmonization in the EU.&#160;&#160;Accordingly, member countries may apply and enforce the MDD&#8217;s terms differently, and certain EU member countries may request or require performance and/or safety data in addition to the MDD&#8217;s requirements from time to time, on a case-by-case basis. The CE Mark also permits the sale in countries that have an MDD Mutual Recognition Agreement with the EU. On August 31, 2015, we received approval from the Notified Body for improvements to the GlucoTrack&#174; model DF-F which simplify and shorten (from approximately 2.5 hours to approximately half an hour) the initial calibration process for the device. These improvements are intended to reduce the backlog created as purchasers of the device await calibration. In addition, we received approval from the Notified Body on the updated intended use for the device, which expands the intended user population to include not only Type 2 diabetics, but persons suffering from pre-diabetes conditions as well, which we believe represents a material expansion of the potential market for the device. In December 2015, we received approval from the Notified Body for further improvements to the GlucoTrack&#174; model DF-F that increase the accuracy and efficacy of the device.&#160;&#160;On February 19, 2016, we received an extension of our ISO 13485:2003 certificate and Annex II certification from the EU.&#160;&#160;The ISO 13485:2003 certification signifies that we have met the standards required for company-wide implementation of device quality management system(s).&#160;&#160;The scope of the certification is design, development, manufacture and service of non-invasive glucose monitoring systems for home use.&#160;&#160;Annex II also addresses quality control systems. The certification allows us to self-certify certain modifications and changes and simplifies some of the reporting to and review by the relevant Notified Body.&#160;&#160;This can shorten CE-mark review process of future GlucoTrack&#174; model DF-F enhancements or revisions. Without an Annex II certification, each new device enhancement or modified version would be subject to the full EU CE-mark review process.&#160;&#160;The ISO 13485:2003 and Annex II certifications enable us to potentially improve the time to market for product sales on new, enhanced or modified GlucoTrack&#174;&#160;model DF-F devices.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are in the process of seeking regulatory approval for the GlucoTrack&#174; model DF-F in China (where we have a distribution agreement in place), South Korea (where we have a distribution agreement in place) and Japan (where we do not yet have a distribution agreement in place), and are awaiting local regulatory approval in each of those countries.&#160;&#160;We may also seek regulatory approval to market the GlucoTrack&#174; devices in other foreign countries that do not rely on the CE Mark. To the extent that we seek to market our devices in other non-CE Mark countries in the future, we will be required to comply with the applicable regulatory requirements in each such country. Such regulatory requirements vary by country and may be onerous. As a result, no assurance can be given that we will be able to satisfy the regulatory requirements to sell our products in any such country.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the United States, under Section 201(h) of the Food, Drug, and Cosmetic Act, a medical device is an article which, among other things, is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment or prevention of disease in man or other animals. We believe that GlucoTrack&#174; devices will be classified as medical devices and subject to regulation by numerous agencies and legislative bodies, including the FDA and its foreign counterparts. Devices are subject to varying levels of regulatory control, the most comprehensive of which requires that a clinical evaluation be conducted before a device receives approval for commercial distribution. The FDA classifies medical devices into one of three classes. Class I devices are relatively simple and can be manufactured and distributed with general controls. Class II devices are somewhat more complex and require greater scrutiny. Class III devices are new and frequently help sustain life.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the United States, a company generally can obtain permission to distribute a new device in two ways &#8211; through a so-called &#8220;510(k)&#8221; premarket notification application or through a Section 515 premarket approval (&#8220;PMA&#8221;) application. The 510(k) submission applies to any device that is substantially equivalent to a device first marketed prior to May 28, 1976 or to another device marketed after that date, but which was substantially equivalent to a pre-May 28, 1976 device. These devices are either Class I or Class II devices. Under the 510(k) submission process, the FDA will issue an order finding substantial equivalence to a predicate device (pre-May 28, 1976 or post-May 28, 1976 device that was substantially equivalent to a pre-May 28, 1976 device) and permitting commercial distribution of that device for its intended use. A 510(k) submission must provide information supporting its claim of substantial equivalence to the predicate device. The FDA permits certain low risk medical devices to be marketed without requiring the manufacturer to submit a premarket notification. In other instances, the FDA may require that a premarket notification not only be submitted, but also be accompanied by clinical data. If clinical data from human experiments are required to support the 510(k) submission, these data must be gathered in compliance with investigational device exemption regulations for investigations performed in the United States. The FDA review process for premarket notifications submitted pursuant to section 510(k) should take about 90 days, but it can take substantially longer if the FDA has concerns, and there is no guarantee that the FDA will clear the device for marketing, in which case the device cannot be lawfully distributed in the United States. <a name="v232648_s1_htm_page52"><!--EFPlaceholder--></a>If the FDA finds that the device subject to the premarket notification is substantially equivalent to a proper predicate device, then the FDA may &#8220;clear&#8221; that device for marketing. These devices are not &#8220;approved&#8221; by the FDA. There is no guarantee, however, that the FDA will deem the device subject to the 510(k) process, as opposed to the more time-consuming, resource intensive and problematic PMA application process described below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The more comprehensive PMA process applies to a new device that either is not substantially equivalent to a pre-May 28, 1976 product or is to be used in supporting or sustaining life or preventing impairment. These devices are normally Class III devices and can only be marketed following approval of a PMA application. For example, most implantable devices are subject to the PMA approval process. Two steps of FDA approval generally are required before a company can market a product in the U.S. that is subject to Section 515 PMA approval, as compared to a Section 510(k) clearance. First, a company must comply with investigational device exemption regulations in connection with any human clinical investigation of the device; however those regulations permit a company to undertake a clinical study of a &#8220;non-significant risk&#8221; device without formal FDA approval. Prior express FDA approval is required if the device is a significant risk device. If there is any doubt as to whether a device is a &#8220;non-significant risk&#8221; device, companies normally seek prior approval from the FDA. Normally, clinical studies of new diagnostic products are conducted in tandem with a cleared or approved device and treatment decisions are based on the results from the existing diagnostic device. In such a setting, the FDA may consider the clinical trial as one not posing a significant risk. However, FDA action is always uncertain and dependent on the contours of the design of the clinical trial and the device and there is no assurance that the FDA would consider any proposed clinical trial as one posing a non-significant risk. Moreover, before undertaking any clinical trial, the company sponsoring the trial and the investigator conducting the trial are required by federal law to seek and obtain the approval of institutional review boards (&#8220;IRB&#8221;). An IRB weighs the risks and benefits of a proposed trial to ensure that the human subjects are not exposed to unnecessary risk and reviews the informed consent form to ensure that it meets federal requirements and accurately describes the risks and benefits, if any, of the clinical trial. IRB review occurs annually and annual re-approval is required. University medical centers as well as other entities maintain and operate IRB. Second, the FDA must review a company&#8217;s PMA, which contains, among other things, clinical information acquired under the investigational device exemption. The FDA will approve the PMA if it finds there is reasonable assurance that the device is safe and effective for its intended use. The premarket approval process takes substantially longer than the 510(k) process.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The GlucoTrack&#174; model DF-F has not yet been approved for commercial sale in the United States. We believe that the GlucoTrack&#174; model DF-F device will be classified as a Class III device that will be subject to the PMA process and require human clinical trials, although that may not be true with other products mentioned in this report.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 10, 2015, we submitted pre-submission documents to the FDA in connection with our proposed future application for FDA approval of our U.S. clinical trial protocol.&#160;&#160;The pre-submission documentation was submitted to the FDA in order to obtain the FDA&#8217;s guidance regarding the U.S. regulatory pathway for the GlucoTrack&#174; model DF-F, the proper approach to refining the trial protocol, and preparing the pre-marketing application. On October 19, 2015, we met with the FDA to discuss the pre-submission documents, including the approach to and details of the clinical trial protocol for the GlucoTrack&#174;&#160;Model DF-F.&#160;We are in the process of amending our proposed clinical trial protocol to reflect the feedback received from the FDA at the meeting. If our clinical trial protocol is approved by the FDA, and subject to our raising sufficient funds to do so, we expect to begin clinical trials in the United States in the first half of 2016.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Even when a clinical study has been approved or cleared by the FDA or a notified body or deemed approved, the study is subject to factors beyond a manufacturer&#8217;s control, including, but not limited to the fact that the IRB at a given clinical site might not approve the study, might decline to renew approval which is required annually, or might suspend or terminate the study before the study has been completed. Also, the interim results of a study may not be satisfactory, in which case the sponsor may terminate or suspend the study on its own initiative or the FDA or a notified body may terminate or suspend the study. There is no assurance that a clinical study at any given site will progress as anticipated; there may be an insufficient number of patients who qualify for the study or who agree to participate in the study, or the investigator at the site may have priorities other than the study. Also, there can be no assurance that the clinical study will provide sufficient evidence to assure the FDA or a notified body that the product is safe and effective, a prerequisite for FDA approval of a PMA, or substantially equivalent in terms of safety and effectiveness to a predicate device, a prerequisite for clearance under 510(k). Even if the FDA or a notified body approves or clears a device, it may limit its intended uses in such a way that manufacturing and distributing the device may not be commercially feasible.<a name="v232648_s1_htm_page53"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">After clearance or approval to market is given, the FDA and foreign regulatory agencies, upon the occurrence of certain events, are authorized under various circumstances to withdraw the clearance or approval or require changes to a device, its manufacturing process or its labeling or additional proof that regulatory requirements have been met.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A manufacturer of a device approved through the PMA process is not permitted to make changes to the device which affects its safety or effectiveness without first submitting a supplement application to its PMA and obtaining FDA approval for that supplement. In some instances, the FDA may require clinical trials to support a supplement application. A manufacturer of a device cleared through a 510(k) submission must submit another premarket notification if it intends to make a change or modification in the device that could significantly affect the safety or effectiveness of the device, such as a significant change or modification in design, material, chemical composition, energy source or manufacturing process. Any change in the intended uses of a PMA device or a 510(k) device requires an approval supplement or cleared premarket notification. Exported devices are subject to the regulatory requirements of each country to which the device is exported, as well as certain FDA export requirements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recently Enacted Health Care Reform Legislation in the United States</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Congress recently passed health care reform legislation, known as the Patient Protection and Affordable Care Act. The President signed the measure into law on March 23, 2010 and on March 30, 2010, the President signed into law a reconciliation bill that modifies certain provisions of the same. These two laws are jointly referred to as the &#8220;Affordable Care Act&#8221; or &#8220;ACA.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The principal aim of the reform legislation as currently enacted is to expand health insurance coverage to approximately 32 million Americans who are currently uninsured. The law&#8217;s most far-reaching changes did not take effect until 2014, including a requirement that most Americans carry health insurance. The consequences of these significant coverage expansions on the sales of our products is still unknown and speculative at this point, although the ACA and certain state initiatives may compel private insurers to reduce coverage or reimbursement for various items and services, including medical devices of the type that we contemplate distributing.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The enacted legislation contains many provisions designed to generate the revenues necessary to fund the coverage expansions. The most relevant of these provisions are those that impose fees or taxes on certain health-related industries, including medical device manufacturers. Beginning in 2013, each medical device manufacturer is required to pay an excise tax (or sales tax) in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices. The tax applies to all medical devices, including our products and product candidates. The ACA also provides for increased enforcement of the fraud and abuse regulations previously mentioned.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In June, 2012, the United States Supreme Court upheld most of the provisions of the Affordable Care Act. While federal regulatory agencies are moving forward with implementation of the provisions of the Affordable Care Act, Congress is attempting to pass legislation which would reverse the Affordable Care Act. Furthermore, various health insurance reform proposals are also emerging at the state level. Due to the unsettled nature of these reforms and the numerous steps required to implement them, we cannot predict to what extent (if at all) Congress will succeed in limiting or reversing the Affordable Care Act, whether (and if so, what) additional health insurance reforms will be implemented at the federal or state level and/or the effect that any future legislation or regulation will have on our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 2, 2011, President Obama and Congress enacted the Budget Control Act of 2011 to increase the federal government&#8217;s borrowing authority (the so-called &#8220;debt ceiling&#8221;) and reduce the federal government&#8217;s projected operating deficit. To implement this legislation, President Obama and members of Congress have proposed various spending cuts and tax reform initiatives, some of which could result in changes (including substantial reductions in funding) to Medicare, Medicaid or Medicare Advantage Plans. Under the agreement reached to allow the federal government to raise the debt ceiling in August 2011, a 12-member, bipartisan committee was given a deadline of November 23, 2011 to develop recommendations for reducing the federal budget deficit by a total of at least $1.2 trillion over ten years. However, the committee was not able to agree on a plan and, therefore, $1.2 trillion in automatic spending cuts, including a two-percent reduction in Medicare payments to dialysis facilities went into effect on January 1, 2013. In November 2013, CMS released a final rule that included a 12% cut for reimbursement of dialysis intravenous services.&#160;&#160;While CMS created other offsets to make the first two years of the cut budget neutral, the adjustment itself in the bundle went down by 3.3% starting in January 2014, as part of a 3-4 year transition period to reach the 12% reduction. This means that Medicare dialysis rates were flat in 2014 and will be flat 2015 in an environment of increasing expenses. These measures and any future federal legislation relating to the debt ceiling or deficit reduction could have a material adverse effect on us.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There are ongoing discussions in the EU regarding amending the relevant regulatory framework.&#160;&#160;It is difficult to predict what effect any amendments to the existing EU legislation may have.&#160;&#160;Furthermore, each individual EU member country has the authority to amend its regulations and requirements additional to the minimum harmonization required by the MDD.&#160;&#160;Because the EU member countries have diverse legal systems, it is difficult to predict what, if any, amendments may be implemented in each of the EU member countries and whether they may adversely affect us.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Reimbursement</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We anticipate that sales volumes and prices of the GlucoTrack&#174; model DF-F and any other products we commercialize will depend in large part on the availability of reimbursement from third-party payors. Third-party payors include governmental programs such as Medicare and Medicaid, private insurance plans and workers&#8217; compensation plans. These third-party payors may deny reimbursement for a product or therapy if they determine that the product was not medically appropriate or necessary. Also, third-party payors are increasingly challenging the prices charged for medical products and services. Some third-party payors must also approve coverage for new or innovative devices before they will reimburse health care providers who use the products. Even though a new product may have been cleared for commercial distribution, it may find limited demand for the device until reimbursement approval has been obtained from governmental and private third-party payors.<a name="v232648_s1_htm_page54"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Inasmuch as a percentage of the projected patient population that could potentially benefit from the GlucoTrack&#174; model DF-F is elderly, Medicare would likely be a potential source of reimbursement in the United States. Medicare is a federal program that provides certain hospital and medical insurance benefits to persons age 65 and over, certain disabled persons, persons with end-stage renal disease and those suffering from Lou Gehrig&#8217;s Disease. In contrast, Medicaid is a medical assistance program jointly funded by United States federal and state governments and administered by each state pursuant to which benefits are available to certain indigent patients. The Medicare and Medicaid statutory framework is subject to administrative rulings, interpretations and discretion that affect the amount and timing of reimbursement made under Medicare and Medicaid.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Medicare reimburses for medical devices in a variety of ways depending on where and how the device is used. However, Medicare only provides reimbursement if CMS determines that the device should be covered and that the use of the device is consistent with the coverage criteria. A coverage determination can be made at the local level by the Medicare administrative contractor (formerly called carriers and fiscal intermediaries) or a private contractor that processes and pays claims on behalf of CMS for the geographic area where the services were rendered, or at the national level by CMS. There are new statutory provisions intended to facilitate coverage determinations for new technologies under the Medicare Prescription Drug Improvement and Modernization Act of 2003 &#167;731 and &#167;942, but it is unclear how these new provisions will be implemented. Coverage presupposes that the device has been cleared or approved by the FDA and, further, that the coverage will be no broader than the approved intended uses of the device (i.e., the device&#8217;s label) as cleared or approved by the FDA, but coverage can be narrower. In that regard, a narrow Medicare coverage determination may undermine the commercial viability of a device.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Obtaining a coverage determination, whether local or national, is a time-consuming, expensive and highly uncertain proposition, especially for a new technology, and inconsistent local determinations are possible. On average, according to an industry report, Medicare coverage determinations for medical devices lag 15 months to five years or more behind FDA approval for respective devices. Moreover, Medicaid programs and private insurers are frequently influenced by Medicare coverage determinations. A key component in the reimbursement decision by most private insurers will be whether the GlucoTrack&#174; model DF-F is reimbursed by virtue of a national coverage determination by CMS. We may negotiate contracted rates for the GlucoTrack&#174; model DF-F with private insurance providers for the purchase of the GlucoTrack&#174; model DF-F by their members pending a coverage determination by CMS. Our inability to obtain a favorable coverage determination for the GlucoTrack&#174; model DF-F may adversely affect our ability to market the GlucoTrack&#174; model DF-F and thus, the commercial viability of the product. In international markets, reimbursement and healthcare payment systems vary significantly by country and many countries have instituted price ceilings on specific product lines. Distributors expressly support the reimbursement process and, depending on the distribution agreement and geographic area, may assume responsibility for the process.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe that the overall escalating cost of medical products and services has led to, and will continue to lead to, increased pressures on the healthcare industry to reduce the costs of products and services. Furthermore, deficit reduction and austerity measures in the United States and abroad may put further pressure on governments to limit coverage of, and reimbursement for, our products. There can be no assurance that third-party reimbursement and coverage will be available or adequate, or that future legislation, regulation, or reimbursement policies of third-party payors will not adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third-party payor coverage or reimbursement could have a material adverse effect on our business, operating results and financial condition. Until reimbursement or insurance coverage is established, patients will have to bear the financial cost of GlucoTrack&#174;. Third-party coverage may be particularly difficult to obtain while the GlucoTrack&#174; model DF-F is not approved by the FDA as a replacement for existing single-point finger stick devices.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Outside the United States, availability of reimbursement from third parties varies widely from country to country.&#160;&#160;Within the EU, member countries&#8217; medical reimbursement and healthcare coverage regulations and systems differ significantly.&#160;&#160;It is, therefore, difficult to analyze and predict the prospect of consistent availability of adequate reimbursement in the various EU member countries.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Until a reimbursement code is achieved, in order to reduce out of pocket expenses for users and increase the number of devices sold, we are suggesting to distributors of the GlucoTrack&#174; model DF-F in the United States (and would anticipate suggesting to our distributors in the United States in the future if and when we receive FDA approval to market the GlucoTrack&#174; model DF-F in the United States) that they consider offering end users financing and/or leasing options to lessen the initial financial burden associated with purchasing a GlucoTrack&#174; device.&#160;&#160;There can be no assurance that any such alternatives will be made available to end users.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Anti-Fraud and Abuse Rule</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There are extensive United States federal and state laws and regulations prohibiting fraud and abuse in the healthcare industry that can result in significant criminal and civil penalties that can materially affect us, if and when we receive FDA approval to market the GlucoTrack&#174; model DF-F in the United States. These federal laws include, by way of example, the following:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The anti-kickback statute (Section 1128B(b) of the Social Security Act), which prohibits certain business practices and relationships that might affect the provision and cost of healthcare services reimbursable under Medicare, Medicaid and other federal healthcare programs, including the payment or receipt of remuneration for the referral of patients whose care will be paid by Medicare or other governmental programs;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The physician self-referral prohibition (Ethics in Patient Referral Act of 1989, as amended, commonly referred to as the Stark Law, Section 1877 of the Social Security Act), which prohibits referrals by physicians of Medicare or Medicaid patients to providers of a broad range of designated healthcare services in which the physicians (or their immediate family members) have ownership interests or with which they have certain other financial arrangements;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The anti-inducement provisions of the Civil Monetary Penalties Law (Section 1128A(a)(5) of the Social Security Act), which prohibit providers from offering anything to a Medicare or Medicaid beneficiary to induce that beneficiary to use items or services covered by either program;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The False Claims Act (31 U.S.C. &#167; 3729 et seq.), which prohibits any person from knowingly presenting or causing to be presented false or fraudulent claims for payment to the federal government (including the Medicare and Medicaid programs); and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Civil Monetary Penalties Law (Section 1128A of the Social Security Act), which authorizes the United States Department of Health and Human Services to impose civil penalties administratively for fraudulent or abusive acts.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sanctions for violating these federal laws include criminal and civil penalties that range from punitive sanctions, damage assessments, monetary penalties, imprisonment and/or denial of Medicare and Medicaid payments or exclusion from the Medicare and Medicaid programs, or both. These laws also impose an affirmative duty on those receiving Medicare or Medicaid funding to ensure that they do not employ or contract with persons excluded from the Medicare and other government programs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Many states have adopted or are considering legislative proposals similar to the federal fraud and abuse laws, some of which extend beyond the Medicare and Medicaid programs, to prohibit the payment or receipt of remuneration for the referral of patients and physician self-referrals regardless of whether the service was reimbursed by Medicare or Medicaid. Many states have also adopted or are considering legislative proposals to increase patient protections, such as limiting the use and disclosure of patient specific health information. These state laws also impose criminal and civil penalties similar to the federal laws.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">21</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Similarly the EU and EU member countries may have similar fraud and abuse laws which would regulate our business in those jurisdictions.&#160;&#160;However, given the diversity of legal systems within the EU, it is difficult to predict with specificity what anti-fraud legislation and regulations may be implemented and the penalties that they impose.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the ordinary course of their business, medical device manufacturers and suppliers have been and are subject regularly to inquiries, investigations and audits by federal and state agencies that oversee these laws and regulations. Recent federal and state legislation has greatly increased funding for investigations and enforcement actions, which have increased dramatically over the past several years. This trend is expected to continue. Private enforcement of healthcare fraud also has increased due in large part to amendments to the civil False Claims Act in 1986 that were designed to encourage private persons to sue on behalf of the government. These whistleblower suits by private persons, known as qui tam relators, may be filed by almost anyone, including present and former patients or nurses and other employees, as well as competitors. HIPAA, in addition to its privacy provisions, created a series of new healthcare-related crimes.<a name="v232648_s1_htm_page56"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As federal and state budget pressures continue, federal and state administrative agencies may also continue to escalate investigation and enforcement efforts to root out waste and to control fraud and abuse in governmental healthcare programs. A violation of any of these federal and state fraud and abuse laws and regulations could have a material adverse effect on a supplier&#8217;s liquidity and financial condition. An investigation into the use of a device by physicians may dissuade physicians from recommending that their patients use the device. This could have a material adverse effect on our ability to commercialize the GlucoTrack&#174; model DF-F.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The Privacy Provisions of HIPAA</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the United States, HIPAA, among other things, protects the privacy and security of individually identifiable health information by limiting its use and disclosure. HIPAA directly regulates &#8220;covered entities,&#8221; such as healthcare providers, insurers and clearinghouses, and regulates &#8220;business associates,&#8221; with respect to the privacy of patients&#8217; medical information. All entities that receive and process protected health information are required to adopt certain procedures to safeguard the security of that information. It is uncertain whether we would be deemed to be a covered entity under HIPAA and, owing to changes in the law, it is uncertain, based on our current business model, whether we would be a business associate. Nevertheless, we will likely be contractually required to physically safeguard the integrity and security of any patient information that we receive, store, create or transmit in the United States. If we fail to adhere to our contractual commitments, then our physician, hospital or insurance customers may be subject to civil monetary penalties, which could adversely affect our ability to market our devices. Changes in the law wrought by the provisions of Health Information Technology for Economic and Clinical Health (HITECH) Act, enacted as part of the American Recovery and Reinvestment Act of 2009, increase the duties of business associates and covered entities with respect to protected health information that thereby subject them to direct government regulation, increasing its compliance costs and exposure to civil monetary penalties and other government sanctions. While HITECH does not alter the definition of a business associate, it makes it more likely that covered entities with whom we are likely to do business in the United States, if and when we receive FDA approval to market the GlucoTrack&#174; model DF-F in the United States, will require us to enter into business associate agreements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Intellectual Property</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe that intellectual property is important to our business and to the medical device industry overall. We rely on a combination of patent, copyright and other intellectual property laws, trade secrets, nondisclosure agreements and other measures to protect our intellectual property and proprietary rights.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We understand the importance of obtaining patent and trade secret protection for new technologies, products and processes. Our success will depend in large part on our ability to file for and obtain patent protection of our principal products and procedures, to defend existing or future patents, to maintain trade secrets and to operate without infringing upon the proprietary rights of others.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have obtained an issued patent for &#8220;A Method of Monitoring Glucose Level&#8221; in the United States, Europe, Australia, Canada, China, India, Israel, Japan, Mexico, the Philippines, Russia, South Africa and South Korea. This patent expires in 2023 in the United States and 2023 or 2024 in most other jurisdictions. One additional patent application is under examination in Brazil.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">22</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have also obtained an issued patent in the United States for an invention entitled &#8220;Device For Non-Invasively Measuring Glucose,&#8221; which covers the technologies related to the GlucoTrack&#174; measurement process. The issued United States patent expires in 2031. Additional patents have now issued in Europe, Australia, China, Hong Kong, Israel, Japan, Russia, South Africa and Taiwan, and they will also expire in 2031. Applications are still pending in Brazil, Canada, India and South Korea and the application in Chile was abandoned. Regarding the three measuring technologies used in the GlucoTrack&#174; device, continuation applications are pending in the US, Europe, Australia, China, Hong Kong, Israel, Japan and Taiwan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Regarding the &#8220;Ear Clip for Medical Monitoring Device&#8221; and its structure, in 2013 we filed a utility patent application in Israel and in March 2014 filed a corresponding Patent Cooperation Treaty application and a corresponding application in Taiwan. A favorable report on patentability under Chapter II of the PCT was received. National Stage applications have been filed in China, the US, Europe, Australia, Canada, Japan, South Korea, Philippines and South Africa.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Regarding the unique designs for the glucose monitoring device, we have design registrations in China, Europe, India, Israel, Japan, the Philippines, South Korea, Taiwan and the U.S. for the Hinge Pin Joint and pending design applications in Israel, South Korea and the U.S. We also have design registrations in China, Europe, India, Japan, the Philippines, and South Korea and pending design applications in the U.S., Brazil, and Taiwan for the Ear Clip; design registrations in Europe and China for the Temperature Sensor; and a design registration in China for the Measuring Device.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have obtained trademark registrations for GlucoTrack&#174; in the U.S., Europe and 21 other countries, including Argentina, Australia, Azerbaijan, Brazil, Chile, China, India, Indonesia, Israel, Japan, Kazakhstan, Latvia, Mexico, New Zealand, Philippines, Russia, South Africa, South Korea, Taiwan, Turkey, and Uruguay and have trademark applications pending for GlucoTrack&#174; in Belarus, Canada and Thailand.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Trademark registrations were issued in France, Italy, Japan, Lithuania, South Korea, Philippines and Spain for "JUST CLIP IT&#8221; and additional applications are pending in the U.S., Belarus, Brazil, Canada, China, India, Latvia and South Africa to register the trademark. In addition, trademark registrations were issued in France, Italy, Japan, Philippines, South Korea and Spain for &#8220;YOUR TRACK TO HEALTH&#8221;, and additional applications are pending in the U.S., Canada, China and India to register the trademark.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Applications have been filed in Israel to register &#8220;Integrity&#8221;, the Company&#8217;s logo and also the GlucoTrack&#174; logo.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Trademark applications are in the process of being filed for GlucoTrack&#174; and the company name in Chinese Characters in China, Hong Kong and Taiwan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Trademark registration applications in Israel for "JUST CLIP IT&#8221; and &#8220;YOUR TRACK TO HEALTH&#8221; were rejected. The Company decided to abandon these applications. The trademark applications in Estonia and Thailand for &#8220;JUST CLIP IT&#8221; and in Thailand for &#8220;YOUR TRACK TO HEALTH&#8221; have also been abandoned during the past year. Regarding these trademarks in Israel, Thailand and Estonia, the Company still maintains its common law rights in such marks, to the extent that such rights are recognized in the respective countries.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Patent protection is highly uncertain and involves complex legal and factual questions and issues. The patent application and issuance process can be expected to take several years and entails considerable expense. There can be no assurance that patents will issue as a result of any applications or that any patents resulting from such applications or our existing patents will be sufficiently broad to afford protection against competitors with similar or competing technology. Patents that we obtain may be challenged, invalidated or circumvented, or the rights granted under such patents may not provide us with any competitive advantages.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe that our patents and products do not and will not infringe patents or violate proprietary rights of others, although it is possible that our existing patent rights may not be valid or that infringement of existing or future patents or proprietary rights may occur. Litigation may be necessary to defend or enforce our patent rights or to determine the scope and validity of the proprietary rights of others. Defense and enforcement of patent claims can be expensive and time consuming, even in those instances in which the outcome is favorable, and could result in the diversion of substantial resources and management time and attention from our other activities. An adverse outcome could subject us to significant liability to third parties, require us to obtain licenses from third parties, alter our products or processes, or require that we cease altogether any related research and development activities or product sales.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">23</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Competition</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The market for blood glucose monitoring devices is intensely competitive, subject to rapid change and significantly affected by new product introductions. Four companies, Roche Disetronic, a division of Roche Diagnostics; LifeScan, Inc., a division of Johnson &amp; Johnson; Abbott Laboratories; and Bayer Corporation, currently account for substantially all of the worldwide sales of self-monitored glucose testing systems. These competitors&#8217; products use a meter and disposable test strips to test blood obtained by pricking the finger or, in some cases, the palm or forearm.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Within the last few years, CGMS devices have been introduced into the market and will compete with the GlucoTrack&#174; model DF-F and our future devices, if any. Currently, three different brands have obtained FDA clearance to market, and are selling, CGMS devices in the U.S. and EU markets. These brands are sold by Medtronic plc., Abbott Laboratories (not available in the U.S.) and Dexcom, Inc.. CGMS devices are invasive devices, in which a needle is inserted under the skin (either in the abdomen or the upper arm) and measures interstitial fluid. Although we cannot predict what standards will be employed by applicable regulatory authorities as we seek FDA clearance, the results achieved by the GlucoTrack&#174; model DF-F in our safety and performance clinical trial conducted in 2012 and 2013 were similar to the results obtained from the CGMS devices that have been introduced to the market, as of the time of their introduction.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Abbott FreeStyle Libre is a relatively new device which was introduced to the market during 2014 and is targeted for type 1 and type 2 diabetics. It contains a tiny glucose sensor that is inserted into the upper arm and must be replaced every two weeks. In order to receive a reading, the user scans the device over the sensor and receives an immediate reading.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, other companies are developing non-invasive glucose testing devices and technologies that could compete with our devices. There are also a number of academic and other institutions involved in various phases of technology development regarding blood glucose monitoring devices. We believe that the majority of non-invasive glucose monitors in development require frequent calibrations (from a few hours to a few days, compared to the GlucoTrack&#174; model DF-F, which has a demonstrated efficacy period of six months from the initial calibration). Among the companies developing non-invasive glucose testing devices is Echo Therapeutics, Inc. Other companies developing continuous measurement devices, based on minimally invasive methods, such as implants or subdermal needles include Medtronic, Inc., Abbot Laboratories and Dexcom, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Some of our competitors are either publicly traded or are divisions of publicly-traded companies, and they enjoy several competitive advantages, including:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">significantly greater name recognition;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">established relations with healthcare professionals, customers and third-party payors;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">established distribution networks;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">additional lines of products, and the ability to offer rebates or bundle products to offer higher discounts or incentives to gain a competitive advantage;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">greater experience in conducting research and development, manufacturing, clinical trials, obtaining regulatory approval for products and marketing approved products; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">greater financial and human resources for product development, sales and marketing, and patent litigation.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Some of our other competitors also enjoy these competitive advantages. As a result, we cannot assure that we will be able to compete effectively against these companies or their products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To our knowledge, a summary of potential competitors with non-invasive products in development is set forth below in Figure D.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">24</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Figure D</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Company</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Product</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Technology</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Calibration</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Type of Measurement</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Technology Description</font></div>
</div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="16%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td valign="top" width="12%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Echo Therapeutics (MA, USA)</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="10%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Symphony</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">UltraSound</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="11%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Daily calibration</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="13%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Continuous</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="16%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Needle-free skin permeation and non-invasive, continuous transdermal glucose biosensor (device attached to skin).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td valign="top" width="12%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Freedom Meditech (MA, USA)</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="10%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Optical Polarimetry (in front of the eye)</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="11%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Not known</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="13%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Spot; Screening</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="16%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-invasive direct measurement of glucose levels in front of the eye via optical polarimetry.</font></div>
</td>
</tr><tr>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td valign="top" width="12%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cybiocare (Quebec, Canada)</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="10%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">OHD</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Optical</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="11%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Not known</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="13%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Continuous</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="16%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Through a device strapped to a patient&#8217;s arm, continuously measures glucose levels by using infrared light to detect hypoglycemia in the patient.</font></div>
</td>
</tr><tr>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td valign="top" width="12%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CNOGA Medical (Israel)</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="10%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">TensorTip CGM Combo Glucometer</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Optical Look-up table</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="11%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">At least 200 pricking within a few weeks</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="13%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Spot</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="16%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Four LED signals are beamed through&#160;&#160;the finger; color image sensor executes a special algorithm.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Employees</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December 31, 2015, we had&#160;29 full-time employees and 8 part-time employees. None of our employees are represented by a collective bargaining agreement.<a name="page65"><!--EFPlaceholder--></a> In addition as of December 31, 2015 we had four full-time consultants.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item1ARiskFactors">Item 1A. Risk Factors</a>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">An investment in our common stock involves a high degree of risk. Before making an investment decision, you should carefully consider the following risk factors. If any of these risks actually occur, our business, financial condition and results of operations could be materially harmed. In addition, risks and uncertainties not presently known to us or that we currently deem immaterial may also materially harm our business, financial condition and results of operations. If this were to happen, the value of our common stock could decline significantly and you could lose all or part of your investment.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline">We will need to secure additional financing in 2016</font><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline"> in order to continue to finance our operations. If we are unable to secure </font>additional<font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline"> financing on acceptable terms, or at all, we may be forced to curtail or cease our operations.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our cash on hand was approximately $84,000 as of March 28, 2016. Based on our current cash burn rate, strategy and operating plan, we believe that our cash and cash equivalents will enable us to operate for a period of less than thirty days from the date of this report and we have deferred payments on our accounts payable as well as payroll payments to certain management employees who voluntarily elected to have their salaries deferred. In order to fund our anticipated liquidity needs beyond such period (or possibly earlier if our current cash burn rate, strategy or operating plan change in a way that accelerates or increases our liquidity needs), we will need to raise additional capital.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">25</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through public or private equity offerings, debt financings or strategic collaborations. We do not know whether additional funding will be available on acceptable terms, or at all. If we are unable to secure additional financing in the near term, we may be forced to: curtail or abandon our existing business plans; limit or terminate our applications for the regulatory approvals or clearances, as the case may be, in the countries in which we intend to market the GlucoTrack&#174; model DF-F; reduce our headcount; default on our debt obligations; file for bankruptcy; seek to sell some or all of our assets; and/or cease our operations.&#160;&#160;If we are forced to take any of these steps, any investment in our securities may be worthless.&#160;&#160;To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution, and debt financing, if available, may involve restrictive covenants. &#160;In addition to the dilution normally attendant to an equity offering, holders of our shares of Common Stock may experience additional dilution as a result of the anti-dilution and most favored nation provisions of our Series A Preferred Stock, Series B Preferred Stock and Series A Warrants.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have a history of operating losses, and there is no assurance that we will generate material revenues or become profitable in the near future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are a medical device company with a limited operating history. We are not profitable and have incurred losses since our inception. To date we have not generated material revenue from the sale of products and we do not anticipate that we will report operating income in the near future. Our initial product, the GlucoTrack&#174; model DF-F, has not been approved for marketing in the United States and may not be sold or marketed without FDA clearance or approval in the United States. While our GlucoTrack&#174; model DF-F received CE Mark approval in 2013, there is no assurance that we will be able to generate any material revenues from sales of such model in the EU or any other jurisdictions. We continue to incur research and development and selling, marketing and general and administrative expenses related to our operations, development and commercialization of our first product. Our operating losses for the years ended December 31, 2015 and 2014 were approximately $4.7 million and $3.6 million, respectively, and we had an accumulated deficit of approximately $29.4 million as of December 31, 2015. We expect to continue to incur losses for the foreseeable future, and these losses will likely increase as we prepare for and begin to commercialize the GlucoTrack&#174; model DF-F. If we are not successful in manufacturing and distribution the GlucoTrack&#174; model DF-F, or if the GlucoTrack&#174; model DF-F does not achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our independent registered public accounting firm noted in its report accompanying our financial statements for the fiscal year ended December 31, 2015 that we had suffered significant accumulated deficit and had negative operating cash flows and that the development and commercialization of our product is expected to require substantial expenditures. We have not yet generated any material revenues from our operations to fund our activities, and are therefore dependent upon external sources for financing our operations. There can be no assurance that we will succeed in obtaining the necessary financing to continue our operations. As a result, our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. If we cannot successfully continue as a going concern, our stockholders may lose their entire investment in our common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The agreements governing our outstanding Preferred Stock contain various covenants that limit our ability to take certain actions and our failure to comply with any of the covenants would have a material adverse effect on our business, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The agreements governing our outstanding Preferred Stock contain a number of significant covenants that, among other things, limit our ability to incur indebtedness or liens, and repay, repurchase, pay dividends on or otherwise make distributions in respect of any shares of common stock or other securities junior to the Preferred Stock. Unless we receive a consent or a waiver from the holders of our Preferred Stock, these covenants may restrict our ability to take certain actions that we would have otherwise taken in the absence of these covenants and which may be in the best interests of the Company and our stockholders. There can be no assurance that we will be able to receive a consent or waiver on acceptable terms, if at all. If we fail to comply with these covenants, we will be in default of the agreements governing our outstanding Preferred Stock, which would have a material adverse effect on our business, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">26</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may be required to redeem our Preferred Stock upon the occurrence of certain events, which would have a material adverse effect on our financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We may become obligated to redeem the Preferred Stock in cash upon the occurrence of certain triggering events, including, among others, a material breach by us of certain contractual obligations to the holders of the Preferred Stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the common stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or a regulated quotation service. In addition, upon the occurrence of certain triggering events, each holder of Preferred Stock will have the option to require us to redeem such holder&#8217;s shares of Preferred Stock for a redemption price payable in shares of common stock or receive an increased dividend rate of 9% on all of such holder&#8217;s outstanding Preferred Stock.&#160;&#160;Any obligation to redeem the Preferred Stock would require a large expenditure of cash by us, which would have a material adverse effect on our financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The recent worldwide economic crisis and market instability may materially and adversely affect the demand for our products, as well as our ability to obtain credit or secure funds through sales of our stock, which may materially and adversely affect our business, financial condition and ability to fund our operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The recent worldwide economic crisis may reduce the demand for new and innovative medical devices, resulting in delayed market acceptance of our products, if and when they are approved. Such a delay could have a material adverse impact on our business, expected cash flows, results of operations and financial condition. Additionally, we have funded our operations to date primarily through private sales of securities, including common stock and other securities convertible into or exercisable for shares of our common stock. The recent economic turmoil and instability in the world&#8217;s equity and credit markets may materially adversely affect our ability to sell additional securities and/or borrow cash.&#160;&#160;There can be no assurance that we will be able to raise additional working capital on acceptable terms or at all, and any failure to do so may materially adversely affect our ability to continue operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Healthcare reforms, changes in healthcare policies, including recently enacted legislation reforming the U.S. healthcare system, and changes to third-party reimbursements for diabetes-related products may affect demand for our products and have a material adverse effect on our financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The United States government has in the past considered and may in the future consider healthcare policies and proposals intended to curb rising healthcare costs, including those that could significantly affect reimbursement for healthcare products such as the GlucoTrack&#174; model DF-F. These policies have included, and may in the future include: basing reimbursement policies and rates on clinical outcomes, the comparative effectiveness and costs of different treatment technologies and modalities; imposing price controls and taxes on medical device providers; and other measures.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Congress passed healthcare reform legislation that the President signed into law on March 23, 2010 and March 30, 2010. The package signed into law is considered by some to be the most dramatic change to the country&#8217;s healthcare system in decades. The principal aim of the law currently enacted is to expand health insurance coverage to approximately 32 million Americans who are currently uninsured. The law&#8217;s most far-reaching changes did not take effect until 2014, including a requirement that most Americans carry health insurance. The consequences of these significant coverage expansions on the sale of our products are still unknown and speculative at this point.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The enacted legislation contains many provisions designed to generate the revenues necessary to fund the coverage expansions. The most relevant of these provisions are those that impose fees or taxes on certain health-related industries, including medical device manufacturers like us. The legislation imposed an annual excise tax (or sales tax) on medical devices like ours, beginning with calendar year 2013. The taxes are allocated based on our proportionate share of the prior-year&#8217;s aggregate domestic gross receipts from medical device sales.<a name="v232648_s1_htm_page14"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition to the new legislation discussed above, the effect of which cannot presently be quantified given its recent enactment, various healthcare reform proposals have also emerged at the state level. Future significant changes in the healthcare systems in the United States or elsewhere could also have a negative impact on the demand for the GlucoTrack&#174; model DF-F or other GlucoTrack&#174; products, if approved for sale, or our future products, if any. These include changes that may lower reimbursement rates for such products from what we might otherwise have obtained and changes that may be proposed or implemented by the current administration or Congress.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">27</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We cannot predict what healthcare initiatives, if any, will be implemented at the federal or state level, or the effect any future legislation or regulation will have on us. In addition to the taxes imposed by the new federal legislation, any further expansion in government&#8217;s role in the U.S. healthcare industry may lower reimbursements for our products, reduce medical procedure volumes and materially adversely affect our business, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the EU, although there have not been any recent amendments to the relevant regulatory legislation, there are ongoing discussions regarding amending the current regulatory framework for medical devices.&#160;&#160;Moreover, because the MDD requires only minimum harmonization in the EU, member countries may alter their enforcement of the directives or amend their national regulatory rules.&#160;&#160;We cannot predict what healthcare initiatives, if any, will be implemented by the EU or EU member countries, or the effect any future legislation or regulation will have on us.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The GlucoTrack&#174; model DF-F may not be approved for sale in the United States or other (non-CE Mark) jurisdictions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We will likely be required to undertake significant clinical trials to demonstrate to the FDA that the GlucoTrack&#174; model DF-F is either safe and effective for its intended use or is substantially equivalent in terms of safety and effectiveness to an existing, lawfully marketed non-Section 515 premarket approval device. We may also be required to undertake clinical trials by non-U.S. regulatory agencies in non-CE Mark jurisdictions. Clinical trials are expensive and uncertain processes that may take years to complete. Failure can occur at any point in the process and early positive results do not ensure that the entire clinical trial will be successful. Product candidates in clinical trials may fail to show desired efficacy and safety traits despite early promising results. A number of companies in the medical device industry have suffered significant setbacks in advanced clinical trials, even after their product candidates demonstrated promising results at earlier points.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Positive results from the limited pre-clinical trials and safety and performance clinical trial that we have conducted should not be relied upon as evidence that later-stage or large-scale clinical trials will succeed. These trials involved limited patient populations and there is no assurance that the experimental protocol or protocols, as the case may be, used in these informal trials will be methodologically similar to ones submitted to the FDA or any other regulatory body for its approval. Because of the sample size, possible variation in methodology, differences in exclusion/inclusion criteria, or differences in endpoints, the results of these pre-clinical trials may not be indicative of future results. We will likely be required to demonstrate through well-controlled clinical trials that the GlucoTrack&#174; model DF-F or future product candidates, if any, are safe and effective for their intended uses. In the event that the FDA deems GlucoTrack&#174; model DF-F to be a Class II device, which we do not believe is likely at this point, then we would be required to demonstrate that it is substantially equivalent in terms of safety and effectiveness to a device lawfully marketed either through a premarket notification or prior to May 28, 1976.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additionally, although we have received our CE Mark approval for the GlucoTrack&#174; model DF-F non-invasive glucose monitoring device, EU member countries may request or require additional performance and/or safety data from time to time, on a case-by-case basis.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Further, the GlucoTrack&#174; model DF-F or our future product candidates, if any, may not be cleared or approved, as the case may be, even if the clinical data are satisfactory and support, in our view, its or their clearance or approval. The FDA or other non-U.S. regulatory authorities may disagree with our trial design or interpretation of the clinical data. In addition, any of these regulatory authorities may change requirements for the clearance or approval of a product candidate even after reviewing and providing comment on a protocol for a pivotal clinical trial that has the potential to result in FDA approval. In addition, any of these regulatory authorities may also clear or approve a product candidate for fewer or more limited uses than we request or may grant clearance or approval contingent on the performance of costly post-marketing clinical trials. In addition, the FDA or other non-U.S. regulatory authorities may not approve the labeling claims necessary or desirable for the successful commercialization of the GlucoTrack&#174; model DF-F or our future product candidates, if any.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">28</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are highly dependent on the success of our initial product candidate, the GlucoTrack&#174; model DF-F, and cannot give any assurance that it will receive regulatory approval or clearance or be successfully commercialized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are highly dependent on the success of our initial product candidate, the GlucoTrack&#174; model DF-F. We cannot give any assurance that the FDA will permit us to clinically test the device, nor can we give any assurance that the clinical trials will be successful or that the GlucoTrack&#174; model DF-F will receive regulatory clearance or approval or be successfully commercialized, for a number of reasons, including, without limitation, the potential introduction by our competitors of more clinically-effective or cost-effective alternatives, failure in our sales and marketing efforts, or the failure to obtain positive coverage determinations or reimbursement. Any failure to obtain approval to conduct clinical trials, favorable clinical data, clearance or approval of or to successfully commercialize the GlucoTrack&#174; model DF-F would have a material adverse effect on our business.<a name="v232648_s1_htm_page15"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If our competitors develop and market products that are more effective, safer or less expensive than GlucoTrack&#174; model DF-F or our future product candidates, if any, our commercial opportunities will be adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The life sciences industry is highly competitive and we face significant competition from many medical device companies that are researching and marketing products designed to address the needs of persons suffering from diabetes. We are currently developing medical devices that will compete with other medical devices that currently exist or are being developed. Products that we may develop in the future are also likely to face competition from other medical devices and therapies. Some of our competitors have significantly greater financial, manufacturing, marketing and product development resources than we do. Large medical device companies, in particular, have extensive experience in clinical testing and in obtaining regulatory clearances or approvals for medical devices. These companies also have significantly greater research and marketing capabilities than us. Some of the medical device companies that we expect to compete with include Roche Disetronic, a division of Roche Diagnostics; LifeScan, Inc., a division of Johnson &amp; Johnson; the MediSense and TheraSense divisions of Abbott Laboratories; Bayer Corporation; Echo Therapeutics, Inc.; Grove Instruments; and Medtronic, Inc. In addition, many other universities and private and public research institutions are or may become active in research involving blood glucose measurement devices.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe that our ability to successfully compete will depend on, among other things:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">our ability to have partners manufacture and sell commercial quantities of any approved products to the market;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">acceptance of product candidates by physicians and other health care providers;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the results of our clinical trials;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">our ability to recruit and enroll patients for our clinical trials;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the efficacy, safety, performance and reliability of our product candidates;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the speed at which we develop product candidates;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">our ability to obtain prompt and favorable IRB review and approval at each of our clinical sites;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">our ability to commercialize and market any of our product candidates that may receive regulatory clearance or approval;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">our ability to design and successfully execute appropriate clinical trials;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the timing and scope of regulatory clearances or approvals;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">appropriate coverage and adequate levels of reimbursement under private and governmental health insurance plans, including Medicare; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">our ability to protect intellectual property rights related to our products.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If our competitors market products that are more effective, safer, easier to use or less expensive than GlucoTrack&#174; model DF-F or our future product candidates, if any, or that reach the market sooner than GlucoTrack&#174; model DF-F or our future product candidates, if any, we may not achieve commercial success. In addition, the medical device industry is characterized by rapid technological change. It may be difficult for us to stay abreast of the rapid changes in each technology. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete or less competitive.<a name="v232648_s1_htm_page16"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">29</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our product development activities could be delayed or stopped.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not know whether our future clinical trials will begin on time, or at all, and whether ongoing and/or future clinical trials will be completed on schedule, or at all.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The commencement of future clinical trials could be substantially delayed or prevented by several factors, including:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the failure to obtain sufficient funding to pay for all necessary clinical trials;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">limited number of, and competition for, suitable patients that meet the protocol&#8217;s inclusion criteria and do not meet any of the exclusion criteria;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">limited number of, and competition for, suitable sites to conduct the clinical trials, and delay or failure to obtain FDA approval, if necessary, to commence a clinical trial;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">delay or failure to obtain sufficient supplies of the product candidate for clinical trials;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">requirements to provide the medical device required in clinical trials at cost, which may require significant expenditures that we are unable or unwilling to make;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or investigators; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">delay or failure to obtain IRB approval or renewal of such approval to conduct a clinical trial at a prospective or accruing site, respectively.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The completion of clinical trials in connection with our application for FDA approval could also be substantially delayed or prevented by several factors, including:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">slower than expected rates of patient recruitment and enrollment;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">failure of patients to complete the clinical trial;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">unforeseen safety issues;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">lack of efficacy evidenced during clinical trials;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">termination of clinical trials by one or more clinical trial sites;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">inability or unwillingness of patients or medical investigators to follow clinical trial protocols; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">inability to monitor patients adequately during or after treatment.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB for any given site, or us. Any failure or significant delay in completing clinical trials for GlucoTrack&#174; or future product candidates, if any, could materially harm our financial results and the commercial prospects for our product candidates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The regulatory approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of GlucoTrack&#174; model DF-F or our future product candidates, if any.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of medical devices are subject to extensive regulation by the FDA and other non-U.S. regulatory authorities, which regulations differ from country to country. We are not permitted to market our product candidates in the United States until we receive a clearance letter under the 510(k) premarket notification process or approval of a Section 515 premarket approval, from the FDA, depending on the nature of the device. We have not submitted an application or premarket notification for or received marketing clearance or approval for any of our product candidates. Obtaining approval of any premarket approval can be a lengthy, expensive and uncertain process. While the FDA normally reviews and clears a premarket notification in three months, there is no guarantee that our products will qualify for this more expeditious regulatory process, which is reserved for Class I and II devices, nor is there any assurance that, even if a device is reviewed under the 510(k) premarket notification process, the FDA will review it expeditiously or determine that the device is substantially equivalent to a lawfully marketed non-premarket approval device. If the FDA fails to make this finding, then we cannot market the device. In lieu of acting on a premarket notification, the FDA may seek additional information or additional data which would further delay our ability to market the product. In addition, failure to comply with FDA, non-U.S. regulatory authorities or other applicable U.S. and non-U.S. regulatory requirements may, either before or after product clearance or approval, if any, subject us to administrative or judicially imposed sanctions, including:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">restrictions on the products, manufacturers or manufacturing process;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">30</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">adverse inspectional observations (Form 483), warning letters or non-warning letters incorporating inspectional observations, i.e., so-called &#8220;untitled letter&#8221;;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">civil and criminal penalties;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">injunctions;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">suspension or withdrawal of regulatory clearances or approvals;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">product seizures, detentions or import bans;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">voluntary or mandatory product recalls and publicity requirements;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">total or partial suspension of production;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">imposition of restrictions on operations, including costly new manufacturing requirements; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">refusal to clear or approve pending applications or premarket notifications.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Regulatory approval of a PMA or PMA supplement or clearance pursuant to a 510(k) premarket notification is not guaranteed, and the approval or clearance process, as the case may be, is expensive and may, especially in the case of the PMA, take several years. The FDA also has substantial discretion in the medical device clearance or approval processes. Despite the time and expense exerted, failure can occur at any stage and we could encounter problems that cause us to abandon clinical trials or to repeat or perform additional pre-clinical studies and clinical trials. The number of pre-clinical studies and clinical trials that will be required for FDA clearance or approval varies depending on the medical device candidate, the disease or condition that the medical device candidate is designed to address, and the regulations applicable to any particular medical device candidate. The FDA can delay, limit or deny clearance or approval of a medical device candidate for many reasons, including:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a medical device candidate may not be deemed safe or effective, in the case of a PMA;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a medical device candidate may not be deemed to be substantially equivalent to a lawfully marketed non-premarket approval device in the case of a 510(k) premarket notification;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">FDA officials may not find the data from the clinical trials sufficient;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the FDA might not approve our third-party manufacturer&#8217;s processes or facilities; or</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the FDA may change its clearance or approval policies or adopt new regulations.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Further, while we have received CE Mark approval for the GlucoTrack&#174; model DF-F, the MDD requires only minimum harmonization.&#160;&#160;In practice, uniform regulation throughout the EU is not ensured.&#160;&#160;Rather, member countries may apply and enforce the MDD&#8217;s terms differently, and certain EU member countries may request or require performance and/or safety data additional to the MDD&#8217;s requirements from time to time, on a case-by-case basis. Therefore, we cannot predict whether we will be able to successfully commercialize the GlucoTrack&#174; model DF-F or our future product candidates, if any, in the EU.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Failure to recruit and enroll patients for clinical trials may cause the development of our product candidates to be delayed.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We may encounter delays if we are unable to recruit and enroll and retain enough patients to complete clinical trials. Patient enrollment depends on many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the trial. Delays in patient enrollment are not unusual. Any such delays in planned patient enrollment may result in increased costs, which could harm our ability to develop products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The terms of clearances or approvals and ongoing regulation of our products may limit how we manufacture and market our product candidates, which could materially impair our ability to generate anticipated revenues.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Once regulatory clearance or approval has been granted, the cleared or approved product and its manufacturer are subject to continual review. Any cleared or approved product may only be promoted for its indicated uses. In addition, if the FDA or other non-U.S. regulatory authorities clear or approve GlucoTrack&#174; model DF-F or our future product candidates, if any, the labeling, packaging, adverse event reporting, storage, advertising and promotion for the product will be subject to extensive regulatory requirements. We, and the manufacturers of our products, if other than us, also will be required to comply with the FDA&#8217;s Quality System Regulation, which includes requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation. Moreover, device manufacturers are required to report adverse events by filing Medical Device Reports with the FDA, which are publicly available. Further, regulatory agencies must approve our manufacturing facilities before they can be used to manufacture products, and these facilities are subject to ongoing regulatory inspection. If we fail to comply with the regulatory requirements of the FDA and other non-U.S. regulatory authorities, or if previously unknown problems with our products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions, including:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">restrictions on the products, manufacturers or manufacturing process;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">31</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">adverse inspectional observations (Form 483), warning letters, or non-warning letters incorporating inspectional observations;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">civil or criminal penalties or fines;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">injunctions;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">product seizures, detentions or import bans;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">voluntary or mandatory product recalls and publicity requirements;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">suspension or withdrawal of regulatory clearances or approvals;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">total or partial suspension of production;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">imposition of restrictions on operations, including costly new manufacturing requirements; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">refusal to clear or approve pending applications or premarket notifications.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, the FDA and other non-U.S. regulatory authorities, including the EU and each of the EU member countries individually, may change their policies and additional regulations may be enacted that could prevent or delay regulatory clearance or approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are not able to maintain regulatory compliance, we will likely not be permitted to market future product candidates and may not achieve or sustain profitability.<a name="v232648_s1_htm_page19"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Even if we receive regulatory clearance or approval to market the GlucoTrack&#174; model DF-F or our future product candidates, if any, the market may not be receptive to our products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Even if GlucoTrack&#174; model DF-F or our future product candidates, if any, obtain regulatory clearance or approval, resulting products may not gain market acceptance among physicians, patients, health care payors or the medical community. We believe that the degree of market acceptance will depend on a number of factors, including:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">timing of market introduction of competitive products;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">safety and efficacy of our product;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">prevalence and severity of any side effects;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">potential advantages or disadvantages over alternative treatments;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">strength of marketing and distribution support;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">price of our product candidates, both in absolute terms and relative to alternative treatments; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">availability of coverage and reimbursement from government and other third-party payors.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If the GlucoTrack&#174; model DF-F or our future product candidates, if any, fail to achieve market acceptance, we may not be able to generate significant revenue or achieve or sustain profitability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The coverage and reimbursement status of newly cleared or approved medical devices is uncertain, and failure to obtain adequate coverage and adequate reimbursement could limit our ability to market GlucoTrack&#174; model DF-F or future product candidates, if any, and may inhibit our ability to generate revenue from GlucoTrack&#174; model DF-F or our future product candidates, if any, that may be cleared or approved.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There is significant uncertainty related to the third-party coverage and reimbursement of newly cleared or approved medical devices. The commercial success of GlucoTrack&#174; model DF-F or our future product candidates, if any, in both domestic and international markets will depend in part on the availability of coverage and adequate reimbursement from third-party payors, including government payors, such as the Medicare and Medicaid programs, managed care organizations and other third-party payors. Government and other third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement for new products and, as a result, they may not cover or provide adequate payment for GlucoTrack&#174; model DF-F or our future product candidates, if any. These payors may conclude that our products are not as safe or effective as existing devices or that the overall cost of using one of our devices exceeds the overall cost of the competing device, and third-party payors may not approve GlucoTrack&#174; model DF-F or our future product candidates, if any, for coverage and adequate reimbursement. Furthermore, deficit reduction and austerity measures in the United States and abroad may put further pressure on governments to limit coverage of, and reimbursement for, our products. The failure to obtain coverage and adequate reimbursement for GlucoTrack&#174; model DF-F or our future product candidates, if any, or health care cost containment initiatives that limit or restrict reimbursement for such products may reduce any future product revenue.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">32</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we fail to attract and retain key management and scientific personnel, we may be unable to successfully develop or commercialize the GlucoTrack&#174; model DF-F or our future product candidates, if any.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We will need to expand and effectively manage our managerial, operational, financial, development and other resources in order to successfully pursue our research, development and commercialization efforts for GlucoTrack&#174; model DF-F or our future product candidates, if any. Our success depends on our continued ability to attract, retain and motivate highly qualified management and pre-clinical and clinical personnel. The loss of the services of any of our senior management, particularly Avner Gal, our Chairman of the Board and Chief Executive Officer, could delay or prevent the development or commercialization of GlucoTrack&#174; model DF-F or our future product candidates, if any. At present we maintain key man insurance on Mr. Gal, but do not have key man insurance policies with respect to any of our other employees. We will need to hire additional personnel as we continue to expand our research and development activities and build a sales and marketing function. Although we currently have employment agreements with each of Messrs. Hertz, Gal and Malka, those agreements provide that they may be terminated by Mr. Hertz, Gal or Malka, as applicable, upon 60, 180 or 90 days written notice to us, respectively.<a name="v232648_s1_htm_page20"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We may not be able to attract or retain qualified management and scientific personnel in the future due to the intense competition for qualified personnel among medical device and other businesses. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our research and development objectives, our ability to raise additional capital and our ability to implement our business strategy. In particular, if we lose any members of our senior management team, we may not be able to find suitable replacements in a timely fashion or at all and our business may be harmed as a result.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">As we continue to evolve from a company primarily involved in development to a company also involved in commercialization, we may encounter difficulties in managing our growth and expanding our operations successfully.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As the GlucoTrack&#174; model DF-F has received a CE Mark, we have begun to expand our manufacturing, marketing and sales capabilities by contracting with third parties to provide these capabilities. We anticipate that, as our operations expand, we will need to manage additional relationships with such third parties. Maintaining these relationships and managing our future growth will impose significant added responsibilities on members of our management. We must be able to manage our development efforts effectively; manage our clinical trials effectively; hire, train and integrate additional management, development, administrative and sales and marketing personnel; improve managerial, development, operational and finance systems; and expand our facilities, all of which may impose a strain on our administrative and operational infrastructure.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We rely on third parties to manufacture and supply our product.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not own or operate manufacturing facilities for clinical or commercial production of the GlucoTrack&#174; model DF-F, other than a prototype lab. We have no experience in medical device manufacturing, and lack the resources and the capability to manufacture the GlucoTrack&#174; model DF-F on a commercial scale. We currently manufacture the GlucoTrack<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#174;</font> model DF-F with a third party manufacturer in Israel.&#160;&#160;In July 2014, we entered into a manufacturing agreement with Wistron.&#160;&#160;Wistron is in the process of preparing a production line for the GlucoTrack&#174; model DF-F. Wistron has produced a small pilot batch and is in the process of producing a second pilot batch of the GlucoTrack&#174; model DF-F device. Subject to satisfactory completion of a GMP (Good Manufacturing Practice) audit by the local regulatory authorities in Taiwan, we now anticipate that the production line for the GlucoTrack&#174; model DF-F will be operational during the second or third quarter of 2016.&#160;&#160;Following the completion of Wistron&#8217;s production line, we intend to utilize the services of both Wistron and the Israeli third-party manufacturer to produce the GlucoTrack&#174; model DF-F.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If our manufacturing partners are unable to produce our products in the amounts, timing or pricing that we require, we may not be able to establish a contract and obtain a sufficient alternative supply from another supplier on a timely basis and in the quantities or pricing we require. We expect to depend on third-party contract manufacturers for the foreseeable future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">33</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The GlucoTrack&#174; model DF-F does, and our future product candidates, if any, likely will require precise, high quality manufacturing. Any of our contract manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and other non-U.S. regulatory authorities to ensure strict compliance with quality system regulations, including current good manufacturing practices and other applicable government regulations and corresponding standards. If our contract manufacturers fail to achieve and maintain high manufacturing standards in compliance with quality system regulations, we may experience manufacturing errors resulting in patient injury or death, product recalls or withdrawals, delays or interruptions of production or failures in product testing or delivery, delay or prevention of filing or approval of marketing applications for our products, cost overruns or other problems that could seriously harm our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any performance failure on the part of our contract manufacturers could delay clinical development or regulatory clearance or approval of our product candidates or commercialization of our future product candidates, depriving us of potential product revenue and resulting in additional losses. In addition, our dependence on a third-party for manufacturing may adversely affect our future profit margins. Our ability to replace an existing manufacturer may be difficult because the number of potential manufacturers is limited and the FDA must approve any replacement manufacturer before it can begin manufacturing our product candidates. Such approval would require additional non-clinical testing and compliance inspections. It may be difficult or impossible for us to identify and engage a replacement manufacturer on acceptable terms in a timely manner, or at all.<a name="v232648_s1_htm_page21"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are dependent on third-party distributors to market and sell our products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have limited internal marketing, sales or distribution capabilities and currently we do not intend to develop extensive internal marketing, sales or distribution capabilities in the future.&#160;&#160;Rather, we intend to utilize third-party distributors to market our products, and have entered into exclusive distribution agreements with respect to certain territories.&#160;&#160;There is no assurance that third party distributors will achieve acceptable levels of sales or that, if any of our existing arrangements expire or terminate, we will be able to replace any distributors on terms advantageous to us, or at all. Further, there is no assurance that we will be able to expand our distribution network by adding additional distributors. If third party distributors cease to promote our products, or if we are unable to make acceptable arrangements with distributors or sales personnel in other markets, our business, prospects, operating results or financial condition could be materially adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Independent clinical investigators and contract research organizations that we engage to conduct our clinical trials may not be diligent, careful or timely.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We will depend on independent clinical investigators to conduct our clinical trials. Contract research organizations may also assist us in the collection and analysis of data. These investigators and contract research organizations will not be our employees and we will not be able to control, other than by contract, the amount of resources, including time, that they devote to products that we develop. If independent investigators fail to devote sufficient resources to the clinical trials, or if their performance is substandard, it will delay the approval or clearance and commercialization of any products that we develop. Further, the FDA requires that we comply with standards, commonly referred to as good clinical practice, for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. If our independent clinical investigators and contract research organizations fail to comply with good clinical practice, the results of our clinical trials could be called into question and the clinical development of our product candidates could be delayed. Failure of clinical investigators or contract research organizations to meet their obligations to us or comply with federal regulations could adversely affect the clinical development of our product candidates and harm our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we are unable to obtain and enforce patent protection for our products, our business could be materially harmed.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our success depends, among other things, on our ability to protect proprietary methods and technologies that we develop under the patent and other intellectual property laws of the United States and other countries, so that we can prevent others from unlawfully using our inventions and proprietary information. However, we may not hold proprietary rights to some patents required for us to commercialize proposed products. For this and other reasons, we may be unable to secure desired patent rights, thereby losing desired exclusivity. Although we do not believe that we need any licenses for the GlucoTrack&#174; model DF-F, we may need to obtain licenses in the future for other products or in certain circumstances, such as if one of our patents were declared invalid in the future. If such licenses are not available to us on acceptable terms, we will not be able to market the affected products or conduct the desired activities, unless we successfully challenge the validity, enforceability or infringement of the third-party patent or otherwise circumvent the third-party patent.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">34</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our strategy depends on our ability to rapidly identify and seek patent protection for our discoveries. The process of obtaining patent protection is expensive and time-consuming. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary.<a name="v232648_s1_htm_page22"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The issuance of a patent does not guarantee that it is valid or enforceable. Any patents we have obtained, or which we may obtain in the future, may be challenged, invalidated, unenforceable or circumvented. Moreover, the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) may commence interference proceedings involving our patents or patent applications. Any challenge to, finding of unenforceability or invalidation or circumvention of our patents or patent applications would be costly, would require significant time and attention of our management and could have a material adverse effect on our business. In addition, court decisions may introduce uncertainty in the enforceability or scope of patents owned by medical device companies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our pending patent applications may not result in issued patents. The patent position of medical device companies, including us, is generally uncertain and involves complex legal and factual considerations. The standards that the USPTO and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in medical device patents. Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any patents issued to us or to others. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Therefore, the enforceability or scope of our patents in the United States or in foreign countries cannot be predicted with certainty, and, as a result, any patents that we own may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection for our pending patent applications or those we may file in the future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We cannot assure you that any patents that will issue, that may issue or that may be licensed to us will be enforceable or valid or will not expire prior to the commercialization of our product candidates, thus allowing others to more effectively compete with us. Therefore, any patents that we own may not adequately protect our product candidates or our future products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, know-how and confidential and proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we will seek to enter into confidentiality and non-disclosure agreements with our employees, consultants and collaborators upon the commencement of their relationships with us. These agreements generally require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees also generally provide and will generally provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information. The disclosure of trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Some jurisdictions may require us to grant licenses to third parties. Such compulsory licenses could be extended to include some of our product candidates, which may limit potential revenue opportunities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, most countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may be limited to monetary relief and may be unable to enjoin infringement, which could materially diminish the value of the patent. Compulsory licensing of life-saving products is also becoming increasingly popular in developing countries, either through direct legislation or international initiatives. Such compulsory licenses could be extended to include some of our product candidates, which may limit our potential revenue opportunities.<a name="v232648_s1_htm_page23"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">35</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other entities may have or obtain patents or proprietary rights that could limit our ability to manufacture, use, sell, offer for sale or import products or impair our competitive position. In addition, to the extent that a third party develops new technology that covers our products, we may be required to obtain licenses to that technology, which licenses may not be available on commercially reasonable terms, if at all. If licenses are not available on acceptable terms, we will not be able to market the affected products or conduct the desired activities unless we successfully challenge the validity, enforceability or infringement of the third-party patent or circumvent the third-party patent, which would be costly and would require significant time and attention of our management. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing products using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our product development and commercialization efforts.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Third parties may sue us for infringing their patent rights. Likewise, we may need to resort to litigation to enforce a patent issued or licensed to us or to determine the scope and validity of proprietary rights of others. In addition, a third party may claim that we have improperly obtained or used our confidential or proprietary information. The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial, and the litigation would divert management&#8217;s efforts. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of any litigation could limit our ability to continue our operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If any parties successfully claim that our creation or use of proprietary technologies infringes upon their intellectual property rights, we might be forced to pay damages, potentially including treble damages, if we are found to have willfully infringed on such parties&#8217; patent rights. In addition to any damages we might have to pay, a court could require us to stop the infringing activity or obtain a license. Any license required under any patent may not be made available on commercially acceptable terms, if at all. In addition, such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same technology. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and products, which could limit our ability to generate revenues or achieve profitability and possibly prevent us from generating revenue sufficient to sustain operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Failure to obtain additional regulatory approvals outside the United States will prevent or limit us from marketing our product candidates abroad.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We intend to market our product candidates in non-U.S. markets. In order to market product candidates in the EU and many other non-U.S. jurisdictions, we must obtain separate regulatory approvals. In December 2012, we submitted our technical file to the Notified Body in connection with our application to obtain CE Mark approval for the GlucoTrack&#174; model DF-F non-invasive glucose monitoring device. On June 4, 2013, we received CE Mark approval for the GlucoTrack&#174; model DF-F non-invasive glucose monitoring device from the Notified Body. Receipt of the CE Mark allows us to market and sell the GlucoTrack&#174; model DF-F glucose monitoring device in EU member countries that have adopted the MDD without being subject to additional national regulations with regard to demonstration of performance and safety. The CE Mark also permits the sale in countries that have an MDD Mutual Recognition Agreement with the EU.&#160;&#160;However, member countries may apply and enforce the MDD&#8217;s terms differently, and certain EU member countries may request or require that we provide performance and/or safety data additional to the MDD&#8217;s requirements from time to time, on a case-by-case basis, in order to be cleared to market and sale the GlucoTrack&#174; model DF-F in such countries. Receipt of FDA approval does not ensure approval by regulatory authorities in countries, and approval by one or more non-U.S. regulatory authorities (including receipt of the CE Mark) does not ensure approval by regulatory authorities in other countries or by the FDA. The non-U.S. regulatory approval process may include all of the risks associated with obtaining FDA approval or clearance. We may not obtain additional non-U.S. regulatory approvals on a timely basis, if at all. We may not be able to file for additional non-U.S. regulatory approvals and may not receive necessary approvals to commercialize our product candidates in any market.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">36</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Non-U.S. governments often impose strict price controls, which may adversely affect our future profitability.<a name="v232648_s1_htm_page24"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We intend to seek approval to market GlucoTrack&#174; model DF-F and our future product candidates, if any, in both the U.S. and in non-U.S. jurisdictions. If we obtain approval in one or more non-U.S. jurisdictions, we will be subject to rules and regulations in those jurisdictions relating to our products. In some countries, particularly countries of the EU, each of which has developed its own rules and regulations, pricing may be subject to governmental control under certain circumstances. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a medical device candidate. Each of the EU member states has its own unique legal system and thus it is difficult to predict the particular requirements to which we may be subject. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available products. If reimbursement of our product candidates is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our business may become subject to economic, political, regulatory and other risks associated with international operations, which could harm our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our business is subject to risks associated with conducting business internationally. Accordingly, our future results could be harmed by a variety of factors, including:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">difficulties in compliance with non-U.S. laws and regulations;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">changes in non-U.S. regulations and customs;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">changes in non-U.S. currency exchange rates and currency controls;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">changes in a specific country&#8217;s or region&#8217;s political or economic environment;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">negative consequences from changes in tax laws; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">difficulties associated with staffing and managing foreign operations, including differing labor relations.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conditions in Israel may harm our ability to produce and sell our products and may adversely affect our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our principal executive offices and research and development facilities, as well as some of our suppliers, are located in Israel. Political, economic and military conditions in Israel directly affect our operations. Specifically, we could be materially adversely affected by:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">any major hostilities involving Israel;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a full or partial mobilization of the reserve forces of the Israeli army;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the interruption or curtailment of trade between Israel and its present trading partners; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a significant downturn in the economic or financial conditions in Israel.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighbors. A state of hostility, varying in degree and intensity, has led to security and economic problems for Israel. <a name="v232648_s1_htm_page25"><!--EFPlaceholder--></a>Despite the progress towards peace between Israel and its neighbors, the future of these peace efforts remains uncertain. Since October 2000, there has been a substantial deterioration in the relationship between Israel and the Palestinian Authority and a significant increase in violence, civil unrest and hostility, including armed clashes between the State of Israel and Palestinian militants, and acts of terror have been committed inside Israel and against Israeli targets in the West Bank and Gaza Strip. During the summer of 2006 and the fall of 2012, Israel was engaged in an armed conflict with Hezbollah, a Lebanese Islamist Shiite militia group and political party. In December 2008, January 2009, November 2012 and July 2014, there were escalations in violence between Israel, on the one hand, and Hamas, the Palestinian Authority and/or other groups, on the other hand, as well as extensive hostilities along Israel&#8217;s border with the Gaza Strip, which resulted in missiles being fired from the Gaza Strip into Southern and central Israel, including near Tel Aviv and at areas surrounding Jerusalem. These conflicts involved missile strikes against civilian targets in various parts of Israel, including areas in which our employees and some of our consultants are located, and negatively affected business conditions in Israel. Our offices are located in Ashkelon, Israel, which is within the range of the missiles and rockets that have been fired at Israeli cities and towns from Gaza sporadically since 2006, with escalations in violence (such as the recent escalation in July 2014) during which there were a substantially larger number of rocket and missile attacks aimed at Israel. Since December 2010, there has been a wave of protests and civil resistance demonstrations in several countries in the Middle East and North Africa, including Egypt and Syria, which share a border with Israel. The demonstrations and acts of civil resistance in Egypt led to the resignation of the former Egyptian president Hosni Mubarak and to extensive revisions in the Egyptian governmental structure. The demonstrations and acts of civil resistance in Syria have led to an extended period of violence and political instability in Syria. It is not clear how this revolutionary wave, also known as the Arab Spring, will develop and how it will affect the political and security situation in the Middle East. It is also not clear how it will affect Israel and its relationship with its neighbors. Presently, there is great international concern in connection with Iran&#8217;s efforts to develop and enrich uranium which could lead to the development of nuclear weapons. Iran&#8217;s successful enrichment of uranium could significantly alter the geopolitical landscape in the Middle East, including the threat of international war, which could significantly impact business conditions in Israel. Any on-going or future violence between Israel and the Palestinians, armed conflicts, terrorist activities, tension along the Israeli borders or with other countries in the region, including Iran, or political instability in the region could disrupt international trading activities in Israel and may materially and negatively affect our business and results of operations and could make it more difficult for us to raise capital. Parties with whom we do business may decline to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary in order to meet our business partners face to face. In addition, the political and security situation in Israel may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions in such agreements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">37</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, Israel&#8217;s economy has been subject to numerous destabilizing factors, including a period of rampant inflation in the early to middle 1980s, low foreign exchange reserves, fluctuations in world commodity prices, military conflicts and civil unrest. Furthermore, several countries restrict business with Israel and Israeli companies, which may limit our ability to make sales in those countries. These restrictions, continuing or escalating hostilities in the region or curtailment of trade between Israel and its present trading partners may have an adverse effect on our operating results and financial condition, including our ability to develop, manufacture and market our products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our operations could be disrupted as a result of the obligations of key personnel to perform Israeli military service.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Some of our employees in Israel are obligated to perform up to 40 days, depending on rank and position, of military reserve duty annually and are subject to being called for active duty under emergency circumstances. Moreover, in light of escalating hostilities and threats of armed conflict in the Middle East since October 2000, our executive officers and employees may be called for active military duty for an unlimited period of time. Increased military activity could also result in a reduction of prospective qualified employees available to work for us to increase our business or replace employees on active military duty. Our operations could be disrupted by the absence for a significant period of our executive officers or key employees as a result of military service. Any disruption in our operations could adversely affect our ability to develop and market products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">It may be difficult to enforce a United States judgment against us or our officers and directors to the extent they are located in Israel based upon asserted United States securities law claims.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All of our executive officers and two of our directors are non-residents of the United States and a substantial portion of our assets and the assets of these persons will be located outside of the United States. Therefore, it may be difficult for an investor, or any other person or entity, to enforce a United States court judgment, including a judgment based upon the civil liability provisions of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), in original actions instituted in an Israeli court against any of these persons. Furthermore, service of process upon these persons may be difficult to obtain within the United States.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">38</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may not be able to enforce covenants not-to-compete under current Israeli law, which might result in added competition for our products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have non-competition agreements or provisions with all of our employees and executive officers, all of which are governed by Israeli law. These agreements or provisions prohibit our employees from competing with us or working for our competitors, generally during, and for up to nine months after termination of, their employment with us. However, Israeli courts are reluctant to enforce non-compete undertakings of former employees and tend, if at all, to enforce those provisions for only relatively brief periods of time or in restricted geographical areas. In addition, Israeli courts typically require the presence of additional circumstances, such as a demonstration of an employer&#8217;s legitimate interest which was damaged; breach of fiduciary duties, loyalty and acting not in good faith; a payment of a special consideration for employee&#8217;s non-compete obligation; material concern for disclosing employer's trade secrets; or a demonstration that an employee has unique value to the employer specific to that employer&#8217;s business, before enforcing a non-competition undertaking against such employee.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The funding that we received through the Office of the Chief Scientist (the &#8220;OCS&#8221;) for research and development activities restricts our ability to manufacture products or to transfer technology outside of Israel.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 4, 2004, the OCS agreed to provide us with a grant of 420,000 New Israeli Shekels (&#8220;NIS&#8221;), or approximately $93,300 at an exchange rate of 4.502 NIS/dollar (the exchange rate in effect on such date), for our plan to develop a non-invasive blood glucose monitor (the &#8220;development plan&#8221;). This grant constituted 60% of our research and development budget for the development plan at that time. Due to our acceptance of this grant, we are subject to the provisions of the Israeli Law for the Encouragement of Industrial Research and Development, 1984 (the &#8220;R&amp;D Law&#8221;). Among other things, the R&amp;D Law restricts our ability to sell or transfer rights in technology or know-how developed with OCS funding or transfer any Means of Control (as defined in the R&amp;D Law) of us to non-Israeli entities. The Industrial Research and Development Committee at the OCS (the &#8220;research committee&#8221;) may, under special circumstances, approve the transfer outside of Israel of rights in technology or know-how developed with OCS funding subject to certain conditions, including the condition that certain payments be made to the OCS. Additionally, we may not manufacture products developed with OCS funding outside of Israel without the approval of the research committee. The restrictions regarding the sale or transfer of technology or manufacturing rights out of Israel could have a material adverse effect on our ability to enter into strategic alliances or enter into merger or acquisition transactions in the future that provide for the sale or transfer of our technology or manufacturing rights.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we are successful in bringing the GlucoTrack&#174; model DF-F to market, we will be required to use a portion of our net sales to repay certain loans and to pay royalties to the OCS, which will have a negative impact on our profitability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Integrity Israel is required to pay royalties to the OCS on the proceeds from the sale of our systems resulting from research and development projects for which the OCS provided a grant. During the first three years of sales, we will be required to pay royalties of 3% of the sales of such products. In the fourth, fifth and sixth years of sales, we will be required to pay royalties of 4% of such sales and from the seventh year on we will be required to pay royalties of 5% of such sales, in all cases, up to 100% of the amount of grants received by us from the OCS plus interest at the London Interbank Offered Rate (&#8220;LIBOR&#8221;). We do not have any other future performance obligations related to the OCS grants. As of December 31, 2015, the contingent liabilities with respect to OCS grants subject to repayment under these royalty agreements equaled $83,341, not including interest.<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#160;</font>To the extent that we are required to pay royalties to the OCS, such payments will increase our expenses for the year(s) in which such payment(s) are accrued, and, as a result, will reduce our profits (or increase our losses, as applicable) for such periods. Payments made to the OCS in lieu of royalties and repayment of the loans described above will reduce our free cash-flow and our cash balance for the year(s) in which such payment(s) are made.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Messrs. Avner Gal and Zvi Cohen collectively loaned us NIS 176,000 ($45,105 based on the exchange rate of 3.902 NIS/dollar as of December 31, 2015) in May 2002 pursuant to an oral agreement (the &#8220;Gal/Cohen Loan&#8221;). Messrs. Nir Tarlovsky, Yitzhak Fisher and Asher Kugler loaned us NIS 336,300 ($86,187 based on the same exchange rate) on March 16, 2004 (the &#8220;Tarlovsky/Fisher/Kugler Loan&#8221;). These loans are not required to be repaid until the first year in which we realize profits in our statement of operations. At such time, the loans are to be repaid on a quarterly basis in an amount equal to 10% of our total sales after deduction of VAT in the relevant quarter, beginning the quarter following the first year in which we realize profits in our annual statement of operations. The total amount to be repaid by us to each lender shall be an amount equal to the aggregate principal amount loaned by such lender to us, plus an amount equal to the product of the amount of each payment made by us in respect of such loan multiplied by the percentage difference between the Israeli Consumer Price Index on the date on which the loan was made and the Israeli Consumer Price Index on the date of such payment. However, notwithstanding the abovementioned mechanism, we will not be required to repay the loans during any time when such repayment would cause a deficit in our working capital. &#160;The Israeli Consumer Price Index was 177.6386, and 178.5793, respectively, as of the dates of the Gal/Cohen Loan and the Tarlovsky/Fisher/Kugler Loan. The Israeli Consumer Price Index as of December 31, 2015 was 222.3267. Our board of directors is entitled to modify the repayment terms of these loans, so long as such modification does not discriminate against any particular lender, and provided that all payments must be allocated among the lenders on a pro-rata basis.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">39</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are subject to certain employee severance obligations, which may result in an increase in our expenditures.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under Israeli law, employers are required to make severance payments to dismissed employees and employees leaving employment in certain other circumstances, on the basis of the latest monthly salary for each year of service. This obligation results in an increase in our expenses, including accrued expenses. Integrity Israel currently makes monthly deposits to insurance policies and severance pay funds in order to provide for this liability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s and its Israeli subsidiary&#8217;s agreements with certain of their Israeli employees are in accordance with Section 14 of the Israeli Severance Pay Law -1963 (&#8220;Section 14&#8221;). Payments in accordance with Section 14 release the Company from any other future severance payments in respect of those employees. Deposits under Section 14 are not recorded as an asset in the Company&#8217;s balance sheet.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">There is a limited trading market for our common stock, which may make it difficult for our stockholders to sell their shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Although our stock is quoted on the OTCQB, few trades in our stock have taken place, to-date, and an active trading market in our securities may not develop, or if developed, may not be sustained. If no active market is ever developed for our common stock, it will be difficult for you to sell any shares you purchase in our Company. In such a case, you may find that you are unable to achieve any benefit from your investment or liquidate your shares without considerable delay, if at all.&#160;&#160;In the absence of an active public trading market, an investor may be unable to liquidate an investment in our common stock. As a result, investors: (i) may be precluded from transferring their shares of common stock; (ii) may have to hold their shares of common stock for an indefinite period of time; and (iii) must be able to bear the complete economic risk of losing their investment in us. In the event a market should develop for the common stock, there can be no assurance that the market price will equal or exceed the price paid for such share by any of our stockholders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The market price of our common stock may fluctuate significantly.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The market price of the common stock may fluctuate significantly in response to numerous factors, some of which are beyond our control, such as:<a name="v232648_s1_htm_page27"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the announcement of new products or product enhancements by us or our competitors;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">developments concerning intellectual property rights and regulatory approvals;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">variations in our and our competitors&#8217; results of operations;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">changes in earnings estimates or recommendations by securities analysts, if the common stock is covered by analysts;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">developments in the medical device industry;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the results of product liability or intellectual property lawsuits;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">future issuances of common stock or other securities;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the addition or departure of key personnel;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">announcements by us or our competitors of acquisitions, investments or strategic alliances; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">general market conditions and other factors, including factors unrelated to our operating performance.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Further, in recent years, the stock market in general, and the market for medical device companies in particular, have experienced extreme price and volume fluctuations. Continued or renewed market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of the common stock. Price volatility of our common stock might be significant if the trading volume of the common stock is low, which often occurs with respect to newly traded securities on the OTCQB.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">40</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Future sales of common stock could reduce our stock price.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March 30, 2016, we had 5,690,097 shares of common stock outstanding. In addition, the shares of Preferred Stock, Warrants and employees&#8217; stock options outstanding on such date were convertible into, or exercisable for, an aggregate of 9,433,505 shares of common stock. Pursuant to the registration rights agreement we entered into with certain of our stockholders who participated in the private placement of units of the Company consisting of our Series A Preferred Stock and Warrants to purchase shares of Common Stock and the placement agent agreement entered into with Andrew Garrett, Inc., we have filed a registration statement registering for resale an aggregate of 2,824,471 shares of common stock underlying the Series A Preferred Stock and related Warrants and the placement agent Warrants issued in respect thereof. Pursuant to the registration rights agreement entered into in connection with our sale of the Series B Units, on March 31, 2015 we filed a Registration Statement on Form S-1 registering the resale of an aggregate of 4,836,408 shares of Common Stock underlying the Series B Units and related Warrants and the placement agent Warrants issued in respect thereof.&#160;&#160;In addition, the shares of Common Stock sold by us in a previous private placement consummated in the period from December 16, 2010 through July 29, 2011 may be eligible for resale without registration in accordance with one or more exceptions under the Securities Act. Sales by stockholders of substantial amounts of shares of Common Stock (pursuant to the registration statement described in the preceding sentence or pursuant to an exemption from registration), the issuance of new shares of Common Stock (or securities convertible into or exercisable for shares of our common stock) by us or the perception that these sales may occur in the future, could materially and adversely affect the market price of the Common Stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because our common stock may be a &#8220;penny stock,&#8221; it may be more difficult for investors to sell shares of the common stock, and the market price of the common stock may be adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our common stock may be a penny stock if, among other things, the stock price is below $5.00 per share, it is not listed on a national securities exchange or approved for quotation on the Nasdaq Stock Market or any other national securities exchange or it has not met certain net tangible asset or average revenue requirements. Broker-dealers who sell penny stocks must provide purchasers of these stocks with a standardized risk-disclosure document prepared by the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;).&#160;&#160;This document provides information about penny stocks and the nature and level of risks involved in investing in the penny-stock market. A broker must also give a purchaser, orally or in writing, bid and offer quotations and information regarding broker and salesperson compensation, make a written determination that the penny stock is a suitable investment for the purchaser and obtain the purchaser&#8217;s written agreement to the purchase. Broker-dealers must also provide customers that hold penny stock in their accounts with such broker-dealer a monthly statement containing price and market information relating to the penny stock. If a penny stock is sold to an investor in violation of the penny stock rules, the investor may be able to cancel its purchase and get its money back.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If applicable, the penny stock rules may make it difficult for investors to sell their shares of common stock. Because of the rules and restrictions applicable to a penny stock, there is less trading in penny stocks and the market price of the common stock may be adversely affected. Also, many brokers choose not to participate in penny stock transactions. Accordingly, investors may not always be able to resell their shares of common stock publicly at times and prices that they feel are appropriate.<a name="v232648_s1_htm_page28"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Compliance with changing regulations concerning corporate governance and public disclosure may result in additional expenses.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There have been changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002, new regulations promulgated by the SEC and rules promulgated by the national securities exchanges. These new or changed laws, regulations and standards are subject to varying interpretations in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. As a result, our efforts to comply with evolving laws, regulations and standards are likely to continue to result in increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities. Our directors, Chief Executive Officer and Chief Financial Officer could face an increased risk of personal liability in connection with the performance of their duties. As a result, we may have difficulty attracting and retaining qualified directors and executive officers, which could harm our business. If our efforts to comply with new or changed laws, regulations and standards differ from the activities intended by regulatory or governing bodies, we could be subject to liability under applicable laws or our reputation may be harmed.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">41</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because a certain portion of our expenses is incurred in currencies other than the NIS, our results of operations may be harmed by currency fluctuations and inflation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The functional currency of Integrity Israel is the NIS, and we pay a substantial portion of our expenses in NIS. However, we expect a portion of our future revenues to be denominated in U.S. dollars or in Euros. As a result, we will be exposed to the currency fluctuation risks relating to the recording of our revenues in NIS. For example, if the NIS strengthens against either the U.S. dollar or the Euro, our reported expenses in NIS may be higher than anticipated. The Israeli rate of inflation has not offset or compounded the effects caused by fluctuations between the NIS and the U.S. dollar or the Euro. To date, we have not engaged in hedging transactions. Although the Israeli rate of inflation has not had a material adverse effect on our financial condition to date, we may, in the future, decide to enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of the currencies mentioned above in relation to the NIS. These measures, however, may not adequately protect us from material adverse effects.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The adoption of the &#8220;Conflict Minerals&#8221; regulations may adversely affect the manufacturing of our current and future products</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Recent regulatory requirements regarding the use of &#8220;conflict minerals&#8221; could affect the sourcing and availability of the raw materials used by our third party manufacturers. We may be subject to costs associated with the new regulations, including for the diligence pertaining to the presence of any conflict minerals used in our products and the cost of remediation and other changes to products, processes, or sources of supply as a consequence of such verification activities. The impact of the regulations may result in a limited pool of suppliers who provide conflict free minerals, and we cannot assure that we will be able to obtain products in sufficient quantities or at competitive prices. We may face reputational challenges with our customers and other stakeholders if we are unable to sufficiently verify the origins for the metals used in the products we sell. As a result, we may not be able to obtain the materials necessary to manufacture our products, which could force us to cease production or search for alternative supply sources, possibly at a higher cost. Such disruptions may have a material adverse effect on our business, financial condition, results of operations and cash flows.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item1BUnresolvedStaffComments">Item 1B. Unresolved Staff Comments</a>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Not applicable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item2">Item 2</a>. Properties.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Until mid-December 2015, Integrity Israel leased approximately 3,100 square feet of office space in the city of Ashkelon, Israel as its principal offices and prototype laboratory.&#160;&#160;Pursuant to a verbal agreement with the landlord, Integrity Israel leased this facility on a monthly basis at a cost of approximately $2,934 (NIS 11,500). Currently, Integrity Israel leases approximately 5,500 square feet of office space in the city of Ashdod, Israel for its principal offices.&#160;&#160;The lease term began on December&#160;1, 2015 for a period of 5 years which can be extended for an additional 5 years at the option of the Company. Monthly lease payments including maintenance are approximately $10,000. The Company estimates that its minimal rent and maintenance payments will be approximately $120,000 per year over each of the next 5 years. In connection with the lease agreement, Integrity Israel provided the landlord a bank guarantee in the amount of approximately $35,000 (NIS&#160;137,162) that can be exercised by the landlord in the case Integrity Israel fails to pay the monthly rent payments.&#160;&#160;The guarantee is renewed on an annual basis for a period of 5 years and is secured by funds on deposit with the bank, which generally must be sufficient to cover the principal amount guarantee.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item3">Item 3</a>. Legal Proceedings.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are not presently a party to any material litigation. We may, however, become involved in litigation from time to time relating to claims arising in the ordinary course of our business. These claims, even if not meritorious, could result in the expenditure of significant financial and managerial resources.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item4">Item 4</a>. Mine Safety Disclosures.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Not applicable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">42</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="PARTII">PART II</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item5">Item 5</a>. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Trading Market</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our stock is quoted on the OTCQB under the symbol &#8220;IGAP.&#8221;&#160;&#160;Although our common stock is traded on the OTCQB, there is no established public trading market for our common stock due to limited and sporadic quotations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table sets forth, for each quarter during the period commencing January 1, 2014 and ending on December 31, 2015, the reported high and low bid prices of our Common Stock on the OTCQB.&#160;&#160;The bid information was obtained from the OTC Markets, Inc. and reflects prices between dealers, without retail mark-up, markdown or commission, and may not represent actual transactions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div align="center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Quarter Ended</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">High Bid</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Low Bid</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31, 2015</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.83</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.25</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">September 30, 2015</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.75</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.00</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">June 30, 2015</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.50</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.25</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 31, 2015</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.25</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.90</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31, 2014</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.45</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.00</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">September 30, 2014</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.95</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.00</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">June 30, 2014</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.40</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.00</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 31, 2014</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.90</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.05</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Holders</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March 30, 2016, there were&#160;265 holders of record of our Common Stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Dividends</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have never declared or paid any cash dividends on our Common Stock and do not anticipate paying any dividends on our Common Stock in the foreseeable future. Any cash that might be available for payment of dividends will be used to expand our business. Payments of any cash dividends in the future will depend on our financial condition, results of operation and capital requirements, as well as other factors deemed relevant to our board of directors. Furthermore, pursuant to the certificate of designations, preferences and rights governing the Series B Preferred Stock (the &#8220;Series B Certificate of Designations&#8221;), as long as any shares of Series B Preferred Stock are outstanding, without the written consent of the holders of a majority in stated value of the then outstanding Series B Preferred Stock, we will not be permitted to, among other things, pay dividends on or otherwise make distributions in respect of any shares of our Common Stock or other securities junior to the Series B Preferred Stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the Series A Certificate of Designations, the holders of Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, based on the stated value per share of Series A Preferred Stock, which was initially $1,000 per share. Dividends on the Series A Preferred Stock are payable quarterly on March 31, June 30, September 30 and December 31 of each year, and on each conversion date (with respect to the shares of Series A Preferred Stock being converted). For the year ending December 31, 2015, we paid an amount of $57,061 in cash dividends to holders of Series A Preferred Stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the Series B Certificate of Designations, the holders of Series B Preferred Stock are entitled to receive cumulative dividends at a rate of 5.5% per annum, based on the stated value per share of Series B Preferred Stock, which was initially $1,000 per share. Dividends on the Series B Preferred Stock are payable quarterly on March 31, June 30, September 30 and December 31 of each year, and on each conversion date (with respect to the shares of Series B Preferred Stock being converted). For the year ending December 31, 2015, we distributed a total of 168,926 shares of Common Stock at an estimated fair value of $390,219 as stock dividends to holders of Series B Preferred Stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">43</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item6">Item 6</a>. Selected Financial Data</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Not required for smaller reporting companies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item7">Item 7</a>. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Prospective investors should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes </font>and<font style="FONT-STYLE: italic; DISPLAY: inline"> other financial information included elsewhere in this report. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should review the &#8220;Risk Factors&#8221; section of this report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Overview</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Integrity Israel was founded in 2001 with a mission to develop, produce and market non-invasive glucose monitors for home use by diabetics. We have developed a non-invasive blood glucose monitor, the GlucoTrack&#174; model DF-F glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The GlucoTrack&#174; model DF-F utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain blood glucose measurements in less than one minute via a small sensor that is clipped onto one&#8217;s earlobe and connected to a small, handheld control and display unit, all without drawing blood.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On June 4, 2013, we received initial CE Mark approval for the GlucoTrack&#174; model DF-F non-invasive glucose monitoring device from DEKRA Certification B.V., our European notified body (the &#8220;Notified Body&#8221;). In March 2014 we received CE Mark approval for six months calibration validity of the same device. Receipt of the CE Mark allows us to market and sell the GlucoTrack&#174; model DF-F glucose monitoring device in European Union (&#8220;EU&#8221;) member countries that have adopted the European Medical Device Directive (the &#8220;MDD&#8221;) without being subject to additional national regulations with regard to demonstration of performance and safety. However, although the MDD is applicable throughout the EU, in practice it does not ensure uniform regulation throughout the EU.&#160;&#160;Accordingly, member countries may apply and enforce the MDD&#8217;s terms differently, and certain EU member countries may request or require performance and/or safety data additional to the MDD&#8217;s requirements from time to time, on a case-by-case basis. The CE Mark also permits the sale in countries that have an MDD Mutual Recognition Agreement with the EU.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 31, 2015, we received approval from the Notified Body for improvements to the GlucoTrack&#174; model DF-F which simplify and shorten (from approximately 2.5 hours to approximately half an hour) the initial calibration process for the device. These improvements are intended to reduce the backlog created as purchasers of the device await calibration. In addition, we received approval from the Notified Body on the updated intended use for the device, which expands the intended user population to include not only Type 2 diabetics, but persons suffering from pre-diabetes conditions as well, which we believe represents a material expansion of the potential market for the device. In December 2015, we received approval from the Notified Body for further improvements to the GlucoTrack&#174; model DF-F that increase the accuracy and efficacy of the device.&#160;&#160;On February 19, 2016, we received an extension of our ISO 13485:2003 certificate and Annex II certification from the EU. The ISO 13485:2003 certification signifies that we have met the standards required for company-wide implementation of device quality management system(s). The scope of the certification is design, development, manufacture and service of non-invasive glucose monitoring systems for home use. Annex II also addresses quality control systems. The certification allows us to self-certify certain modifications and changes and simplifies some of the reporting to and review by the relevant Notified Body. This can shorten CE-mark review process of future GlucoTrack&#174; model DF-F enhancements or revisions. Without an Annex II certification, each new device enhancement or modified version would be subject to the full EU CE-mark review process. The ISO 13485:2003 and Annex II certifications enable us to potentially improve the time to market for product sales on new, enhanced or modified GlucoTrack&#174; model DF-F devices.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">44</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Given the improvements to the device that were submitted for approval in the second half of 2015 and approved in August and December 2015, we postponed sales of the GlucoTrack&#174; model DF-F in the second half of 2015.&#160;&#160;We held an international distributors&#8217; conference in October 2015 in which, among other things, we educated our international distributors as to the improvements to the device and our expectation to begin taking orders for the improved device in the first quarter of 2016.&#160;&#160;In the first quarter of 2016, after introducing the improved version of GlucoTrack&#174; model DF-F, we received orders totaling approximately $300,000, of which over $100,000 has been paid. We also received orders, totaling approximately $1.75 million, that are contingent on the receipt of local regulatory approval to market the GlucoTrack&#174; model DF-F in certain countries; however, we cannot guarantee that these orders will be fulfilled, due to the pending application process and we have not received any payments towards these orders.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition to the improvements to the GlucoTrack&#174; model DF-F described above, we have also continued to work on additional improvements to the device and the development of new devices and, subject to our raising sufficient funds to do so, intend to continue these efforts in 2016.&#160;&#160;Specifically, we are developing a wireless communication module (WLM) which will be hooked to the GlucoTrack&#174; model DF-F and will allow the device to communicate with other electronic devices (e.g., clinician devices, etc.) using the cloud.&#160;&#160;We also started to design the next generation of GlucoTrack&#174; model DF-F, as well as a simple model, DF-B, for sale in developing countries.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Going Concern</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have not yet generated material revenues from our operations and as of December 31, 2015, have incurred an accumulated deficit of $29,376,515, stockholder&#8217;s deficit of $6,970,914 and negative operating cash flows. We currently have no material sources of recurring revenue and therefor are dependent upon external sources for financing our operations. There can be no assurance that we will succeed in obtaining the necessary financing to continue our operations. As a result, our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Corporate Developments</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Resolution of Dimri Arbitration</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 11, 2015, the arbitrator in the previously disclosed arbitration proceeding among Integrity Israel, Avner Gal, David Malka, Zvi Cohen, Ilana Freger and Alexander Raykhman, as defendants, and Dimri, as plaintiff, issued the Arbitration Decision.&#160;&#160;Pursuant to the terms of the Arbitration Decision, (1) Avner Gal, David Malka, Zvi Cohen, Ilana Freger and Alexander Raykhman transferred to Dimri, on March 18, 2015, an aggregate of 440,652 shares of the Company&#8217;s outstanding Common Stock held collectively by such shareholders, (2) Integrity Israel (A) paid to Dimri on March 23, 2015, NIS 1,767,674 ($439,939 based on the exchange rate of 4.018 NIS:$1 as of March 23, 2015), as repayment in full of the outstanding principal amount under the Investment Agreement, as adjusted for changes in the Israeli consumer price index since the date on which the loan was made, and (B) paid to Dimri on April 30, 2015, NIS 316,100 ($81,870 based on the exchange rate of 3.861 NIS:$1 as of April 30, 2015), as partial reimbursement of Dimri&#8217;s attorney&#8217;s fees in the arbitration. The Company accrued for the fee reimbursement obligation as part of professional fees within selling, marketing and general and administrative expenses included in its results of operations for the fiscal year ended December 31, 2014. As of December 31, 2015 such amount was fully paid.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Following the completion of the abovementioned transfers and payments, pursuant to the Arbitration Decision, Integrity Israel, the Company and the other defendants in the arbitration were released from any legal claim by Yigal Dimri, the principal shareholder of Dimri, and any other companies under his control in respect of the subject matter of the arbitration, including the shareholder loan granted under and any claim of anti-dilution rights under the Investment Agreement, and Mr. Dimri and all companies under his control were released from any legal claim by Integrity Israel, the Company and the other defendants in the arbitration in respect of the subject matter of the arbitration.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exchange of Series A Unit for Series B Units</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As more fully described in Note 10 to the Company's financial statements included in this Annual Report on Form 10-K, on March 13, 2013, the Company entered into the Series A Purchase Agreement with the Series A Unit Purchasers pursuant to which the Company issued to the Series A Unit Purchasers an aggregate of 6,300 Series A Units,<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">&#160;</font>at a price of $1,000 per unit, each consisting of (i) one share of Series A Preferred Stock, convertible into shares of Common Stock at an initial conversion price of $5.80 per share, and (b) a Series A Warrant.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">45</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The issuance and sale of the Series A Units constituted the second and final closing of an offering under the terms of the Series A Purchase Agreement. On November 19, 2012, the Company completed the First Closing, pursuant to which the Company issued and sold an aggregate of 165,057 shares of Common Stock at a price of $7.00 per share to First Closing Purchasers. As a result of the conversion of the offering from an offering of Common Stock to an offering of Series A Units, the Company agreed with the Placement Agent that, following the closing of the sale of the Series A Units, the Company would exchange the shares of Common Stock acquired by each First Closing Purchaser in the First Closing for such number of Series A Units equal to the aggregate purchase price paid by such First Closing Purchaser in the First Closing, divided by $1,000, in each case subject to the execution by the First Closing Purchasers of a consent to such modification. Pursuant to this agreement, on May 13, 2013, the Company cancelled 162,907 of the 165,057 shares of Common Stock issued to the First Closing Purchasers and issued to such First Closing Purchasers an aggregate of 1,140.35 Series A Units. Such Series A Units include Series A Preferred Stock convertible into an aggregate of 196,597 shares of Common Stock at a conversion price of $5.80 per share and Series A Warrants exercisable for 196,597 shares of Common Stock at an exercise price of $6.96 per share.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on the terms the Purchase Agreement, so long as any initial Series A Unit Purchaser holds any shares of Series A Preferred Stock, if (1) the Company sells any shares of Common Stock or other securities convertible into, or rights to acquire, Common Stock and (2) a Series A Unit Purchaser then holding Series A Preferred Stock, Series A Warrants, conversion shares or warrant shares reasonably believes that any of the terms and conditions appurtenant to such issuance or sale are more favorable to the purchaser in such subsequent sale of securities than are the terms and conditions granted to such Series A Unit Purchaser, then the Series A Unit Purchaser will be permitted to require the Company to amend the terms of the Series A Unit Sale transaction (only with respect to such Series A Unit Purchaser) so as to match the terms of the subsequent issuance (including, for the avoidance of doubt, any terms and provisions that are or may be less favorable to such Purchaser).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Between August and December of 2014, we received aggregate net proceeds of approximately $7.3 million (net of related cash expenses) from the issuance and sale in a private placement transaction, at a price of $1,000 per unit, of 8,500 Series B Units, each consisting of (a) one share of Series B Preferred Stock, convertible into shares of our common stock, par value $0.001 per share, at an initial conversion price of $5.80 per share, (b) a Series B-1 Warrant and (c) a Series B-2 Warrant.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the Series A Purchase Agreement, the Company was required to and did notify the holders of the Series A Preferred Stock of the closing of the sale of the Series B Units, and following receipt thereof such holders of Series A Preferred Stock were entitled, pursuant to the &#8220;most favored nation&#8221; provisions contained in the Purchase Agreement (as described above), to elect to amend the terms of their purchase of Series A Units to match the terms of the Series B Units. The Company was obligated to amend the terms of any Series A Units held by a Series A Purchaser who timely made such election and tendered its Series A Units for exchange.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December 31, 2015, the holders of approximately 6,931 Series A Units have elected, pursuant to the &#8220;most favored nation&#8221; provision in the Series A Purchase Agreement, to amend the terms of their Series A Units to match the terms of the Series B Units. Accordingly, the Company has exchange 6,931 share of Series A Preferred Stock into 6,931 shares of Series B Stock and 1,440,880 Series A Warrants into 1,200,710 Series B-1 Warrants and 1,200,710 Series B-2 Warrants. Due to the differences in the contractual terms of each of the financial instruments exchanged management determined that the exchange constitutes an extinguishment of the existing instruments and an issuance of new financial instruments. As a result of the exchange elections, the Company recorded during the year ended December 31, 2015 a non-cash loss on extinguishment of Series A Preferred Stock and Series A Warrants in the amount of $1,284,354, resulting from the differences between the fair market value estimate of the new Series B Units less the net book value of the exchanged Series A Preferred Stock and less the fair value of the exchanged Warrants with down-round protection.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">46</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Policies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations discuss our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events, and apply judgments that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends and other factors that management believes to be relevant at the time our consolidated financial statements are prepared. On a regular basis, management reviews the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with U.S. GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material. As applicable to the consolidated financial statements included elsewhere in this report, the most significant estimates and assumptions relate to (a) the fair value estimate of the warrants with down-round protection, (b) the fair value measurement of the Series B Units and the estimate of the loss arising from the partial extinguishment of the Series A Units and the exchange thereof for Series B Units, and (c) the going concern assumptions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our significant accounting policies are discussed in Note 2, Summary of Significant Accounting Policies, of the Notes to Consolidated Financial Statements included elsewhere in this report. Our management believes that, as for the financial statements for the periods included in this report, the going concern assessment is a critical accounting policy. However, due to the early stage of operations of the Company, there are no other accounting policies that are considered to be critical accounting policies by management.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Going Concern Uncertainty</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The development and commercialization of our product will require substantial expenditures. We have not yet generated any material revenues and have incurred substantial accumulated deficit and negative operating cash flows. We currently have no sources of recurring revenue and are therefore dependent upon external sources for financing our operations. There can be no assurance that we will succeed in obtaining the necessary financing to continue our operations. As a result, our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recently Issued Accounting Pronouncements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accounting Standard Update 2014-09, &#8220;Revenue from Contracts with Customers&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In May 2014, the FASB issued Accounting Standard Update 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09").</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In accordance with a recent amendment to ASU 2014-09, introduced by Accounting Standards Update 2015-11, "Revenue from Contracts with Customers - Deferral of the Effective Date", for a public entity, the amendments in ASU 2014-09 are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period (the first quarter of fiscal year 2018 for the Company). Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is in the process of assessing the impact, if any, of ASU 2014-09 on its consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">47</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">2.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accounting Standards Update 2014-15, &#8220;Presentation of Financial Statements&#8212;Going Concern&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial Statements&#8212;Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern ("ASU 2014-15").</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ASU 2014-15 provides guidance on management&#8217;s responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ASU 2014-15 also provides guidance related to the required disclosures as a result of management&#8217;s evaluation.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is in the process of assessing the impact, if any, of ASU 2014-15 on its consolidated financial statements or related disclosures.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accounting Standard Update 2014-16, &#8220;Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In November 2014, the FASB issued Accounting Standard Update 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity ("ASU 2014-16").</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The amendments in ASU 2014-16 clarify how current U.S. GAAP should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. Specifically, the amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract. Furthermore, the amendments clarify that no single term or feature would necessarily determine the economic characteristics and risks of the host contract. Rather, the nature of the host contract depends upon the economic characteristics and risks of the entire hybrid financial instrument. The amendments also clarify that, in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (i.e., the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weigh those terms and features. The assessment of the substance of the relevant terms and features should incorporate a consideration of the characteristics of the terms and features themselves; the circumstances under which the hybrid financial instrument was issued or acquired; and the potential outcomes of the hybrid financial instrument, as well as the likelihood of those potential outcomes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The amendments in ASU 2014-16 apply to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of a share.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The amendments in ASU 2014-16 are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015 (fiscal 2016 for the Company). Early adoption, including adoption in an interim period, is permitted. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The effects of initially adopting the amendments in ASU 2014-16 should be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">4.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Management believes that the provisions of ASU 2014-16 will not impact the classification of the Series A or Series B Preferred Stock. <font style="DISPLAY: inline; FONT-WEIGHT: bold">Accounting Standard Update 2015-11, &#8220;Simplifying the Measurement of Inventory&#8221;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In July, 2015, The FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11").</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out (LIFO) and the retail inventory method (RIM) are not impacted by the new guidance. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">48</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early adoption is permitted as of the beginning of an interim or annual reporting period.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is in the process of assessing the impact, if any, of ASU 2015-11 on its consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results of Operations</font></div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following discussion of the our operating results explains material changes in our results of operations for the years ended, December 31, 2015, December 31, 2014 and December 31, 2013. The discussion should be read in conjunction with the financial statements and related notes included elsewhere in this report.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31, 2015 Compared to Year Ended December 31, 2014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the year ended December 31, 2015, we had revenues of $143,167 from orders for our GlucoTrack&#174; model DF-F glucose monitoring device and personal ear-clip (&#8220;PEC&#8221;) that are replaced every six months, as compared with $59,775 for the prior-year period.&#160;&#160;The increase in revenues resulted from increased orders from customers. We did not have any revenue from orders for our GlucoTrack&#174; model DF-F and PEC in the six month period ended December 31, 2015, as we were working on improvements to the GlucoTrack&#174; model DF-F for which we received approval from the Notified Body on August 31, 2015 and December 2015 deferred sales until January 2016.&#160;&#160;We recognize revenues from GlucoTrack&#174; model DF-F and PEC when delivery has occurred, persuasive evidence of an agreement exists, the fee is fixed and determinable, collectability is reasonably assured and no further obligations exist.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Research and development expenses</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development expenses were $2,268,345<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>for the year ended December 31, 2015, as compared to $1,849,624 for the prior-year period. The increase is attributable primarily to the addition of new employees, increased salaries and related expenses for existing employees, higher professional fees relating primarily to the enhancement we made to the GlucoTrack&#174; model DF-F and relating to regulatory related consulting services, and due to higher material usage resulting from research and development involvement in the quality assurance process relating to initial manufacturing of the GlucoTrack&#174; model DF-F. Research and development expenses consist primarily of salaries and other personnel-related expenses, including stock-based compensation expenses, materials, travel expenses, clinical trials and other expenses. Subject to the receipt of additional funds to finance our operations (of which there can be no assurance), we expect&#160;&#160;research and development expenses to increase in 2016 and beyond, primarily due to hiring additional personnel and developing our product line, as well as improvement of the GlucoTrack&#174; model DF-F; however, we may adjust or allocate the level of our research and development expenses based on available financial resources and based on our commercial needs including the FDA registration process, specific requirements from customers, development of new GlucoTrack&#174; models and others.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Selling, marketing and general and administrative expenses</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Selling, marketing and general and administrative expenses were $2,530,175 for the year ended December 31, 2015, as compared to $1,817,510 for the prior-year period. The increase is attributable primarily to higher salaries and related expenses relating to the hiring of new sales, marketing and business development personnel. In addition, the increase is also attributable in part to higher traveling expenses and higher professional fees primarily due to the engagement during the second quarter of 2015 of Ogilvy CommonHealth (Paris), a well-known marketing firm in Europe. Selling, marketing and general and administrative expenses consist primarily of professional services, salaries, travel expenses and other related expenses for executive, finance and administrative personnel, including stock-based compensation expense. Other general and administrative costs and expenses include facility-related costs not otherwise included in research and development costs and expenses, and professional fees for legal and accounting services. Subject to the receipt of additional funds to finance our operations (of which there can be no assurance), we expect selling, marketing and general and administrative expenses to increase in 2016 and beyond as we continue our focus on marketing and sales of the GlucoTrack<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#174;</font> model DF-F and incur increased costs to comply with the reporting and other obligations applicable to public reporting companies; however, we may adjust or allocate the level of our marketing and general and administrative expenses based on available financial resources and based on our commercial needs including the FDA registration process, specific requirements from customers, development of new GlucoTrack&#174; models and others.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">49</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Financing (Income) expenses, net</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Financing expenses, net was $1,186,819 for the year ended December 31, 2015, as compared to financing income, net of $(6,587,785) for the prior-year period. The change is primarily attributable to the non-cash loss on partial extinguishment of Series A Preferred Stock and Series A Warrants (see Note 10C to our Financial Statements) during the year ended December 31, 2015 and the decrease in the fair value estimate during the years ended December 31, 2015 and 2014 relating to our Series A Warrants with down-round protection that were issued to investors. In accordance with U.S. GAAP, we mark the Series A Warrants to market on a quarterly basis based on the fair value estimate derived by using a binomial pricing model, with the changes in fair value recognized as finance expense or income, as applicable, in our consolidated statement of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Net Income (Loss)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net loss was $(5,842,172)<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>for the year ended December 31, 2015, as compared to a net income of $2,980,426 for the prior-year period.&#160;&#160;The increase in net income is attributable primarily to the change in financing income, net, as described above.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31, 2014 Compared to Year Ended December 31, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Revenues</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the year ended December 31, 2014, we had revenues of $59,775<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>from the first orders for our GlucoTrack&#174; model DF-F glucose monitoring device.&#160;&#160;We did not have any revenue in the prior-year period, as we had not yet commenced sales of the GlucoTrack&#174; model DF-F.&#160;&#160;We recognize revenues from GlucoTrack&#174; model DF-F when delivery has occurred, persuasive evidence of an agreement exists, the fee is fixed and determinable, collectability is reasonably assured and no further obligations exist.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Research and development expenses</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development expenses were $1,849,624<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>for the year ended December 31, 2014, as compared to $1,986,754 for the prior-year period. The decrease is attributable primarily to lower salaries and related expenses resulting from our shift of resources towards the marketing of <font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline">the GlucoTrack</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#174;</font><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline"> model DF-F and lower expenses associated with materials used in the development of the GlucoTrack</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#174;</font><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline"> model DF-F, offset partially by higher costs associated with patent and trademarks</font>. Research and development expenses consist primarily of salaries and other personnel-related expenses, including stock-based compensation expenses, materials, travel expenses, clinical trials and other expenses including patents and trademark registration expenses.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Selling, marketing and general and administrative expenses</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Selling, marketing and general and administrative expenses were $1,817,510 for the year ended December 31, 2014, as compared to $1,041,140 for the prior-year period. The increase is attributable primarily to increased salaries and related expenses resulting from our shift of resources from research and development activities and from an increase in consultancy fees relating the Arbitration Decision and travel expenses resulting from our focus on marketing the GlucoTrack<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#174;</font> model DF-F. Selling, marketing and general and administrative expenses consist primarily of professional services, salaries, travel expenses and other related expenses for executive, finance and administrative personnel, including stock-based compensation expense. Other general and administrative costs and expenses include facility-related costs not otherwise included in research and development costs and expenses, and professional fees for legal and accounting services.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Financing (Income) expenses, net</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Financing income, net was $(6,587,785) for the year ended December 31, 2014, as compared to financing expense of $6,768,959<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>for the prior-year period. The change is primarily attributable to a decrease in the fair value estimate relating to our warrants with down-round protection that were issued to investors and by issuance expenses allocated to such warrants at the issuance date. In accordance with U.S. GAAP, we mark the warrants to market on a quarterly basis based on the fair value estimate derived by using a binomial pricing model, with the changes in fair value recognized as finance expense or income, as applicable, in our consolidated statement of operations. During the years ended December 31, 2014 and 2013, the estimated fair value of our warrants with down-round protection decreased by $6,559,758 and increased by $6,251,242, respectively,&#160;&#160;resulting primarily from management&#8217;s estimate of the Company&#8217;s fair value per share (see Note 2T and Note 11D to our consolidated financial statements included elsewhere in this report).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">50</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Net Income (Loss)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net income was $2,980,426<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>for the year ended December 31, 2014, as compared to a net loss $(9,796,853) for the prior-year period.&#160;&#160;The increase in net income is attributable primarily to the change in financing income, net, as described above.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December 31, 2015 and March 28, 2016, cash on hand was approximately $608,000 and $84,000, respectively.&#160;&#160;During the first quarter of 2016 we started fulfilling orders for our improved GlucoTrack<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#174;</font> model DF-F, which resulted in cash collections of approximately $100,000 from our customers.&#160;&#160;While we expect to continue to generate additional cash from sales, we do not anticipate that our income from operations will be sufficient to sustain our operations in the next 12 months.&#160;&#160;Based on our current cash burn rate, strategy and operating plan, we believe that our cash and cash equivalents will enable us to operate for a period of less than thirty days from the date of this report and have deferred payments to accounts payable and payroll payments to certain management employees who voluntarily elected to have their salaries deferred. In order to fund our anticipated liquidity needs beyond such period (or possibly earlier if our current cash burn rate, strategy or operating plan change in a way that accelerates or increases our liquidity needs), we will need to raise additional capital.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December&#160;31, 2015, we had an unutilized credit line of approximately $38,500 (NIS&#160;150,000) with our Israeli bank. Borrowings under the line of credit are secured by funds on deposit with the bank at the time of borrowing, which generally must be sufficient to cover the principal amount of the borrowings in full. As of March 30, 2016 the credit line was increase for a period of two months by an additional $12,833 (NIS 50,000).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Messrs. Avner Gal and Zvi Cohen collectively loaned us NIS 176,000 ($45,105 based on the exchange rate of 3.902 NIS/dollar as of December 31, 2015) in May 2002 pursuant to an oral agreement. Messrs. Nir Tarlovsky, Yitzhak Fisher and Asher Kugler loaned us NIS 336,300 ($86,187 based on the same exchange rate) on March 16, 2004. These loans are not required to be repaid until the first year in which we realize profits in our statement of operations. At such time, the loans are to be repaid on a quarterly basis in an amount equal to 10% of our total sales after deduction of VAT in the relevant quarter, beginning the quarter following the first year in which we realize profits in our annual statement of operations. The total amount to be repaid by us to each lender shall be an amount equal to the aggregate principal amount loaned by such lender to us, plus an amount equal to the product of the amount of each payment made by us in respect of such loan multiplied by the percentage difference between the Israeli Consumer Price Index on the date on which the loan was made and the Israeli Consumer Price Index on the date of such payment. However, notwithstanding the abovementioned mechanism, we will not be required to repay the loans during any time when such repayment would cause a deficit in our working capital. &#160;The Israeli Consumer Price Index was 177.6386, and 178.5793, respectively, as of the dates of the Gal/Cohen Loan and the Tarlovsky/Fisher/Kugler Loan. The Israeli Consumer Price Index as of December 31, 2015 was 222.3267. Our board of directors is entitled to modify the repayment terms of these loans, so long as such modification does not discriminate against any particular lender, and provided that all payments must be allocated among the lenders on a pro-rata basis.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are required to pay royalties to the OCS at a rate ranging between 3-5% of the proceeds from the sale of the Company&#8217;s products arising from the development plan up to an amount equal to $93,300, plus interest at LIBOR from the date of grant. As of December&#160;31, 2015, the contingent liability with respect to royalty payment on future sales equals to approximately $83,341, excluding interest.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Used in Operating Activities for the Years Ended December 31, 2015 and December 31, 2014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash used in operating activities was $4,565,224 and $3,361,645 for the years ended December 31, 2015 and 2014, respectively. Net cash used in operating activities primarily reflects the net income (loss) for those periods of $(5,842,172) and $2,980,426, respectively, increased and offset by non-cash changes in fair value of Warrants with down-round protection of $(149,092) and $(6,559,758), respectively. Net cash used in operating activities was also partially offset by the non-cash loss on partial extinguishment of Series A Preferred Stock and Series A Warrants in the amount of $1,284,354 and $0, respectively and net changes in operating assets and liabilities in the amounts of $81,303 and $133,180, respectively. Net changes in operating assets for the year ended December 31, 2015 reflect primarily the increase in accounts payable in the amount of $982,215 resulting from deferral of payments, offset partially by build-up of inventory in the amount of $737,554 in anticipation of future orders by our distributors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">51</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Used in Investing Activities for the Years Ended December 31, 2015 and December 31, 2014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash used in investing activities was $203,167 and $91,513 for the years ended December 1, 2015, and 2014, respectively. During the years ended December 31, 2015, and 2014, cash used in investment activities consist of equipment purchases (such as computers, research and development and office equipment) in the amount of $143,736 and $63,455 respectively, cash used to fund deposits in respect of employees rights upon retirement in the amount of $24,279 and $28,058, respectively, and cash used in investments in certificates of deposit, which are used to secure Integrity Israel&#8217;s obligations in respect of its headquarters lease in the amount of $35,152 and $0, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Provided by (Used in) Financing Activities for the Years Ended December 31, 2015 and December 31, 2014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash provided by (used in) financing activities was $(460,863) and $6,972,950 for the years ended December 31, 2015 and 2014, respectively. Cash used in financing activities for the year ended December 31, 2015, reflects primarily the repayment of stockholders loan to Dimri in the amount of $439,939 and cash dividends paid to the holders of our Series A Preferred Stock in the amounts of $57,061, offset partially by proceeds from exercise of stock options by our employees in the amount of $36,137. Cash provided by financing activities for the year ended December 31, 2014, reflects net capital raised in the amounts of $7,343,391, offset partially by cash dividends paid to the holders of our Series A Preferred Stock in the amounts of $370,441.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Used in Operating Activities for the Years Ended December 31, 2014 and December 31, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash used in operating activities was $3,361,645 and $3,217,767 for the years ended December 31, 2014 and 2013, respectively. Net cash used in operating activities primarily reflects the net income (loss) for those periods of $2,980,426 and $(9,796,853), respectively. For the year ended December 31, 2014, the net income was partially offset by non-cash charges in the amount of $(6,559,758), $50,380 and $34,683, resulting from changes in the fair value of warrants with down-round protection, stock-based compensation and depreciation, respectively and by changes in operating assets and liabilities in the amounts of $133,180. For the year ended December 31, 2013, the net loss was partially offset by non-cash charges in the amount of $6,251,242, $390,928, $35,619 and $33,684, resulting from changes in the fair value of warrants with down-round protection, issuance costs allocated to warrants with down-round protection, stock-based compensation and depreciation, respectively and by changes in operating assets and liabilities in the amount of $(136,810).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Used in Investing Activities for the Years Ended December 31, 2014 and December 31, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash used in investing activities was $91,513 and $104,281 for the years ended December 31, 2014 and 2013, respectively. During years ended December 31, 2014, and 2013, cash used primarily to purchase equipment (such as computers, research and development and office equipment) amounted to $63,455 and $64,252 respectively, and cash used to fund deposits in respect of employees rights upon retirement amounted to $28,058 and $40,029, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Provided by Financing Activities for the Years Ended December 31, 2014 and December 31, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash provided by financing activities was $6,972,950 and $5,055,892 for the years ended December 31, 2014 and 2013, respectively. Cash provided by financing activities reflects net capital raised in the amounts of $7,343,391 and $5,382,941 for the years&#160;&#160;ended December 31, 2014 and 2013, respectively, offset partially by cash dividends paid to the holders of our Series A Preferred Stock in the amounts of $370,441and $288,248 for the years ended December 31, 2014 and 2013, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">52</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Off-Balance Sheet Arrangements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December 31, 2015, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item7A">Item 7A</a>. Quantitative and Qualitative Disclosures About Market Risk.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Not required for smaller reporting companies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item8">Item 8</a>. Financial Statements and Supplementary Data.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The financial statements required by this Item 8 are filed herewith commencing on page F-1 hereto and are incorporated herein by reference.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item9">Item 9</a>. Change in and Disagreements With Accountants on Accounting and Financial Disclosure.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item9A">Item 9A</a>. Controls and Procedures.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Evaluation of Disclosure Controls and Procedures</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2015. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2015, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Management&#8217;s Report on Internal Control Over Financial Reporting</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2015. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in Internal Control &#8212; the 1992 Integrated Framework. Management has concluded that, as of December 31, 2015, its internal control over financial reporting was effective based on these criteria.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">53</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Changes in Internal Control over Financial Reporting</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There were no changes in our internal control over financial reporting during the fiscal year ended December 31, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Attestation Report of the Registered Public Accounting Firm</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm because we are a smaller reporting company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item9B">Item 9B</a>. Other Information.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">54</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="PARTIII">PART III</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item10">Item 10</a>. Directors, Executive Officers and Corporate Governance.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The information required for this item is incorporated by reference from our Proxy Statement to be filed in connection with our 2016 Annual Meeting of Stockholders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item11">Item 11</a>. Executive Compensation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The information required for this item is incorporated by reference from our Proxy Statement to be filed in connection with our 2016 Annual Meeting of Stockholders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item12">Item 12</a>. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The information required for this item is incorporated by reference from our Proxy Statement to be filed in connection with our 2016 Annual Meeting of Stockholders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item13">Item 13</a>. Certain Relationships and Related Transactions, and Director Independence.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The information required for this item is incorporated by reference from our Proxy Statement to be filed in connection with our 2016 Annual Meeting of Stockholders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item14">Item 14</a>. Principal Accounting Fees and Services.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The information required for this item is incorporated by reference from our Proxy Statement to be filed in connection with our 2016 Annual Meeting of Stockholders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">55</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="PARTIV">PART IV</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Item15">Item 15</a>. Exhibits, Financial Statement Schedules.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Document List</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Financial Statements:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The financial statements of the Company filed herewith are set forth in Part II, Item 8 of this report.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Financial Statement Schedules:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Exhibits:</font></font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit Number</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="70%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>
</div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Merger Agreement and Plan of Reorganization, dated as of May 25, 2010, by and among Integrity Applications, Inc., Integrity Acquisition Ltd. and A.D. Integrity Applications Ltd. (1)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificate of Incorporation of Integrity Applications, Inc. (1)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.2</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificate of Amendment to Certificate of Incorporation of Integrity Applications, Inc. (1)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.3</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="middle" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificate of Designation of Preferences and Rights of Series A 5% Convertible Preferred Stock (2)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.4</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bylaws of Integrity Applications, Inc. (1)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.5</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificate of Designation of Preferences and Rights of Series B 5.5% Convertible Preferred Stock (3)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Specimen Certificate Evidencing Shares of Common Stock (1)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.2</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Common Stock Purchase Warrant (1)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.3</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Series A Securities Purchase Agreement (2)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.4</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="middle" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Series A Common Stock Purchase Warrant (2)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.5</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="middle" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Series A Registration Rights Agreement (2)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.6</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Series B Securities Purchase Agreement (3)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.7</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Series B-1 Common Stock Purchase Warrant (3)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.8</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="middle" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Series B-2 Common Stock Purchase Warrant (3)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.9</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="middle" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Series B Registration Rights Agreement (3)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.1*</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Integrity Applications, Inc. 2010 Incentive Compensation Plan (1)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.2*</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Director and Officer Indemnification Agreement (1)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.3*</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Personal Employment Agreement, dated as of July 22, 2009, between A.D. Integrity Applications Ltd. and Avner Gal (1)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.4*</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Personal Employment Agreement, dated as of July 22, 2010, between A.D. Integrity Applications Ltd. and David Malka (1)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.5</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Irrevocable Undertaking of Indemnification, dated as of July 26, 2010, by and among Integrity Applications, Inc., Avner Gal, Zvi Cohen, Ilana Freger, David Malka and Alexander Raykhman (1)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.6</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Agreement, dated as of November 1, 2005 by and between A.D. Integrity Applications Ltd. and Diabeasy Diabeasy cc. (4)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.7</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Agreement, dated as of October 2, 2005, by and between Technology Transfer Group and Integrity Applications Ltd. (1)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.8*</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Stock Option Agreement (1)</font></div>
</td>
</tr></table>
</div>

<div align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">56</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div>
<table cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit Number</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="70%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>
</div>
</td>
</tr></table>
</div>

<div align="left">
<table cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.9*</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Stock Option Agreement (ESOP) (1)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.10</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Letter of Approval, addressed to Integrity Applications Ltd. from the Ministry of Industry, Trade and Employment of the State of Israel (5)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.11</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Letter of Undertaking, addressed to the Ministry of Industry, Trade and Employment of the State of Israel - Office of the Chief Scientist from Integrity Applications Ltd. (6)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.12</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Investment Agreement, dated March 16, 2004, by and among A.D. Integrity Applications Ltd., Yitzhak Fisher, Asher Kugler and Nir Tarlovsky (4)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.13*</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Personal Employment Agreement, dated as of October 22, 2013, between A.D. Integrity Applications Ltd. and Eran Hertz. (7)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21.1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Subsidiaries of Integrity Applications, Inc. (1)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31.1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of Chief Executive Officer Pursuant to Exchange Act Rule 13a-14(a) or 15(d)-14(a), as Adopted Pursuant to Section 302 of the Sarbanes Oxley Act of 2002</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31.2</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of Chief Financial Officer Pursuant to Exchange Act Rule 13a-14(a) or 15(d)-14(a), as Adopted Pursuant to Section 302 of the Sarbanes Oxley Act of 2002</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32.1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32.2</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.INS</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Instance Document (8)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.SCH</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Schema Document (8)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.CAL</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Calculation Linkbase Document (8)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.LAB</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Label Linkbase Document (8)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.PRE</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Presentation Linkbase Document (8)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.DEF</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Definition Linkbase Document (8)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Previously filed as an exhibit to the Company&#8217;s Registration Statement on Form S-1, as filed with the SEC on August 22, 2011.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Previously filed as an exhibit to the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on March 18, 2013.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(3)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Previously filed as an exhibit to the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on September 5, 2014.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(4)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Previously filed as an exhibit to Amendment No. 2 to the Company&#8217;s Registration Statement on Form S-1, as filed with the SEC on October 27, 2011.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(5)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Previously filed as an exhibit to Amendment No. 3 to the Company&#8217;s Registration Statement on Form S-1, as filed with the SEC on November 10, 2011.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(6)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Previously filed as an exhibit to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1, as filed with the SEC on October 7, 2011</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(7)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Previously filed as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as filed with the SEC on March 28, 2014.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(8)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to Rule 406T of Regulation S-T, the interactive files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Compensation Plan or Arrangement or Management Contract</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">57</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="SIGNATURES">SIGNATURES</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized as of this&#160;30th day of March, 2016.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Avner Gal</font></font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:&#160;<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Avner Gal</font></font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:&#160;<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chairman of the Board </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">and Chief Executive Officer</font></font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons in the capacities and on the dates indicated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Signature</font></div>
</td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="43%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Title</font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date</font></div>
</td>
</tr><tr>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">/s/ Avner Gal</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="43%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chairman of the Board</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">and Chief Executive Officer</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 30, 2016</font></div>
</td>
</tr><tr>
<td valign="bottom" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Avner Gal</font></div>
</td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="43%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Principal Executive Officer)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">/s/ Eran Hertz</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="43%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 30, 2016</font></div>
</td>
</tr><tr>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Eran Hertz</font></div>
</td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="43%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Principal Financial Officer and Principal Accounting Officer)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">/s / Dr. Robert Fischell</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="43%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 30, 2016</font></div>
</td>
</tr><tr>
<td valign="bottom" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dr. Robert Fischell</font></div>
</td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">/s/ David Malka</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="43%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director and Executive Vice President of Operations</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 30, 2016</font></div>
</td>
</tr><tr>
<td valign="bottom" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">David Malka</font></div>
</td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="43%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 30, 2016</font></div>
</td>
</tr><tr>
<td valign="bottom" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Angela Strand</font></div>
</td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="43%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 30, 2016</font></div>
</td>
</tr><tr>
<td valign="bottom" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Leslie Seff</font></div>
</td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">58</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">as of December 31, 2015</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Table of Contents</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div align="left">
<table cellpadding="3" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="63%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Page</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#f2">Report of Independent Registered Public Accounting Firm</a></font></div>
</td>
<td valign="bottom" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F - 2</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Financial Statements</font></div>
</td>
<td valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#f3">Balance Sheets</a></font></div>
</td>
<td valign="bottom" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F - 3</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#f4">Statements of Operations and Comprehensive Income (Loss)</a></font></div>
</td>
<td valign="bottom" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F - 4</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#f5">Statements of Changes in Stockholders&#8217; Deficit</a></font></div>
</td>
<td valign="bottom" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F - 5 &#8211; F - 6</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#f7">Statements of Cash Flows</a></font></div>
</td>
<td valign="bottom" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F - 7 &#8211; F - 8</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#f9">Notes to Consolidated Financial Statements</a></font></div>
</td>
<td valign="bottom" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F - 9 &#8211; F - 40</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><img src="logo.jpg" alt=""></div>

<div align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160; </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="82%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Independent Registered Public Ac<a name="f2">cou</a>nting Firm</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">To the Stockholders of</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>
</td>
<td width="18%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="trad_name"><!--efplaceholder--></a>Fahn Kanne &amp; Co.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a name="address_block"><!--efplaceholder--></a>Head Office</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32 Hamasger Street</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel-Aviv 6721118, ISRAEL</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PO Box 36172, 6136101</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">T <a name="tel"><!--efplaceholder--></a>+972 3 7106666</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F <a name="fax"><!--efplaceholder--></a>+972 3 7106660</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a name="dual"><!--efplaceholder--></a><a name="web"><!--efplaceholder--></a><font style="DISPLAY: inline; TEXT-DECORATION: underline">www.gtfk.co.il</font></font></font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have audited the accompanying consolidated balance sheets of <font style="DISPLAY: inline; FONT-WEIGHT: bold">Integrity Applications, Inc. </font>and subsidiary (hereinafter: the "Company") as of December&#160;31, 2015 and 2014, and the related consolidated statements of operations and comprehensive income (loss), changes in stockholders&#8217; deficit and cash flows for each of the three years in the period ended December&#160;31, 2015. These financial statements are the responsibility of the Company&#8217;s management.&#160;&#160;Our responsibility is to express an opinion on these financial statements based on our audits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).&#160;&#160;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.&#160;&#160;We were not engaged to perform an audit of the Company&#8217;s internal control over financial reporting.&#160;&#160;Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting.&#160;&#160;Accordingly, we express no such opinion.&#160;&#160;An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.&#160;&#160;We believe that our audits provide a reasonable basis for our opinion.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Integrity Applications, Inc. and subsidiary as of December&#160;31, 2015 and 2014, and the results of their operations and their cash flows for each of the three years in the period ended December&#160;31, 2015, in conformity with accounting principles generally accepted in the United States of America.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.&#160;&#160;As discussed in Note&#160;1, the Company has not yet generated material revenues from its operations to fund its activities and is therefore dependent upon external sources for financing its operations.&#160;&#160;As of December&#160;31, 2015, the Company has incurred accumulated deficit of $29,376,515, stockholder's deficit of $6,970,914 and negative operating cash flows.&#160;&#160;These factors among others, as discussed in Note 1 to the consolidated financial statements raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regards to these matters are also described in Note 1B.&#160;&#160;The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FAHN KANNE &amp; CO. GRANT THORNTON ISRAEL</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certified Public Accountants (Isr.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Tel-Aviv, Israel</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">March 30, 2016</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: normal">Certified Public Accountants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: normal">Fahn Kanne &amp; Co. is the Israeli member firm of Grant Thornton International Ltd</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font><br>
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160; </font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED BALANCE S<a name="F3">HE</a>ETS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">US dollars (except share data)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">A S S E T S</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Assets</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">608,701</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,827,560</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts receivable, net</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,446</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,250</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Inventories (Note 3)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">816,223</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">83,653</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other current assets (Note 4)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">268,792</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">113,842</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,712,162</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,048,305</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Property and Equipment, Net (Note 5)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">220,463</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">122,491</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Long-Term Restricted Cash</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35,152</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Funds in Respect of Employee Rights Upon Retirement</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">164,883</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">177,470</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,132,660</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,348,266</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS&#8217; DEFICIT</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -72pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,082,546</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">104,711</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other current liabilities (Note 6)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">427,886</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">440,764</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Long-Term Loans from Stockholders, current portion (Note 8)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">454,532</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total current liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,510,432</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,000,007</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -72pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Long-Term Liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Long-Term Loans from Stockholders (Note 8)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">160,314</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">163,459</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Liability for Employee Rights Upon Retirement (Note 2J)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">174,137</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">210,700</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants with Down-Round Protection (Note 10D)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">321,695</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,057,618</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total long-term liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">656,146</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,431,777</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,166,578</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,431,784</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -72pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commitments and Contingent Liabilities (Note 9)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -72pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Temporary Equity</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -72pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Convertible Preferred Stock of $&#160;0.001 par value ("Preferred Stock"):</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,000,000 shares of Preferred Stock authorized as of December 31, 2015 and as of December 31, 2014</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preferred Stock Series A issued and outstanding 376 shares as of December&#160;31, 2015 and 7,407 shares as of December&#160;31, 2014</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">221,152</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,356,657</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preferred Stock Series B issued and outstanding 15,031 shares as of December&#160;31, 2015 and 8,500 shares as of December&#160;31, 2014</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,715,844</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,392,028</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total temporary equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,936,996</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,748,685</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stockholders' Deficit</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common Stock of $&#160;0.001 par value ("Common Stock"):</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">40,000,000 shares authorized as of December&#160;31, 2015 and December&#160;31, 2014; issued and outstanding 5,690,097 shares and 5,323,058 shares as of December&#160;31, 2015 and December&#160;31, 2014, respectively</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,691</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,324</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional paid in capital</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22,309,742</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,182,866</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated other comprehensive income</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">90,168</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">66,670</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated deficit</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(29,376,515</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(23,087,063</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total stockholders' deficit</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,970,914</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,832,203</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total liabilities, temporary equity and stockholders&#8217; deficit</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,132,660</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,348,266</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The accompanying notes are an integral part of the consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE IN<a name="F4">CO</a>ME (LOSS)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">US dollars (except share data)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year ended December 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenues</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">143,167</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,775</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development expenses (Note 11)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,268,345</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,849,624</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,986,754</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Selling, marketing and general and administrative expenses (Note 12)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,530,175</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,817,510</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,041,140</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total operating expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,798,520</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,667,134</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,027,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating loss</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,655,353</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,607,359</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,027,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Financing (income) expenses, net (Note 13)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,186,819</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,587,785</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,768,959</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income (loss) for the period</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,842,172</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,980,426</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9,796,853</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other comprehensive income (loss):</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Foreign currency translation adjustment</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,498</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,968</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,777</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Comprehensive income (loss) for the period</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,818,674</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,994,394</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9,753,076</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income (loss) per share (Basic) (Note 15)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1.15</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.37</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1.95</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income (loss) per share (Diluted) (Note 15)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1.15</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.37</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1.95</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common shares used in computing Basic income (loss) per share (Note 15)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,476,870</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,304,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,325,714</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common shares used in computing Diluted income (loss) per share (Note 15)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,476,870</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,349,242</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,325,714</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The accompanying capital notes are an integral part of the consolidated financial statements.</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">STATEMENTS OF CHANGES IN STOCKH<a name="F5">OLDE</a>RS&#8217; DEFICIT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="22" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">US Dollars (except share data)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common Stock</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" rowspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Additional paid in capital</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" rowspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accumulated other</font> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">comprehensive income</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" rowspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accumulated deficit</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" rowspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">stockholders&#8217; deficit</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number of</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;shares</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Balance as of January 1, 2013</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,460,600</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,461</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,772,371</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,925</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(15,289,826</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(503,069</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss for the year</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9,796,853</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9,796,853</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other comprehensive income</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,777</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,777</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amount classified out of stockholders equity and presented as liability and temporary equity with respect to Common Stock replaced with units comprised of convertible Preferred Stock and warrants with down-round protection</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(162,907</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(163</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,140,186</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,140,349</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conversion of Preferred Stock</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,196</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,200</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock dividend to certain Common Stock holders</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">278,263</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(278,263</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants issued as consideration for placement services</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">562,805</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">562,805</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash dividend on Series A Preferred Stock</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(288,248</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(288,248</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35,619</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35,619</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Balance as of December 31, 2013</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,301,693</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,302</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,532,068</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52,702</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(25,653,190</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(11,063,118</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="28%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income for the year</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,980,426</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,980,426</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other comprehensive income</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,968</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,968</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amounts allocated to Series B-1 and Series B-2 Warrants, net</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,320,429</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,320,429</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amount classified out of stockholders deficit and presented as Warrants with Down-Round Protection within long-term liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(400,671</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(400,671</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conversion of Series A Preferred Stock into Common Stock</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,725</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,886</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,888</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants issued as consideration for placement services</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">630,936</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">630,936</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock dividend to certain Common Stock holders</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">654</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock dividend on Series B Preferred Stock</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,986</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,839</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(43,858</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash dividend on Series A Preferred Stock</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(370,441</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(370,441</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50,380</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50,380</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Balance as of December 31, 2014</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,323,058</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,324</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,182,866</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">66,670</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(23,087,063</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,832,203</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The accompanying notes are an integral part of the consolidated financial statements.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; DEFICIT (cont.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="22" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">US Dollars (except share data)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common Stock</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" rowspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Additional paid in capital</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" rowspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accumulated other</font> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">comprehensive income</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" rowspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accumulated deficit</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" rowspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">stockholders&#8217; deficit</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of shares</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Balance as of January 1, 2015</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,323,058</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,324</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,182,866</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">66,670</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(23,087,063</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,832,203</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss for the year</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,842,172</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,842,172</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other comprehensive income</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,498</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,498</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of Series B-1 and Series B-2 Warrants</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,445,337</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,445,337</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conversion of Series A and Series B Preferred Stock into Common Stock</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">86,208</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">86</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">237,451</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">237,537</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock dividend to certain Common Stock holders</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">92,136</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">92</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(92</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock dividend on Series B Preferred Stock</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">168,926</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">169</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">390,050</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(390,219</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash dividend on Series A Preferred Stock</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(57,061</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(57,061</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise of employees&#8217; stock options</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,769</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36,117</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36,137</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,013</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,013</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Balance as of December 31, 2015</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5,690,097</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5,691</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">22,309,742</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">90,168</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(29,376,515</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(6,970,914</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The accompanying notes are an integral part of the consolidated financial statements.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED STATEMENTS OF CASH FL<a name="F7">O</a>WS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">US dollars</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year ended December 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash flows from operating activities:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income (loss) for the year</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,842,172</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,980,426</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9,796,853</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjustments to reconcile income (loss) for the year to net cash used in operating activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">44,891</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34,683</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33,684</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Decrease in liability for employee rights upon retirement</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9,959</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,013</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50,380</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35,619</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance costs allocated to warrants with down-round protection</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">390,928</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in the fair value of warrants issued with down-round protection</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(149,092</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,559,758</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,251,242</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Linkage difference on principal of loans from stockholders</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,521</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(556</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,382</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,284,354</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Changes in assets and liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Decrease (increase) in accounts receivable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,131</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(24,539</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Increase in inventory</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(737,554</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(94,895</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Increase in other current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(156,302</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(32,416</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,234</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Increase (decrease) in accounts payable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">982,215</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">68,838</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(77,259</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Increase (decrease) in other current liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(11,187</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">216,192</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(54,317</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in operating activities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,565,224</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,361,645</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,217,767</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash flows from investment activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Increase in funds in respect of employee rights upon retirement</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(24,279</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(28,058</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(40,029</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Purchase of property and equipment</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(143,736</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(63,455</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(64,252</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Increase in long-term restricted cash</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(35,152</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in investment activities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(203,167</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(91,513</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(104,281</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash flows from financing activities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Repayment of credit from banking institutions</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(38,801</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash dividend on Series A Preferred Stock</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(57,061</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(370,441</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(288,248</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds allocated to convertible Preferred Stock, net of cash issuance expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,710,860</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,960,958</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds allocated to Series A Warrants with down-round protection, net of cash&#160;&#160;issuance expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,421,983</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds allocated to Series B Warrants, net of cash issuance expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,632,531</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from exercise of employees&#8217; stock options</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36,137</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Repayment of loan from stockholders</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(439,939</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash provided by (used in) financing activities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(460,863</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,972,950</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,055,892</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Effect of exchange rate changes on cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,395</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(78,143</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">108,656</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Increase (decrease) in cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,218,859</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,441,649</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,842,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents at beginning of the year</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,827,560</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,385,911</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">543,411</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents at end of the year</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">608,701</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,827,560</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,385,911</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The accompanying notes are an integral part of the consolidated financial statements.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED STATEMENTS OF CASH FLOWS (cont.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Supplementary information on financing activities not involving cash flows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the year ended December 31, 2015, 100 shares of Series A Preferred Stock and 400 shares of Series B Preferred Stock were converted into 17,242 and 68,966 shares of Common Stock, respectively. Accordingly, $58,817 and $178,720, representing the carrying value of such shares of Series A Preferred Stock shares of Series B Preferred Stock, respectively, were reclassified from temporary equity to stockholders&#8217; deficit.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the year ended December 31, 2015, 6,931 shares of the Company&#8217;s Series A Preferred Stock were exchanged into 6,931 shares of Series B Preferred Stock. In addition, 1,440,880 Warrants with down-round protection were exchanged into 1,200,710 Series B-1 Warrants and 1,200,710 Series B-2 Warrants. As a result of the exchange, the balances of the Series A Preferred Stock and the Warrants with down-round protection decreased by $4,076,688 and $1,586,831, respectively and the balances of the Series B Preferred Stock, Series B-1 Warrants and Series B-2 Warrants increased by $3,502,536, $1,833,876 and $1,612,186, respectively. In addition, the Company recorded a non-cash charge in the amount of $1,284,354 included in finance expenses within the Company&#8217;s statement of operations (See Note 13B).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">$390,219, representing the fair value of the shares of Common Stock issued to owners of Series B Preferred Stock, was accounted for as a stock dividend in the statement of changes in stockholders&#8217; deficit and was charged to accumulated deficit against additional paid in capital and Common Stock therein.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The accompanying notes are an integral part of the consolidated financial statements.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 1</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GENERAL</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">A.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Integrity Applications, Inc. (the "Company") was incorporated on May&#160;18, 2010 under the laws of the State of Delaware.&#160;&#160;On July&#160;15, 2010, Integrity Acquisition Corp. Ltd. (hereinafter: "Integrity Acquisition"), a wholly owned Israeli subsidiary of the Company, which was established on May&#160;23, 2010, completed a merger with A.D. Integrity Applications Ltd. (hereinafter: "Integrity Israel"), an Israeli corporation that was previously held by the stockholders of the Company.&#160;&#160;Pursuant to the merger, all equity holders of Integrity Israel received the same proportional ownership in the Company as they had in Integrity Israel prior to the merger. Following the merger, Integrity Israel remained a wholly-owned subsidiary of the Company.&#160;&#160;As the merger transaction constituted a structural reorganization, the merger has been accounted for at historical cost in a manner similar to a pooling of interests.&#160;&#160;Integrity Israel was incorporated in 2001 and commenced its operations in 2002.&#160;&#160;Integrity Israel, a medical device company, focuses on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">B.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Going concern uncertainty</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Since its incorporation, the Company did not conduct any material operations other than those carried out by Integrity Israel.&#160;&#160;The development and commercialization of Integrity Israel's product is expected to require substantial expenditures.&#160;&#160;Integrity Israel and the Company (collectively, the "Group") have not yet generated any material revenues from operations, and therefore they are dependent upon external sources for financing their operations. As of December 31, 2015, the Group has incurred accumulated deficit of $29,376,515, stockholder's deficit of $6,970,914 and negative operating cash flows.&#160;&#160;These factors raise substantial doubt about the Group&#8217;s ability to continue as a going concern.&#160;&#160;The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&#160;&#160;During 2012, the Company raised a total amount of approximately $1.0 million (net of related expenses) from the issuance of Common Stock. During 2013, the Company raised funds in an approximate amount of $5.3 million (net of related cash expenses) from the issuance of units (the &#8220;Series A Units&#8221;) consisting of shares of the Company&#8217;s Series A Convertible Preferred Stock (the &#8220;Series A Preferred Stock&#8221;) and detachable warrants to purchase shares of the Company&#8217;s Common Stock (the &#8220;Series A Warrants&#8221; or &#8220;warrants with down round protection&#8221;), see also Note 10A.2, Note 10B and Note 10D.&#160;&#160;During the period between August and December of 2014, the Company raised funds in an aggregate amount of approximately $7.3 million (net of related cash expenses) from the issuance of units (the &#8220;Series B Units&#8221;), each consisting of (a) one share of the Company&#8217;s newly designated Series B 5.5% Convertible Preferred Stock, par value $0.001 per share (the &#8220;Series B Preferred Stock&#8221;), convertible into Common Stock at an initial conversion price of $5.80 per share, (b) a five year warrant to purchase, at an exercise price of $5.80 per share, up to such number of shares of Common Stock issuable upon conversion of such share of Series B Preferred Stock (each a &#8220;Series B-1 Warrant&#8221;) and (c) a five year warrant to purchase, at an exercise price of $10.00 per share, up to such number of shares of Common Stock issuable upon conversion of such share of Series B Preferred Stock (each a &#8220;Series B-2 Warrant&#8221; and, together with the Series B-1 Warrants, collectively, the &#8220;Series B Warrants&#8221;), see Also Note 10A.3 and Note 10C.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Until such time as the Group generates sufficient revenue to fund its operations (if ever), the Group plans to finance its operations through the sale of equity or equity-linked securities and/or debt securities and, to the extent available, short term and long term loans. There can be no assurance that the Group will succeed in obtaining the necessary financing to continue its operations as a going concern.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 9</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STAT<a name="F9">EME</a>NTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 1</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GENERAL (cont.)</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">C.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risk factors</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As described in Note 1A and Note 1B above, the Group has a limited operating history and faces a number of risks and uncertainties, including risks and uncertainties regarding continuation of the development process, demand and market acceptance of the Group's products, the effects of technological changes, competition and the development of products by competitors.&#160;&#160;Additionally, other risk factors also exist, such as the ability to manage growth and the effect of planned expansion of operations on the Group's future results and the availability of necessary financing. In addition, the Group expects to continue incurring significant operating costs and losses in connection with the development of its products and marketing efforts. The Group has not yet generated material revenues from its operations to fund its activities and therefore is dependent on the receipt of additional funding from its stockholders and/ or new investors in order to continue its operations.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 2</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">A.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Use of estimates in the preparation of financial statements</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to (i) the fair value estimate of the Warrants with down-round protection, (ii) the fair value measurement of the Series B Units and the estimate of the loss arising from the partial extinguishment of the Series A Units and the exchange thereof for Series B Units, and (iii) the going concern assumptions.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">B.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Functional currency</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The functional currency of the Company is the US dollar, which is the currency of the primary economic environment in which it operates.&#160;&#160;In accordance with ASC 830, &#8220;Foreign Currency Matters&#8221; (ASC 830), balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date.&#160;&#160;For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used.&#160;&#160;Gains or losses arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses. The functional currency of Integrity Israel is the New Israeli Shekel ("NIS") and its financial statements are included in consolidation, based on translation into US dollars.&#160;&#160;Accordingly, assets and liabilities were translated from NIS to US dollars using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or losses resulting from translation adjustments are reflected in stockholders' equity (deficit), under &#8220;accumulated other comprehensive income (loss)&#8221;.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="87%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year ended December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Official exchange rate of NIS&#160;1 to US dollar</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.256</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.257</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.288</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 10</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 2</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">C.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Principles of consolidation</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated in consolidation.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">D.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash and cash equivalents</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less at the date of purchase, to be cash equivalents.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-SIZE: 10pt">E.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inventories</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Inventories are stated at the lower of cost or market value.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cost is determined as follows:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">With respect to raw materials, the Group calculates cost using the average cost method.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">With respect to work in process and finished products, the Group calculates the cost on the basis of the average direct manufacturing costs, including materials, labor, subcontracting costs and other direct manufacturing costs.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Management evaluates whether inventory reserve for slow-moving or obsolete items is required. To date, the Group has not recorded any reserves with respect to its inventory.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">F.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Property and equipment, net</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 100pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Property and equipment are stated at cost, net of accumulated depreciation.&#160;&#160;Depreciation is calculated using the straight-line method over the estimated useful lives of the assets.&#160;&#160;When an asset is retired or otherwise disposed of, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in the statements of operations.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 100pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Rates of depreciation:</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="83%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="85%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">%</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Computers</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Furniture and office equipment</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7-15</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Leasehold improvements</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shorter of lease term</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">and 10 years</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">G.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Impairment of long-lived assets</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Group's long-lived assets are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment&#8221;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;&#160;Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset.&#160;&#160;If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.&#160;&#160;To date the Group did not incur any material impairment losses.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 11</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 2</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">H.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Long-term restricted cash</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Restricted cash is invested in certificates of deposit, which are used to secure Integrity Israel&#8217;s obligations in respect of its headquarters lease.&#160; See Note 9B</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">I.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income tax</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Group accounts for income taxes in accordance with ASC 740, "Income Taxes". Accordingly, deferred income taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities under the applicable tax law.&#160;&#160;Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences reverse.&#160;&#160;Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Group accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise&#8217;s financial statements. According to ASC Topic 740-10, tax positions must meet a more-likely-than-not recognition threshold. The Group&#8217;s accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Group did not recognize such items in its fiscal 2015, 2014 and 2013 financial statements and did not recognize any liability with respect to unrecognized tax position in its balance sheet.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">J.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liability for employee rights upon retirement</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Integrity Israel's liability for employee rights upon retirement with respect to its Israeli employees is calculated pursuant to the Israeli Severance Pay Law, based on the most recent salary of each employee multiplied by the number of years of employment of each such employee as of the balance sheet date. Employees are entitled to one month's salary for each year of employment, or ratable portion thereof for periods less than one year. Integrity Israel makes monthly deposits to insurance policies and severance pay funds.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The deposited funds may be withdrawn upon the fulfillment of Integrity Israel's severance obligations pursuant to Israeli severance pay laws or labor agreements with its employees.&#160;&#160;The value of the deposited funds is based on the cash surrender value of these policies, and includes immaterial profits or losses.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commencing in 2011, Integrity Israel&#8217;s agreements with its Israeli employees are in accordance with Section 14 of the Severance Pay Law. Payments in accordance with Section 14 release the employer from any future severance payments in respect of those employees. Related obligations and liabilities under Section 14 are not recorded as an asset or as a liability in the Company's balance sheet.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Severance expenses for the year ended December&#160;31, 2015, 2014 and 2013 amounted to&#160;$111,030, $101,220 and $91,588, respectively.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">K.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenue recognition</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Revenues are recognized in accordance with ASC 605, "Revenue Recognition" and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) No. 104, &#8220;Revenue Recognition&#8221;, when delivery has occurred, persuasive evidence of an agreement exists, the fee is fixed and determinable, collectability is reasonably assured and no further obligations exist. Provisions are made at the time of revenue recognition for any applicable warranty cost expected to be incurred (See Note 2N).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company derives its revenues from sales of its GlucoTrack&#174; model DF-F glucose monitoring device to distributors. The Company's products sold through agreements with distributors are generally non-exchangeable, non-refundable and non-returnable and, to date, the Company has not granted to any of its distributors any rights of price protection or stock rotation. Accordingly, the Company considers its distributors as end-users for revenue recognition purposes.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 12</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 2</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">L.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and development expenses</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development expenses are charged to operations as incurred.&#160;&#160;Grants received by Integrity Israel from the Government of Israel through the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor (the "OCS") for development of approved projects were recognized as a reduction of expenses when the related costs were incurred.</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">M.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Royalty-bearing grants</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Royalty-bearing grants from the OCS to fund approved research and development projects are recognized at the time Integrity Israel is entitled to such grants, on the basis of the costs incurred and reduce research and development costs.&#160;&#160;The cumulative research and development grants received by Integrity Israel from inception through December 2004 amounted to $93,300.&#160;&#160;Integrity Israel has not received any research and development grants since December 2004.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December&#160;31, 2015 and 2014, the Group accrued royalties to the OCS in the amounts of $8,167 and $1,793, respectively.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">N.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warranty</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Group provides a 24 month warranty for its products at no cost. The Group estimates the costs that may be incurred during the warranty period and records a liability for the amounts of such costs at the time revenues are recognized. As of December 31, 2015 and 2014 warranty expenses were immaterial.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">O.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basic and diluted income (loss) per share</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Basic income (loss) per share is computed by dividing the income (loss) for the period applicable for Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Securities that may participate in dividends with the Common Stock (such as the convertible Preferred Stock) are considered in the computation of basic income per share using the two class method. However, in periods of net loss, such participating securities are not included since the holders of such securities do not have a contractual obligation to share the losses of the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In computing diluted income per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the &#8220;treasury stock method&#8221; and upon the conversion of Preferred Stock using the "if-converted method", if the effect of each of such financial instruments is dilutive.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">P.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock-based compensation</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Group measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values in accordance with ASC 718, &#8220;Compensation-Stock Compensation&#8221;. Share-based payments including grants of stock options are recognized in the statement of operations as an operating expense based on the fair value of the award at the date of grant.&#160;&#160;The fair value of stock options granted is estimated using the Black-Scholes option-pricing model.&#160;&#160;The Group has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Share-based payments awarded to consultants (non-employees) are accounted for in accordance with ASC Topic 505-50, "Equity-Based Payments to Non-Employees".</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 13</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 2</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Q.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair value of financial instruments</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ASC Topic 825-10, "Financial Instruments" defines financial instruments and requires disclosure of the fair value of financial instruments held by the Group. The Group considers the carrying amount of cash and cash equivalents, accounts receivable, other current assets, accounts payable, current portion of long-term loans from stockholders and other current liabilities balances, to approximate their fair values due to the short term maturities of such financial instruments.&#160;&#160;The Series A Warrants with down-round protection represent a derivative liability and therefore are measured and presented on the balance sheet at fair value. ASC Topic 825-10, establishes the following fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 3 - Unobservable inputs are used when little or no market data is available. Level 3 inputs are considered as the lowest priority under the fair value hierarchy.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The fair value measurement of the warrants is classified as level 3. The Group did not estimate the fair value of the long-term loans from stockholders since their repayment schedule has not yet been determined.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">R.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Concentrations of credit risk</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Financial instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.&#160;&#160;Cash and cash equivalents are deposited with major banks in Israel and the United States of America. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. As of December 31, 2015 and 2014 the balances of accounts receivable was not material and accordingly such balances do not represent substantial concentration of credit risk. The Group does not have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">S.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contingencies</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">T.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Preferred Stock</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 96.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Temporary Equity Classification</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As more fully described in Note 10A.2, Note 10B, Note 10A.3 and Note 10C, in March 2013 and during the period between August until December 31, 2014, the Company issued Series A Preferred Stock and Series B Preferred Stock, respectively, which provide a liquidation preference and certain redemption rights for the benefit of the holders of such Preferred Stock upon the occurrence of certain contingent events, some of which are not solely within the Company&#8217;s control.&#160;&#160;Accordingly, both the Series A Preferred Stock and the Series B Preferred Stock are presented as temporary equity.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 96.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;2.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Initial Measurement</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Upon initial recognition, the Series A Preferred Stock issued together with detachable Series A Warrants (classified as a derivative liability) were measured based on the "residual approach" and were presented net of the direct issuance expenses that were allocated to them. Upon initial recognition, the Series B Preferred Stock issued together with the detachable Series B Warrants (classified as equity) were measured based on the relative fair value basis and were presented net of the direct issuance expenses that were allocated to them.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 14</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 2</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">T.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Preferred Stock (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 96.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;3.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subsequent Measurement</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On each balance sheet date, the Company&#8217;s management assesses the probability of redemption of the Preferred Stock. In the event that management determines such redemption to be probable as of an applicable balance sheet date, the Company will reclassify the outstanding balance of the Preferred Stock as of that date as a liability and the difference between such amount and the aggregate redemption price of the Preferred Stock will be accreted against accumulated deficit over the period beginning on the date that it becomes probable that the Preferred Stock will become redeemable and ending on the earliest redemption date.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 96.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;4.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conversion Feature Analysis</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has determined that due to the economic characteristics and risks of the Preferred Stock, based on their stated or implied substantive terms and features, Series A and Series B Preferred Stock, are both considered as more akin to equity than debt. Accordingly, it was determined that the economic characteristics and the risks of the embedded conversion option to Common Stock and those of the Preferred Stock themselves (the 'host contract') are clearly and closely related. As a result, the embedded conversion feature was not required to be bifurcated. Also, since at the respective issuance dates of the Series A Preferred Stock and the Series B Preferred Stock, the exercise price of the conversion feature (based on the effective conversion rate of the Series A Preferred Stock and the Series B Preferred Stock into Common Stock) was higher than the estimated fair value of the Company&#8217;s Common Stock, it was determined that the conversion feature was not beneficial.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 96.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;5.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Modifications or Exchanges</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Modifications to, or exchanges of, the Preferred Stock are accounted for as a modification or an extinguishment. Such an assessment is done by management either qualitatively or quantitatively based on the facts and circumstances of each transaction. A qualitative assessment is generally appropriate when the changes to a Preferred Stock instrument are either so inconsequential or is very significant, otherwise, a quantitative test is also applied. Since the periodic contractual cash flows of the Preferred Stock are not defined, the quantitative test is generally applied using the fair value model. Under the fair value model, the Company compares the fair value of the Preferred Stock immediately before and after the modification or exchange. If the fair values before and after the modification or exchange are substantially different, the modification or exchange is accounted for as an extinguishment, otherwise it is accounted for as a modification.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 15</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 2</font></div>
</td>
<td align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">U.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Series A Warrants with Down-Round Protection</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company considered the provisions of ASC 815-40, &#8220;Derivatives and Hedging: Contracts in Entity&#8217;s Own Equity&#8221;, with respect to the detachable Warrants that were issued to the Series A Unit Purchasers, as described in Note&#160;10D, and determined that as a result of the &#8220;down-round&#8221; protection that would adjust the number of Warrants and the exercise price of the Warrants based on the price at which the Company subsequently issues shares or other equity-linked financial instruments, if that price is less than the original exercise price of the Warrants, such Warrants cannot be considered as indexed to the Company's own stock. Accordingly, the Warrants were recognized as derivative liability at their fair value on initial recognition. In subsequent periods, the Warrants are marked to market with the changes in fair value recognized as financing expense or income in the consolidated statement of operations. The direct issuance expenses that were allocated to the detachable Warrants were expensed as incurred.</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">V.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recently Issued Accounting Pronouncements</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 96.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accounting Standard Update 2014-09, &#8220;Revenue from Contracts with Customers&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In May 2014, the FASB issued Accounting Standard Update 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09").</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In accordance with a recent amendment to ASU 2014-09, introduced by Accounting Standards Update 2015-11, "Revenue from Contracts with Customers - Deferral of the Effective Date", for a public entity, the amendments in ASU 2014-09 are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period (the first quarter of fiscal year 2018 for the Company). Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is in the process of assessing the impact, if any, of ASU 2014-09 on its consolidated financial statements.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 16</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 2</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">V.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recently Issued Accounting Pronouncements (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 96.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;2.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accounting Standards Update 2014-15, &#8220;Presentation of Financial Statements&#8212;Going Concern&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial Statements&#8212;Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern ("ASU 2014-15").</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ASU 2014-15 provides guidance on management&#8217;s responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ASU 2014-15 also provides guidance related to the required disclosures as a result of management&#8217;s evaluation.&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is in the process of assessing the impact, if any, of ASU 2014-15 on its consolidated financial statements or related disclosures.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 17</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 2</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">V.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recently Issued Accounting Pronouncements (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 96.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;3.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accounting Standard Update 2014-16, &#8220;Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In November 2014, the FASB issued Accounting Standard Update 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity ("ASU 2014-16").</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The amendments in ASU 2014-16 clarify how current U.S. GAAP should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. Specifically, the amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract. Furthermore, the amendments clarify that no single term or feature would necessarily determine the economic characteristics and risks of the host contract. Rather, the nature of the host contract depends upon the economic characteristics and risks of the entire hybrid financial instrument. The amendments also clarify that, in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (i.e., the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weigh those terms and features. The assessment of the substance of the relevant terms and features should incorporate a consideration of the characteristics of the terms and features themselves; the circumstances under which the hybrid financial instrument was issued or acquired; and the potential outcomes of the hybrid financial instrument, as well as the likelihood of those potential outcomes.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The amendments in ASU 2014-16 apply to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of a share.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The amendments in ASU 2014-16 are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015 (fiscal 2016 for the Company). Early adoption, including adoption in an interim period, is permitted. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The effects of initially adopting the amendments in ASU 2014-16 should be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Management believes that the provisions of ASU 2014-16 will not impact the classification of the Series A or Series B Preferred Stock.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 18</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC</font></font></div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 2</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">V.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recently Issued Accounting Pronouncements (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 96.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;4.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accounting Standard Update 2015-11, &#8220;Simplifying the Measurement of Inventory&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In July, 2015, The FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11").</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out (LIFO) and the retail inventory method (RIM) are not impacted by the new guidance. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early adoption is permitted as of the beginning of an interim or annual reporting period.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is in the process of assessing the impact, if any, of ASU 2015-11 on its consolidated financial statements.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 19</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 3</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INVENTORIES</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="91%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">US dollars</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Raw materials</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">205,645</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">55,557</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Work in process</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">551,111</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,459</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Finished products</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,467</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,637</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">816,223</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">83,653</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 4</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OTHER CURRENT ASSETS</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="91%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">US dollars</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,206</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">46,094</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Government Institution (*)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">211,586</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">67,748</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">268,792</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">113,842</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 68.05pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(*)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Represents amounts advanced by Integrity Israel to the Israeli tax authorities or amounts owed to Integrity Israel by the Israeli Value Added Tax authorities.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 5</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PROPERTY AND EQUIPMENT, NET</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="91%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">US dollars</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Computers</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">240,066</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">124,161</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Furniture and office equipment</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">200,548</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">184,379</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Leasehold improvements</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32,898</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22,992</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">473,512</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">331,532</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less &#8211; accumulated depreciation</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(253,049</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(209,041</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">220,463</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">122,491</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the years ended December&#160;31, 2015, 2014 and 2013, depreciation expenses amounted to $44,891, $34,683 and $33,684, respectively, and new equipment purchases amounted to $143,736, $63,455 and $64,252, respectively.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 6</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OTHER CURRENT LIABILITIES</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="91%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">US dollars</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Employees and related institutions</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">240,358</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">204,890</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued expenses and other</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">187,528</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">235,874</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">427,886</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">440,764</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 20</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 7</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LINE OF CREDIT</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December&#160;31, 2015, the Group had an unutilized credit line of approximately $38,500 (NIS&#160;150,000) with its Israeli bank. Borrowings under the line of credit are secured by funds on deposit with the bank at the time of borrowing, which generally must be sufficient to cover the principal amount of the borrowings in full.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 8</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LONG-TERM LOANS FROM STOCKHOLDERS</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the years 2003-2004, Integrity Israel received loans from stockholders (three separate lenders).&#160;&#160;The loans are indexed to the Israeli Consumer Price Index from their origination date and bear no interest.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Group will be required to pay the loans, in quarterly installments, commencing on the first quarter following the first fiscal year in which the Group reports net profit in its annual report.&#160;&#160;At such time, the Group will be required to make quarterly payments equal to 10% of its total sales for each quarter until the loans have been repaid in full.&#160;&#160;Notwithstanding the repayment mechanism, the Group will not be required to repay the loans during any period in which such payment would cause a deficit in the Group's working capital. See Note 9D for a description of the repayment of the stockholder loan previously owing to Y.H. Dimri Holdings (2001) Ltd. (&#8220;Dimri&#8221;).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December 31, 2015, the Group does not expect to make any additional material repayments during the following 12 months period, if any, and accordingly other loans from stockholders have been presented as long-term liabilities.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 21</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 9</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMITMENTS AND CONTINGENT LIABILITIES</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">A.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 4, 2004, the OCS provided Integrity Israel with a grant of approximately $93,300 (NIS 420,000), for its plan to develop a non-invasive blood glucose monitor (the &#8220;Development Plan&#8221;). Integrity Israel is required to pay royalties to the OCS at a rate ranging between 3-5% of the proceeds from the sale of the Group's products arising from the Development Plan up to an amount equal to $93,300, plus interest at LIBOR from the date of grant. As of December&#160;31, 2015, the contingent liability with respect to royalty payment on future sales equals approximately $83,341, excluding interest. Such contingent obligation has no expiration date.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">B.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Until mid of December 2015, Integrity Israel leased approximately 3,100 sq. ft. of office space in the city of Ashkelon, Israel as its principal offices and prototype laboratory.&#160;&#160;Pursuant to a verbal agreement with the landlord, Integrity Israel leased this facility on a monthly basis at a cost of approximately $2,934 (NIS 11,500). Currently, Integrity Israel leases approximately 5,500 sq. ft. of office space in the city of Ashdod, Israel for its principal offices.&#160;&#160;The lease term began on December&#160;1, 2015 for a period of 5 years which can be extended for an additional 5 years at the option of the Company. Monthly lease payments including maintenance approximate $10,000. The Company estimates that its minimal rent and maintenance payments will approximate $120,000 per&#160;year over each of&#160;the next 5 years. In connection with the lease agreement, Integrity Israel provided the landlord a bank guarantee in the amount of approximately $35,000 (NIS&#160;137,162) that can be exercised by the landlord in the case Integrity Israel fails to pay the monthly rent payments.&#160;&#160;The guarantee is renewed on an annual basis for a period of 5 years and is secured by funds on deposit with the bank, which generally must be sufficient to cover the principal amount guarantee.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">C.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During 2014, the Company engaged the Placement Agent in connection with an offering of up $25,000,000 of its securities, which engagement ultimately culminated in the issuance and sale of $8,500,000 Series B Units (the &#8220;2014 Offering&#8221;). Pursuant to a placement agent agreement with the Placement Agent entered into with respect to such private placement, the Placement Agent (or its sub-agents) was paid, as a commission, an amount equal to 6% of the funds raised in each, such offering, plus 4% of the funds as a management fee plus a 3% non-accountable expense allowance (13% in the aggregate), all in cash.&#160;&#160;In addition, pursuant to such placement agent agreement, the Company was required to and did issue to the Placement Agent (or its sub-agents) warrants to purchase up to 10% of the shares of Common Stock issued to investors (or underlying convertible securities issued to investors) in connection with such offerings at a price per share equal to the offering price subject to certain price adjustments.&#160;&#160;Based on the agreement signed on 2014, the Placement Agent will have a right of first refusal on any private equity, debt or rights offering for a period of 24 months from the date on which marketing efforts with respect to the 2014 Offering began. In addition, pursuant to such agreement, the Company is required to use its reasonable efforts to have the Placement Agent named as a co-underwriter in any secondary public offering by the Company in the 12 months following completion of the 2014 Offering. In addition, starting in September 2013, the Company retained the Placement Agent to provide certain advisory services for a monthly fee of $12,500 for the period September 2013 until December 2014 and $20,000 per month starting from January 2015.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company paid the Placement Agent $185,000 $1,255,606 and $820,493, in cash during 2015, 2014, and 2013, respectively.&#160;&#160;See Notes 10B, Note 10C and Note 10E.1 with respect to warrants issued to the Placement Agent.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 22</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 9</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMITMENTS AND CONTINGENT LIABILITIES (cont.)</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">D.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">From June of 2011 Integrity Israel, Avner Gal, David Malka, Zvi Cohen, Ilana Freger and Alexander Raykhman, on the one hand, and Dimri, on the other hand, which was a shareholder of Integrity Israel prior to the reorganization and merger (See Note 1A above), were involved in arbitration proceedings resulting from certain claims asserted by Dimri following such reorganization. On March 11, 2015, the arbitrator issued a binding arbitration decision (the &#8220;Arbitration Decision&#8221;) which documents the parties&#8217; negotiated settlement of such arbitration proceedings.&#160;&#160;Pursuant to the terms of the Arbitration Decision, (1) Avner Gal, David Malka, Zvi Cohen, Ilana Freger and Alexander Raykhman transferred to Dimri, on March 18, 2015, an aggregate of 440,652 shares of the Company&#8217;s outstanding Common Stock held collectively by such shareholders, (2) Integrity Israel (A) paid to Dimri on March 23, 2015, NIS 1,767,674 or $439,939 (based on the exchange rate of 4.018 NIS:$1 as of March 23, 2015), as repayment in full of the outstanding principal amount under Dimri&#8217;s investment agreement with Integrity Israel and the founders (the &#8220;Investment Agreement&#8221;), as adjusted for changes in the Israeli consumer price index since the date on which the loan was made, and (B) paid to Dimri on April 30, 2015, NIS 316,100 or $81,870 (based on the exchange rate of 3.861 NIS:$1 as of April 30, 2015), as partial reimbursement of Dimri&#8217;s attorney&#8217;s fees in the arbitration. The Company accrued for the fee reimbursement obligation as part of professional fees within selling, marketing and general and administrative expenses included in its results of operations for the fiscal year ended December 31, 2014. During March 2015, such amount was fully paid.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Following the completion of the abovementioned transfers and payments, pursuant to the Arbitration Decision, Integrity Israel, the Company and the other defendants in the arbitration were released from any legal claim by Yigal Dimri, the principal shareholder of Dimri, and any other companies under his control in respect of the subject matter of the arbitration, including the shareholder loan granted under and any claim of anti-dilution rights under the Investment Agreement, and Mr. Dimri and all companies under his control were released from any legal claim by Integrity Israel, the Company and the other defendants in the arbitration in respect of the subject matter of the arbitration.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 23</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 10</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">A.</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description of the rights attached to the Common Stock</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Each share of Common Stock entitles the holder to one vote, either in person or by proxy, on each matter submitted to the approval of the Company&#8217;s stockholders.&#160;&#160;The holders of Common Stock are not permitted to vote their shares cumulatively.&#160;&#160;As described below, holders of Preferred Stock are entitled to vote together with the holders of Common Stock on an as-converted basis.&#160;&#160;Accordingly, the holders of the Company's Common Stock together with the holders of the Preferred Stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of the directors and, in such event, the holders of the remaining shares will not be able to elect any of such directors.&#160;&#160;The vote of the holders of a majority of the issued and outstanding shares of Common Stock, voting together with the holders of the Preferred Stock on an as converted basis, are entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to any act or action submitted to the vote of the Company&#8217;s stockholders, except as otherwise provided by law.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.</font></font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Description of the rights attached to the Series A Preferred Stock</font></font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Holders of Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, based on the stated value per share of the Series A Preferred Stock, which was initially $1,000 per share.&#160;&#160;Dividends on the Series A Preferred Stock are payable quarterly on March 31, June 30, September 30 and December 31 of each year, beginning on March 31, 2013, and on each conversion date (with respect to the shares of Series A Preferred Stock being converted).&#160;&#160;Until September 13, 2013, dividends were payable only in cash. Thereafter, dividends on the Series A Preferred Stock became payable, at the option of the Company, in cash and/or, if certain conditions are satisfied (including, among others, that the volume weighted average trading price for the Common Stock on its principal trading market is equal to or greater than 110% of the then current conversion price for the Series A Preferred Stock for five consecutive trading days prior to the dividend payment date), in shares of Common Stock, valued at the then current conversion price of the Series A Preferred Stock.&#160;&#160;The Company will incur a late fee of 9% per annum, payable in cash, on dividends that are not paid within three trading days of the applicable dividend payment date. During the years ended December 31, 2015, 2014 and 2013 the Company paid an aggregate of $57,061, $370,441 and $288,248, respectively, in cash dividends to its Series A Preferred Stockholders.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company may become obligated to redeem the Series A Preferred Stock in cash upon the occurrence of certain triggering events, including, among others, a material breach by the Company of certain contractual obligations to the holders of the Series A Preferred Stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Common Stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or a regulated quotation service.&#160;&#160;In addition, upon the occurrence of certain triggering events, each holder of Series A Preferred Stock will have the option to require the Company to redeem such holder&#8217;s shares of Series A Preferred Stock for a redemption price payable in shares of Common Stock or receive an increased dividend rate of 9% on all of such holder&#8217;s outstanding Series A Preferred Stock.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subject to certain conditions, the Company will have the option to force the conversion of the Series A Preferred Stock (in whole or in part) if the volume weighted average price for the Common Stock on its principal trading market exceeds $11.60 for each of any 20 trading days during any 30 consecutive Trading Day period and the average daily dollar trading value for the Common Stock during such 30 day period exceeds $100,000.&#160;&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 24</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 10</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">A.</font></font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2</font>.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Description of the rights attached to the Series A Preferred Stock (cont.)</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If the Company fails to timely deliver certificates for shares of Common Stock issuable upon conversion of the Series A Preferred Stock (the &#8220;Series A Conversion Shares&#8221;) and, as a result, the holder is required by its brokerage firm to purchase shares of Common Stock to deliver in satisfaction of a sale by such holder of the Series A Conversion Shares (a &#8220;Buy-In&#8221;), the Company will be required to: (a) pay the converting holder in cash an amount equal to the amount, if any, by which such holder&#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds the product of (i) the aggregate number of Series A Conversion Shares due to the holder, multiplied by (ii) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions); and (b) at the option of such holder, either reissue (if surrendered) the shares of Series A Preferred Stock equal to the number of shares of Series A Preferred Stock submitted for conversion (in which case, such conversion will be deemed rescinded) or deliver to such holder the number of shares of Common Stock that would have been issued if the Company had timely complied with its delivery requirements.&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, the Company will be required to pay partial liquidated damages of $10 for each $1,000 of stated value of any shares of Series A Preferred Stock which have been converted by a holder and in respect of which the Company fails to deliver Series A Conversion Shares by the eighth trading day following the applicable conversion date.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subject to the beneficial ownership limitation described below, holders of Series A Preferred Stock will vote together with the holders of Common Stock on an as-converted basis.&#160;&#160;Holders will not be permitted to convert their Series A Preferred Stock if such conversion would cause such holder to beneficially own more than 4.99% of the outstanding number of shares of Common Stock outstanding after giving effect to such conversion (subject to increase to 9.99%, at the option of the holder, upon no less than 61 days prior written notice to the Company) (the &#8220;Beneficial Ownership Limitation&#8221;).&#160;&#160;In addition, no holder may vote any shares of Series A Preferred Stock (on an as converted to Common Stock basis) in excess of the Beneficial Ownership Limitation.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subject to certain limitations, so long as any initial Series A Unit purchaser holds any shares of Series A Preferred Stock, if (1) the Company sells any shares of Common Stock or other securities convertible into, or rights to acquire, Common Stock and (2) a Purchaser then holding Series A Preferred Stock, Warrants, Conversion Shares or Warrant Shares (defined below) reasonably believes that any of the terms and conditions appurtenant to such issuance or sale are more favorable to the purchaser in such subsequent sale of securities than are the terms and conditions granted to such Purchaser, then the Purchaser will be permitted to require the Company to amend the terms of this transaction (only with respect to such Purchaser) so as to match the terms of the subsequent issuance (including, for the avoidance of doubt, any terms and provisions that are or may be less favorable to such Purchaser).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The conversion price of the shares of Series A Preferred Stock that were included in the Series A Units is subject to adjustment for certain issuances of Common Stock or other securities of the Company at an effective price per share that is lower than the conversion price then in effect ($5.80 per share at December 31, 2015 and 2014), as well as for stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 25</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 10</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">A.</font></font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3</font>.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Description of the rights attached to the Series B Preferred Stock</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Holders of Series B Preferred Stock are entitled to receive cumulative dividends at a rate of 5.5% per annum, based on the stated value per share of Series B Preferred Stock. Dividends on the Series B Preferred Stock are payable quarterly on March 31, June 30, September 30 and December 31 of each year, beginning on September 30, 2014, and on each conversion date (with respect to the shares of Series B Preferred Stock being converted). For so long as required under the terms of the Certificate of Designations for the Company&#8217;s outstanding Series A Preferred Stock, dividends on Series B Preferred Stock will be payable only in shares of Common Stock. Thereafter, dividends on the Series B Preferred Stock will be payable, at the option of the Company, in cash and/or, if certain conditions are satisfied, shares of Common Stock or a combination of both. Shares of Common Stock issued as payment of dividends will be valued at the lower of (a) the then current conversion price of the Series B Preferred Stock or (b) the average of the volume weighted average price for the Common Stock on the principal trading market therefor for the 10 trading days immediately prior to the applicable dividend payment date. The Company will incur a late fee of 9% per annum, payable in cash, on dividends that are not paid within three trading days of the applicable dividend payment date. As of December 31, 2015 and 2014 the Company issued a total of 168,926 and 18,986 shares of Common Stock, respectively at an estimated fair value of $390,219 and $43,858, respectively as in kind dividends to holders of Series B Preferred Stock.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subject to certain ownership limitations described below, the Series B Preferred Stock is convertible at the option of the holder at any time and from time to time into shares of Common Stock at a conversion price of $5.80 per share (calculated by dividing the stated value per share of Series B Preferred Stock, which is initially $1,000, by the conversion price per share). The conversion price of the Series B Preferred Stock is subject to adjustment for certain issuances of Common Stock or other securities of the Company at an effective price per share that is lower than the conversion price then in effect, as well as for stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. In addition, the holders of Series B Preferred Stock will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of Common Stock to the same extent as if such holders of Series B Preferred Stock had converted all of their shares of Series B Preferred Stock prior to such distribution. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations of the Company, the holders of Series B Preferred Stock will be entitled to receive, upon conversion of their shares of Series B Preferred Stock, any securities or other consideration received by the holders of the Common Stock pursuant to the fundamental transaction.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subject to certain conditions contained in the Certificate of Designations, Preferences and Rights relating to the Series B Preferred Stock, the Company will have the option to force the conversion of the Series B Preferred Stock (in whole or in part) if (a) the volume weighted average price for the Common Stock on its principal trading market exceeds $10.00 for each of any 20 trading days during any 30 consecutive Trading Day period and the average daily dollar trading value for the Common Stock during such 30 day period exceeds $50,000 or (b) the Company receives approval to list the Common Stock on a national securities exchange.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 26</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 10</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">A.</font></font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3</font>.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Description of the rights attached to the Series B Preferred Stock (cont.)</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If the Company fails to timely deliver certificates for shares of Common Stock issuable upon conversion of the Series B Preferred Stock (the &#8220;Series B Conversion Shares&#8221;) which results in a Buy-In, the Company will be required to: (a) pay the converting holder in cash an amount equal to the amount, if any, by which such holder&#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds the product of (i) the aggregate number of Series B Conversion Shares due to the holder, multiplied by (ii) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions); and (b) at the option of such holder, either reissue (if surrendered) the shares of Series B Preferred Stock equal to the number of shares of Series B Preferred Stock submitted for conversion (in which case, such conversion will be deemed rescinded) or deliver to such holder the number of shares of Common Stock that would have been issued if the Company had timely complied with its delivery requirements.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, the Company will be required to pay partial liquidated damages of $10 for each $1,000 of stated value of any shares of Series B Preferred Stock which have been converted by a holder and in respect of which the Company fails to deliver Series B Conversion Shares by the eighth trading day following the applicable conversion date.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As long as at least 35% of the originally issued shares of Series B Preferred Stock are outstanding, without the written consent of the holders of a majority in stated value of the outstanding Preferred Stock, the Company will not be permitted to, among other things, incur indebtedness or liens not permitted under the Certificate of Designations for the Series B Preferred Stock; repay, repurchase, pay dividends on or otherwise make distributions in respect of any shares of Common Stock or other securities junior to the Series B Preferred Stock; or enter into certain transactions with affiliates of the Company.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subject to any limitations under the terms of the Certificate of Designations for the Company&#8217;s outstanding Series A Preferred Stock, the Company may become obligated to redeem the Series B Preferred Stock in cash upon the occurrence of certain triggering events, including, among others, a material breach by the Company of certain contractual obligations to the holders of the Series B Preferred Stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Common Stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or a regulated quotation service. In addition, upon the occurrence of certain triggering events, each holder of Series B Preferred Stock will have the option to require the Company to redeem such holder&#8217;s shares of Series B Preferred Stock for a redemption price payable in shares of Common Stock or receive an increased dividend rate of 9% on all of such holder&#8217;s outstanding Series B Preferred Stock.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subject to the Beneficial Ownership Limitation, holders of Series B Preferred Stock will vote together with the holders of Common Stock and Series A Preferred Stock on an as-converted basis. Holders will not be permitted to convert their Series B Preferred Stock if such conversion would cause such holder to beneficially own shares of outstanding Common Stock in excess of the Beneficial Ownership Limitation.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subject to certain limitations, so long as any Purchaser holds any shares of Series B Preferred Stock, if (a) the Company sells any shares of Common Stock or other securities convertible into, or rights to acquire, Common Stock and (b) a Purchaser then holding Series B Preferred Stock, Series B Warrants, Conversion Shares or Warrant Shares (defined below) reasonably believes that any of the terms and conditions appurtenant to such issuance or sale are more favorable to the purchaser in such subsequent sale of securities than are the terms and conditions granted to such Purchaser, then the Purchaser will be permitted to require the Company to amend the terms of this transaction (only with respect to such Purchaser) so as to match the terms of the subsequent issuance (including, for the avoidance of doubt, any terms and provisions that are or may be less favorable to such Purchaser).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 27</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 10</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">&#160;</td>
<td align="right" style="WIDTH: 27pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">B.</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The 2012 Offering</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On November 19, 2012, the Company issued 165,057 shares of its Common Stock at a price of $7.00 per share, for a total consideration of $1,155,399.&#160;&#160;The issuance and sale of such shares constituted the initial closing (the &#8220;Initial Closing&#8221;) of the 2012 Offering, which was originally structured as an offering of up to&#160;&#160;785,714 shares of its Common Stock to accredited investors (the &#8220;First Closing Purchasers&#8221;) at a price of $7.00 per share in a private placement transaction.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subsequent to the Initial Closing, the 2012 Offering was converted from an offering of Common Stock to an offering of Units and, on March 13, 2013, the Company entered into a Securities Purchase Agreement with certain accredited investors (the &#8220;Series A Unit Purchasers&#8221;) pursuant to which the Company issued to the Series A Unit Purchasers an aggregate of 6,300 Series A Units.&#160;&#160;The shares of Series A Preferred Stock comprising the Series A Units were convertible into an aggregate of 1,086,178 shares of Common Stock (based on a conversion price per share of $5.80) and the Series A Warrants comprising the Series A Units were exercisable into an aggregate of 1,086,178 shares of Common Stock at an original exercise price per share of $6.96, in each case subject to adjustment as described below (See also Note10D). After giving effect to the payment of commissions to the Placement Agent for the offering and the payment of certain offering expenses, the Company received net proceeds from the offering of approximately $5.4 million (See Note 9C).&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The issuance and sale of the Series A Units constituted the second and final closing of an offering of the Company&#8217;s securities in a private placement transaction.&#160;&#160; As a result of the conversion of the offering from an offering of Common Stock to an offering of Series A Units, the Company agreed with the Placement Agent that the Company would exchange the shares of Common Stock acquired by each First Closing Purchaser in the Initial Closing for such number of Series A Units equal to the aggregate purchase price paid by such First Closing Purchaser in the Initial Closing, divided by $1,000, in each case subject to the execution by the First Closing Purchaser of a consent to such modification.&#160;&#160;Pursuant to this agreement, on May 13, 2013, the Company cancelled 162,907 of the 165,057 shares of Common Stock issued to the First Closing Purchasers and issued to such purchasers an aggregate of 1,140.35 Series A Units.&#160;&#160;These Units included Series A Preferred Stock convertible into an aggregate of 196,597 shares of Common Stock and Series A Warrants exercisable for 196,597 shares of Common Stock.&#160;&#160;The total fair value of such Series A Units was equal to the amount originally invested by the First Closing Purchasers that consented to exchange their shares into Units ($1,140,349).&#160;&#160;As a result, during 2013, the total fair value of such Series A Units was classified out of stockholders equity and was presented as temporary equity (convertible Series A Preferred Stock) and liability (warrant with down-round protection), as applicable to each instrument.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the 2012 Offering, the Company also agreed with the Placement Agent for the offering that, following the closing of the sale of the Series A Units, the Company would issue to the holders of the 1,295,535 shares of Common Stock issued by the Company at a price of $6.25 per share pursuant to the Company&#8217;s previously completed private placement of Common Stock (occurred during 2011 and 2010) such number of shares of Common Stock as would effectively reduce the per share purchase price paid by such holders for such shares from $6.25 per share to $5.80 per share, in each case subject to the execution by the holder of a consent to such modification. As a result, upon the receipt of executed consents to modification from all such holders, the Company has issued or will be required to issue to such holders an aggregate of additional 100,526 shares of Common Stock, of which 92,136 and 654 shares of Common Stock were issued during the years ended December 31, 2015 and 2014, respectively.&#160;The issuance or proposed issuance of such shares has been accounted for as a stock dividend.&#160;&#160;As of September 30, 2013, the Common Stock had an estimated fair value of $2.77 per share.&#160;&#160; Accordingly, an amount of $278,263 representing the fair value of the shares was charged to the accumulated deficit against additional paid in capital.</font></font></div>
</div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the 2012 Offering the Company incurred a total of $1,479,864 of issuance costs of which $562,805 attributable to non-cash compensation expenses relating to warrants issued to the Placement Agent (See Notes 9C and <font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline">Note 10E.1.d</font>). The allocation of the issuance proceeds to the Preferred Stock and to the detachable warrants and their respective issuance costs is described in Note 2T and Note&#160;2U above.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 28</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 10</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 74pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">C.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The 2014 Offering</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 9pt">&#160;</td>
<td style="WIDTH: 90.75pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During August until December 31, 2014, the Company raised $8.5 million in gross proceeds from the issuance of 8,500 Series B Units. After giving effect to the payment of commissions to the Placement Agent (See Note 9C) for the offering and the payment of certain offering expenses, the Company received net proceeds from the offering of approximately $7.3 million. The Series B Warrants have a five-year term commencing on the closing dates, as applicable. Until the end of the term, the Series B Warrants included in the Series B Units will be exercisable into Common Stock at any time and from time to time at an exercise price of $5.80 per share (with respect to the Series B-1 Warrants) or $10.00 per share (with respect to the Series B-2 Warrants). The Series B Warrants contain adjustment provisions substantially similar to those of the Series B Preferred Stock (See Note 10.A.3), except that the Series B Warrants shall not include dilution protection for issuances of securities at an effective price per share lower than the conversion price of such Series B Warrants. No holder may exercise its Series B Warrants in excess of the Beneficial Ownership Limitation.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90.75pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>&#160;</td>
</tr></table>
</div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 9pt">&#160;</td>
<td style="WIDTH: 90.75pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the 2014 Offering the Company incurred a total of $1,787,545 of issuance costs of which $630,936 attributable to non-cash compensation expenses relating to warrants issued to the Placement Agent (See Notes 9C and Note 10E.1.d). The allocation of the issuance proceeds to the Series B Preferred Stock and to the detachable Series B Warrants and their respective issuance costs is described in Note 2T.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 9pt">&#160;</td>
<td style="WIDTH: 90.75pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the Securities Purchase Agreement, dated March 13, 2013, relating to the issuance by the Company of Series A Units, the Company was required to and did notify the holders of the Series A Preferred Stock of the closing of the sale of the Series B Units, and following receipt thereof such holders of Series A Preferred Stock were entitled pursuant to the &#8220;most favored nation&#8221; provision included in the Securities Purchase Agreement for the 2012 Offering, to elect to amend the terms of their purchase of Series A Units to match the terms of the Series B Units. As of December 31, 2015, the holders of an aggregate of approximately 6,931 Series A Units have so elected to amend the terms of their Series A Units to match the terms of the Series B Units. Accordingly, the Company has exchanged 6,931 shares of Series A Preferred Stock into 6,931 shares of Series B Preferred Stock and 1,440,880 Series A Warrants into 1,200,710 Series B-1 Warrants and 1,200,710 Series B-2 Warrants. Due to the differences in the contractual terms of each of the financial instruments exchanged, management determined that the exchange constituted an extinguishment of the existing instruments and an issuance of new financial instruments. As a result of the exchange elections, the Company recorded during the year ended December 31, 2015 a non-cash loss on extinguishment of Series A Preferred Stock and Series A Warrants in the amount of $1,284,354, resulting from the differences between the fair market value estimate of the new Series B Units less the net book value of the exchanged Series A Preferred Stock and less the fair value of the exchanged Warrants with down-round protection as of the date of the exchange.</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 74pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">D.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrants with down round protection</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Series A Warrants included in the Series A Units have a five-year term commencing on their issuance date. In accordance with their original terms, the Warrants were exercisable at any time at an exercise price of $6.96 per share.&#160;&#160;The Series A Warrants contain adjustment provisions substantially similar to the adjustment provisions of the Series A Preferred Stock (See Note 10A.2), including provisions requiring an adjustment of the number of shares and the exercise price of the Series A Warrants to the price at which the Company subsequently issues shares or other equity-linked financial instruments, if that price is less than the original exercise price of the Series A Warrants (down-round protection).&#160;&#160;In addition, the Series A Warrants provide for protection for a Buy-In on substantially the same terms as described above with respect to the Series A Preferred Stock.&#160;&#160;No holder may exercise its Series A Warrants in excess of the Beneficial Ownership Limitation.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 29</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 10</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 74pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">D.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrants with down round protection (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As a result of the issuance of the Series B Units, pursuant to the terms of the Series A Warrants, on August 29, 2014, the exercise price per share of the Series A Warrants decreased from $6.96 per share to $5.80 per share and the number of shares of Common Stock issuable upon exercise of each such warrant, in the aggregate, increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price, will be equal to the aggregate exercise price prior to such adjustment. During the year ended December 31, 2015, the Company exchanged 1,440,880 Series A Warrants into 1,200,710 Series B-1 Warrants and 1,200,710 Series B-2 Warrants (See Note 10C). As of December 31, 2015 and 2014, an aggregate of 380,953, 1,539,364 Series A Warrants, respectively, were outstanding and exercisable into the identical number of shares of Common Stock.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has determined its derivative warrant liability to be a Level 3 fair value measurement and has used the Binomial pricing model to calculate its fair value. Because the warrants contain a price protection feature, the probability that the exercise price of the warrants would decrease as the stock price decreased was incorporated into the valuation calculations.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The changes in the fair value of the Level 3 liability are as follows (in US dollars):</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="87%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Series A Warrants</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance, Beginning of the year</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,057,618</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,216,705</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Classification from stockholders deficit</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">400,671</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exchange of Series A Warrants pursuant to the &#8220;Most favored nation&#8221; provision</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,586,831</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value of Series A Warrants</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(149,092</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,559,758</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance, End of year</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">321,695</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,057,618</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The key inputs used in the fair value calculations were as follows:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="87%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dividend yield (%)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected volatility (%) (*)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">105.14</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">105.14</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk free interest rate (%)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.99</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.14</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected term of options (years) (**)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.20</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.20</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise price (US dollars)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.80</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.80</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Share price (US dollars) (***)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.31</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.31</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value (US dollars)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.84</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.13</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 100pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(*)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Due to the low trading volume of the Company&#8217;s Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 100pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(**)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No.&#160;110.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(***)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Common Stock price, per share reflects the Company&#8217;s management&#8217;s estimation of the fair value per share of Common Stock as of December 31, 2015 and 2014. In reaching its estimation for December 31, 2015 and 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the 2014 Offering.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 30</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 10</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">E.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock-based compensation</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 96.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Grants to non-employees</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In August 2005, Integrity Israel granted 21,640 options with an exercise price of $0.001 per share in consideration of regulatory services. In October 2006, Integrity Israel granted 45,531 options with an exercise price of $4.305 per share in consideration of investor finders, of which 17,657 were forfeited. In November 2008, Integrity Israel granted 8,989 options with an exercise price of $5.517 per share in consideration of investor finders, of which 5,365 were forfeited. Following the merger with Integrity Israel, the options were replaced with options of the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the 2010 Offering, the Company issued to the Placement Agent warrants to purchase 45,097 and 84,459 shares, respectively, of the Company's Common Stock, with an exercise price of $6.25 per share, in 2011 and 2010, respectively.&#160;&#160;The warrants expire on the fifth anniversary of the date on which the shares of Common Stock underlying such warrants are fully registered with the SEC.&#160;&#160;The warrants include customary adjustment provisions for stock splits, reorganizations and other similar transactions. As a result of the issuance of the Series B Units, pursuant to the terms of the warrants, on August 29, 2014, the exercise price per share of the applicable warrants decreased from $6.25 per share to $5.80 per share and the number of shares of Common Stock issuable upon exercise of each such warrant, in the aggregate, increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price, will be equal to the aggregate exercise price prior to such adjustment. As of December 31, 2015 and 2014 the Placement Agent was entitled to an aggregate of 139,608 shares of Common Stock at an exercise price of $5.80 in connection with the 2010 Offering. See also Note 18.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the 2012 Offering, the Company issued to the Placement Agent (a) 5 year warrants to purchase up to 128,277 shares of Common Stock at an exercise price of $5.80 per share and (b) 5 year warrants to purchase up to 128,277 shares of Common Stock at an exercise price of $6.96 per share and (c) 5 year warrants to purchase up to 215 shares of Common Stock at an exercise price of $7.00 per share.&#160;&#160;Such warrants have substantially the same terms as those issued to the Series A Unit Purchasers except that the Placement Agent warrants may also be exercisable on a cashless basis at all times.&#160;As a result of the issuance of the Series B Units, pursuant to the terms of the warrants, on August 29, 2014, the exercise price per share of the applicable warrants decreased from $6.96 and $7.00 per share to $5.80 per share and the number of shares of Common Stock issuable upon exercise of each such warrant, in the aggregate, increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price, will be equal to the aggregate exercise price prior to such adjustment. As of December 31, 2015 and 2014 the Placement Agent was entitled to an aggregate of 282,469 shares of Common Stock at an exercise price of $5.80 in connection with the 2012 Offering. See also Note 18.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 144pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December 31, 2015 and 2014, the average fair value per warrant that were affected by the down-round protection, were estimated at $0.84 and $1.13, respectively using the following assumptions: dividend yield of 0% for both years, expected volatility of 105.14% for both years, risk free interest rate of 0.99% and 1.14%, respectively, stock price of $2.31 for both years and exercise price of $5.80 for both years. As a result of the anti-dilution protection, the Company classified during the year ended December 31, 2014 an amount of $400,671 out of stockholders deficit and presented as Warrants with Down-Round Protection within long-term liabilities see also Note 10D.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 31</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 10</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">E.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock-based compensation (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Grants to non-employees (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">d.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the 2014 Offering, the Company issued to the Placement Agent (a) 5 year warrants to purchase up to 293,115 shares of Common Stock at an exercise price of $5.80 per share and (b) 5 year warrants to purchase up to 146,559 shares of Common Stock at an exercise price of $10.00 per share. The terms of the Placement Agent warrants are substantially similar to the terms of the Series B Warrants except that the Placement Agent warrants may also be exercisable on a cashless basis at all times.&#160;The average fair value per warrant of approximately $1.40 was estimated using the following assumptions: dividend yield of 0%, expected volatility of 105.14%, risk free interest rate of 1.66%, stock price of $2.31 and exercise price ranging between $5.80 and 10.00, as applicable.</font></div>
</td>
</tr></table>
</div>

<div>
<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">e.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September 10, 2013 the Company granted 26,484 options with an exercise price of $9.50 per share in consideration of investor relations services. The options vest ratably over a period of 12 months from the date of grant and will expire on the fifth anniversary thereof, subject to certain limitations. During 2014, following the termination of the agreement with the investor relations company, 8,828 options were forfeited. In connection with this grant the Company recorded during the years ended December 31, 2014 and 2013 non-cash compensation expenses amounting to $18,204 and $16,657, respectively. At December 31, 2014 and 2013 the fair value per option of $1.17 and $2.52, respectively was estimated using the Black-Scholes option pricing model with the following assumptions for 2014: dividend yield of 0%, expected volatility of 105.14%, risk free interest rate of 1.14%, stock price of $2.31 and exercise price of $9.50 and with the following assumptions for 2013: dividend yield of 0%, expected volatility of 105.14%, risk free interest rate of 0.12%, stock price of $8.50 and exercise price of $9.50.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Grants to employees</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In August 2007, Integrity Israel&#8217;s Board of Directors ("Integrity Israel's Board") approved a stock option plan ("Integrity Israel's plan") for the grant, without consideration of options exercisable into ordinary shares of NIS&#160;0.01 par value of Integrity Israel to employees, officers and directors of Integrity Israel.&#160;&#160;The exercise price and vesting period for each grantee of options was determined by Integrity Israel's Board and specified in such grantee's option agreement.&#160;&#160;The options vested over a period of 1-12 quarters based on each grantee's option agreements.&#160;&#160;Any option not exercised within 10 years after the date of grant thereof will expire.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In July 2010, following the merger with Integrity Israel, the Company adopted the 2010 Share Incentive Plan (the "2010 Share Incentive Plan"), pursuant to which the Company's Board of Directors is authorized to grant options exercisable into Common Stock of the Company.&#160;&#160;As of December 31, 2015, the Company had reserved 529,555 shares of Common Stock for issuance under the 2010 Share Incentive Plan.&#160;&#160;On March 17, 2016, the Company&#8217;s Board of Directors approved an amendment to the 2010 Share Incentive Plan to increase the number of shares of the Company&#8217;s Common Stock reserved for issuance under the 2010 Share Incentive Plan to 1,000,000 shares.&#160;&#160;The purpose of the 2010 Share Incentive Plan is to offer an incentive to employees, directors, officers, consultants, advisors, suppliers and any other person or entity whose services are considered valuable to the Company, as well as to replace the Integrity Israel Plan and to replace all options granted in the past by Integrity Israel.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Upon the adoption of the 2010 Share Incentive Plan, all options granted under the Integrity Israel's Plan were replaced by options subject to the 2010 Share Incentive Plan on a 1 for 1 basis. As of December 31, 2015, there are 96,313 shares available for future grants under the 2010 Share Incentive Plan.</font></font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 32</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 10</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">E.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock-based compensation (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Grants to employees (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the terms of their respective employment agreements with the Company, in March 2012, the Company issued to Avner Gal, the Company&#8217;s Chief Executive Officer, and David Malka, the Company&#8217;s Executive Vice President of Operations, options to purchase up to 264,778 and 79,434 shares of Common Stock, respectively.&#160;&#160;The Options are exercisable at an exercise price of $6.25 per share.&#160;&#160;The options vested or will vest (as applicable), in 3 equal parts, upon the achievement of each of the following milestones: (i) submission of clinical trials&#8217; results to the Notified Body; (ii) receipt of CE mark approval; (iii) receipt of FDA approval.&#160;&#160;In the event of a merger and/or acquisition in which one or more of the abovementioned milestones have not yet been met, the options shall be deemed vested on the date of the merger and/or acquisition.&#160;&#160;All options granted as described above are subject to the terms of the 2010 Share Incentive Plan.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December 31, 2015, approximately $353,000 of unrecognized compensation costs are expected to be recognized upon receipt of the FDA approval, if and when received. The fair value of the shares was based on the recent share price applicable prior to the date of grant of such options.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following tables present a summary of the status of the grants to employees, officers and directors as of December&#160;31, 2015 and 2014:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="85%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted average exercise price (US$)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year ended December 31, 2015</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance outstanding at beginning of year</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">450,847</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.85</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(19,769</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.82</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Forfeited</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(17,605</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.01</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance outstanding at end of the year</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">413,473</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.04</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance exercisable at the end of the year</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">293,736</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.95</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 33</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 10</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">E.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock-based compensation (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Grants to employees (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="85%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted average exercise price (US$)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year ended December 31, 2014</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance outstanding at beginning of year</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">414,847</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.74</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">44,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.00</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Forfeited</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.25</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance outstanding at end of the year</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">450,847</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.85</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance exercisable at the end of the year</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">302,360</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.58</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The aggregate intrinsic value of the awards exercisable as of December&#160;31, 2015, 2014 and 2013 was $12,845, $23,830 and $882,471, respectively.&#160;&#160;The aggregate intrinsic value of the awards outstanding as of December 31, 2015, 2014 and 2013 was $12,845, $23,830 and $1,143,330, respectively. For the year ended December 31, 2015 and 2014 the amount represents the total intrinsic value based on the Company&#8217;s management&#8217;s estimation of the fair value per share of Common Stock based among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series B Units (See Note 10C). For the year 2013 management&#8217;s estimate of the Company&#8217;s stock price of $8.50 was determined based among other factors on the closing sale price for the Common Stock as reported on the OTCQB on December 27, 2013, which was the last reported sale of Common Stock in 2013.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following tables summarize information about options outstanding at December&#160;31, 2015:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="85%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exercise</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">price (US$)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Outstanding at December&#160;31, 2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted average remaining contractual life (years)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted average exercise price</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exercisable at December&#160;31, 2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted average remaining contractual life (years)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.72</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,758</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.60</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.72</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,758</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.60</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.63</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,730</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.60</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.63</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,730</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.60</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.01</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,273</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.04</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.03</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,273</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.04</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.25</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">351,712</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.20</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.25</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">236,975</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.20</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.00</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.00</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.50</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">413,473</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">293,736</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December 31, 2015, approximately $2,200 of unrecognized compensation costs (excluding compensation cost related to stock options granted to Mr. Avner Gal and Mr. David Malka) are expected to be recognized during the year ending December 31, 2016.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 34</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 10</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">E.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock-based compensation (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 99.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Grants to employees (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The fair value of options granted was estimated at the dates of grant using the Black-Scholes option pricing model.&#160;&#160;The following are the data and assumptions used:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="83%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dividend yield (%)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected volatility (%) (*)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">105.14</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk free interest rate (%)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.61</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected term of options (years) (**)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5-6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise price (US dollars)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.00</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock price (US dollars) (***)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.31</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value (US dollars)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.59</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 112.5pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(*)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Due to the low trading volume of the Company&#8217;s Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 113.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(**)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No.&#160;110.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 112.5pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(***)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Common Stock price, per share for the year ended December 31, 2014 reflects the Company&#8217;s management&#8217;s estimation of the fair value per share of Common Stock. In reaching its estimation for December 31, 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the 2014 Offering.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 35</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 11</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">RESEARCH AND DEVELOPMENT EXPENSES</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">US dollars</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year ended December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Salaries and related expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,303,614</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,128,672</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,293,067</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Professional fees</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">525,144</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">377,918</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">247,888</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Materials</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">166,736</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">96,699</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">154,522</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,132</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,156</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32,858</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Travel expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">39,324</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,867</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,131</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vehicle maintenance</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">54,936</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,888</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35,955</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">159,459</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">176,424</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">179,333</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,268,345</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,849,624</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,986,754</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 12</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">US dollars</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year ended December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Salaries and related expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">803,319</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">651,900</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">260,276</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Professional fees</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">990,390</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">739,893</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">562,435</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Travel &amp; expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">468,126</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">200,348</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">128,095</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vehicle maintenance</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">41,180</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">40,087</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,529</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">227,160</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">185,282</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">63,805</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,530,175</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,817,510</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,041,140</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 13</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FINANCING (INCOME) EXPENSES, NET</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">US dollars</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year ended December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Israeli CPI linkage difference on principal of loans from stockholders</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,521</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(556</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,382</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exchange rate differences</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">38,873</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(25,282</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">94,815</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value of Series A Warrants</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(149,092</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,559,758</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,251,242</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance cost allocated to warrants with down-round protection</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">390,928</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expenses on credit from banks and other</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,205</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,189</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,592</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,284,354</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,186,819</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,587,785</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,768,959</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 36</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 14</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INCOME TAX</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">A.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Measurement of results for tax purposes under the Israeli Income Tax (Inflationary Adjustments) Law, 1985 (the &#8220;Inflationary Adjustment Law&#8221;)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 9pt">&#160;</td>
<td style="WIDTH: 90.75pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commencing January&#160;1, 2008, the results of operations of Integrity Israel for tax purposes are measured on a nominal basis.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold">B</font>.</font></div>
</td>
<td>
<div align="justify">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Changes in the Israeli corporate tax rates</font></font></font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 6, 2011, the Law for the Change in the Tax Burden (Legislative Amendments) &#8211; 2011 was published.&#160;&#160;As part of this law, among other things, commencing from 2012 the corporate tax rate was increased to 25%.&#160;&#160;In addition, commencing in 2012, the tax rate on capital gains in real terms and the tax rate applicable to betterment in real terms were increased to 25%.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On July 30, 2013, the Israeli parliament approved the Law for the Change in National Priorities (Legislative Amendments to Achieve Budgetary Goals for 2013 and 2014) &#8211; 2013, which, among other things increased the standard Israeli corporate income tax rate from 25% to 26.5% effective as of January&#160;1, 2014.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 4, 2016, the Israeli parliament passed the Law for Amendment of the Income Tax Ordinance No. 216, which, among other things reduced the standard Israeli corporate income tax rate from 26.5% to 25% effective as of January 2016.</font></div>
</div>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">C.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Tax assessments</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company and Integrity Israel have not received final tax assessments since their inception.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">D.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Carryforward tax losses</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December&#160;31, 2015, the Company had cumulative net operating losses (NOL) for US federal purposes of approximately $3.1 million that will expire between the years 2031-2035. Integrity Israel has losses carry forward balances for Israeli income tax purposes of nearly $20.7 million to offset against future taxable income for an indefinite period of time.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">E.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following is a reconciliation between the theoretical tax on pre-tax income, at the tax rate applicable to the Company (federal tax rate) and the tax expense reported in the financial statements:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<table cellpadding="0" cellspacing="0" width="87%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">US dollars</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year ended December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pretax income (loss)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,842,172</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,980,426</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9,796,853</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Federal tax rate</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income tax expenses (benefit) computed at the ordinary tax rate</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,986, 338</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,043,149</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,428,899</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-deductible expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,050</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,250</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,250</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,503</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,415</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,570</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amortization of warrants with down round protection</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(50,691</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,295,915</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,324,760</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">436,680</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tax in respect of differences in corporate tax rates</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">340,263</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">278,466</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">253,942</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Losses and timing differences in respect of which no deferred taxes assets were recognized</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,224,533</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">932,635</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">818,377</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 37</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 14</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INCOME TAX (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">F.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Deferred taxes result principally from temporary differences in the recognition of certain revenue and expense items for financial and income tax reporting purposes.&#160;&#160;Significant components of the Group's future tax assets are as follows:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<table cellpadding="0" cellspacing="0" width="87%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">US dollars</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Composition of deferred tax assets:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Provision for employee-related obligation</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,494</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,220</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33,629</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-capital loss carry forwards</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,233,314</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,810,780</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,364,466</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Valuation allowance</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,256,808</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,831,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,398,095</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 15</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INCOME (LOSS) PER SHARE</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The loss and the weighted average number of shares used in computing basic and diluted loss per share for the years ended December 31, 2015, 2014 and 2013, are as follows:</font></font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<table cellpadding="0" cellspacing="0" width="91%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">US dollars</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year ended December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income (loss) for the year</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,842,172</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,980,426</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9,796,853</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock dividend to certain Common Stockholder</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(278,263</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash dividend on Series A Preferred Stock</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(57,061</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(370,441</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(288,247</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock dividend on Series B Preferred Stock</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(390,219</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(43,858</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income attributable to participating securities (Preferred Stock)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(596,472</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income (loss) for the period attributable to common stockholders</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,289,452</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,969,655</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,363,363</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<table cellpadding="0" cellspacing="0" width="91%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number of shares</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year ended December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common shares used in computing Basic income (loss) per share</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,476, 870</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,304,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,325,714</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Common shares used in computing Diluted income (loss) per share</font><font style="DISPLAY: inline; FONT-SIZE: 10pt"> (*)</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,476, 870</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,349,242</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,325,714</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total weighted average number of Common shares related to outstanding convertible Preferred Stock, options and warrants excluded from the calculations of diluted income (loss) per share (**)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,431,728</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,557,612</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,813,493</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(*)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In applying the treasury method, the average market price of Common Stock was based on management estimate. For December 31, 2015 and 2014, management estimation considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series B Units (See Note 10C). The fair value per share of the Company&#8217;s Common Stock as of December 31, 2013 was based on the management&#8217;s estimate which was based among other factors on the closing price per share of the Company&#8217;s Common Stock on December 27, 2013, as reported on the OTCQB, which was the last reported sale of Common Stock in 2013.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">&#160;</td>
<td>&#160;</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">&#160;</td>
<td align="right" style="WIDTH: 27pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(**)</font></div>
</td>
<td style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company excludes from the calculation of diluted income (loss) per share, shares that will be issued upon the exercise of options and warrants with exercise prices, that are greater than the estimated average market value of the Company&#8217;s Common Stockand shares issuable upon conversion of Preferred Stock because their effect would be anti-dilutive. Outstanding shares that will be issued upon conversion or exercise, as applicable, of all convertible Preferred Stock, stock options and warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was anti-dilutive.</font></div>
</td>
</tr></table>
</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div id="FTR"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 38</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 16</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SEGMENT INFORMATION</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company operates in one operating segment, the following is a summary of operations within geographic areas:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year ended December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenues based on the customer&#8217;s location:</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Europe</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,420</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Asia and Pacific</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">129,747</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,775</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">143,167</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,775</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All long-lived assets are owned by Integrity Israel and are located in Israel.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 17</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">RELATED PARTIES</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">A.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Avner Gal, the beneficial owner of approximately 7.7% of the Company's outstanding Common Stock as of December&#160;31, 2015, entered into an employment agreement with Integrity Israel in July 2010 pursuant to which Mr.&#160;Gal agreed to continue to serve as the chief executive officer and managing director of Integrity Israel.&#160;&#160;The agreement was approved by the board of directors and stockholders of Integrity Israel. Mr. Gal&#8217;s employment agreement provides for an annual salary of approximately $123,457, $134,769 and $134,111 (NIS&#160;480,000) for the year ended December 31, 2015, 2014 and 2013 respectively. In addition, Mr. Gal is entitled to an annual bonus to be determined by the board of directors and an additional sum provided that Mr. Gal reaches certain milestones approved by the board, as well as the payment of certain social and insurance benefits and the use of a car.&#160;&#160;During the year ended December 31, 2015, 2014 and 2013 the Company paid Mr. Gal $0, $0 and $61,087, respectively as bonuses.&#160;&#160;The agreement also provides for a renegotiation of Mr. Gal&#8217;s annual salary on the one-year anniversary thereof and the renegotiation of Mr. Gal&#8217;s bonus formula once Integrity Israel has begun commercialization of its products.&#160;&#160;The agreement is terminable by either party on 180 days&#8217; notice, immediately by Integrity Israel with the payment of an amount equal to 180 days of annual salary, or immediately by Integrity Israel for cause (as defined in the agreement) without the payment of severance.&#160;&#160;Mr. Gal is subject to a non-compete and a confidentiality agreement during the term of the agreement and for one year thereafter. As of December 31, 2015 the Company did not make any amendments to Mr. Gal&#8217;s employment agreement.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">F - 39</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INTEGRITY APPLICATIONS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 17</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">RELATED PARTIES (cont.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">B.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">David Malka, the beneficial owner of 3.07% of the Company's outstanding Common Stock as of December&#160;31, 2015, entered into an employment agreement with Integrity Israel in July 2010 pursuant to which Mr. Malka agreed to continue to serve as the vice president of operations of Integrity Israel.&#160;&#160;The agreement was approved by the board of directors and stockholders of Integrity Israel. Mr.&#160;Malka&#8217;s employment agreement provides for an annual salary of approximately $61,728, 67,302 and $66,639 (NIS&#160;240,000) for the year ended December 31, 2015, 2014 and 2013 respectively. In addition, Mr. Malka is entitled to an annual bonus to be determined by the Board of Directors in its sole discretion and an additional sum provided that Mr. Malka reaches certain milestones approved by the Board, as well as the payment of certain social and insurance benefits and the use of a group three car.&#160;&#160;During the year ended December 31, 2015, 2014 and 2013 the Company paid Mr. Malka $0, $0 and $30,544, respectively as bonuses. The agreement also provided for a renegotiation of Mr. Malka&#8217;s annual salary on the one-year anniversary thereof and the renegotiation of Mr. Malka&#8217;s bonus formula once Integrity Israel has begun commercialization of its products.&#160;&#160;The agreement is terminable by either party on 90 days&#8217; notice, immediately by Integrity Israel with the payment of an amount equal to 90 days of annual salary, or immediately by Integrity Israel for cause (as defined in the agreement) without the payment of severance.&#160;&#160;Mr.&#160;Malka is subject to a non-compete and confidentiality agreement during the term of the agreement and for one year thereafter. As of December 31, 2015, the Company did not make any amendments to Mr. Malka&#8217;s employment agreement.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 18</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SUBSEQUENT EVENTS</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During February 2016, the Company entered into an Advisory Agreement with the Placement Agent, according to which, the Company retained the Placement Agent on a non-exclusive basis to provide certain advisory services. In accordance with the terms of the Advisory Agreement, the Company extended the expiration date of the warrants issued to the Placement Agent in connection with the 2010 Offering and the 2012 Offering until December 31, 2019. The Advisory Agreement has a term of six months and shall automatically renew thereafter for additional 30 day terms unless terminated by either party upon receipt of 30 days prior written notice.&#160;&#160;The Company is in the process of evaluating the impact, if any, of the expiration date extension of the abovementioned warrants on the results of its operations.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">B.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 17, 2016, the Company&#8217;s Board of Directors appointed two new directors, Leslie Seff and Angela Strand, to the Board of Directors and approved the following compensation for all three non-employee directors serving on the Board: (i) an annual cash payment in the amount of $15,000, payable in four equal quarterly installments of $3,750 each on the last day of each calendar quarter commencing with the second quarter of 2016, subject to the director&#8217;s continued service as of each such date; (ii) an annual cash payment to the chairperson of the Nominating and Corporate Governance Committee in the amount of $10,000, payable in four equal quarterly installments of $2,500 each, on the last day of each calendar quarter commencing with the second quarter of 2016, subject to the chairperson&#8217;s continued service as of each such date; and (iii) a one-time grant of options to each non-employee director to purchase up to an aggregate of 26,666 shares of the Company&#8217;s Common Stock, at an exercise price of $4.50 per share, under and pursuant to the 2010 Share Incentive Plan.&#160;&#160;Each director&#8217;s option grant will vest in eight equal quarterly increments of 3,333.25 each (subject to the director&#8217;s continued service as of each such date) commencing with the second quarter of 2016.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 70.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">C.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 17, 2016, the Company&#8217;s Board of Directors approved an amendment to the 2010 Share Incentive Plan to increase the number of shares of the Company&#8217;s Common Stock reserved for issuance under the 2010 Share Incentive Plan from 529,555 shares to 1,000,000 shares.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">F - 40</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit_31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
    <title>exhibit_31-1.htm</title>
    <!--Licensed to: zk global-->
    <!--Document Created using EDGARizer 2020 5.5.2.0-->
    <!--Copyright 1995 - 2015 Summit Financial Printing. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit 31.1</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Avner Gal, certify that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2015 of Integrity Applications, Inc.;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the Audit Committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date:&#160; March 30, 2016</font></div>
</td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td valign="top" width="47%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">/s/ Avner Gal</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Avner Gal</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chairman of the Board and Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div>&#160;</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit_31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
<head>
    <title>exhibit_31-2.htm</title>
    <!--Licensed to: zk global-->
    <!--Document Created using EDGARizer 2020 5.5.2.0-->
    <!--Copyright 1995 - 2015 Summit Financial Printing. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit 31.2</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Eran Hertz, certify that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2015 of Integrity Applications, Inc.;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the Audit Committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: March 30, 2016</font></div>
</td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td valign="top" width="47%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Eran Hertz</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Eran Hertz</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>



<div>
<div>&#160;</div>
</div>

<div align="center">&#160;</div>

<div>&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit_32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
    <title>exhibit_32-1.htm</title>
    <!--Licensed to: zk global-->
    <!--Document Created using EDGARizer 2020 5.5.2.0-->
    <!--Copyright 1995 - 2015 Summit Financial Printing. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit 32.1</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18 U.S.C. SECTION 1350,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AS ADOPTED PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the Annual Report on Form 10-K of Integrity Applications, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Report</font>&#8221;), I, Avner Gal, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td valign="top" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Avner Gal</font></div>
</td>
</tr><tr>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: March 30, 2016</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Avner Gal</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chairman of the Board and Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit_32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
<head>
    <title>exhibit_32-2.htm</title>
    <!--Licensed to: zk global-->
    <!--Document Created using EDGARizer 2020 5.5.2.0-->
    <!--Copyright 1995 - 2015 Summit Financial Printing. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit 32.2</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18 U.S.C. SECTION 1350,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AS ADOPTED PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the Annual Report on Form 10-k of Integrity Applications, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Report</font>&#8221;), I, Eran Hertz, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td valign="top" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Eran Hertz</font></div>
</td>
</tr><tr>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: March 30, 2016</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Eran Hertz</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>igap-20151231.xml
<DESCRIPTION>INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: Integrity Applications, Inc. 12%2D31%2D15 10K Final To Use To File.xfr; Date: 2016%2D03%2D30T13:08:15Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80460001 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:igap="http://integrity-app.com/20151231">
    <link:schemaRef xlink:href="igap-20151231.xsd" xlink:type="simple" />
    <xbrli:context id="C618125">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618154">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C620431">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618122">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618134">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618114">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618117">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618118">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619537">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619541">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619542">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619543">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619544">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618155">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619585">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619586">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619587">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619588">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618123">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618361">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619593">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619594">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619595">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618169">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619612">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619613">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619614">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618133">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618121">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618360">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619582">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619583">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619584">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C620910">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C620650">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">igap:ConversionOfPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618137">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-08-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618138">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-08-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619667">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">igap:SeriesB1WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C623225">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">igap:SeriesB1WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C660587">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">igap:SeriesB2WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618150">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">igap:SeriesB2WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618151">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-12</xbrli:startDate>
        <xbrli:endDate>2013-05-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618152">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-05-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2004-01-01to2004-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2004-01-01</xbrli:startDate>
        <xbrli:endDate>2004-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618159">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618160">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618161">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618162">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618344">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618343">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618173">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618174">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618175">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618374">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:AgreementWithPlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618375">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:AgreementWithPlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_AgreementWithPlacementAgentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:AgreementWithPlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618363">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">igap:PaymentOfRoyaltiesToOcsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2004-01-01</xbrli:startDate>
        <xbrli:endDate>2004-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_PaymentOfRoyaltiesToOcsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">igap:PaymentOfRoyaltiesToOcsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618368">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:RegistrationPaymentCommissionRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2010-01-01</xbrli:startDate>
        <xbrli:endDate>2010-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618369">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:RegistrationPaymentArrangementManagementFeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2010-01-01</xbrli:startDate>
        <xbrli:endDate>2010-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618370">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:RegistrationPaymentArrangementExpenseAllowanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2010-01-01</xbrli:startDate>
        <xbrli:endDate>2010-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2010-01-01to2010-12-31_custom_DecemberOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:DecemberOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2010-01-01</xbrli:startDate>
        <xbrli:endDate>2010-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_CommonStockMember_custom_TwoThousandTwelveOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618373">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C661186">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:RegistrationPaymentCommissionRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-12-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C661187">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:RegistrationPaymentArrangementManagementFeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-12-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_TwoThousandFourteenOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandFourteenOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618176">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-11-18</xbrli:startDate>
        <xbrli:endDate>2012-11-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618177">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-12</xbrli:startDate>
        <xbrli:endDate>2013-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618178">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-12</xbrli:startDate>
        <xbrli:endDate>2013-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C620658">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618179">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-12</xbrli:startDate>
        <xbrli:endDate>2013-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618180">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-12</xbrli:startDate>
        <xbrli:endDate>2013-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618181">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-12</xbrli:startDate>
        <xbrli:endDate>2013-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618182">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619661">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618183">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618187">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandFourteenOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-08-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618191">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandFourteenOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618340">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">igap:SeriesAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618341">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">igap:SeriesAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-08-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618356">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618358">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619618">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:InvestorFindersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2006-01-01</xbrli:startDate>
        <xbrli:endDate>2006-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619619">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:InvestorFindersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">igap:GrantDate1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619622">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:InvestorFindersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2008-01-01</xbrli:startDate>
        <xbrli:endDate>2008-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619620">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">igap:GrantDate2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:InvestorFindersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619623">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619624">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2010-01-01</xbrli:startDate>
        <xbrli:endDate>2010-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619625">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember_custom_ClassOfWarrantOrRightExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="igap:ClassOfWarrantOrRightExercisePriceAxis">igap:ClassOfWarrantOrRightExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618380">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="igap:ClassOfWarrantOrRightExercisePriceAxis">igap:ClassOfWarrantOrRightExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember_custom_ClassOfWarrantOrRightExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="igap:ClassOfWarrantOrRightExercisePriceAxis">igap:ClassOfWarrantOrRightExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618663">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="igap:ClassOfWarrantOrRightExercisePriceAxis">igap:ClassOfWarrantOrRightExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember_custom_ClassOfWarrantOrRightExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="igap:ClassOfWarrantOrRightExercisePriceAxis">igap:ClassOfWarrantOrRightExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618665">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="igap:ClassOfWarrantOrRightExercisePriceAxis">igap:ClassOfWarrantOrRightExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619627">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">igap:WarrantsIssuedToPlacementAgentTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618666">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-08-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618667">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C620670">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_TwoThousandFourteenOfferingMember_custom_ClassOfWarrantOrRightExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandFourteenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="igap:ClassOfWarrantOrRightExercisePriceAxis">igap:ClassOfWarrantOrRightExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618729">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandFourteenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="igap:ClassOfWarrantOrRightExercisePriceAxis">igap:ClassOfWarrantOrRightExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_TwoThousandFourteenOfferingMember_custom_ClassOfWarrantOrRightExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandFourteenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="igap:ClassOfWarrantOrRightExercisePriceAxis">igap:ClassOfWarrantOrRightExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618732">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandFourteenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="igap:ClassOfWarrantOrRightExercisePriceAxis">igap:ClassOfWarrantOrRightExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618771">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandFourteenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618772">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandFourteenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618795">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:InvestorRelationsServicesProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-09-09</xbrli:startDate>
        <xbrli:endDate>2013-09-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618796">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:InvestorRelationsServicesProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618815">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:InvestorRelationsServicesProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618816">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:InvestorRelationsServicesProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618817">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:InvestorRelationsServicesProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619282">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">igap:IntegrityIsraelPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2007-01-01</xbrli:startDate>
        <xbrli:endDate>2007-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619283">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">igap:ShareIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619494">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-03-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619495">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveVicePresidentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-03-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619501">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619502">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619503">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619513">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619515">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">igap:ShareIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">igap:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">igap:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">igap:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">igap:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">igap:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">igap:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">igap:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">igap:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">igap:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">igap:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C620666">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C620667">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C623424">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">igap:ConversionOfPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C623425">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">igap:ConversionOfPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C619626">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C620664">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">igap:WarrantsIssuedToPlacementAgentTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C623420">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">igap:WarrantsIssuedUnderSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C623421">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">igap:WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C660799">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C660784">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-09-29</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_ParentCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_AdIntegrityApplicationsLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">igap:AdIntegrityApplicationsLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C623432">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C620414">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C620415">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C620417">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaPacificMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C620418">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaPacificMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_AsiaPacificMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaPacificMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618115">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">igap:AvnerGalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C618116">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">igap:DavidMalkaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_currency_ILS">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_SeriesAWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">igap:SeriesAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_SeriesAWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">igap:SeriesAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_ShareIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">igap:ShareIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember_custom_GrantsToMessrsGalAndMalkaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">igap:GrantsToMessrsGalAndMalkaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2004-01-01to2004-12-31_custom_PaymentOfRoyaltiesToOcsMember_currency_ILS">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">igap:PaymentOfRoyaltiesToOcsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2004-01-01</xbrli:startDate>
        <xbrli:endDate>2004-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_TwoThousandFourteenOfferingsMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandFourteenOfferingsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_ConversionOfPreferredStockIntoCommonStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">igap:ConversionOfPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_ConversionOfPreferredStockIntoCommonStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">igap:ConversionOfPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2005-01-01to2005-12-31_custom_RegulatoryServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:RegulatoryServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2005-01-01</xbrli:startDate>
        <xbrli:endDate>2005-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_PlacementAgentMember_custom_TwoThousandTenOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTenOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_PlacementAgentMember_custom_TwoThousandTenOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTenOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">igap:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_SeriesB1WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">igap:SeriesB1WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_SeriesB2WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">igap:SeriesB2WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_AgreementWithPlacementAgentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:AgreementWithPlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-23_us-gaap_JudicialRulingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-23_us-gaap_JudicialRulingMember_currency_ILS">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-04-30_us-gaap_JudicialRulingMember_currency_ILS">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-04-30_us-gaap_JudicialRulingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-18_us-gaap_JudicialRulingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_PropertyAshkelonIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">igap:PropertyAshkelonIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_PropertyAshkelonIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">igap:PropertyAshkelonIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_PropertyAshdodIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">igap:PropertyAshdodIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_PropertyAshkelonIsraelMember_currency_ILS">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">igap:PropertyAshkelonIsraelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_PropertyAshdodIsraelMember_currency_ILS">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">igap:PropertyAshdodIsraelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-17_custom_ShareIncentivePlanMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">igap:ShareIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_AvnerGalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">igap:AvnerGalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_AvnerGalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">igap:AvnerGalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_DavidMalkaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">igap:DavidMalkaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_DavidMalkaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">igap:DavidMalkaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_AvnerGalMember_currency_ILS">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">igap:AvnerGalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_DavidMalkaMember_currency_ILS">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">igap:DavidMalkaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-17_us-gaap_SubsequentEventMember_custom_DirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">igap:DirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_CommonStockMember_custom_TwoThousandTwelveOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">igap:TwoThousandTwelveOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPerShare">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="ils">
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="ILSPerShare">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:ILS</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="SquareFoot">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Item">
      <xbrli:measure>igap:item</xbrli:measure>
    </xbrli:unit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="C618125" unitRef="USD" decimals="0">5827560</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="C618154" unitRef="USD" decimals="0">2385911</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="C618155" unitRef="USD" decimals="0">543411</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">608701</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="C618125" unitRef="USD" decimals="0">23250</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">18446</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="C618125" unitRef="USD" decimals="0">83653</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">816223</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="C618125" unitRef="USD" decimals="0">113842</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">268792</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="C618125" unitRef="USD" decimals="0">6048305</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">1712162</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="C618125" unitRef="USD" decimals="0">122491</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">220463</us-gaap:PropertyPlantAndEquipmentNet>
    <igap:FundsInRespectOfEmployeeRightsUponRetirementNoncurrent contextRef="C618125" unitRef="USD" decimals="0">177470</igap:FundsInRespectOfEmployeeRightsUponRetirementNoncurrent>
    <igap:FundsInRespectOfEmployeeRightsUponRetirementNoncurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">164883</igap:FundsInRespectOfEmployeeRightsUponRetirementNoncurrent>
    <us-gaap:Assets contextRef="C618125" unitRef="USD" decimals="0">6348266</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">2132660</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="C618125" unitRef="USD" decimals="0">104711</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">1082546</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="C618125" unitRef="USD" decimals="0">440764</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">427886</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DueToOfficersOrStockholdersCurrent contextRef="C618125" unitRef="USD" decimals="0">454532</us-gaap:DueToOfficersOrStockholdersCurrent>
    <us-gaap:DueToOfficersOrStockholdersCurrent contextRef="AsOf2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesCurrent contextRef="C618125" unitRef="USD" decimals="0">1000007</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">1510432</us-gaap:LiabilitiesCurrent>
    <us-gaap:DueToOfficersOrStockholdersNoncurrent contextRef="C618125" unitRef="USD" decimals="0">163459</us-gaap:DueToOfficersOrStockholdersNoncurrent>
    <us-gaap:DueToOfficersOrStockholdersNoncurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">160314</us-gaap:DueToOfficersOrStockholdersNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent contextRef="C618125" unitRef="USD" decimals="0">210700</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">174137</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="C618125" unitRef="USD" decimals="0">2057618</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">321695</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LiabilitiesNoncurrent contextRef="C618125" unitRef="USD" decimals="0">2431777</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">656146</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="C618125" unitRef="USD" decimals="0">3431784</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">2166578</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="C620431" unitRef="USDPerShare" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="AsOf2015-12-31_us-gaap_PreferredStockMember" unitRef="USDPerShare" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="C620431" unitRef="Shares" decimals="INF">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="AsOf2015-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued contextRef="C618122" unitRef="Shares" decimals="INF">7407</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued contextRef="AsOf2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">376</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued contextRef="C618134" unitRef="Shares" decimals="INF">8500</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued contextRef="AsOf2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">15031</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount contextRef="C618125" unitRef="USD" decimals="0">7748685</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount contextRef="C618122" unitRef="USD" decimals="0">4356657</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount contextRef="AsOf2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USD" decimals="0">221152</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount contextRef="C618134" unitRef="USD" decimals="0">3392028</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount contextRef="AsOf2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">6715844</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">6936996</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="C618125" unitRef="USDPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2015-12-31" unitRef="USDPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="C618125" unitRef="Shares" decimals="INF">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="C618125" unitRef="Shares" decimals="INF">5323058</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">5690097</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="C618125" unitRef="USD" decimals="0">5324</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">5691</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="C618125" unitRef="USD" decimals="0">18182866</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">22309742</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="C618125" unitRef="USD" decimals="0">66670</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">90168</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="C618125" unitRef="USD" decimals="0">-23087063</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="C618154" unitRef="USD" decimals="0">-25653190</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">-29376515</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="C618125" unitRef="USD" decimals="0">-4832203</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="C618154" unitRef="USD" decimals="0">-11063118</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="C619541" unitRef="USD" decimals="0">5461</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="C619542" unitRef="USD" decimals="0">14772371</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="C619543" unitRef="USD" decimals="0">8925</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="C619544" unitRef="USD" decimals="0">-15289826</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="C618155" unitRef="USD" decimals="0">-503069</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="C618361" unitRef="USD" decimals="0">5302</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="C619593" unitRef="USD" decimals="0">14532068</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="C619594" unitRef="USD" decimals="0">52702</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="C619595" unitRef="USD" decimals="0">-25653190</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="C618360" unitRef="USD" decimals="0">5324</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="C619582" unitRef="USD" decimals="0">18182866</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="C619583" unitRef="USD" decimals="0">66670</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="C619584" unitRef="USD" decimals="0">-23087063</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">-6970914</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5691</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">22309742</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">90168</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-29376515</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="C618125" unitRef="USD" decimals="0">6348266</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">2132660</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="C618122" unitRef="Shares" decimals="INF">7407</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="AsOf2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">376</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="C618134" unitRef="Shares" decimals="INF">8500</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="AsOf2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">15031</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="C618125" unitRef="Shares" decimals="INF">5323058</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="C619541" unitRef="Shares" decimals="INF">5460600</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="C618361" unitRef="Shares" decimals="INF">5301693</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="C618360" unitRef="Shares" decimals="INF">5323058</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">5690097</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2015-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5690097</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommitmentsAndContingencies contextRef="C618125" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="C618114" unitRef="USD" decimals="0">59775</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="C618117" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="C620414" unitRef="USD" decimals="INF">32000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="C620415" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="From2015-01-01to2015-12-31_us-gaap_EuropeMember" unitRef="USD" decimals="INF">13420</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="C620417" unitRef="USD" decimals="INF">27775</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="C620418" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="From2015-01-01to2015-12-31_us-gaap_AsiaPacificMember" unitRef="USD" decimals="INF">129747</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="INF">143167</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="C618114" unitRef="USD" decimals="0">1849624</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="C618117" unitRef="USD" decimals="0">1986754</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="C618344" unitRef="USD" decimals="0">1986754</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="C618343" unitRef="USD" decimals="0">1849624</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">2268345</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">2268345</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="C618114" unitRef="USD" decimals="0">1817510</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="C618117" unitRef="USD" decimals="0">1041140</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">2530175</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="C618114" unitRef="USD" decimals="0">3667134</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="C618117" unitRef="USD" decimals="0">3027894</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">4798520</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="C618114" unitRef="USD" decimals="0">-3607359</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="C618117" unitRef="USD" decimals="0">-3027894</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-4655353</us-gaap:OperatingIncomeLoss>
    <igap:FinancingIncomeExpensesNet contextRef="C618114" unitRef="USD" decimals="0">-6587785</igap:FinancingIncomeExpensesNet>
    <igap:FinancingIncomeExpensesNet contextRef="C618117" unitRef="USD" decimals="0">6768959</igap:FinancingIncomeExpensesNet>
    <igap:FinancingIncomeExpensesNet contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">1186819</igap:FinancingIncomeExpensesNet>
    <us-gaap:NetIncomeLoss contextRef="C618114" unitRef="USD" decimals="0">2980426</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="C618117" unitRef="USD" decimals="0">-9796853</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="C619585" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="C619586" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="C619587" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="C619588" unitRef="USD" decimals="INF">-9796853</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="C618169" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="C619612" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="C619613" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="C619614" unitRef="USD" decimals="INF">2980426</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="INF">-5842172</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="INF">-5842172</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="C618114" unitRef="USD" decimals="0">13968</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="C618117" unitRef="USD" decimals="0">43777</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">23498</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="C618114" unitRef="USD" decimals="0">2994394</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="C618117" unitRef="USD" decimals="0">-9753076</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-5818674</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic contextRef="C618114" unitRef="USDPerShare" decimals="2">0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="C618117" unitRef="USDPerShare" decimals="2">-1.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2015-01-01to2015-12-31" unitRef="USDPerShare" decimals="2">-1.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="C618114" unitRef="USDPerShare" decimals="2">0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="C618117" unitRef="USDPerShare" decimals="2">-1.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2015-01-01to2015-12-31" unitRef="USDPerShare" decimals="2">-1.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="C618114" unitRef="Shares" decimals="INF">5304500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="C618117" unitRef="Shares" decimals="INF">5325714</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2015-01-01to2015-12-31" unitRef="Shares" decimals="INF">5476870</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="C618114" unitRef="USD" decimals="0">13968</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="C618117" unitRef="USD" decimals="0">43777</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="C619585" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="C619586" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="C619587" unitRef="USD" decimals="INF">43777</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="C619588" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="C618169" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="C619612" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="C619613" unitRef="USD" decimals="INF">13968</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="C619614" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="INF">23498</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2015-01-01to2015-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="INF">23498</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="C619537" unitRef="Shares" decimals="INF">165057</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="C618151" unitRef="Shares" decimals="INF">2824471</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="C618176" unitRef="Shares" decimals="INF">165057</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="C618181" unitRef="Shares" decimals="INF">1295535</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="C618182" unitRef="Shares" decimals="INF">654</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember_custom_TwoThousandTwelveOfferingMember" unitRef="Shares" decimals="INF">92136</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="C618114" unitRef="USD" decimals="0">630936</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="C618117" unitRef="USD" decimals="0">562805</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="C619585" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="C619586" unitRef="USD" decimals="INF">562805</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="C619587" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="C619588" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="C618169" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="C619612" unitRef="USD" decimals="INF">630936</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="C619613" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="C619614" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="C618114" unitRef="USD" decimals="0">50380</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="C618117" unitRef="USD" decimals="0">35619</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="C619585" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="C619586" unitRef="USD" decimals="INF">35619</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="C619587" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="C619588" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="C618169" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="C619612" unitRef="USD" decimals="INF">50380</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="C619613" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="C619614" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="INF">18013</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="INF">18013</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2015-01-01to2015-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <igap:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock contextRef="C619585" unitRef="Shares" decimals="INF">4000</igap:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock>
    <igap:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock contextRef="C618169" unitRef="Shares" decimals="INF">1725</igap:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock>
    <igap:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">86208</igap:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock>
    <igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock contextRef="C618114" unitRef="USD" decimals="0">5888</igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock>
    <igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock contextRef="C618117" unitRef="USD" decimals="0">23200</igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock>
    <igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock contextRef="C619585" unitRef="USD" decimals="0">4</igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock>
    <igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock contextRef="C619586" unitRef="USD" decimals="0">23196</igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock>
    <igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock contextRef="C619587" unitRef="USD" xsi:nil="true" />
    <igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock contextRef="C619588" unitRef="USD" xsi:nil="true" />
    <igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock contextRef="C618169" unitRef="USD" decimals="INF">2</igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock>
    <igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock contextRef="C619612" unitRef="USD" decimals="INF">5886</igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock>
    <igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock contextRef="C619613" unitRef="USD" xsi:nil="true" />
    <igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock contextRef="C619614" unitRef="USD" xsi:nil="true" />
    <igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="INF">237537</igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock>
    <igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="INF">86</igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock>
    <igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="INF">237451</igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock>
    <igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock contextRef="From2015-01-01to2015-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <igap:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsStock contextRef="C618114" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsStock contextRef="C618117" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsStock contextRef="C619585" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsStock contextRef="C619586" unitRef="USD" decimals="INF">-278263</us-gaap:DividendsStock>
    <us-gaap:DividendsStock contextRef="C619587" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsStock contextRef="C619588" unitRef="USD" decimals="INF">278263</us-gaap:DividendsStock>
    <us-gaap:DividendsStock contextRef="C618169" unitRef="USD" decimals="INF">-1</us-gaap:DividendsStock>
    <us-gaap:DividendsStock contextRef="C619612" unitRef="USD" decimals="INF">1</us-gaap:DividendsStock>
    <us-gaap:DividendsStock contextRef="C619613" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsStock contextRef="C619614" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsStock contextRef="C660784" unitRef="USD" decimals="INF">278263</us-gaap:DividendsStock>
    <us-gaap:DividendsStock contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsStock contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="INF">-92</us-gaap:DividendsStock>
    <us-gaap:DividendsStock contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="INF">92</us-gaap:DividendsStock>
    <us-gaap:DividendsStock contextRef="From2015-01-01to2015-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsStock contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsPreferredStock contextRef="C618114" unitRef="USD" decimals="0">370441</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock contextRef="C618117" unitRef="USD" decimals="0">288248</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock contextRef="C619585" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsPreferredStock contextRef="C619586" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsPreferredStock contextRef="C619587" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsPreferredStock contextRef="C619588" unitRef="USD" decimals="0">288248</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock contextRef="C618169" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsPreferredStock contextRef="C619612" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsPreferredStock contextRef="C619613" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsPreferredStock contextRef="C619614" unitRef="USD" decimals="0">370441</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock contextRef="C618121" unitRef="USD" decimals="0">370441</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">57061</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsPreferredStock contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsPreferredStock contextRef="From2015-01-01to2015-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsPreferredStock contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">57061</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USD" decimals="0">57061</us-gaap:DividendsPreferredStock>
    <igap:AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued contextRef="C618114" unitRef="USD" decimals="0">3320429</igap:AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued>
    <igap:AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued contextRef="C618169" unitRef="USD" xsi:nil="true" />
    <igap:AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued contextRef="C619612" unitRef="USD" decimals="INF">3320429</igap:AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued>
    <igap:AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued contextRef="C619613" unitRef="USD" xsi:nil="true" />
    <igap:AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued contextRef="C619614" unitRef="USD" xsi:nil="true" />
    <igap:AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="INF">3445337</igap:AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued>
    <igap:AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <igap:AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="INF">3445337</igap:AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued>
    <igap:AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued contextRef="From2015-01-01to2015-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <igap:AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <igap:StockIssuedDuringPeriodSharesStockDividend contextRef="C618169" unitRef="Shares" decimals="INF">-654</igap:StockIssuedDuringPeriodSharesStockDividend>
    <igap:StockIssuedDuringPeriodSharesStockDividend contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">-92136</igap:StockIssuedDuringPeriodSharesStockDividend>
    <us-gaap:PreferredStockDividendsShares contextRef="C618169" unitRef="Shares" decimals="INF">18986</us-gaap:PreferredStockDividendsShares>
    <us-gaap:PreferredStockDividendsShares contextRef="C618138" unitRef="Shares" decimals="INF">18986</us-gaap:PreferredStockDividendsShares>
    <us-gaap:PreferredStockDividendsShares contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">168926</us-gaap:PreferredStockDividendsShares>
    <us-gaap:PreferredStockDividendsShares contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">168926</us-gaap:PreferredStockDividendsShares>
    <us-gaap:DividendsPreferredStockStock contextRef="C618114" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsPreferredStockStock contextRef="C618169" unitRef="USD" decimals="0">19</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock contextRef="C619612" unitRef="USD" decimals="0">43839</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock contextRef="C619613" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsPreferredStockStock contextRef="C619614" unitRef="USD" decimals="0">-43858</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsPreferredStockStock contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">169</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">390050</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock contextRef="From2015-01-01to2015-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsPreferredStockStock contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-390219</us-gaap:DividendsPreferredStockStock>
    <igap:AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities contextRef="C618114" unitRef="USD" decimals="0">400671</igap:AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities>
    <igap:AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities contextRef="C618169" unitRef="USD" xsi:nil="true" />
    <igap:AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities contextRef="C619612" unitRef="USD" decimals="INF">400671</igap:AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities>
    <igap:AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities contextRef="C619613" unitRef="USD" xsi:nil="true" />
    <igap:AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities contextRef="C619614" unitRef="USD" xsi:nil="true" />
    <us-gaap:Depreciation contextRef="C618114" unitRef="USD" decimals="0">34683</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="C618117" unitRef="USD" decimals="0">33684</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">44891</us-gaap:Depreciation>
    <us-gaap:IncreaseDecreaseInPostemploymentObligations contextRef="C618114" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInPostemploymentObligations contextRef="C618117" unitRef="USD" decimals="INF">-9959</us-gaap:IncreaseDecreaseInPostemploymentObligations>
    <us-gaap:IncreaseDecreaseInPostemploymentObligations contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="C618114" unitRef="USD" decimals="0">50380</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="C618117" unitRef="USD" decimals="0">35619</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">18013</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashExpense contextRef="C618114" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherNoncashExpense contextRef="C618117" unitRef="USD" decimals="0">390928</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="C618114" unitRef="USD" decimals="0">-6559758</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="C618117" unitRef="USD" decimals="0">6251242</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-149092</us-gaap:FairValueAdjustmentOfWarrants>
    <igap:LinkageDifferenceOnPrincipalOfLoansFromStockholders contextRef="C618114" unitRef="USD" decimals="0">-556</igap:LinkageDifferenceOnPrincipalOfLoansFromStockholders>
    <igap:LinkageDifferenceOnPrincipalOfLoansFromStockholders contextRef="C618117" unitRef="USD" decimals="0">14382</igap:LinkageDifferenceOnPrincipalOfLoansFromStockholders>
    <igap:LinkageDifferenceOnPrincipalOfLoansFromStockholders contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-2521</igap:LinkageDifferenceOnPrincipalOfLoansFromStockholders>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="C618114" unitRef="USD" decimals="0">24539</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="C618117" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="INF">-4131</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="C618114" unitRef="USD" decimals="0">94895</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="C618117" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="INF">737554</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="C618114" unitRef="USD" decimals="0">32416</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="C618117" unitRef="USD" decimals="0">5234</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">156302</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="C618114" unitRef="USD" decimals="0">68838</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="C618117" unitRef="USD" decimals="0">-77259</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">982215</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="C618114" unitRef="USD" decimals="0">216192</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="C618117" unitRef="USD" decimals="0">-54317</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-11187</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="C618114" unitRef="USD" decimals="0">-3361645</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="C618117" unitRef="USD" decimals="0">-3217767</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-4565224</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <igap:IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement contextRef="C618114" unitRef="USD" decimals="0">-28058</igap:IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement>
    <igap:IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement contextRef="C618117" unitRef="USD" decimals="0">-40029</igap:IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement>
    <igap:IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-24279</igap:IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="C618114" unitRef="USD" decimals="0">63455</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="C618117" unitRef="USD" decimals="0">64252</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">143736</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="C618114" unitRef="USD" decimals="0">-91513</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="C618117" unitRef="USD" decimals="0">-104281</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-203167</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt contextRef="C618114" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt contextRef="C618117" unitRef="USD" decimals="INF">-38801</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock contextRef="C618114" unitRef="USD" decimals="0">370441</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock contextRef="C618117" unitRef="USD" decimals="0">288248</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">57061</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="C618114" unitRef="USD" decimals="0">3710860</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="C618117" unitRef="USD" decimals="0">3960958</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="C618114" unitRef="USD" decimals="0">3632531</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="C618117" unitRef="USD" decimals="0">1421983</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="C618114" unitRef="USD" decimals="0">6972950</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="C618117" unitRef="USD" decimals="0">5055892</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-460863</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="C618114" unitRef="USD" decimals="0">-78143</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="C618117" unitRef="USD" decimals="0">108656</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">10395</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="C618114" unitRef="USD" decimals="0">3441649</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="C618117" unitRef="USD" decimals="0">1842500</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-5218859</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="C618123" unitRef="Shares" decimals="INF">23.2</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="C618121" unitRef="Shares" decimals="INF">10.01</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="C620910" unitRef="Shares" decimals="INF">10.01</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="From2015-01-01to2015-12-31_custom_ConversionOfPreferredStockIntoCommonStockMember_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">100</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="From2015-01-01to2015-12-31_custom_ConversionOfPreferredStockIntoCommonStockMember_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">400</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="C620650" unitRef="Shares" decimals="INF">1725</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="C623424" unitRef="Shares" decimals="INF">1725</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="C623425" unitRef="Shares" decimals="INF">4000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="From2015-01-01to2015-12-31_custom_ConversionOfPreferredStockIntoCommonStockMember_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">17242</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="From2015-01-01to2015-12-31_custom_ConversionOfPreferredStockIntoCommonStockMember_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">68966</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="C620650" unitRef="USD" decimals="0">5888</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="C623424" unitRef="USD" decimals="0">5888</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="C623425" unitRef="USD" decimals="0">23200</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="From2015-01-01to2015-12-31_custom_ConversionOfPreferredStockIntoCommonStockMember_us-gaap_SeriesAPreferredStockMember" unitRef="USD" decimals="0">58817</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="From2015-01-01to2015-12-31_custom_ConversionOfPreferredStockIntoCommonStockMember_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">178720</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="C618114" unitRef="USD" decimals="0">630936</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="C618183" unitRef="USD" decimals="0">562805</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="C618191" unitRef="USD" decimals="0">630936</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="C618796" unitRef="USD" decimals="0">18204</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="C618815" unitRef="USD" decimals="0">16657</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:DividendsCommonStockStock contextRef="C618138" unitRef="USD" decimals="0">43858</us-gaap:DividendsCommonStockStock>
    <us-gaap:DividendsCommonStockStock contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">390219</us-gaap:DividendsCommonStockStock>
    <us-gaap:DividendsCommonStockStock contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">390219</us-gaap:DividendsCommonStockStock>
    <us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock contextRef="C618117" unitRef="USD" decimals="-5">5300000</us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock>
    <us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock contextRef="C618137" unitRef="USD" decimals="-5">7300000</us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock>
    <us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock contextRef="C620658" unitRef="USD" decimals="-5">5400000</us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock>
    <us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock contextRef="C618187" unitRef="USD" decimals="-5">7300000</us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock>
    <us-gaap:PreferredStockDividendRatePercentage contextRef="C618138" unitRef="Pure" decimals="3">0.055</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Pure" decimals="2">0.05</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Pure" decimals="3">0.055</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="C618134" unitRef="USDPerShare" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <igap:PreferredStockConversionPrice contextRef="C618122" unitRef="USDPerShare" decimals="2">5.80</igap:PreferredStockConversionPrice>
    <igap:PreferredStockConversionPrice contextRef="AsOf2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USDPerShare" decimals="2">5.80</igap:PreferredStockConversionPrice>
    <igap:PreferredStockConversionPrice contextRef="C618134" unitRef="USDPerShare" decimals="2">5.80</igap:PreferredStockConversionPrice>
    <igap:PreferredStockConversionPrice contextRef="AsOf2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USDPerShare" decimals="2">5.80</igap:PreferredStockConversionPrice>
    <igap:ClassOfWarrantOrRightTerm contextRef="C619667">P5Y</igap:ClassOfWarrantOrRightTerm>
    <igap:ClassOfWarrantOrRightTerm contextRef="C660587">P5Y</igap:ClassOfWarrantOrRightTerm>
    <igap:ClassOfWarrantOrRightTerm contextRef="C618187">P5Y</igap:ClassOfWarrantOrRightTerm>
    <igap:ClassOfWarrantOrRightTerm contextRef="From2012-01-01to2012-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember_custom_ClassOfWarrantOrRightExercisePriceOneMember">P5Y</igap:ClassOfWarrantOrRightTerm>
    <igap:ClassOfWarrantOrRightTerm contextRef="From2012-01-01to2012-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember_custom_ClassOfWarrantOrRightExercisePriceTwoMember">P5Y</igap:ClassOfWarrantOrRightTerm>
    <igap:ClassOfWarrantOrRightTerm contextRef="From2012-01-01to2012-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember_custom_ClassOfWarrantOrRightExercisePriceThreeMember">P5Y</igap:ClassOfWarrantOrRightTerm>
    <igap:ClassOfWarrantOrRightTerm contextRef="From2014-01-01to2014-12-31_custom_TwoThousandFourteenOfferingMember_custom_ClassOfWarrantOrRightExercisePriceFourMember">P5Y</igap:ClassOfWarrantOrRightTerm>
    <igap:ClassOfWarrantOrRightTerm contextRef="From2014-01-01to2014-12-31_custom_TwoThousandFourteenOfferingMember_custom_ClassOfWarrantOrRightExercisePriceFiveMember">P5Y</igap:ClassOfWarrantOrRightTerm>
    <igap:ClassOfWarrantOrRightTerm contextRef="From2015-01-01to2015-12-31_custom_SeriesAWarrantMember">P5Y</igap:ClassOfWarrantOrRightTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C623225" unitRef="USDPerShare" decimals="2">5.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C618150" unitRef="USDPerShare" decimals="2">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C618341" unitRef="USDPerShare" decimals="2">5.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C619625" unitRef="USDPerShare" decimals="2">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C618380" unitRef="USDPerShare" decimals="2">5.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C618663" unitRef="USDPerShare" decimals="2">6.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C618665" unitRef="USDPerShare" decimals="2">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C619627" unitRef="USDPerShare" decimals="2">6.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C618666" unitRef="USDPerShare" decimals="2">5.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C618667" unitRef="USDPerShare" decimals="2">5.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C618729" unitRef="USDPerShare" decimals="2">5.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C618732" unitRef="USDPerShare" decimals="2">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C619626" unitRef="USDPerShare" decimals="2">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C620664" unitRef="USDPerShare" decimals="2">5.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C623420" unitRef="USDPerShare" decimals="2">6.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2015-12-31_custom_SeriesAWarrantMember" unitRef="USDPerShare" decimals="2">6.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2014-12-31_custom_PlacementAgentMember_custom_TwoThousandTenOfferingMember" unitRef="USDPerShare" decimals="2">5.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2015-12-31_custom_PlacementAgentMember_custom_TwoThousandTenOfferingMember" unitRef="USDPerShare" decimals="2">5.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2015-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember" unitRef="USDPerShare" decimals="2">5.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <igap:ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion contextRef="C618151" unitRef="Shares" decimals="INF">1284925</igap:ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion>
    <igap:ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion contextRef="C618178" unitRef="Shares" decimals="INF">1086178</igap:ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion>
    <igap:ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion contextRef="C618180" unitRef="Shares" decimals="INF">196597</igap:ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C618152" unitRef="Shares" decimals="INF">1539546</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C618667" unitRef="Shares" decimals="INF">282469</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C623420" unitRef="Shares" decimals="INF">1086178</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C623421" unitRef="Shares" decimals="INF">196597</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2014-12-31_custom_PlacementAgentMember_custom_TwoThousandTenOfferingMember" unitRef="Shares" decimals="INF">139608</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2015-12-31_custom_PlacementAgentMember_custom_TwoThousandTenOfferingMember" unitRef="Shares" decimals="INF">139608</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2015-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember" unitRef="Shares" decimals="INF">282469</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:RevenueFromGrants contextRef="C618114" unitRef="USD" decimals="0">1793</us-gaap:RevenueFromGrants>
    <us-gaap:RevenueFromGrants contextRef="C618117" unitRef="USD" xsi:nil="true" />
    <us-gaap:RevenueFromGrants contextRef="From2004-01-01to2004-12-31" unitRef="USD" decimals="0">93300</us-gaap:RevenueFromGrants>
    <us-gaap:RevenueFromGrants contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">8167</us-gaap:RevenueFromGrants>
    <us-gaap:RevenueFromGrants contextRef="From2004-01-01to2004-12-31_custom_PaymentOfRoyaltiesToOcsMember_currency_ILS" unitRef="ils" decimals="0">420000</us-gaap:RevenueFromGrants>
    <igap:AverageForeignCurrencyExchangeRateTranslation contextRef="C618114" unitRef="Pure" decimals="3">0.257</igap:AverageForeignCurrencyExchangeRateTranslation>
    <igap:AverageForeignCurrencyExchangeRateTranslation contextRef="C618117" unitRef="Pure" decimals="3">0.288</igap:AverageForeignCurrencyExchangeRateTranslation>
    <igap:AverageForeignCurrencyExchangeRateTranslation contextRef="From2015-01-01to2015-12-31" unitRef="Pure" decimals="3">0.256</igap:AverageForeignCurrencyExchangeRateTranslation>
    <igap:PropertyPlantAndEquipmentDepreciationRate contextRef="C618159" unitRef="Pure" decimals="2">0.33</igap:PropertyPlantAndEquipmentDepreciationRate>
    <igap:PropertyPlantAndEquipmentDepreciationRate contextRef="C618160" unitRef="Pure" decimals="2">0.07</igap:PropertyPlantAndEquipmentDepreciationRate>
    <igap:PropertyPlantAndEquipmentDepreciationRate contextRef="C618161" unitRef="Pure" decimals="2">0.15</igap:PropertyPlantAndEquipmentDepreciationRate>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="C618162">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PostemploymentBenefitsPeriodExpense contextRef="C618114" unitRef="USD" decimals="0">101220</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:PostemploymentBenefitsPeriodExpense contextRef="C618117" unitRef="USD" decimals="0">91588</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:PostemploymentBenefitsPeriodExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">111030</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:InventoryWorkInProcess contextRef="C618125" unitRef="USD" decimals="0">16459</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">551111</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="C618125" unitRef="USD" decimals="0">11637</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">59467</us-gaap:InventoryFinishedGoods>
    <us-gaap:PrepaidExpenseCurrent contextRef="C618125" unitRef="USD" decimals="0">46094</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">57206</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidTaxes contextRef="C618125" unitRef="USD" id="Foot-00-0" decimals="0">67748</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes contextRef="AsOf2015-12-31" unitRef="USD" id="Foot-00-1" decimals="0">211586</us-gaap:PrepaidTaxes>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="C618125" unitRef="USD" decimals="0">235874</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">187528</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ProfessionalFees contextRef="C618114" unitRef="USD" decimals="0">739893</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="C618117" unitRef="USD" decimals="0">562435</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="C618344" unitRef="USD" decimals="0">247888</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="C618343" unitRef="USD" decimals="0">377918</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">990390</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">525144</us-gaap:ProfessionalFees>
    <us-gaap:OtherCostAndExpenseOperating contextRef="C618344" unitRef="USD" decimals="0">154522</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating contextRef="C618343" unitRef="USD" decimals="0">96699</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">166736</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:InventoryRawMaterials contextRef="C618125" unitRef="USD" decimals="0">55557</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">205645</us-gaap:InventoryRawMaterials>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="C618125" unitRef="USD" decimals="0">331532</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="C618173" unitRef="USD" decimals="0">124161</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-31_us-gaap_ComputerEquipmentMember" unitRef="USD" decimals="0">240066</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="C618174" unitRef="USD" decimals="0">184379</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-31_us-gaap_OfficeEquipmentMember" unitRef="USD" decimals="0">200548</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="C618175" unitRef="USD" decimals="0">22992</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">32898</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">473512</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="C618125" unitRef="USD" decimals="0">209041</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">253049</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="C618125" unitRef="USD" decimals="0">204890</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">240358</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">38500</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="AsOf2015-12-31_currency_ILS" unitRef="ils" decimals="0">150000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LaborAndRelatedExpense contextRef="C618114" unitRef="USD" decimals="0">651900</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="C618117" unitRef="USD" decimals="0">260276</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="C618344" unitRef="USD" decimals="0">1293067</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="C618343" unitRef="USD" decimals="0">1128672</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">803319</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">1303614</us-gaap:LaborAndRelatedExpense>
    <igap:RoyaltyPercentMinimum contextRef="C618363" unitRef="Pure" decimals="2">0.03</igap:RoyaltyPercentMinimum>
    <igap:RoyaltyPercentMaximum contextRef="C618363" unitRef="Pure" decimals="2">0.05</igap:RoyaltyPercentMaximum>
    <us-gaap:LossContingencyRangeOfPossibleLossPortionNotAccrued contextRef="AsOf2015-12-31_custom_PaymentOfRoyaltiesToOcsMember" unitRef="USD" decimals="0">83341</us-gaap:LossContingencyRangeOfPossibleLossPortionNotAccrued>
    <igap:PreferredStockStatedValue contextRef="AsOf2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USDPerShare" decimals="0">1000</igap:PreferredStockStatedValue>
    <igap:PreferredStockStatedValue contextRef="AsOf2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USDPerShare" decimals="0">1000</igap:PreferredStockStatedValue>
    <igap:PreferredStockDividendPaymentRequirementThreshold contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Pure" decimals="2">1.1</igap:PreferredStockDividendPaymentRequirementThreshold>
    <igap:PreferredStockDividendLateFee contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Pure" decimals="2">0.09</igap:PreferredStockDividendLateFee>
    <igap:PreferredStockDividendLateFee contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Pure" decimals="2">0.09</igap:PreferredStockDividendLateFee>
    <igap:PreferredStockConvertibleStockPriceTrigger contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Pure" decimals="2">11.60</igap:PreferredStockConvertibleStockPriceTrigger>
    <igap:PreferredStockConvertibleStockPriceTrigger contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Pure" decimals="2">10.00</igap:PreferredStockConvertibleStockPriceTrigger>
    <igap:PreferredStockConvertibleTradingVolumeTrigger contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USD" decimals="0">100000</igap:PreferredStockConvertibleTradingVolumeTrigger>
    <igap:PreferredStockConvertibleTradingVolumeTrigger contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">50000</igap:PreferredStockConvertibleTradingVolumeTrigger>
    <us-gaap:PreferredStockLiquidationPreference contextRef="AsOf2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USDPerShare" decimals="2">10</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference contextRef="AsOf2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USDPerShare" decimals="2">10</us-gaap:PreferredStockLiquidationPreference>
    <igap:PreferredStockPercentageOutstandingGoverningDistributions contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Pure" decimals="2">0.15</igap:PreferredStockPercentageOutstandingGoverningDistributions>
    <igap:PreferredStockPercentageOutstandingGoverningDistributions contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Pure" decimals="2">0.35</igap:PreferredStockPercentageOutstandingGoverningDistributions>
    <igap:NumberOfSharesOffered contextRef="C618176" unitRef="Shares" decimals="INF">785714</igap:NumberOfSharesOffered>
    <igap:NumberOfUnitsSold contextRef="C618177" unitRef="Shares" decimals="INF">6300</igap:NumberOfUnitsSold>
    <igap:NumberOfUnitsSold contextRef="C618179" unitRef="Shares" decimals="INF">1140.35</igap:NumberOfUnitsSold>
    <igap:NumberOfUnitsSold contextRef="C618187" unitRef="Shares" decimals="INF">8500</igap:NumberOfUnitsSold>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="C618179" unitRef="Shares" decimals="INF">162907</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TemporaryEquityOtherChanges contextRef="C618179" unitRef="USD" decimals="0">1140349</us-gaap:TemporaryEquityOtherChanges>
    <igap:StockPriceAtWhichStockDividendIsDeclared contextRef="C618125" unitRef="USDPerShare" decimals="2">5.80</igap:StockPriceAtWhichStockDividendIsDeclared>
    <us-gaap:StockDividendsShares contextRef="C618182" unitRef="Shares" decimals="INF">100526</us-gaap:StockDividendsShares>
    <us-gaap:SharePrice contextRef="C618360" unitRef="USDPerShare" id="Foot-01-0" decimals="2">2.31</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2014-12-31_custom_TwoThousandFourteenOfferingMember" unitRef="USDPerShare" decimals="2">2.31</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="C619661" unitRef="USDPerShare" decimals="2">2.77</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="C618667" unitRef="USDPerShare" decimals="2">2.31</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="C618816" unitRef="USDPerShare" decimals="2">2.31</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="C618817" unitRef="USDPerShare" decimals="2">8.50</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="C619501" unitRef="USDPerShare" id="Foot-02-0" xsi:nil="true" />
    <us-gaap:SharePrice contextRef="C619503" unitRef="USDPerShare" id="Foot-02-1" decimals="INF">2.31</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPerShare" id="Foot-02-2" xsi:nil="true" />
    <us-gaap:SharePrice contextRef="C619515" unitRef="USDPerShare" decimals="INF">8.50</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2015-12-31_us-gaap_CommonStockMember" unitRef="USDPerShare" id="Foot-01-1" decimals="INF">2.31</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2015-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember" unitRef="USDPerShare" decimals="INF">2.31</us-gaap:SharePrice>
    <igap:OfferingCostsIncurred contextRef="C618183" unitRef="USD" decimals="0">1479864</igap:OfferingCostsIncurred>
    <igap:OfferingCostsIncurred contextRef="C618191" unitRef="USD" decimals="0">1787545</igap:OfferingCostsIncurred>
    <igap:ProceedsFromUnitsSold contextRef="C618187" unitRef="USD" decimals="-5">8500000</igap:ProceedsFromUnitsSold>
    <igap:ClassOfWarrantOrRightNumberOfWarrantsExercisable contextRef="C618340" unitRef="Shares" decimals="INF">1539364</igap:ClassOfWarrantOrRightNumberOfWarrantsExercisable>
    <igap:ClassOfWarrantOrRightNumberOfWarrantsExercisable contextRef="AsOf2015-12-31_custom_SeriesAWarrantMember" unitRef="Shares" decimals="INF">380953</igap:ClassOfWarrantOrRightNumberOfWarrantsExercisable>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="C618356" unitRef="Pure" id="Foot-03-0" decimals="4">1.0514</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Pure" id="Foot-03-1" decimals="INF">1.0514</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="C618356" unitRef="Pure" decimals="4">0.0114</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="4">.0099</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="C618356" id="Foot-04-0">P3Y2M12D</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" id="Foot-04-1">P2Y2M12D</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExercisePrice contextRef="C618358" unitRef="USDPerShare" decimals="2">5.8</us-gaap:FairValueAssumptionsExercisePrice>
    <us-gaap:FairValueAssumptionsExercisePrice contextRef="AsOf2015-12-31_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="2">5.80</us-gaap:FairValueAssumptionsExercisePrice>
    <igap:ClassOfWarrantOrRightFairValue contextRef="C618358" unitRef="USDPerShare" decimals="2">1.13</igap:ClassOfWarrantOrRightFairValue>
    <igap:ClassOfWarrantOrRightFairValue contextRef="AsOf2015-12-31_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="2">0.84</igap:ClassOfWarrantOrRightFairValue>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued contextRef="C619618" unitRef="Shares" decimals="INF">45531</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued contextRef="C619622" unitRef="Shares" decimals="INF">8989</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued contextRef="C619623" unitRef="Shares" decimals="INF">45097</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued contextRef="C619624" unitRef="Shares" decimals="INF">84459</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued contextRef="From2012-01-01to2012-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember_custom_ClassOfWarrantOrRightExercisePriceOneMember" unitRef="Shares" decimals="INF">128277</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued contextRef="From2012-01-01to2012-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember_custom_ClassOfWarrantOrRightExercisePriceTwoMember" unitRef="Shares" decimals="INF">128277</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued contextRef="From2012-01-01to2012-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember_custom_ClassOfWarrantOrRightExercisePriceThreeMember" unitRef="Shares" decimals="INF">215</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued contextRef="From2014-01-01to2014-12-31_custom_TwoThousandFourteenOfferingMember_custom_ClassOfWarrantOrRightExercisePriceFourMember" unitRef="Shares" decimals="INF">293115</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued contextRef="From2014-01-01to2014-12-31_custom_TwoThousandFourteenOfferingMember_custom_ClassOfWarrantOrRightExercisePriceFiveMember" unitRef="Shares" decimals="INF">146559</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued contextRef="C618795" unitRef="Shares" decimals="INF">26484</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued contextRef="From2005-01-01to2005-12-31_custom_RegulatoryServicesMember" unitRef="Shares" decimals="INF">21640</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="C619619" unitRef="Shares" decimals="INF">17657</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="C619620" unitRef="Shares" decimals="INF">5365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="C618796" unitRef="Shares" decimals="INF">8828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="C619502" unitRef="Shares" decimals="INF">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">17605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice contextRef="C619618" unitRef="USDPerShare" decimals="3">4.305</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>
    <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice contextRef="C619622" unitRef="USDPerShare" decimals="3">5.517</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>
    <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice contextRef="C618795" unitRef="USDPerShare" decimals="2">9.50</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>
    <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice contextRef="C619494" unitRef="USDPerShare" decimals="2">6.25</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>
    <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice contextRef="C619495" unitRef="USDPerShare" decimals="2">6.25</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>
    <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice contextRef="From2005-01-01to2005-12-31_custom_RegulatoryServicesMember" unitRef="USDPerShare" decimals="3">0.001</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="C618191" unitRef="USDPerShare" decimals="2">1.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2015-01-01to2015-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember" unitRef="USDPerShare" decimals="2">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="C620670" unitRef="USDPerShare" decimals="2">1.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="C618796" unitRef="USDPerShare" decimals="2">1.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="C618815" unitRef="USDPerShare" decimals="2">2.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="C619502" unitRef="USDPerShare" decimals="2">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="C619513" unitRef="USDPerShare" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPerShare" xsi:nil="true" />
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="C618191" unitRef="Pure" decimals="2">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2015-01-01to2015-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember" unitRef="Pure" decimals="2">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="C620670" unitRef="Pure" decimals="2">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="C618796" unitRef="Pure" decimals="2">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="C618815" unitRef="Pure" decimals="2">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="C618191" unitRef="Pure" decimals="4">1.0514</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2015-01-01to2015-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember" unitRef="Pure" decimals="4">1.0514</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="C620670" unitRef="Pure" decimals="4">1.0514</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="C618796" unitRef="Pure" decimals="4">1.0514</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="C618815" unitRef="Pure" decimals="4">1.0514</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="C618191" unitRef="Pure" decimals="4">0.0166</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2015-01-01to2015-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember" unitRef="Pure" decimals="4">.0099</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="C620670" unitRef="Pure" decimals="4">0.0114</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="C618796" unitRef="Pure" decimals="4">0.0114</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="C618815" unitRef="Pure" decimals="4">0.0012</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="C618667" unitRef="USDPerShare" decimals="2">5.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="C618771" unitRef="USDPerShare" decimals="2">5.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="C618772" unitRef="USDPerShare" decimals="2">10.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="C618816" unitRef="USDPerShare" decimals="2">9.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="C618817" unitRef="USDPerShare" decimals="2">9.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="C619501" unitRef="USDPerShare" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="C619503" unitRef="USDPerShare" decimals="INF">7.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPerShare" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2015-12-31_custom_PlacementAgentMember_custom_TwoThousandTwelveOfferingMember" unitRef="USDPerShare" decimals="INF">5.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="C619282">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2015-12-31_custom_ShareIncentivePlanMember" unitRef="Shares" decimals="INF">96313</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="C619494" unitRef="Shares" decimals="INF">264778</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="C619495" unitRef="Shares" decimals="INF">79434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="C619502" unitRef="Shares" decimals="INF">44000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="C619513" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="C619501" unitRef="Shares" decimals="INF">414847</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="C619503" unitRef="Shares" decimals="INF">450847</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">413473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="C619501" unitRef="USDPerShare" decimals="2">5.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="C619503" unitRef="USDPerShare" decimals="2">5.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPerShare" decimals="2">6.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="C619502" unitRef="USDPerShare" decimals="2">7.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPerShare" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="C619502" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-12-31" unitRef="Shares" decimals="INF">36137</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">20</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="Shares" decimals="INF">36117</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-19769</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="C619502" unitRef="USDPerShare" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPerShare" decimals="INF">1.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="C619502" unitRef="USDPerShare" decimals="2">6.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPerShare" decimals="2">6.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="C619501" unitRef="Shares" decimals="INF">298910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="C619503" unitRef="Shares" decimals="INF">302360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">293736</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="C619501" unitRef="USDPerShare" decimals="2">5.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="C619503" unitRef="USDPerShare" decimals="2">5.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPerShare" decimals="2">5.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="C619283" unitRef="USD" decimals="0">23830</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="C619515" unitRef="USD" decimals="0">882471</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2015-12-31_custom_ShareIncentivePlanMember" unitRef="USD" decimals="0">1284500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="C619283" unitRef="USD" decimals="0">23830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="C619515" unitRef="USD" decimals="0">1143330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2015-12-31_custom_ShareIncentivePlanMember" unitRef="USD" decimals="0">1284500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2015-01-01to2015-12-31_custom_RangeOneMember" unitRef="USDPerShare" decimals="2">1.72</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2015-01-01to2015-12-31_custom_RangeTwoMember" unitRef="USDPerShare" decimals="2">3.63</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2015-01-01to2015-12-31_custom_RangeThreeMember" unitRef="USDPerShare" decimals="2">6.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2015-01-01to2015-12-31_custom_RangeFourMember" unitRef="USDPerShare" decimals="2">6.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2015-01-01to2015-12-31_custom_RangeFiveMember" unitRef="USDPerShare" decimals="2">7.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2015-12-31_custom_RangeOneMember" unitRef="Shares" decimals="INF">21758</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2015-12-31_custom_RangeTwoMember" unitRef="Shares" decimals="INF">3730</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2015-12-31_custom_RangeThreeMember" unitRef="Shares" decimals="INF">4273</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2015-12-31_custom_RangeFourMember" unitRef="Shares" decimals="INF">351712</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2015-12-31_custom_RangeFiveMember" unitRef="Shares" decimals="INF">32000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">413473</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-12-31_custom_RangeOneMember">P1Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-12-31_custom_RangeTwoMember">P1Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-12-31_custom_RangeThreeMember">P2Y15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-12-31_custom_RangeFourMember">P6Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-12-31_custom_RangeFiveMember">P8Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2015-12-31_custom_RangeOneMember" unitRef="USDPerShare" decimals="2">1.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2015-12-31_custom_RangeTwoMember" unitRef="USDPerShare" decimals="2">3.63</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2015-12-31_custom_RangeThreeMember" unitRef="USDPerShare" decimals="2">6.03</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2015-12-31_custom_RangeFourMember" unitRef="USDPerShare" decimals="2">6.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2015-12-31_custom_RangeFiveMember" unitRef="USDPerShare" decimals="2">7.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2015-12-31_custom_RangeOneMember" unitRef="Shares" decimals="INF">21758</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2015-12-31_custom_RangeTwoMember" unitRef="Shares" decimals="INF">3730</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2015-12-31_custom_RangeThreeMember" unitRef="Shares" decimals="INF">4273</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2015-12-31_custom_RangeFourMember" unitRef="Shares" decimals="INF">236975</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2015-12-31_custom_RangeFiveMember" unitRef="Shares" decimals="INF">27000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">293736</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-12-31_custom_RangeOneMember">P1Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-12-31_custom_RangeTwoMember">P1Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-12-31_custom_RangeThreeMember">P2Y15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-12-31_custom_RangeFourMember">P6Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-12-31_custom_RangeFiveMember">P8Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="C619502" unitRef="Pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="C619513" unitRef="Pure" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="C619502" unitRef="Pure" id="Foot-03-2" decimals="4">1.0514</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="C619513" unitRef="Pure" id="Foot-03-3" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" id="Foot-03-4" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="C619502" unitRef="Pure" decimals="4">0.0161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="C619513" unitRef="Pure" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C619513" id="Foot-04-2" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C620666" id="Foot-04-3">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C620667" id="Foot-04-4">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="C618356" unitRef="Pure" xsi:nil="true" />
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Pure" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2015-01-01to2015-12-31_custom_RangeOneMember" unitRef="USDPerShare" decimals="2">1.72</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2015-01-01to2015-12-31_custom_RangeTwoMember" unitRef="USDPerShare" decimals="2">3.63</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2015-01-01to2015-12-31_custom_RangeThreeMember" unitRef="USDPerShare" decimals="2">6.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2015-01-01to2015-12-31_custom_RangeFourMember" unitRef="USDPerShare" decimals="2">6.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2015-01-01to2015-12-31_custom_RangeFiveMember" unitRef="USDPerShare" decimals="2">7.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <igap:ConvertiblePreferredStockConversionPrice contextRef="C660799" unitRef="USDPerShare" decimals="2">5.80</igap:ConvertiblePreferredStockConversionPrice>
    <igap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember_custom_GrantsToMessrsGalAndMalkaMember" unitRef="USD" decimals="0">35300</igap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne>
    <igap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember_custom_GrantsToMessrsGalAndMalkaMember" unitRef="USD" decimals="0">2200</igap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo>
    <us-gaap:DepreciationAndAmortization contextRef="C618344" unitRef="USD" decimals="0">32858</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="C618343" unitRef="USD" decimals="0">16156</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">19132</us-gaap:DepreciationAndAmortization>
    <us-gaap:TravelAndEntertainmentExpense contextRef="C618114" unitRef="USD" decimals="0">200348</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense contextRef="C618117" unitRef="USD" decimals="0">128095</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense contextRef="C618344" unitRef="USD" decimals="0">43131</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense contextRef="C618343" unitRef="USD" decimals="0">27867</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">468126</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">39324</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:CostOfPropertyRepairsAndMaintenance contextRef="C618114" unitRef="USD" decimals="0">40087</us-gaap:CostOfPropertyRepairsAndMaintenance>
    <us-gaap:CostOfPropertyRepairsAndMaintenance contextRef="C618117" unitRef="USD" decimals="0">26529</us-gaap:CostOfPropertyRepairsAndMaintenance>
    <us-gaap:CostOfPropertyRepairsAndMaintenance contextRef="C618344" unitRef="USD" decimals="0">35955</us-gaap:CostOfPropertyRepairsAndMaintenance>
    <us-gaap:CostOfPropertyRepairsAndMaintenance contextRef="C618343" unitRef="USD" decimals="0">25888</us-gaap:CostOfPropertyRepairsAndMaintenance>
    <us-gaap:CostOfPropertyRepairsAndMaintenance contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">41180</us-gaap:CostOfPropertyRepairsAndMaintenance>
    <us-gaap:CostOfPropertyRepairsAndMaintenance contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">54936</us-gaap:CostOfPropertyRepairsAndMaintenance>
    <us-gaap:OtherGeneralExpense contextRef="C618344" unitRef="USD" decimals="0">179333</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense contextRef="C618343" unitRef="USD" decimals="0">176424</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">159459</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="C618114" unitRef="USD" decimals="0">185282</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="C618117" unitRef="USD" decimals="0">63805</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">227160</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="C618114" unitRef="USD" decimals="0">25282</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="C618117" unitRef="USD" decimals="0">-94815</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-38873</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="C618114" unitRef="USD" decimals="0">6559758</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="C618117" unitRef="USD" decimals="0">-6251242</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">149092</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:RecapitalizationCosts contextRef="C618114" unitRef="USD" xsi:nil="true" />
    <us-gaap:RecapitalizationCosts contextRef="C618117" unitRef="USD" decimals="INF">390928</us-gaap:RecapitalizationCosts>
    <us-gaap:RecapitalizationCosts contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestExpenseDebt contextRef="C618114" unitRef="USD" decimals="0">-2189</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="C618117" unitRef="USD" decimals="0">17592</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">15205</us-gaap:InterestExpenseDebt>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2015-12-31_us-gaap_ParentCompanyMember" unitRef="USD" decimals="-5">3100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2015-12-31_custom_AdIntegrityApplicationsLtdMember" unitRef="USD" decimals="-5">20700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="C618114" unitRef="USD" decimals="0">2980426</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="C618117" unitRef="USD" decimals="0">-9796853</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-5842172</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="C618114" unitRef="Pure" decimals="2">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="C618117" unitRef="Pure" decimals="2">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2015-01-01to2015-12-31" unitRef="Pure" decimals="2">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="C618114" unitRef="USD" decimals="0">1043149</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="C618117" unitRef="USD" decimals="0">-3428899</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-1986338</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="C618114" unitRef="USD" decimals="0">27250</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="C618117" unitRef="USD" decimals="0">21250</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">31050</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="C618114" unitRef="USD" decimals="0">14415</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="C618117" unitRef="USD" decimals="0">10570</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">4503</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="C618114" unitRef="USD" decimals="0">-2295915</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="C618117" unitRef="USD" decimals="0">2324760</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-50691</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="C618114" unitRef="USD" decimals="0">278466</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="C618117" unitRef="USD" decimals="0">253942</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">340263</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="C618114" unitRef="USD" decimals="0">932635</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="C618117" unitRef="USD" decimals="0">818377</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">1224533</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="C618114" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="C618117" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="C618125" unitRef="USD" decimals="0">20220</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="C618154" unitRef="USD" decimals="0">33629</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">23494</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="C618125" unitRef="USD" decimals="0">4810780</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="C618154" unitRef="USD" decimals="0">4364466</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">6233314</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="C618125" unitRef="USD" decimals="0">4831000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="C618154" unitRef="USD" decimals="0">4398095</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">6256808</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="C618125" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="C618154" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherPreferredStockDividendsAndAdjustments contextRef="C618114" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherPreferredStockDividendsAndAdjustments contextRef="C618117" unitRef="USD" decimals="INF">278263</us-gaap:OtherPreferredStockDividendsAndAdjustments>
    <us-gaap:OtherPreferredStockDividendsAndAdjustments contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="C618123" unitRef="USD" decimals="0">288247</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="C618133" unitRef="USD" decimals="0">43858</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="C618121" unitRef="USD" decimals="0">370441</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="C623432" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USD" decimals="INF">57061</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="INF">390219</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="C618114" unitRef="USD" decimals="0">596472</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="C618117" unitRef="USD" xsi:nil="true" />
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="C618114" unitRef="USD" decimals="0">1969655</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="C618117" unitRef="USD" decimals="0">-10363363</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-6289452</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="C618114" unitRef="Shares" id="Foot-05-0" decimals="INF">5349242</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="C618117" unitRef="Shares" id="Foot-05-1" decimals="INF">5325714</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2015-01-01to2015-12-31" unitRef="Shares" id="Foot-05-2" decimals="INF">5476870</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C618114" unitRef="Shares" id="Foot-06-0" decimals="INF">4557612</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C618117" unitRef="Shares" id="Foot-06-1" decimals="INF">2813493</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-12-31" unitRef="Shares" id="Foot-06-2" decimals="INF">9431728</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NumberOfOperatingSegments contextRef="From2015-01-01to2015-12-31" unitRef="Item" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
    <dei:EntityPublicFloat contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">42798070</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2016-03-30" unitRef="Shares" decimals="INF">5323059</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentFiscalYearFocus contextRef="From2015-01-01to2015-12-31">2015</dei:DocumentFiscalYearFocus>
    <dei:DocumentType contextRef="From2015-01-01to2015-12-31">10-K</dei:DocumentType>
    <dei:AmendmentFlag contextRef="From2015-01-01to2015-12-31">false</dei:AmendmentFlag>
    <dei:DocumentPeriodEndDate contextRef="From2015-01-01to2015-12-31">2015-12-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2015-01-01to2015-12-31">Integrity Applications, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2015-01-01to2015-12-31">0001506983</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="From2015-01-01to2015-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2015-01-01to2015-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityFilerCategory contextRef="From2015-01-01to2015-12-31">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:EntityCurrentReportingStatus contextRef="From2015-01-01to2015-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2015-01-01to2015-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2015-01-01to2015-12-31">No</dei:EntityVoluntaryFilers>
    <igap:PercentOfFutureSalesDesignatedToRepayStockholdersLoans contextRef="From2015-01-01to2015-12-31" unitRef="Pure" decimals="2">0.10</igap:PercentOfFutureSalesDesignatedToRepayStockholdersLoans>
    <igap:PreferredStockMaximumBeneficialOwnership contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Pure" decimals="4">0.0499</igap:PreferredStockMaximumBeneficialOwnership>
    <igap:PreferredStockMaximumBeneficialOwnershipSubjectToTerms contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Pure" decimals="4">0.0999</igap:PreferredStockMaximumBeneficialOwnershipSubjectToTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2015-12-31_custom_ShareIncentivePlanMember" unitRef="Shares" decimals="INF">529555</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2016-03-17_custom_ShareIncentivePlanMember_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="C618374" unitRef="USD" decimals="0">1255606</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="C618375" unitRef="USD" decimals="0">820493</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="From2015-01-01to2015-12-31_custom_AgreementWithPlacementAgentMember" unitRef="USD" decimals="0">185000</us-gaap:PaymentsOfStockIssuanceCosts>
    <igap:RegistrationPaymentArrangementCommissionPercentage contextRef="C618368" unitRef="Pure" decimals="2">0.07</igap:RegistrationPaymentArrangementCommissionPercentage>
    <igap:RegistrationPaymentArrangementCommissionPercentage contextRef="C618369" unitRef="Pure" decimals="2">.03</igap:RegistrationPaymentArrangementCommissionPercentage>
    <igap:RegistrationPaymentArrangementCommissionPercentage contextRef="C618370" unitRef="Pure" decimals="2">.03</igap:RegistrationPaymentArrangementCommissionPercentage>
    <igap:RegistrationPaymentArrangementCommissionPercentage contextRef="From2010-01-01to2010-12-31_custom_DecemberOfferingMember" unitRef="Pure" decimals="2">.13</igap:RegistrationPaymentArrangementCommissionPercentage>
    <igap:RegistrationPaymentArrangementCommissionPercentage contextRef="C661186" unitRef="Pure" decimals="2">.06</igap:RegistrationPaymentArrangementCommissionPercentage>
    <igap:RegistrationPaymentArrangementCommissionPercentage contextRef="C661187" unitRef="Pure" decimals="2">.04</igap:RegistrationPaymentArrangementCommissionPercentage>
    <us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration contextRef="AsOf2012-12-31_us-gaap_CommonStockMember_custom_TwoThousandTwelveOfferingMember" unitRef="USD" decimals="0">5000000</us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration>
    <us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration contextRef="C618373" unitRef="USD" decimals="0">7500000</us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration>
    <us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration contextRef="AsOf2014-12-31_custom_TwoThousandFourteenOfferingMember" unitRef="USD" decimals="0">25000000</us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration>
    <us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration contextRef="AsOf2014-12-31_custom_TwoThousandFourteenOfferingsMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">8500000</us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration>
    <igap:AreaOfLeasedSpace contextRef="AsOf2015-12-31_custom_PropertyAshkelonIsraelMember" unitRef="SquareFoot" decimals="0">3100</igap:AreaOfLeasedSpace>
    <igap:AreaOfLeasedSpace contextRef="AsOf2015-12-31_custom_PropertyAshdodIsraelMember" unitRef="SquareFoot" decimals="0">5500</igap:AreaOfLeasedSpace>
    <igap:MonthlyLeaseCommitment contextRef="AsOf2015-12-31_custom_PropertyAshkelonIsraelMember" unitRef="USD" decimals="0">2934</igap:MonthlyLeaseCommitment>
    <igap:MonthlyLeaseCommitment contextRef="AsOf2015-12-31_custom_PropertyAshdodIsraelMember" unitRef="USD" decimals="0">10000</igap:MonthlyLeaseCommitment>
    <igap:MonthlyLeaseCommitment contextRef="AsOf2015-12-31_custom_PropertyAshkelonIsraelMember_currency_ILS" unitRef="ils" decimals="0">11500</igap:MonthlyLeaseCommitment>
    <igap:EquityIssuancePricePerShare contextRef="C618176" unitRef="USDPerShare" decimals="2">7.00</igap:EquityIssuancePricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="C618176" unitRef="USD" decimals="0">1155399</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">19769</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <igap:GainLossOnUnitConversion contextRef="C618114" unitRef="USD" xsi:nil="true" />
    <igap:GainLossOnUnitConversion contextRef="C618117" unitRef="USD" xsi:nil="true" />
    <igap:GainLossOnUnitConversion contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-1284354</igap:GainLossOnUnitConversion>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="C618114" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="C618117" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">36137</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="C618114" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="C618117" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-439939</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <igap:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts contextRef="C618118" unitRef="USD" decimals="-6">1000000</igap:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <igap:IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants contextRef="C618114" unitRef="USD" xsi:nil="true" />
    <igap:IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants contextRef="C618117" unitRef="USD" xsi:nil="true" />
    <igap:IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">436680</igap:IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants>
    <igap:LeaseGuaranteeProvidedToLandlord contextRef="AsOf2015-12-31_custom_PropertyAshdodIsraelMember" unitRef="USD" decimals="0">35000</igap:LeaseGuaranteeProvidedToLandlord>
    <igap:LeaseGuaranteeProvidedToLandlord contextRef="AsOf2015-12-31_custom_PropertyAshdodIsraelMember_currency_ILS" unitRef="USD" decimals="0">137162</igap:LeaseGuaranteeProvidedToLandlord>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="C618125" unitRef="USD" decimals="0">2057618</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="C618154" unitRef="USD" decimals="0">8216705</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">321695</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="C618114" unitRef="USD" decimals="0">400671</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <igap:ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">1586831</igap:ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision>
    <igap:ChangeInFairValueOfSeriesaWarrants contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">149092</igap:ChangeInFairValueOfSeriesaWarrants>
    <igap:AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">-6931</igap:AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock>
    <igap:AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">6931</igap:AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock>
    <igap:NumberOfWarrantsExchanged contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-1440880</igap:NumberOfWarrantsExchanged>
    <igap:NumberOfWarrantsExchanged contextRef="From2015-01-01to2015-12-31_custom_SeriesB1WarrantMember" unitRef="Shares" decimals="INF">1200710</igap:NumberOfWarrantsExchanged>
    <igap:NumberOfWarrantsExchanged contextRef="From2015-01-01to2015-12-31_custom_SeriesB2WarrantMember" unitRef="Shares" decimals="INF">1200710</igap:NumberOfWarrantsExchanged>
    <igap:IncreaseDecreaseInEquityDueToExchangeOfWarrants contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USD" decimals="0">-4076688</igap:IncreaseDecreaseInEquityDueToExchangeOfWarrants>
    <igap:IncreaseDecreaseInEquityDueToExchangeOfWarrants contextRef="From2015-01-01to2015-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">3502536</igap:IncreaseDecreaseInEquityDueToExchangeOfWarrants>
    <igap:IncreaseDecreaseInEquityDueToExchangeOfWarrants contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">-1586831</igap:IncreaseDecreaseInEquityDueToExchangeOfWarrants>
    <igap:IncreaseDecreaseInEquityDueToExchangeOfWarrants contextRef="From2015-01-01to2015-12-31_custom_SeriesB1WarrantMember" unitRef="USD" decimals="0">1833876</igap:IncreaseDecreaseInEquityDueToExchangeOfWarrants>
    <igap:IncreaseDecreaseInEquityDueToExchangeOfWarrants contextRef="From2015-01-01to2015-12-31_custom_SeriesB2WarrantMember" unitRef="USD" decimals="0">1612186</igap:IncreaseDecreaseInEquityDueToExchangeOfWarrants>
    <igap:NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">1284354</igap:NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange>
    <igap:MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen contextRef="AsOf2015-12-31_custom_AgreementWithPlacementAgentMember" unitRef="USD" decimals="0">12500</igap:MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen>
    <igap:MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen contextRef="AsOf2015-12-31_custom_AgreementWithPlacementAgentMember" unitRef="USD" decimals="0">20000</igap:MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen>
    <igap:AmountPaidAsRepaymentOfPrincipalAmount contextRef="AsOf2015-03-23_us-gaap_JudicialRulingMember" unitRef="USD" decimals="0">439939</igap:AmountPaidAsRepaymentOfPrincipalAmount>
    <igap:AmountPaidAsRepaymentOfPrincipalAmount contextRef="AsOf2015-03-23_us-gaap_JudicialRulingMember_currency_ILS" unitRef="ils" decimals="0">1767674</igap:AmountPaidAsRepaymentOfPrincipalAmount>
    <igap:PartialReimbursementOfAttorneyFeesRequiredToPay contextRef="AsOf2015-04-30_us-gaap_JudicialRulingMember_currency_ILS" unitRef="ils" decimals="0">316100</igap:PartialReimbursementOfAttorneyFeesRequiredToPay>
    <igap:PartialReimbursementOfAttorneyFeesRequiredToPay contextRef="AsOf2015-04-30_us-gaap_JudicialRulingMember" unitRef="USD" decimals="0">81870</igap:PartialReimbursementOfAttorneyFeesRequiredToPay>
    <igap:ForeignCurrencyExchangeRate contextRef="AsOf2015-03-23_us-gaap_JudicialRulingMember_currency_ILS" unitRef="Pure" decimals="3">4.018</igap:ForeignCurrencyExchangeRate>
    <igap:ForeignCurrencyExchangeRate contextRef="AsOf2015-04-30_us-gaap_JudicialRulingMember_currency_ILS" unitRef="Pure" decimals="3">3.861</igap:ForeignCurrencyExchangeRate>
    <igap:NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision contextRef="AsOf2015-03-18_us-gaap_JudicialRulingMember" unitRef="Shares" decimals="INF">440652</igap:NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision>
    <us-gaap:StockholdersEquityOther contextRef="C618117" unitRef="USD" decimals="0">-1140349</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="C619585" unitRef="USD" decimals="0">-163</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="C619586" unitRef="USD" decimals="0">-1140186</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="C619587" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityOther contextRef="C619588" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityOtherShares contextRef="C619585" unitRef="Shares" decimals="INF">-162907</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="C618125" unitRef="USD" xsi:nil="true" />
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">35152</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="C618114" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="C618117" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">35152</us-gaap:IncreaseDecreaseInRestrictedCash>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2015-12-31_custom_PropertyAshdodIsraelMember" unitRef="USD" decimals="0">120000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2015-12-31_custom_PropertyAshdodIsraelMember" unitRef="USD" decimals="0">120000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2015-12-31_custom_PropertyAshdodIsraelMember" unitRef="USD" decimals="0">120000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2015-12-31_custom_PropertyAshdodIsraelMember" unitRef="USD" decimals="0">120000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="AsOf2015-12-31_custom_PropertyAshdodIsraelMember" unitRef="USD" decimals="0">120000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:LeaseExpirationDate1 contextRef="From2015-01-01to2015-12-31_custom_PropertyAshkelonIsraelMember">2015-12-31</us-gaap:LeaseExpirationDate1>
    <igap:RelatedPartyTransactionOwnershipInterestInEntity contextRef="From2015-01-01to2015-12-31_custom_AvnerGalMember" unitRef="Pure" decimals="3">.077</igap:RelatedPartyTransactionOwnershipInterestInEntity>
    <igap:RelatedPartyTransactionOwnershipInterestInEntity contextRef="From2015-01-01to2015-12-31_custom_DavidMalkaMember" unitRef="Pure" decimals="4">.0307</igap:RelatedPartyTransactionOwnershipInterestInEntity>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="C618115" unitRef="USD" decimals="0">134769</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="C618116" unitRef="USD" decimals="0">67302</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2015-01-01to2015-12-31_custom_AvnerGalMember" unitRef="USD" decimals="0">123457</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2013-01-01to2013-12-31_custom_AvnerGalMember" unitRef="USD" decimals="0">134111</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2015-01-01to2015-12-31_custom_DavidMalkaMember" unitRef="USD" decimals="0">61728</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2013-01-01to2013-12-31_custom_DavidMalkaMember" unitRef="USD" decimals="0">66639</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2015-01-01to2015-12-31_custom_AvnerGalMember_currency_ILS" unitRef="ils" decimals="0">480000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2015-01-01to2015-12-31_custom_DavidMalkaMember_currency_ILS" unitRef="ils" decimals="0">240000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <igap:PortionOfRelatedPartySalaryRelatingToBonusesPaid contextRef="C618115" unitRef="USD" xsi:nil="true" />
    <igap:PortionOfRelatedPartySalaryRelatingToBonusesPaid contextRef="C618116" unitRef="USD" xsi:nil="true" />
    <igap:PortionOfRelatedPartySalaryRelatingToBonusesPaid contextRef="From2015-01-01to2015-12-31_custom_AvnerGalMember" unitRef="USD" xsi:nil="true" />
    <igap:PortionOfRelatedPartySalaryRelatingToBonusesPaid contextRef="From2013-01-01to2013-12-31_custom_AvnerGalMember" unitRef="USD" decimals="0">61087</igap:PortionOfRelatedPartySalaryRelatingToBonusesPaid>
    <igap:PortionOfRelatedPartySalaryRelatingToBonusesPaid contextRef="From2015-01-01to2015-12-31_custom_DavidMalkaMember" unitRef="USD" xsi:nil="true" />
    <igap:PortionOfRelatedPartySalaryRelatingToBonusesPaid contextRef="From2013-01-01to2013-12-31_custom_DavidMalkaMember" unitRef="USD" decimals="0">30544</igap:PortionOfRelatedPartySalaryRelatingToBonusesPaid>
    <igap:AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors contextRef="AsOf2016-03-17_us-gaap_SubsequentEventMember_custom_DirectorsMember" unitRef="USD" decimals="0">15000</igap:AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors>
    <igap:AmountOfQuarterlyCompensationOwedToEachDirector contextRef="AsOf2016-03-17_us-gaap_SubsequentEventMember_custom_DirectorsMember" unitRef="USD" decimals="0">3750</igap:AmountOfQuarterlyCompensationOwedToEachDirector>
    <igap:AnnualCompensationOwedToChairperson contextRef="AsOf2016-03-17_us-gaap_SubsequentEventMember_custom_DirectorsMember" unitRef="USD" decimals="0">10000</igap:AnnualCompensationOwedToChairperson>
    <igap:AmountOfQuarterlyCompensationOwedChairperson contextRef="AsOf2016-03-17_us-gaap_SubsequentEventMember_custom_DirectorsMember" unitRef="USD" decimals="0">2500</igap:AmountOfQuarterlyCompensationOwedChairperson>
    <igap:TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant contextRef="AsOf2016-03-17_us-gaap_SubsequentEventMember_custom_DirectorsMember" unitRef="Shares" decimals="INF">26666</igap:TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant>
    <igap:ExercisePriceOfOptionsGranted contextRef="AsOf2016-03-17_us-gaap_SubsequentEventMember_custom_DirectorsMember" unitRef="USDPerShare" decimals="2">4.50</igap:ExercisePriceOfOptionsGranted>
    <igap:NumberOfSharesVestingInEachIncrement contextRef="AsOf2016-03-17_us-gaap_SubsequentEventMember_custom_DirectorsMember" unitRef="Shares" decimals="2">3333.25</igap:NumberOfSharesVestingInEachIncrement>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 54pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;NOTE 3&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;INVENTORIES&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;205,645&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;55,557&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;551,111&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;16,459&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Finished products&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;59,467&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;11,637&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;816,223&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;83,653&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-align: center"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 54pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;NOTE 4&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;OTHER CURRENT ASSETS&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Prepaid expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;57,206&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;46,094&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Government Institution (*)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;211,586&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;67,748&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;268,792&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;113,842&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 68.05pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;(*)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Represents amounts advanced by Integrity Israel to the Israeli tax authorities or amounts owed to Integrity Israel by the Israeli Value Added Tax authorities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-align: center"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 54pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;NOTE 5&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;PROPERTY AND EQUIPMENT, NET&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Computers&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;240,066&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;124,161&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Furniture and office equipment&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;200,548&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;184,379&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;32,898&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;22,992&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;473,512&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;331,532&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Less &amp;#8211; accumulated depreciation&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(253,049&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(209,041&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;220,463&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;122,491&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;During the years ended December&amp;#160;31, 2015, 2014 and 2013, depreciation expenses amounted to $44,891, $34,683 and $33,684, respectively, and new equipment purchases amounted to $143,736, $63,455 and $64,252, respectively.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <igap:OtherCurrentLiabilitiesDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-align: center"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 54pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;NOTE 6&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;OTHER CURRENT LIABILITIES&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Employees and related institutions&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;240,358&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;204,890&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;187,528&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;235,874&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;427,886&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;440,764&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</igap:OtherCurrentLiabilitiesDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-align: center"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 54pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;NOTE 7&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;LINE OF CREDIT&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As of December&amp;#160;31, 2015, the Group had an unutilized credit line of approximately $38,500 (NIS&amp;#160;150,000) with its Israeli bank. Borrowings under the line of credit are secured by funds on deposit with the bank at the time of borrowing, which generally must be sufficient to cover the principal amount of the borrowings in full.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LongTermDebtTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-align: center"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 54pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;NOTE 8&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;LONG-TERM LOANS FROM STOCKHOLDERS&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;During the years 2003-2004, Integrity Israel received loans from stockholders (three separate lenders).&amp;#160;&amp;#160;The loans are indexed to the Israeli Consumer Price Index from their origination date and bear no interest.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Group will be required to pay the loans, in quarterly installments, commencing on the first quarter following the first fiscal year in which the Group reports net profit in its annual report.&amp;#160;&amp;#160;At such time, the Group will be required to make quarterly payments equal to 10% of its total sales for each quarter until the loans have been repaid in full.&amp;#160;&amp;#160;Notwithstanding the repayment mechanism, the Group will not be required to repay the loans during any period in which such payment would cause a deficit in the Group's working capital. See Note 9D for a description of the repayment of the stockholder loan previously owing to Y.H. Dimri Holdings (2001) Ltd. (&amp;#8220;Dimri&amp;#8221;).&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As of December 31, 2015, the Group does not expect to make any additional material repayments during the following 12 months period, if any, and accordingly other loans from stockholders have been presented as long-term liabilities.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-align: center"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 54pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;NOTE 9&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;COMMITMENTS AND CONTINGENT LIABILITIES&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;A.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On March 4, 2004, the OCS provided Integrity Israel with a grant of approximately $93,300 (NIS 420,000), for its plan to develop a non-invasive blood glucose monitor (the &amp;#8220;Development Plan&amp;#8221;). Integrity Israel is required to pay royalties to the OCS at a rate ranging between 3-5% of the proceeds from the sale of the Group's products arising from the Development Plan up to an amount equal to $93,300, plus interest at LIBOR from the date of grant. As of December&amp;#160;31, 2015, the contingent liability with respect to royalty payment on future sales equals approximately $83,341, excluding interest. Such contingent obligation has no expiration date.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;B.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Until mid of December 2015,&#13;Integrity Israel leased approximately 3,100 sq. ft. of office space in the city of Ashkelon, Israel as its principal offices&#13;and prototype laboratory.&amp;#160;&amp;#160;Pursuant to a verbal agreement with the landlord, Integrity Israel leased this facility&#13;on a monthly basis at a cost of approximately $2,934 (NIS 11,500). Currently, Integrity Israel leases approximately 5,500 sq.&#13;ft. of office space in the city of Ashdod, Israel for its principal offices.&amp;#160;&amp;#160;The lease term began on&#13;December&amp;#160;1, 2015 for a period of 5 years which can be extended for an additional 5 years at the option of the Company.&#13;Monthly lease payments including maintenance approximate $10,000. The Company estimates that its minimal rent and maintenance&#13;payments will approximate $120,000 per year over each of the next 5 years. In connection with the lease&#13;agreement, Integrity Israel provided the landlord a bank guarantee in the amount of approximately $35,000 (NIS&amp;#160;137,162)&#13;that can be exercised by the landlord in the case Integrity Israel fails to pay the monthly rent payments.&amp;#160;&amp;#160;The&#13;guarantee is renewed on an annual basis for a period of 5 years and is secured by funds on deposit with the bank, which&#13;generally must be sufficient to cover the principal amount guarantee.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;C.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;During 2014, the Company engaged the Placement Agent in connection with an offering of up $25,000,000 of its securities, which engagement ultimately culminated in the issuance and sale of $8,500,000 Series B Units (the &amp;#8220;2014 Offering&amp;#8221;). Pursuant to a placement agent agreement with the Placement Agent entered into with respect to such private placement, the Placement Agent (or its sub-agents) was paid, as a commission, an amount equal to 6% of the funds raised in each, such offering, plus 4% of the funds as a management fee plus a 3% non-accountable expense allowance (13% in the aggregate), all in cash.&amp;#160;&amp;#160;In addition, pursuant to such placement agent agreement, the Company was required to and did issue to the Placement Agent (or its sub-agents) warrants to purchase up to 10% of the shares of Common Stock issued to investors (or underlying convertible securities issued to investors) in connection with such offerings at a price per share equal to the offering price subject to certain price adjustments.&amp;#160;&amp;#160;Based on the agreement signed on 2014, the Placement Agent will have a right of first refusal on any private equity, debt or rights offering for a period of 24 months from the date on which marketing efforts with respect to the 2014 Offering began. In addition, pursuant to such agreement, the Company is required to use its reasonable efforts to have the Placement Agent named as a co-underwriter in any secondary public offering by the Company in the 12 months following completion of the 2014 Offering. In addition, starting in September 2013, the Company retained the Placement Agent to provide certain advisory services for a monthly fee of $12,500 for the period September 2013 until December 2014 and $20,000 per month starting from January 2015.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company paid the Placement Agent $185,000 $1,255,606 and $820,493, in cash during 2015, 2014, and 2013, respectively.&amp;#160;&amp;#160;See Notes 10B, Note 10C and Note 10E.1 with respect to warrants issued to the Placement Agent.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;D.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;From June of 2011 Integrity Israel, Avner Gal, David Malka, Zvi Cohen, Ilana Freger and Alexander Raykhman, on the one hand, and Dimri, on the other hand, which was a shareholder of Integrity Israel prior to the reorganization and merger (See Note 1A above), were involved in arbitration proceedings resulting from certain claims asserted by Dimri following such reorganization. On March 11, 2015, the arbitrator issued a binding arbitration decision (the &amp;#8220;Arbitration Decision&amp;#8221;) which documents the parties&amp;#8217; negotiated settlement of such arbitration proceedings.&amp;#160;&amp;#160;Pursuant to the terms of the Arbitration Decision, (1) Avner Gal, David Malka, Zvi Cohen, Ilana Freger and Alexander Raykhman transferred to Dimri, on March 18, 2015, an aggregate of 440,652 shares of the Company&amp;#8217;s outstanding Common Stock held collectively by such shareholders, (2) Integrity Israel (A) paid to Dimri on March 23, 2015, NIS 1,767,674 or $439,939 (based on the exchange rate of 4.018 NIS:$1 as of March 23, 2015), as repayment in full of the outstanding principal amount under Dimri&amp;#8217;s investment agreement with Integrity Israel and the founders (the &amp;#8220;Investment Agreement&amp;#8221;), as adjusted for changes in the Israeli consumer price index since the date on which the loan was made, and (B) paid to Dimri on April 30, 2015, NIS 316,100 or $81,870 (based on the exchange rate of 3.861 NIS:$1 as of April 30, 2015), as partial reimbursement of Dimri&amp;#8217;s attorney&amp;#8217;s fees in the arbitration. The Company accrued for the fee reimbursement obligation as part of professional fees within selling, marketing and general and administrative expenses included in its results of operations for the fiscal year ended December 31, 2014. During March 2015, such amount was fully paid.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Following the completion of the abovementioned transfers and payments, pursuant to the Arbitration Decision, Integrity Israel, the Company and the other defendants in the arbitration were released from any legal claim by Yigal Dimri, the principal shareholder of Dimri, and any other companies under his control in respect of the subject matter of the arbitration, including the shareholder loan granted under and any claim of anti-dilution rights under the Investment Agreement, and Mr. Dimri and all companies under his control were released from any legal claim by Integrity Israel, the Company and the other defendants in the arbitration in respect of the subject matter of the arbitration.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 54pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;NOTE 11&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;RESEARCH AND DEVELOPMENT EXPENSES&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Salaries and related expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,303,614&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,128,672&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,293,067&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;525,144&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;377,918&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;247,888&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Materials&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;166,736&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;96,699&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;154,522&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Depreciation&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;19,132&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;16,156&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;32,858&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Travel expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;39,324&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;27,867&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;43,131&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Vehicle maintenance&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;54,936&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;25,888&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;35,955&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Other&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;159,459&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;176,424&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;179,333&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,268,345&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,849,624&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,986,754&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <igap:SellingGeneralAndAdministrativeExpenseTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 54pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;NOTE 12&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Salaries and related expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;803,319&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;651,900&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;260,276&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;990,390&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;739,893&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;562,435&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Travel &amp;#38; expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;468,126&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;200,348&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;128,095&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Vehicle maintenance&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;41,180&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;40,087&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;26,529&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Other&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;227,160&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;185,282&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;63,805&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,530,175&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,817,510&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,041,140&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</igap:SellingGeneralAndAdministrativeExpenseTextBlock>
    <igap:FinancingExpensesNetDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 54pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;NOTE 13&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;FINANCING (INCOME) EXPENSES, NET&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Israeli CPI linkage difference on principal of loans from stockholders&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(2,521&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(556&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;14,382&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exchange rate differences&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;38,873&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(25,282&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;94,815&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Change in fair value of Series A Warrants&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(149,092&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(6,559,758&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6,251,242&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Issuance cost allocated to warrants with down-round protection&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;390,928&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Interest expenses on credit from banks and other&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;15,205&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(2,189&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;17,592&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,284,354&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,186,819&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(6,587,785&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6,768,959&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</igap:FinancingExpensesNetDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 54pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;NOTE 16&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;SEGMENT INFORMATION&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company operates in one operating segment, the following is a summary of operations within geographic areas:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Revenues based on the customer&amp;#8217;s location:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Europe&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;13,420&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;32,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Asia and Pacific&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;129,747&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;27,775&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Total&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;143,167&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;59,775&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;All long-lived assets are owned by Integrity Israel and are located in Israel.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 54pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;NOTE 17&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;RELATED PARTIES&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;A.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Avner Gal, the beneficial owner of approximately 7.7% of the Company's outstanding Common Stock as of December&amp;#160;31, 2015, entered into an employment agreement with Integrity Israel in July 2010 pursuant to which Mr.&amp;#160;Gal agreed to continue to serve as the chief executive officer and managing director of Integrity Israel.&amp;#160;&amp;#160;The agreement was approved by the board of directors and stockholders of Integrity Israel. Mr. Gal&amp;#8217;s employment agreement provides for an annual salary of approximately $123,457, $134,769 and $134,111 (NIS&amp;#160;480,000) for the year ended December 31, 2015, 2014 and 2013 respectively. In addition, Mr. Gal is entitled to an annual bonus to be determined by the board of directors and an additional sum provided that Mr. Gal reaches certain milestones approved by the board, as well as the payment of certain social and insurance benefits and the use of a car.&amp;#160;&amp;#160;During the year ended December 31, 2015, 2014 and 2013 the Company paid Mr. Gal $0, $0 and $61,087, respectively as bonuses.&amp;#160;&amp;#160;The agreement also provides for a renegotiation of Mr. Gal&amp;#8217;s annual salary on the one-year anniversary thereof and the renegotiation of Mr. Gal&amp;#8217;s bonus formula once Integrity Israel has begun commercialization of its products.&amp;#160;&amp;#160;The agreement is terminable by either party on 180 days&amp;#8217; notice, immediately by Integrity Israel with the payment of an amount equal to 180 days of annual salary, or immediately by Integrity Israel for cause (as defined in the agreement) without the payment of severance.&amp;#160;&amp;#160;Mr. Gal is subject to a non-compete and a confidentiality agreement during the term of the agreement and for one year thereafter. As of December 31, 2015 the Company did not make any amendments to Mr. Gal&amp;#8217;s employment agreement.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;B.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;David Malka, the beneficial owner of 3.07% of the Company's outstanding Common Stock as of December&amp;#160;31, 2015, entered into an employment agreement with Integrity Israel in July 2010 pursuant to which Mr. Malka agreed to continue to serve as the vice president of operations of Integrity Israel.&amp;#160;&amp;#160;The agreement was approved by the board of directors and stockholders of Integrity Israel. Mr.&amp;#160;Malka&amp;#8217;s employment agreement provides for an annual salary of approximately $61,728, 67,302 and $66,639 (NIS&amp;#160;240,000) for the year ended December 31, 2015, 2014 and 2013 respectively. In addition, Mr. Malka is entitled to an annual bonus to be determined by the Board of Directors in its sole discretion and an additional sum provided that Mr. Malka reaches certain milestones approved by the Board, as well as the payment of certain social and insurance benefits and the use of a group three car.&amp;#160;&amp;#160;During the year ended December 31, 2015, 2014 and 2013 the Company paid Mr. Malka $0, $0 and $30,544, respectively as bonuses. The agreement also provided for a renegotiation of Mr. Malka&amp;#8217;s annual salary on the one-year anniversary thereof and the renegotiation of Mr. Malka&amp;#8217;s bonus formula once Integrity Israel has begun commercialization of its products.&amp;#160;&amp;#160;The agreement is terminable by either party on 90 days&amp;#8217; notice, immediately by Integrity Israel with the payment of an amount equal to 90 days of annual salary, or immediately by Integrity Israel for cause (as defined in the agreement) without the payment of severance.&amp;#160;&amp;#160;Mr.&amp;#160;Malka is subject to a non-compete and confidentiality agreement during the term of the agreement and for one year thereafter. As of December 31, 2015, the Company did not make any amendments to Mr. Malka&amp;#8217;s employment agreement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 54pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;NOTE 18&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;SUBSEQUENT EVENTS&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;A.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;During February 2016, the Company entered into an Advisory Agreement with the Placement Agent, according to which, the Company retained the Placement Agent on a non-exclusive basis to provide certain advisory services. In accordance with the terms of the Advisory Agreement, the Company extended the expiration date of the warrants issued to the Placement Agent in connection with the 2010 Offering and the 2012 Offering until December 31, 2019. The Advisory Agreement has a term of six months and shall automatically renew thereafter for additional 30 day terms unless terminated by either party upon receipt of 30 days prior written notice.&amp;#160;&amp;#160;The Company is in the process of evaluating the impact, if any, of the expiration date extension of the abovementioned warrants on the results of its operations.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;B.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On March 17, 2016, the Company&amp;#8217;s Board of Directors appointed two new directors, Leslie Seff and Angela Strand, to the Board of Directors and approved the following compensation for all three non-employee directors serving on the Board: (i) an annual cash payment in the amount of $15,000, payable in four equal quarterly installments of $3,750 each on the last day of each calendar quarter commencing with the second quarter of 2016, subject to the director&amp;#8217;s continued service as of each such date; (ii) an annual cash payment to the chairperson of the Nominating and Corporate Governance Committee in the amount of $10,000, payable in four equal quarterly installments of $2,500 each, on the last day of each calendar quarter commencing with the second quarter of 2016, subject to the chairperson&amp;#8217;s continued service as of each such date; and (iii) a one-time grant of options to each non-employee director to purchase up to an aggregate of 26,666 shares of the Company&amp;#8217;s Common Stock, at an exercise price of $4.50 per share, under and pursuant to the 2010 Share Incentive Plan.&amp;#160;&amp;#160;Each director&amp;#8217;s option grant will vest in eight equal quarterly increments of 3,333.25 each (subject to the director&amp;#8217;s continued service as of each such date) commencing with the second quarter of 2016.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;C.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On March 17, 2016, the Company&amp;#8217;s Board of Directors approved an amendment to the 2010 Share Incentive Plan to increase the number of shares of the Company&amp;#8217;s Common Stock reserved for issuance under the 2010 Share Incentive Plan from 529,555 shares to 1,000,000 shares.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 27pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;A.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Use of estimates in the preparation of financial statements&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to (i) the fair value estimate of the Warrants with down-round protection, (ii) the fair value measurement of the Series B Units and the estimate of the loss arising from the partial extinguishment of the Series A Units and the exchange thereof for Series B Units, and (iii) the going concern assumptions.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 27pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;B.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Functional currency&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The functional currency of the Company is the US dollar, which is the currency of the primary economic environment in which it operates.&amp;#160;&amp;#160;In accordance with ASC 830, &amp;#8220;Foreign Currency Matters&amp;#8221; (ASC 830), balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date.&amp;#160;&amp;#160;For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used.&amp;#160;&amp;#160;Gains or losses arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses. The functional currency of Integrity Israel is the New Israeli Shekel ("NIS") and its financial statements are included in consolidation, based on translation into US dollars.&amp;#160;&amp;#160;Accordingly, assets and liabilities were translated from NIS to US dollars using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or losses resulting from translation adjustments are reflected in stockholders' equity (deficit), under &amp;#8220;accumulated other comprehensive income (loss)&amp;#8221;.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Official exchange rate of NIS&amp;#160;1 to US dollar&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.256&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.257&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.288&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 27pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;C.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Principles of consolidation&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 70.9pt"&gt;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;D.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less at the date of purchase, to be cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 27pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;F.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 100pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;1.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Property and equipment are stated at cost, net of accumulated depreciation.&amp;#160;&amp;#160;Depreciation is calculated using the straight-line method over the estimated useful lives of the assets.&amp;#160;&amp;#160;When an asset is retired or otherwise disposed of, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in the statements of operations.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 100pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;2.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Rates of depreciation:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 83%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 85%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 13%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;%&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 85%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Computers&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 13%; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;33&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 85%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Furniture and office equipment&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 13%; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7-15&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 85%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 13%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Shorter of lease term&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;and 10 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 70.9pt"&gt;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;G.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Impairment of long-lived assets&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Group's long-lived assets are reviewed for impairment in accordance with ASC 360, &amp;#8220;Property, Plant and Equipment&amp;#8221;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&amp;#160;&amp;#160;Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset.&amp;#160;&amp;#160;If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.&amp;#160;&amp;#160;To date the Group did not incur any material impairment losses.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 27pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;H.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Long-term restricted cash&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Restricted cash is invested in certificates of deposit, which are used to secure Integrity Israel&amp;#8217;s obligations in respect of its headquarters lease.&amp;#160; See Note 9B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 70.9pt"&gt;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;I.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Income tax&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Group accounts for income taxes in accordance with ASC 740, "Income Taxes". Accordingly, deferred income taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities under the applicable tax law.&amp;#160;&amp;#160;Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences reverse.&amp;#160;&amp;#160;Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Group accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise&amp;#8217;s financial statements. According to ASC Topic 740-10, tax positions must meet a more-likely-than-not recognition threshold. The Group&amp;#8217;s accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Group did not recognize such items in its fiscal 2015, 2014 and 2013 financial statements and did not recognize any liability with respect to unrecognized tax position in its balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 27pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;J.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Liability for employee rights upon retirement&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Integrity Israel's liability for employee rights upon retirement with respect to its Israeli employees is calculated pursuant to the Israeli Severance Pay Law, based on the most recent salary of each employee multiplied by the number of years of employment of each such employee as of the balance sheet date. Employees are entitled to one month's salary for each year of employment, or ratable portion thereof for periods less than one year. Integrity Israel makes monthly deposits to insurance policies and severance pay funds.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The deposited funds may be withdrawn upon the fulfillment of Integrity Israel's severance obligations pursuant to Israeli severance pay laws or labor agreements with its employees.&amp;#160;&amp;#160;The value of the deposited funds is based on the cash surrender value of these policies, and includes immaterial profits or losses.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Commencing in 2011, Integrity Israel&amp;#8217;s agreements with its Israeli employees are in accordance with Section 14 of the Severance Pay Law. Payments in accordance with Section 14 release the employer from any future severance payments in respect of those employees. Related obligations and liabilities under Section 14 are not recorded as an asset or as a liability in the Company's balance sheet.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Severance expenses for the year ended December&amp;#160;31, 2015, 2014 and 2013 amounted to&amp;#160;$111,030, $101,220 and $91,588, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 27pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;K.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Revenue recognition&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Revenues are recognized in accordance with ASC 605, "Revenue Recognition" and SEC Staff Accounting Bulletin (&amp;#8220;SAB&amp;#8221;) No. 104, &amp;#8220;Revenue Recognition&amp;#8221;, when delivery has occurred, persuasive evidence of an agreement exists, the fee is fixed and determinable, collectability is reasonably assured and no further obligations exist. Provisions are made at the time of revenue recognition for any applicable warranty cost expected to be incurred (See Note 2N).&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company derives its revenues from sales of its GlucoTrack&amp;#174; model DF-F glucose monitoring device to distributors. The Company's products sold through agreements with distributors are generally non-exchangeable, non-refundable and non-returnable and, to date, the Company has not granted to any of its distributors any rights of price protection or stock rotation. Accordingly, the Company considers its distributors as end-users for revenue recognition purposes.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 70.9pt"&gt;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;L.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Research and development expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Research and development expenses are charged to operations as incurred.&amp;#160;&amp;#160;Grants received by Integrity Israel from the Government of Israel through the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor (the "OCS") for development of approved projects were recognized as a reduction of expenses when the related costs were incurred.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueRecognitionServicesRoyaltyFees contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 70.9pt"&gt;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;M.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Royalty-bearing grants&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Royalty-bearing grants from the OCS to fund approved research and development projects are recognized at the time Integrity Israel is entitled to such grants, on the basis of the costs incurred and reduce research and development costs.&amp;#160;&amp;#160;The cumulative research and development grants received by Integrity Israel from inception through December 2004 amounted to $93,300.&amp;#160;&amp;#160;Integrity Israel has not received any research and development grants since December 2004.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As of December&amp;#160;31, 2015 and 2014, the Group accrued royalties to the OCS in the amounts of $8,167 and $1,793, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionServicesRoyaltyFees>
    <us-gaap:StandardProductWarrantyPolicy contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 27pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;N.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Warranty&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Group provides a 24 month warranty for its products at no cost. The Group estimates the costs that may be incurred during the warranty period and records a liability for the amounts of such costs at the time revenues are recognized. As of December 31, 2015 and 2014 warranty expenses were immaterial.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StandardProductWarrantyPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 70.9pt"&gt;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;O.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Basic and diluted income (loss) per share&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Basic income (loss) per share is computed by dividing the income (loss) for the period applicable for Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Securities that may participate in dividends with the Common Stock (such as the convertible Preferred Stock) are considered in the computation of basic income per share using the two class method. However, in periods of net loss, such participating securities are not included since the holders of such securities do not have a contractual obligation to share the losses of the Company.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In computing diluted income per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the &amp;#8220;treasury stock method&amp;#8221; and upon the conversion of Preferred Stock using the "if-converted method", if the effect of each of such financial instruments is dilutive.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 70.9pt"&gt;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;P.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Group measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values in accordance with ASC 718, &amp;#8220;Compensation-Stock Compensation&amp;#8221;. Share-based payments including grants of stock options are recognized in the statement of operations as an operating expense based on the fair value of the award at the date of grant.&amp;#160;&amp;#160;The fair value of stock options granted is estimated using the Black-Scholes option-pricing model.&amp;#160;&amp;#160;The Group has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Share-based payments awarded to consultants (non-employees) are accounted for in accordance with ASC Topic 505-50, "Equity-Based Payments to Non-Employees".&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 70.9pt"&gt;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Q.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Fair value of financial instruments&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;ASC Topic 825-10, "Financial Instruments" defines financial instruments and requires disclosure of the fair value of financial instruments held by the Group. The Group considers the carrying amount of cash and cash equivalents, accounts receivable, other current assets, accounts payable, current portion of long-term loans from stockholders and other current liabilities balances, to approximate their fair values due to the short term maturities of such financial instruments.&amp;#160;&amp;#160;The Series A Warrants with down-round protection represent a derivative liability and therefore are measured and presented on the balance sheet at fair value. ASC Topic 825-10, establishes the following fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Level 2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Level 3 - Unobservable inputs are used when little or no market data is available. Level 3 inputs are considered as the lowest priority under the fair value hierarchy.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The fair value measurement of the warrants is classified as level 3. The Group did not estimate the fair value of the long-term loans from stockholders since their repayment schedule has not yet been determined.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 27pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;R.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Concentrations of credit risk&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Financial instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.&amp;#160;&amp;#160;Cash and cash equivalents are deposited with major banks in Israel and the United States of America. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. As of December 31, 2015 and 2014 the balances of accounts receivable was not material and accordingly such balances do not represent substantial concentration of credit risk. The Group does not have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 27pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;S.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Contingencies&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <igap:TemporaryEquityPolicyPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;T.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;1.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;Temporary Equity Classification&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As more fully described in Note 10A.2, Note 10B, Note 10A.3 and Note 10C, in March 2013 and during the period between August until December 31, 2014, the Company issued Series A Preferred Stock and Series B Preferred Stock, respectively, which provide a liquidation preference and certain redemption rights for the benefit of the holders of such Preferred Stock upon the occurrence of certain contingent events, some of which are not solely within the Company&amp;#8217;s control.&amp;#160;&amp;#160;Accordingly, both the Series A Preferred Stock and the Series B Preferred Stock are presented as temporary equity.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;2.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Initial Measurement&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Upon initial recognition, the Series A Preferred Stock issued together with detachable Series A Warrants (classified as a derivative liability) were measured based on the "residual approach" and were presented net of the direct issuance expenses that were allocated to them. Upon initial recognition, the Series B Preferred Stock issued together with the detachable Series B Warrants (classified as equity) were measured based on the relative fair value basis and were presented net of the direct issuance expenses that were allocated to them.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;3.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Subsequent Measurement&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On each balance sheet date, the Company&amp;#8217;s management assesses the probability of redemption of the Preferred Stock. In the event that management determines such redemption to be probable as of an applicable balance sheet date, the Company will reclassify the outstanding balance of the Preferred Stock as of that date as a liability and the difference between such amount and the aggregate redemption price of the Preferred Stock will be accreted against accumulated deficit over the period beginning on the date that it becomes probable that the Preferred Stock will become redeemable and ending on the earliest redemption date.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;4.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Conversion Feature Analysis&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company has determined that due to the economic characteristics and risks of the Preferred Stock, based on their stated or implied substantive terms and features, Series A and Series B Preferred Stock, are both considered as more akin to equity than debt. Accordingly, it was determined that the economic characteristics and the risks of the embedded conversion option to Common Stock and those of the Preferred Stock themselves (the 'host contract') are clearly and closely related. As a result, the embedded conversion feature was not required to be bifurcated. Also, since at the respective issuance dates of the Series A Preferred Stock and the Series B Preferred Stock, the exercise price of the conversion feature (based on the effective conversion rate of the Series A Preferred Stock and the Series B Preferred Stock into Common Stock) was higher than the estimated fair value of the Company&amp;#8217;s Common Stock, it was determined that the conversion feature was not beneficial.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;5.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Modifications or Exchanges&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Modifications to, or exchanges of, the Preferred Stock are accounted for as a modification or an extinguishment. Such an assessment is done by management either qualitatively or quantitatively based on the facts and circumstances of each transaction. A qualitative assessment is generally appropriate when the changes to a Preferred Stock instrument are either so inconsequential or is very significant, otherwise, a quantitative test is also applied. Since the periodic contractual cash flows of the Preferred Stock are not defined, the quantitative test is generally applied using the fair value model. Under the fair value model, the Company compares the fair value of the Preferred Stock immediately before and after the modification or exchange. If the fair values before and after the modification or exchange are substantially different, the modification or exchange is accounted for as an extinguishment, otherwise it is accounted for as a modification.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</igap:TemporaryEquityPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;V.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;1.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Accounting Standard Update 2014-09, &amp;#8220;Revenue from Contracts with Customers&amp;#8221;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In May 2014, the FASB issued Accounting Standard Update 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09").&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In accordance with a recent amendment to ASU 2014-09, introduced by Accounting Standards Update 2015-11, "Revenue from Contracts with Customers - Deferral of the Effective Date", for a public entity, the amendments in ASU 2014-09 are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period (the first quarter of fiscal year 2018 for the Company). Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company is in the process of assessing the impact, if any, of ASU 2014-09 on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;2.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Accounting Standards Update 2014-15, &amp;#8220;Presentation of Financial Statements&amp;#8212;Going Concern&amp;#8221;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial Statements&amp;#8212;Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern ("ASU 2014-15").&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;ASU 2014-15 provides guidance on management&amp;#8217;s responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&amp;#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable).&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;ASU 2014-15 also provides guidance related to the required disclosures as a result of management&amp;#8217;s evaluation.&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company is in the process of assessing the impact, if any, of ASU 2014-15 on its consolidated financial statements or related disclosures.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;3.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Accounting Standard Update 2014-16, &amp;#8220;Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity&amp;#8221;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In November 2014, the FASB issued Accounting Standard Update 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity ("ASU 2014-16").&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The amendments in ASU 2014-16 clarify how current U.S. GAAP should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. Specifically, the amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract. Furthermore, the amendments clarify that no single term or feature would necessarily determine the economic characteristics and risks of the host contract. Rather, the nature of the host contract depends upon the economic characteristics and risks of the entire hybrid financial instrument. The amendments also clarify that, in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (i.e., the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weigh those terms and features. The assessment of the substance of the relevant terms and features should incorporate a consideration of the characteristics of the terms and features themselves; the circumstances under which the hybrid financial instrument was issued or acquired; and the potential outcomes of the hybrid financial instrument, as well as the likelihood of those potential outcomes.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The amendments in ASU 2014-16 apply to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of a share.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The amendments in ASU 2014-16 are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015 (fiscal 2016 for the Company). Early adoption, including adoption in an interim period, is permitted. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The effects of initially adopting the amendments in ASU 2014-16 should be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Management believes that the provisions of ASU 2014-16 will not impact the classification of the Series A or Series B Preferred Stock.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;4.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Accounting Standard Update 2015-11, &amp;#8220;Simplifying the Measurement of Inventory&amp;#8221;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In July, 2015, The FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11").&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out (LIFO) and the retail inventory method (RIM) are not impacted by the new guidance. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin).&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early adoption is permitted as of the beginning of an interim or annual reporting period.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company is in the process of assessing the impact, if any, of ASU 2015-11 on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-align: right"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Official exchange rate of NIS&amp;#160;1 to US dollar&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.256&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.257&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.288&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock>
    <igap:ScheduleOfPropertyRatesOfDepreciationTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td&gt;&lt;div style="text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Rates of depreciation:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 83%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 85%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 13%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;%&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 85%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Computers&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 13%; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;33&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 85%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Furniture and office equipment&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 13%; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7-15&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 85%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 13%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Shorter of lease term&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;and 10 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</igap:ScheduleOfPropertyRatesOfDepreciationTableTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-align: right"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr&gt;&lt;td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;205,645&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;55,557&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;551,111&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;16,459&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Finished products&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;59,467&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;11,637&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;816,223&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;83,653&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-align: right"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Prepaid expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;57,206&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;46,094&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Government Institution (*)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;211,586&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;67,748&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;268,792&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;113,842&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 68.05pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;(*)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Represents amounts advanced by Integrity Israel to the Israeli tax authorities or amounts owed to Integrity Israel by the Israeli Value Added Tax authorities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2015-01-01to2015-12-31">&lt;table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Computers&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;240,066&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;124,161&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Furniture and office equipment&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;200,548&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;184,379&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;32,898&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;22,992&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;473,512&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;331,532&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Less &amp;#8211; accumulated depreciation&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(253,049&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(209,041&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;220,463&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;122,491&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-align: right"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Employees and related institutions&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;240,358&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;204,890&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;187,528&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;235,874&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;427,886&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;440,764&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The changes in the fair value of the Level 3 liability are as follows (in US dollars):&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Series A Warrants&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance, Beginning of the year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,057,618&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;8,216,705&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Classification from stockholders deficit&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;400,671&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exchange of Series A Warrants pursuant to the &amp;#8220;Most favored nation&amp;#8221; provision&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(1,586,831&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Change in fair value of Series A Warrants&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(149,092&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(6,559,758&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance, End of year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;321,695&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,057,618&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The key inputs used in the fair value calculations were as follows:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Dividend yield (%)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Expected volatility (%) (*)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;105.14&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;105.14&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Risk free interest rate (%)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.99&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.14&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Expected term of options (years) (**)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.20&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3.20&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exercise price (US dollars)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5.80&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5.80&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Share price (US dollars) (***)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.31&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.31&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Fair value (US dollars)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.84&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.13&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 100pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 36pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(*)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Due to the low trading volume of the Company&amp;#8217;s Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 100pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 36pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(**)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No.&amp;#160;110.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 36pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(***)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Common Stock price, per share reflects the Company&amp;#8217;s management&amp;#8217;s estimation of the fair value per share of Common Stock as of December 31, 2015 and 2014. In reaching its estimation for December 31, 2015 and 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the 2014 Offering.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The following tables present a summary of the status of the grants to employees, officers and directors as of December&amp;#160;31, 2015 and 2014:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 85%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Number&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Weighted average exercise price (US$)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31, 2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance outstanding at beginning of year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;450,847&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5.85&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Granted&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(19,769&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.82&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(17,605&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.01&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance outstanding at end of the year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;413,473&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.04&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance exercisable at the end of the year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;293,736&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5.95&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 85%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Number&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Weighted average exercise price (US$)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31, 2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance outstanding at beginning of year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;414,847&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5.74&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Granted&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;44,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7.00&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(8,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance outstanding at end of the year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;450,847&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5.85&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance exercisable at the end of the year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;302,360&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5.58&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The following tables summarize information about options outstanding at December&amp;#160;31, 2015:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 85%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;price (US$)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Outstanding at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Weighted average remaining contractual life (years)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Weighted average exercise price&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Exercisable at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Weighted average remaining contractual life (years)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.72&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;21,758&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.60&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.72&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;21,758&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.60&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3.63&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3,730&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.60&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3.63&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3,730&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.60&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.01&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4,273&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.04&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.03&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4,273&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.04&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;351,712&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.20&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;236,975&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.20&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7.00&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;32,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;8.5&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7.00&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;27,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;8.50&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;413,473&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;293,736&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The fair value of options granted was estimated at the dates of grant using the Black-Scholes option pricing model.&amp;#160;&amp;#160;The following are the data and assumptions used:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 83%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="text-align: right; vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="text-align: right; vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="text-align: right; vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Dividend yield (%)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Expected volatility (%) (*)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;105.14&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Risk free interest rate (%)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.61&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Expected term of options (years) (**)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5-6&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exercise price (US dollars)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7.00&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Stock price (US dollars) (***)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.31&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Fair value (US dollars)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.59&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 112.5pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 36pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(*)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Due to the low trading volume of the Company&amp;#8217;s Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 113.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 36pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(**)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No.&amp;#160;110.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 112.5pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 36pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(***)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Common Stock price, per share for the year ended December 31, 2014 reflects the Company&amp;#8217;s management&amp;#8217;s estimation of the fair value per share of Common Stock. In reaching its estimation for December 31, 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the 2014 Offering.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <igap:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-align: right"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Salaries and related expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,303,614&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,128,672&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,293,067&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;525,144&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;377,918&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;247,888&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Materials&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;166,736&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;96,699&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;154,522&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Depreciation&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;19,132&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;16,156&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;32,858&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Travel expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;39,324&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;27,867&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;43,131&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Vehicle maintenance&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;54,936&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;25,888&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;35,955&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Other&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;159,459&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;176,424&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;179,333&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,268,345&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,849,624&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,986,754&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;/div&gt;</igap:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock>
    <igap:SellingGeneralAndAdministrativeExpenseTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-align: right"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Salaries and related expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;803,319&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;651,900&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;260,276&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;990,390&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;739,893&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;562,435&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Travel &amp;#38; expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;468,126&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;200,348&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;128,095&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Vehicle maintenance&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;41,180&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;40,087&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;26,529&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Other&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;227,160&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;185,282&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;63,805&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,530,175&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,817,510&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,041,140&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</igap:SellingGeneralAndAdministrativeExpenseTableTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-align: right"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Israeli CPI linkage difference on principal of loans from stockholders&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(2,521&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(556&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;14,382&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exchange rate differences&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;38,873&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(25,282&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;94,815&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Change in fair value of Series A Warrants&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(149,092&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(6,559,758&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6,251,242&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Issuance cost allocated to warrants with down-round protection&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;390,928&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Interest expenses on credit from banks and other&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;15,205&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(2,189&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;17,592&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,284,354&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,186,819&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(6,587,785&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6,768,959&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td&gt;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The following is a reconciliation between the theoretical tax on pre-tax income, at the tax rate applicable to the Company (federal tax rate) and the tax expense reported in the financial statements:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Pretax income (loss)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(5,842,172&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,980,426&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(9,796,853&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Federal tax rate&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;34&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;35&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;35&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Income tax expenses (benefit) computed at the ordinary tax rate&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(1,986, 338&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,043,149&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(3,428,899&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Non-deductible expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;31,050&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;27,250&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;21,250&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4,503&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;14,415&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;10,570&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Amortization of warrants with down round protection&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(50,691&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(2,295,915&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,324,760&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;436,680&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Tax in respect of differences in corporate tax rates&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;340,263&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;278,466&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;253,942&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Losses and timing differences in respect of which no deferred taxes assets were recognized&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,224,533&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;932,635&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;818,377&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-align: right"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Composition of deferred tax assets:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Provision for employee-related obligation&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;23,494&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;20,220&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;33,629&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Non-capital loss carry forwards&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6,233,314&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4,810,780&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4,364,466&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(6,256,808&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(4,831,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(4,398,095&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company operates in one operating segment, the following is a summary of operations within geographic areas:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Revenues based on the customer&amp;#8217;s location:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Europe&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;13,420&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;32,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Asia and Pacific&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;129,747&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;27,775&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Total&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;143,167&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;59,775&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 54pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;NOTE 2&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 72pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP).&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;A.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Use of estimates in the preparation of financial statements&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to (i) the fair value estimate of the Warrants with down-round protection, (ii) the fair value measurement of the Series B Units and the estimate of the loss arising from the partial extinguishment of the Series A Units and the exchange thereof for Series B Units, and (iii) the going concern assumptions.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;B.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Functional currency&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The functional currency of the Company is the US dollar, which is the currency of the primary economic environment in which it operates.&amp;#160;&amp;#160;In accordance with ASC 830, &amp;#8220;Foreign Currency Matters&amp;#8221; (ASC 830), balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date.&amp;#160;&amp;#160;For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used.&amp;#160;&amp;#160;Gains or losses arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses. The functional currency of Integrity Israel is the New Israeli Shekel ("NIS") and its financial statements are included in consolidation, based on translation into US dollars.&amp;#160;&amp;#160;Accordingly, assets and liabilities were translated from NIS to US dollars using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or losses resulting from translation adjustments are reflected in stockholders' equity (deficit), under &amp;#8220;accumulated other comprehensive income (loss)&amp;#8221;.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Official exchange rate of NIS&amp;#160;1 to US dollar&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.256&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.257&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.288&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;C.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Principles of consolidation&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;D.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less at the date of purchase, to be cash equivalents.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;font style="display: inline; font-size: 10pt"&gt;E.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Inventories are stated at the lower of cost or market value.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Cost is determined as follows:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;With respect to raw materials, the Group calculates cost using the average cost method.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;With respect to work in process and finished products, the Group calculates the cost on the basis of the average direct manufacturing costs, including materials, labor, subcontracting costs and other direct manufacturing costs.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Management evaluates whether inventory reserve for slow-moving or obsolete items is required. To date, the Group has not recorded any reserves with respect to its inventory.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;F.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 100pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;1.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Property and equipment are stated at cost, net of accumulated depreciation.&amp;#160;&amp;#160;Depreciation is calculated using the straight-line method over the estimated useful lives of the assets.&amp;#160;&amp;#160;When an asset is retired or otherwise disposed of, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in the statements of operations.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 100pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;2.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Rates of depreciation:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 83%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 85%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 13%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;%&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 85%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Computers&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 13%; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;33&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 85%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Furniture and office equipment&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 13%; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7-15&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 85%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 13%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Shorter of lease term&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;and 10 years&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;G.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Impairment of long-lived assets&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Group's long-lived assets are reviewed for impairment in accordance with ASC 360, &amp;#8220;Property, Plant and Equipment&amp;#8221;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&amp;#160;&amp;#160;Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset.&amp;#160;&amp;#160;If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.&amp;#160;&amp;#160;To date the Group did not incur any material impairment losses.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;H.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Long-term restricted cash&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Restricted cash is invested in certificates of deposit, which are used to secure Integrity Israel&amp;#8217;s obligations in respect of its headquarters lease.&amp;#160; See Note 9B&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;I.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Income tax&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Group accounts for income taxes in accordance with ASC 740, "Income Taxes". Accordingly, deferred income taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities under the applicable tax law.&amp;#160;&amp;#160;Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences reverse.&amp;#160;&amp;#160;Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Group accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise&amp;#8217;s financial statements. According to ASC Topic 740-10, tax positions must meet a more-likely-than-not recognition threshold. The Group&amp;#8217;s accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Group did not recognize such items in its fiscal 2015, 2014 and 2013 financial statements and did not recognize any liability with respect to unrecognized tax position in its balance sheet.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;J.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Liability for employee rights upon retirement&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Integrity Israel's liability for employee rights upon retirement with respect to its Israeli employees is calculated pursuant to the Israeli Severance Pay Law, based on the most recent salary of each employee multiplied by the number of years of employment of each such employee as of the balance sheet date. Employees are entitled to one month's salary for each year of employment, or ratable portion thereof for periods less than one year. Integrity Israel makes monthly deposits to insurance policies and severance pay funds.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The deposited funds may be withdrawn upon the fulfillment of Integrity Israel's severance obligations pursuant to Israeli severance pay laws or labor agreements with its employees.&amp;#160;&amp;#160;The value of the deposited funds is based on the cash surrender value of these policies, and includes immaterial profits or losses.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Commencing in 2011, Integrity Israel&amp;#8217;s agreements with its Israeli employees are in accordance with Section 14 of the Severance Pay Law. Payments in accordance with Section 14 release the employer from any future severance payments in respect of those employees. Related obligations and liabilities under Section 14 are not recorded as an asset or as a liability in the Company's balance sheet.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Severance expenses for the year ended December&amp;#160;31, 2015, 2014 and 2013 amounted to&amp;#160;$111,030, $101,220 and $91,588, respectively.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;K.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Revenue recognition&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Revenues are recognized in accordance with ASC 605, "Revenue Recognition" and SEC Staff Accounting Bulletin (&amp;#8220;SAB&amp;#8221;) No. 104, &amp;#8220;Revenue Recognition&amp;#8221;, when delivery has occurred, persuasive evidence of an agreement exists, the fee is fixed and determinable, collectability is reasonably assured and no further obligations exist. Provisions are made at the time of revenue recognition for any applicable warranty cost expected to be incurred (See Note 2N).&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company derives its revenues from sales of its GlucoTrack&amp;#174; model DF-F glucose monitoring device to distributors. The Company's products sold through agreements with distributors are generally non-exchangeable, non-refundable and non-returnable and, to date, the Company has not granted to any of its distributors any rights of price protection or stock rotation. Accordingly, the Company considers its distributors as end-users for revenue recognition purposes.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;L.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Research and development expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Research and development expenses are charged to operations as incurred.&amp;#160;&amp;#160;Grants received by Integrity Israel from the Government of Israel through the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor (the "OCS") for development of approved projects were recognized as a reduction of expenses when the related costs were incurred.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;M.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Royalty-bearing grants&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Royalty-bearing grants from the OCS to fund approved research and development projects are recognized at the time Integrity Israel is entitled to such grants, on the basis of the costs incurred and reduce research and development costs.&amp;#160;&amp;#160;The cumulative research and development grants received by Integrity Israel from inception through December 2004 amounted to $93,300.&amp;#160;&amp;#160;Integrity Israel has not received any research and development grants since December 2004.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As of December&amp;#160;31, 2015 and 2014, the Group accrued royalties to the OCS in the amounts of $8,167 and $1,793, respectively.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;N.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Warranty&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Group provides a 24 month warranty for its products at no cost. The Group estimates the costs that may be incurred during the warranty period and records a liability for the amounts of such costs at the time revenues are recognized. As of December 31, 2015 and 2014 warranty expenses were immaterial.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;O.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Basic and diluted income (loss) per share&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Basic income (loss) per share is computed by dividing the income (loss) for the period applicable for Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Securities that may participate in dividends with the Common Stock (such as the convertible Preferred Stock) are considered in the computation of basic income per share using the two class method. However, in periods of net loss, such participating securities are not included since the holders of such securities do not have a contractual obligation to share the losses of the Company.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In computing diluted income per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the &amp;#8220;treasury stock method&amp;#8221; and upon the conversion of Preferred Stock using the "if-converted method", if the effect of each of such financial instruments is dilutive.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;P.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Group measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values in accordance with ASC 718, &amp;#8220;Compensation-Stock Compensation&amp;#8221;. Share-based payments including grants of stock options are recognized in the statement of operations as an operating expense based on the fair value of the award at the date of grant.&amp;#160;&amp;#160;The fair value of stock options granted is estimated using the Black-Scholes option-pricing model.&amp;#160;&amp;#160;The Group has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Share-based payments awarded to consultants (non-employees) are accounted for in accordance with ASC Topic 505-50, "Equity-Based Payments to Non-Employees".&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Q.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Fair value of financial instruments&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;ASC Topic 825-10, "Financial Instruments" defines financial instruments and requires disclosure of the fair value of financial instruments held by the Group. The Group considers the carrying amount of cash and cash equivalents, accounts receivable, other current assets, accounts payable, current portion of long-term loans from stockholders and other current liabilities balances, to approximate their fair values due to the short term maturities of such financial instruments.&amp;#160;&amp;#160;The Series A Warrants with down-round protection represent a derivative liability and therefore are measured and presented on the balance sheet at fair value. ASC Topic 825-10, establishes the following fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Level 2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Level 3 - Unobservable inputs are used when little or no market data is available. Level 3 inputs are considered as the lowest priority under the fair value hierarchy.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The fair value measurement of the warrants is classified as level 3. The Group did not estimate the fair value of the long-term loans from stockholders since their repayment schedule has not yet been determined.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;R.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Concentrations of credit risk&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Financial instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.&amp;#160;&amp;#160;Cash and cash equivalents are deposited with major banks in Israel and the United States of America. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. As of December 31, 2015 and 2014 the balances of accounts receivable was not material and accordingly such balances do not represent substantial concentration of credit risk. The Group does not have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;S.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Contingencies&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;T.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;1.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;Temporary Equity Classification&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As more fully described in Note 10A.2, Note 10B, Note 10A.3 and Note 10C, in March 2013 and during the period between August until December 31, 2014, the Company issued Series A Preferred Stock and Series B Preferred Stock, respectively, which provide a liquidation preference and certain redemption rights for the benefit of the holders of such Preferred Stock upon the occurrence of certain contingent events, some of which are not solely within the Company&amp;#8217;s control.&amp;#160;&amp;#160;Accordingly, both the Series A Preferred Stock and the Series B Preferred Stock are presented as temporary equity.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;2.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Initial Measurement&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Upon initial recognition, the Series A Preferred Stock issued together with detachable Series A Warrants (classified as a derivative liability) were measured based on the "residual approach" and were presented net of the direct issuance expenses that were allocated to them. Upon initial recognition, the Series B Preferred Stock issued together with the detachable Series B Warrants (classified as equity) were measured based on the relative fair value basis and were presented net of the direct issuance expenses that were allocated to them.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;3.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Subsequent Measurement&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On each balance sheet date, the Company&amp;#8217;s management assesses the probability of redemption of the Preferred Stock. In the event that management determines such redemption to be probable as of an applicable balance sheet date, the Company will reclassify the outstanding balance of the Preferred Stock as of that date as a liability and the difference between such amount and the aggregate redemption price of the Preferred Stock will be accreted against accumulated deficit over the period beginning on the date that it becomes probable that the Preferred Stock will become redeemable and ending on the earliest redemption date.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;4.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Conversion Feature Analysis&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company has determined that due to the economic characteristics and risks of the Preferred Stock, based on their stated or implied substantive terms and features, Series A and Series B Preferred Stock, are both considered as more akin to equity than debt. Accordingly, it was determined that the economic characteristics and the risks of the embedded conversion option to Common Stock and those of the Preferred Stock themselves (the 'host contract') are clearly and closely related. As a result, the embedded conversion feature was not required to be bifurcated. Also, since at the respective issuance dates of the Series A Preferred Stock and the Series B Preferred Stock, the exercise price of the conversion feature (based on the effective conversion rate of the Series A Preferred Stock and the Series B Preferred Stock into Common Stock) was higher than the estimated fair value of the Company&amp;#8217;s Common Stock, it was determined that the conversion feature was not beneficial.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;5.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Modifications or Exchanges&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Modifications to, or exchanges of, the Preferred Stock are accounted for as a modification or an extinguishment. Such an assessment is done by management either qualitatively or quantitatively based on the facts and circumstances of each transaction. A qualitative assessment is generally appropriate when the changes to a Preferred Stock instrument are either so inconsequential or is very significant, otherwise, a quantitative test is also applied. Since the periodic contractual cash flows of the Preferred Stock are not defined, the quantitative test is generally applied using the fair value model. Under the fair value model, the Company compares the fair value of the Preferred Stock immediately before and after the modification or exchange. If the fair values before and after the modification or exchange are substantially different, the modification or exchange is accounted for as an extinguishment, otherwise it is accounted for as a modification.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;U.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Series A Warrants with Down-Round Protection&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&#13;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company considered the provisions of ASC 815-40, &amp;#8220;Derivatives and Hedging: Contracts in Entity&amp;#8217;s Own Equity&amp;#8221;, with respect to the detachable Warrants that were issued to the Series A Unit Purchasers, as described in Note&amp;#160;10D, and determined that as a result of the &amp;#8220;down-round&amp;#8221; protection that would adjust the number of Warrants and the exercise price of the Warrants based on the price at which the Company subsequently issues shares or other equity-linked financial instruments, if that price is less than the original exercise price of the Warrants, such Warrants cannot be considered as indexed to the Company's own stock. Accordingly, the Warrants were recognized as derivative liability at their fair value on initial recognition. In subsequent periods, the Warrants are marked to market with the changes in fair value recognized as financing expense or income in the consolidated statement of operations. The direct issuance expenses that were allocated to the detachable Warrants were expensed as incurred.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;V.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;1.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Accounting Standard Update 2014-09, &amp;#8220;Revenue from Contracts with Customers&amp;#8221;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In May 2014, the FASB issued Accounting Standard Update 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09").&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In accordance with a recent amendment to ASU 2014-09, introduced by Accounting Standards Update 2015-11, "Revenue from Contracts with Customers - Deferral of the Effective Date", for a public entity, the amendments in ASU 2014-09 are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period (the first quarter of fiscal year 2018 for the Company). Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company is in the process of assessing the impact, if any, of ASU 2014-09 on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;2.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Accounting Standards Update 2014-15, &amp;#8220;Presentation of Financial Statements&amp;#8212;Going Concern&amp;#8221;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial Statements&amp;#8212;Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern ("ASU 2014-15").&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;ASU 2014-15 provides guidance on management&amp;#8217;s responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&amp;#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable).&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;ASU 2014-15 also provides guidance related to the required disclosures as a result of management&amp;#8217;s evaluation.&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company is in the process of assessing the impact, if any, of ASU 2014-15 on its consolidated financial statements or related disclosures.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;3.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Accounting Standard Update 2014-16, &amp;#8220;Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity&amp;#8221;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In November 2014, the FASB issued Accounting Standard Update 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity ("ASU 2014-16").&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The amendments in ASU 2014-16 clarify how current U.S. GAAP should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. Specifically, the amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract. Furthermore, the amendments clarify that no single term or feature would necessarily determine the economic characteristics and risks of the host contract. Rather, the nature of the host contract depends upon the economic characteristics and risks of the entire hybrid financial instrument. The amendments also clarify that, in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (i.e., the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weigh those terms and features. The assessment of the substance of the relevant terms and features should incorporate a consideration of the characteristics of the terms and features themselves; the circumstances under which the hybrid financial instrument was issued or acquired; and the potential outcomes of the hybrid financial instrument, as well as the likelihood of those potential outcomes.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The amendments in ASU 2014-16 apply to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of a share.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The amendments in ASU 2014-16 are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015 (fiscal 2016 for the Company). Early adoption, including adoption in an interim period, is permitted. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The effects of initially adopting the amendments in ASU 2014-16 should be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Management believes that the provisions of ASU 2014-16 will not impact the classification of the Series A or Series B Preferred Stock.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#160;4.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Accounting Standard Update 2015-11, &amp;#8220;Simplifying the Measurement of Inventory&amp;#8221;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In July, 2015, The FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11").&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out (LIFO) and the retail inventory method (RIM) are not impacted by the new guidance. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin).&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early adoption is permitted as of the beginning of an interim or annual reporting period.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company is in the process of assessing the impact, if any, of ASU 2015-11 on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 54pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;NOTE 1&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;GENERAL&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;A.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Integrity Applications, Inc. (the "Company") was incorporated on May&amp;#160;18, 2010 under the laws of the State of Delaware.&amp;#160;&amp;#160;On July&amp;#160;15, 2010, Integrity Acquisition Corp. Ltd. (hereinafter: "Integrity Acquisition"), a wholly owned Israeli subsidiary of the Company, which was established on May&amp;#160;23, 2010, completed a merger with A.D. Integrity Applications Ltd. (hereinafter: "Integrity Israel"), an Israeli corporation that was previously held by the stockholders of the Company.&amp;#160;&amp;#160;Pursuant to the merger, all equity holders of Integrity Israel received the same proportional ownership in the Company as they had in Integrity Israel prior to the merger. Following the merger, Integrity Israel remained a wholly-owned subsidiary of the Company.&amp;#160;&amp;#160;As the merger transaction constituted a structural reorganization, the merger has been accounted for at historical cost in a manner similar to a pooling of interests.&amp;#160;&amp;#160;Integrity Israel was incorporated in 2001 and commenced its operations in 2002.&amp;#160;&amp;#160;Integrity Israel, a medical device company, focuses on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;B.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Going concern uncertainty&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Since its incorporation, the Company did not conduct any material operations other than those carried out by Integrity Israel.&amp;#160;&amp;#160;The development and commercialization of Integrity Israel's product is expected to require substantial expenditures.&amp;#160;&amp;#160;Integrity Israel and the Company (collectively, the "Group") have not yet generated any material revenues from operations, and therefore they are dependent upon external sources for financing their operations. As of December 31, 2015, the Group has incurred accumulated deficit of $29,376,515, stockholder's deficit of $6,970,914 and negative operating cash flows.&amp;#160;&amp;#160;These factors raise substantial doubt about the Group&amp;#8217;s ability to continue as a going concern.&amp;#160;&amp;#160;The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&amp;#160;&amp;#160;During 2012, the Company raised a total amount of approximately $1.0 million (net of related expenses) from the issuance of Common Stock. During 2013, the Company raised funds in an approximate amount of $5.3 million (net of related cash expenses) from the issuance of units (the &amp;#8220;Series A Units&amp;#8221;) consisting of shares of the Company&amp;#8217;s Series A Convertible Preferred Stock (the &amp;#8220;Series A Preferred Stock&amp;#8221;) and detachable warrants to purchase shares of the Company&amp;#8217;s Common Stock (the &amp;#8220;Series A Warrants&amp;#8221; or &amp;#8220;warrants with down round protection&amp;#8221;), see also Note 10A.2, Note 10B and Note 10D.&amp;#160;&amp;#160;During the period between August and December of 2014, the Company raised funds in an aggregate amount of approximately $7.3 million (net of related cash expenses) from the issuance of units (the &amp;#8220;Series B Units&amp;#8221;), each consisting of (a) one share of the Company&amp;#8217;s newly designated Series B 5.5% Convertible Preferred Stock, par value $0.001 per share (the &amp;#8220;Series B Preferred Stock&amp;#8221;), convertible into Common Stock at an initial conversion price of $5.80 per share, (b) a five year warrant to purchase, at an exercise price of $5.80 per share, up to such number of shares of Common Stock issuable upon conversion of such share of Series B Preferred Stock (each a &amp;#8220;Series B-1 Warrant&amp;#8221;) and (c) a five year warrant to purchase, at an exercise price of $10.00 per share, up to such number of shares of Common Stock issuable upon conversion of such share of Series B Preferred Stock (each a &amp;#8220;Series B-2 Warrant&amp;#8221; and, together with the Series B-1 Warrants, collectively, the &amp;#8220;Series B Warrants&amp;#8221;), see Also Note 10A.3 and Note 10C.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Until such time as the Group generates sufficient revenue to fund its operations (if ever), the Group plans to finance its operations through the sale of equity or equity-linked securities and/or debt securities and, to the extent available, short term and long term loans. There can be no assurance that the Group will succeed in obtaining the necessary financing to continue its operations as a going concern.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;C.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Risk factors&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As described in Note 1A and Note 1B above, the Group has a limited operating history and faces a number of risks and uncertainties, including risks and uncertainties regarding continuation of the development process, demand and market acceptance of the Group's products, the effects of technological changes, competition and the development of products by competitors.&amp;#160;&amp;#160;Additionally, other risk factors also exist, such as the ability to manage growth and the effect of planned expansion of operations on the Group's future results and the availability of necessary financing. In addition, the Group expects to continue incurring significant operating costs and losses in connection with the development of its products and marketing efforts. The Group has not yet generated material revenues from its operations to fund its activities and therefore is dependent on the receipt of additional funding from its stockholders and/ or new investors in order to continue its operations.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <igap:StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 54pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;NOTE 10&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;A.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;1.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Description of the rights attached to the Common Stock&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Each share of Common Stock entitles the holder to one vote, either in person or by proxy, on each matter submitted to the approval of the Company&amp;#8217;s stockholders.&amp;#160;&amp;#160;The holders of Common Stock are not permitted to vote their shares cumulatively.&amp;#160;&amp;#160;As described below, holders of Preferred Stock are entitled to vote together with the holders of Common Stock on an as-converted basis.&amp;#160;&amp;#160;Accordingly, the holders of the Company's Common Stock together with the holders of the Preferred Stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of the directors and, in such event, the holders of the remaining shares will not be able to elect any of such directors.&amp;#160;&amp;#160;The vote of the holders of a majority of the issued and outstanding shares of Common Stock, voting together with the holders of the Preferred Stock on an as converted basis, are entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to any act or action submitted to the vote of the Company&amp;#8217;s stockholders, except as otherwise provided by law.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; width: 18pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;2.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;Description of the rights attached to the Series A Preferred Stock&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Holders of Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, based on the stated value per share of the Series A Preferred Stock, which was initially $1,000 per share.&amp;#160;&amp;#160;Dividends on the Series A Preferred Stock are payable quarterly on March 31, June 30, September 30 and December 31 of each year, beginning on March 31, 2013, and on each conversion date (with respect to the shares of Series A Preferred Stock being converted).&amp;#160;&amp;#160;Until September 13, 2013, dividends were payable only in cash. Thereafter, dividends on the Series A Preferred Stock became payable, at the option of the Company, in cash and/or, if certain conditions are satisfied (including, among others, that the volume weighted average trading price for the Common Stock on its principal trading market is equal to or greater than 110% of the then current conversion price for the Series A Preferred Stock for five consecutive trading days prior to the dividend payment date), in shares of Common Stock, valued at the then current conversion price of the Series A Preferred Stock.&amp;#160;&amp;#160;The Company will incur a late fee of 9% per annum, payable in cash, on dividends that are not paid within three trading days of the applicable dividend payment date. During the years ended December 31, 2015, 2014 and 2013 the Company paid an aggregate of $57,061, $370,441 and $288,248, respectively, in cash dividends to its Series A Preferred Stockholders.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company may become obligated to redeem the Series A Preferred Stock in cash upon the occurrence of certain triggering events, including, among others, a material breach by the Company of certain contractual obligations to the holders of the Series A Preferred Stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Common Stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or a regulated quotation service.&amp;#160;&amp;#160;In addition, upon the occurrence of certain triggering events, each holder of Series A Preferred Stock will have the option to require the Company to redeem such holder&amp;#8217;s shares of Series A Preferred Stock for a redemption price payable in shares of Common Stock or receive an increased dividend rate of 9% on all of such holder&amp;#8217;s outstanding Series A Preferred Stock.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Subject to certain conditions, the Company will have the option to force the conversion of the Series A Preferred Stock (in whole or in part) if the volume weighted average price for the Common Stock on its principal trading market exceeds $11.60 for each of any 20 trading days during any 30 consecutive Trading Day period and the average daily dollar trading value for the Common Stock during such 30 day period exceeds $100,000.&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;If the Company fails to timely deliver certificates for shares of Common Stock issuable upon conversion of the Series A Preferred Stock (the &amp;#8220;Series A Conversion Shares&amp;#8221;) and, as a result, the holder is required by its brokerage firm to purchase shares of Common Stock to deliver in satisfaction of a sale by such holder of the Series A Conversion Shares (a &amp;#8220;Buy-In&amp;#8221;), the Company will be required to: (a) pay the converting holder in cash an amount equal to the amount, if any, by which such holder&amp;#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds the product of (i) the aggregate number of Series A Conversion Shares due to the holder, multiplied by (ii) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions); and (b) at the option of such holder, either reissue (if surrendered) the shares of Series A Preferred Stock equal to the number of shares of Series A Preferred Stock submitted for conversion (in which case, such conversion will be deemed rescinded) or deliver to such holder the number of shares of Common Stock that would have been issued if the Company had timely complied with its delivery requirements.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In addition, the Company will be required to pay partial liquidated damages of $10 for each $1,000 of stated value of any shares of Series A Preferred Stock which have been converted by a holder and in respect of which the Company fails to deliver Series A Conversion Shares by the eighth trading day following the applicable conversion date.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Subject to the beneficial ownership limitation described below, holders of Series A Preferred Stock will vote together with the holders of Common Stock on an as-converted basis.&amp;#160;&amp;#160;Holders will not be permitted to convert their Series A Preferred Stock if such conversion would cause such holder to beneficially own more than 4.99% of the outstanding number of shares of Common Stock outstanding after giving effect to such conversion (subject to increase to 9.99%, at the option of the holder, upon no less than 61 days prior written notice to the Company) (the &amp;#8220;Beneficial Ownership Limitation&amp;#8221;).&amp;#160;&amp;#160;In addition, no holder may vote any shares of Series A Preferred Stock (on an as converted to Common Stock basis) in excess of the Beneficial Ownership Limitation.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Subject to certain limitations, so long as any initial Series A Unit purchaser holds any shares of Series A Preferred Stock, if (1) the Company sells any shares of Common Stock or other securities convertible into, or rights to acquire, Common Stock and (2) a Purchaser then holding Series A Preferred Stock, Warrants, Conversion Shares or Warrant Shares (defined below) reasonably believes that any of the terms and conditions appurtenant to such issuance or sale are more favorable to the purchaser in such subsequent sale of securities than are the terms and conditions granted to such Purchaser, then the Purchaser will be permitted to require the Company to amend the terms of this transaction (only with respect to such Purchaser) so as to match the terms of the subsequent issuance (including, for the avoidance of doubt, any terms and provisions that are or may be less favorable to such Purchaser).&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The conversion price of the shares of Series A Preferred Stock that were included in the Series A Units is subject to adjustment for certain issuances of Common Stock or other securities of the Company at an effective price per share that is lower than the conversion price then in effect ($5.80 per share at December 31, 2015 and 2014), as well as for stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;A.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;3&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;Description of the rights attached to the Series B Preferred Stock&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Holders of Series B Preferred Stock are entitled to receive cumulative dividends at a rate of 5.5% per annum, based on the stated value per share of Series B Preferred Stock. Dividends on the Series B Preferred Stock are payable quarterly on March 31, June 30, September 30 and December 31 of each year, beginning on September 30, 2014, and on each conversion date (with respect to the shares of Series B Preferred Stock being converted). For so long as required under the terms of the Certificate of Designations for the Company&amp;#8217;s outstanding Series A Preferred Stock, dividends on Series B Preferred Stock will be payable only in shares of Common Stock. Thereafter, dividends on the Series B Preferred Stock will be payable, at the option of the Company, in cash and/or, if certain conditions are satisfied, shares of Common Stock or a combination of both. Shares of Common Stock issued as payment of dividends will be valued at the lower of (a) the then current conversion price of the Series B Preferred Stock or (b) the average of the volume weighted average price for the Common Stock on the principal trading market therefor for the 10 trading days immediately prior to the applicable dividend payment date. The Company will incur a late fee of 9% per annum, payable in cash, on dividends that are not paid within three trading days of the applicable dividend payment date. As of December 31, 2015 and 2014 the Company issued a total of 168,926 and 18,986 shares of Common Stock, respectively at an estimated fair value of $390,219 and $43,858, respectively as in kind dividends to holders of Series B Preferred Stock.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Subject to certain ownership limitations described below, the Series B Preferred Stock is convertible at the option of the holder at any time and from time to time into shares of Common Stock at a conversion price of $5.80 per share (calculated by dividing the stated value per share of Series B Preferred Stock, which is initially $1,000, by the conversion price per share). The conversion price of the Series B Preferred Stock is subject to adjustment for certain issuances of Common Stock or other securities of the Company at an effective price per share that is lower than the conversion price then in effect, as well as for stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. In addition, the holders of Series B Preferred Stock will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of Common Stock to the same extent as if such holders of Series B Preferred Stock had converted all of their shares of Series B Preferred Stock prior to such distribution. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations of the Company, the holders of Series B Preferred Stock will be entitled to receive, upon conversion of their shares of Series B Preferred Stock, any securities or other consideration received by the holders of the Common Stock pursuant to the fundamental transaction.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Subject to certain conditions contained in the Certificate of Designations, Preferences and Rights relating to the Series B Preferred Stock, the Company will have the option to force the conversion of the Series B Preferred Stock (in whole or in part) if (a) the volume weighted average price for the Common Stock on its principal trading market exceeds $10.00 for each of any 20 trading days during any 30 consecutive Trading Day period and the average daily dollar trading value for the Common Stock during such 30 day period exceeds $50,000 or (b) the Company receives approval to list the Common Stock on a national securities exchange.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;If the Company fails to timely deliver certificates for shares of Common Stock issuable upon conversion of the Series B Preferred Stock (the &amp;#8220;Series B Conversion Shares&amp;#8221;) which results in a Buy-In, the Company will be required to: (a) pay the converting holder in cash an amount equal to the amount, if any, by which such holder&amp;#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds the product of (i) the aggregate number of Series B Conversion Shares due to the holder, multiplied by (ii) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions); and (b) at the option of such holder, either reissue (if surrendered) the shares of Series B Preferred Stock equal to the number of shares of Series B Preferred Stock submitted for conversion (in which case, such conversion will be deemed rescinded) or deliver to such holder the number of shares of Common Stock that would have been issued if the Company had timely complied with its delivery requirements.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In addition, the Company will be required to pay partial liquidated damages of $10 for each $1,000 of stated value of any shares of Series B Preferred Stock which have been converted by a holder and in respect of which the Company fails to deliver Series B Conversion Shares by the eighth trading day following the applicable conversion date.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As long as at least 35% of the originally issued shares of Series B Preferred Stock are outstanding, without the written consent of the holders of a majority in stated value of the outstanding Preferred Stock, the Company will not be permitted to, among other things, incur indebtedness or liens not permitted under the Certificate of Designations for the Series B Preferred Stock; repay, repurchase, pay dividends on or otherwise make distributions in respect of any shares of Common Stock or other securities junior to the Series B Preferred Stock; or enter into certain transactions with affiliates of the Company.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Subject to any limitations under the terms of the Certificate of Designations for the Company&amp;#8217;s outstanding Series A Preferred Stock, the Company may become obligated to redeem the Series B Preferred Stock in cash upon the occurrence of certain triggering events, including, among others, a material breach by the Company of certain contractual obligations to the holders of the Series B Preferred Stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Common Stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or a regulated quotation service. In addition, upon the occurrence of certain triggering events, each holder of Series B Preferred Stock will have the option to require the Company to redeem such holder&amp;#8217;s shares of Series B Preferred Stock for a redemption price payable in shares of Common Stock or receive an increased dividend rate of 9% on all of such holder&amp;#8217;s outstanding Series B Preferred Stock.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Subject to the Beneficial Ownership Limitation, holders of Series B Preferred Stock will vote together with the holders of Common Stock and Series A Preferred Stock on an as-converted basis. Holders will not be permitted to convert their Series B Preferred Stock if such conversion would cause such holder to beneficially own shares of outstanding Common Stock in excess of the Beneficial Ownership Limitation.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Subject to certain limitations, so long as any Purchaser holds any shares of Series B Preferred Stock, if (a) the Company sells any shares of Common Stock or other securities convertible into, or rights to acquire, Common Stock and (b) a Purchaser then holding Series B Preferred Stock, Series B Warrants, Conversion Shares or Warrant Shares (defined below) reasonably believes that any of the terms and conditions appurtenant to such issuance or sale are more favorable to the purchaser in such subsequent sale of securities than are the terms and conditions granted to such Purchaser, then the Purchaser will be permitted to require the Company to amend the terms of this transaction (only with respect to such Purchaser) so as to match the terms of the subsequent issuance (including, for the avoidance of doubt, any terms and provisions that are or may be less favorable to such Purchaser).&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 72pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; width: 27pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;B.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;The 2012 Offering&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On November 19, 2012, the Company issued 165,057 shares of its Common Stock at a price of $7.00 per share, for a total consideration of $1,155,399.&amp;#160;&amp;#160;The issuance and sale of such shares constituted the initial closing (the &amp;#8220;Initial Closing&amp;#8221;) of the 2012 Offering, which was originally structured as an offering of up to&amp;#160;&amp;#160;785,714 shares of its Common Stock to accredited investors (the &amp;#8220;First Closing Purchasers&amp;#8221;) at a price of $7.00 per share in a private placement transaction.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Subsequent to the Initial Closing, the 2012 Offering was converted from an offering of Common Stock to an offering of Units and, on March 13, 2013, the Company entered into a Securities Purchase Agreement with certain accredited investors (the &amp;#8220;Series A Unit Purchasers&amp;#8221;) pursuant to which the Company issued to the Series A Unit Purchasers an aggregate of 6,300 Series A Units.&amp;#160;&amp;#160;The shares of Series A Preferred Stock comprising the Series A Units were convertible into an aggregate of 1,086,178 shares of Common Stock (based on a conversion price per share of $5.80) and the Series A Warrants comprising the Series A Units were exercisable into an aggregate of 1,086,178 shares of Common Stock at an original exercise price per share of $6.96, in each case subject to adjustment as described below (See also Note10D). After giving effect to the payment of commissions to the Placement Agent for the offering and the payment of certain offering expenses, the Company received net proceeds from the offering of approximately $5.4 million (See Note 9C).&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The issuance and sale of the Series A Units constituted the second and final closing of an offering of the Company&amp;#8217;s securities in a private placement transaction.&amp;#160;&amp;#160; As a result of the conversion of the offering from an offering of Common Stock to an offering of Series A Units, the Company agreed with the Placement Agent that the Company would exchange the shares of Common Stock acquired by each First Closing Purchaser in the Initial Closing for such number of Series A Units equal to the aggregate purchase price paid by such First Closing Purchaser in the Initial Closing, divided by $1,000, in each case subject to the execution by the First Closing Purchaser of a consent to such modification.&amp;#160;&amp;#160;Pursuant to this agreement, on May 13, 2013, the Company cancelled 162,907 of the 165,057 shares of Common Stock issued to the First Closing Purchasers and issued to such purchasers an aggregate of 1,140.35 Series A Units.&amp;#160;&amp;#160;These Units included Series A Preferred Stock convertible into an aggregate of 196,597 shares of Common Stock and Series A Warrants exercisable for 196,597 shares of Common Stock.&amp;#160;&amp;#160;The total fair value of such Series A Units was equal to the amount originally invested by the First Closing Purchasers that consented to exchange their shares into Units ($1,140,349).&amp;#160;&amp;#160;As a result, during 2013, the total fair value of such Series A Units was classified out of stockholders equity and was presented as temporary equity (convertible Series A Preferred Stock) and liability (warrant with down-round protection), as applicable to each instrument.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&#13;&lt;div&gt;&#13;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In connection with the 2012 Offering, the Company also agreed with the Placement Agent for the offering that, following the closing of the sale of the Series A Units, the Company would issue to the holders of the 1,295,535 shares of Common Stock issued by the Company at a price of $6.25 per share pursuant to the Company&amp;#8217;s previously completed private placement of Common Stock (occurred during 2011 and 2010) such number of shares of Common Stock as would effectively reduce the per share purchase price paid by such holders for such shares from $6.25 per share to $5.80 per share, in each case subject to the execution by the holder of a consent to such modification. As a result, upon the receipt of executed consents to modification from all such holders, the Company has issued or will be required to issue to such holders an aggregate of additional 100,526 shares of Common Stock, of which 92,136 and 654 shares of Common Stock were issued during the years ended December 31, 2015 and 2014, respectively.&amp;#160;The issuance or proposed issuance of such shares has been accounted for as a stock dividend.&amp;#160;&amp;#160;As of September 30, 2013, the Common Stock had an estimated fair value of $2.77 per share.&amp;#160;&amp;#160; Accordingly, an amount of $278,263 representing the fair value of the shares was charged to the accumulated deficit against additional paid in capital.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&#13;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In connection with the 2012 Offering the Company incurred a total of $1,479,864 of issuance costs of which $562,805 attributable to non-cash compensation expenses relating to warrants issued to the Placement Agent (See Notes 9C and &lt;font style="background-color: #ffffff; display: inline"&gt;Note 10E.1.d&lt;/font&gt;). The allocation of the issuance proceeds to the Preferred Stock and to the detachable warrants and their respective issuance costs is described in Note 2T and Note&amp;#160;2U above.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 74pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;C.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;The 2014 Offering&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 90.75pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;During August until December 31, 2014, the Company raised $8.5 million in gross proceeds from the issuance of 8,500 Series B Units. After giving effect to the payment of commissions to the Placement Agent (See Note 9C) for the offering and the payment of certain offering expenses, the Company received net proceeds from the offering of approximately $7.3 million. The Series B Warrants have a five-year term commencing on the closing dates, as applicable. Until the end of the term, the Series B Warrants included in the Series B Units will be exercisable into Common Stock at any time and from time to time at an exercise price of $5.80 per share (with respect to the Series B-1 Warrants) or $10.00 per share (with respect to the Series B-2 Warrants). The Series B Warrants contain adjustment provisions substantially similar to those of the Series B Preferred Stock (See Note 10.A.3), except that the Series B Warrants shall not include dilution protection for issuances of securities at an effective price per share lower than the conversion price of such Series B Warrants. No holder may exercise its Series B Warrants in excess of the Beneficial Ownership Limitation.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 90.75pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 90.75pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In connection with the 2014 Offering the Company incurred a total of $1,787,545 of issuance costs of which $630,936 attributable to non-cash compensation expenses relating to warrants issued to the Placement Agent (See Notes 9C and Note 10E.1.d). The allocation of the issuance proceeds to the Series B Preferred Stock and to the detachable Series B Warrants and their respective issuance costs is described in Note 2T.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 90.75pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Pursuant to the Securities Purchase Agreement, dated March 13, 2013, relating to the issuance by the Company of Series A Units, the Company was required to and did notify the holders of the Series A Preferred Stock of the closing of the sale of the Series B Units, and following receipt thereof such holders of Series A Preferred Stock were entitled pursuant to the &amp;#8220;most favored nation&amp;#8221; provision included in the Securities Purchase Agreement for the 2012 Offering, to elect to amend the terms of their purchase of Series A Units to match the terms of the Series B Units. As of December 31, 2015, the holders of an aggregate of approximately 6,931 Series A Units have so elected to amend the terms of their Series A Units to match the terms of the Series B Units. Accordingly, the Company has exchanged 6,931 shares of Series A Preferred Stock into 6,931 shares of Series B Preferred Stock and 1,440,880 Series A Warrants into 1,200,710 Series B-1 Warrants and 1,200,710 Series B-2 Warrants. Due to the differences in the contractual terms of each of the financial instruments exchanged, management determined that the exchange constituted an extinguishment of the existing instruments and an issuance of new financial instruments. As a result of the exchange elections, the Company recorded during the year ended December 31, 2015 a non-cash loss on extinguishment of Series A Preferred Stock and Series A Warrants in the amount of $1,284,354, resulting from the differences between the fair market value estimate of the new Series B Units less the net book value of the exchanged Series A Preferred Stock and less the fair value of the exchanged Warrants with down-round protection as of the date of the exchange.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 74pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;D.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Warrants with down round protection&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Series A Warrants included in the Series A Units have a five-year term commencing on their issuance date. In accordance with their original terms, the Warrants were exercisable at any time at an exercise price of $6.96 per share.&amp;#160;&amp;#160;The Series A Warrants contain adjustment provisions substantially similar to the adjustment provisions of the Series A Preferred Stock (See Note 10A.2), including provisions requiring an adjustment of the number of shares and the exercise price of the Series A Warrants to the price at which the Company subsequently issues shares or other equity-linked financial instruments, if that price is less than the original exercise price of the Series A Warrants (down-round protection).&amp;#160;&amp;#160;In addition, the Series A Warrants provide for protection for a Buy-In on substantially the same terms as described above with respect to the Series A Preferred Stock.&amp;#160;&amp;#160;No holder may exercise its Series A Warrants in excess of the Beneficial Ownership Limitation.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As a result of the issuance of the Series B Units, pursuant to the terms of the Series A Warrants, on August 29, 2014, the exercise price per share of the Series A Warrants decreased from $6.96 per share to $5.80 per share and the number of shares of Common Stock issuable upon exercise of each such warrant, in the aggregate, increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price, will be equal to the aggregate exercise price prior to such adjustment. During the year ended December 31, 2015, the Company exchanged 1,440,880 Series A Warrants into 1,200,710 Series B-1 Warrants and 1,200,710 Series B-2 Warrants (See Note 10C). As of December 31, 2015 and 2014, an aggregate of 380,953, 1,539,364 Series A Warrants, respectively, were outstanding and exercisable into the identical number of shares of Common Stock.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company has determined its derivative warrant liability to be a Level 3 fair value measurement and has used the Binomial pricing model to calculate its fair value. Because the warrants contain a price protection feature, the probability that the exercise price of the warrants would decrease as the stock price decreased was incorporated into the valuation calculations.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The changes in the fair value of the Level 3 liability are as follows (in US dollars):&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Series A Warrants&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; width: 22%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance, Beginning of the year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,057,618&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;8,216,705&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Classification from stockholders deficit&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;400,671&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exchange of Series A Warrants pursuant to the &amp;#8220;Most favored nation&amp;#8221; provision&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(1,586,831&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Change in fair value of Series A Warrants&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(149,092&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(6,559,758&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance, End of year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;321,695&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,057,618&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The key inputs used in the fair value calculations were as follows:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Dividend yield (%)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Expected volatility (%) (*)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;105.14&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;105.14&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Risk free interest rate (%)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.99&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.14&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Expected term of options (years) (**)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.20&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3.20&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exercise price (US dollars)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5.80&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5.80&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Share price (US dollars) (***)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.31&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.31&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Fair value (US dollars)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.84&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.13&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 100pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 36pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(*)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Due to the low trading volume of the Company&amp;#8217;s Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 100pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 36pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(**)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No.&amp;#160;110.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 36pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(***)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Common Stock price, per share reflects the Company&amp;#8217;s management&amp;#8217;s estimation of the fair value per share of Common Stock as of December 31, 2015 and 2014. In reaching its estimation for December 31, 2015 and 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the 2014 Offering.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;E.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 96.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;1.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Grants to non-employees&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;a.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In August 2005, Integrity Israel granted 21,640 options with an exercise price of $0.001 per share in consideration of regulatory services. In October 2006, Integrity Israel granted 45,531 options with an exercise price of $4.305 per share in consideration of investor finders, of which 17,657 were forfeited. In November 2008, Integrity Israel granted 8,989 options with an exercise price of $5.517 per share in consideration of investor finders, of which 5,365 were forfeited. Following the merger with Integrity Israel, the options were replaced with options of the Company.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;b.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In connection with the 2010 Offering, the Company issued to the Placement Agent warrants to purchase 45,097 and 84,459 shares, respectively, of the Company's Common Stock, with an exercise price of $6.25 per share, in 2011 and 2010, respectively.&amp;#160;&amp;#160;The warrants expire on the fifth anniversary of the date on which the shares of Common Stock underlying such warrants are fully registered with the SEC.&amp;#160;&amp;#160;The warrants include customary adjustment provisions for stock splits, reorganizations and other similar transactions. As a result of the issuance of the Series B Units, pursuant to the terms of the warrants, on August 29, 2014, the exercise price per share of the applicable warrants decreased from $6.25 per share to $5.80 per share and the number of shares of Common Stock issuable upon exercise of each such warrant, in the aggregate, increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price, will be equal to the aggregate exercise price prior to such adjustment. As of December 31, 2015 and 2014 the Placement Agent was entitled to an aggregate of 139,608 shares of Common Stock at an exercise price of $5.80 in connection with the 2010 Offering. See also Note 18.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;c.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In connection with the 2012 Offering, the Company issued to the Placement Agent (a) 5 year warrants to purchase up to 128,277 shares of Common Stock at an exercise price of $5.80 per share and (b) 5 year warrants to purchase up to 128,277 shares of Common Stock at an exercise price of $6.96 per share and (c) 5 year warrants to purchase up to 215 shares of Common Stock at an exercise price of $7.00 per share.&amp;#160;&amp;#160;Such warrants have substantially the same terms as those issued to the Series A Unit Purchasers except that the Placement Agent warrants may also be exercisable on a cashless basis at all times.&amp;#160;As a result of the issuance of the Series B Units, pursuant to the terms of the warrants, on August 29, 2014, the exercise price per share of the applicable warrants decreased from $6.96 and $7.00 per share to $5.80 per share and the number of shares of Common Stock issuable upon exercise of each such warrant, in the aggregate, increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price, will be equal to the aggregate exercise price prior to such adjustment. As of December 31, 2015 and 2014 the Placement Agent was entitled to an aggregate of 282,469 shares of Common Stock at an exercise price of $5.80 in connection with the 2012 Offering. See also Note 18.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 144pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As of December 31, 2015 and 2014, the average fair value per warrant that were affected by the down-round protection, were estimated at $0.84 and $1.13, respectively using the following assumptions: dividend yield of 0% for both years, expected volatility of 105.14% for both years, risk free interest rate of 0.99% and 1.14%, respectively, stock price of $2.31 for both years and exercise price of $5.80 for both years. As a result of the anti-dilution protection, the Company classified during the year ended December 31, 2014 an amount of $400,671 out of stockholders deficit and presented as Warrants with Down-Round Protection within long-term liabilities see also Note 10D.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;d.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In connection with the 2014 Offering, the Company issued to the Placement Agent (a) 5 year warrants to purchase up to 293,115 shares of Common Stock at an exercise price of $5.80 per share and (b) 5 year warrants to purchase up to 146,559 shares of Common Stock at an exercise price of $10.00 per share. The terms of the Placement Agent warrants are substantially similar to the terms of the Series B Warrants except that the Placement Agent warrants may also be exercisable on a cashless basis at all times.&amp;#160;The average fair value per warrant of approximately $1.40 was estimated using the following assumptions: dividend yield of 0%, expected volatility of 105.14%, risk free interest rate of 1.66%, stock price of $2.31 and exercise price ranging between $5.80 and 10.00, as applicable.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 116.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;e.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On September 10, 2013 the Company granted 26,484 options with an exercise price of $9.50 per share in consideration of investor relations services. The options vest ratably over a period of 12 months from the date of grant and will expire on the fifth anniversary thereof, subject to certain limitations. During 2014, following the termination of the agreement with the investor relations company, 8,828 options were forfeited. In connection with this grant the Company recorded during the years ended December 31, 2014 and 2013 non-cash compensation expenses amounting to $18,204 and $16,657, respectively. At December 31, 2014 and 2013 the fair value per option of $1.17 and $2.52, respectively was estimated using the Black-Scholes option pricing model with the following assumptions for 2014: dividend yield of 0%, expected volatility of 105.14%, risk free interest rate of 1.14%, stock price of $2.31 and exercise price of $9.50 and with the following assumptions for 2013: dividend yield of 0%, expected volatility of 105.14%, risk free interest rate of 0.12%, stock price of $8.50 and exercise price of $9.50.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;2.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Grants to employees&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In August 2007, Integrity Israel&amp;#8217;s Board of Directors ("Integrity Israel's Board") approved a stock option plan ("Integrity Israel's plan") for the grant, without consideration of options exercisable into ordinary shares of NIS&amp;#160;0.01 par value of Integrity Israel to employees, officers and directors of Integrity Israel.&amp;#160;&amp;#160;The exercise price and vesting period for each grantee of options was determined by Integrity Israel's Board and specified in such grantee's option agreement.&amp;#160;&amp;#160;The options vested over a period of 1-12 quarters based on each grantee's option agreements.&amp;#160;&amp;#160;Any option not exercised within 10 years after the date of grant thereof will expire.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In July 2010, following the merger with Integrity Israel, the Company adopted the 2010 Share Incentive Plan (the "2010 Share Incentive Plan"), pursuant to which the Company's Board of Directors is authorized to grant options exercisable into Common Stock of the Company.&amp;#160;&amp;#160;As of December 31, 2015, the Company had reserved 529,555 shares of Common Stock for issuance under the 2010 Share Incentive Plan.&amp;#160;&amp;#160;On March 17, 2016, the Company&amp;#8217;s Board of Directors approved an amendment to the 2010 Share Incentive Plan to increase the number of shares of the Company&amp;#8217;s Common Stock reserved for issuance under the 2010 Share Incentive Plan to 1,000,000 shares.&amp;#160;&amp;#160;The purpose of the 2010 Share Incentive Plan is to offer an incentive to employees, directors, officers, consultants, advisors, suppliers and any other person or entity whose services are considered valuable to the Company, as well as to replace the Integrity Israel Plan and to replace all options granted in the past by Integrity Israel.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Upon the adoption of the 2010 Share Incentive Plan, all options granted under the Integrity Israel's Plan were replaced by options subject to the 2010 Share Incentive Plan on a 1 for 1 basis. As of December 31, 2015, there are 96,313 shares available for future grants under the 2010 Share Incentive Plan.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Pursuant to the terms of their respective employment agreements with the Company, in March 2012, the Company issued to Avner Gal, the Company&amp;#8217;s Chief Executive Officer, and David Malka, the Company&amp;#8217;s Executive Vice President of Operations, options to purchase up to 264,778 and 79,434 shares of Common Stock, respectively.&amp;#160;&amp;#160;The Options are exercisable at an exercise price of $6.25 per share.&amp;#160;&amp;#160;The options vested or will vest (as applicable), in 3 equal parts, upon the achievement of each of the following milestones: (i) submission of clinical trials&amp;#8217; results to the Notified Body; (ii) receipt of CE mark approval; (iii) receipt of FDA approval.&amp;#160;&amp;#160;In the event of a merger and/or acquisition in which one or more of the abovementioned milestones have not yet been met, the options shall be deemed vested on the date of the merger and/or acquisition.&amp;#160;&amp;#160;All options granted as described above are subject to the terms of the 2010 Share Incentive Plan.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As of December 31, 2015, approximately $353,000 of unrecognized compensation costs are expected to be recognized upon receipt of the FDA approval, if and when received. The fair value of the shares was based on the recent share price applicable prior to the date of grant of such options.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The following tables present a summary of the status of the grants to employees, officers and directors as of December&amp;#160;31, 2015 and 2014:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 85%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Number&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Weighted average exercise price (US$)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31, 2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance outstanding at beginning of year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;450,847&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5.85&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Granted&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(19,769&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.82&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(17,605&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.01&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance outstanding at end of the year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;413,473&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.04&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance exercisable at the end of the year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;293,736&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5.95&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 85%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Number&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Weighted average exercise price (US$)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31, 2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance outstanding at beginning of year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;414,847&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5.74&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Granted&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;44,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7.00&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(8,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance outstanding at end of the year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;450,847&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5.85&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance exercisable at the end of the year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;302,360&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5.58&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&#13;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The aggregate intrinsic value of the awards exercisable as of December&amp;#160;31, 2015, 2014 and 2013 was $12,845, $23,830 and $882,471, respectively.&amp;#160;&amp;#160;The aggregate intrinsic value of the awards outstanding as of December 31, 2015, 2014 and 2013 was $12,845, $23,830 and $1,143,330, respectively. For the year ended December 31, 2015 and 2014 the amount represents the total intrinsic value based on the Company&amp;#8217;s management&amp;#8217;s estimation of the fair value per share of Common Stock based among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series B Units (See Note 10C). For the year 2013 management&amp;#8217;s estimate of the Company&amp;#8217;s stock price of $8.50 was determined based among other factors on the closing sale price for the Common Stock as reported on the OTCQB on December 27, 2013, which was the last reported sale of Common Stock in 2013.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The following tables summarize information about options outstanding at December&amp;#160;31, 2015:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 85%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;price (US$)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Outstanding at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Weighted average remaining contractual life (years)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Weighted average exercise price&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Exercisable at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Weighted average remaining contractual life (years)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.72&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;21,758&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.60&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.72&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;21,758&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.60&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3.63&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3,730&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.60&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3.63&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3,730&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.60&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.01&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4,273&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.04&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.03&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4,273&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.04&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;351,712&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.20&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;236,975&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.20&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7.00&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;32,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;8.5&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7.00&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;27,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;8.50&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;413,473&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;293,736&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As of December 31, 2015, approximately $2,200 of unrecognized compensation costs (excluding compensation cost related to stock options granted to Mr. Avner Gal and Mr. David Malka) are expected to be recognized during the year ending December 31, 2016.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The fair value of options granted was estimated at the dates of grant using the Black-Scholes option pricing model.&amp;#160;&amp;#160;The following are the data and assumptions used:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 83%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="text-align: right; vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="text-align: right; vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="text-align: right; vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Dividend yield (%)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Expected volatility (%) (*)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;105.14&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Risk free interest rate (%)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.61&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Expected term of options (years) (**)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5-6&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exercise price (US dollars)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7.00&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Stock price (US dollars) (***)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.31&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Fair value (US dollars)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.59&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 112.5pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 36pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(*)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Due to the low trading volume of the Company&amp;#8217;s Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 113.4pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 36pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(**)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No.&amp;#160;110.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 112.5pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 36pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(***)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Common Stock price, per share for the year ended December 31, 2014 reflects the Company&amp;#8217;s management&amp;#8217;s estimation of the fair value per share of Common Stock. In reaching its estimation for December 31, 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the 2014 Offering.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;</igap:StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 54pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;NOTE 15&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;INCOME (LOSS) PER SHARE&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"&gt;&#13;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The loss and the weighted average number of shares used in computing basic and diluted loss per share for the years ended December 31, 2015, 2014 and 2013, are as follows:&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Income (loss) for the year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(5,842,172&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,980,426&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(9,796,853&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Stock dividend to certain Common Stockholder&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(278,263&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Cash dividend on Series A Preferred Stock&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(57,061&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(370,441&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(288,247&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Stock dividend on Series B Preferred Stock&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(390,219&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(43,858&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Income attributable to participating securities (Preferred Stock)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(596,472&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Income (loss) for the period attributable to common stockholders&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(6,289,452&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,969,655&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(10,363,363&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Number of shares&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Common shares used in computing Basic income (loss) per share&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5,476, 870&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5,304,500&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5,325,714&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font-size: 10pt"&gt;Common shares used in computing Diluted income (loss) per share&lt;/font&gt;&lt;font style="display: inline; font-size: 10pt"&gt; (*)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5,476, 870&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5,349,242&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5,325,714&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Total weighted average number of Common shares related to outstanding convertible Preferred Stock, options and warrants excluded from the calculations of diluted income (loss) per share (**)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;9,431,728&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4,557,612&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,813,493&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 72pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(*)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In applying the treasury method, the average market price of Common Stock was based on management estimate. For December 31, 2015 and 2014, management estimation considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series B Units (See Note 10C). The fair value per share of the Company&amp;#8217;s Common Stock as of December 31, 2013 was based on the management&amp;#8217;s estimate which was based among other factors on the closing price per share of the Company&amp;#8217;s Common Stock on December 27, 2013, as reported on the OTCQB, which was the last reported sale of Common Stock in 2013.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 72pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 72pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; width: 27pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(**)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: justify"&gt;&#13;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company excludes from the calculation of diluted income (loss) per share, shares that will be issued upon the exercise of options and warrants with exercise prices, that are greater than the estimated average market value of the Company&amp;#8217;s Common Stockand shares issuable upon conversion of Preferred Stock because their effect would be anti-dilutive. Outstanding shares that will be issued upon conversion or exercise, as applicable, of all convertible Preferred Stock, stock options and warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 27pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;font style="display: inline; font-size: 10pt"&gt;E.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Inventories are stated at the lower of cost or market value.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Cost is determined as follows:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;With respect to raw materials, the Group calculates cost using the average cost method.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;With respect to work in process and finished products, the Group calculates the cost on the basis of the average direct manufacturing costs, including materials, labor, subcontracting costs and other direct manufacturing costs.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 99.25pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Management evaluates whether inventory reserve for slow-moving or obsolete items is required. To date, the Group has not recorded any reserves with respect to its inventory.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 27pt"&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;U.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Series A Warrants with Down-Round Protection&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company considered the provisions of ASC 815-40, &amp;#8220;Derivatives and Hedging: Contracts in Entity&amp;#8217;s Own Equity&amp;#8221;, with respect to the detachable Warrants that were issued to the Series A Unit Purchasers, as described in Note&amp;#160;10D, and determined that as a result of the &amp;#8220;down-round&amp;#8221; protection that would adjust the number of Warrants and the exercise price of the Warrants based on the price at which the Company subsequently issues shares or other equity-linked financial instruments, if that price is less than the original exercise price of the Warrants, such Warrants cannot be considered as indexed to the Company's own stock. Accordingly, the Warrants were recognized as derivative liability at their fair value on initial recognition. In subsequent periods, the Warrants are marked to market with the changes in fair value recognized as financing expense or income in the consolidated statement of operations. The direct issuance expenses that were allocated to the detachable Warrants were expensed as incurred.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The loss and the weighted average number of shares used in computing basic and diluted loss per share for the years ended December 31, 2015, 2014 and 2013, are as follows:&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Income (loss) for the year&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(5,842,172&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,980,426&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(9,796,853&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Stock dividend to certain Common Stockholder&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(278,263&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Cash dividend on Series A Preferred Stock&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(57,061&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(370,441&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(288,247&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Stock dividend on Series B Preferred Stock&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(390,219&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(43,858&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Income attributable to participating securities (Preferred Stock)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(596,472&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Income (loss) for the period attributable to common stockholders&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(6,289,452&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,969,655&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(10,363,363&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Number of shares&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Common shares used in computing Basic income (loss) per share&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5,476, 870&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5,304,500&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5,325,714&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font-size: 10pt"&gt;Common shares used in computing Diluted income (loss) per share&lt;/font&gt;&lt;font style="display: inline; font-size: 10pt"&gt; (*)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5,476, 870&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5,349,242&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5,325,714&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Total weighted average number of Common shares related to outstanding convertible Preferred Stock, options and warrants excluded from the calculations of diluted income (loss) per share (**)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;9,431,728&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4,557,612&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,813,493&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 72pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(*)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In applying the treasury method, the average market price of Common Stock was based on management estimate. For December 31, 2015 and 2014, management estimation considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series B Units (See Note 10C). The fair value per share of the Company&amp;#8217;s Common Stock as of December 31, 2013 was based on the management&amp;#8217;s estimate which was based among other factors on the closing price per share of the Company&amp;#8217;s Common Stock on December 27, 2013, as reported on the OTCQB, which was the last reported sale of Common Stock in 2013.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 72pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 72pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; width: 27pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;(**)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: justify"&gt;&#13;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company excludes from the calculation of diluted income (loss) per share, shares that will be issued upon the exercise of options and warrants with exercise prices, that are greater than the estimated average market value of the Company&amp;#8217;s Common Stockand shares issuable upon conversion of Preferred Stock because their effect would be anti-dilutive. Outstanding shares that will be issued upon conversion or exercise, as applicable, of all convertible Preferred Stock, stock options and warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 54pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;NOTE 14&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&amp;#8211;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;INCOME TAX&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;A.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Measurement of results for tax purposes under the Israeli Income Tax (Inflationary Adjustments) Law, 1985 (the &amp;#8220;Inflationary Adjustment Law&amp;#8221;)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 90.75pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Commencing January&amp;#160;1, 2008, the results of operations of Integrity Israel for tax purposes are measured on a nominal basis.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-weight: bold"&gt;B&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt; &lt;/font&gt;&lt;/font&gt;&#13;&lt;div style="text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Changes in the Israeli corporate tax rates&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&#13;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On December 6, 2011, the Law for the Change in the Tax Burden (Legislative Amendments) &amp;#8211; 2011 was published.&amp;#160;&amp;#160;As part of this law, among other things, commencing from 2012 the corporate tax rate was increased to 25%.&amp;#160;&amp;#160;In addition, commencing in 2012, the tax rate on capital gains in real terms and the tax rate applicable to betterment in real terms were increased to 25%.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On July 30, 2013, the Israeli parliament approved the Law for the Change in National Priorities (Legislative Amendments to Achieve Budgetary Goals for 2013 and 2014) &amp;#8211; 2013, which, among other things increased the standard Israeli corporate income tax rate from 25% to 26.5% effective as of January&amp;#160;1, 2014.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On January 4, 2016, the Israeli parliament passed the Law for Amendment of the Income Tax Ordinance No. 216, which, among other things reduced the standard Israeli corporate income tax rate from 26.5% to 25% effective as of January 2016.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;C.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Tax assessments&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company and Integrity Israel have not received final tax assessments since their inception.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;D.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;Carryforward tax losses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As of December&amp;#160;31, 2015, the Company had cumulative net operating losses (NOL) for US federal purposes of approximately $3.1 million that will expire between the years 2031-2035. Integrity Israel has losses carry forward balances for Israeli income tax purposes of nearly $20.7 million to offset against future taxable income for an indefinite period of time.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;br /&gt;&#13;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;E.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The following is a reconciliation between the theoretical tax on pre-tax income, at the tax rate applicable to the Company (federal tax rate) and the tax expense reported in the financial statements:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Pretax income (loss)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(5,842,172&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,980,426&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(9,796,853&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Federal tax rate&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;34&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;35&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;35&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Income tax expenses (benefit) computed at the ordinary tax rate&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(1,986, 338&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,043,149&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(3,428,899&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Non-deductible expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;31,050&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;27,250&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;21,250&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4,503&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;14,415&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;10,570&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Amortization of warrants with down round protection&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(50,691&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(2,295,915&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,324,760&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;436,680&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Tax in respect of differences in corporate tax rates&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;340,263&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;278,466&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;253,942&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Losses and timing differences in respect of which no deferred taxes assets were recognized&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,224,533&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;932,635&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;818,377&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&#13;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 70.9pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 27pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;F.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Deferred taxes result principally from temporary differences in the recognition of certain revenue and expense items for financial and income tax reporting purposes.&amp;#160;&amp;#160;Significant components of the Group's future tax assets are as follows:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;US dollars&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; width: 34%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Composition of deferred tax assets:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Provision for employee-related obligation&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;23,494&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;20,220&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;33,629&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Non-capital loss carry forwards&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6,233,314&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4,810,780&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4,364,466&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(6,256,808&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(4,831,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(4,398,095&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="#Foot-00-0" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-1" xlink:label="Foot-00_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-00_loc" xlink:to="Footnote-01" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-0" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-1" xlink:label="Foot-01_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-01_loc" xlink:to="Footnote-04" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-0" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-1" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-2" xlink:label="Foot-02_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-02_loc" xlink:to="Footnote-05" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-0" xlink:label="Foot-03_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-1" xlink:label="Foot-03_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-2" xlink:label="Foot-03_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-3" xlink:label="Foot-03_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-4" xlink:label="Foot-03_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-03_loc" xlink:to="Footnote-02" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-0" xlink:label="Foot-04_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-1" xlink:label="Foot-04_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-2" xlink:label="Foot-04_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-3" xlink:label="Foot-04_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-4" xlink:label="Foot-04_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-04_loc" xlink:to="Footnote-03" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-0" xlink:label="Foot-05_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-1" xlink:label="Foot-05_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-2" xlink:label="Foot-05_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-05_loc" xlink:to="Footnote-06" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-06-0" xlink:label="Foot-06_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-06-1" xlink:label="Foot-06_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-06-2" xlink:label="Foot-06_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-06_loc" xlink:to="Footnote-07" order="1" />
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">Represents amounts advanced by Integrity Israel to the Israeli tax authorities or amounts owed to Integrity Israel by the Israeli Value Added Tax authorities.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-02" xml:lang="en-US">Due to the low trading volume of the Company's Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-03" xml:lang="en-US">Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No. 110.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-04" xml:lang="en-US">The Common Stock price, per share reflects the Company's management's estimation of the fair value per share of Common Stock as of December 31, 2015 and 2014. In reaching its estimation for December 31, 2015 and 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the 2014 Offering. </link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-05" xml:lang="en-US">The Common Stock price, per share for the year ended December 31, 2014 reflects the Company's management's estimation of the fair value per share of Common Stock. In reaching its estimation for December 31, 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the 2014 Offering. </link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-06" xml:lang="en-US">In applying the treasury method, the average market price of Common Stock was based on management estimate. For December 31, 2015 and 2014, management estimation considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series B Units (See Note 10C). The fair value per share of the Company's Common Stock as of December 31, 2013 was based on the management's estimate which was based among other factors on the closing price per share of the Company's Common Stock on December 27, 2013, as reported on the OTCQB, which was the last reported sale of Common Stock in 2013.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-07" xml:lang="en-US">The Company excludes from the calculation of diluted income (loss) per share, shares that will be issued upon the exercise of options and warrants with exercise prices, that are greater than the estimated average market value of the Company's Common Stock and shares issuable upon conversion of Preferred Stock because their effect would be anti-dilutive. Outstanding shares that will be issued upon conversion or exercise, as applicable, of all convertible Preferred Stock, stock options and warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was anti-dilutive.</link:footnote>
    </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>igap-20151231.xsd
<DESCRIPTION>TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: Integrity Applications, Inc. 12%2D31%2D15 10K Final To Use To File.xfr; Date: 2016%2D03%2D30T13:08:15Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80460001 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +a45o7xRiXhun8uHZnVMWaSCmbPtx5R6aekxs2RwHdk6/ygkcEcuAS3h1S3GYS0H -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:igap="http://integrity-app.com/20151231" elementFormDefault="qualified" targetNamespace="http://integrity-app.com/20151231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://integrity-app.com/role/igap-daei1" id="igap-daei1">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cbs" id="igap-cbs">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cbsp" id="igap-cbsp">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/Statement-CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" id="Statement-CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/StatementsOfChangesInStockholdersDeficit" id="StatementsOfChangesInStockholdersDeficit">
	  <link:definition>00000005 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-csocf" id="igap-csocf">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-csocfp" id="igap-csocfp">
	  <link:definition>00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-g" id="igap-g">
	  <link:definition>00000008 - Disclosure - GENERAL</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-sosap" id="igap-sosap">
	  <link:definition>00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-i" id="igap-i">
	  <link:definition>00000010 - Disclosure - INVENTORIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-oca" id="igap-oca">
	  <link:definition>00000011 - Disclosure - OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-paen" id="igap-paen">
	  <link:definition>00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-ocl" id="igap-ocl">
	  <link:definition>00000013 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-loc" id="igap-loc">
	  <link:definition>00000014 - Disclosure - LINE OF CREDIT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-llfs" id="igap-llfs">
	  <link:definition>00000015 - Disclosure - LONG-TERM LOANS FROM STOCKHOLDERS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cacl" id="igap-cacl">
	  <link:definition>00000016 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cspsawwrp" id="igap-cspsawwrp">
	  <link:definition>00000017 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-rade" id="igap-rade">
	  <link:definition>00000018 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-smagaae" id="igap-smagaae">
	  <link:definition>00000019 - Disclosure - SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-fien" id="igap-fien">
	  <link:definition>00000020 - Disclosure - FINANCING (INCOME) EXPENSES, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-it" id="igap-it">
	  <link:definition>00000021 - Disclosure - INCOME TAX</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-ilps" id="igap-ilps">
	  <link:definition>00000022 - Disclosure - INCOME (LOSS) PER SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-si" id="igap-si">
	  <link:definition>00000023 - Disclosure - SEGMENT INFORMATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-rp" id="igap-rp">
	  <link:definition>00000024 - Disclosure - RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-se" id="igap-se">
	  <link:definition>00000025 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-sosapp" id="igap-sosapp">
	  <link:definition>00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-sosapt" id="igap-sosapt">
	  <link:definition>00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-it1" id="igap-it1">
	  <link:definition>00000028 - Disclosure - INVENTORIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-ocat" id="igap-ocat">
	  <link:definition>00000029 - Disclosure - OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-paent" id="igap-paent">
	  <link:definition>00000030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-oclt" id="igap-oclt">
	  <link:definition>00000031 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cspsawwdpt" id="igap-cspsawwdpt">
	  <link:definition>00000032 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-radet" id="igap-radet">
	  <link:definition>00000033 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-smagaaet" id="igap-smagaaet">
	  <link:definition>00000034 - Disclosure - SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-fient" id="igap-fient">
	  <link:definition>00000035 - Disclosure - FINANCING (INCOME) EXPENSES, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-itt" id="igap-itt">
	  <link:definition>00000036 - Disclosure - INCOME TAX (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-ilpst" id="igap-ilpst">
	  <link:definition>00000037 - Disclosure - INCOME (LOSS) PER SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-sit" id="igap-sit">
	  <link:definition>00000038 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-gd" id="igap-gd">
	  <link:definition>00000039 - Disclosure - GENERAL (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-sosapd" id="igap-sosapd">
	  <link:definition>00000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Functional Currency) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" id="SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails">
	  <link:definition>00000041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property and equipment, net) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesLiabilityForEmployeeRightsUponRetirementDetails" id="SummaryOfSignificantAccountingPoliciesLiabilityForEmployeeRightsUponRetirementDetails">
	  <link:definition>00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Liability for employee rights upon retirement) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesRoyalty-bearingGrantsDetails" id="SummaryOfSignificantAccountingPoliciesRoyalty-bearingGrantsDetails">
	  <link:definition>00000043 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Royalty-bearing grants) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-id" id="igap-id">
	  <link:definition>00000044 - Disclosure - INVENTORIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-ocad1" id="igap-ocad1">
	  <link:definition>00000045 - Disclosure - OTHER CURRENT ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-paend" id="igap-paend">
	  <link:definition>00000046 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-ocld" id="igap-ocld">
	  <link:definition>00000047 - Disclosure - OTHER CURRENT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-locd" id="igap-locd">
	  <link:definition>00000048 - Disclosure - LINE OF CREDIT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-llfsd" id="igap-llfsd">
	  <link:definition>00000049 - Disclosure - LONG-TERM LOANS FROM STOCKHOLDERS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cacld" id="igap-cacld">
	  <link:definition>00000050 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Grants) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLeasesDetails" id="CommitmentsAndContingentLiabilitiesLeasesDetails">
	  <link:definition>00000051 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Leases) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesOfferingDetails" id="CommitmentsAndContingentLiabilitiesOfferingDetails">
	  <link:definition>00000052 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Offering) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLitigationDetails" id="CommitmentsAndContingentLiabilitiesLitigationDetails">
	  <link:definition>00000053 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Litigation) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cspsawwrpdoratsd" id="igap-cspsawwrpdoratsd">
	  <link:definition>00000054 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Description of Rights Attached to Stock) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cspsawwrpod" id="igap-cspsawwrpod">
	  <link:definition>00000055 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Offering) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cspsawwrpwwdrpd" id="igap-cspsawwrpwwdrpd">
	  <link:definition>00000056 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Warrants with down round protection) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/CommonStockPreferredStockAndWarrantsWith-downRoundProtectionChangesInFairValueOfLevel3LiabilityDetails" id="CommonStockPreferredStockAndWarrantsWith-downRoundProtectionChangesInFairValueOfLevel3LiabilityDetails">
	  <link:definition>00000057 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Changes in Fair Value of Level 3 Liability) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cspsawwrpsowid" id="igap-cspsawwrpsowid">
	  <link:definition>00000058 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Warrant Inputs) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cspsawwrpgtnd" id="igap-cspsawwrpgtnd">
	  <link:definition>00000059 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Non-Employees) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cspsawwrpgtend" id="igap-cspsawwrpgtend">
	  <link:definition>00000060 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Employees Narrative) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cspsawwrpsosogted" id="igap-cspsawwrpsosogted">
	  <link:definition>00000061 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Status of Grants to Employees) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cspsawwrpsoiaood" id="igap-cspsawwrpsoiaood">
	  <link:definition>00000062 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Information about Options Outstanding) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cspsawwrpsoautvod" id="igap-cspsawwrpsoautvod">
	  <link:definition>00000063 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Assumptions Used to Value Options) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-cspsawwrpcsapsd" id="igap-cspsawwrpcsapsd">
	  <link:definition>00000064 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Convertible Series A Preferred Stock) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-raded" id="igap-raded">
	  <link:definition>00000065 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-smagaaed" id="igap-smagaaed">
	  <link:definition>00000066 - Disclosure - SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-fiend" id="igap-fiend">
	  <link:definition>00000067 - Disclosure - FINANCING (INCOME) EXPENSES, NET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-itdtd" id="igap-itdtd">
	  <link:definition>00000068 - Disclosure - INCOME TAX (Narrative) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-itrostrteitrd" id="igap-itrostrteitrd">
	  <link:definition>00000069 - Disclosure - INCOME TAX (Reconciliation of Statutory Tax Rate to the Effective Income Tax Rate) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/IncomeTaxDeferredTaxesDetails" id="IncomeTaxDeferredTaxesDetails">
	  <link:definition>00000070 - Disclosure - INCOME TAX (Deferred Taxes) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-ilpsd1" id="igap-ilpsd1">
	  <link:definition>00000071 - Disclosure - INCOME (LOSS) PER SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/igap-sirbotcld" id="igap-sirbotcld">
	  <link:definition>00000072 - Disclosure - SEGMENT INFORMATION (Revenues based on the customer's location) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/RelatedPartiesDetails" id="RelatedPartiesDetails">
	  <link:definition>00000073 - Disclosure - RELATED PARTIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
	  <link:definition>00000074 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="igap-20151231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="igap-20151231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="igap-20151231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="igap-20151231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" />
    <element id="igap_FundsInRespectOfEmployeeRightsUponRetirementNoncurrent" name="FundsInRespectOfEmployeeRightsUponRetirementNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_FinancingIncomeExpensesNet" name="FinancingIncomeExpensesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" name="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" name="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued" name="AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_StockIssuedDuringPeriodSharesStockDividend" name="StockIssuedDuringPeriodSharesStockDividend" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities" name="AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders" name="LinkageDifferenceOnPrincipalOfLoansFromStockholders" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement" name="IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PreferredStockConversionPrice" name="PreferredStockConversionPrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ClassOfWarrantOrRightTerm" name="ClassOfWarrantOrRightTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion" name="ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="igap_AverageForeignCurrencyExchangeRateTranslation" name="AverageForeignCurrencyExchangeRateTranslation" nillable="true" xbrli:periodType="duration" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PropertyPlantAndEquipmentDepreciationRate" name="PropertyPlantAndEquipmentDepreciationRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RoyaltyPercentMinimum" name="RoyaltyPercentMinimum" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RoyaltyPercentMaximum" name="RoyaltyPercentMaximum" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PreferredStockStatedValue" name="PreferredStockStatedValue" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PreferredStockDividendPaymentRequirementThreshold" name="PreferredStockDividendPaymentRequirementThreshold" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PreferredStockDividendLateFee" name="PreferredStockDividendLateFee" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PreferredStockConvertibleStockPriceTrigger" name="PreferredStockConvertibleStockPriceTrigger" nillable="true" xbrli:periodType="duration" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PreferredStockConvertibleTradingVolumeTrigger" name="PreferredStockConvertibleTradingVolumeTrigger" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PreferredStockPercentageOutstandingGoverningDistributions" name="PreferredStockPercentageOutstandingGoverningDistributions" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="igap_NumberOfSharesOffered" name="NumberOfSharesOffered" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="igap_NumberOfUnitsSold" name="NumberOfUnitsSold" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="igap_StockPriceAtWhichStockDividendIsDeclared" name="StockPriceAtWhichStockDividendIsDeclared" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="igap_OfferingCostsIncurred" name="OfferingCostsIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ProceedsFromUnitsSold" name="ProceedsFromUnitsSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ClassOfWarrantOrRightNumberOfWarrantsExercisable" name="ClassOfWarrantOrRightNumberOfWarrantsExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ClassOfWarrantOrRightFairValue" name="ClassOfWarrantOrRightFairValue" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ConvertiblePreferredStockConversionPrice" name="ConvertiblePreferredStockConversionPrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne" name="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo" name="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PercentOfFutureSalesDesignatedToRepayStockholdersLoans" name="PercentOfFutureSalesDesignatedToRepayStockholdersLoans" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PreferredStockMaximumBeneficialOwnership" name="PreferredStockMaximumBeneficialOwnership" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PreferredStockMaximumBeneficialOwnershipSubjectToTerms" name="PreferredStockMaximumBeneficialOwnershipSubjectToTerms" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RegistrationPaymentArrangementCommissionPercentage" name="RegistrationPaymentArrangementCommissionPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="igap_AreaOfLeasedSpace" name="AreaOfLeasedSpace" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="igap_MonthlyLeaseCommitment" name="MonthlyLeaseCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_EquityIssuancePricePerShare" name="EquityIssuancePricePerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="igap_GainLossOnUnitConversion" name="GainLossOnUnitConversion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" name="ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants" name="IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_LeaseGuaranteeProvidedToLandlord" name="LeaseGuaranteeProvidedToLandlord" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision" name="ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ChangeInFairValueOfSeriesaWarrants" name="ChangeInFairValueOfSeriesaWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock" name="AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="igap_NumberOfWarrantsExchanged" name="NumberOfWarrantsExchanged" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants" name="IncreaseDecreaseInEquityDueToExchangeOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange" name="NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen" name="MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen" name="MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_AmountPaidAsRepaymentOfPrincipalAmount" name="AmountPaidAsRepaymentOfPrincipalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PartialReimbursementOfAttorneyFeesRequiredToPay" name="PartialReimbursementOfAttorneyFeesRequiredToPay" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ForeignCurrencyExchangeRate" name="ForeignCurrencyExchangeRate" nillable="true" xbrli:periodType="instant" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" />
    <element id="igap_NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision" name="NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RelatedPartyTransactionOwnershipInterestInEntity" name="RelatedPartyTransactionOwnershipInterestInEntity" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PortionOfRelatedPartySalaryRelatingToBonusesPaid" name="PortionOfRelatedPartySalaryRelatingToBonusesPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors" name="AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_AmountOfQuarterlyCompensationOwedToEachDirector" name="AmountOfQuarterlyCompensationOwedToEachDirector" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_AnnualCompensationOwedToChairperson" name="AnnualCompensationOwedToChairperson" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_AmountOfQuarterlyCompensationOwedChairperson" name="AmountOfQuarterlyCompensationOwedChairperson" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="igap_TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant" name="TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ExercisePriceOfOptionsGranted" name="ExercisePriceOfOptionsGranted" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="igap_NumberOfSharesVestingInEachIncrement" name="NumberOfSharesVestingInEachIncrement" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="igap_OtherCurrentLiabilitiesDisclosureTextBlock" name="OtherCurrentLiabilitiesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="igap_SellingGeneralAndAdministrativeExpenseTextBlock" name="SellingGeneralAndAdministrativeExpenseTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="igap_FinancingExpensesNetDisclosureTextBlock" name="FinancingExpensesNetDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="igap_TemporaryEquityPolicyPolicyTextBlock" name="TemporaryEquityPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ScheduleOfPropertyRatesOfDepreciationTableTextBlock" name="ScheduleOfPropertyRatesOfDepreciationTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" name="ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="igap_SellingGeneralAndAdministrativeExpenseTableTextBlock" name="SellingGeneralAndAdministrativeExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="igap_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" name="StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ConversionOfPreferredStockIntoCommonStockMember" name="ConversionOfPreferredStockIntoCommonStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_SeriesB1AndSeriesB2WarrantsMember" name="SeriesB1AndSeriesB2WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_SeriesB1WarrantMember" name="SeriesB1WarrantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_SeriesB2WarrantMember" name="SeriesB2WarrantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PurchasersOfPreviouslyIssuedCommonStockMember" name="PurchasersOfPreviouslyIssuedCommonStockMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_TwoThousandFourteenOfferingMember" name="TwoThousandFourteenOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_AgreementWithPlacementAgentMember" name="AgreementWithPlacementAgentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ArbitrationProceedingsWithShareholderMember" name="ArbitrationProceedingsWithShareholderMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PaymentOfRoyaltiesToOcsMember" name="PaymentOfRoyaltiesToOcsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RegistrationPaymentCommissionRateMember" name="RegistrationPaymentCommissionRateMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RegistrationPaymentArrangementManagementFeeMember" name="RegistrationPaymentArrangementManagementFeeMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RegistrationPaymentArrangementExpenseAllowanceMember" name="RegistrationPaymentArrangementExpenseAllowanceMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_DecemberOfferingMember" name="DecemberOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_TwoThousandTwelveOfferingMember" name="TwoThousandTwelveOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_SeriesAWarrantMember" name="SeriesAWarrantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ConsultantsMember" name="ConsultantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_InvestorFindersMember" name="InvestorFindersMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_GrantDate1Member" name="GrantDate1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_GrantDate2Member" name="GrantDate2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PlacementAgentMember" name="PlacementAgentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ClassOfWarrantOrRightExercisePriceOneMember" name="ClassOfWarrantOrRightExercisePriceOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ClassOfWarrantOrRightExercisePriceTwoMember" name="ClassOfWarrantOrRightExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ClassOfWarrantOrRightExercisePriceThreeMember" name="ClassOfWarrantOrRightExercisePriceThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_WarrantsIssuedToPlacementAgentTrancheOneMember" name="WarrantsIssuedToPlacementAgentTrancheOneMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ClassOfWarrantOrRightExercisePriceFourMember" name="ClassOfWarrantOrRightExercisePriceFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ClassOfWarrantOrRightExercisePriceFiveMember" name="ClassOfWarrantOrRightExercisePriceFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_InvestorRelationsServicesProviderMember" name="InvestorRelationsServicesProviderMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_IntegrityIsraelPlanMember" name="IntegrityIsraelPlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ShareIncentivePlanMember" name="ShareIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_GrantsToMessrsGalAndMalkaMember" name="GrantsToMessrsGalAndMalkaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RangeOneMember" name="RangeOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RangeTwoMember" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RangeThreeMember" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RangeFourMember" name="RangeFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RangeFiveMember" name="RangeFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RangeSixMember" name="RangeSixMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RangeSevenMember" name="RangeSevenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_WarrantsIssuedToPlacementAgentTrancheTwoMember" name="WarrantsIssuedToPlacementAgentTrancheTwoMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_WarrantsIssuedUnderSecuritiesPurchaseAgreementMember" name="WarrantsIssuedUnderSecuritiesPurchaseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember" name="WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_AdIntegrityApplicationsLtdMember" name="AdIntegrityApplicationsLtdMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_AvnerGalMember" name="AvnerGalMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_DavidMalkaMember" name="DavidMalkaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_TwoThousandFourteenOfferingsMember" name="TwoThousandFourteenOfferingsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RegulatoryServicesMember" name="RegulatoryServicesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_TwoThousandTenOfferingMember" name="TwoThousandTenOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PropertyAshkelonIsraelMember" name="PropertyAshkelonIsraelMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_PropertyAshdodIsraelMember" name="PropertyAshdodIsraelMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_DirectorsMember" name="DirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RoyaltyPercentForYearsFourThroughSix" name="RoyaltyPercentForYearsFourThroughSix" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="igap_RegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal" name="RegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ClassOfWarrantOrRightExercisePriceAxis" name="ClassOfWarrantOrRightExercisePriceAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="igap_ClassOfWarrantOrRightExercisePriceDomain" name="ClassOfWarrantOrRightExercisePriceDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ClassOfWarrantOrRightPostAdjustmentFairValue" name="ClassOfWarrantOrRightPostAdjustmentFairValue" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ClassOfWarrantOrRightPreAdjustmentFairValue" name="ClassOfWarrantOrRightPreAdjustmentFairValue" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="igap_ClassOfWarrantRightExpenseOrRevenueRecognized" name="ClassOfWarrantRightExpenseOrRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>igap-20151231_cal.xml
<DESCRIPTION>TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: Integrity Applications, Inc. 12%2D31%2D15 10K Final To Use To File.xfr; Date: 2016%2D03%2D30T13:08:15Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80460001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://integrity-app.com/role/igap-daei1" xlink:href="igap-20151231.xsd#igap-daei1" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cbs" xlink:href="igap-20151231.xsd#igap-cbs" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cbsp" xlink:href="igap-20151231.xsd#igap-cbsp" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/Statement-CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:href="igap-20151231.xsd#Statement-CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="igap-20151231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-csocf" xlink:href="igap-20151231.xsd#igap-csocf" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-csocfp" xlink:href="igap-20151231.xsd#igap-csocfp" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-g" xlink:href="igap-20151231.xsd#igap-g" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sosap" xlink:href="igap-20151231.xsd#igap-sosap" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-i" xlink:href="igap-20151231.xsd#igap-i" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-oca" xlink:href="igap-20151231.xsd#igap-oca" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-paen" xlink:href="igap-20151231.xsd#igap-paen" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ocl" xlink:href="igap-20151231.xsd#igap-ocl" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-loc" xlink:href="igap-20151231.xsd#igap-loc" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-llfs" xlink:href="igap-20151231.xsd#igap-llfs" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cacl" xlink:href="igap-20151231.xsd#igap-cacl" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrp" xlink:href="igap-20151231.xsd#igap-cspsawwrp" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-rade" xlink:href="igap-20151231.xsd#igap-rade" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-smagaae" xlink:href="igap-20151231.xsd#igap-smagaae" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-fien" xlink:href="igap-20151231.xsd#igap-fien" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-it" xlink:href="igap-20151231.xsd#igap-it" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ilps" xlink:href="igap-20151231.xsd#igap-ilps" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-si" xlink:href="igap-20151231.xsd#igap-si" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-rp" xlink:href="igap-20151231.xsd#igap-rp" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-se" xlink:href="igap-20151231.xsd#igap-se" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sosapp" xlink:href="igap-20151231.xsd#igap-sosapp" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sosapt" xlink:href="igap-20151231.xsd#igap-sosapt" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-it1" xlink:href="igap-20151231.xsd#igap-it1" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ocat" xlink:href="igap-20151231.xsd#igap-ocat" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-paent" xlink:href="igap-20151231.xsd#igap-paent" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-oclt" xlink:href="igap-20151231.xsd#igap-oclt" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwdpt" xlink:href="igap-20151231.xsd#igap-cspsawwdpt" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-radet" xlink:href="igap-20151231.xsd#igap-radet" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-smagaaet" xlink:href="igap-20151231.xsd#igap-smagaaet" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-fient" xlink:href="igap-20151231.xsd#igap-fient" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-itt" xlink:href="igap-20151231.xsd#igap-itt" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ilpst" xlink:href="igap-20151231.xsd#igap-ilpst" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sit" xlink:href="igap-20151231.xsd#igap-sit" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-gd" xlink:href="igap-20151231.xsd#igap-gd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sosapd" xlink:href="igap-20151231.xsd#igap-sosapd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" xlink:href="igap-20151231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesLiabilityForEmployeeRightsUponRetirementDetails" xlink:href="igap-20151231.xsd#SummaryOfSignificantAccountingPoliciesLiabilityForEmployeeRightsUponRetirementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesRoyalty-bearingGrantsDetails" xlink:href="igap-20151231.xsd#SummaryOfSignificantAccountingPoliciesRoyalty-bearingGrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-id" xlink:href="igap-20151231.xsd#igap-id" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ocad1" xlink:href="igap-20151231.xsd#igap-ocad1" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-paend" xlink:href="igap-20151231.xsd#igap-paend" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ocld" xlink:href="igap-20151231.xsd#igap-ocld" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-locd" xlink:href="igap-20151231.xsd#igap-locd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-llfsd" xlink:href="igap-20151231.xsd#igap-llfsd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cacld" xlink:href="igap-20151231.xsd#igap-cacld" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLeasesDetails" xlink:href="igap-20151231.xsd#CommitmentsAndContingentLiabilitiesLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesOfferingDetails" xlink:href="igap-20151231.xsd#CommitmentsAndContingentLiabilitiesOfferingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLitigationDetails" xlink:href="igap-20151231.xsd#CommitmentsAndContingentLiabilitiesLitigationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpdoratsd" xlink:href="igap-20151231.xsd#igap-cspsawwrpdoratsd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpod" xlink:href="igap-20151231.xsd#igap-cspsawwrpod" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpwwdrpd" xlink:href="igap-20151231.xsd#igap-cspsawwrpwwdrpd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommonStockPreferredStockAndWarrantsWith-downRoundProtectionChangesInFairValueOfLevel3LiabilityDetails" xlink:href="igap-20151231.xsd#CommonStockPreferredStockAndWarrantsWith-downRoundProtectionChangesInFairValueOfLevel3LiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpsowid" xlink:href="igap-20151231.xsd#igap-cspsawwrpsowid" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpgtnd" xlink:href="igap-20151231.xsd#igap-cspsawwrpgtnd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpgtend" xlink:href="igap-20151231.xsd#igap-cspsawwrpgtend" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpsosogted" xlink:href="igap-20151231.xsd#igap-cspsawwrpsosogted" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpsoiaood" xlink:href="igap-20151231.xsd#igap-cspsawwrpsoiaood" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpsoautvod" xlink:href="igap-20151231.xsd#igap-cspsawwrpsoautvod" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpcsapsd" xlink:href="igap-20151231.xsd#igap-cspsawwrpcsapsd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-raded" xlink:href="igap-20151231.xsd#igap-raded" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-smagaaed" xlink:href="igap-20151231.xsd#igap-smagaaed" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-fiend" xlink:href="igap-20151231.xsd#igap-fiend" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-itdtd" xlink:href="igap-20151231.xsd#igap-itdtd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-itrostrteitrd" xlink:href="igap-20151231.xsd#igap-itrostrteitrd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/IncomeTaxDeferredTaxesDetails" xlink:href="igap-20151231.xsd#IncomeTaxDeferredTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ilpsd1" xlink:href="igap-20151231.xsd#igap-ilpsd1" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sirbotcld" xlink:href="igap-20151231.xsd#igap-sirbotcld" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/RelatedPartiesDetails" xlink:href="igap-20151231.xsd#RelatedPartiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SubsequentEventsDetails" xlink:href="igap-20151231.xsd#SubsequentEventsDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-daei1" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cbs" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaapRestrictedCashAndInvestmentsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCashAndInvestmentsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_FundsInRespectOfEmployeeRightsUponRetirementNoncurrent" xlink:label="loc_igapFundsInRespectOfEmployeeRightsUponRetirementNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_igapFundsInRespectOfEmployeeRightsUponRetirementNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapDueToOfficersOrStockholdersNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaapPostemploymentBenefitsLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapPostemploymentBenefitsLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityPreferredCarryingAmount" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cbsp" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/Statement-CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_FinancingIncomeExpensesNet" xlink:label="loc_igapFinancingIncomeExpensesNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_igapFinancingIncomeExpensesNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-csocf" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPostemploymentObligations" xlink:label="loc_us-gaapIncreaseDecreaseInPostemploymentObligations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInPostemploymentObligations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:label="loc_igapLinkageDifferenceOnPrincipalOfLoansFromStockholders" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_igapLinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_GainLossOnUnitConversion" xlink:label="loc_igapGainLossOnUnitConversion" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_igapGainLossOnUnitConversion" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_igapIncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_igapIncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaapIncreaseDecreaseInRestrictedCash" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInRestrictedCash" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfShortTermDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapPaymentsOfDividendsPreferredStockAndPreferenceStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapPaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-csocfp" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-g" xlink:title="00000008 - Disclosure - GENERAL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sosap" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-i" xlink:title="00000010 - Disclosure - INVENTORIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-oca" xlink:title="00000011 - Disclosure - OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-paen" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ocl" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-loc" xlink:title="00000014 - Disclosure - LINE OF CREDIT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-llfs" xlink:title="00000015 - Disclosure - LONG-TERM LOANS FROM STOCKHOLDERS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cacl" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrp" xlink:title="00000017 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-rade" xlink:title="00000018 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-smagaae" xlink:title="00000019 - Disclosure - SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-fien" xlink:title="00000020 - Disclosure - FINANCING (INCOME) EXPENSES, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-it" xlink:title="00000021 - Disclosure - INCOME TAX" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ilps" xlink:title="00000022 - Disclosure - INCOME (LOSS) PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-si" xlink:title="00000023 - Disclosure - SEGMENT INFORMATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-rp" xlink:title="00000024 - Disclosure - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-se" xlink:title="00000025 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sosapp" xlink:title="00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sosapt" xlink:title="00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-it1" xlink:title="00000028 - Disclosure - INVENTORIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ocat" xlink:title="00000029 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-paent" xlink:title="00000030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-oclt" xlink:title="00000031 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwdpt" xlink:title="00000032 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-radet" xlink:title="00000033 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-smagaaet" xlink:title="00000034 - Disclosure - SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-fient" xlink:title="00000035 - Disclosure - FINANCING (INCOME) EXPENSES, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-itt" xlink:title="00000036 - Disclosure - INCOME TAX (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ilpst" xlink:title="00000037 - Disclosure - INCOME (LOSS) PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sit" xlink:title="00000038 - Disclosure - SEGMENT INFORMATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-gd" xlink:title="00000039 - Disclosure - GENERAL (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sosapd" xlink:title="00000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Functional Currency) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" xlink:title="00000041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property and equipment, net) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesLiabilityForEmployeeRightsUponRetirementDetails" xlink:title="00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Liability for employee rights upon retirement) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesRoyalty-bearingGrantsDetails" xlink:title="00000043 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Royalty-bearing grants) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-id" xlink:title="00000044 - Disclosure - INVENTORIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ocad1" xlink:title="00000045 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-paend" xlink:title="00000046 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ocld" xlink:title="00000047 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-locd" xlink:title="00000048 - Disclosure - LINE OF CREDIT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-llfsd" xlink:title="00000049 - Disclosure - LONG-TERM LOANS FROM STOCKHOLDERS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cacld" xlink:title="00000050 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Grants) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLeasesDetails" xlink:title="00000051 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Leases) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesOfferingDetails" xlink:title="00000052 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Offering) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLitigationDetails" xlink:title="00000053 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Litigation) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpdoratsd" xlink:title="00000054 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Description of Rights Attached to Stock) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpod" xlink:title="00000055 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Offering) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpwwdrpd" xlink:title="00000056 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Warrants with down round protection) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommonStockPreferredStockAndWarrantsWith-downRoundProtectionChangesInFairValueOfLevel3LiabilityDetails" xlink:title="00000057 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Changes in Fair Value of Level 3 Liability) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpsowid" xlink:title="00000058 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Warrant Inputs) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpgtnd" xlink:title="00000059 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Non-Employees) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpgtend" xlink:title="00000060 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Employees Narrative) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpsosogted" xlink:title="00000061 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Status of Grants to Employees) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpsoiaood" xlink:title="00000062 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Information about Options Outstanding) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpsoautvod" xlink:title="00000063 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Assumptions Used to Value Options) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpcsapsd" xlink:title="00000064 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Convertible Series A Preferred Stock) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-raded" xlink:title="00000065 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_us-gaapTravelAndEntertainmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:label="loc_us-gaapCostOfPropertyRepairsAndMaintenance" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_us-gaapCostOfPropertyRepairsAndMaintenance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_us-gaapOtherGeneralExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-smagaaed" xlink:title="00000066 - Disclosure - SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapTravelAndEntertainmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:label="loc_us-gaapCostOfPropertyRepairsAndMaintenance" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapCostOfPropertyRepairsAndMaintenance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-fiend" xlink:title="00000067 - Disclosure - FINANCING (INCOME) EXPENSES, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_FinancingIncomeExpensesNet" xlink:label="loc_igapFinancingIncomeExpensesNet" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:label="loc_igapLinkageDifferenceOnPrincipalOfLoansFromStockholders" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_igapFinancingIncomeExpensesNet" xlink:to="loc_igapLinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_igapFinancingIncomeExpensesNet" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_igapFinancingIncomeExpensesNet" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RecapitalizationCosts" xlink:label="loc_us-gaapRecapitalizationCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_igapFinancingIncomeExpensesNet" xlink:to="loc_us-gaapRecapitalizationCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_igapFinancingIncomeExpensesNet" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_GainLossOnUnitConversion" xlink:label="loc_igapGainLossOnUnitConversion" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_igapFinancingIncomeExpensesNet" xlink:to="loc_igapGainLossOnUnitConversion" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-itdtd" xlink:title="00000068 - Disclosure - INCOME TAX (Narrative) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-itrostrteitrd" xlink:title="00000069 - Disclosure - INCOME TAX (Reconciliation of Statutory Tax Rate to the Effective Income Tax Rate) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants" xlink:label="loc_igapIncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_igapIncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/IncomeTaxDeferredTaxesDetails" xlink:title="00000070 - Disclosure - INCOME TAX (Deferred Taxes) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ilpsd1" xlink:title="00000071 - Disclosure - INCOME (LOSS) PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="loc_us-gaapOtherPreferredStockDividendsAndAdjustments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapOtherPreferredStockDividendsAndAdjustments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaapUndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapUndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sirbotcld" xlink:title="00000072 - Disclosure - SEGMENT INFORMATION (Revenues based on the customer's location) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/RelatedPartiesDetails" xlink:title="00000073 - Disclosure - RELATED PARTIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SubsequentEventsDetails" xlink:title="00000074 - Disclosure - SUBSEQUENT EVENTS (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>igap-20151231_def.xml
<DESCRIPTION>TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: Integrity Applications, Inc. 12%2D31%2D15 10K Final To Use To File.xfr; Date: 2016%2D03%2D30T13:08:15Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80460001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://integrity-app.com/role/igap-daei1" xlink:href="igap-20151231.xsd#igap-daei1" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cbs" xlink:href="igap-20151231.xsd#igap-cbs" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cbsp" xlink:href="igap-20151231.xsd#igap-cbsp" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/Statement-CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:href="igap-20151231.xsd#Statement-CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="igap-20151231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-csocf" xlink:href="igap-20151231.xsd#igap-csocf" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-csocfp" xlink:href="igap-20151231.xsd#igap-csocfp" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-g" xlink:href="igap-20151231.xsd#igap-g" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sosap" xlink:href="igap-20151231.xsd#igap-sosap" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-i" xlink:href="igap-20151231.xsd#igap-i" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-oca" xlink:href="igap-20151231.xsd#igap-oca" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-paen" xlink:href="igap-20151231.xsd#igap-paen" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ocl" xlink:href="igap-20151231.xsd#igap-ocl" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-loc" xlink:href="igap-20151231.xsd#igap-loc" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-llfs" xlink:href="igap-20151231.xsd#igap-llfs" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cacl" xlink:href="igap-20151231.xsd#igap-cacl" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrp" xlink:href="igap-20151231.xsd#igap-cspsawwrp" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-rade" xlink:href="igap-20151231.xsd#igap-rade" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-smagaae" xlink:href="igap-20151231.xsd#igap-smagaae" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-fien" xlink:href="igap-20151231.xsd#igap-fien" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-it" xlink:href="igap-20151231.xsd#igap-it" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ilps" xlink:href="igap-20151231.xsd#igap-ilps" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-si" xlink:href="igap-20151231.xsd#igap-si" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-rp" xlink:href="igap-20151231.xsd#igap-rp" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-se" xlink:href="igap-20151231.xsd#igap-se" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sosapp" xlink:href="igap-20151231.xsd#igap-sosapp" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sosapt" xlink:href="igap-20151231.xsd#igap-sosapt" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-it1" xlink:href="igap-20151231.xsd#igap-it1" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ocat" xlink:href="igap-20151231.xsd#igap-ocat" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-paent" xlink:href="igap-20151231.xsd#igap-paent" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-oclt" xlink:href="igap-20151231.xsd#igap-oclt" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwdpt" xlink:href="igap-20151231.xsd#igap-cspsawwdpt" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-radet" xlink:href="igap-20151231.xsd#igap-radet" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-smagaaet" xlink:href="igap-20151231.xsd#igap-smagaaet" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-fient" xlink:href="igap-20151231.xsd#igap-fient" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-itt" xlink:href="igap-20151231.xsd#igap-itt" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ilpst" xlink:href="igap-20151231.xsd#igap-ilpst" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sit" xlink:href="igap-20151231.xsd#igap-sit" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-gd" xlink:href="igap-20151231.xsd#igap-gd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sosapd" xlink:href="igap-20151231.xsd#igap-sosapd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" xlink:href="igap-20151231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesLiabilityForEmployeeRightsUponRetirementDetails" xlink:href="igap-20151231.xsd#SummaryOfSignificantAccountingPoliciesLiabilityForEmployeeRightsUponRetirementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesRoyalty-bearingGrantsDetails" xlink:href="igap-20151231.xsd#SummaryOfSignificantAccountingPoliciesRoyalty-bearingGrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-id" xlink:href="igap-20151231.xsd#igap-id" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ocad1" xlink:href="igap-20151231.xsd#igap-ocad1" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-paend" xlink:href="igap-20151231.xsd#igap-paend" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ocld" xlink:href="igap-20151231.xsd#igap-ocld" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-locd" xlink:href="igap-20151231.xsd#igap-locd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-llfsd" xlink:href="igap-20151231.xsd#igap-llfsd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cacld" xlink:href="igap-20151231.xsd#igap-cacld" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLeasesDetails" xlink:href="igap-20151231.xsd#CommitmentsAndContingentLiabilitiesLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesOfferingDetails" xlink:href="igap-20151231.xsd#CommitmentsAndContingentLiabilitiesOfferingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLitigationDetails" xlink:href="igap-20151231.xsd#CommitmentsAndContingentLiabilitiesLitigationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpdoratsd" xlink:href="igap-20151231.xsd#igap-cspsawwrpdoratsd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpod" xlink:href="igap-20151231.xsd#igap-cspsawwrpod" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpwwdrpd" xlink:href="igap-20151231.xsd#igap-cspsawwrpwwdrpd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommonStockPreferredStockAndWarrantsWith-downRoundProtectionChangesInFairValueOfLevel3LiabilityDetails" xlink:href="igap-20151231.xsd#CommonStockPreferredStockAndWarrantsWith-downRoundProtectionChangesInFairValueOfLevel3LiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpsowid" xlink:href="igap-20151231.xsd#igap-cspsawwrpsowid" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpgtnd" xlink:href="igap-20151231.xsd#igap-cspsawwrpgtnd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpgtend" xlink:href="igap-20151231.xsd#igap-cspsawwrpgtend" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpsosogted" xlink:href="igap-20151231.xsd#igap-cspsawwrpsosogted" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpsoiaood" xlink:href="igap-20151231.xsd#igap-cspsawwrpsoiaood" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpsoautvod" xlink:href="igap-20151231.xsd#igap-cspsawwrpsoautvod" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpcsapsd" xlink:href="igap-20151231.xsd#igap-cspsawwrpcsapsd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-raded" xlink:href="igap-20151231.xsd#igap-raded" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-smagaaed" xlink:href="igap-20151231.xsd#igap-smagaaed" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-fiend" xlink:href="igap-20151231.xsd#igap-fiend" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-itdtd" xlink:href="igap-20151231.xsd#igap-itdtd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-itrostrteitrd" xlink:href="igap-20151231.xsd#igap-itrostrteitrd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/IncomeTaxDeferredTaxesDetails" xlink:href="igap-20151231.xsd#IncomeTaxDeferredTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ilpsd1" xlink:href="igap-20151231.xsd#igap-ilpsd1" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sirbotcld" xlink:href="igap-20151231.xsd#igap-sirbotcld" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/RelatedPartiesDetails" xlink:href="igap-20151231.xsd#RelatedPartiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SubsequentEventsDetails" xlink:href="igap-20151231.xsd#SubsequentEventsDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-daei1" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cbs" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapInventoryNet_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapOtherAssetsCurrent_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaapRestrictedCashAndInvestmentsNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapRestrictedCashAndInvestmentsNoncurrent_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_FundsInRespectOfEmployeeRightsUponRetirementNoncurrent" xlink:label="loc_igapFundsInRespectOfEmployeeRightsUponRetirementNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_igapFundsInRespectOfEmployeeRightsUponRetirementNoncurrent_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableCurrent_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapDueToOfficersOrStockholdersNoncurrent_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaapPostemploymentBenefitsLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapPostemploymentBenefitsLiabilityNoncurrent_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesNoncurrent_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommitmentsAndContingencies_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaapTemporaryEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapTemporaryEquityAbstract_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityPreferredCarryingAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityAbstract_70" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityPreferredCarryingAmount_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="32" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cbsp" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaapTemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_90" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_90" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_90" xlink:to="loc_us-gaapTemporaryEquitySharesIssued_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_90" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_90" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/Statement-CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaapStockholdersEquityOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityOther_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityOtherShares" xlink:label="loc_us-gaapStockholdersEquityOtherShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityOtherShares_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued" xlink:label="loc_igapAdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapAdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities" xlink:label="loc_igapAdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapAdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" xlink:label="loc_igapStockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapStockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" xlink:label="loc_igapStockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapStockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsStock" xlink:label="loc_us-gaapDividendsStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsStock_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_StockIssuedDuringPeriodSharesStockDividend" xlink:label="loc_igapStockIssuedDuringPeriodSharesStockDividend_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapStockIssuedDuringPeriodSharesStockDividend_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="loc_us-gaapDividendsPreferredStockStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStockStock_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="loc_us-gaapPreferredStockDividendsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendsShares_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-csocf" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-csocfp" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaapConversionOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaapConversionOfStockTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConversionOfStockTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConversionOfStockTable" xlink:to="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaapConversionOfStockNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" xlink:to="loc_us-gaapConversionOfStockNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaapConversionOfStockNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" xlink:to="loc_us-gaapConversionOfStockNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ConversionOfPreferredStockIntoCommonStockMember" xlink:label="loc_igapConversionOfPreferredStockIntoCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConversionOfStockNameDomain" xlink:to="loc_igapConversionOfPreferredStockIntoCommonStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConversionOfStockTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConversionOfStockTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConversionOfStockTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB1WarrantMember" xlink:label="loc_igapSeriesB1WarrantMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB1WarrantMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB2WarrantMember" xlink:label="loc_igapSeriesB2WarrantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB2WarrantMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock" xlink:label="loc_igapAmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_igapAmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfWarrantsExchanged" xlink:label="loc_igapNumberOfWarrantsExchanged_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_igapNumberOfWarrantsExchanged_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants" xlink:label="loc_igapIncreaseDecreaseInEquityDueToExchangeOfWarrants_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_igapIncreaseDecreaseInEquityDueToExchangeOfWarrants_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange" xlink:label="loc_igapNoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_igapNoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsCommonStockStock" xlink:label="loc_us-gaapDividendsCommonStockStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_us-gaapDividendsCommonStockStock_100" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-g" xlink:title="00000008 - Disclosure - GENERAL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sosap" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-i" xlink:title="00000010 - Disclosure - INVENTORIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-oca" xlink:title="00000011 - Disclosure - OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-paen" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ocl" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-loc" xlink:title="00000014 - Disclosure - LINE OF CREDIT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-llfs" xlink:title="00000015 - Disclosure - LONG-TERM LOANS FROM STOCKHOLDERS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cacl" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrp" xlink:title="00000017 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-rade" xlink:title="00000018 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-smagaae" xlink:title="00000019 - Disclosure - SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-fien" xlink:title="00000020 - Disclosure - FINANCING (INCOME) EXPENSES, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-it" xlink:title="00000021 - Disclosure - INCOME TAX" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ilps" xlink:title="00000022 - Disclosure - INCOME (LOSS) PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-si" xlink:title="00000023 - Disclosure - SEGMENT INFORMATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-rp" xlink:title="00000024 - Disclosure - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-se" xlink:title="00000025 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sosapp" xlink:title="00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sosapt" xlink:title="00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-it1" xlink:title="00000028 - Disclosure - INVENTORIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ocat" xlink:title="00000029 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-paent" xlink:title="00000030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-oclt" xlink:title="00000031 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwdpt" xlink:title="00000032 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-radet" xlink:title="00000033 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-smagaaet" xlink:title="00000034 - Disclosure - SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-fient" xlink:title="00000035 - Disclosure - FINANCING (INCOME) EXPENSES, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-itt" xlink:title="00000036 - Disclosure - INCOME TAX (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ilpst" xlink:title="00000037 - Disclosure - INCOME (LOSS) PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sit" xlink:title="00000038 - Disclosure - SEGMENT INFORMATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-gd" xlink:title="00000039 - Disclosure - GENERAL (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaapCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB1WarrantMember" xlink:label="loc_igapSeriesB1WarrantMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB1WarrantMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB2WarrantMember" xlink:label="loc_igapSeriesB2WarrantMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB2WarrantMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquity_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="loc_igapProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_igapProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:label="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockConversionPrice" xlink:label="loc_igapPreferredStockConversionPrice_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_igapPreferredStockConversionPrice_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightTerm" xlink:label="loc_igapClassOfWarrantOrRightTerm_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_igapClassOfWarrantOrRightTerm_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion" xlink:label="loc_igapConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_igapConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_150" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sosapd" xlink:title="00000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Functional Currency) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" xlink:title="00000041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property and equipment, net) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PropertyPlantAndEquipmentDepreciationRate" xlink:label="loc_igapPropertyPlantAndEquipmentDepreciationRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_igapPropertyPlantAndEquipmentDepreciationRate_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesLiabilityForEmployeeRightsUponRetirementDetails" xlink:title="00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Liability for employee rights upon retirement) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesRoyalty-bearingGrantsDetails" xlink:title="00000043 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Royalty-bearing grants) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-id" xlink:title="00000044 - Disclosure - INVENTORIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ocad1" xlink:title="00000045 - Disclosure - OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-paend" xlink:title="00000046 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciation_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_120" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ocld" xlink:title="00000047 - Disclosure - OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-locd" xlink:title="00000048 - Disclosure - LINE OF CREDIT (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaapCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCurrencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-llfsd" xlink:title="00000049 - Disclosure - LONG-TERM LOANS FROM STOCKHOLDERS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cacld" xlink:title="00000050 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Grants) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaapLossContingenciesByNatureOfContingencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapLossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaapLossContingencyNatureDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLossContingenciesByNatureOfContingencyAxis" xlink:to="loc_us-gaapLossContingencyNatureDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaapLossContingencyNatureDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesByNatureOfContingencyAxis" xlink:to="loc_us-gaapLossContingencyNatureDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PaymentOfRoyaltiesToOcsMember" xlink:label="loc_igapPaymentOfRoyaltiesToOcsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingencyNatureDomain" xlink:to="loc_igapPaymentOfRoyaltiesToOcsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaapCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaapRevenueFromGrants_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapRevenueFromGrants_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyRangeOfPossibleLossMaximum" xlink:label="loc_us-gaapLossContingencyRangeOfPossibleLossMaximum_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapLossContingencyRangeOfPossibleLossMaximum_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RoyaltyPercentMinimum" xlink:label="loc_igapRoyaltyPercentMinimum_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_igapRoyaltyPercentMinimum_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RoyaltyPercentForYearsFourThroughSix" xlink:label="loc_igapRoyaltyPercentForYearsFourThroughSix_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_igapRoyaltyPercentForYearsFourThroughSix_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RoyaltyPercentMaximum" xlink:label="loc_igapRoyaltyPercentMaximum_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_igapRoyaltyPercentMaximum_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:label="loc_us-gaapLossContingencyRangeOfPossibleLossPortionNotAccrued_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapLossContingencyRangeOfPossibleLossPortionNotAccrued_80" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLeasesDetails" xlink:title="00000051 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Leases) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaapOperatingLeasedAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaapScheduleOfOperatingLeasedAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLeasedAssetsLineItems" xlink:to="loc_us-gaapScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaapLeaseArrangementTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfOperatingLeasedAssetsTable" xlink:to="loc_us-gaapLeaseArrangementTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaapLeaseArrangementTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLeaseArrangementTypeAxis" xlink:to="loc_us-gaapLeaseArrangementTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaapLeaseArrangementTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLeaseArrangementTypeAxis" xlink:to="loc_us-gaapLeaseArrangementTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PropertyAshkelonIsraelMember" xlink:label="loc_igapPropertyAshkelonIsraelMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseArrangementTypeDomain" xlink:to="loc_igapPropertyAshkelonIsraelMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PropertyAshdodIsraelMember" xlink:label="loc_igapPropertyAshdodIsraelMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseArrangementTypeDomain" xlink:to="loc_igapPropertyAshdodIsraelMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaapCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfOperatingLeasedAssetsTable" xlink:to="loc_us-gaapCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLeasedAssetsLineItems" xlink:to="loc_us-gaapLeasesAbstract_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeasesAbstract_60" xlink:to="loc_us-gaapLeaseExpirationDate1_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AreaOfLeasedSpace" xlink:label="loc_igapAreaOfLeasedSpace_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeasesAbstract_60" xlink:to="loc_igapAreaOfLeasedSpace_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_MonthlyLeaseCommitment" xlink:label="loc_igapMonthlyLeaseCommitment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeasesAbstract_60" xlink:to="loc_igapMonthlyLeaseCommitment_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_LeaseGuaranteeProvidedToLandlord" xlink:label="loc_igapLeaseGuaranteeProvidedToLandlord_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeasesAbstract_60" xlink:to="loc_igapLeaseGuaranteeProvidedToLandlord_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeasesAbstract_60" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeasesAbstract_60" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeasesAbstract_60" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeasesAbstract_60" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeasesAbstract_60" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears_60" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesOfferingDetails" xlink:title="00000052 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Offering) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:to="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaapRegistrationPaymentArrangementArrangementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:to="loc_us-gaapRegistrationPaymentArrangementArrangementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AgreementWithPlacementAgentMember" xlink:label="loc_igapAgreementWithPlacementAgentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapAgreementWithPlacementAgentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_DecemberOfferingMember" xlink:label="loc_igapDecemberOfferingMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapDecemberOfferingMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegistrationPaymentArrangementManagementFeeMember" xlink:label="loc_igapRegistrationPaymentArrangementManagementFeeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapRegistrationPaymentArrangementManagementFeeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegistrationPaymentArrangementExpenseAllowanceMember" xlink:label="loc_igapRegistrationPaymentArrangementExpenseAllowanceMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapRegistrationPaymentArrangementExpenseAllowanceMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandTwelveOfferingMember" xlink:label="loc_igapTwoThousandTwelveOfferingMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandTwelveOfferingMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegistrationPaymentCommissionRateMember" xlink:label="loc_igapRegistrationPaymentCommissionRateMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapRegistrationPaymentCommissionRateMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandFourteenOfferingMember" xlink:label="loc_igapTwoThousandFourteenOfferingMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandFourteenOfferingMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandFourteenOfferingsMember" xlink:label="loc_igapTwoThousandFourteenOfferingsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandFourteenOfferingsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:label="loc_us-gaapRegistrationPaymentArrangementMaximumPotentialConsideration_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRegistrationPaymentArrangementMaximumPotentialConsideration_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegistrationPaymentArrangementCommissionPercentage" xlink:label="loc_igapRegistrationPaymentArrangementCommissionPercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapRegistrationPaymentArrangementCommissionPercentage_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal" xlink:label="loc_igapRegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapRegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen" xlink:label="loc_igapMonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapMonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen" xlink:label="loc_igapMonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapMonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen_150" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLitigationDetails" xlink:title="00000053 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Litigation) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaapLitigationStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLitigationStatusAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaapLitigationStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLitigationStatusAxis" xlink:to="loc_us-gaapLitigationStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaapLitigationStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLitigationStatusAxis" xlink:to="loc_us-gaapLitigationStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_JudicialRulingMember" xlink:label="loc_us-gaapJudicialRulingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLitigationStatusDomain" xlink:to="loc_us-gaapJudicialRulingMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaapCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision" xlink:label="loc_igapNumberOfCommonStockOfEntityTransferredUnderArbitrationDecision_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_igapNumberOfCommonStockOfEntityTransferredUnderArbitrationDecision_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountPaidAsRepaymentOfPrincipalAmount" xlink:label="loc_igapAmountPaidAsRepaymentOfPrincipalAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_igapAmountPaidAsRepaymentOfPrincipalAmount_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ForeignCurrencyExchangeRate" xlink:label="loc_igapForeignCurrencyExchangeRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_igapForeignCurrencyExchangeRate_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PartialReimbursementOfAttorneyFeesRequiredToPay" xlink:label="loc_igapPartialReimbursementOfAttorneyFeesRequiredToPay_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_igapPartialReimbursementOfAttorneyFeesRequiredToPay_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpdoratsd" xlink:title="00000054 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Description of Rights Attached to Stock) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaapTemporaryEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaapTemporaryEquityByClassOfStockTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaapCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapStatementScenarioAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockStatedValue" xlink:label="loc_igapPreferredStockStatedValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockStatedValue_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockDividendPaymentRequirementThreshold" xlink:label="loc_igapPreferredStockDividendPaymentRequirementThreshold_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockDividendPaymentRequirementThreshold_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockDividendLateFee" xlink:label="loc_igapPreferredStockDividendLateFee_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockDividendLateFee_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="loc_us-gaapPreferredStockDividendsShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapPreferredStockDividendsShares_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapDividendsPreferredStock_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsCommonStockStock" xlink:label="loc_us-gaapDividendsCommonStockStock_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapDividendsCommonStockStock_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockConvertibleStockPriceTrigger" xlink:label="loc_igapPreferredStockConvertibleStockPriceTrigger_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockConvertibleStockPriceTrigger_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockConvertibleTradingVolumeTrigger" xlink:label="loc_igapPreferredStockConvertibleTradingVolumeTrigger_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockConvertibleTradingVolumeTrigger_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockPercentageOutstandingGoverningDistributions" xlink:label="loc_igapPreferredStockPercentageOutstandingGoverningDistributions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockPercentageOutstandingGoverningDistributions_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockMaximumBeneficialOwnership" xlink:label="loc_igapPreferredStockMaximumBeneficialOwnership_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockMaximumBeneficialOwnership_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockMaximumBeneficialOwnershipSubjectToTerms" xlink:label="loc_igapPreferredStockMaximumBeneficialOwnershipSubjectToTerms_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockMaximumBeneficialOwnershipSubjectToTerms_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockConversionPrice" xlink:label="loc_igapPreferredStockConversionPrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockConversionPrice_90" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpod" xlink:title="00000055 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Offering) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaapTemporaryEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaapTemporaryEquityByClassOfStockTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:to="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaapRegistrationPaymentArrangementArrangementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:to="loc_us-gaapRegistrationPaymentArrangementArrangementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandTwelveOfferingMember" xlink:label="loc_igapTwoThousandTwelveOfferingMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandTwelveOfferingMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandFourteenOfferingMember" xlink:label="loc_igapTwoThousandFourteenOfferingMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandFourteenOfferingMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapStatementScenarioAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaapScenarioPlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_us-gaapScenarioPlanMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB1WarrantMember" xlink:label="loc_igapSeriesB1WarrantMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB1WarrantMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB2WarrantMember" xlink:label="loc_igapSeriesB2WarrantMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB2WarrantMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_WarrantsIssuedUnderSecuritiesPurchaseAgreementMember" xlink:label="loc_igapWarrantsIssuedUnderSecuritiesPurchaseAgreementMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapWarrantsIssuedUnderSecuritiesPurchaseAgreementMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember" xlink:label="loc_igapWarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapWarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_360" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_EquityIssuancePricePerShare" xlink:label="loc_igapEquityIssuancePricePerShare_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapEquityIssuancePricePerShare_360" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_360" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfSharesOffered" xlink:label="loc_igapNumberOfSharesOffered_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapNumberOfSharesOffered_360" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ProceedsFromUnitsSold" xlink:label="loc_igapProceedsFromUnitsSold_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapProceedsFromUnitsSold_360" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfUnitsSold" xlink:label="loc_igapNumberOfUnitsSold_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapNumberOfUnitsSold_360" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ConvertiblePreferredStockConversionPrice" xlink:label="loc_igapConvertiblePreferredStockConversionPrice_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapConvertiblePreferredStockConversionPrice_360" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion" xlink:label="loc_igapConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion_360" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_360" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightTerm" xlink:label="loc_igapClassOfWarrantOrRightTerm_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapClassOfWarrantOrRightTerm_360" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_360" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:label="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock_360" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_360" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityOtherChanges" xlink:label="loc_us-gaapTemporaryEquityOtherChanges_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapTemporaryEquityOtherChanges_360" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_StockPriceAtWhichStockDividendIsDeclared" xlink:label="loc_igapStockPriceAtWhichStockDividendIsDeclared_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapStockPriceAtWhichStockDividendIsDeclared_360" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsStock" xlink:label="loc_us-gaapDividendsStock_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapDividendsStock_360" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockDividendsShares" xlink:label="loc_us-gaapStockDividendsShares_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapStockDividendsShares_360" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_OfferingCostsIncurred" xlink:label="loc_igapOfferingCostsIncurred_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapOfferingCostsIncurred_360" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_360" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued_360" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapTemporaryEquityStockIssuedDuringPeriodValueNewIssues_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapTemporaryEquityStockIssuedDuringPeriodValueNewIssues_360" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock" xlink:label="loc_igapAmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapAmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock_360" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfWarrantsExchanged" xlink:label="loc_igapNumberOfWarrantsExchanged_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapNumberOfWarrantsExchanged_360" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange" xlink:label="loc_igapNoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapNoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange_360" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpwwdrpd" xlink:title="00000056 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Warrants with down round protection) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesAWarrantMember" xlink:label="loc_igapSeriesAWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesAWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB1WarrantMember" xlink:label="loc_igapSeriesB1WarrantMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB1WarrantMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB2WarrantMember" xlink:label="loc_igapSeriesB2WarrantMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB2WarrantMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightTerm" xlink:label="loc_igapClassOfWarrantOrRightTerm_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_igapClassOfWarrantOrRightTerm_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightNumberOfWarrantsExercisable" xlink:label="loc_igapClassOfWarrantOrRightNumberOfWarrantsExercisable_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_igapClassOfWarrantOrRightNumberOfWarrantsExercisable_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfWarrantsExchanged" xlink:label="loc_igapNumberOfWarrantsExchanged_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_igapNumberOfWarrantsExchanged_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommonStockPreferredStockAndWarrantsWith-downRoundProtectionChangesInFairValueOfLevel3LiabilityDetails" xlink:title="00000057 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Changes in Fair Value of Level 3 Liability) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpsowid" xlink:title="00000058 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Warrant Inputs) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementScenarioAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaapFairValueAssumptionsExpectedTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedTerm_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapFairValueAssumptionsExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExercisePrice_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightFairValue" xlink:label="loc_igapClassOfWarrantOrRightFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_igapClassOfWarrantOrRightFairValue_70" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpgtnd" xlink:title="00000059 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Non-Employees) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:label="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:to="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaapRegistrationPaymentArrangementArrangementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:to="loc_us-gaapRegistrationPaymentArrangementArrangementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandTwelveOfferingMember" xlink:label="loc_igapTwoThousandTwelveOfferingMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandTwelveOfferingMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandTenOfferingMember" xlink:label="loc_igapTwoThousandTenOfferingMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandTenOfferingMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandFourteenOfferingMember" xlink:label="loc_igapTwoThousandFourteenOfferingMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandFourteenOfferingMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceAxis" xlink:label="loc_igapClassOfWarrantOrRightExercisePriceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="loc_igapClassOfWarrantOrRightExercisePriceAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceDomain" xlink:label="loc_igapClassOfWarrantOrRightExercisePriceDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_igapClassOfWarrantOrRightExercisePriceAxis" xlink:to="loc_igapClassOfWarrantOrRightExercisePriceDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceDomain" xlink:label="loc_igapClassOfWarrantOrRightExercisePriceDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_igapClassOfWarrantOrRightExercisePriceAxis" xlink:to="loc_igapClassOfWarrantOrRightExercisePriceDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceOneMember" xlink:label="loc_igapClassOfWarrantOrRightExercisePriceOneMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_igapClassOfWarrantOrRightExercisePriceDomain" xlink:to="loc_igapClassOfWarrantOrRightExercisePriceOneMember_130" xlink:type="arc" order="133" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceTwoMember" xlink:label="loc_igapClassOfWarrantOrRightExercisePriceTwoMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_igapClassOfWarrantOrRightExercisePriceDomain" xlink:to="loc_igapClassOfWarrantOrRightExercisePriceTwoMember_150" xlink:type="arc" order="153" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceThreeMember" xlink:label="loc_igapClassOfWarrantOrRightExercisePriceThreeMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_igapClassOfWarrantOrRightExercisePriceDomain" xlink:to="loc_igapClassOfWarrantOrRightExercisePriceThreeMember_170" xlink:type="arc" order="173" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceFourMember" xlink:label="loc_igapClassOfWarrantOrRightExercisePriceFourMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_igapClassOfWarrantOrRightExercisePriceDomain" xlink:to="loc_igapClassOfWarrantOrRightExercisePriceFourMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceFiveMember" xlink:label="loc_igapClassOfWarrantOrRightExercisePriceFiveMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_igapClassOfWarrantOrRightExercisePriceDomain" xlink:to="loc_igapClassOfWarrantOrRightExercisePriceFiveMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_310" xlink:type="arc" order="312" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_320" xlink:type="arc" order="322" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_WarrantsIssuedToPlacementAgentTrancheOneMember" xlink:label="loc_igapWarrantsIssuedToPlacementAgentTrancheOneMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapWarrantsIssuedToPlacementAgentTrancheOneMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_WarrantsIssuedToPlacementAgentTrancheTwoMember" xlink:label="loc_igapWarrantsIssuedToPlacementAgentTrancheTwoMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapWarrantsIssuedToPlacementAgentTrancheTwoMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegulatoryServicesMember" xlink:label="loc_igapRegulatoryServicesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="loc_igapRegulatoryServicesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_InvestorFindersMember" xlink:label="loc_igapInvestorFindersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="loc_igapInvestorFindersMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PlacementAgentMember" xlink:label="loc_igapPlacementAgentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="loc_igapPlacementAgentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_InvestorRelationsServicesProviderMember" xlink:label="loc_igapInvestorRelationsServicesProviderMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="loc_igapInvestorRelationsServicesProviderMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_GrantDate1Member" xlink:label="loc_igapGrantDate1Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_igapGrantDate1Member_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_GrantDate2Member" xlink:label="loc_igapGrantDate2Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_igapGrantDate2Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued_410" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_410" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_410" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_410" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExercisePrice_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualExercisePrice_410" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_410" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_410" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightTerm" xlink:label="loc_igapClassOfWarrantOrRightTerm_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_igapClassOfWarrantOrRightTerm_410" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_410" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_410" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_410" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_410" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_410" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_410" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapSharePrice_410" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities" xlink:label="loc_igapAdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_igapAdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities_410" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightPostAdjustmentFairValue" xlink:label="loc_igapClassOfWarrantOrRightPostAdjustmentFairValue_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_igapClassOfWarrantOrRightPostAdjustmentFairValue_410" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightPreAdjustmentFairValue" xlink:label="loc_igapClassOfWarrantOrRightPreAdjustmentFairValue_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_igapClassOfWarrantOrRightPreAdjustmentFairValue_410" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantRightExpenseOrRevenueRecognized" xlink:label="loc_igapClassOfWarrantRightExpenseOrRevenueRecognized_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_igapClassOfWarrantRightExpenseOrRevenueRecognized_410" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpgtend" xlink:title="00000060 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Employees Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_IntegrityIsraelPlanMember" xlink:label="loc_igapIntegrityIsraelPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_igapIntegrityIsraelPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ShareIncentivePlanMember" xlink:label="loc_igapShareIncentivePlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_igapShareIncentivePlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaapChiefExecutiveOfficerMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapChiefExecutiveOfficerMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExecutiveVicePresidentMember" xlink:label="loc_us-gaapExecutiveVicePresidentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapExecutiveVicePresidentMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_GrantsToMessrsGalAndMalkaMember" xlink:label="loc_igapGrantsToMessrsGalAndMalkaMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_igapGrantsToMessrsGalAndMalkaMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExercisePrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualExercisePrice_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne" xlink:label="loc_igapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_igapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo" xlink:label="loc_igapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_igapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo_140" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpsosogted" xlink:title="00000061 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Status of Grants to Employees) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpsoiaood" xlink:title="00000062 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Information about Options Outstanding) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeOneMember" xlink:label="loc_igapRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_igapRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeTwoMember" xlink:label="loc_igapRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_igapRangeTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeThreeMember" xlink:label="loc_igapRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_igapRangeThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeFourMember" xlink:label="loc_igapRangeFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_igapRangeFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeFiveMember" xlink:label="loc_igapRangeFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_igapRangeFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_120" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpsoautvod" xlink:title="00000063 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Assumptions Used to Value Options) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_110" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_110" xlink:to="loc_us-gaapSharePrice_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpcsapsd" xlink:title="00000064 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Convertible Series A Preferred Stock) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaapTemporaryEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaapTemporaryEquityByClassOfStockTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaapConversionOfStockNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" xlink:to="loc_us-gaapConversionOfStockNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaapConversionOfStockNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" xlink:to="loc_us-gaapConversionOfStockNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ConversionOfPreferredStockIntoCommonStockMember" xlink:label="loc_igapConversionOfPreferredStockIntoCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConversionOfStockNameDomain" xlink:to="loc_igapConversionOfPreferredStockIntoCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityOtherChanges" xlink:label="loc_us-gaapTemporaryEquityOtherChanges_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapTemporaryEquityOtherChanges_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-raded" xlink:title="00000065 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLaborAndRelatedExpense_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfessionalFees_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTravelAndEntertainmentExpense_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:label="loc_us-gaapCostOfPropertyRepairsAndMaintenance_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfPropertyRepairsAndMaintenance_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherGeneralExpense_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-smagaaed" xlink:title="00000066 - Disclosure - SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-fiend" xlink:title="00000067 - Disclosure - FINANCING (INCOME) EXPENSES, NET (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-itdtd" xlink:title="00000068 - Disclosure - INCOME TAX (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="loc_us-gaapParentCompanyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_us-gaapParentCompanyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AdIntegrityApplicationsLtdMember" xlink:label="loc_igapAdIntegrityApplicationsLtdMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_igapAdIntegrityApplicationsLtdMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-itrostrteitrd" xlink:title="00000069 - Disclosure - INCOME TAX (Reconciliation of Statutory Tax Rate to the Effective Income Tax Rate) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/IncomeTaxDeferredTaxesDetails" xlink:title="00000070 - Disclosure - INCOME TAX (Deferred Taxes) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ilpsd1" xlink:title="00000071 - Disclosure - INCOME (LOSS) PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="loc_us-gaapOtherPreferredStockDividendsAndAdjustments_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherPreferredStockDividendsAndAdjustments_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaapUndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_100" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_100" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_100" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sirbotcld" xlink:title="00000072 - Disclosure - SEGMENT INFORMATION (Revenues based on the customer's location) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaapStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_us-gaapStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaapSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementGeographicalAxis" xlink:to="loc_us-gaapSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaapSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementGeographicalAxis" xlink:to="loc_us-gaapSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaapEuropeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_us-gaapEuropeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AsiaPacificMember" xlink:label="loc_us-gaapAsiaPacificMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_us-gaapAsiaPacificMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapRevenues_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_100" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/RelatedPartiesDetails" xlink:title="00000073 - Disclosure - RELATED PARTIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AvnerGalMember" xlink:label="loc_igapAvnerGalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_igapAvnerGalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_DavidMalkaMember" xlink:label="loc_igapDavidMalkaMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_igapDavidMalkaMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaapCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RelatedPartyTransactionOwnershipInterestInEntity" xlink:label="loc_igapRelatedPartyTransactionOwnershipInterestInEntity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_igapRelatedPartyTransactionOwnershipInterestInEntity_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PortionOfRelatedPartySalaryRelatingToBonusesPaid" xlink:label="loc_igapPortionOfRelatedPartySalaryRelatingToBonusesPaid_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_igapPortionOfRelatedPartySalaryRelatingToBonusesPaid_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SubsequentEventsDetails" xlink:title="00000074 - Disclosure - SUBSEQUENT EVENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ShareIncentivePlanMember" xlink:label="loc_igapShareIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_igapShareIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_DirectorsMember" xlink:label="loc_igapDirectorsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_igapDirectorsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors" xlink:label="loc_igapAmountOfAnnualCashPaymentOwedToEachBoardOfDirectors_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_igapAmountOfAnnualCashPaymentOwedToEachBoardOfDirectors_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountOfQuarterlyCompensationOwedToEachDirector" xlink:label="loc_igapAmountOfQuarterlyCompensationOwedToEachDirector_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_igapAmountOfQuarterlyCompensationOwedToEachDirector_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AnnualCompensationOwedToChairperson" xlink:label="loc_igapAnnualCompensationOwedToChairperson_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_igapAnnualCompensationOwedToChairperson_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountOfQuarterlyCompensationOwedChairperson" xlink:label="loc_igapAmountOfQuarterlyCompensationOwedChairperson_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_igapAmountOfQuarterlyCompensationOwedChairperson_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant" xlink:label="loc_igapTotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_igapTotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ExercisePriceOfOptionsGranted" xlink:label="loc_igapExercisePriceOfOptionsGranted_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_igapExercisePriceOfOptionsGranted_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfSharesVestingInEachIncrement" xlink:label="loc_igapNumberOfSharesVestingInEachIncrement_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_igapNumberOfSharesVestingInEachIncrement_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_30" xlink:type="arc" order="7" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>igap-20151231_lab.xml
<DESCRIPTION>TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: Integrity Applications, Inc. 12%2D31%2D15 10K Final To Use To File.xfr; Date: 2016%2D03%2D30T13:08:15Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80460001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid in capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated other comprehensive income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ConversionOfPreferredStockIntoCommonStockMember" xlink:label="igap_ConversionOfPreferredStockIntoCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ConversionOfPreferredStockIntoCommonStockMember" xlink:to="igap_ConversionOfPreferredStockIntoCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ConversionOfPreferredStockIntoCommonStockMember_lbl" xml:lang="en-US">Conversion of Preferred Stock Into Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB1AndSeriesB2WarrantsMember" xlink:label="igap_SeriesB1AndSeriesB2WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_SeriesB1AndSeriesB2WarrantsMember" xlink:to="igap_SeriesB1AndSeriesB2WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_SeriesB1AndSeriesB2WarrantsMember_lbl" xml:lang="en-US">Series B1 and Series B2 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB1WarrantMember" xlink:label="igap_SeriesB1WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_SeriesB1WarrantMember" xlink:to="igap_SeriesB1WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_SeriesB1WarrantMember_lbl" xml:lang="en-US">Series B-1 Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB2WarrantMember" xlink:label="igap_SeriesB2WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_SeriesB2WarrantMember" xlink:to="igap_SeriesB2WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_SeriesB2WarrantMember_lbl" xml:lang="en-US">Series B-2 Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US">Scenario, Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PurchasersOfPreviouslyIssuedCommonStockMember" xlink:label="igap_PurchasersOfPreviouslyIssuedCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PurchasersOfPreviouslyIssuedCommonStockMember" xlink:to="igap_PurchasersOfPreviouslyIssuedCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PurchasersOfPreviouslyIssuedCommonStockMember_lbl" xml:lang="en-US">Purchasers of Previously Issued Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Furniture and Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandFourteenOfferingMember" xlink:label="igap_TwoThousandFourteenOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_TwoThousandFourteenOfferingMember" xlink:to="igap_TwoThousandFourteenOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_TwoThousandFourteenOfferingMember_lbl" xml:lang="en-US">2014 Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="us-gaap_RegistrationPaymentArrangementByArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis_lbl" xml:lang="en-US">Registration Payment Arrangement by Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AgreementWithPlacementAgentMember" xlink:label="igap_AgreementWithPlacementAgentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AgreementWithPlacementAgentMember" xlink:to="igap_AgreementWithPlacementAgentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_AgreementWithPlacementAgentMember_lbl" xml:lang="en-US">Agreement with Placement Agent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ArbitrationProceedingsWithShareholderMember" xlink:label="igap_ArbitrationProceedingsWithShareholderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ArbitrationProceedingsWithShareholderMember" xlink:to="igap_ArbitrationProceedingsWithShareholderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ArbitrationProceedingsWithShareholderMember_lbl" xml:lang="en-US">Arbitration Proceedings with Shareholder [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PaymentOfRoyaltiesToOcsMember" xlink:label="igap_PaymentOfRoyaltiesToOcsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PaymentOfRoyaltiesToOcsMember" xlink:to="igap_PaymentOfRoyaltiesToOcsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PaymentOfRoyaltiesToOcsMember_lbl" xml:lang="en-US">Payment of Royalties to OCS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegistrationPaymentCommissionRateMember" xlink:label="igap_RegistrationPaymentCommissionRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RegistrationPaymentCommissionRateMember" xlink:to="igap_RegistrationPaymentCommissionRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RegistrationPaymentCommissionRateMember_lbl" xml:lang="en-US">Registration Payment Commission Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegistrationPaymentArrangementManagementFeeMember" xlink:label="igap_RegistrationPaymentArrangementManagementFeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RegistrationPaymentArrangementManagementFeeMember" xlink:to="igap_RegistrationPaymentArrangementManagementFeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RegistrationPaymentArrangementManagementFeeMember_lbl" xml:lang="en-US">Registration Payment Arrangement Management Fee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegistrationPaymentArrangementExpenseAllowanceMember" xlink:label="igap_RegistrationPaymentArrangementExpenseAllowanceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RegistrationPaymentArrangementExpenseAllowanceMember" xlink:to="igap_RegistrationPaymentArrangementExpenseAllowanceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RegistrationPaymentArrangementExpenseAllowanceMember_lbl" xml:lang="en-US">Registration Payment Arrangement Expense Allowance [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_DecemberOfferingMember" xlink:label="igap_DecemberOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_DecemberOfferingMember" xlink:to="igap_DecemberOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_DecemberOfferingMember_lbl" xml:lang="en-US">2010 December Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandTwelveOfferingMember" xlink:label="igap_TwoThousandTwelveOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_TwoThousandTwelveOfferingMember" xlink:to="igap_TwoThousandTwelveOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_TwoThousandTwelveOfferingMember_lbl" xml:lang="en-US">2012 Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesAWarrantMember" xlink:label="igap_SeriesAWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_SeriesAWarrantMember" xlink:to="igap_SeriesAWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_SeriesAWarrantMember_lbl" xml:lang="en-US">Series A Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ConsultantsMember" xlink:label="igap_ConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ConsultantsMember" xlink:to="igap_ConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ConsultantsMember_lbl" xml:lang="en-US">Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xml:lang="en-US">Supplier [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_InvestorFindersMember" xlink:label="igap_InvestorFindersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_InvestorFindersMember" xlink:to="igap_InvestorFindersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_InvestorFindersMember_lbl" xml:lang="en-US">Investor Finders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_GrantDate1Member" xlink:label="igap_GrantDate1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_GrantDate1Member" xlink:to="igap_GrantDate1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_GrantDate1Member_lbl" xml:lang="en-US">Grant Date 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_GrantDate2Member" xlink:label="igap_GrantDate2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_GrantDate2Member" xlink:to="igap_GrantDate2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_GrantDate2Member_lbl" xml:lang="en-US">Grant Date 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PlacementAgentMember" xlink:label="igap_PlacementAgentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PlacementAgentMember" xlink:to="igap_PlacementAgentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PlacementAgentMember_lbl" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceOneMember" xlink:label="igap_ClassOfWarrantOrRightExercisePriceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightExercisePriceOneMember" xlink:to="igap_ClassOfWarrantOrRightExercisePriceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ClassOfWarrantOrRightExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price $5.80 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceAxis" xlink:label="igap_ClassOfWarrantOrRightExercisePriceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightExercisePriceAxis" xlink:to="igap_ClassOfWarrantOrRightExercisePriceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ClassOfWarrantOrRightExercisePriceAxis_lbl" xml:lang="en-US">Class of Warrant or Right Exercise Price [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceTwoMember" xlink:label="igap_ClassOfWarrantOrRightExercisePriceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightExercisePriceTwoMember" xlink:to="igap_ClassOfWarrantOrRightExercisePriceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ClassOfWarrantOrRightExercisePriceTwoMember_lbl" xml:lang="en-US">Exercies Price $6.96 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceThreeMember" xlink:label="igap_ClassOfWarrantOrRightExercisePriceThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightExercisePriceThreeMember" xlink:to="igap_ClassOfWarrantOrRightExercisePriceThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ClassOfWarrantOrRightExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price $7.00 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_WarrantsIssuedToPlacementAgentTrancheOneMember" xlink:label="igap_WarrantsIssuedToPlacementAgentTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_WarrantsIssuedToPlacementAgentTrancheOneMember" xlink:to="igap_WarrantsIssuedToPlacementAgentTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_WarrantsIssuedToPlacementAgentTrancheOneMember_lbl" xml:lang="en-US">Warrants Issued to Placement Agent, Tranche One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceFourMember" xlink:label="igap_ClassOfWarrantOrRightExercisePriceFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightExercisePriceFourMember" xlink:to="igap_ClassOfWarrantOrRightExercisePriceFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="igap_ClassOfWarrantOrRightExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price $5.80 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceFiveMember" xlink:label="igap_ClassOfWarrantOrRightExercisePriceFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightExercisePriceFiveMember" xlink:to="igap_ClassOfWarrantOrRightExercisePriceFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ClassOfWarrantOrRightExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price $10.00 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_InvestorRelationsServicesProviderMember" xlink:label="igap_InvestorRelationsServicesProviderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_InvestorRelationsServicesProviderMember" xlink:to="igap_InvestorRelationsServicesProviderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_InvestorRelationsServicesProviderMember_lbl" xml:lang="en-US">Investor Relations Services Provider [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_IntegrityIsraelPlanMember" xlink:label="igap_IntegrityIsraelPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_IntegrityIsraelPlanMember" xlink:to="igap_IntegrityIsraelPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_IntegrityIsraelPlanMember_lbl" xml:lang="en-US">Integrity Israel Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ShareIncentivePlanMember" xlink:label="igap_ShareIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ShareIncentivePlanMember" xlink:to="igap_ShareIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ShareIncentivePlanMember_lbl" xml:lang="en-US">2010 Share Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Options Issued to Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChiefExecutiveOfficerMember" xlink:to="us-gaap_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExecutiveVicePresidentMember" xlink:label="us-gaap_ExecutiveVicePresidentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExecutiveVicePresidentMember" xlink:to="us-gaap_ExecutiveVicePresidentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExecutiveVicePresidentMember_lbl" xml:lang="en-US">Executive Vice President [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_GrantsToMessrsGalAndMalkaMember" xlink:label="igap_GrantsToMessrsGalAndMalkaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_GrantsToMessrsGalAndMalkaMember" xlink:to="igap_GrantsToMessrsGalAndMalkaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_GrantsToMessrsGalAndMalkaMember_lbl" xml:lang="en-US">Grants To Messrs Gal And Malka [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeOneMember" xlink:label="igap_RangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RangeOneMember" xlink:to="igap_RangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RangeOneMember_lbl" xml:lang="en-US">$1.72 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeTwoMember" xlink:label="igap_RangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RangeTwoMember" xlink:to="igap_RangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RangeTwoMember_lbl" xml:lang="en-US">$3.63 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeThreeMember" xlink:label="igap_RangeThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RangeThreeMember" xlink:to="igap_RangeThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RangeThreeMember_lbl" xml:lang="en-US">$6.01 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeFourMember" xlink:label="igap_RangeFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RangeFourMember" xlink:to="igap_RangeFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RangeFourMember_lbl" xml:lang="en-US">$6.25 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeFiveMember" xlink:label="igap_RangeFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RangeFiveMember" xlink:to="igap_RangeFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RangeFiveMember_lbl" xml:lang="en-US">$7.00 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeSixMember" xlink:label="igap_RangeSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RangeSixMember" xlink:to="igap_RangeSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RangeSixMember_lbl" xml:lang="en-US">Range Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeSevenMember" xlink:label="igap_RangeSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RangeSevenMember" xlink:to="igap_RangeSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RangeSevenMember_lbl" xml:lang="en-US">Range Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_WarrantsIssuedToPlacementAgentTrancheTwoMember" xlink:label="igap_WarrantsIssuedToPlacementAgentTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_WarrantsIssuedToPlacementAgentTrancheTwoMember" xlink:to="igap_WarrantsIssuedToPlacementAgentTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_WarrantsIssuedToPlacementAgentTrancheTwoMember_lbl" xml:lang="en-US">Warrants Issued to Placement Agent, Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_WarrantsIssuedUnderSecuritiesPurchaseAgreementMember" xlink:label="igap_WarrantsIssuedUnderSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_WarrantsIssuedUnderSecuritiesPurchaseAgreementMember" xlink:to="igap_WarrantsIssuedUnderSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_WarrantsIssuedUnderSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Warrants Issued under Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember" xlink:label="igap_WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember" xlink:to="igap_WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Warrants Issued under Second Closing of Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="us-gaap_ParentCompanyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentCompanyMember" xlink:to="us-gaap_ParentCompanyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentCompanyMember_lbl" xml:lang="en-US">Parent Company [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AdIntegrityApplicationsLtdMember" xlink:label="igap_AdIntegrityApplicationsLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AdIntegrityApplicationsLtdMember" xlink:to="igap_AdIntegrityApplicationsLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_AdIntegrityApplicationsLtdMember_lbl" xml:lang="en-US">Ad Integrity Applications Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EuropeMember" xlink:label="us-gaap_EuropeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EuropeMember" xlink:to="us-gaap_EuropeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EuropeMember_lbl" xml:lang="en-US">Europe [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AsiaPacificMember" xlink:label="us-gaap_AsiaPacificMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AsiaPacificMember" xlink:to="us-gaap_AsiaPacificMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AsiaPacificMember_lbl" xml:lang="en-US">Asia and Pacific [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AvnerGalMember" xlink:label="igap_AvnerGalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AvnerGalMember" xlink:to="igap_AvnerGalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_AvnerGalMember_lbl" xml:lang="en-US">Avner Gal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_DavidMalkaMember" xlink:label="igap_DavidMalkaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_DavidMalkaMember" xlink:to="igap_DavidMalkaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_DavidMalkaMember_lbl" xml:lang="en-US">David Malka [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_ILS" xlink:label="currency_ILS" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_ILS_lbl" xml:lang="en-US">ILS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrencyAxis" xlink:to="us-gaap_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandFourteenOfferingsMember" xlink:label="igap_TwoThousandFourteenOfferingsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_TwoThousandFourteenOfferingsMember" xlink:to="igap_TwoThousandFourteenOfferingsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="igap_TwoThousandFourteenOfferingsMember_lbl" xml:lang="en-US">2014 Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegulatoryServicesMember" xlink:label="igap_RegulatoryServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RegulatoryServicesMember" xlink:to="igap_RegulatoryServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RegulatoryServicesMember_lbl" xml:lang="en-US">Regulatory Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandTenOfferingMember" xlink:label="igap_TwoThousandTenOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_TwoThousandTenOfferingMember" xlink:to="igap_TwoThousandTenOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_TwoThousandTenOfferingMember_lbl" xml:lang="en-US">2010 Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_JudicialRulingMember" xlink:label="us-gaap_JudicialRulingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_JudicialRulingMember" xlink:to="us-gaap_JudicialRulingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_JudicialRulingMember_lbl" xml:lang="en-US">Arbitration Ruling [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusAxis_lbl" xml:lang="en-US">Litigation Status [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PropertyAshkelonIsraelMember" xlink:label="igap_PropertyAshkelonIsraelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PropertyAshkelonIsraelMember" xlink:to="igap_PropertyAshkelonIsraelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PropertyAshkelonIsraelMember_lbl" xml:lang="en-US">Property Ashkelon, Israel [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PropertyAshdodIsraelMember" xlink:label="igap_PropertyAshdodIsraelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PropertyAshdodIsraelMember" xlink:to="igap_PropertyAshdodIsraelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PropertyAshdodIsraelMember_lbl" xml:lang="en-US">Property Ashdod, Israel [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_DirectorsMember" xlink:label="igap_DirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_DirectorsMember" xlink:to="igap_DirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_DirectorsMember_lbl" xml:lang="en-US">Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_DocumentAndEntityInformationAbstract" xlink:label="igap_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_DocumentAndEntityInformationAbstract" xlink:to="igap_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">A S S E T S</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories (Note 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets (Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and Equipment, Net (Note 5)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl" xml:lang="en-US">Long-Term Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_FundsInRespectOfEmployeeRightsUponRetirementNoncurrent" xlink:label="igap_FundsInRespectOfEmployeeRightsUponRetirementNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_FundsInRespectOfEmployeeRightsUponRetirementNoncurrent" xlink:to="igap_FundsInRespectOfEmployeeRightsUponRetirementNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_FundsInRespectOfEmployeeRightsUponRetirementNoncurrent_lbl" xml:lang="en-US">Funds in Respect of Employee Rights Upon Retirement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS' DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities (Note 6)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOfficersOrStockholdersCurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent_lbl" xml:lang="en-US">Long-Term Loans from Stockholders, current portion (Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long-Term Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOfficersOrStockholdersNoncurrent_lbl" xml:lang="en-US">Long-Term Loans from Stockholders (Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="us-gaap_PostemploymentBenefitsLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:to="us-gaap_PostemploymentBenefitsLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PostemploymentBenefitsLiabilityNoncurrent_lbl" xml:lang="en-US">Liability for Employee Rights Upon Retirement (Note 2J)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants with Down-Round Protection (Note 10D)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingent Liabilities (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US">Temporary Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount_lbl" xml:lang="en-US">Convertible Preferred Stock of $ 0.001 par value ("Preferred Stock")</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock of $ 0.001 par value ("Common Stock"): 40,000,000 shares authorized as of December 31, 2015 and December 31, 2014; issued and outstanding 5,690,097 shares and 5,323,058 shares as of December 31, 2015 and December 31, 2014, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities, temporary equity and stockholders' deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US">Temporary Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Convertible Preferred Stock, par value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Convertible Preferred Stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Convertible Preferred Stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Convertible Preferred Stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, par value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses (Note 11)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, marketing and general and administrative expenses (Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_FinancingIncomeExpensesNet" xlink:label="igap_FinancingIncomeExpensesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_FinancingIncomeExpensesNet" xlink:to="igap_FinancingIncomeExpensesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_FinancingIncomeExpensesNet_lbl" xml:lang="en-US">Financing (income) expenses, net (Note 13)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Income (loss) for the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss):</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive income (loss) for the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Income (loss) per share (Basic) (Note 15)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Income (loss) per share (Diluted) (Note 15)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Common shares used in computing Basic income (loss) per share (Note 15)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Common shares used in computing Diluted income (loss) per share (Note 15)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Income (loss) for the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="us-gaap_StockholdersEquityOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityOther" xlink:to="us-gaap_StockholdersEquityOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityOther_lbl" xml:lang="en-US">Amount classified out of stockholders equity and presented as liability and temporary equity with respect to Common Stock replaced with units comprised of convertible Preferred Stock and warrants with down-round protection</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityOtherShares" xlink:label="us-gaap_StockholdersEquityOtherShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityOtherShares" xlink:to="us-gaap_StockholdersEquityOtherShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityOtherShares_lbl" xml:lang="en-US">Amount classified out of stockholders equity and presented as liability and temporary equity with respect to Common Stock replaced with units comprised of convertible Preferred Stock and warrants with down-round protection, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued" xlink:label="igap_AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued" xlink:to="igap_AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued_lbl" xml:lang="en-US">Amounts allocated to Series B-1 and Series B-2 Warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities" xlink:label="igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities" xlink:to="igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities_lbl" xml:lang="en-US">Amount classified out of stockholders deficit and presented as Warrants with Down-Round Protection within long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" xlink:label="igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" xlink:to="igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock_lbl" xml:lang="en-US">Conversion of Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" xlink:label="igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" xlink:to="igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock_lbl" xml:lang="en-US">Conversion of Preferred Stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrants issued as consideration for placement services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsStock" xlink:label="us-gaap_DividendsStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsStock" xlink:to="us-gaap_DividendsStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsStock_lbl" xml:lang="en-US">Stock dividend to certain Common Stock holders</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_StockIssuedDuringPeriodSharesStockDividend" xlink:label="igap_StockIssuedDuringPeriodSharesStockDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_StockIssuedDuringPeriodSharesStockDividend" xlink:to="igap_StockIssuedDuringPeriodSharesStockDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="igap_StockIssuedDuringPeriodSharesStockDividend_lbl" xml:lang="en-US">Stock dividend to certain Common Stock holders, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US">Stock dividend on Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="us-gaap_PreferredStockDividendsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsShares" xlink:to="us-gaap_PreferredStockDividendsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsShares_lbl" xml:lang="en-US">Stock dividend on Series B Preferred Stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Dividend on convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of employees' stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Exercise of employees' stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile income (loss) for the year to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPostemploymentObligations" xlink:label="us-gaap_IncreaseDecreaseInPostemploymentObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPostemploymentObligations" xlink:to="us-gaap_IncreaseDecreaseInPostemploymentObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPostemploymentObligations_lbl" xml:lang="en-US">Decrease in liability for employee rights upon retirement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Issuance costs allocated to warrants with down-round protection</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in the fair value of warrants issued with down-round protection</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:label="igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:to="igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders_lbl" xml:lang="en-US">Linkage difference on principal of loans from stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_GainLossOnUnitConversion" xlink:label="igap_GainLossOnUnitConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_GainLossOnUnitConversion" xlink:to="igap_GainLossOnUnitConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="igap_GainLossOnUnitConversion_lbl" xml:lang="en-US">Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease (increase) in accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase in inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Increase in other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Increase (decrease) in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Increase (decrease) in other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investment activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement" xlink:label="igap_IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement" xlink:to="igap_IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Increase in funds in respect of employee rights upon retirement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Increase in long-term restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in investment activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfShortTermDebt_lbl" xml:lang="en-US">Repayment of credit from banking institutions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Cash dividend on Series A Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds allocated to convertible Preferred Stock, net of cash issuance expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds allocated to warrants, net of cash issuance expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of employees' stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment of loan from stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="us-gaap_ConversionOfStockTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockTable" xlink:to="us-gaap_ConversionOfStockTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockTable_lbl" xml:lang="en-US">Conversion of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="us-gaap_ConversionOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_ConversionOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockLineItems_lbl" xml:lang="en-US">Conversion of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Number of preferred shares converted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Stock issued upon conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Amount of stock converted</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock" xlink:label="igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock" xlink:to="igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock_lbl" xml:lang="en-US">Number of Series A Preferred Stock shares exchanged for Series B Preferred Stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfWarrantsExchanged" xlink:label="igap_NumberOfWarrantsExchanged" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_NumberOfWarrantsExchanged" xlink:to="igap_NumberOfWarrantsExchanged_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_NumberOfWarrantsExchanged_lbl" xml:lang="en-US">Number of warrants exchanged</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants" xlink:label="igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants" xlink:to="igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants_lbl" xml:lang="en-US">Increase (decrease) in equity due to exchange of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange" xlink:label="igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange" xlink:to="igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange_lbl" xml:lang="en-US">Non-cash charge recorded to finance expense as result of warrant exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsCommonStockStock" xlink:label="us-gaap_DividendsCommonStockStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockStock" xlink:to="us-gaap_DividendsCommonStockStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStockStock_lbl" xml:lang="en-US">Stock dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">GENERAL</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_OtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="igap_OtherCurrentLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_OtherCurrentLiabilitiesDisclosureTextBlock" xlink:to="igap_OtherCurrentLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_OtherCurrentLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="us-gaap_LineOfCreditFacilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAbstract_lbl" xml:lang="en-US">Line of Credit Facility [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">LINE OF CREDIT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">LONG-TERM LOANS FROM STOCKHOLDERS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_2_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" xlink:label="igap_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" xlink:to="igap_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">Selling, General and Administrative Expense [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SellingGeneralAndAdministrativeExpenseTextBlock" xlink:label="igap_SellingGeneralAndAdministrativeExpenseTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_SellingGeneralAndAdministrativeExpenseTextBlock" xlink:to="igap_SellingGeneralAndAdministrativeExpenseTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_SellingGeneralAndAdministrativeExpenseTextBlock_lbl" xml:lang="en-US">SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_FinancingExpensesNetDisclosureTextBlock" xlink:label="igap_FinancingExpensesNetDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_FinancingExpensesNetDisclosureTextBlock" xlink:to="igap_FinancingExpensesNetDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_FinancingExpensesNetDisclosureTextBlock_lbl" xml:lang="en-US">FINANCING (INCOME) EXPENSES, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAX</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">INCOME (LOSS) PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates in the preparation of financial statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional currency</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Long-term restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:label="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:to="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_lbl" xml:lang="en-US">Liability for employee rights upon retirement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionServicesRoyaltyFees" xlink:label="us-gaap_RevenueRecognitionServicesRoyaltyFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionServicesRoyaltyFees" xlink:to="us-gaap_RevenueRecognitionServicesRoyaltyFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionServicesRoyaltyFees_lbl" xml:lang="en-US">Royalty-bearing grants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="us-gaap_StandardProductWarrantyPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StandardProductWarrantyPolicy" xlink:to="us-gaap_StandardProductWarrantyPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StandardProductWarrantyPolicy_lbl" xml:lang="en-US">Warranty</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and diluted income (loss) per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Other comprehensive income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair value of financial instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of credit risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TemporaryEquityPolicyPolicyTextBlock" xlink:label="igap_TemporaryEquityPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_TemporaryEquityPolicyPolicyTextBlock" xlink:to="igap_TemporaryEquityPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_TemporaryEquityPolicyPolicyTextBlock_lbl" xml:lang="en-US">Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Series A Warrants with Down-Round Protection</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" xlink:label="us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" xlink:to="us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_lbl" xml:lang="en-US">Schedule of Official Exchange Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ScheduleOfPropertyRatesOfDepreciationTableTextBlock" xlink:label="igap_ScheduleOfPropertyRatesOfDepreciationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ScheduleOfPropertyRatesOfDepreciationTableTextBlock" xlink:to="igap_ScheduleOfPropertyRatesOfDepreciationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ScheduleOfPropertyRatesOfDepreciationTableTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment, Rates of Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Fair Value of Level 3 Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:to="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions Used</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Grants Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Stock Grants, by Exercise Price Range</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumptions Used to Value Options</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xlink:label="igap_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xlink:to="igap_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SellingGeneralAndAdministrativeExpenseTableTextBlock" xlink:label="igap_SellingGeneralAndAdministrativeExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_SellingGeneralAndAdministrativeExpenseTableTextBlock" xlink:to="igap_SellingGeneralAndAdministrativeExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_SellingGeneralAndAdministrativeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of selling, marketing and general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Financing (Income) Expenses, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Reconciliation of Statutory Tax Rate to the Effective Income Tax Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Loss and Weighted Average Number of Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xml:lang="en-US">Summary of operations within geographic areas</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="igap_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:to="igap_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from issuance of Common Stock, net of issuance expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:label="us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:to="us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock_lbl" xml:lang="en-US">Proceeds from convertible preferred stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Par value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockConversionPrice" xlink:label="igap_PreferredStockConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockConversionPrice" xlink:to="igap_PreferredStockConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PreferredStockConversionPrice_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightTerm" xlink:label="igap_ClassOfWarrantOrRightTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightTerm" xlink:to="igap_ClassOfWarrantOrRightTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ClassOfWarrantOrRightTerm_lbl" xml:lang="en-US">Warrants term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock issued, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion" xlink:label="igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion" xlink:to="igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion_lbl" xml:lang="en-US">Shares convertible into</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of shares covered by warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionAbstract" xlink:label="us-gaap_ForeignCurrencyTransactionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionAbstract_lbl" xml:lang="en-US">Functional currency</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AverageForeignCurrencyExchangeRateTranslation" xlink:label="igap_AverageForeignCurrencyExchangeRateTranslation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AverageForeignCurrencyExchangeRateTranslation" xlink:to="igap_AverageForeignCurrencyExchangeRateTranslation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_AverageForeignCurrencyExchangeRateTranslation_lbl" xml:lang="en-US">Official exchange rate of NIS 1 to US dollar</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PropertyPlantAndEquipmentDepreciationRate" xlink:label="igap_PropertyPlantAndEquipmentDepreciationRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PropertyPlantAndEquipmentDepreciationRate" xlink:to="igap_PropertyPlantAndEquipmentDepreciationRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PropertyPlantAndEquipmentDepreciationRate_lbl" xml:lang="en-US">%</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="us-gaap_PostemploymentBenefitsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_PostemploymentBenefitsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PostemploymentBenefitsAbstract_lbl" xml:lang="en-US">Liability for employee rights upon retirement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" xml:lang="en-US">Severance expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_2_lbl" xml:lang="en-US">Royalty-bearing grants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US">Research and development grants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished products</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidTaxes_lbl" xml:lang="en-US">Government Institution</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsCurrent_2_lbl" xml:lang="en-US">Total other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less - accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employees and related institutions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Amount of unutilized credit line</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PercentOfFutureSalesDesignatedToRepayStockholdersLoans" xlink:label="igap_PercentOfFutureSalesDesignatedToRepayStockholdersLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PercentOfFutureSalesDesignatedToRepayStockholdersLoans" xlink:to="igap_PercentOfFutureSalesDesignatedToRepayStockholdersLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PercentOfFutureSalesDesignatedToRepayStockholdersLoans_lbl" xml:lang="en-US">Percent of future sales to be transferred to lenders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US">Other Commitments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Other Commitments [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyRangeOfPossibleLossMaximum" xlink:label="us-gaap_LossContingencyRangeOfPossibleLossMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyRangeOfPossibleLossMaximum" xlink:to="us-gaap_LossContingencyRangeOfPossibleLossMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyRangeOfPossibleLossMaximum_lbl" xml:lang="en-US">Maximum royalties payable</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RoyaltyPercentMinimum" xlink:label="igap_RoyaltyPercentMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RoyaltyPercentMinimum" xlink:to="igap_RoyaltyPercentMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RoyaltyPercentMinimum_lbl" xml:lang="en-US">Royalty on the sale of any product developed, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RoyaltyPercentForYearsFourThroughSix" xlink:label="igap_RoyaltyPercentForYearsFourThroughSix" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RoyaltyPercentForYearsFourThroughSix" xlink:to="igap_RoyaltyPercentForYearsFourThroughSix_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RoyaltyPercentForYearsFourThroughSix_lbl" xml:lang="en-US">Royalty on the sale of any product developed within years 4, 5, and 6</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RoyaltyPercentMaximum" xlink:label="igap_RoyaltyPercentMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RoyaltyPercentMaximum" xlink:to="igap_RoyaltyPercentMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RoyaltyPercentMaximum_lbl" xml:lang="en-US">Royalty on the sale of any product developed, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:label="us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:to="us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued_lbl" xml:lang="en-US">Contingent liabilities with respect to the grants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Lease Disclosures:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AreaOfLeasedSpace" xlink:label="igap_AreaOfLeasedSpace" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AreaOfLeasedSpace" xlink:to="igap_AreaOfLeasedSpace_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_AreaOfLeasedSpace_lbl" xml:lang="en-US">Office space leased</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_MonthlyLeaseCommitment" xlink:label="igap_MonthlyLeaseCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_MonthlyLeaseCommitment" xlink:to="igap_MonthlyLeaseCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_MonthlyLeaseCommitment_lbl" xml:lang="en-US">Monthly lease payment</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_LeaseGuaranteeProvidedToLandlord" xlink:label="igap_LeaseGuaranteeProvidedToLandlord" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_LeaseGuaranteeProvidedToLandlord" xlink:to="igap_LeaseGuaranteeProvidedToLandlord_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_LeaseGuaranteeProvidedToLandlord_lbl" xml:lang="en-US">Lease guarantee provided to landlord</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">Estimated minimal rent and maintenance payments, year one</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">Estimated minimal rent and maintenance payments, year two</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">Estimated minimal rent and maintenance payments, year three</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">Estimated minimal rent and maintenance payments, year four</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US">Estimated minimal rent and maintenance payments, year five</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:label="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:to="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_lbl" xml:lang="en-US">Value of shares to be issued in offering</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegistrationPaymentArrangementCommissionPercentage" xlink:label="igap_RegistrationPaymentArrangementCommissionPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RegistrationPaymentArrangementCommissionPercentage" xlink:to="igap_RegistrationPaymentArrangementCommissionPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RegistrationPaymentArrangementCommissionPercentage_lbl" xml:lang="en-US">Commission fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal" xlink:label="igap_RegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal" xlink:to="igap_RegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal_lbl" xml:lang="en-US">Period during which Placement Agent will have a right of first refusal on any private equity, debt or rights offering.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments made to agent</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen" xlink:label="igap_MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen" xlink:to="igap_MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen_lbl" xml:lang="en-US">Monthly advisory fee owed to Placement Agent from January 2013 through December 2014</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen" xlink:label="igap_MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen" xlink:to="igap_MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen_lbl" xml:lang="en-US">Monthly advisory fee owed to Placement Agent starting January 2015</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision" xlink:label="igap_NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision" xlink:to="igap_NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision_lbl" xml:lang="en-US">Number of shares of the Company's outstanding Common Stock transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountPaidAsRepaymentOfPrincipalAmount" xlink:label="igap_AmountPaidAsRepaymentOfPrincipalAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AmountPaidAsRepaymentOfPrincipalAmount" xlink:to="igap_AmountPaidAsRepaymentOfPrincipalAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_AmountPaidAsRepaymentOfPrincipalAmount_lbl" xml:lang="en-US">Amount paid as repayment in full of the outstanding principal amount under the Investment Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ForeignCurrencyExchangeRate" xlink:label="igap_ForeignCurrencyExchangeRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ForeignCurrencyExchangeRate" xlink:to="igap_ForeignCurrencyExchangeRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ForeignCurrencyExchangeRate_lbl" xml:lang="en-US">Exchange rate</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PartialReimbursementOfAttorneyFeesRequiredToPay" xlink:label="igap_PartialReimbursementOfAttorneyFeesRequiredToPay" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PartialReimbursementOfAttorneyFeesRequiredToPay" xlink:to="igap_PartialReimbursementOfAttorneyFeesRequiredToPay_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PartialReimbursementOfAttorneyFeesRequiredToPay_lbl" xml:lang="en-US">Partial reimbursement of attorney's fees required to pay</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_2_lbl" xml:lang="en-US">Dividend rate, percentages</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockStatedValue" xlink:label="igap_PreferredStockStatedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockStatedValue" xlink:to="igap_PreferredStockStatedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PreferredStockStatedValue_lbl" xml:lang="en-US">Convertible preferred stock, stated value</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockDividendPaymentRequirementThreshold" xlink:label="igap_PreferredStockDividendPaymentRequirementThreshold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockDividendPaymentRequirementThreshold" xlink:to="igap_PreferredStockDividendPaymentRequirementThreshold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PreferredStockDividendPaymentRequirementThreshold_lbl" xml:lang="en-US">Dividend requirement threshold</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockDividendLateFee" xlink:label="igap_PreferredStockDividendLateFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockDividendLateFee" xlink:to="igap_PreferredStockDividendLateFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PreferredStockDividendLateFee_lbl" xml:lang="en-US">Dividend late fee rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsShares" xlink:to="us-gaap_PreferredStockDividendsShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockDividendsShares_2_lbl" xml:lang="en-US">Stock dividend on Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_2_lbl" xml:lang="en-US">Preferred dividends paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockStock" xlink:to="us-gaap_DividendsCommonStockStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DividendsCommonStockStock_2_lbl" xml:lang="en-US">Dividends, Common Stock, Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockConvertibleStockPriceTrigger" xlink:label="igap_PreferredStockConvertibleStockPriceTrigger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockConvertibleStockPriceTrigger" xlink:to="igap_PreferredStockConvertibleStockPriceTrigger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PreferredStockConvertibleStockPriceTrigger_lbl" xml:lang="en-US">Convertible preferred stock, stock price trigger</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockConvertibleTradingVolumeTrigger" xlink:label="igap_PreferredStockConvertibleTradingVolumeTrigger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockConvertibleTradingVolumeTrigger" xlink:to="igap_PreferredStockConvertibleTradingVolumeTrigger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PreferredStockConvertibleTradingVolumeTrigger_lbl" xml:lang="en-US">Convertible preferred stock, trading volume trigger</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Preferred stock, liquidating damages</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockPercentageOutstandingGoverningDistributions" xlink:label="igap_PreferredStockPercentageOutstandingGoverningDistributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockPercentageOutstandingGoverningDistributions" xlink:to="igap_PreferredStockPercentageOutstandingGoverningDistributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PreferredStockPercentageOutstandingGoverningDistributions_lbl" xml:lang="en-US">Convertible preferred stock, percentage dividend regulation</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockMaximumBeneficialOwnership" xlink:label="igap_PreferredStockMaximumBeneficialOwnership" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockMaximumBeneficialOwnership" xlink:to="igap_PreferredStockMaximumBeneficialOwnership_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PreferredStockMaximumBeneficialOwnership_lbl" xml:lang="en-US">Convertible preferred stock, maximum beneficial ownership</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockMaximumBeneficialOwnershipSubjectToTerms" xlink:label="igap_PreferredStockMaximumBeneficialOwnershipSubjectToTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockMaximumBeneficialOwnershipSubjectToTerms" xlink:to="igap_PreferredStockMaximumBeneficialOwnershipSubjectToTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PreferredStockMaximumBeneficialOwnershipSubjectToTerms_lbl" xml:lang="en-US">Convertible preferred stock, maximum beneficial ownership, subject to term</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_EquityIssuancePricePerShare" xlink:label="igap_EquityIssuancePricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_EquityIssuancePricePerShare" xlink:to="igap_EquityIssuancePricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_EquityIssuancePricePerShare_lbl" xml:lang="en-US">Common stock issued, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Amount of issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfSharesOffered" xlink:label="igap_NumberOfSharesOffered" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_NumberOfSharesOffered" xlink:to="igap_NumberOfSharesOffered_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_NumberOfSharesOffered_lbl" xml:lang="en-US">Number of shares offered</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ProceedsFromUnitsSold" xlink:label="igap_ProceedsFromUnitsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ProceedsFromUnitsSold" xlink:to="igap_ProceedsFromUnitsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ProceedsFromUnitsSold_lbl" xml:lang="en-US">Gross proceeds from issuance of Units</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfUnitsSold" xlink:label="igap_NumberOfUnitsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_NumberOfUnitsSold" xlink:to="igap_NumberOfUnitsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_NumberOfUnitsSold_lbl" xml:lang="en-US">Number of units sold</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ConvertiblePreferredStockConversionPrice" xlink:label="igap_ConvertiblePreferredStockConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ConvertiblePreferredStockConversionPrice" xlink:to="igap_ConvertiblePreferredStockConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ConvertiblePreferredStockConversionPrice_lbl" xml:lang="en-US">Preferred stock conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xml:lang="en-US">Cancellation of shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityOtherChanges" xlink:label="us-gaap_TemporaryEquityOtherChanges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityOtherChanges" xlink:to="us-gaap_TemporaryEquityOtherChanges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityOtherChanges_lbl" xml:lang="en-US">Value of temporary equity reclassified</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_StockPriceAtWhichStockDividendIsDeclared" xlink:label="igap_StockPriceAtWhichStockDividendIsDeclared" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_StockPriceAtWhichStockDividendIsDeclared" xlink:to="igap_StockPriceAtWhichStockDividendIsDeclared_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_StockPriceAtWhichStockDividendIsDeclared_lbl" xml:lang="en-US">Stock price at which stock dividend is declared</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsStock" xlink:to="us-gaap_DividendsStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DividendsStock_2_lbl" xml:lang="en-US">Stock dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockDividendsShares" xlink:label="us-gaap_StockDividendsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockDividendsShares" xlink:to="us-gaap_StockDividendsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockDividendsShares_lbl" xml:lang="en-US">Stock dividend, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_OfferingCostsIncurred" xlink:label="igap_OfferingCostsIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_OfferingCostsIncurred" xlink:to="igap_OfferingCostsIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_OfferingCostsIncurred_lbl" xml:lang="en-US">Total issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Non-cash compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued_lbl" xml:lang="en-US">Number of warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Value of units issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightNumberOfWarrantsExercisable" xlink:label="igap_ClassOfWarrantOrRightNumberOfWarrantsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightNumberOfWarrantsExercisable" xlink:to="igap_ClassOfWarrantOrRightNumberOfWarrantsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ClassOfWarrantOrRightNumberOfWarrantsExercisable_lbl" xml:lang="en-US">Number of warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Balance, Beginning of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US">Classification from stockholders deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision" xlink:label="igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision" xlink:to="igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision_lbl" xml:lang="en-US">Exchange of Series A Warrants pursuant to the 'Most favored nation' provision</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ChangeInFairValueOfSeriesaWarrants" xlink:label="igap_ChangeInFairValueOfSeriesaWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ChangeInFairValueOfSeriesaWarrants" xlink:to="igap_ChangeInFairValueOfSeriesaWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="igap_ChangeInFairValueOfSeriesaWarrants_lbl" xml:lang="en-US">Change in fair value of Series A Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Balance, End of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US">Expected term of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="us-gaap_FairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExercisePrice" xlink:to="us-gaap_FairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightFairValue" xlink:label="igap_ClassOfWarrantOrRightFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightFairValue" xlink:to="igap_ClassOfWarrantOrRightFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ClassOfWarrantOrRightFairValue_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_lbl" xml:lang="en-US">Schedule of Share-based Goods and Nonemployee Services Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued_2_lbl" xml:lang="en-US">Number of securities issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_lbl" xml:lang="en-US">Service period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xml:lang="en-US">Assumed dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xml:lang="en-US">Assumed risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Assumed exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities" xlink:to="igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities_2_lbl" xml:lang="en-US">Amount classified out of stockholders deficit and presented as Warrants with Down-Round Protection within long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightPostAdjustmentFairValue" xlink:label="igap_ClassOfWarrantOrRightPostAdjustmentFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightPostAdjustmentFairValue" xlink:to="igap_ClassOfWarrantOrRightPostAdjustmentFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ClassOfWarrantOrRightPostAdjustmentFairValue_lbl" xml:lang="en-US">Post adjustment fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightPreAdjustmentFairValue" xlink:label="igap_ClassOfWarrantOrRightPreAdjustmentFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightPreAdjustmentFairValue" xlink:to="igap_ClassOfWarrantOrRightPreAdjustmentFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ClassOfWarrantOrRightPreAdjustmentFairValue_lbl" xml:lang="en-US">Pre adjustment fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantRightExpenseOrRevenueRecognized" xlink:label="igap_ClassOfWarrantRightExpenseOrRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantRightExpenseOrRevenueRecognized" xlink:to="igap_ClassOfWarrantRightExpenseOrRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ClassOfWarrantRightExpenseOrRevenueRecognized_lbl" xml:lang="en-US">Warrant expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted during period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xml:lang="en-US">Non-cash compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Maximum contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Common Stock reserved for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for future grants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value of the awards exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value of the awards outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne" xlink:label="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne" xlink:to="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne_lbl" xml:lang="en-US">Unrecognized compensation costs expected to be recognized during the years ending December 31, 2015</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo" xlink:label="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo" xlink:to="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo_lbl" xml:lang="en-US">Unrecognized compensation costs expected to be recognized during the years ending December 31, 2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Number</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Balance outstanding at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Balance outstanding at end of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Balance exercisable at the end of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Weighted average exercise price (US$)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Balance outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Balance outstanding at end of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Balance exercisable at the end of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Minimum exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Maximum exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Outstanding at December 31</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life years</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Exercisable at December 31</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life years</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">The following are the data and assumptions used:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term of options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Salaries and related expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US">Materials</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="us-gaap_TravelAndEntertainmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TravelAndEntertainmentExpense_lbl" xml:lang="en-US">Travel expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:label="us-gaap_CostOfPropertyRepairsAndMaintenance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:to="us-gaap_CostOfPropertyRepairsAndMaintenance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfPropertyRepairsAndMaintenance_lbl" xml:lang="en-US">Vehicle maintenance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherGeneralExpense" xlink:label="us-gaap_OtherGeneralExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralExpense_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Total research and development expenses, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TravelAndEntertainmentExpense_2_lbl" xml:lang="en-US">Travel &amp; expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Total selling, marketing and general and administrative expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:to="igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders_2_lbl" xml:lang="en-US">Israeli CPI linkage difference on principal of loans from stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Exchange rate differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US">Warrants with down-round protection</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RecapitalizationCosts" xlink:label="us-gaap_RecapitalizationCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecapitalizationCosts" xlink:to="us-gaap_RecapitalizationCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecapitalizationCosts_lbl" xml:lang="en-US">Issuance cost allocated to warrants with down-round protection</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expenses on credit from banks and other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_FinancingIncomeExpensesNet" xlink:to="igap_FinancingIncomeExpensesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="igap_FinancingIncomeExpensesNet_2_lbl" xml:lang="en-US">Financing expenses, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Loss carry forward balances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Pretax income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Tax expense reported in the financial statements:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax expenses (benefit) computed at the ordinary tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Non-deductible expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Amortization of warrants with down round protection</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants" xlink:label="igap_IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants" xlink:to="igap_IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants_lbl" xml:lang="en-US">Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Tax in respect of differences in corporate tax rates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Losses and timing differences in respect of which no deferred taxes assets were recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Tax expense reported in the financial statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxesAbstract" xlink:label="us-gaap_DeferredIncomeTaxesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAbstract_lbl" xml:lang="en-US">Composition of deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Provision for employee-related obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Non-capital loss carry forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total deferred taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl" xml:lang="en-US">Stock dividend to certain Common Stockholder</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Dividend on Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl" xml:lang="en-US">Income attributable to participating securities (Preferred Stock)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Income (loss) for the period attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US">Number of shares:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Common shares used in computing Basic income (loss) per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Common shares used in computing Diluted income (loss) per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total weighted average number of Common shares related to outstanding convertible Preferred Stock, options and warrants excluded from the calculations of diluted income (loss) per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RelatedPartyTransactionOwnershipInterestInEntity" xlink:label="igap_RelatedPartyTransactionOwnershipInterestInEntity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RelatedPartyTransactionOwnershipInterestInEntity" xlink:to="igap_RelatedPartyTransactionOwnershipInterestInEntity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_RelatedPartyTransactionOwnershipInterestInEntity_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Amount of related party transaction relating to annual salary</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PortionOfRelatedPartySalaryRelatingToBonusesPaid" xlink:label="igap_PortionOfRelatedPartySalaryRelatingToBonusesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PortionOfRelatedPartySalaryRelatingToBonusesPaid" xlink:to="igap_PortionOfRelatedPartySalaryRelatingToBonusesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_PortionOfRelatedPartySalaryRelatingToBonusesPaid_lbl" xml:lang="en-US">Bonuses paid to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors" xlink:label="igap_AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors" xlink:to="igap_AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors_lbl" xml:lang="en-US">Amount of annual cash payment owed to each director</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountOfQuarterlyCompensationOwedToEachDirector" xlink:label="igap_AmountOfQuarterlyCompensationOwedToEachDirector" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AmountOfQuarterlyCompensationOwedToEachDirector" xlink:to="igap_AmountOfQuarterlyCompensationOwedToEachDirector_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_AmountOfQuarterlyCompensationOwedToEachDirector_lbl" xml:lang="en-US">Amount of quarterly compensation owed to each director</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AnnualCompensationOwedToChairperson" xlink:label="igap_AnnualCompensationOwedToChairperson" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AnnualCompensationOwedToChairperson" xlink:to="igap_AnnualCompensationOwedToChairperson_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_AnnualCompensationOwedToChairperson_lbl" xml:lang="en-US">Annual compensation owed to the chairperson of the Nominating and Corporate Governance Committee</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountOfQuarterlyCompensationOwedChairperson" xlink:label="igap_AmountOfQuarterlyCompensationOwedChairperson" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AmountOfQuarterlyCompensationOwedChairperson" xlink:to="igap_AmountOfQuarterlyCompensationOwedChairperson_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_AmountOfQuarterlyCompensationOwedChairperson_lbl" xml:lang="en-US">Amount of quarterly compensation owed to the chairperson of the Nominating and Corporate Governance Committee</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant" xlink:label="igap_TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant" xlink:to="igap_TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant_lbl" xml:lang="en-US">Total number of common shares allowed for purchase through one-time grant of options to each non-employee director</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ExercisePriceOfOptionsGranted" xlink:label="igap_ExercisePriceOfOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ExercisePriceOfOptionsGranted" xlink:to="igap_ExercisePriceOfOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ExercisePriceOfOptionsGranted_lbl" xml:lang="en-US">Exercise price of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfSharesVestingInEachIncrement" xlink:label="igap_NumberOfSharesVestingInEachIncrement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_NumberOfSharesVestingInEachIncrement" xlink:to="igap_NumberOfSharesVestingInEachIncrement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_NumberOfSharesVestingInEachIncrement_lbl" xml:lang="en-US">Number of shares vesting</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AdIntegrityApplicationsLtdMember" xlink:to="igap_AdIntegrityApplicationsLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_AdIntegrityApplicationsLtdMember_doc" xml:lang="en-US">A.D. Integrity Applications Ltd. [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued" xlink:to="igap_AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued_doc" xml:lang="en-US">Amount of increase in additional paid in capital (APIC) resulting from the issuance of investor warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities" xlink:to="igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities_doc" xml:lang="en-US">Amount of decrease in additional paid in capital (APIC) resulting from reclassification out of stockholders deficit to liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AgreementWithPlacementAgentMember" xlink:to="igap_AgreementWithPlacementAgentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_AgreementWithPlacementAgentMember_doc" xml:lang="en-US">Agreement with Placement Agent [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ArbitrationProceedingsWithShareholderMember" xlink:to="igap_ArbitrationProceedingsWithShareholderMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ArbitrationProceedingsWithShareholderMember_doc" xml:lang="en-US">Arbitration Proceedings with Shareholder [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AreaOfLeasedSpace" xlink:to="igap_AreaOfLeasedSpace_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_AreaOfLeasedSpace_doc" xml:lang="en-US">Area Of Leased Space.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AverageForeignCurrencyExchangeRateTranslation" xlink:to="igap_AverageForeignCurrencyExchangeRateTranslation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_AverageForeignCurrencyExchangeRateTranslation_doc" xml:lang="en-US">The foreign exchange rates used to translate income and expense items denominated in the functional currency to the reporting currency.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AvnerGalMember" xlink:to="igap_AvnerGalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_AvnerGalMember_doc" xml:lang="en-US">Avner Gal [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightExercisePriceAxis" xlink:to="igap_ClassOfWarrantOrRightExercisePriceAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ClassOfWarrantOrRightExercisePriceAxis_doc" xml:lang="en-US">Information by type of exercise price of warrants issued.</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceDomain" xlink:label="igap_ClassOfWarrantOrRightExercisePriceDomain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightExercisePriceDomain" xlink:to="igap_ClassOfWarrantOrRightExercisePriceDomain_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ClassOfWarrantOrRightExercisePriceDomain_doc" xml:lang="en-US">Various exercise price of warrants issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightExercisePriceFiveMember" xlink:to="igap_ClassOfWarrantOrRightExercisePriceFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ClassOfWarrantOrRightExercisePriceFiveMember_doc" xml:lang="en-US">Represents information pertaining to warrant's exercise price five.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightExercisePriceFourMember" xlink:to="igap_ClassOfWarrantOrRightExercisePriceFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ClassOfWarrantOrRightExercisePriceFourMember_doc" xml:lang="en-US">Represents information pertaining to warrant's exercise price four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightExercisePriceOneMember" xlink:to="igap_ClassOfWarrantOrRightExercisePriceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ClassOfWarrantOrRightExercisePriceOneMember_doc" xml:lang="en-US">Represents information pertaining to warrant's exercise price one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightExercisePriceThreeMember" xlink:to="igap_ClassOfWarrantOrRightExercisePriceThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ClassOfWarrantOrRightExercisePriceThreeMember_doc" xml:lang="en-US">Represents information pertaining to warrant's exercise price three.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightExercisePriceTwoMember" xlink:to="igap_ClassOfWarrantOrRightExercisePriceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ClassOfWarrantOrRightExercisePriceTwoMember_doc" xml:lang="en-US">Represents information pertaining to warrant's exercise price two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightFairValue" xlink:to="igap_ClassOfWarrantOrRightFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ClassOfWarrantOrRightFairValue_doc" xml:lang="en-US">Class Of Warrant Or Right, Fair Value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightNumberOfWarrantsExercisable" xlink:to="igap_ClassOfWarrantOrRightNumberOfWarrantsExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ClassOfWarrantOrRightNumberOfWarrantsExercisable_doc" xml:lang="en-US">Represents number of warrants are exercisable into an shares of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightPostAdjustmentFairValue" xlink:to="igap_ClassOfWarrantOrRightPostAdjustmentFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ClassOfWarrantOrRightPostAdjustmentFairValue_doc" xml:lang="en-US">Represents post adjustment fair value of warrant due to down-round protection.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightPreAdjustmentFairValue" xlink:to="igap_ClassOfWarrantOrRightPreAdjustmentFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ClassOfWarrantOrRightPreAdjustmentFairValue_doc" xml:lang="en-US">Represents pre adjustment fair value of warrant due to down-round protection.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightTerm" xlink:to="igap_ClassOfWarrantOrRightTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ClassOfWarrantOrRightTerm_doc" xml:lang="en-US">Class Of Warrant Or Right, Term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantRightExpenseOrRevenueRecognized" xlink:to="igap_ClassOfWarrantRightExpenseOrRevenueRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ClassOfWarrantRightExpenseOrRevenueRecognized_doc" xml:lang="en-US">Amount of expense or revenue offset related to the warrants or rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ConsultantsMember" xlink:to="igap_ConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ConsultantsMember_doc" xml:lang="en-US">Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ConversionOfPreferredStockIntoCommonStockMember" xlink:to="igap_ConversionOfPreferredStockIntoCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ConversionOfPreferredStockIntoCommonStockMember_doc" xml:lang="en-US">Conversion of Preferred Stock ino Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion" xlink:to="igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion_doc" xml:lang="en-US">Convertible Preferred Stock, Aggregate Number of Shares Issued upon Conversion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ConvertiblePreferredStockConversionPrice" xlink:to="igap_ConvertiblePreferredStockConversionPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ConvertiblePreferredStockConversionPrice_doc" xml:lang="en-US">Represents the preferred stock conversion price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_DavidMalkaMember" xlink:to="igap_DavidMalkaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_DavidMalkaMember_doc" xml:lang="en-US">David Malka [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_DecemberOfferingMember" xlink:to="igap_DecemberOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_DecemberOfferingMember_doc" xml:lang="en-US">December Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_DocumentAndEntityInformationAbstract" xlink:to="igap_DocumentAndEntityInformationAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_DocumentAndEntityInformationAbstract_doc" xml:lang="en-US">Document and Entity Information [Abstract].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne" xlink:to="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne_doc" xml:lang="en-US">Represents the amount of unrecognized cost of unvested share-based compensation awards expected to be recognized in year one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo" xlink:to="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo_doc" xml:lang="en-US">Represents the amount of unrecognized cost of unvested share-based compensation awards expected to be recognized in year two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_FinancingExpensesNetDisclosureTextBlock" xlink:to="igap_FinancingExpensesNetDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_FinancingExpensesNetDisclosureTextBlock_doc" xml:lang="en-US">The entire disclosure relating to financing expenses, net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_FinancingIncomeExpensesNet" xlink:to="igap_FinancingIncomeExpensesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_FinancingIncomeExpensesNet_doc" xml:lang="en-US">Financing Income (Expenses), Net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_FundsInRespectOfEmployeeRightsUponRetirementNoncurrent" xlink:to="igap_FundsInRespectOfEmployeeRightsUponRetirementNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_FundsInRespectOfEmployeeRightsUponRetirementNoncurrent_doc" xml:lang="en-US">Funds In Respect Of Employee Rights Upon Retirement, Noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_GrantDate1Member" xlink:to="igap_GrantDate1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_GrantDate1Member_doc" xml:lang="en-US">Grant Date 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_GrantDate2Member" xlink:to="igap_GrantDate2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_GrantDate2Member_doc" xml:lang="en-US">Grant Date 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_GrantsToMessrsGalAndMalkaMember" xlink:to="igap_GrantsToMessrsGalAndMalkaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_GrantsToMessrsGalAndMalkaMember_doc" xml:lang="en-US">Grants to Messrs. Gal and Malka [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement" xlink:to="igap_IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement_doc" xml:lang="en-US">Increase (Decrease) In Funds In Respect Of Employee Rights Upon Retirement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_IntegrityIsraelPlanMember" xlink:to="igap_IntegrityIsraelPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_IntegrityIsraelPlanMember_doc" xml:lang="en-US">Integrity Israel Plan [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_InvestorFindersMember" xlink:to="igap_InvestorFindersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_InvestorFindersMember_doc" xml:lang="en-US">Investor Finders [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_InvestorRelationsServicesProviderMember" xlink:to="igap_InvestorRelationsServicesProviderMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_InvestorRelationsServicesProviderMember_doc" xml:lang="en-US">Investor Relations Services Provider [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:to="igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders_doc" xml:lang="en-US">Linkage difference on principal of loans from stockholders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_MonthlyLeaseCommitment" xlink:to="igap_MonthlyLeaseCommitment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_MonthlyLeaseCommitment_doc" xml:lang="en-US">Monthly Lease Commitment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_NumberOfSharesOffered" xlink:to="igap_NumberOfSharesOffered_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_NumberOfSharesOffered_doc" xml:lang="en-US">Number Of Shares Offered.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_NumberOfUnitsSold" xlink:to="igap_NumberOfUnitsSold_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_NumberOfUnitsSold_doc" xml:lang="en-US">Number Of Units Sold.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_OfferingCostsIncurred" xlink:to="igap_OfferingCostsIncurred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_OfferingCostsIncurred_doc" xml:lang="en-US">Offering costs incurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_OtherCurrentLiabilitiesDisclosureTextBlock" xlink:to="igap_OtherCurrentLiabilitiesDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_OtherCurrentLiabilitiesDisclosureTextBlock_doc" xml:lang="en-US">The entire disclosure relating to other current liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PaymentOfRoyaltiesToOcsMember" xlink:to="igap_PaymentOfRoyaltiesToOcsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PaymentOfRoyaltiesToOcsMember_doc" xml:lang="en-US">Payment of Royalties to OCS [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PercentOfFutureSalesDesignatedToRepayStockholdersLoans" xlink:to="igap_PercentOfFutureSalesDesignatedToRepayStockholdersLoans_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PercentOfFutureSalesDesignatedToRepayStockholdersLoans_doc" xml:lang="en-US">Percent Of Future Sales Designated To Repay Stockholders' Loans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PlacementAgentMember" xlink:to="igap_PlacementAgentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PlacementAgentMember_doc" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockConversionPrice" xlink:to="igap_PreferredStockConversionPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PreferredStockConversionPrice_doc" xml:lang="en-US">Preferred Stock, Conversion Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockConvertibleStockPriceTrigger" xlink:to="igap_PreferredStockConvertibleStockPriceTrigger_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PreferredStockConvertibleStockPriceTrigger_doc" xml:lang="en-US">Preferred Stock, Convertible, Stock Price Trigger.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockConvertibleTradingVolumeTrigger" xlink:to="igap_PreferredStockConvertibleTradingVolumeTrigger_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PreferredStockConvertibleTradingVolumeTrigger_doc" xml:lang="en-US">Preferred Stock, Convertible, Trading Volume Trigger.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockDividendLateFee" xlink:to="igap_PreferredStockDividendLateFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PreferredStockDividendLateFee_doc" xml:lang="en-US">Preferred Stock, Dividend, Late Fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockDividendPaymentRequirementThreshold" xlink:to="igap_PreferredStockDividendPaymentRequirementThreshold_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PreferredStockDividendPaymentRequirementThreshold_doc" xml:lang="en-US">Preferred Stock, Dividend, Payment Requirement Threshold.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockMaximumBeneficialOwnership" xlink:to="igap_PreferredStockMaximumBeneficialOwnership_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PreferredStockMaximumBeneficialOwnership_doc" xml:lang="en-US">Preferred Stock, Maximum Beneficial Ownership.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockMaximumBeneficialOwnershipSubjectToTerms" xlink:to="igap_PreferredStockMaximumBeneficialOwnershipSubjectToTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PreferredStockMaximumBeneficialOwnershipSubjectToTerms_doc" xml:lang="en-US">Preferred Stock, Maximum Beneficial Ownership, Subject To Terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockPercentageOutstandingGoverningDistributions" xlink:to="igap_PreferredStockPercentageOutstandingGoverningDistributions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PreferredStockPercentageOutstandingGoverningDistributions_doc" xml:lang="en-US">Preferred Stock, Percentage Outstanding Governing Distributions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PreferredStockStatedValue" xlink:to="igap_PreferredStockStatedValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PreferredStockStatedValue_doc" xml:lang="en-US">Preferred Stock, Stated Value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ProceedsFromUnitsSold" xlink:to="igap_ProceedsFromUnitsSold_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ProceedsFromUnitsSold_doc" xml:lang="en-US">Represents gross proceeds from issuance of Units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PropertyPlantAndEquipmentDepreciationRate" xlink:to="igap_PropertyPlantAndEquipmentDepreciationRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PropertyPlantAndEquipmentDepreciationRate_doc" xml:lang="en-US">Property, Plant And Equipment, Depreciation Rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PurchasersOfPreviouslyIssuedCommonStockMember" xlink:to="igap_PurchasersOfPreviouslyIssuedCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PurchasersOfPreviouslyIssuedCommonStockMember_doc" xml:lang="en-US">Purchasers of Previously Issued Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RangeFiveMember" xlink:to="igap_RangeFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RangeFiveMember_doc" xml:lang="en-US">Range Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RangeFourMember" xlink:to="igap_RangeFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RangeFourMember_doc" xml:lang="en-US">Range Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RangeOneMember" xlink:to="igap_RangeOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RangeOneMember_doc" xml:lang="en-US">Range One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RangeSevenMember" xlink:to="igap_RangeSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RangeSevenMember_doc" xml:lang="en-US">Represents information pertaining to range seven member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RangeSixMember" xlink:to="igap_RangeSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RangeSixMember_doc" xml:lang="en-US">Range Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RangeThreeMember" xlink:to="igap_RangeThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RangeThreeMember_doc" xml:lang="en-US">Range Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RangeTwoMember" xlink:to="igap_RangeTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RangeTwoMember_doc" xml:lang="en-US">Range Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RegistrationPaymentArrangementExpenseAllowanceMember" xlink:to="igap_RegistrationPaymentArrangementExpenseAllowanceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RegistrationPaymentArrangementExpenseAllowanceMember_doc" xml:lang="en-US">Registration Payment Arrangement Expense Allowance [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RegistrationPaymentArrangementManagementFeeMember" xlink:to="igap_RegistrationPaymentArrangementManagementFeeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RegistrationPaymentArrangementManagementFeeMember_doc" xml:lang="en-US">Registration Payment Arrangement Management Fee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RegistrationPaymentCommissionRateMember" xlink:to="igap_RegistrationPaymentCommissionRateMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RegistrationPaymentCommissionRateMember_doc" xml:lang="en-US">Registration Payment Commission Rate [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RoyaltyPercentForYearsFourThroughSix" xlink:to="igap_RoyaltyPercentForYearsFourThroughSix_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RoyaltyPercentForYearsFourThroughSix_doc" xml:lang="en-US">Royalty Percent For Years Four Through Six.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RoyaltyPercentMaximum" xlink:to="igap_RoyaltyPercentMaximum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RoyaltyPercentMaximum_doc" xml:lang="en-US">Royalty Percent, Maximum.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RoyaltyPercentMinimum" xlink:to="igap_RoyaltyPercentMinimum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RoyaltyPercentMinimum_doc" xml:lang="en-US">Royalty Percent, Minimum.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ScheduleOfPropertyRatesOfDepreciationTableTextBlock" xlink:to="igap_ScheduleOfPropertyRatesOfDepreciationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ScheduleOfPropertyRatesOfDepreciationTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of accumulated depreciation percentage of property and equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xlink:to="igap_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of each component of research and development costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_SellingGeneralAndAdministrativeExpenseTableTextBlock" xlink:to="igap_SellingGeneralAndAdministrativeExpenseTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_SellingGeneralAndAdministrativeExpenseTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of selling, marketing and general and administrative (or similar) expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_SellingGeneralAndAdministrativeExpenseTextBlock" xlink:to="igap_SellingGeneralAndAdministrativeExpenseTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_SellingGeneralAndAdministrativeExpenseTextBlock_doc" xml:lang="en-US">Disclosure of selling, marketing and general and administrative (or similar) expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_SeriesAWarrantMember" xlink:to="igap_SeriesAWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_SeriesAWarrantMember_doc" xml:lang="en-US">Represents information pertaining to Series A warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_SeriesB1AndSeriesB2WarrantsMember" xlink:to="igap_SeriesB1AndSeriesB2WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_SeriesB1AndSeriesB2WarrantsMember_doc" xml:lang="en-US">Series B1 and Series B2 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_SeriesB1WarrantMember" xlink:to="igap_SeriesB1WarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_SeriesB1WarrantMember_doc" xml:lang="en-US">Represents information pertaining to series B warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_SeriesB2WarrantMember" xlink:to="igap_SeriesB2WarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_SeriesB2WarrantMember_doc" xml:lang="en-US">Series B2 Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ShareIncentivePlanMember" xlink:to="igap_ShareIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ShareIncentivePlanMember_doc" xml:lang="en-US">2010 Share Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" xlink:to="igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock_doc" xml:lang="en-US">Stock Issued During Period, Shares, Conversion Of Convertible Preferred Stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_StockIssuedDuringPeriodSharesStockDividend" xlink:to="igap_StockIssuedDuringPeriodSharesStockDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_StockIssuedDuringPeriodSharesStockDividend_doc" xml:lang="en-US">Represents number of stock issued to shareholders as a dividend during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" xlink:to="igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock_doc" xml:lang="en-US">Stock Issued During Period, Value, Conversion Of Convertible Preferred Stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_StockPriceAtWhichStockDividendIsDeclared" xlink:to="igap_StockPriceAtWhichStockDividendIsDeclared_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_StockPriceAtWhichStockDividendIsDeclared_doc" xml:lang="en-US">Stock Price At Which Stock Dividend Is Declared.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" xlink:to="igap_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock_doc" xml:lang="en-US">Stockholders Equity and Temporary Equity Note Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_TemporaryEquityPolicyPolicyTextBlock" xlink:to="igap_TemporaryEquityPolicyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_TemporaryEquityPolicyPolicyTextBlock_doc" xml:lang="en-US">Temporary Equity Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_TwoThousandFourteenOfferingMember" xlink:to="igap_TwoThousandFourteenOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_TwoThousandFourteenOfferingMember_doc" xml:lang="en-US">Represents information pertaining to 2014 Offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_TwoThousandTwelveOfferingMember" xlink:to="igap_TwoThousandTwelveOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_TwoThousandTwelveOfferingMember_doc" xml:lang="en-US">2012 Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_WarrantsIssuedToPlacementAgentTrancheOneMember" xlink:to="igap_WarrantsIssuedToPlacementAgentTrancheOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_WarrantsIssuedToPlacementAgentTrancheOneMember_doc" xml:lang="en-US">Warrants Issued to Placement Agent, Tranche One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_WarrantsIssuedToPlacementAgentTrancheTwoMember" xlink:to="igap_WarrantsIssuedToPlacementAgentTrancheTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_WarrantsIssuedToPlacementAgentTrancheTwoMember_doc" xml:lang="en-US">Warrants Issued to Placement Agent, Tranche Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember" xlink:to="igap_WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Warrants Issued under Second Closing of Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_WarrantsIssuedUnderSecuritiesPurchaseAgreementMember" xlink:to="igap_WarrantsIssuedUnderSecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_WarrantsIssuedUnderSecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Warrants Issued under Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RegistrationPaymentArrangementCommissionPercentage" xlink:to="igap_RegistrationPaymentArrangementCommissionPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RegistrationPaymentArrangementCommissionPercentage_doc" xml:lang="en-US">Registration Payment Arrangement, Commission Percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal" xlink:to="igap_RegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal_doc" xml:lang="en-US">Represents period during which Placement Agent will have a right of first refusal on any private equity, debt or rights offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_TwoThousandFourteenOfferingsMember" xlink:to="igap_TwoThousandFourteenOfferingsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_TwoThousandFourteenOfferingsMember_doc" xml:lang="en-US">2014 Offerings [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_EquityIssuancePricePerShare" xlink:to="igap_EquityIssuancePricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_EquityIssuancePricePerShare_doc" xml:lang="en-US">Common stock issued, price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_GainLossOnUnitConversion" xlink:to="igap_GainLossOnUnitConversion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_GainLossOnUnitConversion_doc" xml:lang="en-US">The gain (loss) resulting from a unit conversion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:to="igap_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_doc" xml:lang="en-US">Proceeds from issuance of common stock net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants" xlink:to="igap_IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants_doc" xml:lang="en-US">Tax effect of loss on partial extinguishment of Series A Preferred Stock and Series A Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_LeaseGuaranteeProvidedToLandlord" xlink:to="igap_LeaseGuaranteeProvidedToLandlord_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_LeaseGuaranteeProvidedToLandlord_doc" xml:lang="en-US">Lease guarantee provided to landlord.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision" xlink:to="igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision_doc" xml:lang="en-US">Change in fair value of Level 3 liability due to exchange of Series A Warrants pursuant to the 'Most favored nation' provision</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ChangeInFairValueOfSeriesaWarrants" xlink:to="igap_ChangeInFairValueOfSeriesaWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ChangeInFairValueOfSeriesaWarrants_doc" xml:lang="en-US">Change in fair value of Series A Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RegulatoryServicesMember" xlink:to="igap_RegulatoryServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RegulatoryServicesMember_doc" xml:lang="en-US">Regulatory Services [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_TwoThousandTenOfferingMember" xlink:to="igap_TwoThousandTenOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_TwoThousandTenOfferingMember_doc" xml:lang="en-US">2010 Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock" xlink:to="igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock_doc" xml:lang="en-US">Number of Series A Preferred Stock shares exchanged for Series B Preferred Stock shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_NumberOfWarrantsExchanged" xlink:to="igap_NumberOfWarrantsExchanged_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_NumberOfWarrantsExchanged_doc" xml:lang="en-US">Number of warrants exchanged.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants" xlink:to="igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants_doc" xml:lang="en-US">Increase (decrease) in equity due to exchange of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange" xlink:to="igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange_doc" xml:lang="en-US">Non-cash charge recorded to finance expense as a result of warrants exchanged.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen" xlink:to="igap_MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen_doc" xml:lang="en-US">Monthly advisory fee owed to Placement Agent from January 2013 through December 2014.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen" xlink:to="igap_MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen_doc" xml:lang="en-US">Monthly advisory fee owed to Placement Agent starting January 2015.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AmountPaidAsRepaymentOfPrincipalAmount" xlink:to="igap_AmountPaidAsRepaymentOfPrincipalAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_AmountPaidAsRepaymentOfPrincipalAmount_doc" xml:lang="en-US">Amount paid as repayment in full of the outstanding principal amount under the Investment Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ForeignCurrencyExchangeRate" xlink:to="igap_ForeignCurrencyExchangeRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ForeignCurrencyExchangeRate_doc" xml:lang="en-US">The foreign exchange rates used to translate financial items denominated in the functional currency to the reporting currency.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PartialReimbursementOfAttorneyFeesRequiredToPay" xlink:to="igap_PartialReimbursementOfAttorneyFeesRequiredToPay_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PartialReimbursementOfAttorneyFeesRequiredToPay_doc" xml:lang="en-US">Represents the amount required to pay as partial reimbursement of attorney's fees in the arbitration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision" xlink:to="igap_NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision_doc" xml:lang="en-US">Represents the number of shares of the entity's outstanding common stock transferred under Arbitration Decision.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PropertyAshkelonIsraelMember" xlink:to="igap_PropertyAshkelonIsraelMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PropertyAshkelonIsraelMember_doc" xml:lang="en-US">Property Ashkelon, Israel [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PropertyAshdodIsraelMember" xlink:to="igap_PropertyAshdodIsraelMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PropertyAshdodIsraelMember_doc" xml:lang="en-US">Property Ashdod, Israel [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_RelatedPartyTransactionOwnershipInterestInEntity" xlink:to="igap_RelatedPartyTransactionOwnershipInterestInEntity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_RelatedPartyTransactionOwnershipInterestInEntity_doc" xml:lang="en-US">Related party ownership percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_PortionOfRelatedPartySalaryRelatingToBonusesPaid" xlink:to="igap_PortionOfRelatedPartySalaryRelatingToBonusesPaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_PortionOfRelatedPartySalaryRelatingToBonusesPaid_doc" xml:lang="en-US">Bonuses paid to related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors" xlink:to="igap_AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors_doc" xml:lang="en-US">Amount of annual cash payment owed to each director.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_DirectorsMember" xlink:to="igap_DirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_DirectorsMember_doc" xml:lang="en-US">Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AmountOfQuarterlyCompensationOwedToEachDirector" xlink:to="igap_AmountOfQuarterlyCompensationOwedToEachDirector_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_AmountOfQuarterlyCompensationOwedToEachDirector_doc" xml:lang="en-US">Amount of quarterly compensation owed to each director paid each on the last day of each calendar quarter commencing with the second quarter of 2016, subject to the director&#8217;s continued service as of each such date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AnnualCompensationOwedToChairperson" xlink:to="igap_AnnualCompensationOwedToChairperson_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_AnnualCompensationOwedToChairperson_doc" xml:lang="en-US">Annual compensation owed to the chairperson of the Nominating and Corporate Governance Committee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_AmountOfQuarterlyCompensationOwedChairperson" xlink:to="igap_AmountOfQuarterlyCompensationOwedChairperson_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_AmountOfQuarterlyCompensationOwedChairperson_doc" xml:lang="en-US">Amount of quarterly compensation owed to the chairperson of the Nominating and Corporate Governance Committee payable in four equal quarterly installments, on the last day of each calendar quarter commencing with the second quarter of 2016, subject to the chairperson&#8217;s continued service as of each such date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant" xlink:to="igap_TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant_doc" xml:lang="en-US">Total number of common shares allowed for purchase through one-time grant of options to each non-employee director.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ExercisePriceOfOptionsGranted" xlink:to="igap_ExercisePriceOfOptionsGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_ExercisePriceOfOptionsGranted_doc" xml:lang="en-US">Exercise price of options granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_NumberOfSharesVestingInEachIncrement" xlink:to="igap_NumberOfSharesVestingInEachIncrement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igap_NumberOfSharesVestingInEachIncrement_doc" xml:lang="en-US">Number of shares vesting in eight equal quarterly increments (subject to the director's continued service as of each such date) commencing with the second quarter of 2016.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightExercisePriceFourMember" xlink:to="igap_ClassOfWarrantOrRightExercisePriceFourMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ClassOfWarrantOrRightExercisePriceFourMember_3_lbl" xml:lang="en-US">ClassOfWarrantOrRightExercisePriceFourMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_TwoThousandFourteenOfferingsMember" xlink:to="igap_TwoThousandFourteenOfferingsMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_TwoThousandFourteenOfferingsMember_3_lbl" xml:lang="en-US">TwoThousandFourteenOfferingsMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_5_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_2_lbl" xml:lang="en-US">Temporary Equity, Other Disclosures [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_2_lbl" xml:lang="en-US">Costs and Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsStock" xlink:to="us-gaap_DividendsStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsStock_3_lbl" xml:lang="en-US">Dividends, Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_StockIssuedDuringPeriodSharesStockDividend" xlink:to="igap_StockIssuedDuringPeriodSharesStockDividend_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_StockIssuedDuringPeriodSharesStockDividend_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodSharesStockDividend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based Compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_GainLossOnUnitConversion" xlink:to="igap_GainLossOnUnitConversion_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_GainLossOnUnitConversion_3_lbl" xml:lang="en-US">GainLossOnUnitConversion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_2_lbl" xml:lang="en-US">Increase (Decrease) in Restricted Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_2_lbl" xml:lang="en-US">Payments of Ordinary Dividends, Preferred Stock and Preference Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionAbstract_2_lbl" xml:lang="en-US">Foreign Currency Transaction [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_PostemploymentBenefitsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PostemploymentBenefitsAbstract_2_lbl" xml:lang="en-US">Postemployment Benefits [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision" xlink:to="igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision_3_lbl" xml:lang="en-US">ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ChangeInFairValueOfSeriesaWarrants" xlink:to="igap_ChangeInFairValueOfSeriesaWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ChangeInFairValueOfSeriesaWarrants_3_lbl" xml:lang="en-US">ChangeInFairValueOfSeriesaWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_2_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_2_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_2_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Compensation Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_2_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Other General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_2_lbl" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments_2_lbl" xml:lang="en-US">Other Preferred Stock Dividends and Adjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_2_lbl" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igap_ClassOfWarrantOrRightExercisePriceDomain" xlink:to="igap_ClassOfWarrantOrRightExercisePriceDomain_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igap_ClassOfWarrantOrRightExercisePriceDomain_2_lbl" xml:lang="en-US">ClassOfWarrantOrRightExercisePriceDomain</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>igap-20151231_pre.xml
<DESCRIPTION>TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: Integrity Applications, Inc. 12%2D31%2D15 10K Final To Use To File.xfr; Date: 2016%2D03%2D30T13:08:15Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80460001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://integrity-app.com/role/igap-daei1" xlink:href="igap-20151231.xsd#igap-daei1" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cbs" xlink:href="igap-20151231.xsd#igap-cbs" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cbsp" xlink:href="igap-20151231.xsd#igap-cbsp" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/Statement-CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:href="igap-20151231.xsd#Statement-CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="igap-20151231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-csocf" xlink:href="igap-20151231.xsd#igap-csocf" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-csocfp" xlink:href="igap-20151231.xsd#igap-csocfp" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-g" xlink:href="igap-20151231.xsd#igap-g" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sosap" xlink:href="igap-20151231.xsd#igap-sosap" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-i" xlink:href="igap-20151231.xsd#igap-i" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-oca" xlink:href="igap-20151231.xsd#igap-oca" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-paen" xlink:href="igap-20151231.xsd#igap-paen" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ocl" xlink:href="igap-20151231.xsd#igap-ocl" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-loc" xlink:href="igap-20151231.xsd#igap-loc" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-llfs" xlink:href="igap-20151231.xsd#igap-llfs" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cacl" xlink:href="igap-20151231.xsd#igap-cacl" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrp" xlink:href="igap-20151231.xsd#igap-cspsawwrp" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-rade" xlink:href="igap-20151231.xsd#igap-rade" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-smagaae" xlink:href="igap-20151231.xsd#igap-smagaae" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-fien" xlink:href="igap-20151231.xsd#igap-fien" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-it" xlink:href="igap-20151231.xsd#igap-it" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ilps" xlink:href="igap-20151231.xsd#igap-ilps" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-si" xlink:href="igap-20151231.xsd#igap-si" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-rp" xlink:href="igap-20151231.xsd#igap-rp" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-se" xlink:href="igap-20151231.xsd#igap-se" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sosapp" xlink:href="igap-20151231.xsd#igap-sosapp" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sosapt" xlink:href="igap-20151231.xsd#igap-sosapt" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-it1" xlink:href="igap-20151231.xsd#igap-it1" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ocat" xlink:href="igap-20151231.xsd#igap-ocat" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-paent" xlink:href="igap-20151231.xsd#igap-paent" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-oclt" xlink:href="igap-20151231.xsd#igap-oclt" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwdpt" xlink:href="igap-20151231.xsd#igap-cspsawwdpt" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-radet" xlink:href="igap-20151231.xsd#igap-radet" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-smagaaet" xlink:href="igap-20151231.xsd#igap-smagaaet" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-fient" xlink:href="igap-20151231.xsd#igap-fient" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-itt" xlink:href="igap-20151231.xsd#igap-itt" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ilpst" xlink:href="igap-20151231.xsd#igap-ilpst" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sit" xlink:href="igap-20151231.xsd#igap-sit" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-gd" xlink:href="igap-20151231.xsd#igap-gd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sosapd" xlink:href="igap-20151231.xsd#igap-sosapd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" xlink:href="igap-20151231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesLiabilityForEmployeeRightsUponRetirementDetails" xlink:href="igap-20151231.xsd#SummaryOfSignificantAccountingPoliciesLiabilityForEmployeeRightsUponRetirementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesRoyalty-bearingGrantsDetails" xlink:href="igap-20151231.xsd#SummaryOfSignificantAccountingPoliciesRoyalty-bearingGrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-id" xlink:href="igap-20151231.xsd#igap-id" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ocad1" xlink:href="igap-20151231.xsd#igap-ocad1" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-paend" xlink:href="igap-20151231.xsd#igap-paend" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ocld" xlink:href="igap-20151231.xsd#igap-ocld" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-locd" xlink:href="igap-20151231.xsd#igap-locd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-llfsd" xlink:href="igap-20151231.xsd#igap-llfsd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cacld" xlink:href="igap-20151231.xsd#igap-cacld" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLeasesDetails" xlink:href="igap-20151231.xsd#CommitmentsAndContingentLiabilitiesLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesOfferingDetails" xlink:href="igap-20151231.xsd#CommitmentsAndContingentLiabilitiesOfferingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLitigationDetails" xlink:href="igap-20151231.xsd#CommitmentsAndContingentLiabilitiesLitigationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpdoratsd" xlink:href="igap-20151231.xsd#igap-cspsawwrpdoratsd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpod" xlink:href="igap-20151231.xsd#igap-cspsawwrpod" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpwwdrpd" xlink:href="igap-20151231.xsd#igap-cspsawwrpwwdrpd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommonStockPreferredStockAndWarrantsWith-downRoundProtectionChangesInFairValueOfLevel3LiabilityDetails" xlink:href="igap-20151231.xsd#CommonStockPreferredStockAndWarrantsWith-downRoundProtectionChangesInFairValueOfLevel3LiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpsowid" xlink:href="igap-20151231.xsd#igap-cspsawwrpsowid" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpgtnd" xlink:href="igap-20151231.xsd#igap-cspsawwrpgtnd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpgtend" xlink:href="igap-20151231.xsd#igap-cspsawwrpgtend" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpsosogted" xlink:href="igap-20151231.xsd#igap-cspsawwrpsosogted" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpsoiaood" xlink:href="igap-20151231.xsd#igap-cspsawwrpsoiaood" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpsoautvod" xlink:href="igap-20151231.xsd#igap-cspsawwrpsoautvod" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-cspsawwrpcsapsd" xlink:href="igap-20151231.xsd#igap-cspsawwrpcsapsd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-raded" xlink:href="igap-20151231.xsd#igap-raded" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-smagaaed" xlink:href="igap-20151231.xsd#igap-smagaaed" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-fiend" xlink:href="igap-20151231.xsd#igap-fiend" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-itdtd" xlink:href="igap-20151231.xsd#igap-itdtd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-itrostrteitrd" xlink:href="igap-20151231.xsd#igap-itrostrteitrd" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/IncomeTaxDeferredTaxesDetails" xlink:href="igap-20151231.xsd#IncomeTaxDeferredTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-ilpsd1" xlink:href="igap-20151231.xsd#igap-ilpsd1" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/igap-sirbotcld" xlink:href="igap-20151231.xsd#igap-sirbotcld" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/RelatedPartiesDetails" xlink:href="igap-20151231.xsd#RelatedPartiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SubsequentEventsDetails" xlink:href="igap-20151231.xsd#SubsequentEventsDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-daei1" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_DocumentAndEntityInformationAbstract" xlink:label="loc_igapDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cbs" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaapRestrictedCashAndInvestmentsNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapRestrictedCashAndInvestmentsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_FundsInRespectOfEmployeeRightsUponRetirementNoncurrent" xlink:label="loc_igapFundsInRespectOfEmployeeRightsUponRetirementNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_igapFundsInRespectOfEmployeeRightsUponRetirementNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersNoncurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDueToOfficersOrStockholdersNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaapPostemploymentBenefitsLiabilityNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapPostemploymentBenefitsLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaapTemporaryEquityAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityPreferredCarryingAmount" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityAbstract" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cbsp" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaapTemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" xlink:to="loc_us-gaapTemporaryEquitySharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/Statement-CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_FinancingIncomeExpensesNet" xlink:label="loc_igapFinancingIncomeExpensesNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_igapFinancingIncomeExpensesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaapStockholdersEquityOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityOtherShares" xlink:label="loc_us-gaapStockholdersEquityOtherShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityOtherShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued" xlink:label="loc_igapAdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapAdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities" xlink:label="loc_igapAdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapAdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" xlink:label="loc_igapStockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapStockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" xlink:label="loc_igapStockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapStockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsStock" xlink:label="loc_us-gaapDividendsStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_StockIssuedDuringPeriodSharesStockDividend" xlink:label="loc_igapStockIssuedDuringPeriodSharesStockDividend" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapStockIssuedDuringPeriodSharesStockDividend" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="loc_us-gaapDividendsPreferredStockStock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStockStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="loc_us-gaapPreferredStockDividendsShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-csocf" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPostemploymentObligations" xlink:label="loc_us-gaapIncreaseDecreaseInPostemploymentObligations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPostemploymentObligations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:label="loc_igapLinkageDifferenceOnPrincipalOfLoansFromStockholders" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_igapLinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_GainLossOnUnitConversion" xlink:label="loc_igapGainLossOnUnitConversion" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_igapGainLossOnUnitConversion" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_igapIncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_igapIncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaapIncreaseDecreaseInRestrictedCash" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfShortTermDebt" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapPaymentsOfDividendsPreferredStockAndPreferenceStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-csocfp" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaapConversionOfStockTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapConversionOfStockTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaapConversionOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockTable" xlink:to="loc_us-gaapConversionOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockTable" xlink:to="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaapConversionOfStockNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" xlink:to="loc_us-gaapConversionOfStockNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ConversionOfPreferredStockIntoCommonStockMember" xlink:label="loc_igapConversionOfPreferredStockIntoCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockNameDomain" xlink:to="loc_igapConversionOfPreferredStockIntoCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB1WarrantMember" xlink:label="loc_igapSeriesB1WarrantMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB1WarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB2WarrantMember" xlink:label="loc_igapSeriesB2WarrantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB2WarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock" xlink:label="loc_igapAmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_igapAmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfWarrantsExchanged" xlink:label="loc_igapNumberOfWarrantsExchanged" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_igapNumberOfWarrantsExchanged" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants" xlink:label="loc_igapIncreaseDecreaseInEquityDueToExchangeOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_igapIncreaseDecreaseInEquityDueToExchangeOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange" xlink:label="loc_igapNoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_igapNoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsCommonStockStock" xlink:label="loc_us-gaapDividendsCommonStockStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockLineItems" xlink:to="loc_us-gaapDividendsCommonStockStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-g" xlink:title="00000008 - Disclosure - GENERAL">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sosap" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-i" xlink:title="00000010 - Disclosure - INVENTORIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-oca" xlink:title="00000011 - Disclosure - OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-paen" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ocl" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_OtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="loc_igapOtherCurrentLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_igapOtherCurrentLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-loc" xlink:title="00000014 - Disclosure - LINE OF CREDIT">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="loc_us-gaapLineOfCreditFacilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-llfs" xlink:title="00000015 - Disclosure - LONG-TERM LOANS FROM STOCKHOLDERS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cacl" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrp" xlink:title="00000017 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" xlink:label="loc_igapStockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_igapStockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-rade" xlink:title="00000018 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-smagaae" xlink:title="00000019 - Disclosure - SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpenseAbstract" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SellingGeneralAndAdministrativeExpenseTextBlock" xlink:label="loc_igapSellingGeneralAndAdministrativeExpenseTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_igapSellingGeneralAndAdministrativeExpenseTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-fien" xlink:title="00000020 - Disclosure - FINANCING (INCOME) EXPENSES, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_FinancingExpensesNetDisclosureTextBlock" xlink:label="loc_igapFinancingExpensesNetDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_igapFinancingExpensesNetDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-it" xlink:title="00000021 - Disclosure - INCOME TAX">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ilps" xlink:title="00000022 - Disclosure - INCOME (LOSS) PER SHARE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-si" xlink:title="00000023 - Disclosure - SEGMENT INFORMATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-rp" xlink:title="00000024 - Disclosure - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-se" xlink:title="00000025 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sosapp" xlink:title="00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:label="loc_us-gaapPensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionServicesRoyaltyFees" xlink:label="loc_us-gaapRevenueRecognitionServicesRoyaltyFees" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionServicesRoyaltyFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="loc_us-gaapStandardProductWarrantyPolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStandardProductWarrantyPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaapDebtPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TemporaryEquityPolicyPolicyTextBlock" xlink:label="loc_igapTemporaryEquityPolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_igapTemporaryEquityPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sosapt" xlink:title="00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" xlink:label="loc_us-gaapScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ScheduleOfPropertyRatesOfDepreciationTableTextBlock" xlink:label="loc_igapScheduleOfPropertyRatesOfDepreciationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_igapScheduleOfPropertyRatesOfDepreciationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-it1" xlink:title="00000028 - Disclosure - INVENTORIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ocat" xlink:title="00000029 - Disclosure - OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-paent" xlink:title="00000030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-oclt" xlink:title="00000031 - Disclosure - OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwdpt" xlink:title="00000032 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:label="loc_us-gaapFairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapFairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-radet" xlink:title="00000033 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xlink:label="loc_igapScheduleOfResearchAndDevelopmentExpensesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_igapScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-smagaaet" xlink:title="00000034 - Disclosure - SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpenseAbstract" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SellingGeneralAndAdministrativeExpenseTableTextBlock" xlink:label="loc_igapSellingGeneralAndAdministrativeExpenseTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_igapSellingGeneralAndAdministrativeExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-fient" xlink:title="00000035 - Disclosure - FINANCING (INCOME) EXPENSES, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-itt" xlink:title="00000036 - Disclosure - INCOME TAX (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ilpst" xlink:title="00000037 - Disclosure - INCOME (LOSS) PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sit" xlink:title="00000038 - Disclosure - SEGMENT INFORMATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-gd" xlink:title="00000039 - Disclosure - GENERAL (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaapCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB1WarrantMember" xlink:label="loc_igapSeriesB1WarrantMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB1WarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB2WarrantMember" xlink:label="loc_igapSeriesB2WarrantMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB2WarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="loc_igapProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_igapProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:label="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockConversionPrice" xlink:label="loc_igapPreferredStockConversionPrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_igapPreferredStockConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightTerm" xlink:label="loc_igapClassOfWarrantOrRightTerm" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_igapClassOfWarrantOrRightTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion" xlink:label="loc_igapConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_igapConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sosapd" xlink:title="00000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Functional Currency) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionAbstract" xlink:label="loc_us-gaapForeignCurrencyTransactionAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AverageForeignCurrencyExchangeRateTranslation" xlink:label="loc_igapAverageForeignCurrencyExchangeRateTranslation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapForeignCurrencyTransactionAbstract" xlink:to="loc_igapAverageForeignCurrencyExchangeRateTranslation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" xlink:title="00000041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property and equipment, net) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PropertyPlantAndEquipmentDepreciationRate" xlink:label="loc_igapPropertyPlantAndEquipmentDepreciationRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_igapPropertyPlantAndEquipmentDepreciationRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesLiabilityForEmployeeRightsUponRetirementDetails" xlink:title="00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Liability for employee rights upon retirement) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="loc_us-gaapPostemploymentBenefitsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPostemploymentBenefitsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="loc_us-gaapPostemploymentBenefitsPeriodExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPostemploymentBenefitsAbstract" xlink:to="loc_us-gaapPostemploymentBenefitsPeriodExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesRoyalty-bearingGrantsDetails" xlink:title="00000043 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Royalty-bearing grants) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaapRevenueFromGrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapRevenueFromGrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-id" xlink:title="00000044 - Disclosure - INVENTORIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ocad1" xlink:title="00000045 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-paend" xlink:title="00000046 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ocld" xlink:title="00000047 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-locd" xlink:title="00000048 - Disclosure - LINE OF CREDIT (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="loc_us-gaapLineOfCreditFacilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaapCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCurrencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-llfsd" xlink:title="00000049 - Disclosure - LONG-TERM LOANS FROM STOCKHOLDERS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PercentOfFutureSalesDesignatedToRepayStockholdersLoans" xlink:label="loc_igapPercentOfFutureSalesDesignatedToRepayStockholdersLoans" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_igapPercentOfFutureSalesDesignatedToRepayStockholdersLoans" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cacld" xlink:title="00000050 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Grants) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOtherCommitmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaapLossContingenciesByNatureOfContingencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapLossContingenciesByNatureOfContingencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaapLossContingencyNatureDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesByNatureOfContingencyAxis" xlink:to="loc_us-gaapLossContingencyNatureDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PaymentOfRoyaltiesToOcsMember" xlink:label="loc_igapPaymentOfRoyaltiesToOcsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingencyNatureDomain" xlink:to="loc_igapPaymentOfRoyaltiesToOcsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaapCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaapRevenueFromGrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapRevenueFromGrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyRangeOfPossibleLossMaximum" xlink:label="loc_us-gaapLossContingencyRangeOfPossibleLossMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapLossContingencyRangeOfPossibleLossMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RoyaltyPercentMinimum" xlink:label="loc_igapRoyaltyPercentMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_igapRoyaltyPercentMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RoyaltyPercentForYearsFourThroughSix" xlink:label="loc_igapRoyaltyPercentForYearsFourThroughSix" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_igapRoyaltyPercentForYearsFourThroughSix" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RoyaltyPercentMaximum" xlink:label="loc_igapRoyaltyPercentMaximum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_igapRoyaltyPercentMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:label="loc_us-gaapLossContingencyRangeOfPossibleLossPortionNotAccrued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapLossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLeasesDetails" xlink:title="00000051 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Leases) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaapScheduleOfOperatingLeasedAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOperatingLeasedAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaapOperatingLeasedAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfOperatingLeasedAssetsTable" xlink:to="loc_us-gaapOperatingLeasedAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaapLeaseArrangementTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfOperatingLeasedAssetsTable" xlink:to="loc_us-gaapLeaseArrangementTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaapLeaseArrangementTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseArrangementTypeAxis" xlink:to="loc_us-gaapLeaseArrangementTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PropertyAshkelonIsraelMember" xlink:label="loc_igapPropertyAshkelonIsraelMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseArrangementTypeDomain" xlink:to="loc_igapPropertyAshkelonIsraelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PropertyAshdodIsraelMember" xlink:label="loc_igapPropertyAshdodIsraelMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseArrangementTypeDomain" xlink:to="loc_igapPropertyAshdodIsraelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaapCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfOperatingLeasedAssetsTable" xlink:to="loc_us-gaapCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeasedAssetsLineItems" xlink:to="loc_us-gaapLeasesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AreaOfLeasedSpace" xlink:label="loc_igapAreaOfLeasedSpace" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_igapAreaOfLeasedSpace" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_MonthlyLeaseCommitment" xlink:label="loc_igapMonthlyLeaseCommitment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_igapMonthlyLeaseCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_LeaseGuaranteeProvidedToLandlord" xlink:label="loc_igapLeaseGuaranteeProvidedToLandlord" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_igapLeaseGuaranteeProvidedToLandlord" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesOfferingDetails" xlink:title="00000052 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Offering) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:to="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AgreementWithPlacementAgentMember" xlink:label="loc_igapAgreementWithPlacementAgentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapAgreementWithPlacementAgentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_DecemberOfferingMember" xlink:label="loc_igapDecemberOfferingMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapDecemberOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegistrationPaymentArrangementManagementFeeMember" xlink:label="loc_igapRegistrationPaymentArrangementManagementFeeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapRegistrationPaymentArrangementManagementFeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegistrationPaymentArrangementExpenseAllowanceMember" xlink:label="loc_igapRegistrationPaymentArrangementExpenseAllowanceMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapRegistrationPaymentArrangementExpenseAllowanceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandTwelveOfferingMember" xlink:label="loc_igapTwoThousandTwelveOfferingMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandTwelveOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegistrationPaymentCommissionRateMember" xlink:label="loc_igapRegistrationPaymentCommissionRateMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapRegistrationPaymentCommissionRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandFourteenOfferingMember" xlink:label="loc_igapTwoThousandFourteenOfferingMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandFourteenOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandFourteenOfferingsMember" xlink:label="loc_igapTwoThousandFourteenOfferingsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandFourteenOfferingsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:label="loc_us-gaapRegistrationPaymentArrangementMaximumPotentialConsideration" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRegistrationPaymentArrangementMaximumPotentialConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegistrationPaymentArrangementCommissionPercentage" xlink:label="loc_igapRegistrationPaymentArrangementCommissionPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapRegistrationPaymentArrangementCommissionPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal" xlink:label="loc_igapRegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapRegistrationPaymentArrangementPeriodDuringWhichPlacementAgentHaveRightOfFirstRefusal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen" xlink:label="loc_igapMonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapMonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen" xlink:label="loc_igapMonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_igapMonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLitigationDetails" xlink:title="00000053 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Litigation) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaapLitigationStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLitigationStatusAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaapLitigationStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLitigationStatusAxis" xlink:to="loc_us-gaapLitigationStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_JudicialRulingMember" xlink:label="loc_us-gaapJudicialRulingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLitigationStatusDomain" xlink:to="loc_us-gaapJudicialRulingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaapCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision" xlink:label="loc_igapNumberOfCommonStockOfEntityTransferredUnderArbitrationDecision" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_igapNumberOfCommonStockOfEntityTransferredUnderArbitrationDecision" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountPaidAsRepaymentOfPrincipalAmount" xlink:label="loc_igapAmountPaidAsRepaymentOfPrincipalAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_igapAmountPaidAsRepaymentOfPrincipalAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ForeignCurrencyExchangeRate" xlink:label="loc_igapForeignCurrencyExchangeRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_igapForeignCurrencyExchangeRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PartialReimbursementOfAttorneyFeesRequiredToPay" xlink:label="loc_igapPartialReimbursementOfAttorneyFeesRequiredToPay" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_igapPartialReimbursementOfAttorneyFeesRequiredToPay" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpdoratsd" xlink:title="00000054 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Description of Rights Attached to Stock) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaapTemporaryEquityByClassOfStockTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityByClassOfStockTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaapTemporaryEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapTemporaryEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaapCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapStatementScenarioAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockStatedValue" xlink:label="loc_igapPreferredStockStatedValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockStatedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockDividendPaymentRequirementThreshold" xlink:label="loc_igapPreferredStockDividendPaymentRequirementThreshold" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockDividendPaymentRequirementThreshold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockDividendLateFee" xlink:label="loc_igapPreferredStockDividendLateFee" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockDividendLateFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="loc_us-gaapPreferredStockDividendsShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapPreferredStockDividendsShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsCommonStockStock" xlink:label="loc_us-gaapDividendsCommonStockStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapDividendsCommonStockStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockConvertibleStockPriceTrigger" xlink:label="loc_igapPreferredStockConvertibleStockPriceTrigger" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockConvertibleStockPriceTrigger" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockConvertibleTradingVolumeTrigger" xlink:label="loc_igapPreferredStockConvertibleTradingVolumeTrigger" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockConvertibleTradingVolumeTrigger" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockPercentageOutstandingGoverningDistributions" xlink:label="loc_igapPreferredStockPercentageOutstandingGoverningDistributions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockPercentageOutstandingGoverningDistributions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockMaximumBeneficialOwnership" xlink:label="loc_igapPreferredStockMaximumBeneficialOwnership" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockMaximumBeneficialOwnership" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockMaximumBeneficialOwnershipSubjectToTerms" xlink:label="loc_igapPreferredStockMaximumBeneficialOwnershipSubjectToTerms" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockMaximumBeneficialOwnershipSubjectToTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PreferredStockConversionPrice" xlink:label="loc_igapPreferredStockConversionPrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapPreferredStockConversionPrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpod" xlink:title="00000055 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Offering) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaapTemporaryEquityByClassOfStockTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityByClassOfStockTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaapTemporaryEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapTemporaryEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:to="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandTwelveOfferingMember" xlink:label="loc_igapTwoThousandTwelveOfferingMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandTwelveOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandFourteenOfferingMember" xlink:label="loc_igapTwoThousandFourteenOfferingMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandFourteenOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapStatementScenarioAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaapScenarioPlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_us-gaapScenarioPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB1WarrantMember" xlink:label="loc_igapSeriesB1WarrantMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB1WarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB2WarrantMember" xlink:label="loc_igapSeriesB2WarrantMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB2WarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_WarrantsIssuedUnderSecuritiesPurchaseAgreementMember" xlink:label="loc_igapWarrantsIssuedUnderSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapWarrantsIssuedUnderSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember" xlink:label="loc_igapWarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapWarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_EquityIssuancePricePerShare" xlink:label="loc_igapEquityIssuancePricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapEquityIssuancePricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfSharesOffered" xlink:label="loc_igapNumberOfSharesOffered" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapNumberOfSharesOffered" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ProceedsFromUnitsSold" xlink:label="loc_igapProceedsFromUnitsSold" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapProceedsFromUnitsSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfUnitsSold" xlink:label="loc_igapNumberOfUnitsSold" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapNumberOfUnitsSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ConvertiblePreferredStockConversionPrice" xlink:label="loc_igapConvertiblePreferredStockConversionPrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapConvertiblePreferredStockConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion" xlink:label="loc_igapConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightTerm" xlink:label="loc_igapClassOfWarrantOrRightTerm" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapClassOfWarrantOrRightTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:label="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityOtherChanges" xlink:label="loc_us-gaapTemporaryEquityOtherChanges" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapTemporaryEquityOtherChanges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_StockPriceAtWhichStockDividendIsDeclared" xlink:label="loc_igapStockPriceAtWhichStockDividendIsDeclared" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapStockPriceAtWhichStockDividendIsDeclared" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsStock" xlink:label="loc_us-gaapDividendsStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapDividendsStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockDividendsShares" xlink:label="loc_us-gaapStockDividendsShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapStockDividendsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_OfferingCostsIncurred" xlink:label="loc_igapOfferingCostsIncurred" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapOfferingCostsIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapTemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapTemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock" xlink:label="loc_igapAmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapAmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfWarrantsExchanged" xlink:label="loc_igapNumberOfWarrantsExchanged" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapNumberOfWarrantsExchanged" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange" xlink:label="loc_igapNoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_igapNoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpwwdrpd" xlink:title="00000056 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Warrants with down round protection) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesAWarrantMember" xlink:label="loc_igapSeriesAWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesAWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB1WarrantMember" xlink:label="loc_igapSeriesB1WarrantMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB1WarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_SeriesB2WarrantMember" xlink:label="loc_igapSeriesB2WarrantMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapSeriesB2WarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightTerm" xlink:label="loc_igapClassOfWarrantOrRightTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_igapClassOfWarrantOrRightTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightNumberOfWarrantsExercisable" xlink:label="loc_igapClassOfWarrantOrRightNumberOfWarrantsExercisable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_igapClassOfWarrantOrRightNumberOfWarrantsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfWarrantsExchanged" xlink:label="loc_igapNumberOfWarrantsExchanged" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_igapNumberOfWarrantsExchanged" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommonStockPreferredStockAndWarrantsWith-downRoundProtectionChangesInFairValueOfLevel3LiabilityDetails" xlink:title="00000057 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Changes in Fair Value of Level 3 Liability) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision" xlink:label="loc_igapExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_igapExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ChangeInFairValueOfSeriesaWarrants" xlink:label="loc_igapChangeInFairValueOfSeriesaWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_igapChangeInFairValueOfSeriesaWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpsowid" xlink:title="00000058 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Warrant Inputs) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementScenarioAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaapFairValueAssumptionsExpectedTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightFairValue" xlink:label="loc_igapClassOfWarrantOrRightFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_igapClassOfWarrantOrRightFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpgtnd" xlink:title="00000059 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Non-Employees) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:label="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:to="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandTwelveOfferingMember" xlink:label="loc_igapTwoThousandTwelveOfferingMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandTwelveOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandTenOfferingMember" xlink:label="loc_igapTwoThousandTenOfferingMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandTenOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TwoThousandFourteenOfferingMember" xlink:label="loc_igapTwoThousandFourteenOfferingMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_igapTwoThousandFourteenOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceAxis" xlink:label="loc_igapClassOfWarrantOrRightExercisePriceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="loc_igapClassOfWarrantOrRightExercisePriceAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceDomain" xlink:label="loc_igapClassOfWarrantOrRightExercisePriceDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapClassOfWarrantOrRightExercisePriceAxis" xlink:to="loc_igapClassOfWarrantOrRightExercisePriceDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceOneMember" xlink:label="loc_igapClassOfWarrantOrRightExercisePriceOneMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapClassOfWarrantOrRightExercisePriceDomain" xlink:to="loc_igapClassOfWarrantOrRightExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceTwoMember" xlink:label="loc_igapClassOfWarrantOrRightExercisePriceTwoMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapClassOfWarrantOrRightExercisePriceDomain" xlink:to="loc_igapClassOfWarrantOrRightExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceThreeMember" xlink:label="loc_igapClassOfWarrantOrRightExercisePriceThreeMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapClassOfWarrantOrRightExercisePriceDomain" xlink:to="loc_igapClassOfWarrantOrRightExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceFourMember" xlink:label="loc_igapClassOfWarrantOrRightExercisePriceFourMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapClassOfWarrantOrRightExercisePriceDomain" xlink:to="loc_igapClassOfWarrantOrRightExercisePriceFourMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightExercisePriceFiveMember" xlink:label="loc_igapClassOfWarrantOrRightExercisePriceFiveMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_igapClassOfWarrantOrRightExercisePriceDomain" xlink:to="loc_igapClassOfWarrantOrRightExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="loc_us-gaapRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_WarrantsIssuedToPlacementAgentTrancheOneMember" xlink:label="loc_igapWarrantsIssuedToPlacementAgentTrancheOneMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapWarrantsIssuedToPlacementAgentTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_WarrantsIssuedToPlacementAgentTrancheTwoMember" xlink:label="loc_igapWarrantsIssuedToPlacementAgentTrancheTwoMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_igapWarrantsIssuedToPlacementAgentTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RegulatoryServicesMember" xlink:label="loc_igapRegulatoryServicesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="loc_igapRegulatoryServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_InvestorFindersMember" xlink:label="loc_igapInvestorFindersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="loc_igapInvestorFindersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PlacementAgentMember" xlink:label="loc_igapPlacementAgentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="loc_igapPlacementAgentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_InvestorRelationsServicesProviderMember" xlink:label="loc_igapInvestorRelationsServicesProviderMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="loc_igapInvestorRelationsServicesProviderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="loc_us-gaapAwardDateAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_GrantDate1Member" xlink:label="loc_igapGrantDate1Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_igapGrantDate1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_GrantDate2Member" xlink:label="loc_igapGrantDate2Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_igapGrantDate2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightTerm" xlink:label="loc_igapClassOfWarrantOrRightTerm" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_igapClassOfWarrantOrRightTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities" xlink:label="loc_igapAdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_igapAdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightPostAdjustmentFairValue" xlink:label="loc_igapClassOfWarrantOrRightPostAdjustmentFairValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_igapClassOfWarrantOrRightPostAdjustmentFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantOrRightPreAdjustmentFairValue" xlink:label="loc_igapClassOfWarrantOrRightPreAdjustmentFairValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_igapClassOfWarrantOrRightPreAdjustmentFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ClassOfWarrantRightExpenseOrRevenueRecognized" xlink:label="loc_igapClassOfWarrantRightExpenseOrRevenueRecognized" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="loc_igapClassOfWarrantRightExpenseOrRevenueRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpgtend" xlink:title="00000060 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Employees Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_IntegrityIsraelPlanMember" xlink:label="loc_igapIntegrityIsraelPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_igapIntegrityIsraelPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ShareIncentivePlanMember" xlink:label="loc_igapShareIncentivePlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_igapShareIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaapChiefExecutiveOfficerMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExecutiveVicePresidentMember" xlink:label="loc_us-gaapExecutiveVicePresidentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapExecutiveVicePresidentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_GrantsToMessrsGalAndMalkaMember" xlink:label="loc_igapGrantsToMessrsGalAndMalkaMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_igapGrantsToMessrsGalAndMalkaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne" xlink:label="loc_igapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_igapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo" xlink:label="loc_igapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_igapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpsosogted" xlink:title="00000061 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Status of Grants to Employees) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpsoiaood" xlink:title="00000062 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Information about Options Outstanding) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeOneMember" xlink:label="loc_igapRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_igapRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeTwoMember" xlink:label="loc_igapRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_igapRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeThreeMember" xlink:label="loc_igapRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_igapRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeFourMember" xlink:label="loc_igapRangeFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_igapRangeFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RangeFiveMember" xlink:label="loc_igapRangeFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_igapRangeFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpsoautvod" xlink:title="00000063 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Assumptions Used to Value Options) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-cspsawwrpcsapsd" xlink:title="00000064 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Convertible Series A Preferred Stock) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaapTemporaryEquityByClassOfStockTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityByClassOfStockTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaapTemporaryEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapTemporaryEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaapConversionOfStockNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" xlink:to="loc_us-gaapConversionOfStockNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ConversionOfPreferredStockIntoCommonStockMember" xlink:label="loc_igapConversionOfPreferredStockIntoCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockNameDomain" xlink:to="loc_igapConversionOfPreferredStockIntoCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityByClassOfStockTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityOtherChanges" xlink:label="loc_us-gaapTemporaryEquityOtherChanges" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapTemporaryEquityOtherChanges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-raded" xlink:title="00000065 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTravelAndEntertainmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:label="loc_us-gaapCostOfPropertyRepairsAndMaintenance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfPropertyRepairsAndMaintenance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherGeneralExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-smagaaed" xlink:title="00000066 - Disclosure - SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpenseAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapTravelAndEntertainmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:label="loc_us-gaapCostOfPropertyRepairsAndMaintenance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapCostOfPropertyRepairsAndMaintenance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-fiend" xlink:title="00000067 - Disclosure - FINANCING (INCOME) EXPENSES, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:label="loc_igapLinkageDifferenceOnPrincipalOfLoansFromStockholders" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_igapLinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RecapitalizationCosts" xlink:label="loc_us-gaapRecapitalizationCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapRecapitalizationCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_GainLossOnUnitConversion" xlink:label="loc_igapGainLossOnUnitConversion" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_igapGainLossOnUnitConversion" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_FinancingIncomeExpensesNet" xlink:label="loc_igapFinancingIncomeExpensesNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_igapFinancingIncomeExpensesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-itdtd" xlink:title="00000068 - Disclosure - INCOME TAX (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="loc_us-gaapParentCompanyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_us-gaapParentCompanyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AdIntegrityApplicationsLtdMember" xlink:label="loc_igapAdIntegrityApplicationsLtdMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_igapAdIntegrityApplicationsLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-itrostrteitrd" xlink:title="00000069 - Disclosure - INCOME TAX (Reconciliation of Statutory Tax Rate to the Effective Income Tax Rate) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants" xlink:label="loc_igapIncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_igapIncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/IncomeTaxDeferredTaxesDetails" xlink:title="00000070 - Disclosure - INCOME TAX (Deferred Taxes) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxesAbstract" xlink:label="loc_us-gaapDeferredIncomeTaxesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-ilpsd1" xlink:title="00000071 - Disclosure - INCOME (LOSS) PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="loc_us-gaapOtherPreferredStockDividendsAndAdjustments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherPreferredStockDividendsAndAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaapUndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/igap-sirbotcld" xlink:title="00000072 - Disclosure - SEGMENT INFORMATION (Revenues based on the customer's location) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaapStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_us-gaapStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaapSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementGeographicalAxis" xlink:to="loc_us-gaapSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaapEuropeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_us-gaapEuropeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AsiaPacificMember" xlink:label="loc_us-gaapAsiaPacificMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_us-gaapAsiaPacificMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/RelatedPartiesDetails" xlink:title="00000073 - Disclosure - RELATED PARTIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AvnerGalMember" xlink:label="loc_igapAvnerGalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_igapAvnerGalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_DavidMalkaMember" xlink:label="loc_igapDavidMalkaMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_igapDavidMalkaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaapCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_RelatedPartyTransactionOwnershipInterestInEntity" xlink:label="loc_igapRelatedPartyTransactionOwnershipInterestInEntity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_igapRelatedPartyTransactionOwnershipInterestInEntity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_PortionOfRelatedPartySalaryRelatingToBonusesPaid" xlink:label="loc_igapPortionOfRelatedPartySalaryRelatingToBonusesPaid" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_igapPortionOfRelatedPartySalaryRelatingToBonusesPaid" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SubsequentEventsDetails" xlink:title="00000074 - Disclosure - SUBSEQUENT EVENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ShareIncentivePlanMember" xlink:label="loc_igapShareIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_igapShareIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_DirectorsMember" xlink:label="loc_igapDirectorsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_igapDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors" xlink:label="loc_igapAmountOfAnnualCashPaymentOwedToEachBoardOfDirectors" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_igapAmountOfAnnualCashPaymentOwedToEachBoardOfDirectors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountOfQuarterlyCompensationOwedToEachDirector" xlink:label="loc_igapAmountOfQuarterlyCompensationOwedToEachDirector" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_igapAmountOfQuarterlyCompensationOwedToEachDirector" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AnnualCompensationOwedToChairperson" xlink:label="loc_igapAnnualCompensationOwedToChairperson" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_igapAnnualCompensationOwedToChairperson" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_AmountOfQuarterlyCompensationOwedChairperson" xlink:label="loc_igapAmountOfQuarterlyCompensationOwedChairperson" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_igapAmountOfQuarterlyCompensationOwedChairperson" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant" xlink:label="loc_igapTotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_igapTotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_ExercisePriceOfOptionsGranted" xlink:label="loc_igapExercisePriceOfOptionsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_igapExercisePriceOfOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20151231.xsd#igap_NumberOfSharesVestingInEachIncrement" xlink:label="loc_igapNumberOfSharesVestingInEachIncrement" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_igapNumberOfSharesVestingInEachIncrement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img.jpg
<TEXT>
begin 644 img.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
M A$#$0 _ /[YKBXF29U5\*-N!M4]54GDJ3U-0_:I_P#GI_XZG_Q-%U_KY/\
M@/\ Z M5Z +'VJ?_ )Z?^.I_\30;N<<F3_QQ/_B:KYJ%FR3C./T_"@"R;VX[
M28'^Y'_\32?;;G_GI_XY'_\ $55HH M?;;G_ )Z?^.1__$4?;;G_ )Z?^.1_
M_$55HH M?;;G_GI_XY'_ /$4?;;G_GI_XY'_ /$55HH M?;;G_GI_P".1_\
MQ%'VVY_YZ?\ CD?_ ,156B@"U]MN?^>G_CD?_P 11]MN?^>G_CD?_P 156B@
M"U]MN?\ GI_XY'_\11]MN?\ GI_XY'_\156B@"U]MN?^>G_CD?\ \11]MN?^
M>G_CD?\ \156B@"U]MN?^>G_ (Y'_P#$4?;;G_GI_P".1_\ Q%5:* +7VVY_
MYZ?^.1__ !%'VVY_YZ?^.1__ !%5:* +7VVY_P">G_CD?_Q%*+VYR/WG<?P1
M_P#Q%5*4<8/;- %_[5/_ ,]/_'4_^)H^U3_\]/\ QU/_ (FJX.>Q_&B@"Q]J
MG_YZ?^.I_P#$T?:I_P#GI_XZG_Q-5Z* +'VJ?_GI_P".I_\ $T?:I_\ GI_X
MZG_Q-5Z* +'VJ?\ YZ?^.I_\31]JG_YZ?^.I_P#$U7HH L?:I_\ GI_XZG_Q
M-'VJ?_GI_P".I_\ $U7HH L?:I_^>G_CJ?\ Q-'VJ?\ YZ?^.I_\35>E')Q0
M!/\ :I_^>G_CJ?\ Q-'VJ?\ YZ?^.I_\3413 SG\*90!;6YFQR_O]U>G_?-3
MVTTDDK*S;E"D@;5'\2@= #T-4,G"X]\_3MGVQZ]JLV7^N;_KF?\ T)* ([K_
M %\G_ ?_ $!:KGH>WOZ58NO]?)_P'_T!:K$@8SWH AR>??K_ #I*5L9XZ4E'
M]?UZ[ %%%/".RE@C%1G+!25&.3EL8&!R<G@4:?UKV[76G:][II)L&[;_ -?U
M_P #<917EGB;XX?!_P (2?9]?^)/A&WOMJ,NE6.KV^N:W(LJ2O 8]#T$ZGJ[
M+<"&1+>3[&(IYE%O$[3.B'PGQ9^VY\+O#R3?V=HOBK5W7"0W6M)I'P^T>62:
M%9;)FN?&FHZ=K:V]X?/A5[?PW=7$,MK-]IM(8AYHWIX;$5G&-.C4DYM*-H-)
MMNR5VDKM^?ZF;JP5_>NXIMJ-Y2LMVHQ3D_DKWT/LG- R< <Y.,#G/; ]\U^?
MVJ?M1?%S6&QX=\-_#WPG;2)YL$M]/KOC[4C"TL4T+%()/!VE(\]JPMYE0WD,
M4TJW5K>W,>R(^%>.?C#XQ^SS?\+#^/VO:#9R))%<066OZ!\+[-8WCN'W6Z>'
M;;1]7E=+6:2/9-J=REX((IC;23Q!QZM'A[,JSE&5'V7)\;G&I-JUFTE14G)V
M=W&-Y6:>S1\_6XLR2DZ=.GBX8FK5E%0A1LVN:7*G4E.4(TH74DYU$E%PE=Z-
M+]8M=UW0_"]A+JOB?7-%\-:9!'+--J/B+5;#0["**",S3RR7FJ7%K;I'!$K2
MSN9-L48+R%5YKY4\4?M^_L9>#M1?2=:_:'\ S7\4US;SQ>')=7\8Q6T]H(C-
M%<WGA'2M;LH7Q*AA$EPHN5R]LTJHY'\BOC\Z[KOB_P 01Z_XWUCXB+9:W?VF
MG>)?$'B35/%AU2ULI)+#3-2MKW5;S4IY#<Z9'"$N0YE>+;$7>-3CRSQ;XBTW
MP-;VK:CL::Y<PV]I'-:VUU.JJ9'\BWF='G:% 7:..,_(H)PHK]@RWP;P#ITZ
MN:<05I>TA":I83#1H*//",TG5K^U=U?6]!=EOI\CBO$/$.<J> RN%XSE!3Q%
M:512Y79RY**@N5]&JKW7H?W;?#/XO?"_XS:"?$_PJ\=^&_'>AQND-S>:!J$=
MS+I]Q(@D6UU6PD$.I:3=E#G[+J=G:S]1L)5L>C5_&G_P3]_:5@^$7QU\%^/=
M*U6:'PGKE_!X7\>VF6B%SX=OY8[?48]2M=QC>;3/,&MZ?(0Y@N-/C^SLJS2!
M_P"RL,C!7B=98G59(I4.Y)8G4/'*C#ADD1E=&'#*P(X-?G'''"$^$,SI8:%>
M6,P.,H>WP>*G",)S46HUJ510;@ZE%RBW*"C%PE&3C%WBOL.&\^AGV#G6=)4,
M10J*EB**DY14G'FC.#E:7)45^7F2U3BKV0M%%%?%'T04444 %%%% !1110 4
MI/ [=L?3')'K0#@YHY8_6@"5/NC\?YTZD P,4M !112$@<=\XH 6BBD()Z''
M4?GCI^5 "T4T*/<GUR?Z4Z@ HHHH =\H_O?7 P?IFE0X//I_A3** )7/'!!Y
MJ*BB@"7@DXSG;CCI_G]*L68Q*?\ KD<^QW+Q57:PZ?H?Y_Y-6[-2)6)_N'_T
M): (;K_7R?\  ?\ T!:JLN?8^N*M77^OD_X#_P"@+5(@KTZ'_//O0 SD<5^9
M'[:/_!3GX7?LH>*F^%&A>'KCXK_&B+2+36=9\,66J0Z/X;\ V.K0F709/'.O
M?9[ZYCU76H<W^F>%](L+G5)M*3^T-1GT>RO--N;S].QM<C/!X&?8?IZU_%S_
M ,%#]'2P_;!_:$UZ!)VFU7XKZQ;:E/-.]P\EQ;:9IBZ47>9F:*WM]/A-C:VZ
ME8HK9(88@$5$K[OP]X?R[B+/XX/-)3^JTJ$Z\J-.I*FZ\E.C3A2E4@G.$&ZK
M<W&TFTHJ44V?-\4YIBLJRR5?!QA[>=:%)5)Q4U2BXN3FH/24U9I*7NIM/5)W
M^C?B'_P6(_; \8&:T\)2_#OX66DHE2-O"?A7^WM;@6:.W"%=9\9W.M0O/!+'
M/+#<1Z':HT=R\<\$NR)E^/=0_:K_ &AO&7B_P_XE^)?QA^(OCNQTGQ%IFK7>
M@Z[XGO6\-3V]MJJZA+;MX2M9K7P[/% S32V5O/I3Q0,L4,*I"BQ+\*?M_P#[
M57PU_8N_9^^%?B;2_!&M^/\ Q_\ $77;K2;.U65M(\.(VEZ79ZMK6H^(?%*P
M7DEM*$U"SL_#_AZRLWGU$0ZC>R7$$&GR>=^1ND?M'?\ !5?]H[X;ZQ\7_@;\
M"8O"_P )+2T\43:?XXTCPE!]E\17'@L:?%XLT7P+XB^(.H^1X]\3:&-;L9;S
MP_X-L]3UR.?%K;64EWML7_8,PQ_AWPK7K93#)*+QZIN$\/A<M>,QBA5I*I%>
MWQ"U;I34TUBN;5-PO[Q\!@,-QAGD*.8?VA4^JNHITZE;%*C0E*G4BFG1H\S:
M52'+RRH<K?NV:U/ZI=1_: T71)K.3PUXCU^6?PU')#IFO:#I5QI1\02WUQ#J
M.KZQK4^KWVFS:?9ZKJ6EZ)<WOAB.QOM.AEMM1MK29].NXT'RYXX_X*-?#/X/
M6UW;:O\ %CP#X"N9;N^OIY=:\<:?JOBJ&\N$-@K62:6/^$EM8+722WAZ/1HK
MRYTA=/+EK"+49)[MOX>/B!^TW^T%\4&E_P"$]^,/C_Q##/YGF6$WB.^L]*99
M-F]1I&FO9:6(FV*1&MH(P02%#%B?#6D:1V=RSR.Y=WD8LSLW+,[MEF+,2S$G
M+$\FOS.IQKD>$;65</SJR2LJV:8N6NS3>&PB4&F]>65::BG:/4_3\2^*<THQ
MH9AGN'PN'3BY8;*<KPM&.B:]VO6A4K_;FUS<W+*<N2,8M17]AOQ8_P"#@3X>
MV%G_ &5HOQ-^+7CV"PMHK&ST?X>:&/!&@0P6\8CM8AJFIRZ%>S0Q1Q16YFDC
MOYVC";I+DJQ/YO>+/^"R_P ;?B'JCZ7\%_V?[>^U;49VLM*N_$=SXG^)7B*[
MN6AFNHHHM)T*WTX3W8@M;VX^S+/>;H()I5"I!,U?&?[)OQ^^#7A+3;'PE>?!
M#]GC1_B=:>&/%XT;XU?&Q/$'B+PQ/XM_L_Q2N@:MK&E76G^*(M,UR#3_ !"V
MFZ'_ &>V@>";?6M \,:_K.C:CK=C;W!]R\3?M?Z'X#3XS:'X:_:8\7P>.O"&
MK>+=/^ 7C/\ 9N\+:=\._@]=:;9WWA_5_ .NV^F:CX9E\:SNVC6^N?#.U34K
MWP7XB\!Z"VD7T'B7Q9;G7]#U3/\ UXS>O0;PV.P>40?QT,JR[#4)P3=TG6Q<
MW*<VX;PJ):V=13G3@>72X.R.E/GK4ZF/JR3E[3%UZL^:IS1G)3C%4X=9-7IS
MCS7Y+)2DOESXA?\ !2K]LWX@M+%=?&/4_"UA.FUM-^'^GZ9X1MU1F9@BW>FV
MRZNRA28\OJ3M)&!YS2'D_3'[3W['?QJ_96^ '[%?_!1?PU\;/'?Q<\/?&7Q'
M>6\_BO7K![1/ 7Q4\+VNE^,=!T&WUVT\?^,YM?T#QQX1NYM9T>?6H?"&KS66
MGZUIFH>'(IK>^M[7\H=&\/\ C'XC>)XM(\,Z#XA\;>+_ !#J#O;Z+X:T:_U[
M7]8U"^G+.++2-'M+F\N[BZN9\".UMF9I945$RR@_4GQ]\5_MP_"[X8?"[]D?
M]H7Q9\9?"?P@TOPSH7QG^%WP%\5^);Z+P3I^A?$FWEUO1/&MCX-@O7TVWO\
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M_P 2OB#</J$26=_KWAFYAT7PCX;L+N:9_#ME!>ZM:00W.N1W*_C5&3E#Y(
M(;YR1N  .XG ./D8,<=P0#P,_5[[PO+:&S\17NCO:1NLT5O>2P221SD#]];(
M"]Q;W &52>V$=P1T(KYOBO(ZW$.3ULMP^.GE]6<Z=2-9*3A/D:DZ-6*E"?LZ
ML?=<H2YHNTE&:3B_8R+,:.5YA3QE;"K&0@I1=.\5).:48U:;E&4?:4_BBI)J
M2T=MS^W&\\6^%UMVNIO$.A_9ROF?:)=7L#&4VDAQ(+DC8.<D;LC..!Q^&/\
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MEEB4HR;FX48/?!'0 \Y_+J* /DO6HI4D8!E# D\Y.",'=P,'/3EC^6<_AO\
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M<YX6^!^C>,6\$>(+_28[K4/"6D0:?H5Q*S,FF(J0_:)+-00HDD=%4RCYBL2
MD\Y /YSO#/\ P2L_;,\>:T+G5)_AS;-JDD%Q>:]K'CI[AXHI%C1?-TZRTFXO
MP;2%8XDL88%$,426MNB)$B+_ $&?L ?\$^_"W[(.E:AX@O\ 5%\9?%+Q+9PV
MNO\ BTVC6-E9Z>DGFKH?ANRE>2XMM-,P66ZN[AQ>:A(B&5+>)1"/N'PIX+L]
M(D4"W4,O+-C!?'TQ_%_#^7(KU%PJ*H P!QTYXP/;UH :3Z9XP/\ $C\S]*L0
M<D#GJ?P&*I*Q8_G^ SS_ "XK3MU R20H569F)554 %G9F;"J%4$EF(4 $DX!
M- $>K:MI_A[2;S6=3E\FQLH?-E9>9)78[(+:W3'[VYNIBMO;HO+S2+G"AB/"
M+&;4-6O[_P 9:S ?[5O(?*TO30RF+2-,19)+.T!^7>Z!=UR\?S374_FME/E#
M]6UH?$'7U>%R?!OARX?^SV (CUS5DS'+JQV,4GM8\-#I(95 0RW0'^D+CP+]
MH/XYZS\+-$\53Z#X.\2>*+[P]X>M=0L=&\,:5?ZGK?B;5M6*V^BZ'HZ:?I>L
MRV=O)?S6UKJ.N#2=2@T9)+G4M0BBLK"YV]$%&$%5EO;YI.W3TUM_2#Z 8<&/
M=M#CRE)7YE#DP*Y#$$!8[S3Y&(;K$0!A4:JDC!@&*ET;,S8!(V.IFD49 93Y
M-WJ,85\@>1M/S1L3\._ 7]I3QQ\5(5U9_"'B^+0E\=CX=WZZ^VE:W9ZGK%M)
M8Z-XKUOP-JVD16FM2>%_"GB2:ZT:/5/$6AZ%'K2^']0U"/2;.QDM;UOO)+":
M:5UCC#XE)>-WPNUY7=L3,,A3#<W:8P2AV KP&.L)^T3:4E9VUO;9/1?\ ;36
MZ,0P7-M(]U8W'V&^PPD95#6\\H'[Q+F'Y8Y6EN=.N(S<'9<1)=#RG!;!RI/A
MMX:\5ZS+XQFT&TTKQBT%EIUWJJQ@QZK8Z-)>?V1)=0AC#*UFE_>/I]UY8O($
MNGMYI)(XX1'Z+%IMO9J)+AOM,VTJ[<+$0WE%\H=RDM)"LI)W,)"[)M#L#4N/
M$-K9<(58CJ%^8*H_N]R<]ACD<=:<HJ2LU?JO7_@[$W7='IOA_P /:?X>T^."
MT4.\B+)+<G_63NZYW%NI7D[5SC%:,C!5/U./7_/T[^U4="O1?:%IMRH*^;"0
M,G.?+EEBW?1MA91G@8%32MD=?S[#G_#G]:XFK-KL[?<,J.22>N.G/(.#^O\
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M>QS7-LMP+<^;%%=2JG[J_!GXI>'OBOX&TCQ5X?O8+VWNK:W,PBD5C%*\8;D
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MHU8J?O\ :&*"..&"-(XHT")&B[415 "HJK@  = .F:OD$=?S[4S8.>ISZ_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
M A$#$0 _ /[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ^ ]$_P""GW[$OB76;?0?#OQ9
MUW7KZ[\23>$;:;1_@S\=-2T>;Q!;ZW)X=N;&/Q#9_#6;0&6VUJ&:PN;T:E]@
MMY896FNDBB>1?OROQ-_X)+>.OVFA\"OAGX/_ .%!>"7^ 7_"Q?VAT'QH'QP@
M;Q6EH/C3\5+Q9C\)1X%>9)3XCSHIMCXQ0K9,-:R5(M'\W^(_[:WQ=^%GQO\
M#>I:7^U4GQ[N)_VJO WP7^)OP4^%W[/3W'[-?PS\ _$+XDVO@.R\/:E^T$ND
MW%_I7QK\,6.K:=JE^VH_$+4O[0\607OAB?P3I^FM"UO]QC>%(U<VQV5Y3>$L
M!.O%RQ&84\T^M<E>K0H\TLIR[V.5U9NC+VE+,ZM)4IU:4*E6G=<_KU<N4L36
MP^&T=&4U>=>.)52TY0AKAL.H8>3Y7S1Q$HVE*,7*/7]NO 'Q3\ _%'_A-?\
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M[5O$EM$26:/QSX<@OTC!^_/IEM9ZC- /7?+@=-U>V>!/^"EGP9\27,-EXO\
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M*E3G^]BYN-2"E%J$E[6HDXI64G;51:_-GQ/^P=KOB#]FS]M_X#Q_$?2K:_\
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MU_RW6WQ2M[^RL[Z&4B*^L[:]0;N52ZACG4'OE5D /TR,U^IG_!)?]I2Z\/\
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M3P>'X9]XEGP?VZ_X(#?LI_MV? [X!_#[XG_M._MUWO[3OP6^+?[+O[/U_P#
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MY_9=AIFF:W=Q6?B+PKXR\(>*H--TS4O$GA'7KF37[+^T]*>\O?QE_8 \<?\
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M+3Q1<ZMXC\+?$31!I%KXDUO1+Q)Z /[&Z*_A1/[5/_!9S]JO_@MS_P %(_\
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M1\+OCU\,XUN6T[PFNG>)/"5[/+;:+\0/ VHZQ<Q^*?"&J.BOY/VD6]K>Z;J
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MLC>VAFV7;E?J/]I7]G[P#^U9\ OBY^S=\4SKB_#GXU^!=>^'GC0^&=231_$
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M)9H-6T+PI/JMI)+;^7*?;/\ @T,_U'_!6C_L\^R_] ^(-?TR_L0?L"_LK?\
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MXBN- TZ:>6>1-$TO4XO#EB)C#I>B6-NBPC]-O^"=?_!)?]B?_@EWX8\2Z/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img2.jpg
<TEXT>
begin 644 img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
M A$#$0 _ /[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=S$G[,'[0K2#K&-5_9EWCZK_ ,-'Y_2I[?\ :KUJZ9U@_9:_:)=HP2X_M/\
M9F0J ,GA_P!H]<_AFE_JUG'_ #XP_P#X<LL_^;"_[<RW_G[B/_"#,/\ YE/K
MFBOE&T_:=\2WV[[-^RK^T2VTD$R:K^S% O'7:\_[2,2N!TRA89XI\O[3/B6$
M2%_V5_VA<1#<^S6_V792H]=L7[2KL?P!J?\ 5S-[V]CA;]O[3RN_W?7+]4']
MMY=_S\Q'_A!F'_S*?5=%?(T'[5>LW""2+]EW]H4J6VC?JW[,<+,W/"QS?M(H
MY/!Z*:?<_M3Z[9S6]O<?LM?M#I-=Q^;;H-5_9CD$D>-V[?'^TBZ)P,XD93[5
M7^K6<72]AA[O9?VEEEW;>R^N:A_;>7?\_,1_X09A_P#,I];45\D-^U1K:IO;
M]ES]H0+SS_;'[,)Z=>!^TD3^E,'[5FLLKN/V6_VB2D:%V;^TOV9MNT9SM;_A
MH_#L,<HA9^GR\C-?ZK9WO]5HV[_VAEO_ ,UD?V_E7_/^K_X18[_YF/KJBOCU
M/VM=2D:!4_9>_:))N8GGA)U#]FE5:)&1&9G;]HT)&0TJ#9(R.<DA2%8B?_AJ
MW6-TZC]EW]H9S;!3,(]5_9DE\L-C!)C_ &D&!SD?=)QWQS2?"^=+?#4%ZYCE
MJ_\ =P?]NY8U=5JUMK_4<?;[_JQ]=T5\@O\ M9:I'Y>_]E[]H=?-("#^T_V9
MLG/3@?M'DK_P("IY/VJ-:A@:XD_9=_:#6)"%9AK/[,#,I/(!C7]I,R X(_@H
M_P!6,Z_Z!J'_ (<<L_\ FP7^L&5;?6*M^WU+'?\ S,?6]%?(</[5VKW#!8OV
M7/VB'+.L8/\ :7[,ZKO8%E4NW[1X520I(W$#BI+G]JG6[1HTN/V6_P!H>,RN
M8T/]J_LR.A=0S%3)'^T@R*<*<;V7)X&20"?ZLYS>WU>A?M_:.67_ /4P/[?R
MK_G_ %?_  BQW_S,?7%%?(T?[5>M2EQ'^RU^T2QC^_C4_P!F; Z=_P#AH_!Z
MCH33#^U?JV^>,?LO_M"/);,J3I'J_P"S%*Z,V=J[8_VD6+$X_@#8[XXH_P!6
M,Z_Z!J'_ (<<L_\ FP?]O97_ ,_JW_A#C_\ YF/KRBOD)OVK]7169_V7?VAU
M"8#AM3_9F5ESTW*?VCPPS[BI!^U7K!5&'[+W[0A$@RN-8_9BW$8SG;_PTEN
M]V &>.M'^K&=?] U#_PXY;_\V"_M_*O^?]7_ ,(L=_\ ,Q]<T5\N^&/VGX=<
M\<>"? NO?!3XQ_#VY^(&L:IX?\.:[XNF^#5]H,NM:3X.\4>.I=/NCX"^,/C;
M6[5[CP]X.UZ:VN6T1K$W-M%:W%U;R7,&_P"HJ\W'9=C,MJ4Z6,I*E.K25>G:
MK1K1G2=2I2YXU*%2I3:]I1JP:4KJ4))I'?A,;AL="=3"U'4A3J.C4O3JTY0J
M*$*G+*%6$)I^SJ4Y+W;-233"BBBN(Z@HHHH **** "BBB@ HHHH *\5\!?LY
M_ OX8?$WXO\ QG\ _"SP=X8^+/Q[UO2=?^+WQ$T_28CXN\;7VA>%_#GA#2+;
M4-;N#/>VF@V&C^%=+G@\+Z5+I_AG_A(I]?\ &+:0WB_Q;XJUS6O:J*[\)FN9
MY?0S+"X#,<?@L+G.#AEV;X;"8O$8:AFN7T\;A,RIX',J-&I"GCL'#,<!@<?#
M#8J-6C'&X+"8J,%7PU&I"90A-PE.$92IRYZ;E%2=.;C*#E!M-QDX3E#FC9\L
MI1O9M/YB\&?L2_L9?#CP_P"/?"?P\_9&_9B\!^%?BKHD7AKXH>&?!GP#^%7A
M?P_\2/#D'VOR/#_CW1M#\*6.G>,-$A_M"_\ *TKQ#;:C81_;;O9 /M,V_L-'
M_9M^ ?A[5_!>M:#\(O 6BS?#?X;:S\'_ (<Z9I7AZQT_PO\ #WX9^([C3;CQ
M+X-\">#+6.+PCX.T?Q+_ &+H=KXDC\.:)ILOB#3=!T#2=8FO=+T/2;.S]MHK
MUL5QIQCC:N)KXWBSB7%UL:YRQE;%9[FF(JXN53+UE-26)J5<5.==U,K2RV;J
MN;EEZ6#E?#_NS..'P\5%1H48J-E%1I02C:?M%RI1TM/WU;:?O;ZGS[_PR7^R
MK_PJ#_AGO_AF;]GW_A0?]H_VQ_PH_P#X4S\.?^%0?VM_:O\ ;O\ :G_"M/\
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M=\*_A[<_#;XH^*;OXHCQQ>W/CWPIX5;6?AI\.G\$Z%;:X4^*WB@W\'_"&_\
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M,(8F>"I-3;Q$,)"G6Q:@XP=-3I4Y0J*,ZBE*#FZ<9*$W'UL'PQGN:9!G_$V
MR^KB<DX6JY/2S_'PJ4%#+99]B,1A,I=:C.K'$SIXS$X6M05:C1JT:-;V5/$5
M*4L1AU5]5MK*[GN[?6+6Y*:?) T"*6!42.T;J>> =L;5V4]C<M LANU.U0Q
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M>XN&46TWV-X54!6MH!;1AHF(Y'/S$'GIZFMBQ6"-Y_M"0F"P@$%IN9MTT48
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MOQH_9HU#]L[P+X4U_P :_#N/P;K'B^Z_9X^+_P 1/A9X \:?%CX::$OAG3]
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MMX=XAP]:OEN+DE5AA\14PM76M3A>-6DU)/ED]TS^O7P5_P '-GQ/\2!YX_\
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MAXFS[BI9!#"XS \+0X@XBSKA/*<XPV9Y)AX2XWS?_6NIEW'M/*LUXHX3AD_
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M?C3X ^!S^"?B#\'?%.M^,/AAK/@[XL?&WPHGP]E\>>(-1\4>+?"'A'PWX?\
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MZB=X^[0G>*YY*?PU\=/VUOVP/@1\4_VO/V;_ !7J?[-/Q&^(/P@_X)H>+O\
M@HWX!^*>D?!#XJ?#[PO:-\)?B'KWA;Q?\'/'GPJOOVG?'FL^(V\<:%H]E_PC
M'CW0_BMX';P)JERUYJG@?XB6LD>GBW^RI^V?^UW\0/V@M._9\_:#\#_LVW?C
M;XH_\$YM'_;^^$3_  JU7XI_#;PMH,6O_%K6_AWX,^#WCKQ;XO7XMZYKY\3:
M1J'@G7O$?Q+\+_#W1&\!W\7BW1M+^&_Q.M8M(UJ3[SNO^"<7[&][IOQ9CU/P
M1\4_%>J?&7X:V/P0^*'BCQ[^TW^T]\0OBIK/P;L_$5WXME^%FC_%[QG\8=;^
M*'@KX9>(-8U&XN?'7@/P/XL\.>%/B+#(VG>/=*\1Z:JV@O\ P[_8!_9+^#?Q
MD\$_';PAH?Q(M/BKX)^%6G_!#P;XIUK]H;]I'QM9:=\'-%TR/3--^%4GA/QC
M\7=>\&ZGX'TIUA\0VOAS6/#VH:9#XX2#XAI;CQW;Q>(T]K&^*/T=,1P3GN22
MX S2OQ3BLAY,-GL> >&LF6,XKP7#N2X?!9A?(^/</+A/)L=Q!@\34S7+>'Z&
M+I+!4H8ZA1J5\]SW+9\OU/%^WC/ZS35/VEW#V]27+2E4DY1]^@U5FJ;2C*;C
M[SLVE",B'3_%_P#P4&>R-OI_P!_8R^']O=!;%/B!=_M:?&[XHS^%?MA%K_PE
M+_#>;]BOX,'XD_V )O[5_P"$$;XK?"C_ (2XVO\ 8 ^(O@DZA_PDFF?C+\(O
MVW_VH5_X)L?\$T/B[^RQ\&OV(OA1XR_:U_:3^('[,S?!V'X0?$;P#^SYX4\1
M>)_B%^T%!X'\5>"8OAW\26OO >D6&H_"C4-8^(^AGPSX]OO'>L>,]0U?2-0\
M&3Z=/#K/])'BW0/"7C/0-<\+:C=^)+73]<T?4M#O[[P_XC\0>#=8M++5[*;3
MKNXT;Q5X2U/1/%7A?5X8+EY-+\1>&=<T?Q!HE^MOJ>BZK8:C:VUU%\3>%/\
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ME^A2_P#!+S]AU/A-\>/@2GPG\<ZQ\,/VCO&NE_$SXV^$_%W[1'[1WC%O'/Q
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M_:OA\%^%OV6-5^)GQ0^.GP\\;GP=XHNM#UE/%>B^*H_A,WPA^-FO&7Q;X7U
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M]I;RW+,LR)(#<!UC*':9(\@E<$C*Y'(ST7V73-&MH[=+6]9X6?S;Q[G>MP)
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M/^/:'_=7^2U]^^!^D'T7^0KX"^#'_'M#_NK_ "6OOWP/T@^B_P A7\C>"_\
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M]DZXU+XD'5?B3HOB3X=::/ ]G'-XG_M#Q]X=U[P59_V7]H\4Z+JFA1W]C/\
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M10-@+ ?-C@9X.*R-3LY6FFF06B0Q6Z"QBEBC::>8-)YCM(RM(H(*852 "#@
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M[DPRQQQ-'(S$1*V02H+84CJ.G/?H:U[2/088+R>$/'/%*?,F0;9)0">&<')
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MW;6FVS)JTE4:=[V7I;5;KK_P/D(NG7]Q;P?;?+B00I*%MI$G,ZXX:41%BK,
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MG./FDR?3/MS6+K\].I%R]V$59-Z:N*MLKM]M[_<=4:/LZE&?\\]=%966VO\
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M!=:3;I+<*;N*\<Q$%<NJ [,,?4#@C &?H*QKK5TGBU"'2;)AB%9)')QESNW
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MVD](OJ]%=GV'7YB_\%?8?$MS^Q0+?P9JFA:%XPG_ &Q/^"9</A36_%'AV_\
M%WAK1_$LO_!2W]D=-"U7Q%X3TKQ/X)U/Q/H6GZHUK=ZMX>T[QGX1O]:L(;C3
M;/Q/H%Q<QZK:?IU7Y4?\%IM.TG5_V O$.DZ_\-V^,>A:I^U/_P $X].UKX1+
M8>#-4;XJ:3>_\%'?V3[;4?APNF?$;6?#OP]U%O'%G+-X8%CX\\0:%X,NSJGV
M?Q1K.F:))?7L'Q>'_P!XH?\ 7ZEM=?;CUBFU\DWV5S6M_!J_]>Y]OY7WT^_3
MN>U:/H?B"YT;P[)XAU#1O%'B6TT?38?$5UH^CW?AK0-2UR*SB35;_1?#^I:[
MXJOM!TF]OQ<7.G:/>^)O$=YI=G+#8W.NZQ-!)J%QZ'86E]8:4@\Q/L+28^S@
MY*-GGC'.,[1T'2O+OA]IVGCP1\._#OAKP+=?#718/"OARQL_ ,,/AS1W^'MA
M;:3:6]IX(:V\!ZMJ_@ZQ/A2UCCT+[+X0UK5O#%L;#R= U._TI+6ZE]&%RCQL
M+?4!"EI)]@EM')F66\(S')OD#E>,$X8*3R1FOU7$W^'16<':46Y):VU;3NWM
M+E35O>6Y^>8;=>NCLDKWCVNNO1VUWL;5ZB::RR/':QW%U$BOJ7641;3Y<;87
M.(@=HP1Z^U8<<4L$LB6DJ7V]/-\V$_O=S$9W;BIV\XSG ('K5FT:&>5X[V15
MOK7]S=0G-U XB^42QB3S$0OR<1X(Z  5:TVWT>6_FNX8)84MXB\S">>SA;#*
M, (\:$;\?+C!_ND"N12]G!RL]%=M)6DW:R7,UZ1496U^1W^6W3LBH+%)\W&H
M&\2\A/F6D)QB6:/YHTSOQAG"COD4Y=.FB5YG>ZM99A\H7L<>@8<\^_Y5#J6O
M3OO-U;"&WCE"V=UYI&X @KM8-N<[L@9.3GVJ>WNF*Q3W<TTP?'DYE?"GC&1N
MP>WWL]/S'4KP6D7:=N:.C2M9))I>=K.]G=ZHTC[#_E[*S3NKZ::>??L_4RI?
MM#6T^F2K>20M(3+/= ^4Q&?F^\Q /8X^M%Y!;/:65G!' C6T16.[M@3Y8W$E
M7^53G/(P#U[<5TLFJD6MQ!/&L_F,=HW =2>,#&T$?AZ5P>I^);;1[K2X%MEB
M2_=K7:D:R#SFW;7<X/(P.O44Z<JM::A*FTM9*RM>7*E?HM4[:K_,QQ-3#0HR
M<)7G>*WL[76FC9LV_P!M9,)I0U!X(WSJ;[=T<:K^\1<@L2Z97'O5"RN+JZ:2
MYM6<VR,5FLI@8U##C()&T\]P.AP>M4Y/&YT2(6]Q'<W,\EV\3K;1%0XDP+<>
M7&%3"%@7P/F&=V1FNHFO+._TQ8+M)X[N<;XK2UMELYCD?*7>V2.1CZEF^M;.
MC.+U@^5RLFKN25E[S7:^O1+1WULO*6)BVEJKZ:OT_KY>1F&WGAO$CDUAS!GF
MT7)1QQD9!P*T+BVCN;Z&"WL$:VMKJUQ$2H1&FB1Y) ?F!+.Y<CU..H-4AI^H
MFPA$!6W5R!*TD$5Q-MP02LLB2RJ3@X*L",#'I3[BUGL;>&SM[DF"YECECG>:
M1+E;E=I9F?(D,:R!@B,Q0)A0 N!4O5Z-<UI);[M*[TZJWK;J>@L))K96=G:U
MM[??VTZ^AJ#P[9:3)JUQ?ZA"\4DXE2RFRRVN^*,%HN&7+ ;3C;P!6/<SVF@"
MWU#31=3-=2JL<: BUD.?E$Q+<1G))^5OI6U<%5TZYMKN6WU"^DC4ON@B8LO1
M%#F/Y2,?>!R3SFJ5]<!])TVQN;?[$// C5$WHWW>'==VU/<XQ[FHC[2UI-S3
ME:3=HKEY%>R:NTY:;MM:W9K&G[-<K236O?5M/\K?=W'W^K7ER+5(A:P)<8$I
M0[MG<](Z=@_8[QET]+?2TA*W,@X-S,HVO.H !(ED!<9.<-T[4DMK<V#?9=/6
MRE*1>?*\Z12;DP#M'F@[3S@8 /!QUJ&ZOKFXCN+%EM[O[1!9%;2&=H_L'G)"
MS32B)EW(-Q(5]R@$8& *-/=4(II6MJT^6\;OE?+MT;;V=D[V=%73H%OHX$:*
MZ%NBF6U9!A0H=P!]X $L#^8^@TXM&N]0NGO+B6ZCBM89$4$XRAVY P^.0O'3
M//.<U?N+RYLH]/L(&@ MO*@_T<(PEC8"0L6').Z5DZY^6I[R[2.W=KK4)8[>
M66*U^S0Y\WS9PVUB4R^U=IW G R/6IE.?*FE"*EHGK)\K:2=E%:RCT;M'1-N
MP.7+[S^SK\UMWT_K3IR^KZ=I+::;G3XKMKF,C+8&TR+TR=W0D<]>/:N487LM
MLEP]DMM<(0;B5&!$BCE@"!SG.,8["N@U2_N+9E\-Z3#=2&4@SW#J6VPDCS6W
MR#*80EMPP1VYJ*.V\C3-0A621HK1VCT^WD=GDO%!VK,)7)ED&WYR&8@CKQFN
MW"/E44V_B5MV_><;7TTU?HDNB3MX>.7UE^[\N73I'U]?GMWS-.FAU(7<,.;%
M9_E27&#,0BHVX#!7+JPY)[5MZ)H%[:WD AAAM9XV=H+Q6!:YR07#@#(VX&W)
M.2Q]*YW0_+MKB<W8DENA&S(BQ!8I6(+JL2J%0;/]6VP#+HQ;YBQKI]/5K."/
M4+Y[FUEU6=[6W$UU.PMY$VF-XH3(R1@^8=V% 8 ;@=JXVQ5TK)VNFDFDTW9V
MLFU>R5W>^BLB\)'EC"+N^513^7*M_P!3KDMI;TWRWD<-T(%!NX92!'<@,N <
MC^%]K]\%0/0UAW;QWH+BZM;=K3(CL<$)\@VJ/NX/;G!'XU')/+ S"XNUN[02
M"QO;J-S;S)<'+B8)%Y;2 F)U*;2N&SC@$6;J+2!;K'<1_:3*!Y3Q0B.7!'&9
M(E5R<=2S$YY.37F05G>S>J2Y8V44DKK5V5_-1DEHF[(]A;+^NB^_^K$>R]G"
M1R1W"6S*N]XB-N"!EEPP./[IP.V!FG_V1$?]'L!=R6@/GR7!P"L[_+)']\G*
M*B'CN3TQ6I<71T:RM;;3;9[B>5$,\+W<L[B%\8)6:5B@"#D+C![5S]OJ;W-Q
M-#;3/!M8F>*.9B >ZGYBH/'.WGH,\8H]K5M[2$6K.T5I[R;M=I)O_"U*UM7V
M-(^SO^\E:-M^E]+?\&]K$MU'/:O#/%-J$RPR*%ABS@-M;YCB3H,'H2>?6HK;
MRA?7&IW4$!N)8)8S'= B9D:-D*@;&&YEX'/)QFMJ&_$2I]G+ 1R*90\A8LP#
M?QOEL>P..1QQ6=JFHVTL\TYLXMXADVR-M8*ZH=I .>0PR,4E7K2]UTW:=HMV
MMHW&ZT2>M[_/=6*;P:3]].R=D^Z7KY&-%');S/-;Q&6*;.-,/1LC 7GY3GGU
M]*6_GGMVM;:6P;1I+E?]$6 !Q"I/"L4 VC/S'D]>]8^G>+EOHK:^ *P6=U):
MWBB!5DE:-N"L@0.O!'W6&?Y[FA^-%UNYF+6\Z0VCE+B[N;..X4E><PM/&^P;
M<?ZO!R">:Z)8>HK24&THN]VT]7&UK)INVNS=VEU9X?UF-]WONGZ:]/+[O(DD
MM]0:%O.O1:7$& ;E6^><.-P8@8/R[1U/?VJ>W,<=@\TDYU"\62*.*Z?[Z>;,
MD;[0W/S([(2O0$]JC:WAN]3-SIR7$D4RLWG3L[0NZD$%()"8@ ">!'CH",4L
M&EWSW$ES/<H+NW;S+6%84MK7"'<1)'$B0RX0':75B'*MU -3))*SNEH];IK6
M+Y6M[7T=]MGH=E*C*K"-2-K2V_RN3Q>&6U#3VD+C1WMM525KI&RY&8FR0N&S
M^/\ /F>]TS1)9S:K+&\\"%S]D4^8V.K=%.6(S^)R?6#3FN'ENKNXO4BLFFWW
M=L[F99)$"AF19-PC7 'RIM!["KT4_E:[-=V]C!+&T !N(XXXR!C_ )YJ$W?]
M\Y]ZC]XIS:DWHVHJR2;Y.6+DT[N]WNE:VAT0H^R^))<UM?)=;?=^AG:5XBED
M6ZM$A/E6OF+#-?'%P7'!7I(?+'1/F_ &H[>>YNM\T]M%?7;R^5:1J/\ CV=6
MR)SN4<;04R.?F':EL[:"[.H:BCJS02N?+G4QDL6Z%2%#*ISCJI')XJ<W>J6D
M<LD\FFV0\F&>*X58(BJ-/&FQMJC+,&V@MSN((P1FF[)OE2YFUS:N.ONM;)WO
M=76S5T[ZHLJ:@[1ZFBF!_P"TEM<W"Q<MY8#9 /'S;<CIUJZ;"9(/+LA>*U[Q
M*.!MR.<C?TY/%6],DE-[?:P;>"W/EQVP\V8S23)*BJ]W&)F<A0')4+QE>!C@
MVK&^NKB.4R7'E-YVR*<JH4 GC 'RG [$?_7F\[?##W5'FN_M63:LE)VBN5Z-
M]-[ 45T/3K%+2SU1KJ=C %C P2"%&!@M][MS^E<7<P/::E/:V]A)<6$C$E9R
M!(DG 0H"22 #G/&#VKL=0N[.*2[U)KF[OKG2)9+:3'F^5),A*%D7&PKE3MQ\
MI!SZUR44NHZE<)K4Z3PSSW*0V4;958]/9?WEP\"D1R;'!&^1"1N&#@5KAF[W
M;O>S>Z5]'[JLW;75O737K;SL;4]M%PTT]UM:.^B6OYZ=C(DN&LY?LUU;^9)+
M+&]O'P5BC5E+9R,#:H.!]!TK<FT>2_EAOH5CU(*@!MICM"#G.-V>G3@5F^(8
M6&H?([26D8C,L\<>][J1@,M$V"T:PG)=8RJ, 0PP>=J& ZG+I^FV4=T+=U)F
MNH9I+4@J =K212(PP<$\]/QKTJK7LE*]DX\S<E9)<J>J=FM%MHT]]CSL)2=)
MN+NVYW5][/E27X'465M>V&EVT9E5[%V58XNI0YP/7&._YU_G:_\ !VW:M:_\
M%5?@4CB,R2?L(_"B:21,'S2_Q]_:;",^ /G2%8X?]V)?H/\ 0]^U"9 ]M?K"
MB2_8/L3?O$:_&?W@DD#%1^[?C<$YXS@5_G8?\'8T[3_\%3/@:9%VSQ?L-?#"
MWN5$K3*)H/V@/VG(V*,S-A754D"*0JER !S7Y[QLI?V#F%[;-M*-MY+EVD]D
M[-ZIO>SL?L?A%_R7_"^G_,PI?E_P#\K?@=UM/HG\UK])O O2+ZC^0K\V?@=U
MM/HG\UK])O O2+ZC^0K^$^%O^3G1^7_IZ)_U;87_ )10I>O_ +I1/VB_X(Y(
MTG_!2+P^JRRPL?V%/VK-KQ?>S_PO[]A'CJ.",GZ@?4?UE2B:6UETV:.[:#SF
M+RW8/E,P<EFX9R Q.1QGGGI7\G'_  1MFBA_X*3^''E!_P"3%OVK!'@E<2'X
M^_L(E2<=1@-P<KT)'%?UV3:I_H4]O<1+.6D<KEAP"V<<<#Y<X].U?Z*RJU85
M&H0YDJ67M-+6_P#9N!ZVZ7_'[_\ E>\:'A_^(F\6>TE:7]H1NGV^KT+=?)'.
MZA'!/!96MO'!"]K;A4O;8$A%#N=K_*IW DGOP1SZ+";THS+I*WC6\3M)JK;
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MNY7H3W(S7^N8(W6>!HKE"MP^$D!S'.V<$QG/(8Y('IT]*_R-OVW05_X*>?\
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M)/+Y5XPI0=ZN,A6='V-.4:M5>RQ$N7ZG.,:T,3"3JTZSIP]_]G?^&G?V;/\
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M9Y8XY&4_>VQLJMGKD@D^E;MTUNAVW+2B&"W,:S1NP8S#!1W8$%I   '8[@.
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M/Q7!O"N)QT<-@G'&XCA[**V+BW0J-N.(J8.59-O5M3U/OG_@FY\+OA9\.?\
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M'OVIOVD- _X17PIX%_L/X_\ QBT?_A"/ EQ]L\#^#O[,^(OB.R_X17P;=_\
M"-^#OM7A3P]Y']D>';C_ (1'PKY^D6=G+_PC>A[O[,M?YM\->'J&4<;4,90Q
M.+KO&5Z#Q%/$Y?B<']6K5)5:U+#PJ5::HXAPP/U2O6J4:LTJN*=!PI5,/5B?
M[V<3^-&9>(/@_F'"F9Y)D&6QX<RW&RR?&Y'QAD7$CSC+<#'*LKS#-L5@L!C9
MYIE%/$<42S_*\NPF8Y=AKX+(89E#%X[#9Q@:B_>;_@@C/+#\(/VTA"XDEE_;
MBF2&T9]BO)_PQ7^Q8 ^3D98LJYQD;:_>F6SO[2Q%W<S>5JS+E=.#EMKG)V+T
M!XP>@ZXQS7X0?\$!6A3X2_MJM*T D_X;=N/)\ZV29HW'[%7[%Q$D;M&S1L>
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MGK.I'VB*8C<;<9!38C?NPI3>%5<L2,U5LTCU.UAM=-22.VT=Q=.LJ^6\TB\
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M  3[EG7=$GQR^+[.IZ,!^PE^U_@'ZG%?V:6XUJ*:Z2SO \5QCYF."BGL/O=
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M;;M9*VU['-5E%STDMEU_S-"VMS#J O+B_MM0\I6&;@.92.,_ZIXUSG&<(/\
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M3_X)HV(:4_%3XPZ=,59&CO?V-OVV_+7<,%OG_9TW?+C/WP<>M9-[_P %]/\
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M_ /_ $$5^JOP_P#]7:_]<HO_ $%:_*KX%=++_@'_ *"*_57X?_ZNU_ZY1?\
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M5G5@LIKTHWI<N$P[5:ARQC&4Y9=C53_WIX*X/XQPF-XBXOQ> XDCP5C\HSC
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MY\1Z9^TGX._8RT7]KWXY:U^RAXT_;*O/!?C7XOG]HG6$^*OA2"]_X)T?$?\
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M\?>6F]NJ:;LM.VYJDK+1;+IY#7^TR6,M^R7'GZ;-;VWV2WC011N=A\TXC+[
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M%;026^SND?0<)VGQ'D4I^]-9K@[2E:4E^_AM)W:7^1_)K^PI^S7\3_VC=/\
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MM+ *"3_PGW[!FS(4 #H^,#UK^DC6KG3=/"W5Q-)O6Y@LI88;;*132R!>9A(
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M,'%XC)^2S7]CVTVNLXS=-?+9]MCZ#A:_L,SO_P!#3_WF98%%%%?('U 4444
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M5:+L8U:K4X1LK/7K?=+?_@&C!J&M@?9]5C:6\FN#=+';8#V5BS$CSCE5.Q6
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MV7B;P9JGBOP7XF_IC_;&^.O_  TO\ ?@UJ7P2_9G^!X^"'PPT6TNO'O[0?P
M_8]^(GP4TGX6^,]2^)WQ=NM&_9\U3Q)JMYX@\(^!M+?P?\6?AAXY^(GPUT#Q
M?X]\(GX^^--6U'P?\4/&^E7VEZIJ?\Z7_!,+PS^R-XQO_CSX<_:W^(9^%-OJ
M/[,_C0_L[>/I++XF:CIN@_M/V?C#X<W_ ,-QXCL_A?X&^).KS>#]5T*U\:Z)
MXU_M/P7K-E'X2U+6I=#.F^/8_!NKV']%O[7O@WX%_!'PAXJ\-_L8?M/Z/_PI
M_P"''QI\&_";0_AI\//VH-4^)%W\=HO'7[(FC7/Q3_:@\5>#-,\12^%])UBX
MN?$7BWX">-?&WP\A3X<^/=%\17'PLC\ ?"E_AWK[?&3^),$\QI\0UN7&9=+*
MZV)C2JX2->@\WIXBI7=:+A1DN>&%E#+'5K.M)0DO9PP4HXK$UE+_ *)."X<&
MXOA;@Z4^&>,J7'N582./R_B&OE.;P\.<=E6#P6$RF=/$YGAJDJ%?/H8CCM9?
MECRVA4Q&&J?7,=Q7AL1P_D67RI>0_P#!/LX_X*'?\$^&QN,?QN^,\JK_ 'FB
M_8)_;$D51[LRA1GC)YP*_MDGO=.M40QVSF*09=P"%5B,G(/S'!)["O\ /K\.
M_%_XF? 7XU?LD?%?X.S>!+?XC^%?C=XQ'AN?XF>%/$'C?P/&==_9._:6\-ZP
M=<\+>%O'?PSU[5=V@:QJJ:8+#QQH?V'6&T_4KK^T[*SN=&U'[M^)7_!</_@I
M?X.M;NXD/["^I@KN\I/V:/V@-/5=@_Y9D_MO7NW/<LK^U?Z-^&WA=Q]XG5\#
ME7 O#U3/\=4H86A&A#-<BRM>V^KT)<CJ9UFF64[\LX2YG4]G:5E+FYDO\4/I
M&X.L_$_BG'M1CA:>(C2G4<M5.*YY+DBI5':-6#NHM.[6Z/[)+#4M)NKE=/@/
MDN_S))(DB^8S<L@.WMQST]*_+#_@N-IOV?\ X)R?%%]Z'R?CC^PT<YRSE_V[
M_P!FE,*.N0&W$G P#@\XK^;+P%_P<5?\%+/'>L)8_P#",?L*:2VDW;VD4Z?L
M_P#Q^O/.\OY?-E3_ (;'M&);J4$V >AYK:_;*_X*4_MS_M)_ 6/X>_&74_V4
M3\//%OQL_9/_ .$DLOAC\ _C#X+\8R#1/VJ_@MXCT<:-XG\5?M8?$O0M,\O7
MM(TN743>^!]:-[I27VGVW]FWEW!JUA]YXE?1L\<_!^U3Q%X$J\-T?8RK3E+B
M3@S.>6FHQJ.?_"#Q)FD[>R;DXJ,I](P<M#\/R;#O,YTL3@9PKT</7I5:LEST
MK0HU(SJ-1KPIRE90>B5W:R3NCY#\>_\ +?\ [:5^?OQG_P"/:;_=;^35^@7C
MW_EO_P!M*_/WXS_\>TW^ZW\FK_)_QW_Y.!@?^P^K^;/XM\8O^3B99_V'S_)G
MS+^Q*LC_ /!3K_@GBD0S*_[>'[)"Q@C(,C?M!?#T("/=B*_US]-M[B*YF,D2
MVLUO97,)QD!YS(S _= +=O;N>*_R-?V'YFM_^"H'_!.R= "\'[>O[(LR9Z;H
M_P!H3X>.N?;*C-?Z[(U(@(_VNQNXWENMK,T89S)<2%TSQG8S;.>F*_J'PNJS
MAPW"*2Y92A?O?V,4]+-6M;[_ "/ZIR&FJG#V4W;7[F2_"G<XI[@X6W8;[F66
M0S2$@; &)$3$GK*ORC''(R1760Z=:,]C*76$0JQDM!RS-C.?D)7GW/\ +%:(
MLK=)1<2:+8R"2*23S)F00[E4D$L6"@Y^[GO@=^.<^U+)<32L([-5#+&MHV]=
MW./NY'L<>^.M?J-*I.JG]FW5-:W25K7YE;>]K7VVL;5:2I2Y8WLU?7[OT,C6
MKFX:>PDEN(297!@L<$NH_O<#8. .,\<FO\]O_@['%P?^"I_P/EN)%E>;]ACX
M4.I3.%1/CK^TI!Y9Z<HT+#TZ5_H)VJ?:4<7K8\0V)VM:GJ@/!(&,#&!C\QUY
M_P ^+_@ZX$Z_\%0/@*+C/F_\,+_#$MGG[_[0G[3[C\@VW';&*^7XY2_U:QS7
M2,5MWDGO\EZ^I^D>#S_XV/POYYA#\FS\N/@=UM/HG\UK])O O2+ZC^0K\V?@
M=UM/HG\UK])O O2+ZC^0K^"N%O\ DYT?E_Z>B?\ 6'A?^44*7K_[I1/TB_8"
M_:E^"G[(W[<WA'XE_';Q!XH\.>%-7_8[_:?\%:/>^$OA1\6_C#J4_BK4?C/^
MQ;K]A9S^&?@SX&^('BBPL)-+\,ZS+-X@U'1K7P[:3P6NG7FJV^HZKI-I??N)
M<?\ !>W_ ()KZ+;QCQ=\<?BAITC7DDLD]U^QS^VSIHLK5Y6<)*;W]G:VW^7&
MRHWE%P<'&017\J4W_)P?PH_[(3^T/_ZGG[,-> ?M/_\ 'E>?]<G_ /017^YG
MT7OHY95X^<0PRG->)LPX?I5'@J?M<!@,-C*L.7+LOAS1^L5J<=>>]FGJNQ_R
MR^.V78>GQIQ;F\I5I5?[3G#V2E"%.U+#T;.[I3E=]=3^S.R_X+T_\$I/$L5R
MNA?'WXE>((+E[.XM?['_ &._VU]1BGD#(S39MOV=Y-Q "X(!#*%V%N!7X[_\
M%,/VSOV;_P!KO]H#]D]_V?O%?C'Q1)X#^"?[94OB\^+?@7\?/@N;&/Q=X\_8
ME'AP6#_&_P"&'PY3Q/\ :#X8UW[5_P (J^M_V+Y%M_;G]F_VMI'V_P# ;]DC
M_D&Z)_UZ6?\ Z+BK[2\2?\E\^$G_ &0C]H;_ -3[]E^OI?I5_1;R?Z/&;5<M
MRCB[-.)*-'$T8\^99;@\'4GS5Z.'O?"UIQC9-3=HZR35TF?FO#.!P^,RVIG-
MZU.M2P\FJ7/"=)^U@Z3O^ZC+15)-:[VN?M7_ ,$=-2^(T7Q!^/\ I'PQ^&G[
M0.JZ_?>%?!&I77QB_9OL/V5Y/'/@32=*U?Q!;3_#34]3_:\T6?X:6?A;XL7F
ML6'BB]L-&\1:5XVU'5_@OH=QIVBZ_H.E>);[PW\)?\'*.J_$N;Q7^S?HGQ3^
M$_[16CZ_I_@[XCZK8_'/]IG3?V3(O'/Q%T76-9\,6EO\)]%U?]CC0+;X:7W@
M_P""]]H6H^,+#3?$7BG6/'^E:U\>_$%UJF@>&_#NL>%=1\5^V_\ !/\ _P"%
MP:[K/Q,^'GP8^&7[/W[0FO\ B[Q5\##KGP'_ &E?@A/\7/AK9^&;CQ1XF^'L
MW[3%[J.G7-OKWAA?@'KWQ,\/^%_$5OX>MM=U"Z\ ?&_QGXUN_#MUH/PVUG5M
M$^9O^#@OP5XH\*:=^S3=Z79_"+PM\"]5_P"%UP>"O 'PL_82^*O_  3^?3?B
MUI@^$TGQ?\9>(/A1\8H=1\6^,?\ A+?!VI_ S1-*^)5EXOU+PUJ7_""ZEX7T
M[PUX;U3PGKFJ>+?\:^.ZU65+'T8O,/9T\=AY37UK#1P$N;-Z5K8&I25:LX2Y
M?:8K#5IUL/5J4*5>$,-B(N?\_<38BM/(\5AHRS7V-',</.I%XW!0RN7M.(*3
M7)EU2C'$8B5.?*ZV.PV(J8G"UZN'H8FE3P.*HRJ?DC_P0!D\O_@N!^Q<WG"#
M]Y^T@HE(.%+_ +)7QZ0#@$_,6V=/XJ_U(UBL;,+;2 W8CB6>"5%8^:\K-YJ@
MG&TILCSN./F&,\X_RVO^" ;P1_\ !<#]BQKI2]N+G]HL2@9^ZW[)_P =USQ_
M=)#?ASQ7^J!+!;7$DT4*36]F88);6Y52=RQ^8;@$@'[H:,^F&.#7] >'L^7A
MK"WY[>TDVXI6=J6&5K_%?5NRWC?KJOV/+?\ D597_P!@4/\ T[6.3?6M*0M+
M-;R++$?EB9&;<?ND$@,. 2>>.#R>*WX+>WU"S%[:RH\3=$&Y<-G 7YMHR#Q^
M59L;Z"QO[ZVN6FBEC-M$TJ$HDX(\PG((!VK)Z\XZ]I[-;2'3([*UD:YBNI6\
MV6)C^ZW.Q.""" I.!C!_"ONVY2MR<T?>A\2=G%I.6CVLNMT[II,ZS)DMA:7U
MT\UJ+J&*'S$DBQE&V;L<D,6#<$@=1D'IG_(I_;4E$W_!3/\ X*$3 $"7]NG]
MK60 ]0'^/_C]@#[@'!]Z_P!=9M-U/2-3N]0EO!+IGDJH20[AA4 PV[.3CCU]
M?;_(L_;7=9/^"FW_  4+D3&R3]NS]K=UVC"[7_:!^(#+@=A@C ]*_//%.JZG
M#6MG:32:;Z46MMDWN['[U]%Q<OB[D?\ CC_ZD43Z6^#'_'M#_NK_ "6OOWP/
MT@^B_P A7P%\&/\ CVA_W5_DM??O@?I!]%_D*_D/P7_Y.+B_^PNC^:/^G#Q_
M_P"4;>&O^Q3B_P#TFD7_ (8ZQX]T[Q-^TXOA7XU_M'_#>R7XX:!(^A_!_P#:
M9_:"^#/ABYO6_9I_9Y$FKW_A3X4_$KP=X:U'7YX5M[.Z\0W^E7&N76G6&E:9
M<ZA+I^D:9;6GRO\ '?\ :8_:S\&7T$?AK]M+]N/35;5--M#_ ,9L_M67A^SW
M&H6T,T8:_P#B_=, \4CKD$,N=RD, 1]0_#;_ )&3]I__ ++?X?\ _6:?V>:_
M/K]I_P#Y"-M_V'-'_P#3K9U_T]_L\/"_PTXXS&JN-?#O@7C!2Q>-<EQ3PCD'
M$',_KF(U?]K9?B[OS9_RA^*_^S5LTKX;_9ZT\SS)RK4/W563^N5M95(<LV_-
MML^^_@C\7_VB_%&GPRZY^V#^W/>/(B&0Q_MU_M@V(;=LSE=/^-MJG.3QMQ3?
M!LNJS>,OVG9=:\4>./&FIO\ ''0C=>)OB1X]\:?$_P ::F?^&:OV>/*.M>.?
MB'KWB?QAKAM(/*L-/.L:Y??V;I5K8Z18?9M+L+*TM^*_9Q_Y!=M_USC_ ))7
M;>#O^1R_:=_[+AH/_K-'[.]?S+].S@S@_@_B[,<+PEPIPUPOA56Q5-8;AW(L
MKR2A[/ZCC7R>QRS"X:GR7A%\O+RWC%VNE;C4(/@ZO7<(NO*ARRK.*=6472<F
MI5+<[3:3:;LVD]T?M/\ \$Z/B1_PC6H^"-1\:_!WXW'QWX0^"G[0R_ K]I+X
M/>(?V58M?^$?P&T#X@^&O'_Q \3:KX-_:NT:S^%'P]^'_A[Q7J/[07A2#]JW
MQWXGL=*UZZ^+?Q6_9_TE_$^N>&=.B^%O\T'_  6$\;1?$;]L_P"/?C:#P%K'
MP^@\0ZKX8O(;/Q"?AK+K_CF)/ 'A2VC^.FN7_P &-&T3X/:WK'[2"0#]H+4_
M$GPGM]0^&GB>]^)L_B'P)XF\8>%]3TKQ9K7ZT:I_P4]_;0\#?L]2?LZ>#?C)
MXL\,:!9GPQIFD^/=#\4^-=-^*/AWP'X+NM:U/P[\,_"GB.U\4QZ7X2\+6FK:
MS//=:UX:\/Z5\2=7\/V'AWX9ZQX]O_A%X3\+_#_2/PX_;\_:5^,'[5GQ+U/X
MI?&CQ=K/BK7HM$TOPCX:M-4U[Q/XAL?!7@/PU%+;^&/ _AR^\8Z[XF\43:-H
ML,UQ//JGB;Q%XB\8^+?$.H:]X[^('BCQ=\0O%7BOQ9K?^&.;YW@\1Q!#(Z.*
MQU2OA<?A<=4HU,)AJ.#YY0K8::A4I3]K.M1A&FGB9Q4\12JT</44U@:=9_R!
M5XDR[%YU@N',-C\SKU\#C\%F%:A7R_!8; JK+#U\'.,*E"K*M5KX:G"G'ZY5
MBJF*H5L/A:JJ++J5=_NS_P &=5_-8:__ ,%)Y8;8W :;]CE91M#!(R?VJLLV
M> .^3Z5_<+K-QJ=O>6EQID]L-'1?M5_)R5R\93[,@VE@_FNO;&5ZX-?P[_\
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M/<H7CD(_U:Y^9?NC@=^GO_+W_P '>5N\/_!-[]GK9;-#!'^WC\-X2[9R\H^
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M? #_ )&G4_\ L+S_ /H0K]$/B]_R2KPY_P!EK_9@_P#6E?A)7Z<?M6?L\_\
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M81X#$4\;6PN75,5"O@7.H\'6A7E4C5PCJ3>'FI47.7)S/^D[X+?%RSLO@?\
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MM!TS]H'X_P"F^%?B%J_Q<\+Z?\<_BQ9>&_BOX@\66?CW7_B=H%IX^\10:/\
M$+6_'6FI'IWC35_&FG1V_B34O%EA&EEXCO=2FUBU18+Q /\ 2:KPOC>'^&/$
M3'XK*J^%PG$.75,;DN+K9=X^X;!3P%+/ZM25/AY>+?!/"?"65935AC,'4EE?
MASF_&^7U(4<N]MG6'PN78"KG'^>^158U,YC&,DY4JKC.*>7N2DZ<?XGU/$5J
M\IKE?O8NGAYZOEA)-\O]0G_!$.,S_P#!.'X=*)CLA^.'[=7VBW=%56AE_;N_
M:7!9)0Q=BH^;!0#/RYP,G]03<V?D_8+>$7ET')T\AF,<1R-WFLX7:>F-BL#[
M5^5__!$VS!_X)P_#^[6YD1G^.7[<<!A0MR6_;O\ VEE&57^'!R3TYYK]6K6R
MOYKJQTWRK*SBP93?QR0"0'C =PVY2?1N>OI7^5%5I5*S<E95)R?1KE]Y[;I=
M;='9ML^;S)2>8X^R>N-Q73_I_,K^6^HN]NMO'$T$=GEKEE2[1K8_O"%7S%'3
M*_O!Z'&:CU)[&622Y-Q>2:A([(+G:A9!&Q1%8B;@1(@48)X4<<FHM1TZ47!U
M(?N[Q\F6/[6JB1/XMB^:!(".?E!XXZ=,^+R[N.9M.A:.6'=YD<^<"3^,EG)'
MS/EA@]#6L87M)?92UBKVO:Z<M=)-;*R^9Y+TT>C\R:Z>SU!;73;BXCDN@S[I
MH,FYF4@!8Y@RI\J\D?,W/85K1I##;O81V\UQY";O(B">8_7Y3N= ,X]>U<]!
MINKK-#>)IZ1W?F?++M !4'KG[N,=#TKIU6 3QAVN(]1F*K<&(.%89'W67@'K
MP#^%.\5I&VM]GUZOT76STZ>773H.4%)V6^ZW6]_^'V,=-/U+R)=3O-)9)KXF
MU%BTBD0PMG$Q7HK  <C..Q-?&?\ P4VG2X_X)E_\%$[(6#I;:?\ L&?M91I(
MH1F$]M^S[X]0.3NSL$JY8]0F3MSQ7W/?WLQ\023Q%I+ 6;0[9;C;'')\N'8.
MX53D$$G'7BO@K_@I?"(_^"9O_!1R:VNI5CF_87_:W$HF+K!*Y^ ?Q ,L=M)(
M DX)+B/RF;>"-N17/7YGA*TIQY).A-INZ2<HO3?=)6N^NUM;-?N:^'Y6I<U:
MG&7+;;GCJ]+I;_(_RYOV']4^%^A_&/X,ZU\</#FM>,?@MI'Q,^'^J?%_PCX<
MGFM?$/BKX7Z?XIT>[\?^'-!N;?7O"L]OK6N>$X=6TS2YX/$_AR:&^NH)(]>T
M=U74+?\ L&F^-&G^,_AU^U'I_CK_ ()D?LN?#+X;>"+7XL> /BK\?/@7^RI^
MT)X.:S_:I\,W%G\-OA%:?!WQ'XHL/"__  RUH^E^(+GX%>(/B)\&/BK!X,GU
MC1](^+FM>)-#F^*/QJM?@[K7\B?[ /QT\8?LR?''X0_M > -+\%ZUXS^$?C'
M1/&_AS2_B%X2TOQMX/O=3T>=)H(M7T#58R,\L^GZYHMWHOC#PGJBV/BOP+XF
M\*^--%T#Q)I7]247_!7CQOXI?P[I7P]^ WP0^'7PF^'/P2\5_"7X*?#"]^$'
M[-GBVU\(>(_BGH2^'_C3\5?%&HVO[.GA'2M0UKXJVNN>--4\3^ _@]X5^ ?P
MFUK7;KP:GB_P-XO\'Z)X[\&_%3^%.(LPR_"<0QI8O,)8:MB,R4*>%AD^'QSQ
M*E3<%*KBJ\E['#THRK.<*;IUY-K#TW*ACL94PW_0[]&[@[C;B?PXRW%<,\'4
M<^P>4\*1QF)SO%>)><<&T\DJ83&X?&2I9=E.44*LL7G./K4<LAA,=C*./RO#
MPA/.<5AZ>;<*<.X+._SM^,O_ ";3^T#_ -D+^+G_ *K_ %ZOKKP]IO\ ;7Q;
M^$>C_P#"S_\ A27]K?%3X?:9_P +G_M#^R?^%1?;_%^CVO\ PL_^U?[<\,_V
M;_P@/F_\)7_:'_"2>'OL?]D_:/[<TGR_M]O\B_&7_DVG]H'_ +(7\7/_ %7^
MO5]2)J/P[T?Q]\/-6^+^@ZMXJ^$NE^/O!^H_%'PQH,TMOKGB/X=67B/3;GQM
MH.BW$&M>')H-6UCPU%J>GZ=-#XAT&6*\N(7CUK2W47T'^LGT.%5EF.!C1CB)
M5I93AU2CA,-A<9BY5'',%".%PF/:P.*Q#E94<-C&L)7J<M+$-493/\V?I??\
MG+XDO;^%'>Z7\?%[M:V]->Q_1]^WQI?[4FL?LD?M*VGQ!^*__!2_X,>!(?A)
MXJU75O%_QYU'_@CGI?P2UAM#M?[;T[X4>*;G]F+7_#?[1\LGQYU33['X&Z!I
MW@K4;B+6/$GQ%T;2/%&@>*_"%]XA\+ZQ_,!\)_\ D$6O^XE?07A[]IOP3^UI
M\1/VBOV=? G_  3"_8S\47T_P8^+/B[7OB)^QM^RQ\?_ !)\;/%GQ:T"YMOA
MK\#?B/\ LSG3(K'7OV<_@QIGB";X!>*_B9X+^(&C>%_"OB/P]X>^-WB#Q M]
M\5?CI9?!3Q!\^_"?_D$6O^XE?W3Q)X>9SX7>"_$7"F?Y3D>0YG6S/)N(WE7#
MW"?#_">"AA,YR2E0PV.Q&&RGBKBS'XK,,=++*ZG6S/&8*,<OP^61IY7EV:2S
MW!T/XXX4Q,,7G'M:<ZE2,>>CS5:U2L^:G5CS1BYT:*C&/,O=C&7ON;YYPY)/
M^R?_ ()<W ?_ ()J?\$\8U\0V\5VG["O[(XM[.[-PJ1[?@#\/<1-LBE78%^1
M3SGY>!GC[\%]?S6YM[Z&S:< ^4MG,_VB?' ,>(5'09!=U..N.:_S'?A3\!/@
M9J?[/GP/US4O@O\ "?4-:UCX-?#'5=6U>]^'/@^[U35-4U#P5HEW?ZEJ.H3Z
M/)=WM_?74TMS>7ES++<7-Q+)--(\CLQ_KM_9:_:&U?X._LW?#'X.^"?AW_P4
M7_9UTSX/_LU?!7QY<?#C]D[X1?\ !,QO@!=^'/BG#I>F?#_QO\(]?^-OPTL]
M>\>_$C]K/QYJ=]XNL_A;IU]XK^+7C/\ :"\5_$KX<>%=#\5^+/"FN6MM_BOG
M_'&$X6QE++L9E^(Q,_8T94ZF%G%IN5+GDO?ITE'EIPG.4957/V<*DX1E&G5G
M#X#-N(,NR;-J^68M9A4J-J<*F&PM.K&;J*=24/WF)I0C[.E3J5I*53VDJ5.K
M5ITI4Z->=/\ =-7GD;4OM.G7OE6\7^KG*>82$R2 )''7/.<D]JZ!+&T;2X1)
M%;^1)'YPA3S9+R-F9AN93"L8'RC&)L]>,"O\;_\ ;/U+X<^//C)\9?B7\/O@
M_P""?@OX3^(/Q,\?^.?"WPM\&Z5H5MX>^&GA[Q;XKU;7]$\ >'VT3P]X8TTZ
M-X-TW4+;P[I;:=X>T&Q-CIT!M-%TNW\NQ@_U/?\ @F=K6K1_\$W_ /@G@XU9
M"\G["'[(]S>BXB-S-()_@-X%D:>>Z>.1C+,V]G:27>S9=^26/J\(\7TN,*-3
M$83"SPE*E:4'.MS^VBW:+M[&$H*4;32:YE?E:339I@<SPV<Y6LPPGM/83K<D
M/:0Y7.&\*J7-S)3C:2C.,91O:23NE]KQZCJ$%X]AIS2FWF1H6DD4!$4LO!^8
MD'CCC]:OP1KIKO;-?1S3."S1D?(<@L5!Y.[' .W@X-9\\\4(;4]KI;-&<RIU
M:1MI#A!SY6 <R;=@RH+#<N:6FR)=M)>1K]H27?&LQ(8*S H"K9Y<$\ 9.1@<
MU]U9>\U;5>]HM6DDFWW27DM06Z]4=)8Q3-(VJ!S;6:M]GD14664R\#>$9E38
M"R\E@>#Q7\L__!W[;+!_P3L_9\,LBRW0_;I^&2"0'!DMS\ _VFF#&/D(0Y"D
M!CCL3DX_J9BBC,,>DO<R1M,WF'?N4YR.Q /8FOY7/^#O6W:+_@G?\!3YK3K#
M^W;\,;?S'))W?\*!_:;?"9Y9#@Y8#;D#GD5X&>W_ +)S%W7^Z5=+=-+._P!]
M]]U9(^EX83_UCR/1_P#(UP/3_J(IG\6?P*Z67_ /_017ZJ_#_P#U=K_URB_]
M!6ORJ^!72R_X!_Z"*_57X?\ ^KM?^N47_H*U_GO6_P"3FY;_ -?9_P#IZB?]
M9W@1_P HJYU_V"X'_P!1ZIZEXP_Y'#]F/_LM^O?^LS?M#U]D_LIZKK6@?MD?
M!OQ#X>^%?C'XR:QX<;XA^)+/P;\-M-\!:Y\4K(^'OA5XXUF?XC?"3PY\3]!\
M3^!O%GQ?^#-M8S?&'X3>#M=T#4QXP^(O@3PSX9TZW&K:K821_&WC#_D</V8_
M^RWZ]_ZS-^T/7J>C_%?X[_!+XR> ?B+^S)?:Q8?'K3M6NM ^&+^'O"&D>/\
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MY=D//A:GM98''X6G2K9C7RVAAG6HQJ3Q-.=##XK"3K.5;^:;]BA/,_X*<?\
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M/+A91N)V&,N&'3@C/^1G^VLLB?\ !37_ (*%++S(O[=?[6RR'U<?M >/P_\
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MDX1Y5I9)*T5M:VRMI;1Q:BEJD[)K\SE?F=][MO?=OSU^_7OJ?XNOP._Y=?\
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M:%CB SD&7]E7XYQ,X_W$=G_X#7^H5'_:%A)Y)N?,N(_+:XFD(WVQE!\OR\\
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M"5)3YL0F^9NA)R<[N3FG=ZM_S_X\^/'"OBWGE',.&^&L5POE>$PD\#@LJJ/
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M2DJR4;]4[G^?WCAXVY!XG\59KQ!@<MS#*Z.84U&&'Q3I8BI3?/5G>4Z%HO\
MBI:=O-'\<W_-7/\ MC_[7K];_A/_ ,@BU_W$K];M'_X-6?V)=3U WW_#5_\
MP4:-RH;.J)\<_A-%<LBN<@7$O[/#7"X8'[[ ,PW#@BO3M'_X-B_V4(O.2S_;
M?_X*LZ?9VBDE[/\ :B^%\"3!<[A;1P?  $&+ +*8R3O78#@FO[N^D3]/7A[Q
MCX3RSA[+O#;B+):V7X*CAIXC'9WD^(IU)4H<KE&&'@I)2?PINY^ \*XG!Y+C
M*V*J5Y8A5JKJ*$*,X-*3@[-S=KKJ?SN?!S_DVC]G[_LA?PE_]0+0*_7WQ?\
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M+X5)\<A#_P %0?\ @H%&)?C,G@301\4)HT\'_M:6W@I(W\;#774>$88?# 7
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M\N8I?LS7 *@!5V(S<CH5X^[P,=O7574=/BT]%MH[6^,7WOM#^3NQTW!.O?\
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M#X0R_'<<Y]EN5Y?4SNKD.'H8UQ6/I8W(UG&!SO*.(^%Z^>\)\0^U_P#!/_\
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M6F1^)DUN_M;66VT#3-9U:2UTVY^<?V$?V^_AY_P4*_9TN?VG/@K\+OC#X=\
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MFG*A5DULY8W'-J^]KXGJ?(\G[*NM2W#W4G[4G[0[S.5+,=*_9DVY10B[8_\
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M\&/B=IOA&]L9XK'P?J\WPC=-%N]&\+ZI;7?]85?D;\5/^"0_@SXL?MK^%/\
M@H#JG[8_[9/AS]I'X;Z-XC\(_";7?"Y_9"3PU\+?A[XB?XCQGX?>'/"GB']D
M3Q%I>O:!I&E_%CQOHFF:I\1U\=>-I;#5(KC6_%NL:S96FJQ?TO\ 1QX^X1X1
MI^+^0\?YS0P/"W'?A7GF2X#+L9EF;9M@:WB3EM;#Y[X5<08K"Y7EV8.C0X3X
MRR_!9AC\8Z<J[R3$9OE=/!9KA<UQ^68KQLWPN(Q#R^KA:;E7PN.I5)3C.G3D
ML'.]+'4DYRC=U\/*4(QNE[14Y\T)4X3C\:?\%$/VK?B9\-?^"C/_  3P_P""
M8WP>^'?QQ'P"\??!GXC>./'?@G]ESQAX9^"'Q/\ B+HGA?X<?%SP_P##/X8?
M"OXS>)?BY\#=/\!VOPMO?AG!XW\8:?IGQ2\!:I>^'Y?#FG:?JVLW=Y8^%M6S
M_AY\3?\ @I%\-?V5?V(_^'E'Q:\*?LUZWHO[1OC'X._M(>%=7\8:7J/[0'[9
MWA/Q9X2GLOV>M!_9V\:?LJ^,?%VJP_$NZ\5ZV+#7?#VA7G@3QOKVH^#G\8:C
MXAT+P?HVJV'Q(_77]JW]@WX/?M9^+O@S\5/$&O\ Q%^%'QV_9XUZ]U_X*?'S
MX-:QX;T7XF> 9=7^S1^(M*MD\;>$O'_@/Q'X=\2V-L=,UKP_XT\#^)=+FL;J
M]%K;6ES<O<US_P >_P#@G!^SK^TAK_[.OC'XDOX_D\<_LR?'6#]H[X?^-M!\
M4P:/K^J?%:*^\/:I)K7C(1Z/-H^MVDM_X1\*-!I=MI.F6>C:;X;T;PWX<CT;
MPM:+HC?IN2>.'@RN#/"+A7'\+Y3E5/+,BS6GXF\0K@VIQ)XC/CK#5?%B5'BK
MAC.\SSR'#5'#<8Y;Q]PW@<=FV*R/'\59'G'!V0YG2IU:7 G!4Y\=3+<P^L8^
MO"M4FYU:;P5+ZPJ.#^JM8!.A6IPI.LWAYX6O.%.-2-"K#$58/7%8@_GC_9@_
M:S_:2^)_[.'_  <F? 3QQ\7OC<FB_P#!/]_CMJW[+7B^_P#C#\0;']H_X4#P
MD?VI]4\&>&-:_: \(_$"7Q]XO3P/JW[/G@5Y+C5/'7B:3Q0)_&.@>+_$/CGP
M5XFGT=OT5_X(66/QP_:&_P"">W_!/[]I[XI?M1_'GQ=XO\/ZE^U)_P )SI_B
MWQ[XB\;VOQI\-7WQ:^-OP]\.>'_B==^+=6U6ZUFY\":I9Z3XI\)^)Y/.\3Z7
M%X>T7PA::M;>$(KC1YOJ&W_X(^_LYZ#+_P %%6^'OQ'^//PPM_\ @IWINGZ7
M^T78^$M:^%6I6VE0%/&%OXRF^&;>/OA!XVN]!OOB=8?$;XC67C?4/$MUXQO$
M/CC6-5\&S>$/$%AX8UC0/IC]A#]BSP+_ ,$^_P!G+PU^RY\+/B'\5?B%\,_!
M.N>*]6\$R?%^Z^'FH^)?"MAXSURZ\5ZUX8L=5^'?PX^&MOJ>AOXPU;Q+XIMK
MCQ+IVN^);>_\3ZGIP\0MX:L?#>A:%]!XW^/7@[Q1X;^(66^&.&PF19_Q9XF^
M%7%>!RNOP?3PT\/DF'^C?+P[\7*:Q-7!8_+\'F.?^(6:XO,ZE3#XZ5?,JF"J
M\1?7:694LKJ5\LMRO,*&+PD\;*56E0P6.H2J+$-IU'G$<7@-%*$Y0I82G&"3
MC:":H\K@YV_%+]@/]H3]H;5?VT_#/[(_[>'Q)^/_ ,!OVSOA]\?OCY\<9]"U
MG7?%FL?LQ_\ !1'X0:E\+?B[X6\(Z+\"=.O_ !,?"OPT\.?!#1?&_ACQW:?#
M'P$VN^$]37X31^,_&VC:Y\9[3Q+XC^%_].=?G[\#_P#@F[\"/@=XG_9B\4VG
MB'XG_$BZ_8U^!MY\"?V:;/XJZSX2\16_PJTGQ%X?T'PK\0O&^AZAI'@CP[XB
MN?'WQ)\->&=%\/Z_<ZMKFH>$O#>@07GA_P"%W@_X?:%K>NZ;J?Z!5_._TB>.
MN"/$'C3*<\X$P,<MP-+AFE@<WP.#RFEDG#]'/(<0\1XRK4X5RR?M<TRS(,;E
MN-RO,*609OF.=/A',,7F/!G#N<8W@CAWA:4?6RC#8G"8:I2Q4G.3K.5.4JCJ
MUG3]C1BE7GI"=6,XS@ZM.%/ZQ",,15IQQ-:N@HHHK\#/4"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*_\ IL5'_"N?^"IO_1Y'[ '_ (K3_:*_^FQ5\5?LQ?MK:%\%Q\7O%?Q5\/\
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MVJ6)Q&%G=6:K8:I[.JEWBI?#+JM2/_A7/_!4W_H\C]@#_P 5I_M%?_38J/\
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MX;M==TR_ /3_ /A7/_!4W_H\C]@#_P 5I_M%?_38J/\ A7/_  5-_P"CR/V
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M=]XAU$ ^R_\ A7/_  5-_P"CR/V /_%:?[17_P!-BH_X5S_P5-_Z/(_8 _\
M%:?[17_TV*OO^B@#X _X5S_P5-_Z/(_8 _\ %:?[17_TV*C_ (5S_P %3?\
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M/PXN=*TNS\6?#'4[K6;..X?^V1^VAX>^,_[/OQ5\0_#30?@W\;_V:=&\?_\
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M;Q#>^'+[5=,UO2[+7K72-=O)]'N]2T;5["VU".WFO-,O[=)+67Y>_P"'3O\
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M8?%WB+6?"-AXVM]>C\!^+=3D\;>!_P#A'O&$%KKD'E__  Z=_P""67_2-/\
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MVMO#GC;5[C3!9^(]/2'5HK&YNEO+6&:RN?U_T']F?X->&_BQ??&O2_#FM_\
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MO^SK_P#.YH_X=._\$LO^D:?[ '_B&_[.O_SN: /O^BO@#_AT[_P2R_Z1I_L
M?^(;_LZ__.YH_P"'3O\ P2R_Z1I_L ?^(;_LZ_\ SN: /O\ KX _X)._\HLO
M^":?_9@'[&__ *SK\.:/^'3O_!++_I&G^P!_XAO^SK_\[FON'PMX6\,>!O#'
MASP3X)\.:#X.\&>#M!TCPMX1\(^%M'T_P]X8\+>&/#VGV^DZ!X<\.:!I-O::
M5H>@Z'I5I::9I&D:9:6NGZ;I]K;V5E;PVT,<:@&]1110 4444 %%%% !1110
7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803236288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Integrity Applications, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001506983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,323,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,798,070<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803817280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 608,701<span></span>
</td>
<td class="nump">$ 5,827,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">18,446<span></span>
</td>
<td class="nump">23,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (Note 3)</a></td>
<td class="nump">816,223<span></span>
</td>
<td class="nump">83,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets (Note 4)</a></td>
<td class="nump">268,792<span></span>
</td>
<td class="nump">113,842<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,712,162<span></span>
</td>
<td class="nump">6,048,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, Net (Note 5)</a></td>
<td class="nump">220,463<span></span>
</td>
<td class="nump">$ 122,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Long-Term Restricted Cash</a></td>
<td class="nump">35,152<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_FundsInRespectOfEmployeeRightsUponRetirementNoncurrent', window );">Funds in Respect of Employee Rights Upon Retirement</a></td>
<td class="nump">164,883<span></span>
</td>
<td class="nump">$ 177,470<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,132,660<span></span>
</td>
<td class="nump">6,348,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,082,546<span></span>
</td>
<td class="nump">104,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities (Note 6)</a></td>
<td class="nump">$ 427,886<span></span>
</td>
<td class="nump">440,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrent', window );">Long-Term Loans from Stockholders, current portion (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">454,532<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">$ 1,510,432<span></span>
</td>
<td class="nump">1,000,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersNoncurrent', window );">Long-Term Loans from Stockholders (Note 8)</a></td>
<td class="nump">160,314<span></span>
</td>
<td class="nump">163,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent', window );">Liability for Employee Rights Upon Retirement (Note 2J)</a></td>
<td class="nump">174,137<span></span>
</td>
<td class="nump">210,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants with Down-Round Protection (Note 10D)</a></td>
<td class="nump">321,695<span></span>
</td>
<td class="nump">2,057,618<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">656,146<span></span>
</td>
<td class="nump">2,431,777<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 2,166,578<span></span>
</td>
<td class="nump">$ 3,431,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingent Liabilities (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount', window );">Convertible Preferred Stock of $ 0.001 par value ("Preferred Stock")</a></td>
<td class="nump">$ 6,936,996<span></span>
</td>
<td class="nump">$ 7,748,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock of $ 0.001 par value ("Common Stock"): 40,000,000 shares authorized as of December 31, 2015 and December 31, 2014; issued and outstanding 5,690,097 shares and 5,323,058 shares as of December 31, 2015 and December 31, 2014, respectively</a></td>
<td class="nump">5,691<span></span>
</td>
<td class="nump">5,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">22,309,742<span></span>
</td>
<td class="nump">18,182,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">90,168<span></span>
</td>
<td class="nump">66,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(29,376,515)<span></span>
</td>
<td class="num">(23,087,063)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(6,970,914)<span></span>
</td>
<td class="num">(4,832,203)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, temporary equity and stockholders' deficit</a></td>
<td class="nump">2,132,660<span></span>
</td>
<td class="nump">6,348,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount', window );">Convertible Preferred Stock of $ 0.001 par value ("Preferred Stock")</a></td>
<td class="nump">221,152<span></span>
</td>
<td class="nump">4,356,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount', window );">Convertible Preferred Stock of $ 0.001 par value ("Preferred Stock")</a></td>
<td class="nump">$ 6,715,844<span></span>
</td>
<td class="nump">$ 3,392,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_FundsInRespectOfEmployeeRightsUponRetirementNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funds In Respect Of Employee Rights Upon Retirement, Noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_FundsInRespectOfEmployeeRightsUponRetirementNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3-4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a(1)<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 12<br> -Subparagraph a(1)<br> -Article 6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 12<br> -Subparagraph a(1)<br> -Article 6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 22, 23, 24, 25, 26, 27<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=27011957&amp;loc=SL6540498-122764<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011957&amp;loc=SL6540498-122764<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=27011957&amp;loc=SL6540498-122764<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011957&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803920608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract', window );"><strong>Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
<td class="nump">5,690,097<span></span>
</td>
<td class="nump">5,323,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
<td class="nump">5,690,097<span></span>
</td>
<td class="nump">5,323,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract', window );"><strong>Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible Preferred Stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract', window );"><strong>Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, shares issued</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">7,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, shares outstanding</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">7,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract', window );"><strong>Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, shares issued</a></td>
<td class="nump">15,031<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, shares outstanding</a></td>
<td class="nump">15,031<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27011957&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803815552">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 143,167<span></span>
</td>
<td class="nump">$ 59,775<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses (Note 11)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,268,345<span></span>
</td>
<td class="nump">1,849,624<span></span>
</td>
<td class="nump">$ 1,986,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and general and administrative expenses (Note 12)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,530,175<span></span>
</td>
<td class="nump">1,817,510<span></span>
</td>
<td class="nump">1,041,140<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,798,520<span></span>
</td>
<td class="nump">3,667,134<span></span>
</td>
<td class="nump">3,027,894<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,655,353<span></span>
</td>
<td class="nump">3,607,359<span></span>
</td>
<td class="nump">3,027,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_FinancingIncomeExpensesNet', window );">Financing (income) expenses, net (Note 13)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,186,819<span></span>
</td>
<td class="num">(6,587,785)<span></span>
</td>
<td class="nump">6,768,959<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,842,172)<span></span>
</td>
<td class="nump">2,980,426<span></span>
</td>
<td class="num">(9,796,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,498<span></span>
</td>
<td class="nump">13,968<span></span>
</td>
<td class="nump">43,777<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5,818,674)<span></span>
</td>
<td class="nump">$ 2,994,394<span></span>
</td>
<td class="num">$ (9,753,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Income (loss) per share (Basic) (Note 15)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.15)<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="num">$ (1.95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Income (loss) per share (Diluted) (Note 15)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.15)<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="num">$ (1.95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Common shares used in computing Basic income (loss) per share (Note 15)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,476,870<span></span>
</td>
<td class="nump">5,304,500<span></span>
</td>
<td class="nump">5,325,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Common shares used in computing Diluted income (loss) per share (Note 15)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,476,870<span></span>
</td>
<td class="nump">5,349,242<span></span>
</td>
<td class="nump">5,325,714<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In applying the treasury method, the average market price of Common Stock was based on management estimate. For December 31, 2015 and 2014, management estimation considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series B Units (See Note 10C). The fair value per share of the Company's Common Stock as of December 31, 2013 was based on the management's estimate which was based among other factors on the closing price per share of the Company's Common Stock on December 27, 2013, as reported on the OTCQB, which was the last reported sale of Common Stock in 2013.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_FinancingIncomeExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Income (Expenses), Net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_FinancingIncomeExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51677171&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6804113120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional paid in capital [Member]</div></th>
<th class="th"><div>Accumulated other comprehensive income [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2012</a></td>
<td class="nump">$ 5,461<span></span>
</td>
<td class="nump">$ 14,772,371<span></span>
</td>
<td class="nump">$ 8,925<span></span>
</td>
<td class="num">$ (15,289,826)<span></span>
</td>
<td class="num">$ (503,069)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2012</a></td>
<td class="nump">5,460,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Income (loss) for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (9,796,853)<span></span>
</td>
<td class="num">(9,796,853)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 43,777<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">43,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Amount classified out of stockholders equity and presented as liability and temporary equity with respect to Common Stock replaced with units comprised of convertible Preferred Stock and warrants with down-round protection</a></td>
<td class="num">$ (163)<span></span>
</td>
<td class="num">$ (1,140,186)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,140,349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Amount classified out of stockholders equity and presented as liability and temporary equity with respect to Common Stock replaced with units comprised of convertible Preferred Stock and warrants with down-round protection, shares</a></td>
<td class="num">(162,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock', window );">Conversion of Preferred Stock</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">23,196<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock', window );">Conversion of Preferred Stock, shares</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued as consideration for placement services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">562,805<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 562,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsStock', window );">Stock dividend to certain Common Stock holders</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 278,263<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (278,263)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividend on convertible Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (288,248)<span></span>
</td>
<td class="num">$ (288,248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 35,619<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">35,619<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2013</a></td>
<td class="nump">$ 5,302<span></span>
</td>
<td class="nump">$ 14,532,068<span></span>
</td>
<td class="nump">$ 52,702<span></span>
</td>
<td class="num">$ (25,653,190)<span></span>
</td>
<td class="num">(11,063,118)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2013</a></td>
<td class="nump">5,301,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Income (loss) for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,980,426<span></span>
</td>
<td class="nump">2,980,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 13,968<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued', window );">Amounts allocated to Series B-1 and Series B-2 Warrants, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,320,429<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,320,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities', window );">Amount classified out of stockholders deficit and presented as Warrants with Down-Round Protection within long-term liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(400,671)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(400,671)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock', window );">Conversion of Preferred Stock</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">5,886<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock', window );">Conversion of Preferred Stock, shares</a></td>
<td class="nump">1,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued as consideration for placement services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">630,936<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 630,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsStock', window );">Stock dividend to certain Common Stock holders</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_StockIssuedDuringPeriodSharesStockDividend', window );">Stock dividend to certain Common Stock holders, shares</a></td>
<td class="nump">654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Stock dividend on Series B Preferred Stock</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 43,839<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (43,858)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsShares', window );">Stock dividend on Series B Preferred Stock, shares</a></td>
<td class="nump">18,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividend on convertible Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (370,441)<span></span>
</td>
<td class="num">$ (370,441)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 50,380<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,380<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="nump">$ 5,324<span></span>
</td>
<td class="nump">$ 18,182,866<span></span>
</td>
<td class="nump">$ 66,670<span></span>
</td>
<td class="num">$ (23,087,063)<span></span>
</td>
<td class="num">$ (4,832,203)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2014</a></td>
<td class="nump">5,323,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,323,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Income (loss) for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (5,842,172)<span></span>
</td>
<td class="num">$ (5,842,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 23,498<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued', window );">Amounts allocated to Series B-1 and Series B-2 Warrants, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,445,337<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,445,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock', window );">Conversion of Preferred Stock</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">237,451<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 237,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock', window );">Conversion of Preferred Stock, shares</a></td>
<td class="nump">86,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsStock', window );">Stock dividend to certain Common Stock holders</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_StockIssuedDuringPeriodSharesStockDividend', window );">Stock dividend to certain Common Stock holders, shares</a></td>
<td class="nump">92,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Stock dividend on Series B Preferred Stock</a></td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 390,050<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (390,219)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsShares', window );">Stock dividend on Series B Preferred Stock, shares</a></td>
<td class="nump">168,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividend on convertible Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (57,061)<span></span>
</td>
<td class="num">$ (57,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of employees' stock options</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">36,117<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Exercise of employees' stock options, shares</a></td>
<td class="nump">19,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18,013<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18,013<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">$ 5,691<span></span>
</td>
<td class="nump">$ 22,309,742<span></span>
</td>
<td class="nump">$ 90,168<span></span>
</td>
<td class="num">$ (29,376,515)<span></span>
</td>
<td class="num">$ (6,970,914)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2015</a></td>
<td class="nump">5,690,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,690,097<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of investor warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_AdjustmentsToAdditionalPaidInCapitalInvestorWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from reclassification out of stockholders deficit to liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Conversion Of Convertible Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_StockIssuedDuringPeriodSharesStockDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of stock issued to shareholders as a dividend during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_StockIssuedDuringPeriodSharesStockDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Conversion Of Convertible Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183637&amp;loc=d3e4724-112606<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Warrant<br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid stock dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements in the number of shares included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790090256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Income (loss) for the year</a></td>
<td class="num">$ (5,842,172)<span></span>
</td>
<td class="nump">$ 2,980,426<span></span>
</td>
<td class="num">$ (9,796,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile income (loss) for the year to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 44,891<span></span>
</td>
<td class="nump">$ 34,683<span></span>
</td>
<td class="nump">33,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPostemploymentObligations', window );">Decrease in liability for employee rights upon retirement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 18,013<span></span>
</td>
<td class="nump">$ 50,380<span></span>
</td>
<td class="nump">35,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Issuance costs allocated to warrants with down-round protection</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">390,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in the fair value of warrants issued with down-round protection</a></td>
<td class="num">$ (149,092)<span></span>
</td>
<td class="num">$ (6,559,758)<span></span>
</td>
<td class="nump">6,251,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders', window );">Linkage difference on principal of loans from stockholders</a></td>
<td class="num">(2,521)<span></span>
</td>
<td class="num">$ (556)<span></span>
</td>
<td class="nump">$ 14,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_GainLossOnUnitConversion', window );">Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants</a></td>
<td class="nump">1,284,354<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable</a></td>
<td class="nump">4,131<span></span>
</td>
<td class="num">$ (24,539)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventory</a></td>
<td class="num">(737,554)<span></span>
</td>
<td class="num">(94,895)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Increase in other current assets</a></td>
<td class="num">(156,302)<span></span>
</td>
<td class="num">(32,416)<span></span>
</td>
<td class="num">$ (5,234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Increase (decrease) in accounts payable</a></td>
<td class="nump">982,215<span></span>
</td>
<td class="nump">68,838<span></span>
</td>
<td class="num">(77,259)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Increase (decrease) in other current liabilities</a></td>
<td class="num">(11,187)<span></span>
</td>
<td class="nump">216,192<span></span>
</td>
<td class="num">(54,317)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(4,565,224)<span></span>
</td>
<td class="num">(3,361,645)<span></span>
</td>
<td class="num">(3,217,767)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investment activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement', window );">Increase in funds in respect of employee rights upon retirement</a></td>
<td class="num">(24,279)<span></span>
</td>
<td class="num">(28,058)<span></span>
</td>
<td class="num">(40,029)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(143,736)<span></span>
</td>
<td class="num">$ (63,455)<span></span>
</td>
<td class="num">$ (64,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Increase in long-term restricted cash</a></td>
<td class="num">(35,152)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investment activities</a></td>
<td class="num">$ (203,167)<span></span>
</td>
<td class="num">$ (91,513)<span></span>
</td>
<td class="num">$ (104,281)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Repayment of credit from banking institutions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(38,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Cash dividend on Series A Preferred Stock</a></td>
<td class="num">$ (57,061)<span></span>
</td>
<td class="num">$ (370,441)<span></span>
</td>
<td class="num">(288,248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds allocated to convertible Preferred Stock, net of cash issuance expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,710,860<span></span>
</td>
<td class="nump">3,960,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds allocated to warrants, net of cash issuance expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,632,531<span></span>
</td>
<td class="nump">$ 1,421,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of employees' stock options</a></td>
<td class="nump">$ 36,137<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Repayment of loan from stockholders</a></td>
<td class="num">(439,939)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(460,863)<span></span>
</td>
<td class="nump">$ 6,972,950<span></span>
</td>
<td class="nump">$ 5,055,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">10,395<span></span>
</td>
<td class="num">(78,143)<span></span>
</td>
<td class="nump">108,656<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(5,218,859)<span></span>
</td>
<td class="nump">3,441,649<span></span>
</td>
<td class="nump">1,842,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">5,827,560<span></span>
</td>
<td class="nump">2,385,911<span></span>
</td>
<td class="nump">543,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">$ 608,701<span></span>
</td>
<td class="nump">$ 5,827,560<span></span>
</td>
<td class="nump">$ 2,385,911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_GainLossOnUnitConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) resulting from a unit conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_GainLossOnUnitConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Funds In Respect Of Employee Rights Upon Retirement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_IncreaseDecreaseInFundsInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Linkage difference on principal of loans from stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPostemploymentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the current portion of the liability that represents various benefits due to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPostemploymentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other expenses or losses included in net income that result in no cash outflows or inflows in the period and are not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3098-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789921184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange', window );">Non-cash charge recorded to finance expense as result of warrant exchange</a></td>
<td class="nump">$ 1,284,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB1WarrantMember', window );">Series B-1 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NumberOfWarrantsExchanged', window );">Number of warrants exchanged | shares</a></td>
<td class="nump">1,200,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants', window );">Increase (decrease) in equity due to exchange of warrants</a></td>
<td class="nump">$ 1,833,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB2WarrantMember', window );">Series B-2 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NumberOfWarrantsExchanged', window );">Number of warrants exchanged | shares</a></td>
<td class="nump">1,200,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants', window );">Increase (decrease) in equity due to exchange of warrants</a></td>
<td class="nump">$ 1,612,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NumberOfWarrantsExchanged', window );">Number of warrants exchanged | shares</a></td>
<td class="num">(1,440,880)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants', window );">Increase (decrease) in equity due to exchange of warrants</a></td>
<td class="num">$ (1,586,831)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated deficit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockStock', window );">Stock dividend</a></td>
<td class="nump">$ 390,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock', window );">Number of Series A Preferred Stock shares exchanged for Series B Preferred Stock shares | shares</a></td>
<td class="num">(6,931)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants', window );">Increase (decrease) in equity due to exchange of warrants</a></td>
<td class="num">$ (4,076,688)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Conversion of Preferred Stock Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of preferred shares converted | shares</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock issued upon conversion | shares</a></td>
<td class="nump">17,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Amount of stock converted</a></td>
<td class="nump">$ 58,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock', window );">Number of Series A Preferred Stock shares exchanged for Series B Preferred Stock shares | shares</a></td>
<td class="nump">6,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants', window );">Increase (decrease) in equity due to exchange of warrants</a></td>
<td class="nump">$ 3,502,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockStock', window );">Stock dividend</a></td>
<td class="nump">$ 390,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Conversion of Preferred Stock Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of preferred shares converted | shares</a></td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock issued upon conversion | shares</a></td>
<td class="nump">68,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Amount of stock converted</a></td>
<td class="nump">$ 178,720<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Series A Preferred Stock shares exchanged for Series B Preferred Stock shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in equity due to exchange of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_IncreaseDecreaseInEquityDueToExchangeOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash charge recorded to finance expense as a result of warrants exchanged.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_NumberOfWarrantsExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exchanged.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_NumberOfWarrantsExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB1WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB1WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB2WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB2WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=igap_ConversionOfPreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=igap_ConversionOfPreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793689952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"></font></div>

<div style="text-align: center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 54pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">NOTE 1</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt times new roman">GENERAL</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">A.</font></font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Integrity Applications, Inc. (the "Company") was incorporated on May&#160;18, 2010 under the laws of the State of Delaware.&#160;&#160;On July&#160;15, 2010, Integrity Acquisition Corp. Ltd. (hereinafter: "Integrity Acquisition"), a wholly owned Israeli subsidiary of the Company, which was established on May&#160;23, 2010, completed a merger with A.D. Integrity Applications Ltd. (hereinafter: "Integrity Israel"), an Israeli corporation that was previously held by the stockholders of the Company.&#160;&#160;Pursuant to the merger, all equity holders of Integrity Israel received the same proportional ownership in the Company as they had in Integrity Israel prior to the merger. Following the merger, Integrity Israel remained a wholly-owned subsidiary of the Company.&#160;&#160;As the merger transaction constituted a structural reorganization, the merger has been accounted for at historical cost in a manner similar to a pooling of interests.&#160;&#160;Integrity Israel was incorporated in 2001 and commenced its operations in 2002.&#160;&#160;Integrity Israel, a medical device company, focuses on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">B.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Going concern uncertainty</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Since its incorporation, the Company did not conduct any material operations other than those carried out by Integrity Israel.&#160;&#160;The development and commercialization of Integrity Israel's product is expected to require substantial expenditures.&#160;&#160;Integrity Israel and the Company (collectively, the "Group") have not yet generated any material revenues from operations, and therefore they are dependent upon external sources for financing their operations. As of December 31, 2015, the Group has incurred accumulated deficit of $29,376,515, stockholder's deficit of $6,970,914 and negative operating cash flows.&#160;&#160;These factors raise substantial doubt about the Group&#8217;s ability to continue as a going concern.&#160;&#160;The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&#160;&#160;During 2012, the Company raised a total amount of approximately $1.0 million (net of related expenses) from the issuance of Common Stock. During 2013, the Company raised funds in an approximate amount of $5.3 million (net of related cash expenses) from the issuance of units (the &#8220;Series A Units&#8221;) consisting of shares of the Company&#8217;s Series A Convertible Preferred Stock (the &#8220;Series A Preferred Stock&#8221;) and detachable warrants to purchase shares of the Company&#8217;s Common Stock (the &#8220;Series A Warrants&#8221; or &#8220;warrants with down round protection&#8221;), see also Note 10A.2, Note 10B and Note 10D.&#160;&#160;During the period between August and December of 2014, the Company raised funds in an aggregate amount of approximately $7.3 million (net of related cash expenses) from the issuance of units (the &#8220;Series B Units&#8221;), each consisting of (a) one share of the Company&#8217;s newly designated Series B 5.5% Convertible Preferred Stock, par value $0.001 per share (the &#8220;Series B Preferred Stock&#8221;), convertible into Common Stock at an initial conversion price of $5.80 per share, (b) a five year warrant to purchase, at an exercise price of $5.80 per share, up to such number of shares of Common Stock issuable upon conversion of such share of Series B Preferred Stock (each a &#8220;Series B-1 Warrant&#8221;) and (c) a five year warrant to purchase, at an exercise price of $10.00 per share, up to such number of shares of Common Stock issuable upon conversion of such share of Series B Preferred Stock (each a &#8220;Series B-2 Warrant&#8221; and, together with the Series B-1 Warrants, collectively, the &#8220;Series B Warrants&#8221;), see Also Note 10A.3 and Note 10C.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">Until such time as the Group generates sufficient revenue to fund its operations (if ever), the Group plans to finance its operations through the sale of equity or equity-linked securities and/or debt securities and, to the extent available, short term and long term loans. There can be no assurance that the Group will succeed in obtaining the necessary financing to continue its operations as a going concern.</font></div>
</div>



<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">C.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Risk factors</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">As described in Note 1A and Note 1B above, the Group has a limited operating history and faces a number of risks and uncertainties, including risks and uncertainties regarding continuation of the development process, demand and market acceptance of the Group's products, the effects of technological changes, competition and the development of products by competitors.&#160;&#160;Additionally, other risk factors also exist, such as the ability to manage growth and the effect of planned expansion of operations on the Group's future results and the availability of necessary financing. In addition, the Group expects to continue incurring significant operating costs and losses in connection with the development of its products and marketing efforts. The Group has not yet generated material revenues from its operations to fund its activities and therefore is dependent on the receipt of additional funding from its stockholders and/ or new investors in order to continue its operations.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6801260656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 54pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">NOTE 2</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt times new roman">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 72pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP).</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">A.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Use of estimates in the preparation of financial statements</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to (i) the fair value estimate of the Warrants with down-round protection, (ii) the fair value measurement of the Series B Units and the estimate of the loss arising from the partial extinguishment of the Series A Units and the exchange thereof for Series B Units, and (iii) the going concern assumptions.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">B.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Functional currency</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The functional currency of the Company is the US dollar, which is the currency of the primary economic environment in which it operates.&#160;&#160;In accordance with ASC 830, &#8220;Foreign Currency Matters&#8221; (ASC 830), balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date.&#160;&#160;For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used.&#160;&#160;Gains or losses arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses. The functional currency of Integrity Israel is the New Israeli Shekel ("NIS") and its financial statements are included in consolidation, based on translation into US dollars.&#160;&#160;Accordingly, assets and liabilities were translated from NIS to US dollars using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or losses resulting from translation adjustments are reflected in stockholders' equity (deficit), under &#8220;accumulated other comprehensive income (loss)&#8221;.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt times new roman">Official exchange rate of NIS&#160;1 to US dollar</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">0.256</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">0.257</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">0.288</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>


<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">C.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Principles of consolidation</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated in consolidation.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">D.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Cash and cash equivalents</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less at the date of purchase, to be cash equivalents.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman"><font style="display: inline; font-size: 10pt">E.</font></font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Inventories</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Inventories are stated at the lower of cost or market value.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Cost is determined as follows:</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">With respect to raw materials, the Group calculates cost using the average cost method.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">With respect to work in process and finished products, the Group calculates the cost on the basis of the average direct manufacturing costs, including materials, labor, subcontracting costs and other direct manufacturing costs.</font></div>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Management evaluates whether inventory reserve for slow-moving or obsolete items is required. To date, the Group has not recorded any reserves with respect to its inventory.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">F.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Property and equipment, net</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 100pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">1.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation.&#160;&#160;Depreciation is calculated using the straight-line method over the estimated useful lives of the assets.&#160;&#160;When an asset is retired or otherwise disposed of, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in the statements of operations.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 100pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">2.</font></div>
</td>
<td>
<div style="text-align: left"><font style="display: inline; font: 10pt Times New Roman">Rates of depreciation:</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 83%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 85%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 13%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">%</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 85%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt times new roman">Computers</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 13%; text-align: center"><font style="display: inline; font: 10pt times new roman">33</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 85%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt times new roman">Furniture and office equipment</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 13%; text-align: center"><font style="display: inline; font: 10pt times new roman">7-15</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 85%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt times new roman">Leasehold improvements</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 13%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">Shorter of lease term</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">and 10 years</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">G.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Impairment of long-lived assets</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Group's long-lived assets are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment&#8221;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;&#160;Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset.&#160;&#160;If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.&#160;&#160;To date the Group did not incur any material impairment losses.</font></div>
</td>
</tr></table>
</div>



<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">H.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Long-term restricted cash</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Restricted cash is invested in certificates of deposit, which are used to secure Integrity Israel&#8217;s obligations in respect of its headquarters lease.&#160; See Note 9B</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">I.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Income tax</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Group accounts for income taxes in accordance with ASC 740, "Income Taxes". Accordingly, deferred income taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities under the applicable tax law.&#160;&#160;Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences reverse.&#160;&#160;Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Group accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise&#8217;s financial statements. According to ASC Topic 740-10, tax positions must meet a more-likely-than-not recognition threshold. The Group&#8217;s accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Group did not recognize such items in its fiscal 2015, 2014 and 2013 financial statements and did not recognize any liability with respect to unrecognized tax position in its balance sheet.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">J.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Liability for employee rights upon retirement</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Integrity Israel's liability for employee rights upon retirement with respect to its Israeli employees is calculated pursuant to the Israeli Severance Pay Law, based on the most recent salary of each employee multiplied by the number of years of employment of each such employee as of the balance sheet date. Employees are entitled to one month's salary for each year of employment, or ratable portion thereof for periods less than one year. Integrity Israel makes monthly deposits to insurance policies and severance pay funds.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The deposited funds may be withdrawn upon the fulfillment of Integrity Israel's severance obligations pursuant to Israeli severance pay laws or labor agreements with its employees.&#160;&#160;The value of the deposited funds is based on the cash surrender value of these policies, and includes immaterial profits or losses.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Commencing in 2011, Integrity Israel&#8217;s agreements with its Israeli employees are in accordance with Section 14 of the Severance Pay Law. Payments in accordance with Section 14 release the employer from any future severance payments in respect of those employees. Related obligations and liabilities under Section 14 are not recorded as an asset or as a liability in the Company's balance sheet.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Severance expenses for the year ended December&#160;31, 2015, 2014 and 2013 amounted to&#160;$111,030, $101,220 and $91,588, respectively.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">K.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Revenue recognition</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Revenues are recognized in accordance with ASC 605, "Revenue Recognition" and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) No. 104, &#8220;Revenue Recognition&#8221;, when delivery has occurred, persuasive evidence of an agreement exists, the fee is fixed and determinable, collectability is reasonably assured and no further obligations exist. Provisions are made at the time of revenue recognition for any applicable warranty cost expected to be incurred (See Note 2N).</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Company derives its revenues from sales of its GlucoTrack&#174; model DF-F glucose monitoring device to distributors. The Company's products sold through agreements with distributors are generally non-exchangeable, non-refundable and non-returnable and, to date, the Company has not granted to any of its distributors any rights of price protection or stock rotation. Accordingly, the Company considers its distributors as end-users for revenue recognition purposes.</font></div>
</td>
</tr></table>
</div>



<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">L.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Research and development expenses</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Research and development expenses are charged to operations as incurred.&#160;&#160;Grants received by Integrity Israel from the Government of Israel through the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor (the "OCS") for development of approved projects were recognized as a reduction of expenses when the related costs were incurred.</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">M.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Royalty-bearing grants</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Royalty-bearing grants from the OCS to fund approved research and development projects are recognized at the time Integrity Israel is entitled to such grants, on the basis of the costs incurred and reduce research and development costs.&#160;&#160;The cumulative research and development grants received by Integrity Israel from inception through December 2004 amounted to $93,300.&#160;&#160;Integrity Israel has not received any research and development grants since December 2004.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">As of December&#160;31, 2015 and 2014, the Group accrued royalties to the OCS in the amounts of $8,167 and $1,793, respectively.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">N.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Warranty</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Group provides a 24 month warranty for its products at no cost. The Group estimates the costs that may be incurred during the warranty period and records a liability for the amounts of such costs at the time revenues are recognized. As of December 31, 2015 and 2014 warranty expenses were immaterial.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">O.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Basic and diluted income (loss) per share</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Basic income (loss) per share is computed by dividing the income (loss) for the period applicable for Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Securities that may participate in dividends with the Common Stock (such as the convertible Preferred Stock) are considered in the computation of basic income per share using the two class method. However, in periods of net loss, such participating securities are not included since the holders of such securities do not have a contractual obligation to share the losses of the Company.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In computing diluted income per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the &#8220;treasury stock method&#8221; and upon the conversion of Preferred Stock using the "if-converted method", if the effect of each of such financial instruments is dilutive.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">P.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Stock-based compensation</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Group measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values in accordance with ASC 718, &#8220;Compensation-Stock Compensation&#8221;. Share-based payments including grants of stock options are recognized in the statement of operations as an operating expense based on the fair value of the award at the date of grant.&#160;&#160;The fair value of stock options granted is estimated using the Black-Scholes option-pricing model.&#160;&#160;The Group has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Share-based payments awarded to consultants (non-employees) are accounted for in accordance with ASC Topic 505-50, "Equity-Based Payments to Non-Employees".</font></div>
</td>
</tr></table>
</div>





<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">Q.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Fair value of financial instruments</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">ASC Topic 825-10, "Financial Instruments" defines financial instruments and requires disclosure of the fair value of financial instruments held by the Group. The Group considers the carrying amount of cash and cash equivalents, accounts receivable, other current assets, accounts payable, current portion of long-term loans from stockholders and other current liabilities balances, to approximate their fair values due to the short term maturities of such financial instruments.&#160;&#160;The Series A Warrants with down-round protection represent a derivative liability and therefore are measured and presented on the balance sheet at fair value. ASC Topic 825-10, establishes the following fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Level 2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Level 3 - Unobservable inputs are used when little or no market data is available. Level 3 inputs are considered as the lowest priority under the fair value hierarchy.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The fair value measurement of the warrants is classified as level 3. The Group did not estimate the fair value of the long-term loans from stockholders since their repayment schedule has not yet been determined.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">R.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Concentrations of credit risk</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Financial instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.&#160;&#160;Cash and cash equivalents are deposited with major banks in Israel and the United States of America. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. As of December 31, 2015 and 2014 the balances of accounts receivable was not material and accordingly such balances do not represent substantial concentration of credit risk. The Group does not have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">S.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Contingencies</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">T.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Preferred Stock</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">&#160;1.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">Temporary Equity Classification</font></font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">As more fully described in Note 10A.2, Note 10B, Note 10A.3 and Note 10C, in March 2013 and during the period between August until December 31, 2014, the Company issued Series A Preferred Stock and Series B Preferred Stock, respectively, which provide a liquidation preference and certain redemption rights for the benefit of the holders of such Preferred Stock upon the occurrence of certain contingent events, some of which are not solely within the Company&#8217;s control.&#160;&#160;Accordingly, both the Series A Preferred Stock and the Series B Preferred Stock are presented as temporary equity.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;2.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Initial Measurement</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Upon initial recognition, the Series A Preferred Stock issued together with detachable Series A Warrants (classified as a derivative liability) were measured based on the "residual approach" and were presented net of the direct issuance expenses that were allocated to them. Upon initial recognition, the Series B Preferred Stock issued together with the detachable Series B Warrants (classified as equity) were measured based on the relative fair value basis and were presented net of the direct issuance expenses that were allocated to them.</font></div>
</td>
</tr></table>
</div>





<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;3.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Subsequent Measurement</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">On each balance sheet date, the Company&#8217;s management assesses the probability of redemption of the Preferred Stock. In the event that management determines such redemption to be probable as of an applicable balance sheet date, the Company will reclassify the outstanding balance of the Preferred Stock as of that date as a liability and the difference between such amount and the aggregate redemption price of the Preferred Stock will be accreted against accumulated deficit over the period beginning on the date that it becomes probable that the Preferred Stock will become redeemable and ending on the earliest redemption date.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;4.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Conversion Feature Analysis</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Company has determined that due to the economic characteristics and risks of the Preferred Stock, based on their stated or implied substantive terms and features, Series A and Series B Preferred Stock, are both considered as more akin to equity than debt. Accordingly, it was determined that the economic characteristics and the risks of the embedded conversion option to Common Stock and those of the Preferred Stock themselves (the 'host contract') are clearly and closely related. As a result, the embedded conversion feature was not required to be bifurcated. Also, since at the respective issuance dates of the Series A Preferred Stock and the Series B Preferred Stock, the exercise price of the conversion feature (based on the effective conversion rate of the Series A Preferred Stock and the Series B Preferred Stock into Common Stock) was higher than the estimated fair value of the Company&#8217;s Common Stock, it was determined that the conversion feature was not beneficial.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;5.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Modifications or Exchanges</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Modifications to, or exchanges of, the Preferred Stock are accounted for as a modification or an extinguishment. Such an assessment is done by management either qualitatively or quantitatively based on the facts and circumstances of each transaction. A qualitative assessment is generally appropriate when the changes to a Preferred Stock instrument are either so inconsequential or is very significant, otherwise, a quantitative test is also applied. Since the periodic contractual cash flows of the Preferred Stock are not defined, the quantitative test is generally applied using the fair value model. Under the fair value model, the Company compares the fair value of the Preferred Stock immediately before and after the modification or exchange. If the fair values before and after the modification or exchange are substantially different, the modification or exchange is accounted for as an extinguishment, otherwise it is accounted for as a modification.</font></div>
</td>
</tr></table>
</div>



<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">U.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Series A Warrants with Down-Round Protection</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: center">



<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt">
<div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The Company considered the provisions of ASC 815-40, &#8220;Derivatives and Hedging: Contracts in Entity&#8217;s Own Equity&#8221;, with respect to the detachable Warrants that were issued to the Series A Unit Purchasers, as described in Note&#160;10D, and determined that as a result of the &#8220;down-round&#8221; protection that would adjust the number of Warrants and the exercise price of the Warrants based on the price at which the Company subsequently issues shares or other equity-linked financial instruments, if that price is less than the original exercise price of the Warrants, such Warrants cannot be considered as indexed to the Company's own stock. Accordingly, the Warrants were recognized as derivative liability at their fair value on initial recognition. In subsequent periods, the Warrants are marked to market with the changes in fair value recognized as financing expense or income in the consolidated statement of operations. The direct issuance expenses that were allocated to the detachable Warrants were expensed as incurred.</font></font></div>

<font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">V.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Recently Issued Accounting Pronouncements</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;1.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Accounting Standard Update 2014-09, &#8220;Revenue from Contracts with Customers&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In May 2014, the FASB issued Accounting Standard Update 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09").</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In accordance with a recent amendment to ASU 2014-09, introduced by Accounting Standards Update 2015-11, "Revenue from Contracts with Customers - Deferral of the Effective Date", for a public entity, the amendments in ASU 2014-09 are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period (the first quarter of fiscal year 2018 for the Company). Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Company is in the process of assessing the impact, if any, of ASU 2014-09 on its consolidated financial statements.</font></div>
</td>
</tr></table>
</div>


<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;2.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Accounting Standards Update 2014-15, &#8220;Presentation of Financial Statements&#8212;Going Concern&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial Statements&#8212;Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern ("ASU 2014-15").</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">ASU 2014-15 provides guidance on management&#8217;s responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable).</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">ASU 2014-15 also provides guidance related to the required disclosures as a result of management&#8217;s evaluation.&#160;</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Company is in the process of assessing the impact, if any, of ASU 2014-15 on its consolidated financial statements or related disclosures.</font></div>
</td>
</tr></table>
</div>



<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;3.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Accounting Standard Update 2014-16, &#8220;Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In November 2014, the FASB issued Accounting Standard Update 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity ("ASU 2014-16").</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The amendments in ASU 2014-16 clarify how current U.S. GAAP should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. Specifically, the amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract. Furthermore, the amendments clarify that no single term or feature would necessarily determine the economic characteristics and risks of the host contract. Rather, the nature of the host contract depends upon the economic characteristics and risks of the entire hybrid financial instrument. The amendments also clarify that, in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (i.e., the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weigh those terms and features. The assessment of the substance of the relevant terms and features should incorporate a consideration of the characteristics of the terms and features themselves; the circumstances under which the hybrid financial instrument was issued or acquired; and the potential outcomes of the hybrid financial instrument, as well as the likelihood of those potential outcomes.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The amendments in ASU 2014-16 apply to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of a share.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The amendments in ASU 2014-16 are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015 (fiscal 2016 for the Company). Early adoption, including adoption in an interim period, is permitted. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The effects of initially adopting the amendments in ASU 2014-16 should be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Management believes that the provisions of ASU 2014-16 will not impact the classification of the Series A or Series B Preferred Stock.</font></div>
</td>
</tr></table>
</div>





<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;4.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Accounting Standard Update 2015-11, &#8220;Simplifying the Measurement of Inventory&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In July, 2015, The FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11").</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out (LIFO) and the retail inventory method (RIM) are not impacted by the new guidance. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin).</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early adoption is permitted as of the beginning of an interim or annual reporting period.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Company is in the process of assessing the impact, if any, of ASU 2015-11 on its consolidated financial statements.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793707280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 54pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">NOTE 3</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt times new roman">INVENTORIES</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Raw materials</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">205,645</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">55,557</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Work in process</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">551,111</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">16,459</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Finished products</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">59,467</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">11,637</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">816,223</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">83,653</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 6<br> -Subparagraph a, b, c<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789156784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-align: center"><table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 54pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">NOTE 4</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt times new roman">OTHER CURRENT ASSETS</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Prepaid expenses</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">57,206</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">46,094</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Government Institution (*)</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">211,586</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">67,748</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">268,792</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">113,842</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 68.05pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">&#160;(*)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Represents amounts advanced by Integrity Israel to the Israeli tax authorities or amounts owed to Integrity Israel by the Israeli Value Added Tax authorities.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793670656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-align: center"><table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 54pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">NOTE 5</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt times new roman">PROPERTY AND EQUIPMENT, NET</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Computers</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">240,066</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">124,161</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Furniture and office equipment</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">200,548</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">184,379</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Leasehold improvements</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">32,898</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">22,992</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">473,512</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">331,532</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Less &#8211; accumulated depreciation</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(253,049</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(209,041</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">220,463</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">122,491</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">During the years ended December&#160;31, 2015, 2014 and 2013, depreciation expenses amounted to $44,891, $34,683 and $33,684, respectively, and new equipment purchases amounted to $143,736, $63,455 and $64,252, respectively.</font></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6801422928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_OtherCurrentLiabilitiesDisclosureTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-align: center"><table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 54pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">NOTE 6</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt times new roman">OTHER CURRENT LIABILITIES</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Employees and related institutions</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">240,358</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">204,890</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Accrued expenses and other</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">187,528</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">235,874</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">427,886</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">440,764</font></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_OtherCurrentLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure relating to other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_OtherCurrentLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789181008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LINE OF CREDIT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Line of Credit Facility [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LINE OF CREDIT</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-align: center"><table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 54pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">NOTE 7</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt times new roman">LINE OF CREDIT</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">As of December&#160;31, 2015, the Group had an unutilized credit line of approximately $38,500 (NIS&#160;150,000) with its Israeli bank. Borrowings under the line of credit are secured by funds on deposit with the bank at the time of borrowing, which generally must be sufficient to cover the principal amount of the borrowings in full.</font></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789114384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM LOANS FROM STOCKHOLDERS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">LONG-TERM LOANS FROM STOCKHOLDERS</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-align: center"><table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 54pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">NOTE 8</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt times new roman">LONG-TERM LOANS FROM STOCKHOLDERS</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">During the years 2003-2004, Integrity Israel received loans from stockholders (three separate lenders).&#160;&#160;The loans are indexed to the Israeli Consumer Price Index from their origination date and bear no interest.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The Group will be required to pay the loans, in quarterly installments, commencing on the first quarter following the first fiscal year in which the Group reports net profit in its annual report.&#160;&#160;At such time, the Group will be required to make quarterly payments equal to 10% of its total sales for each quarter until the loans have been repaid in full.&#160;&#160;Notwithstanding the repayment mechanism, the Group will not be required to repay the loans during any period in which such payment would cause a deficit in the Group's working capital. See Note 9D for a description of the repayment of the stockholder loan previously owing to Y.H. Dimri Holdings (2001) Ltd. (&#8220;Dimri&#8221;).</font></font></div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">As of December 31, 2015, the Group does not expect to make any additional material repayments during the following 12 months period, if any, and accordingly other loans from stockholders have been presented as long-term liabilities.</font></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789156496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-align: center"><table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 54pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">NOTE 9</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt times new roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt times new roman">COMMITMENTS AND CONTINGENT LIABILITIES</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">A.</font></font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">On March 4, 2004, the OCS provided Integrity Israel with a grant of approximately $93,300 (NIS 420,000), for its plan to develop a non-invasive blood glucose monitor (the &#8220;Development Plan&#8221;). Integrity Israel is required to pay royalties to the OCS at a rate ranging between 3-5% of the proceeds from the sale of the Group's products arising from the Development Plan up to an amount equal to $93,300, plus interest at LIBOR from the date of grant. As of December&#160;31, 2015, the contingent liability with respect to royalty payment on future sales equals approximately $83,341, excluding interest. Such contingent obligation has no expiration date.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">B.</font></font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Until mid of December 2015,
Integrity Israel leased approximately 3,100 sq. ft. of office space in the city of Ashkelon, Israel as its principal offices
and prototype laboratory.&#160;&#160;Pursuant to a verbal agreement with the landlord, Integrity Israel leased this facility
on a monthly basis at a cost of approximately $2,934 (NIS 11,500). Currently, Integrity Israel leases approximately 5,500 sq.
ft. of office space in the city of Ashdod, Israel for its principal offices.&#160;&#160;The lease term began on
December&#160;1, 2015 for a period of 5 years which can be extended for an additional 5 years at the option of the Company.
Monthly lease payments including maintenance approximate $10,000. The Company estimates that its minimal rent and maintenance
payments will approximate $120,000 per year over each of the next 5 years. In connection with the lease
agreement, Integrity Israel provided the landlord a bank guarantee in the amount of approximately $35,000 (NIS&#160;137,162)
that can be exercised by the landlord in the case Integrity Israel fails to pay the monthly rent payments.&#160;&#160;The
guarantee is renewed on an annual basis for a period of 5 years and is secured by funds on deposit with the bank, which
generally must be sufficient to cover the principal amount guarantee.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">C.</font></font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">During 2014, the Company engaged the Placement Agent in connection with an offering of up $25,000,000 of its securities, which engagement ultimately culminated in the issuance and sale of $8,500,000 Series B Units (the &#8220;2014 Offering&#8221;). Pursuant to a placement agent agreement with the Placement Agent entered into with respect to such private placement, the Placement Agent (or its sub-agents) was paid, as a commission, an amount equal to 6% of the funds raised in each, such offering, plus 4% of the funds as a management fee plus a 3% non-accountable expense allowance (13% in the aggregate), all in cash.&#160;&#160;In addition, pursuant to such placement agent agreement, the Company was required to and did issue to the Placement Agent (or its sub-agents) warrants to purchase up to 10% of the shares of Common Stock issued to investors (or underlying convertible securities issued to investors) in connection with such offerings at a price per share equal to the offering price subject to certain price adjustments.&#160;&#160;Based on the agreement signed on 2014, the Placement Agent will have a right of first refusal on any private equity, debt or rights offering for a period of 24 months from the date on which marketing efforts with respect to the 2014 Offering began. In addition, pursuant to such agreement, the Company is required to use its reasonable efforts to have the Placement Agent named as a co-underwriter in any secondary public offering by the Company in the 12 months following completion of the 2014 Offering. In addition, starting in September 2013, the Company retained the Placement Agent to provide certain advisory services for a monthly fee of $12,500 for the period September 2013 until December 2014 and $20,000 per month starting from January 2015.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The Company paid the Placement Agent $185,000 $1,255,606 and $820,493, in cash during 2015, 2014, and 2013, respectively.&#160;&#160;See Notes 10B, Note 10C and Note 10E.1 with respect to warrants issued to the Placement Agent.</font></font></div>



<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">D.</font></font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">From June of 2011 Integrity Israel, Avner Gal, David Malka, Zvi Cohen, Ilana Freger and Alexander Raykhman, on the one hand, and Dimri, on the other hand, which was a shareholder of Integrity Israel prior to the reorganization and merger (See Note 1A above), were involved in arbitration proceedings resulting from certain claims asserted by Dimri following such reorganization. On March 11, 2015, the arbitrator issued a binding arbitration decision (the &#8220;Arbitration Decision&#8221;) which documents the parties&#8217; negotiated settlement of such arbitration proceedings.&#160;&#160;Pursuant to the terms of the Arbitration Decision, (1) Avner Gal, David Malka, Zvi Cohen, Ilana Freger and Alexander Raykhman transferred to Dimri, on March 18, 2015, an aggregate of 440,652 shares of the Company&#8217;s outstanding Common Stock held collectively by such shareholders, (2) Integrity Israel (A) paid to Dimri on March 23, 2015, NIS 1,767,674 or $439,939 (based on the exchange rate of 4.018 NIS:$1 as of March 23, 2015), as repayment in full of the outstanding principal amount under Dimri&#8217;s investment agreement with Integrity Israel and the founders (the &#8220;Investment Agreement&#8221;), as adjusted for changes in the Israeli consumer price index since the date on which the loan was made, and (B) paid to Dimri on April 30, 2015, NIS 316,100 or $81,870 (based on the exchange rate of 3.861 NIS:$1 as of April 30, 2015), as partial reimbursement of Dimri&#8217;s attorney&#8217;s fees in the arbitration. The Company accrued for the fee reimbursement obligation as part of professional fees within selling, marketing and general and administrative expenses included in its results of operations for the fiscal year ended December 31, 2014. During March 2015, such amount was fully paid.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">Following the completion of the abovementioned transfers and payments, pursuant to the Arbitration Decision, Integrity Israel, the Company and the other defendants in the arbitration were released from any legal claim by Yigal Dimri, the principal shareholder of Dimri, and any other companies under his control in respect of the subject matter of the arbitration, including the shareholder loan granted under and any claim of anti-dilution rights under the Investment Agreement, and Mr. Dimri and all companies under his control were released from any legal claim by Integrity Israel, the Company and the other defendants in the arbitration in respect of the subject matter of the arbitration.</font></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789126480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock', window );">COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"></font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 54pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">NOTE 10</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: left"><font style="display: inline; font: bold 10pt Times New Roman">COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">A.</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">1.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Description of the rights attached to the Common Stock</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">Each share of Common Stock entitles the holder to one vote, either in person or by proxy, on each matter submitted to the approval of the Company&#8217;s stockholders.&#160;&#160;The holders of Common Stock are not permitted to vote their shares cumulatively.&#160;&#160;As described below, holders of Preferred Stock are entitled to vote together with the holders of Common Stock on an as-converted basis.&#160;&#160;Accordingly, the holders of the Company's Common Stock together with the holders of the Preferred Stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of the directors and, in such event, the holders of the remaining shares will not be able to elect any of such directors.&#160;&#160;The vote of the holders of a majority of the issued and outstanding shares of Common Stock, voting together with the holders of the Preferred Stock on an as converted basis, are entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to any act or action submitted to the vote of the Company&#8217;s stockholders, except as otherwise provided by law.</font></font></div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt">
<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99pt">&#160;</td>
<td style="text-align: right; width: 18pt">
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">2.</font></font></div>
</td>
<td style="text-align: left">
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">Description of the rights attached to the Series A Preferred Stock</font></font></div>
</td>
</tr></table>
</div>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">Holders of Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, based on the stated value per share of the Series A Preferred Stock, which was initially $1,000 per share.&#160;&#160;Dividends on the Series A Preferred Stock are payable quarterly on March 31, June 30, September 30 and December 31 of each year, beginning on March 31, 2013, and on each conversion date (with respect to the shares of Series A Preferred Stock being converted).&#160;&#160;Until September 13, 2013, dividends were payable only in cash. Thereafter, dividends on the Series A Preferred Stock became payable, at the option of the Company, in cash and/or, if certain conditions are satisfied (including, among others, that the volume weighted average trading price for the Common Stock on its principal trading market is equal to or greater than 110% of the then current conversion price for the Series A Preferred Stock for five consecutive trading days prior to the dividend payment date), in shares of Common Stock, valued at the then current conversion price of the Series A Preferred Stock.&#160;&#160;The Company will incur a late fee of 9% per annum, payable in cash, on dividends that are not paid within three trading days of the applicable dividend payment date. During the years ended December 31, 2015, 2014 and 2013 the Company paid an aggregate of $57,061, $370,441 and $288,248, respectively, in cash dividends to its Series A Preferred Stockholders.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The Company may become obligated to redeem the Series A Preferred Stock in cash upon the occurrence of certain triggering events, including, among others, a material breach by the Company of certain contractual obligations to the holders of the Series A Preferred Stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Common Stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or a regulated quotation service.&#160;&#160;In addition, upon the occurrence of certain triggering events, each holder of Series A Preferred Stock will have the option to require the Company to redeem such holder&#8217;s shares of Series A Preferred Stock for a redemption price payable in shares of Common Stock or receive an increased dividend rate of 9% on all of such holder&#8217;s outstanding Series A Preferred Stock.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">Subject to certain conditions, the Company will have the option to force the conversion of the Series A Preferred Stock (in whole or in part) if the volume weighted average price for the Common Stock on its principal trading market exceeds $11.60 for each of any 20 trading days during any 30 consecutive Trading Day period and the average daily dollar trading value for the Common Stock during such 30 day period exceeds $100,000.&#160;&#160;&#160;</font></font></div>





<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">If the Company fails to timely deliver certificates for shares of Common Stock issuable upon conversion of the Series A Preferred Stock (the &#8220;Series A Conversion Shares&#8221;) and, as a result, the holder is required by its brokerage firm to purchase shares of Common Stock to deliver in satisfaction of a sale by such holder of the Series A Conversion Shares (a &#8220;Buy-In&#8221;), the Company will be required to: (a) pay the converting holder in cash an amount equal to the amount, if any, by which such holder&#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds the product of (i) the aggregate number of Series A Conversion Shares due to the holder, multiplied by (ii) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions); and (b) at the option of such holder, either reissue (if surrendered) the shares of Series A Preferred Stock equal to the number of shares of Series A Preferred Stock submitted for conversion (in which case, such conversion will be deemed rescinded) or deliver to such holder the number of shares of Common Stock that would have been issued if the Company had timely complied with its delivery requirements.&#160;&#160;</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">In addition, the Company will be required to pay partial liquidated damages of $10 for each $1,000 of stated value of any shares of Series A Preferred Stock which have been converted by a holder and in respect of which the Company fails to deliver Series A Conversion Shares by the eighth trading day following the applicable conversion date.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">Subject to the beneficial ownership limitation described below, holders of Series A Preferred Stock will vote together with the holders of Common Stock on an as-converted basis.&#160;&#160;Holders will not be permitted to convert their Series A Preferred Stock if such conversion would cause such holder to beneficially own more than 4.99% of the outstanding number of shares of Common Stock outstanding after giving effect to such conversion (subject to increase to 9.99%, at the option of the holder, upon no less than 61 days prior written notice to the Company) (the &#8220;Beneficial Ownership Limitation&#8221;).&#160;&#160;In addition, no holder may vote any shares of Series A Preferred Stock (on an as converted to Common Stock basis) in excess of the Beneficial Ownership Limitation.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">Subject to certain limitations, so long as any initial Series A Unit purchaser holds any shares of Series A Preferred Stock, if (1) the Company sells any shares of Common Stock or other securities convertible into, or rights to acquire, Common Stock and (2) a Purchaser then holding Series A Preferred Stock, Warrants, Conversion Shares or Warrant Shares (defined below) reasonably believes that any of the terms and conditions appurtenant to such issuance or sale are more favorable to the purchaser in such subsequent sale of securities than are the terms and conditions granted to such Purchaser, then the Purchaser will be permitted to require the Company to amend the terms of this transaction (only with respect to such Purchaser) so as to match the terms of the subsequent issuance (including, for the avoidance of doubt, any terms and provisions that are or may be less favorable to such Purchaser).</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The conversion price of the shares of Series A Preferred Stock that were included in the Series A Units is subject to adjustment for certain issuances of Common Stock or other securities of the Company at an effective price per share that is lower than the conversion price then in effect ($5.80 per share at December 31, 2015 and 2014), as well as for stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders.</font></font></div>



<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">A.</font></font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">3</font>.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">Description of the rights attached to the Series B Preferred Stock</font></font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">Holders of Series B Preferred Stock are entitled to receive cumulative dividends at a rate of 5.5% per annum, based on the stated value per share of Series B Preferred Stock. Dividends on the Series B Preferred Stock are payable quarterly on March 31, June 30, September 30 and December 31 of each year, beginning on September 30, 2014, and on each conversion date (with respect to the shares of Series B Preferred Stock being converted). For so long as required under the terms of the Certificate of Designations for the Company&#8217;s outstanding Series A Preferred Stock, dividends on Series B Preferred Stock will be payable only in shares of Common Stock. Thereafter, dividends on the Series B Preferred Stock will be payable, at the option of the Company, in cash and/or, if certain conditions are satisfied, shares of Common Stock or a combination of both. Shares of Common Stock issued as payment of dividends will be valued at the lower of (a) the then current conversion price of the Series B Preferred Stock or (b) the average of the volume weighted average price for the Common Stock on the principal trading market therefor for the 10 trading days immediately prior to the applicable dividend payment date. The Company will incur a late fee of 9% per annum, payable in cash, on dividends that are not paid within three trading days of the applicable dividend payment date. As of December 31, 2015 and 2014 the Company issued a total of 168,926 and 18,986 shares of Common Stock, respectively at an estimated fair value of $390,219 and $43,858, respectively as in kind dividends to holders of Series B Preferred Stock.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">Subject to certain ownership limitations described below, the Series B Preferred Stock is convertible at the option of the holder at any time and from time to time into shares of Common Stock at a conversion price of $5.80 per share (calculated by dividing the stated value per share of Series B Preferred Stock, which is initially $1,000, by the conversion price per share). The conversion price of the Series B Preferred Stock is subject to adjustment for certain issuances of Common Stock or other securities of the Company at an effective price per share that is lower than the conversion price then in effect, as well as for stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. In addition, the holders of Series B Preferred Stock will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of Common Stock to the same extent as if such holders of Series B Preferred Stock had converted all of their shares of Series B Preferred Stock prior to such distribution. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations of the Company, the holders of Series B Preferred Stock will be entitled to receive, upon conversion of their shares of Series B Preferred Stock, any securities or other consideration received by the holders of the Common Stock pursuant to the fundamental transaction.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">Subject to certain conditions contained in the Certificate of Designations, Preferences and Rights relating to the Series B Preferred Stock, the Company will have the option to force the conversion of the Series B Preferred Stock (in whole or in part) if (a) the volume weighted average price for the Common Stock on its principal trading market exceeds $10.00 for each of any 20 trading days during any 30 consecutive Trading Day period and the average daily dollar trading value for the Common Stock during such 30 day period exceeds $50,000 or (b) the Company receives approval to list the Common Stock on a national securities exchange.</font></font></div>



<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">If the Company fails to timely deliver certificates for shares of Common Stock issuable upon conversion of the Series B Preferred Stock (the &#8220;Series B Conversion Shares&#8221;) which results in a Buy-In, the Company will be required to: (a) pay the converting holder in cash an amount equal to the amount, if any, by which such holder&#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds the product of (i) the aggregate number of Series B Conversion Shares due to the holder, multiplied by (ii) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions); and (b) at the option of such holder, either reissue (if surrendered) the shares of Series B Preferred Stock equal to the number of shares of Series B Preferred Stock submitted for conversion (in which case, such conversion will be deemed rescinded) or deliver to such holder the number of shares of Common Stock that would have been issued if the Company had timely complied with its delivery requirements.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">In addition, the Company will be required to pay partial liquidated damages of $10 for each $1,000 of stated value of any shares of Series B Preferred Stock which have been converted by a holder and in respect of which the Company fails to deliver Series B Conversion Shares by the eighth trading day following the applicable conversion date.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">As long as at least 35% of the originally issued shares of Series B Preferred Stock are outstanding, without the written consent of the holders of a majority in stated value of the outstanding Preferred Stock, the Company will not be permitted to, among other things, incur indebtedness or liens not permitted under the Certificate of Designations for the Series B Preferred Stock; repay, repurchase, pay dividends on or otherwise make distributions in respect of any shares of Common Stock or other securities junior to the Series B Preferred Stock; or enter into certain transactions with affiliates of the Company.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">Subject to any limitations under the terms of the Certificate of Designations for the Company&#8217;s outstanding Series A Preferred Stock, the Company may become obligated to redeem the Series B Preferred Stock in cash upon the occurrence of certain triggering events, including, among others, a material breach by the Company of certain contractual obligations to the holders of the Series B Preferred Stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Common Stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or a regulated quotation service. In addition, upon the occurrence of certain triggering events, each holder of Series B Preferred Stock will have the option to require the Company to redeem such holder&#8217;s shares of Series B Preferred Stock for a redemption price payable in shares of Common Stock or receive an increased dividend rate of 9% on all of such holder&#8217;s outstanding Series B Preferred Stock.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">Subject to the Beneficial Ownership Limitation, holders of Series B Preferred Stock will vote together with the holders of Common Stock and Series A Preferred Stock on an as-converted basis. Holders will not be permitted to convert their Series B Preferred Stock if such conversion would cause such holder to beneficially own shares of outstanding Common Stock in excess of the Beneficial Ownership Limitation.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">Subject to certain limitations, so long as any Purchaser holds any shares of Series B Preferred Stock, if (a) the Company sells any shares of Common Stock or other securities convertible into, or rights to acquire, Common Stock and (b) a Purchaser then holding Series B Preferred Stock, Series B Warrants, Conversion Shares or Warrant Shares (defined below) reasonably believes that any of the terms and conditions appurtenant to such issuance or sale are more favorable to the purchaser in such subsequent sale of securities than are the terms and conditions granted to such Purchaser, then the Purchaser will be permitted to require the Company to amend the terms of this transaction (only with respect to such Purchaser) so as to match the terms of the subsequent issuance (including, for the avoidance of doubt, any terms and provisions that are or may be less favorable to such Purchaser).</font></font></div>



<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt">
<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 72pt">&#160;</td>
<td style="text-align: right; width: 27pt">
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">B.</font></div>
</td>
<td style="text-align: left">
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">The 2012 Offering</font></div>
</td>
</tr></table>
</div>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">On November 19, 2012, the Company issued 165,057 shares of its Common Stock at a price of $7.00 per share, for a total consideration of $1,155,399.&#160;&#160;The issuance and sale of such shares constituted the initial closing (the &#8220;Initial Closing&#8221;) of the 2012 Offering, which was originally structured as an offering of up to&#160;&#160;785,714 shares of its Common Stock to accredited investors (the &#8220;First Closing Purchasers&#8221;) at a price of $7.00 per share in a private placement transaction.</font></font></div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">Subsequent to the Initial Closing, the 2012 Offering was converted from an offering of Common Stock to an offering of Units and, on March 13, 2013, the Company entered into a Securities Purchase Agreement with certain accredited investors (the &#8220;Series A Unit Purchasers&#8221;) pursuant to which the Company issued to the Series A Unit Purchasers an aggregate of 6,300 Series A Units.&#160;&#160;The shares of Series A Preferred Stock comprising the Series A Units were convertible into an aggregate of 1,086,178 shares of Common Stock (based on a conversion price per share of $5.80) and the Series A Warrants comprising the Series A Units were exercisable into an aggregate of 1,086,178 shares of Common Stock at an original exercise price per share of $6.96, in each case subject to adjustment as described below (See also Note10D). After giving effect to the payment of commissions to the Placement Agent for the offering and the payment of certain offering expenses, the Company received net proceeds from the offering of approximately $5.4 million (See Note 9C).&#160;&#160;</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The issuance and sale of the Series A Units constituted the second and final closing of an offering of the Company&#8217;s securities in a private placement transaction.&#160;&#160; As a result of the conversion of the offering from an offering of Common Stock to an offering of Series A Units, the Company agreed with the Placement Agent that the Company would exchange the shares of Common Stock acquired by each First Closing Purchaser in the Initial Closing for such number of Series A Units equal to the aggregate purchase price paid by such First Closing Purchaser in the Initial Closing, divided by $1,000, in each case subject to the execution by the First Closing Purchaser of a consent to such modification.&#160;&#160;Pursuant to this agreement, on May 13, 2013, the Company cancelled 162,907 of the 165,057 shares of Common Stock issued to the First Closing Purchasers and issued to such purchasers an aggregate of 1,140.35 Series A Units.&#160;&#160;These Units included Series A Preferred Stock convertible into an aggregate of 196,597 shares of Common Stock and Series A Warrants exercisable for 196,597 shares of Common Stock.&#160;&#160;The total fair value of such Series A Units was equal to the amount originally invested by the First Closing Purchasers that consented to exchange their shares into Units ($1,140,349).&#160;&#160;As a result, during 2013, the total fair value of such Series A Units was classified out of stockholders equity and was presented as temporary equity (convertible Series A Preferred Stock) and liability (warrant with down-round protection), as applicable to each instrument.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block">
<div>
<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">In connection with the 2012 Offering, the Company also agreed with the Placement Agent for the offering that, following the closing of the sale of the Series A Units, the Company would issue to the holders of the 1,295,535 shares of Common Stock issued by the Company at a price of $6.25 per share pursuant to the Company&#8217;s previously completed private placement of Common Stock (occurred during 2011 and 2010) such number of shares of Common Stock as would effectively reduce the per share purchase price paid by such holders for such shares from $6.25 per share to $5.80 per share, in each case subject to the execution by the holder of a consent to such modification. As a result, upon the receipt of executed consents to modification from all such holders, the Company has issued or will be required to issue to such holders an aggregate of additional 100,526 shares of Common Stock, of which 92,136 and 654 shares of Common Stock were issued during the years ended December 31, 2015 and 2014, respectively.&#160;The issuance or proposed issuance of such shares has been accounted for as a stock dividend.&#160;&#160;As of September 30, 2013, the Common Stock had an estimated fair value of $2.77 per share.&#160;&#160; Accordingly, an amount of $278,263 representing the fair value of the shares was charged to the accumulated deficit against additional paid in capital.</font></font></div>
</div>

<font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify">
<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">In connection with the 2012 Offering the Company incurred a total of $1,479,864 of issuance costs of which $562,805 attributable to non-cash compensation expenses relating to warrants issued to the Placement Agent (See Notes 9C and <font style="background-color: #ffffff; display: inline">Note 10E.1.d</font>). The allocation of the issuance proceeds to the Preferred Stock and to the detachable warrants and their respective issuance costs is described in Note 2T and Note&#160;2U above.</font></font></font></div>



<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 74pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">C.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">The 2014 Offering</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 9pt">&#160;</td>
<td style="width: 90.75pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">During August until December 31, 2014, the Company raised $8.5 million in gross proceeds from the issuance of 8,500 Series B Units. After giving effect to the payment of commissions to the Placement Agent (See Note 9C) for the offering and the payment of certain offering expenses, the Company received net proceeds from the offering of approximately $7.3 million. The Series B Warrants have a five-year term commencing on the closing dates, as applicable. Until the end of the term, the Series B Warrants included in the Series B Units will be exercisable into Common Stock at any time and from time to time at an exercise price of $5.80 per share (with respect to the Series B-1 Warrants) or $10.00 per share (with respect to the Series B-2 Warrants). The Series B Warrants contain adjustment provisions substantially similar to those of the Series B Preferred Stock (See Note 10.A.3), except that the Series B Warrants shall not include dilution protection for issuances of securities at an effective price per share lower than the conversion price of such Series B Warrants. No holder may exercise its Series B Warrants in excess of the Beneficial Ownership Limitation.</font></div>
</td>
</tr></table>
</div>

<div style="text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt">
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 90.75pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>&#160;</td>
</tr></table>
</div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 9pt">&#160;</td>
<td style="width: 90.75pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In connection with the 2014 Offering the Company incurred a total of $1,787,545 of issuance costs of which $630,936 attributable to non-cash compensation expenses relating to warrants issued to the Placement Agent (See Notes 9C and Note 10E.1.d). The allocation of the issuance proceeds to the Series B Preferred Stock and to the detachable Series B Warrants and their respective issuance costs is described in Note 2T.</font></div>
</td>
</tr></table>
</div>



<font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 9pt">&#160;</td>
<td style="width: 90.75pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Pursuant to the Securities Purchase Agreement, dated March 13, 2013, relating to the issuance by the Company of Series A Units, the Company was required to and did notify the holders of the Series A Preferred Stock of the closing of the sale of the Series B Units, and following receipt thereof such holders of Series A Preferred Stock were entitled pursuant to the &#8220;most favored nation&#8221; provision included in the Securities Purchase Agreement for the 2012 Offering, to elect to amend the terms of their purchase of Series A Units to match the terms of the Series B Units. As of December 31, 2015, the holders of an aggregate of approximately 6,931 Series A Units have so elected to amend the terms of their Series A Units to match the terms of the Series B Units. Accordingly, the Company has exchanged 6,931 shares of Series A Preferred Stock into 6,931 shares of Series B Preferred Stock and 1,440,880 Series A Warrants into 1,200,710 Series B-1 Warrants and 1,200,710 Series B-2 Warrants. Due to the differences in the contractual terms of each of the financial instruments exchanged, management determined that the exchange constituted an extinguishment of the existing instruments and an issuance of new financial instruments. As a result of the exchange elections, the Company recorded during the year ended December 31, 2015 a non-cash loss on extinguishment of Series A Preferred Stock and Series A Warrants in the amount of $1,284,354, resulting from the differences between the fair market value estimate of the new Series B Units less the net book value of the exchanged Series A Preferred Stock and less the fair value of the exchanged Warrants with down-round protection as of the date of the exchange.</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 74pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">D.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Warrants with down round protection</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The Series A Warrants included in the Series A Units have a five-year term commencing on their issuance date. In accordance with their original terms, the Warrants were exercisable at any time at an exercise price of $6.96 per share.&#160;&#160;The Series A Warrants contain adjustment provisions substantially similar to the adjustment provisions of the Series A Preferred Stock (See Note 10A.2), including provisions requiring an adjustment of the number of shares and the exercise price of the Series A Warrants to the price at which the Company subsequently issues shares or other equity-linked financial instruments, if that price is less than the original exercise price of the Series A Warrants (down-round protection).&#160;&#160;In addition, the Series A Warrants provide for protection for a Buy-In on substantially the same terms as described above with respect to the Series A Preferred Stock.&#160;&#160;No holder may exercise its Series A Warrants in excess of the Beneficial Ownership Limitation.</font></font></div>



<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">As a result of the issuance of the Series B Units, pursuant to the terms of the Series A Warrants, on August 29, 2014, the exercise price per share of the Series A Warrants decreased from $6.96 per share to $5.80 per share and the number of shares of Common Stock issuable upon exercise of each such warrant, in the aggregate, increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price, will be equal to the aggregate exercise price prior to such adjustment. During the year ended December 31, 2015, the Company exchanged 1,440,880 Series A Warrants into 1,200,710 Series B-1 Warrants and 1,200,710 Series B-2 Warrants (See Note 10C). As of December 31, 2015 and 2014, an aggregate of 380,953, 1,539,364 Series A Warrants, respectively, were outstanding and exercisable into the identical number of shares of Common Stock.</font></font></div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The Company has determined its derivative warrant liability to be a Level 3 fair value measurement and has used the Binomial pricing model to calculate its fair value. Because the warrants contain a price protection feature, the probability that the exercise price of the warrants would decrease as the stock price decreased was incorporated into the valuation calculations.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The changes in the fair value of the Level 3 liability are as follows (in US dollars):</font></font></div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Series A Warrants</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance, Beginning of the year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2,057,618</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">8,216,705</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Classification from stockholders deficit</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">400,671</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Exchange of Series A Warrants pursuant to the &#8220;Most favored nation&#8221; provision</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(1,586,831</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Change in fair value of Series A Warrants</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(149,092</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(6,559,758</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance, End of year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">321,695</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">2,057,618</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The key inputs used in the fair value calculations were as follows:</font></font></div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Dividend yield (%)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Expected volatility (%) (*)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">105.14</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">105.14</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Risk free interest rate (%)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">0.99</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.14</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Expected term of options (years) (**)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2.20</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">3.20</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Exercise price (US dollars)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">5.80</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">5.80</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Share price (US dollars) (***)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2.31</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2.31</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Fair value (US dollars)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">0.84</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.13</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 100pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 36pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(*)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Due to the low trading volume of the Company&#8217;s Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 100pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 36pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(**)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No.&#160;110.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 36pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(***)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Common Stock price, per share reflects the Company&#8217;s management&#8217;s estimation of the fair value per share of Common Stock as of December 31, 2015 and 2014. In reaching its estimation for December 31, 2015 and 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the 2014 Offering.</font></div>
</td>
</tr></table>
</div>



<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">E.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Stock-based compensation</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">&#160;1.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Grants to non-employees</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">a.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In August 2005, Integrity Israel granted 21,640 options with an exercise price of $0.001 per share in consideration of regulatory services. In October 2006, Integrity Israel granted 45,531 options with an exercise price of $4.305 per share in consideration of investor finders, of which 17,657 were forfeited. In November 2008, Integrity Israel granted 8,989 options with an exercise price of $5.517 per share in consideration of investor finders, of which 5,365 were forfeited. Following the merger with Integrity Israel, the options were replaced with options of the Company.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">b.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In connection with the 2010 Offering, the Company issued to the Placement Agent warrants to purchase 45,097 and 84,459 shares, respectively, of the Company's Common Stock, with an exercise price of $6.25 per share, in 2011 and 2010, respectively.&#160;&#160;The warrants expire on the fifth anniversary of the date on which the shares of Common Stock underlying such warrants are fully registered with the SEC.&#160;&#160;The warrants include customary adjustment provisions for stock splits, reorganizations and other similar transactions. As a result of the issuance of the Series B Units, pursuant to the terms of the warrants, on August 29, 2014, the exercise price per share of the applicable warrants decreased from $6.25 per share to $5.80 per share and the number of shares of Common Stock issuable upon exercise of each such warrant, in the aggregate, increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price, will be equal to the aggregate exercise price prior to such adjustment. As of December 31, 2015 and 2014 the Placement Agent was entitled to an aggregate of 139,608 shares of Common Stock at an exercise price of $5.80 in connection with the 2010 Offering. See also Note 18.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">c.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In connection with the 2012 Offering, the Company issued to the Placement Agent (a) 5 year warrants to purchase up to 128,277 shares of Common Stock at an exercise price of $5.80 per share and (b) 5 year warrants to purchase up to 128,277 shares of Common Stock at an exercise price of $6.96 per share and (c) 5 year warrants to purchase up to 215 shares of Common Stock at an exercise price of $7.00 per share.&#160;&#160;Such warrants have substantially the same terms as those issued to the Series A Unit Purchasers except that the Placement Agent warrants may also be exercisable on a cashless basis at all times.&#160;As a result of the issuance of the Series B Units, pursuant to the terms of the warrants, on August 29, 2014, the exercise price per share of the applicable warrants decreased from $6.96 and $7.00 per share to $5.80 per share and the number of shares of Common Stock issuable upon exercise of each such warrant, in the aggregate, increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price, will be equal to the aggregate exercise price prior to such adjustment. As of December 31, 2015 and 2014 the Placement Agent was entitled to an aggregate of 282,469 shares of Common Stock at an exercise price of $5.80 in connection with the 2012 Offering. See also Note 18.</font></div>
</td>
</tr></table>
</div>



<font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 144pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">As of December 31, 2015 and 2014, the average fair value per warrant that were affected by the down-round protection, were estimated at $0.84 and $1.13, respectively using the following assumptions: dividend yield of 0% for both years, expected volatility of 105.14% for both years, risk free interest rate of 0.99% and 1.14%, respectively, stock price of $2.31 for both years and exercise price of $5.80 for both years. As a result of the anti-dilution protection, the Company classified during the year ended December 31, 2014 an amount of $400,671 out of stockholders deficit and presented as Warrants with Down-Round Protection within long-term liabilities see also Note 10D.</font></font></div>





<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">d.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In connection with the 2014 Offering, the Company issued to the Placement Agent (a) 5 year warrants to purchase up to 293,115 shares of Common Stock at an exercise price of $5.80 per share and (b) 5 year warrants to purchase up to 146,559 shares of Common Stock at an exercise price of $10.00 per share. The terms of the Placement Agent warrants are substantially similar to the terms of the Series B Warrants except that the Placement Agent warrants may also be exercisable on a cashless basis at all times.&#160;The average fair value per warrant of approximately $1.40 was estimated using the following assumptions: dividend yield of 0%, expected volatility of 105.14%, risk free interest rate of 1.66%, stock price of $2.31 and exercise price ranging between $5.80 and 10.00, as applicable.</font></div>
</td>
</tr></table>
</div>





<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">e.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">On September 10, 2013 the Company granted 26,484 options with an exercise price of $9.50 per share in consideration of investor relations services. The options vest ratably over a period of 12 months from the date of grant and will expire on the fifth anniversary thereof, subject to certain limitations. During 2014, following the termination of the agreement with the investor relations company, 8,828 options were forfeited. In connection with this grant the Company recorded during the years ended December 31, 2014 and 2013 non-cash compensation expenses amounting to $18,204 and $16,657, respectively. At December 31, 2014 and 2013 the fair value per option of $1.17 and $2.52, respectively was estimated using the Black-Scholes option pricing model with the following assumptions for 2014: dividend yield of 0%, expected volatility of 105.14%, risk free interest rate of 1.14%, stock price of $2.31 and exercise price of $9.50 and with the following assumptions for 2013: dividend yield of 0%, expected volatility of 105.14%, risk free interest rate of 0.12%, stock price of $8.50 and exercise price of $9.50.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">2.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Grants to employees</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">In August 2007, Integrity Israel&#8217;s Board of Directors ("Integrity Israel's Board") approved a stock option plan ("Integrity Israel's plan") for the grant, without consideration of options exercisable into ordinary shares of NIS&#160;0.01 par value of Integrity Israel to employees, officers and directors of Integrity Israel.&#160;&#160;The exercise price and vesting period for each grantee of options was determined by Integrity Israel's Board and specified in such grantee's option agreement.&#160;&#160;The options vested over a period of 1-12 quarters based on each grantee's option agreements.&#160;&#160;Any option not exercised within 10 years after the date of grant thereof will expire.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">In July 2010, following the merger with Integrity Israel, the Company adopted the 2010 Share Incentive Plan (the "2010 Share Incentive Plan"), pursuant to which the Company's Board of Directors is authorized to grant options exercisable into Common Stock of the Company.&#160;&#160;As of December 31, 2015, the Company had reserved 529,555 shares of Common Stock for issuance under the 2010 Share Incentive Plan.&#160;&#160;On March 17, 2016, the Company&#8217;s Board of Directors approved an amendment to the 2010 Share Incentive Plan to increase the number of shares of the Company&#8217;s Common Stock reserved for issuance under the 2010 Share Incentive Plan to 1,000,000 shares.&#160;&#160;The purpose of the 2010 Share Incentive Plan is to offer an incentive to employees, directors, officers, consultants, advisors, suppliers and any other person or entity whose services are considered valuable to the Company, as well as to replace the Integrity Israel Plan and to replace all options granted in the past by Integrity Israel.</font></font></div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">Upon the adoption of the 2010 Share Incentive Plan, all options granted under the Integrity Israel's Plan were replaced by options subject to the 2010 Share Incentive Plan on a 1 for 1 basis. As of December 31, 2015, there are 96,313 shares available for future grants under the 2010 Share Incentive Plan.</font></font></div>



<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">Pursuant to the terms of their respective employment agreements with the Company, in March 2012, the Company issued to Avner Gal, the Company&#8217;s Chief Executive Officer, and David Malka, the Company&#8217;s Executive Vice President of Operations, options to purchase up to 264,778 and 79,434 shares of Common Stock, respectively.&#160;&#160;The Options are exercisable at an exercise price of $6.25 per share.&#160;&#160;The options vested or will vest (as applicable), in 3 equal parts, upon the achievement of each of the following milestones: (i) submission of clinical trials&#8217; results to the Notified Body; (ii) receipt of CE mark approval; (iii) receipt of FDA approval.&#160;&#160;In the event of a merger and/or acquisition in which one or more of the abovementioned milestones have not yet been met, the options shall be deemed vested on the date of the merger and/or acquisition.&#160;&#160;All options granted as described above are subject to the terms of the 2010 Share Incentive Plan.</font></font></div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">As of December 31, 2015, approximately $353,000 of unrecognized compensation costs are expected to be recognized upon receipt of the FDA approval, if and when received. The fair value of the shares was based on the recent share price applicable prior to the date of grant of such options.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The following tables present a summary of the status of the grants to employees, officers and directors as of December&#160;31, 2015 and 2014:</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 85%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Number</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Weighted average exercise price (US$)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31, 2015</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance outstanding at beginning of year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">450,847</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">5.85</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Granted</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Exercised</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(19,769</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.82</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Forfeited</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(17,605</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">6.01</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance outstanding at end of the year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">413,473</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">6.04</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance exercisable at the end of the year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">293,736</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5.95</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>



<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 85%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Number</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Weighted average exercise price (US$)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31, 2014</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance outstanding at beginning of year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">414,847</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">5.74</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Granted</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">44,000</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">7.00</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Exercised</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Forfeited</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(8,000</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">6.25</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance outstanding at end of the year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">450,847</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5.85</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance exercisable at the end of the year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">302,360</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5.58</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify">
<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The aggregate intrinsic value of the awards exercisable as of December&#160;31, 2015, 2014 and 2013 was $12,845, $23,830 and $882,471, respectively.&#160;&#160;The aggregate intrinsic value of the awards outstanding as of December 31, 2015, 2014 and 2013 was $12,845, $23,830 and $1,143,330, respectively. For the year ended December 31, 2015 and 2014 the amount represents the total intrinsic value based on the Company&#8217;s management&#8217;s estimation of the fair value per share of Common Stock based among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series B Units (See Note 10C). For the year 2013 management&#8217;s estimate of the Company&#8217;s stock price of $8.50 was determined based among other factors on the closing sale price for the Common Stock as reported on the OTCQB on December 27, 2013, which was the last reported sale of Common Stock in 2013.</font></font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The following tables summarize information about options outstanding at December&#160;31, 2015:</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 85%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Exercise</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">price (US$)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Outstanding at December&#160;31, 2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Weighted average remaining contractual life (years)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Weighted average exercise price</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Exercisable at December&#160;31, 2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Weighted average remaining contractual life (years)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.72</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">21,758</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.60</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.72</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">21,758</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.60</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">3.63</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">3,730</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.60</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">3.63</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">3,730</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.60</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6.01</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">4,273</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2.04</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6.03</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">4,273</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2.04</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6.25</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">351,712</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6.20</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6.25</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">236,975</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6.20</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">7.00</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">32,000</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">8.5</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">7.00</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">27,000</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">8.50</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">413,473</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">293,736</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">As of December 31, 2015, approximately $2,200 of unrecognized compensation costs (excluding compensation cost related to stock options granted to Mr. Avner Gal and Mr. David Malka) are expected to be recognized during the year ending December 31, 2016.</font></font></div>



<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The fair value of options granted was estimated at the dates of grant using the Black-Scholes option pricing model.&#160;&#160;The following are the data and assumptions used:</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 83%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="text-align: right; vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="text-align: right; vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="text-align: right; vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Dividend yield (%)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">0</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Expected volatility (%) (*)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">105.14</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Risk free interest rate (%)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.61</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Expected term of options (years) (**)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">5-6</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Exercise price (US dollars)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">7.00</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Stock price (US dollars) (***)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2.31</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Fair value (US dollars)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.59</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 112.5pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 36pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(*)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Due to the low trading volume of the Company&#8217;s Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>


<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 113.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 36pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(**)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No.&#160;110.</font></div>
</td>
</tr></table>


<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 112.5pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 36pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(***)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Common Stock price, per share for the year ended December 31, 2014 reflects the Company&#8217;s management&#8217;s estimation of the fair value per share of Common Stock. In reaching its estimation for December 31, 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the 2014 Offering.</font></div></td></tr></table>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders Equity and Temporary Equity Note Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793636720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 54pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">NOTE 11</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">RESEARCH AND DEVELOPMENT EXPENSES</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Salaries and related expenses</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1,303,614</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1,128,672</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1,293,067</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Professional fees</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">525,144</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">377,918</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">247,888</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Materials</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">166,736</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">96,699</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">154,522</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Depreciation</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">19,132</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">16,156</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">32,858</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Travel expenses</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">39,324</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">27,867</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">43,131</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Vehicle maintenance</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">54,936</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">25,888</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">35,955</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Other</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">159,459</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">176,424</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">179,333</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">2,268,345</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">1,849,624</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">1,986,754</font></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23218-108380<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789126480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_SellingGeneralAndAdministrativeExpenseTextBlock', window );">SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 54pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">NOTE 12</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Salaries and related expenses</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">803,319</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">651,900</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">260,276</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Professional fees</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">990,390</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">739,893</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">562,435</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Travel &#38; expenses</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">468,126</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">200,348</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">128,095</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Vehicle maintenance</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">41,180</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">40,087</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">26,529</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Other</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">227,160</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">185,282</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">63,805</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">2,530,175</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">1,817,510</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">1,041,140</font></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_SellingGeneralAndAdministrativeExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of selling, marketing and general and administrative (or similar) expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_SellingGeneralAndAdministrativeExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793636720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING (INCOME) EXPENSES, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_FinancingExpensesNetDisclosureTextBlock', window );">FINANCING (INCOME) EXPENSES, NET</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 54pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">NOTE 13</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">FINANCING (INCOME) EXPENSES, NET</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Israeli CPI linkage difference on principal of loans from stockholders</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(2,521</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(556</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">14,382</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Exchange rate differences</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">38,873</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(25,282</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">94,815</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Change in fair value of Series A Warrants</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(149,092</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(6,559,758</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6,251,242</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Issuance cost allocated to warrants with down-round protection</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">390,928</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Interest expenses on credit from banks and other</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">15,205</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(2,189</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">17,592</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">1,284,354</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">1,186,819</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">(6,587,785</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">6,768,959</font></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_FinancingExpensesNetDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure relating to financing expenses, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_FinancingExpensesNetDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793637008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAX</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: bold 10pt Times New Roman"></font></font></div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 54pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">NOTE 14</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: left"><font style="display: inline; font: bold 10pt Times New Roman">INCOME TAX</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">A.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Measurement of results for tax purposes under the Israeli Income Tax (Inflationary Adjustments) Law, 1985 (the &#8220;Inflationary Adjustment Law&#8221;)</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 9pt">&#160;</td>
<td style="width: 90.75pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Commencing January&#160;1, 2008, the results of operations of Integrity Israel for tax purposes are measured on a nominal basis.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="font-weight: bold">B</font>.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold"> </font></font>
<div style="text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold"><font style="display: inline; font: bold 10pt Times New Roman">Changes in the Israeli corporate tax rates</font></font></font></div>
</div>
</td>
</tr></table>


<font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">On December 6, 2011, the Law for the Change in the Tax Burden (Legislative Amendments) &#8211; 2011 was published.&#160;&#160;As part of this law, among other things, commencing from 2012 the corporate tax rate was increased to 25%.&#160;&#160;In addition, commencing in 2012, the tax rate on capital gains in real terms and the tax rate applicable to betterment in real terms were increased to 25%.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">On July 30, 2013, the Israeli parliament approved the Law for the Change in National Priorities (Legislative Amendments to Achieve Budgetary Goals for 2013 and 2014) &#8211; 2013, which, among other things increased the standard Israeli corporate income tax rate from 25% to 26.5% effective as of January&#160;1, 2014.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify">&#160;</div>

<div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify">
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">On January 4, 2016, the Israeli parliament passed the Law for Amendment of the Income Tax Ordinance No. 216, which, among other things reduced the standard Israeli corporate income tax rate from 26.5% to 25% effective as of January 2016.</font></div>
</div>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center">
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">C.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Tax assessments</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The Company and Integrity Israel have not received final tax assessments since their inception.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center">
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">D.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Carryforward tax losses</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">As of December&#160;31, 2015, the Company had cumulative net operating losses (NOL) for US federal purposes of approximately $3.1 million that will expire between the years 2031-2035. Integrity Israel has losses carry forward balances for Israeli income tax purposes of nearly $20.7 million to offset against future taxable income for an indefinite period of time.</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center">
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">E.</font></font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The following is a reconciliation between the theoretical tax on pre-tax income, at the tax rate applicable to the Company (federal tax rate) and the tax expense reported in the financial statements:</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Pretax income (loss)</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(5,842,172</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2,980,426</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(9,796,853</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Federal tax rate</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">34</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">%</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">35</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">%</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">35</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">%</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Income tax expenses (benefit) computed at the ordinary tax rate</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(1,986, 338</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1,043,149</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(3,428,899</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Non-deductible expenses</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">31,050</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">27,250</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">21,250</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Stock-based compensation</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">4,503</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">14,415</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">10,570</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Amortization of warrants with down round protection</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(50,691</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(2,295,915</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2,324,760</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">436,680</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Tax in respect of differences in corporate tax rates</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">340,263</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">278,466</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">253,942</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Losses and timing differences in respect of which no deferred taxes assets were recognized</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">1,224,533</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">932,635</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">818,377</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>



<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center">
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">F.</font></font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Deferred taxes result principally from temporary differences in the recognition of certain revenue and expense items for financial and income tax reporting purposes.&#160;&#160;Significant components of the Group's future tax assets are as follows:</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Composition of deferred tax assets:</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Provision for employee-related obligation</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">23,494</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">20,220</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">33,629</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Non-capital loss carry forwards</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6,233,314</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">4,810,780</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">4,364,466</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Valuation allowance</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(6,256,808</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(4,831,000</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(4,398,095</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789160096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">INCOME (LOSS) PER SHARE</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 54pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">NOTE 15</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">INCOME (LOSS) PER SHARE</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify">
<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The loss and the weighted average number of shares used in computing basic and diluted loss per share for the years ended December 31, 2015, 2014 and 2013, are as follows:</font></font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>
</div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Income (loss) for the year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(5,842,172</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2,980,426</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(9,796,853</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Stock dividend to certain Common Stockholder</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(278,263</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Cash dividend on Series A Preferred Stock</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(57,061</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(370,441</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(288,247</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Stock dividend on Series B Preferred Stock</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(390,219</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(43,858</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Income attributable to participating securities (Preferred Stock)</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(596,472</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Income (loss) for the period attributable to common stockholders</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">(6,289,452</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">1,969,655</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">(10,363,363</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Number of shares</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Common shares used in computing Basic income (loss) per share</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5,476, 870</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5,304,500</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5,325,714</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman"><font style="display: inline; font-size: 10pt">Common shares used in computing Diluted income (loss) per share</font><font style="display: inline; font-size: 10pt"> (*)</font></font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5,476, 870</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5,349,242</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5,325,714</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Total weighted average number of Common shares related to outstanding convertible Preferred Stock, options and warrants excluded from the calculations of diluted income (loss) per share (**)</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">9,431,728</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">4,557,612</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">2,813,493</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 72pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(*)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In applying the treasury method, the average market price of Common Stock was based on management estimate. For December 31, 2015 and 2014, management estimation considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series B Units (See Note 10C). The fair value per share of the Company&#8217;s Common Stock as of December 31, 2013 was based on the management&#8217;s estimate which was based among other factors on the closing price per share of the Company&#8217;s Common Stock on December 27, 2013, as reported on the OTCQB, which was the last reported sale of Common Stock in 2013.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center">
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 72pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">&#160;</td>
<td>&#160;</td>
</tr></table>
</div>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center">
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt">
<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 72pt">&#160;</td>
<td style="text-align: right; width: 27pt">
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(**)</font></div>
</td>
<td style="text-align: justify">
<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">The Company excludes from the calculation of diluted income (loss) per share, shares that will be issued upon the exercise of options and warrants with exercise prices, that are greater than the estimated average market value of the Company&#8217;s Common Stockand shares issuable upon conversion of Preferred Stock because their effect would be anti-dilutive. Outstanding shares that will be issued upon conversion or exercise, as applicable, of all convertible Preferred Stock, stock options and warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was anti-dilutive.</font></div></td></tr></table></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803925072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 54pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">NOTE 16</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">SEGMENT INFORMATION</font></div>
</td>
</tr></table>
</div>

<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The Company operates in one operating segment, the following is a summary of operations within geographic areas:</font></font></div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: bold 10pt times new roman">Revenues based on the customer&#8217;s location:</font></div>
</td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Europe</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">13,420</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">32,000</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Asia and Pacific</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">129,747</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">27,775</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Total</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">143,167</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">59,775</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">All long-lived assets are owned by Integrity Israel and are located in Israel.</font></font></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8981-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9038-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 33<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8971-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8595-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8380-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 35<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8984-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9031-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8538-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8864-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8924-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789160096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 54pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">NOTE 17</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">RELATED PARTIES</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">A.</font></font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Avner Gal, the beneficial owner of approximately 7.7% of the Company's outstanding Common Stock as of December&#160;31, 2015, entered into an employment agreement with Integrity Israel in July 2010 pursuant to which Mr.&#160;Gal agreed to continue to serve as the chief executive officer and managing director of Integrity Israel.&#160;&#160;The agreement was approved by the board of directors and stockholders of Integrity Israel. Mr. Gal&#8217;s employment agreement provides for an annual salary of approximately $123,457, $134,769 and $134,111 (NIS&#160;480,000) for the year ended December 31, 2015, 2014 and 2013 respectively. In addition, Mr. Gal is entitled to an annual bonus to be determined by the board of directors and an additional sum provided that Mr. Gal reaches certain milestones approved by the board, as well as the payment of certain social and insurance benefits and the use of a car.&#160;&#160;During the year ended December 31, 2015, 2014 and 2013 the Company paid Mr. Gal $0, $0 and $61,087, respectively as bonuses.&#160;&#160;The agreement also provides for a renegotiation of Mr. Gal&#8217;s annual salary on the one-year anniversary thereof and the renegotiation of Mr. Gal&#8217;s bonus formula once Integrity Israel has begun commercialization of its products.&#160;&#160;The agreement is terminable by either party on 180 days&#8217; notice, immediately by Integrity Israel with the payment of an amount equal to 180 days of annual salary, or immediately by Integrity Israel for cause (as defined in the agreement) without the payment of severance.&#160;&#160;Mr. Gal is subject to a non-compete and a confidentiality agreement during the term of the agreement and for one year thereafter. As of December 31, 2015 the Company did not make any amendments to Mr. Gal&#8217;s employment agreement.</font></div>
</td>
</tr></table>
</div>



<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">B.</font></font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">David Malka, the beneficial owner of 3.07% of the Company's outstanding Common Stock as of December&#160;31, 2015, entered into an employment agreement with Integrity Israel in July 2010 pursuant to which Mr. Malka agreed to continue to serve as the vice president of operations of Integrity Israel.&#160;&#160;The agreement was approved by the board of directors and stockholders of Integrity Israel. Mr.&#160;Malka&#8217;s employment agreement provides for an annual salary of approximately $61,728, 67,302 and $66,639 (NIS&#160;240,000) for the year ended December 31, 2015, 2014 and 2013 respectively. In addition, Mr. Malka is entitled to an annual bonus to be determined by the Board of Directors in its sole discretion and an additional sum provided that Mr. Malka reaches certain milestones approved by the Board, as well as the payment of certain social and insurance benefits and the use of a group three car.&#160;&#160;During the year ended December 31, 2015, 2014 and 2013 the Company paid Mr. Malka $0, $0 and $30,544, respectively as bonuses. The agreement also provided for a renegotiation of Mr. Malka&#8217;s annual salary on the one-year anniversary thereof and the renegotiation of Mr. Malka&#8217;s bonus formula once Integrity Israel has begun commercialization of its products.&#160;&#160;The agreement is terminable by either party on 90 days&#8217; notice, immediately by Integrity Israel with the payment of an amount equal to 90 days of annual salary, or immediately by Integrity Israel for cause (as defined in the agreement) without the payment of severance.&#160;&#160;Mr.&#160;Malka is subject to a non-compete and confidentiality agreement during the term of the agreement and for one year thereafter. As of December 31, 2015, the Company did not make any amendments to Mr. Malka&#8217;s employment agreement.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph b<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6787126240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 54pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">NOTE 18</font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#8211;</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">SUBSEQUENT EVENTS</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">A.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">During February 2016, the Company entered into an Advisory Agreement with the Placement Agent, according to which, the Company retained the Placement Agent on a non-exclusive basis to provide certain advisory services. In accordance with the terms of the Advisory Agreement, the Company extended the expiration date of the warrants issued to the Placement Agent in connection with the 2010 Offering and the 2012 Offering until December 31, 2019. The Advisory Agreement has a term of six months and shall automatically renew thereafter for additional 30 day terms unless terminated by either party upon receipt of 30 days prior written notice.&#160;&#160;The Company is in the process of evaluating the impact, if any, of the expiration date extension of the abovementioned warrants on the results of its operations.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">B.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">On March 17, 2016, the Company&#8217;s Board of Directors appointed two new directors, Leslie Seff and Angela Strand, to the Board of Directors and approved the following compensation for all three non-employee directors serving on the Board: (i) an annual cash payment in the amount of $15,000, payable in four equal quarterly installments of $3,750 each on the last day of each calendar quarter commencing with the second quarter of 2016, subject to the director&#8217;s continued service as of each such date; (ii) an annual cash payment to the chairperson of the Nominating and Corporate Governance Committee in the amount of $10,000, payable in four equal quarterly installments of $2,500 each, on the last day of each calendar quarter commencing with the second quarter of 2016, subject to the chairperson&#8217;s continued service as of each such date; and (iii) a one-time grant of options to each non-employee director to purchase up to an aggregate of 26,666 shares of the Company&#8217;s Common Stock, at an exercise price of $4.50 per share, under and pursuant to the 2010 Share Incentive Plan.&#160;&#160;Each director&#8217;s option grant will vest in eight equal quarterly increments of 3,333.25 each (subject to the director&#8217;s continued service as of each such date) commencing with the second quarter of 2016.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">C.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">On March 17, 2016, the Company&#8217;s Board of Directors approved an amendment to the 2010 Share Incentive Plan to increase the number of shares of the Company&#8217;s Common Stock reserved for issuance under the 2010 Share Incentive Plan from 529,555 shares to 1,000,000 shares.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803879488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates in the preparation of financial statements</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 27pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">A.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Use of estimates in the preparation of financial statements</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to (i) the fair value estimate of the Warrants with down-round protection, (ii) the fair value measurement of the Series B Units and the estimate of the loss arising from the partial extinguishment of the Series A Units and the exchange thereof for Series B Units, and (iii) the going concern assumptions.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 27pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">B.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Functional currency</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The functional currency of the Company is the US dollar, which is the currency of the primary economic environment in which it operates.&#160;&#160;In accordance with ASC 830, &#8220;Foreign Currency Matters&#8221; (ASC 830), balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date.&#160;&#160;For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used.&#160;&#160;Gains or losses arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses. The functional currency of Integrity Israel is the New Israeli Shekel ("NIS") and its financial statements are included in consolidation, based on translation into US dollars.&#160;&#160;Accordingly, assets and liabilities were translated from NIS to US dollars using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or losses resulting from translation adjustments are reflected in stockholders' equity (deficit), under &#8220;accumulated other comprehensive income (loss)&#8221;.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt times new roman">Official exchange rate of NIS&#160;1 to US dollar</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">0.256</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">0.257</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">0.288</font></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 27pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">C.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Principles of consolidation</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated in consolidation.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 70.9pt"><div><font style="display: inline; font: 10pt Times New Roman"></font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">D.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Cash and cash equivalents</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less at the date of purchase, to be cash equivalents.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 27pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman"><font style="display: inline; font-size: 10pt">E.</font></font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Inventories</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Inventories are stated at the lower of cost or market value.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Cost is determined as follows:</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">With respect to raw materials, the Group calculates cost using the average cost method.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">With respect to work in process and finished products, the Group calculates the cost on the basis of the average direct manufacturing costs, including materials, labor, subcontracting costs and other direct manufacturing costs.</font></div>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Management evaluates whether inventory reserve for slow-moving or obsolete items is required. To date, the Group has not recorded any reserves with respect to its inventory.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 27pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">F.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Property and equipment, net</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 100pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">1.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation.&#160;&#160;Depreciation is calculated using the straight-line method over the estimated useful lives of the assets.&#160;&#160;When an asset is retired or otherwise disposed of, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in the statements of operations.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 100pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">2.</font></div>
</td>
<td>
<div style="text-align: left"><font style="display: inline; font: 10pt Times New Roman">Rates of depreciation:</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 83%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 85%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 13%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">%</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 85%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt times new roman">Computers</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 13%; text-align: center"><font style="display: inline; font: 10pt times new roman">33</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 85%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt times new roman">Furniture and office equipment</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 13%; text-align: center"><font style="display: inline; font: 10pt times new roman">7-15</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 85%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt times new roman">Leasehold improvements</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 13%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">Shorter of lease term</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">and 10 years</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 70.9pt"><div><font style="display: inline; font: 10pt Times New Roman"></font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">G.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Impairment of long-lived assets</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Group's long-lived assets are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment&#8221;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;&#160;Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset.&#160;&#160;If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.&#160;&#160;To date the Group did not incur any material impairment losses.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Long-term restricted cash</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 27pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">H.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Long-term restricted cash</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Restricted cash is invested in certificates of deposit, which are used to secure Integrity Israel&#8217;s obligations in respect of its headquarters lease.&#160; See Note 9B</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income tax</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 70.9pt"><div><font style="display: inline; font: 10pt Times New Roman"></font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">I.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Income tax</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Group accounts for income taxes in accordance with ASC 740, "Income Taxes". Accordingly, deferred income taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities under the applicable tax law.&#160;&#160;Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences reverse.&#160;&#160;Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Group accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise&#8217;s financial statements. According to ASC Topic 740-10, tax positions must meet a more-likely-than-not recognition threshold. The Group&#8217;s accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Group did not recognize such items in its fiscal 2015, 2014 and 2013 financial statements and did not recognize any liability with respect to unrecognized tax position in its balance sheet.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy', window );">Liability for employee rights upon retirement</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 27pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">J.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Liability for employee rights upon retirement</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Integrity Israel's liability for employee rights upon retirement with respect to its Israeli employees is calculated pursuant to the Israeli Severance Pay Law, based on the most recent salary of each employee multiplied by the number of years of employment of each such employee as of the balance sheet date. Employees are entitled to one month's salary for each year of employment, or ratable portion thereof for periods less than one year. Integrity Israel makes monthly deposits to insurance policies and severance pay funds.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The deposited funds may be withdrawn upon the fulfillment of Integrity Israel's severance obligations pursuant to Israeli severance pay laws or labor agreements with its employees.&#160;&#160;The value of the deposited funds is based on the cash surrender value of these policies, and includes immaterial profits or losses.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Commencing in 2011, Integrity Israel&#8217;s agreements with its Israeli employees are in accordance with Section 14 of the Severance Pay Law. Payments in accordance with Section 14 release the employer from any future severance payments in respect of those employees. Related obligations and liabilities under Section 14 are not recorded as an asset or as a liability in the Company's balance sheet.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Severance expenses for the year ended December&#160;31, 2015, 2014 and 2013 amounted to&#160;$111,030, $101,220 and $91,588, respectively.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 27pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">K.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Revenue recognition</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Revenues are recognized in accordance with ASC 605, "Revenue Recognition" and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) No. 104, &#8220;Revenue Recognition&#8221;, when delivery has occurred, persuasive evidence of an agreement exists, the fee is fixed and determinable, collectability is reasonably assured and no further obligations exist. Provisions are made at the time of revenue recognition for any applicable warranty cost expected to be incurred (See Note 2N).</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Company derives its revenues from sales of its GlucoTrack&#174; model DF-F glucose monitoring device to distributors. The Company's products sold through agreements with distributors are generally non-exchangeable, non-refundable and non-returnable and, to date, the Company has not granted to any of its distributors any rights of price protection or stock rotation. Accordingly, the Company considers its distributors as end-users for revenue recognition purposes.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 70.9pt"><div><font style="display: inline; font: 10pt Times New Roman"></font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">L.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Research and development expenses</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Research and development expenses are charged to operations as incurred.&#160;&#160;Grants received by Integrity Israel from the Government of Israel through the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor (the "OCS") for development of approved projects were recognized as a reduction of expenses when the related costs were incurred.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionServicesRoyaltyFees', window );">Royalty-bearing grants</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 70.9pt"><div><font style="display: inline; font: 10pt Times New Roman"></font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">M.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Royalty-bearing grants</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Royalty-bearing grants from the OCS to fund approved research and development projects are recognized at the time Integrity Israel is entitled to such grants, on the basis of the costs incurred and reduce research and development costs.&#160;&#160;The cumulative research and development grants received by Integrity Israel from inception through December 2004 amounted to $93,300.&#160;&#160;Integrity Israel has not received any research and development grants since December 2004.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">As of December&#160;31, 2015 and 2014, the Group accrued royalties to the OCS in the amounts of $8,167 and $1,793, respectively.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Warranty</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 27pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">N.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Warranty</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Group provides a 24 month warranty for its products at no cost. The Group estimates the costs that may be incurred during the warranty period and records a liability for the amounts of such costs at the time revenues are recognized. As of December 31, 2015 and 2014 warranty expenses were immaterial.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted income (loss) per share</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 70.9pt"><div><font style="display: inline; font: 10pt Times New Roman"></font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">O.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Basic and diluted income (loss) per share</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Basic income (loss) per share is computed by dividing the income (loss) for the period applicable for Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Securities that may participate in dividends with the Common Stock (such as the convertible Preferred Stock) are considered in the computation of basic income per share using the two class method. However, in periods of net loss, such participating securities are not included since the holders of such securities do not have a contractual obligation to share the losses of the Company.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In computing diluted income per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the &#8220;treasury stock method&#8221; and upon the conversion of Preferred Stock using the "if-converted method", if the effect of each of such financial instruments is dilutive.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 70.9pt"><div><font style="display: inline; font: 10pt Times New Roman"></font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">P.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Stock-based compensation</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Group measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values in accordance with ASC 718, &#8220;Compensation-Stock Compensation&#8221;. Share-based payments including grants of stock options are recognized in the statement of operations as an operating expense based on the fair value of the award at the date of grant.&#160;&#160;The fair value of stock options granted is estimated using the Black-Scholes option-pricing model.&#160;&#160;The Group has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Share-based payments awarded to consultants (non-employees) are accounted for in accordance with ASC Topic 505-50, "Equity-Based Payments to Non-Employees".</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 70.9pt"><div><font style="display: inline; font: 10pt Times New Roman"></font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">Q.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Fair value of financial instruments</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">ASC Topic 825-10, "Financial Instruments" defines financial instruments and requires disclosure of the fair value of financial instruments held by the Group. The Group considers the carrying amount of cash and cash equivalents, accounts receivable, other current assets, accounts payable, current portion of long-term loans from stockholders and other current liabilities balances, to approximate their fair values due to the short term maturities of such financial instruments.&#160;&#160;The Series A Warrants with down-round protection represent a derivative liability and therefore are measured and presented on the balance sheet at fair value. ASC Topic 825-10, establishes the following fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Level 2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Level 3 - Unobservable inputs are used when little or no market data is available. Level 3 inputs are considered as the lowest priority under the fair value hierarchy.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The fair value measurement of the warrants is classified as level 3. The Group did not estimate the fair value of the long-term loans from stockholders since their repayment schedule has not yet been determined.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 27pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">R.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Concentrations of credit risk</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Financial instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.&#160;&#160;Cash and cash equivalents are deposited with major banks in Israel and the United States of America. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. As of December 31, 2015 and 2014 the balances of accounts receivable was not material and accordingly such balances do not represent substantial concentration of credit risk. The Group does not have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 27pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">S.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Contingencies</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_TemporaryEquityPolicyPolicyTextBlock', window );">Preferred Stock</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">T.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Preferred Stock</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">&#160;1.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">Temporary Equity Classification</font></font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">As more fully described in Note 10A.2, Note 10B, Note 10A.3 and Note 10C, in March 2013 and during the period between August until December 31, 2014, the Company issued Series A Preferred Stock and Series B Preferred Stock, respectively, which provide a liquidation preference and certain redemption rights for the benefit of the holders of such Preferred Stock upon the occurrence of certain contingent events, some of which are not solely within the Company&#8217;s control.&#160;&#160;Accordingly, both the Series A Preferred Stock and the Series B Preferred Stock are presented as temporary equity.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;2.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Initial Measurement</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Upon initial recognition, the Series A Preferred Stock issued together with detachable Series A Warrants (classified as a derivative liability) were measured based on the "residual approach" and were presented net of the direct issuance expenses that were allocated to them. Upon initial recognition, the Series B Preferred Stock issued together with the detachable Series B Warrants (classified as equity) were measured based on the relative fair value basis and were presented net of the direct issuance expenses that were allocated to them.</font></div>
</td>
</tr></table>
</div>





<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;3.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Subsequent Measurement</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">On each balance sheet date, the Company&#8217;s management assesses the probability of redemption of the Preferred Stock. In the event that management determines such redemption to be probable as of an applicable balance sheet date, the Company will reclassify the outstanding balance of the Preferred Stock as of that date as a liability and the difference between such amount and the aggregate redemption price of the Preferred Stock will be accreted against accumulated deficit over the period beginning on the date that it becomes probable that the Preferred Stock will become redeemable and ending on the earliest redemption date.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;4.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Conversion Feature Analysis</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Company has determined that due to the economic characteristics and risks of the Preferred Stock, based on their stated or implied substantive terms and features, Series A and Series B Preferred Stock, are both considered as more akin to equity than debt. Accordingly, it was determined that the economic characteristics and the risks of the embedded conversion option to Common Stock and those of the Preferred Stock themselves (the 'host contract') are clearly and closely related. As a result, the embedded conversion feature was not required to be bifurcated. Also, since at the respective issuance dates of the Series A Preferred Stock and the Series B Preferred Stock, the exercise price of the conversion feature (based on the effective conversion rate of the Series A Preferred Stock and the Series B Preferred Stock into Common Stock) was higher than the estimated fair value of the Company&#8217;s Common Stock, it was determined that the conversion feature was not beneficial.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;5.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Modifications or Exchanges</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Modifications to, or exchanges of, the Preferred Stock are accounted for as a modification or an extinguishment. Such an assessment is done by management either qualitatively or quantitatively based on the facts and circumstances of each transaction. A qualitative assessment is generally appropriate when the changes to a Preferred Stock instrument are either so inconsequential or is very significant, otherwise, a quantitative test is also applied. Since the periodic contractual cash flows of the Preferred Stock are not defined, the quantitative test is generally applied using the fair value model. Under the fair value model, the Company compares the fair value of the Preferred Stock immediately before and after the modification or exchange. If the fair values before and after the modification or exchange are substantially different, the modification or exchange is accounted for as an extinguishment, otherwise it is accounted for as a modification.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Series A Warrants with Down-Round Protection</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td style="width: 27pt"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">U.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Series A Warrants with Down-Round Protection</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>



<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt">
<div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The Company considered the provisions of ASC 815-40, &#8220;Derivatives and Hedging: Contracts in Entity&#8217;s Own Equity&#8221;, with respect to the detachable Warrants that were issued to the Series A Unit Purchasers, as described in Note&#160;10D, and determined that as a result of the &#8220;down-round&#8221; protection that would adjust the number of Warrants and the exercise price of the Warrants based on the price at which the Company subsequently issues shares or other equity-linked financial instruments, if that price is less than the original exercise price of the Warrants, such Warrants cannot be considered as indexed to the Company's own stock. Accordingly, the Warrants were recognized as derivative liability at their fair value on initial recognition. In subsequent periods, the Warrants are marked to market with the changes in fair value recognized as financing expense or income in the consolidated statement of operations. The direct issuance expenses that were allocated to the detachable Warrants were expensed as incurred.</font></font></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 70.9pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">V.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Recently Issued Accounting Pronouncements</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;1.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Accounting Standard Update 2014-09, &#8220;Revenue from Contracts with Customers&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In May 2014, the FASB issued Accounting Standard Update 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09").</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In accordance with a recent amendment to ASU 2014-09, introduced by Accounting Standards Update 2015-11, "Revenue from Contracts with Customers - Deferral of the Effective Date", for a public entity, the amendments in ASU 2014-09 are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period (the first quarter of fiscal year 2018 for the Company). Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Company is in the process of assessing the impact, if any, of ASU 2014-09 on its consolidated financial statements.</font></div>
</td>
</tr></table>
</div>





<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;2.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Accounting Standards Update 2014-15, &#8220;Presentation of Financial Statements&#8212;Going Concern&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial Statements&#8212;Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern ("ASU 2014-15").</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">ASU 2014-15 provides guidance on management&#8217;s responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable).</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">ASU 2014-15 also provides guidance related to the required disclosures as a result of management&#8217;s evaluation.&#160;</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Company is in the process of assessing the impact, if any, of ASU 2014-15 on its consolidated financial statements or related disclosures.</font></div>
</td>
</tr></table>
</div>





<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;3.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Accounting Standard Update 2014-16, &#8220;Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In November 2014, the FASB issued Accounting Standard Update 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity ("ASU 2014-16").</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The amendments in ASU 2014-16 clarify how current U.S. GAAP should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. Specifically, the amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract. Furthermore, the amendments clarify that no single term or feature would necessarily determine the economic characteristics and risks of the host contract. Rather, the nature of the host contract depends upon the economic characteristics and risks of the entire hybrid financial instrument. The amendments also clarify that, in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (i.e., the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weigh those terms and features. The assessment of the substance of the relevant terms and features should incorporate a consideration of the characteristics of the terms and features themselves; the circumstances under which the hybrid financial instrument was issued or acquired; and the potential outcomes of the hybrid financial instrument, as well as the likelihood of those potential outcomes.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The amendments in ASU 2014-16 apply to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of a share.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The amendments in ASU 2014-16 are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015 (fiscal 2016 for the Company). Early adoption, including adoption in an interim period, is permitted. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The effects of initially adopting the amendments in ASU 2014-16 should be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Management believes that the provisions of ASU 2014-16 will not impact the classification of the Series A or Series B Preferred Stock.</font></div>
</td>
</tr></table>
</div>





<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 96.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: bold 10pt Times New Roman">&#160;4.</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: bold 10pt Times New Roman">Accounting Standard Update 2015-11, &#8220;Simplifying the Measurement of Inventory&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In July, 2015, The FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11").</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out (LIFO) and the retail inventory method (RIM) are not impacted by the new guidance. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin).</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early adoption is permitted as of the beginning of an interim or annual reporting period.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 116.25pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Company is in the process of assessing the impact, if any, of ASU 2015-11 on its consolidated financial statements.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_TemporaryEquityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_TemporaryEquityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph k<br> -Article 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02, 03<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41620-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5579240-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5579245-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41675-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41638-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51717228&amp;loc=d3e202-110218<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section CC<br> -Subsection 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 206<br> -Paragraph b<br> -Subparagraph i, ii<br> -Chapter 2<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 6<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for plans, other than pension plans, that provide postretirement benefits (including both defined benefit and defined contribution plans). This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235144<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235172<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section B<br> -Paragraph Question 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionServicesRoyaltyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition for royalty fees, which is consideration or a share of the proceeds paid by another party to the owner of a right (that is, the entity) for its use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 20<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51660065&amp;loc=d3e47769-111627<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section B<br> -Paragraph Question 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionServicesRoyaltyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6592177328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock', window );">Schedule of Official Exchange Rate</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-align: right"><table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr><td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman"></font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt times new roman">Official exchange rate of NIS&#160;1 to US dollar</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">0.256</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">0.257</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">0.288</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ScheduleOfPropertyRatesOfDepreciationTableTextBlock', window );">Schedule of Property and Equipment, Rates of Depreciation</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td><div style="text-align: left"><font style="display: inline; font: 10pt Times New Roman">Rates of depreciation:</font></div>
</td>
</tr></table>
</div>

<div><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 83%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 85%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 13%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">%</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 85%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt times new roman">Computers</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 13%; text-align: center"><font style="display: inline; font: 10pt times new roman">33</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 85%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt times new roman">Furniture and office equipment</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 13%; text-align: center"><font style="display: inline; font: 10pt times new roman">7-15</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 85%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt times new roman">Leasehold improvements</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 13%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">Shorter of lease term</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">and 10 years</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ScheduleOfPropertyRatesOfDepreciationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accumulated depreciation percentage of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ScheduleOfPropertyRatesOfDepreciationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the U.S. dollar denominated balances, balances reported for financial reporting purposes and the differences between the two balances by each relevant line item on the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789113664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-align: right"><table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr><td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Raw materials</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">205,645</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">55,557</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Work in process</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">551,111</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">16,459</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Finished products</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">59,467</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">11,637</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">816,223</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">83,653</font></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 2<br> -Paragraph 6<br> -Subparagraph a,b,c<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793521568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-align: right"><table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr><td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman"></font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Prepaid expenses</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">57,206</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">46,094</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Government Institution (*)</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">211,586</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">67,748</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">268,792</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">113,842</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 68.05pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">&#160;(*)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Represents amounts advanced by Integrity Israel to the Israeli tax authorities or amounts owed to Integrity Israel by the Israeli Value Added Tax authorities.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803925072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr><td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman"></font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Computers</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">240,066</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">124,161</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Furniture and office equipment</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">200,548</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">184,379</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Leasehold improvements</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">32,898</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">22,992</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">473,512</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">331,532</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Less &#8211; accumulated depreciation</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(253,049</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(209,041</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">220,463</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">122,491</font></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789156496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-align: right"><table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr><td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman"></font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Employees and related institutions</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">240,358</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">204,890</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Accrued expenses and other</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">187,528</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">235,874</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 76%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">427,886</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">440,764</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6786803568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Fair Value of Level 3 Liability</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The changes in the fair value of the Level 3 liability are as follows (in US dollars):</font></font></div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Series A Warrants</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="6" style="vertical-align: bottom; width: 22%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance, Beginning of the year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2,057,618</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">8,216,705</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Classification from stockholders deficit</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">400,671</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Exchange of Series A Warrants pursuant to the &#8220;Most favored nation&#8221; provision</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(1,586,831</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Change in fair value of Series A Warrants</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(149,092</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(6,559,758</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance, End of year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">321,695</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">2,057,618</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock', window );">Schedule of Fair Value Assumptions Used</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The key inputs used in the fair value calculations were as follows:</font></font></div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Dividend yield (%)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Expected volatility (%) (*)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">105.14</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">105.14</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Risk free interest rate (%)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">0.99</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.14</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Expected term of options (years) (**)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2.20</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">3.20</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Exercise price (US dollars)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">5.80</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">5.80</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Share price (US dollars) (***)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2.31</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2.31</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Fair value (US dollars)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">0.84</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.13</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 100pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 36pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(*)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Due to the low trading volume of the Company&#8217;s Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 100pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 36pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(**)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No.&#160;110.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 99pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 36pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(***)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Common Stock price, per share reflects the Company&#8217;s management&#8217;s estimation of the fair value per share of Common Stock as of December 31, 2015 and 2014. In reaching its estimation for December 31, 2015 and 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the 2014 Offering.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Grants Activity</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The following tables present a summary of the status of the grants to employees, officers and directors as of December&#160;31, 2015 and 2014:</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 85%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Number</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Weighted average exercise price (US$)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31, 2015</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance outstanding at beginning of year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">450,847</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">5.85</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Granted</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Exercised</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(19,769</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.82</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Forfeited</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(17,605</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">6.01</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance outstanding at end of the year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">413,473</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">6.04</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance exercisable at the end of the year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">293,736</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5.95</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>



<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 85%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 76%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Number</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Weighted average exercise price (US$)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31, 2014</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance outstanding at beginning of year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">414,847</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">5.74</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Granted</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">44,000</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">7.00</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%">
<div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Exercised</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Forfeited</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(8,000</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">6.25</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance outstanding at end of the year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">450,847</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5.85</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 76%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Balance exercisable at the end of the year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">302,360</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5.58</font></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Stock Grants, by Exercise Price Range</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The following tables summarize information about options outstanding at December&#160;31, 2015:</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 85%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Exercise</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">price (US$)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Outstanding at December&#160;31, 2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Weighted average remaining contractual life (years)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Weighted average exercise price</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Exercisable at December&#160;31, 2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Weighted average remaining contractual life (years)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.72</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">21,758</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.60</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.72</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">21,758</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.60</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">3.63</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">3,730</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.60</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">3.63</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">3,730</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.60</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6.01</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">4,273</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2.04</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6.03</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">4,273</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2.04</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6.25</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">351,712</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6.20</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6.25</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">236,975</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6.20</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">7.00</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">32,000</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">8.5</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">7.00</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">27,000</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">8.50</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">413,473</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">293,736</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Value Options</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-indent: 0pt; display: block; margin-left: 117pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The fair value of options granted was estimated at the dates of grant using the Black-Scholes option pricing model.&#160;&#160;The following are the data and assumptions used:</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 83%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="text-align: right; vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="text-align: right; vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="text-align: right; vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: right"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Dividend yield (%)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">0</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Expected volatility (%) (*)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">105.14</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Risk free interest rate (%)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.61</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Expected term of options (years) (**)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">5-6</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Exercise price (US dollars)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">7.00</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Stock price (US dollars) (***)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2.31</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Fair value (US dollars)</font></div>
</td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1.59</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: right; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 112.5pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 36pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(*)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Due to the low trading volume of the Company&#8217;s Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 113.4pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 36pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(**)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No.&#160;110.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 112.5pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 36pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(***)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The Common Stock price, per share for the year ended December 31, 2014 reflects the Company&#8217;s management&#8217;s estimation of the fair value per share of Common Stock. In reaching its estimation for December 31, 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the 2014 Offering.</font></div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quantitative information about the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789131936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock', window );">Schedule of Research and Development Expenses</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-align: right"><table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr><td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman"></font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Salaries and related expenses</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1,303,614</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1,128,672</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1,293,067</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Professional fees</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">525,144</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">377,918</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">247,888</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Materials</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">166,736</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">96,699</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">154,522</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Depreciation</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">19,132</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">16,156</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">32,858</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Travel expenses</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">39,324</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">27,867</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">43,131</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Vehicle maintenance</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">54,936</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">25,888</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">35,955</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Other</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">159,459</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">176,424</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">179,333</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">2,268,345</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">1,849,624</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">1,986,754</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each component of research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793670656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_SellingGeneralAndAdministrativeExpenseTableTextBlock', window );">Schedule of selling, marketing and general and administrative expenses</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-align: right"><table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr><td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman"></font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Salaries and related expenses</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">803,319</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">651,900</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">260,276</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Professional fees</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">990,390</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">739,893</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">562,435</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Travel &#38; expenses</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">468,126</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">200,348</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">128,095</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Vehicle maintenance</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">41,180</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">40,087</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">26,529</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Other</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">227,160</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">185,282</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">63,805</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">2,530,175</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">1,817,510</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">1,041,140</font></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_SellingGeneralAndAdministrativeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of selling, marketing and general and administrative (or similar) expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_SellingGeneralAndAdministrativeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793520480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING (INCOME) EXPENSES, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Financing (Income) Expenses, Net</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-align: right"><table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr><td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman"></font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Israeli CPI linkage difference on principal of loans from stockholders</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(2,521</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(556</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">14,382</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Exchange rate differences</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">38,873</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(25,282</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">94,815</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Change in fair value of Series A Warrants</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(149,092</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(6,559,758</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6,251,242</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Issuance cost allocated to warrants with down-round protection</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">390,928</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Interest expenses on credit from banks and other</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">15,205</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(2,189</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">17,592</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">1,284,354</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">1,186,819</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">(6,587,785</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">6,768,959</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6626830304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Statutory Tax Rate to the Effective Income Tax Rate</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr style="vertical-align: top"><td><div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">The following is a reconciliation between the theoretical tax on pre-tax income, at the tax rate applicable to the Company (federal tax rate) and the tax expense reported in the financial statements:</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Pretax income (loss)</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(5,842,172</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2,980,426</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(9,796,853</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Federal tax rate</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">34</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">%</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">35</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">%</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">35</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">%</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Income tax expenses (benefit) computed at the ordinary tax rate</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(1,986, 338</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">1,043,149</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(3,428,899</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Non-deductible expenses</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">31,050</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">27,250</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">21,250</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Stock-based compensation</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">4,503</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">14,415</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">10,570</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Amortization of warrants with down round protection</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(50,691</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(2,295,915</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2,324,760</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">436,680</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Tax in respect of differences in corporate tax rates</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">340,263</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">278,466</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">253,942</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Losses and timing differences in respect of which no deferred taxes assets were recognized</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">1,224,533</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">932,635</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">818,377</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Taxes</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-align: right"><table cellpadding="0" cellspacing="0" style="width: 87%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"><tr><td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman"></font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Composition of deferred tax assets:</font></div>
</td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Provision for employee-related obligation</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">23,494</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">20,220</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">33,629</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Non-capital loss carry forwards</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">6,233,314</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">4,810,780</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">4,364,466</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Valuation allowance</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(6,256,808</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(4,831,000</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(4,398,095</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 64%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793622768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Loss and Weighted Average Number of Shares</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-indent: 0pt; display: block; margin-left: 99pt; margin-right: 0pt; text-align: justify"><div style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt; text-align: justify"><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The loss and the weighted average number of shares used in computing basic and diluted loss per share for the years ended December 31, 2015, 2014 and 2013, are as follows:</font></font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>
</div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">US dollars</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Income (loss) for the year</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(5,842,172</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">2,980,426</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(9,796,853</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Stock dividend to certain Common Stockholder</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(278,263</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Cash dividend on Series A Preferred Stock</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(57,061</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(370,441</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(288,247</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Stock dividend on Series B Preferred Stock</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(390,219</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">(43,858</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Income attributable to participating securities (Preferred Stock)</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">(596,472</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Income (loss) for the period attributable to common stockholders</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">(6,289,452</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">)</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">1,969,655</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">(10,363,363</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">)</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman"><br />
</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 91%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Number of shares</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Common shares used in computing Basic income (loss) per share</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5,476, 870</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5,304,500</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5,325,714</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman"><font style="display: inline; font-size: 10pt">Common shares used in computing Diluted income (loss) per share</font><font style="display: inline; font-size: 10pt"> (*)</font></font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5,476, 870</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5,349,242</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">5,325,714</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Total weighted average number of Common shares related to outstanding convertible Preferred Stock, options and warrants excluded from the calculations of diluted income (loss) per share (**)</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">9,431,728</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">4,557,612</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">2,813,493</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 72pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 27pt">
<div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(*)</font></div>
</td>
<td>
<div style="text-align: justify"><font style="display: inline; font: 10pt Times New Roman">In applying the treasury method, the average market price of Common Stock was based on management estimate. For December 31, 2015 and 2014, management estimation considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series B Units (See Note 10C). The fair value per share of the Company&#8217;s Common Stock as of December 31, 2013 was based on the management&#8217;s estimate which was based among other factors on the closing price per share of the Company&#8217;s Common Stock on December 27, 2013, as reported on the OTCQB, which was the last reported sale of Common Stock in 2013.</font></div>
</td>
</tr></table>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center">
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 72pt">
<div><font style="display: inline; font: 10pt Times New Roman">&#160; </font></div>
</td>
<td style="width: 18pt">&#160;</td>
<td>&#160;</td>
</tr></table>
</div>
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center">
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt">
<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman">
<tr style="vertical-align: top">
<td style="width: 72pt">&#160;</td>
<td style="text-align: right; width: 27pt">
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">(**)</font></div>
</td>
<td style="text-align: justify">
<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">The Company excludes from the calculation of diluted income (loss) per share, shares that will be issued upon the exercise of options and warrants with exercise prices, that are greater than the estimated average market value of the Company&#8217;s Common Stockand shares issuable upon conversion of Preferred Stock because their effect would be anti-dilutive. Outstanding shares that will be issued upon conversion or exercise, as applicable, of all convertible Preferred Stock, stock options and warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was anti-dilutive.</font></div></td></tr></table></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6787558768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Summary of operations within geographic areas</a></td>
<td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font: 10pt Times New Roman">The Company operates in one operating segment, the following is a summary of operations within geographic areas:</font></font></div>

<div style="text-indent: 0pt; display: block"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: right">
<table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="10" style="vertical-align: bottom; width: 34%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">Year ended December 31,</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: bold 10pt times new roman">Revenues based on the customer&#8217;s location:</font></div>
</td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2015</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2014</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt times new roman">2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: bold 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="vertical-align: bottom; width: 64%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; width: 10%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Europe</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">13,420</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">32,000</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 2px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Asia and Pacific</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">129,747</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">27,775</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 64%; padding-bottom: 4px">
<div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Total</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">143,167</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">59,775</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">-</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789754368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 23,087,063<span></span>
</td>
<td class="nump">$ 29,376,515<span></span>
</td>
<td class="nump">$ 23,087,063<span></span>
</td>
<td class="nump">$ 25,653,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' deficit</a></td>
<td class="nump">4,832,203<span></span>
</td>
<td class="nump">$ 6,970,914<span></span>
</td>
<td class="nump">$ 4,832,203<span></span>
</td>
<td class="nump">11,063,118<span></span>
</td>
<td class="nump">$ 503,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from issuance of Common Stock, net of issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock', window );">Proceeds from convertible preferred stock and warrants</a></td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB1WarrantMember', window );">Series B-1 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB2WarrantMember', window );">Series B-2 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockConversionPrice', window );">Conversion price</a></td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ClassOfWarrantOrRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ClassOfWarrantOrRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_PreferredStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Conversion Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_PreferredStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflows (outflows) from issuing and redeeming redeemable preferred stock; includes convertible and nonconvertible redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB1WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB1WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB2WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB2WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6626851488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Functional Currency) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionAbstract', window );"><strong>Functional currency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AverageForeignCurrencyExchangeRateTranslation', window );">Official exchange rate of NIS 1 to US dollar</a></td>
<td class="nump">0.256<span></span>
</td>
<td class="nump">0.257<span></span>
</td>
<td class="nump">0.288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_AverageForeignCurrencyExchangeRateTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The foreign exchange rates used to translate income and expense items denominated in the functional currency to the reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_AverageForeignCurrencyExchangeRateTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6804669696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property and equipment, net) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PropertyPlantAndEquipmentDepreciationRate', window );">%</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Furniture and Office Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PropertyPlantAndEquipmentDepreciationRate', window );">%</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Furniture and Office Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PropertyPlantAndEquipmentDepreciationRate', window );">%</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_PropertyPlantAndEquipmentDepreciationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant And Equipment, Depreciation Rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_PropertyPlantAndEquipmentDepreciationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789285280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Liability for employee rights upon retirement) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Liability for employee rights upon retirement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsPeriodExpense', window );">Severance expenses</a></td>
<td class="nump">$ 111,030<span></span>
</td>
<td class="nump">$ 101,220<span></span>
</td>
<td class="nump">$ 91,588<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsPeriodExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period expense related to postemployment benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsPeriodExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6786759360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Royalty-bearing grants) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2004</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Royalty-bearing grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Research and development grants</a></td>
<td class="nump">$ 8,167<span></span>
</td>
<td class="nump">$ 1,793<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803810832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 205,645<span></span>
</td>
<td class="nump">$ 55,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">551,111<span></span>
</td>
<td class="nump">16,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">59,467<span></span>
</td>
<td class="nump">11,637<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 816,223<span></span>
</td>
<td class="nump">$ 83,653<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789317808">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 57,206<span></span>
</td>
<td class="nump">$ 46,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Government Institution</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">211,586<span></span>
</td>
<td class="nump">67,748<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 268,792<span></span>
</td>
<td class="nump">$ 113,842<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents amounts advanced by Integrity Israel to the Israeli tax authorities or amounts owed to Integrity Israel by the Israeli Value Added Tax authorities.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5865-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789301712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 473,512<span></span>
</td>
<td class="nump">$ 331,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation</a></td>
<td class="num">(253,049)<span></span>
</td>
<td class="num">(209,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">220,463<span></span>
</td>
<td class="nump">122,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">44,891<span></span>
</td>
<td class="nump">34,683<span></span>
</td>
<td class="nump">$ 33,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">143,736<span></span>
</td>
<td class="nump">63,455<span></span>
</td>
<td class="nump">$ 64,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">240,066<span></span>
</td>
<td class="nump">124,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Furniture and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">200,548<span></span>
</td>
<td class="nump">184,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 32,898<span></span>
</td>
<td class="nump">$ 22,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789252928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees and related institutions</a></td>
<td class="nump">$ 240,358<span></span>
</td>
<td class="nump">$ 204,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">187,528<span></span>
</td>
<td class="nump">235,874<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">$ 427,886<span></span>
</td>
<td class="nump">$ 440,764<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6786725488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LINE OF CREDIT (Details) - Dec. 31, 2015<br></strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>ILS (&#8362;)</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Amount of unutilized credit line | $</a></td>
<td class="nump">$ 38,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_ILS', window );">ILS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Amount of unutilized credit line | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793580000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM LOANS FROM STOCKHOLDERS (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PercentOfFutureSalesDesignatedToRepayStockholdersLoans', window );">Percent of future sales to be transferred to lenders</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_PercentOfFutureSalesDesignatedToRepayStockholdersLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent Of Future Sales Designated To Repay Stockholders' Loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_PercentOfFutureSalesDesignatedToRepayStockholdersLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803565616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES (Grants) (Details)<br></strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2004 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2004 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Research and development grants</a></td>
<td class="nump">$ 8,167<span></span>
</td>
<td class="nump">$ 1,793<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=igap_PaymentOfRoyaltiesToOcsMember', window );">Payment of Royalties to OCS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_RoyaltyPercentMinimum', window );">Royalty on the sale of any product developed, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_RoyaltyPercentMaximum', window );">Royalty on the sale of any product developed, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued', window );">Contingent liabilities with respect to the grants</a></td>
<td class="nump">$ 83,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=igap_PaymentOfRoyaltiesToOcsMember', window );">Payment of Royalties to OCS [Member] | ILS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Research and development grants | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 420,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_RoyaltyPercentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Percent, Maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_RoyaltyPercentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_RoyaltyPercentMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Percent, Minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_RoyaltyPercentMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum amount of estimated loss and the amount recorded as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6395354&amp;loc=d3e12631-108344<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=igap_PaymentOfRoyaltiesToOcsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=igap_PaymentOfRoyaltiesToOcsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790689392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES (Leases) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>ILS (&#8362;) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=igap_PropertyAshkelonIsraelMember', window );">Property Ashkelon, Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Dec. 31,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AreaOfLeasedSpace', window );">Office space leased | ft&#178;</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_MonthlyLeaseCommitment', window );">Monthly lease payment</a></td>
<td class="nump">$ 2,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=igap_PropertyAshkelonIsraelMember', window );">Property Ashkelon, Israel [Member] | ILS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_MonthlyLeaseCommitment', window );">Monthly lease payment | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 11,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=igap_PropertyAshdodIsraelMember', window );">Property Ashdod, Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AreaOfLeasedSpace', window );">Office space leased | ft&#178;</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_MonthlyLeaseCommitment', window );">Monthly lease payment</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_LeaseGuaranteeProvidedToLandlord', window );">Lease guarantee provided to landlord</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Estimated minimal rent and maintenance payments, year one</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Estimated minimal rent and maintenance payments, year two</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Estimated minimal rent and maintenance payments, year three</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Estimated minimal rent and maintenance payments, year four</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">Estimated minimal rent and maintenance payments, year five</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=igap_PropertyAshdodIsraelMember', window );">Property Ashdod, Israel [Member] | ILS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_LeaseGuaranteeProvidedToLandlord', window );">Lease guarantee provided to landlord</a></td>
<td class="nump">$ 137,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_AreaOfLeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area Of Leased Space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_AreaOfLeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_LeaseGuaranteeProvidedToLandlord">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease guarantee provided to landlord.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_LeaseGuaranteeProvidedToLandlord</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_MonthlyLeaseCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly Lease Commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_MonthlyLeaseCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=igap_PropertyAshkelonIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=igap_PropertyAshkelonIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=igap_PropertyAshdodIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=igap_PropertyAshdodIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6804229264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES (Offering) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_AgreementWithPlacementAgentMember', window );">Agreement with Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments made to agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,000<span></span>
</td>
<td class="nump">$ 1,255,606<span></span>
</td>
<td class="nump">$ 820,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen', window );">Monthly advisory fee owed to Placement Agent from January 2013 through December 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen', window );">Monthly advisory fee owed to Placement Agent starting January 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_DecemberOfferingMember', window );">2010 December Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_RegistrationPaymentArrangementCommissionPercentage', window );">Commission fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_RegistrationPaymentArrangementManagementFeeMember', window );">Registration Payment Arrangement Management Fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_RegistrationPaymentArrangementCommissionPercentage', window );">Commission fee percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_RegistrationPaymentArrangementExpenseAllowanceMember', window );">Registration Payment Arrangement Expense Allowance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_RegistrationPaymentArrangementCommissionPercentage', window );">Commission fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember', window );">2012 Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration', window );">Value of shares to be issued in offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember', window );">2012 Offering [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration', window );">Value of shares to be issued in offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_RegistrationPaymentCommissionRateMember', window );">Registration Payment Commission Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_RegistrationPaymentArrangementCommissionPercentage', window );">Commission fee percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingMember', window );">2014 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration', window );">Value of shares to be issued in offering</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingsMember', window );">2014 Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration', window );">Value of shares to be issued in offering</a></td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly advisory fee owed to Placement Agent from January 2013 through December 2014.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_MonthlyAdvisoryFeeOwedToPlacementAgentFromJanuaryTwentyThirteenThroughDecemberTwentyFourteen</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly advisory fee owed to Placement Agent starting January 2015.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_MonthlyAdvisoryFeeOwedToPlacementAgentStartingJanuaryTwentyFifteen</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_RegistrationPaymentArrangementCommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Registration Payment Arrangement, Commission Percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_RegistrationPaymentArrangementCommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the maximum potential amount of consideration, undiscounted, that could be transferred under the registration payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_AgreementWithPlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_AgreementWithPlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_DecemberOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_DecemberOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_RegistrationPaymentArrangementManagementFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_RegistrationPaymentArrangementManagementFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_RegistrationPaymentArrangementExpenseAllowanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_RegistrationPaymentArrangementExpenseAllowanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_RegistrationPaymentCommissionRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_RegistrationPaymentCommissionRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789337712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES (Litigation) (Details) - Arbitration Ruling [Member]<br></strong></div></th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Mar. 23, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 23, 2015 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Mar. 18, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision', window );">Number of shares of the Company's outstanding Common Stock transferred | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AmountPaidAsRepaymentOfPrincipalAmount', window );">Amount paid as repayment in full of the outstanding principal amount under the Investment Agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 439,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PartialReimbursementOfAttorneyFeesRequiredToPay', window );">Partial reimbursement of attorney's fees required to pay | $</a></td>
<td class="nump">$ 81,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember', window );">ILS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AmountPaidAsRepaymentOfPrincipalAmount', window );">Amount paid as repayment in full of the outstanding principal amount under the Investment Agreement | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 1,767,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ForeignCurrencyExchangeRate', window );">Exchange rate</a></td>
<td class="nump">3.861<span></span>
</td>
<td class="nump">3.861<span></span>
</td>
<td class="nump">4.018<span></span>
</td>
<td class="nump">4.018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PartialReimbursementOfAttorneyFeesRequiredToPay', window );">Partial reimbursement of attorney's fees required to pay | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 316,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_AmountPaidAsRepaymentOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid as repayment in full of the outstanding principal amount under the Investment Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_AmountPaidAsRepaymentOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ForeignCurrencyExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The foreign exchange rates used to translate financial items denominated in the functional currency to the reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ForeignCurrencyExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares of the entity's outstanding common stock transferred under Arbitration Decision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_NumberOfCommonStockOfEntityTransferredUnderArbitrationDecision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_PartialReimbursementOfAttorneyFeesRequiredToPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount required to pay as partial reimbursement of attorney's fees in the arbitration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_PartialReimbursementOfAttorneyFeesRequiredToPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789924480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Description of Rights Attached to Stock) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred dividends paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,061<span></span>
</td>
<td class="nump">$ 370,441<span></span>
</td>
<td class="nump">$ 288,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate, percentages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockStatedValue', window );">Convertible preferred stock, stated value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockDividendPaymentRequirementThreshold', window );">Dividend requirement threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockDividendLateFee', window );">Dividend late fee rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred dividends paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,061<span></span>
</td>
<td class="nump">$ 370,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockConvertibleStockPriceTrigger', window );">Convertible preferred stock, stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockConvertibleTradingVolumeTrigger', window );">Convertible preferred stock, trading volume trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidating damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockPercentageOutstandingGoverningDistributions', window );">Convertible preferred stock, percentage dividend regulation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockMaximumBeneficialOwnership', window );">Convertible preferred stock, maximum beneficial ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockMaximumBeneficialOwnershipSubjectToTerms', window );">Convertible preferred stock, maximum beneficial ownership, subject to term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockConversionPrice', window );">Conversion price</a></td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate, percentages</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockStatedValue', window );">Convertible preferred stock, stated value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockDividendLateFee', window );">Dividend late fee rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsShares', window );">Stock dividend on Preferred Stock</a></td>
<td class="nump">18,986<span></span>
</td>
<td class="nump">168,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockStock', window );">Dividends, Common Stock, Stock</a></td>
<td class="nump">$ 43,858<span></span>
</td>
<td class="nump">$ 390,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockConvertibleStockPriceTrigger', window );">Convertible preferred stock, stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockConvertibleTradingVolumeTrigger', window );">Convertible preferred stock, trading volume trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidating damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockPercentageOutstandingGoverningDistributions', window );">Convertible preferred stock, percentage dividend regulation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PreferredStockConversionPrice', window );">Conversion price</a></td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_PreferredStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Conversion Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_PreferredStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_PreferredStockConvertibleStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Convertible, Stock Price Trigger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_PreferredStockConvertibleStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_PreferredStockConvertibleTradingVolumeTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Convertible, Trading Volume Trigger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_PreferredStockConvertibleTradingVolumeTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_PreferredStockDividendLateFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Dividend, Late Fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_PreferredStockDividendLateFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_PreferredStockDividendPaymentRequirementThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Dividend, Payment Requirement Threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_PreferredStockDividendPaymentRequirementThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_PreferredStockMaximumBeneficialOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Maximum Beneficial Ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_PreferredStockMaximumBeneficialOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_PreferredStockMaximumBeneficialOwnershipSubjectToTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Maximum Beneficial Ownership, Subject To Terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_PreferredStockMaximumBeneficialOwnershipSubjectToTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_PreferredStockPercentageOutstandingGoverningDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Percentage Outstanding Governing Distributions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_PreferredStockPercentageOutstandingGoverningDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_PreferredStockStatedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Stated Value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_PreferredStockStatedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6807984240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Offering) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>May. 14, 2013</div></th>
<th class="th"><div>May. 13, 2013</div></th>
<th class="th"><div>Mar. 13, 2013</div></th>
<th class="th"><div>Nov. 19, 2012</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock', window );">Proceeds from convertible preferred stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_StockPriceAtWhichStockDividendIsDeclared', window );">Stock price at which stock dividend is declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsStock', window );">Stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-cash compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 630,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange', window );">Non-cash charge recorded to finance expense as result of warrant exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,284,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NumberOfWarrantsExchanged', window );">Number of warrants exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,440,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB1WarrantMember', window );">Series B-1 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NumberOfWarrantsExchanged', window );">Number of warrants exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB2WarrantMember', window );">Series B-2 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NumberOfWarrantsExchanged', window );">Number of warrants exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=igap_WarrantsIssuedUnderSecuritiesPurchaseAgreementMember', window );">Warrants Issued under Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares covered by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=igap_WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember', window );">Warrants Issued under Second Closing of Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares covered by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock', window );">Number of Series A Preferred Stock shares exchanged for Series B Preferred Stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock', window );">Number of Series A Preferred Stock shares exchanged for Series B Preferred Stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember', window );">Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,824,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion', window );">Shares convertible into</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,284,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares covered by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,539,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember', window );">2012 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_EquityIssuancePricePerShare', window );">Common stock issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Amount of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,155,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NumberOfSharesOffered', window );">Number of shares offered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">785,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NumberOfUnitsSold', window );">Number of units sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,140.35<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock', window );">Proceeds from convertible preferred stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Cancellation of shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityOtherChanges', window );">Value of temporary equity reclassified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,140,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_OfferingCostsIncurred', window );">Total issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,479,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-cash compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 562,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember', window );">2012 Offering [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ConvertiblePreferredStockConversionPrice', window );">Preferred stock conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion', window );">Shares convertible into</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,597<span></span>
</td>
<td class="nump">1,086,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember', window );">2012 Offering [Member] | Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,295,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingMember', window );">2014 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ProceedsFromUnitsSold', window );">Gross proceeds from issuance of Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NumberOfUnitsSold', window );">Number of units sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock', window );">Proceeds from convertible preferred stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_OfferingCostsIncurred', window );">Total issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,787,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-cash compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 630,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated deficit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsStock', window );">Stock dividend</a></td>
<td class="nump">$ 278,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 278,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsStock', window );">Stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (92)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | 2012 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,136<span></span>
</td>
<td class="nump">654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockDividendsShares', window );">Stock dividend, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Series A Preferred Stock shares exchanged for Series B Preferred Stock shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_AmountOfSeriesAPreferredStockExchangedForSeriesBPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ClassOfWarrantOrRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ClassOfWarrantOrRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Aggregate Number of Shares Issued upon Conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ConvertiblePreferredStockAggregateNumberOfSharesIssueduponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ConvertiblePreferredStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the preferred stock conversion price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ConvertiblePreferredStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_EquityIssuancePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued, price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_EquityIssuancePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash charge recorded to finance expense as a result of warrants exchanged.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_NoncashChargeRecordedToFinanceExpenseAsResultOfWarrantExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_NumberOfSharesOffered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Offered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_NumberOfSharesOffered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_NumberOfUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Units Sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_NumberOfUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_NumberOfWarrantsExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exchanged.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_NumberOfWarrantsExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_OfferingCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_OfferingCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ProceedsFromUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents gross proceeds from issuance of Units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ProceedsFromUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_StockPriceAtWhichStockDividendIsDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Price At Which Stock Dividend Is Declared.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_StockPriceAtWhichStockDividendIsDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid stock dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflows (outflows) from issuing and redeeming redeemable preferred stock; includes convertible and nonconvertible redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element may be used to disclose other activity associated with temporary equity that is not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB1WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB1WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB2WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB2WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=igap_WarrantsIssuedUnderSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=igap_WarrantsIssuedUnderSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=igap_WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=igap_WarrantsIssuedUnderSecondClosingOfSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6786717520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Warrants with down round protection) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Aug. 29, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NumberOfWarrantsExchanged', window );">Number of warrants exchanged</a></td>
<td class="num">(1,440,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesAWarrantMember', window );">Series A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightTerm', window );">Warrants term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 6.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightNumberOfWarrantsExercisable', window );">Number of warrants exercisable</a></td>
<td class="nump">380,953<span></span>
</td>
<td class="nump">1,539,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB1WarrantMember', window );">Series B-1 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NumberOfWarrantsExchanged', window );">Number of warrants exchanged</a></td>
<td class="nump">1,200,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB2WarrantMember', window );">Series B-2 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NumberOfWarrantsExchanged', window );">Number of warrants exchanged</a></td>
<td class="nump">1,200,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ClassOfWarrantOrRightNumberOfWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of warrants are exercisable into an shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ClassOfWarrantOrRightNumberOfWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ClassOfWarrantOrRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ClassOfWarrantOrRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_NumberOfWarrantsExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exchanged.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_NumberOfWarrantsExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesAWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesAWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB1WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB1WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB2WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=igap_SeriesB2WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789308688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Changes in Fair Value of Level 3 Liability) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, Beginning of the year</a></td>
<td class="nump">$ 2,057,618<span></span>
</td>
<td class="nump">$ 8,216,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Classification from stockholders deficit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">400,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision', window );">Exchange of Series A Warrants pursuant to the 'Most favored nation' provision</a></td>
<td class="num">$ (1,586,831)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ChangeInFairValueOfSeriesaWarrants', window );">Change in fair value of Series A Warrants</a></td>
<td class="num">(149,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, End of year</a></td>
<td class="nump">$ 321,695<span></span>
</td>
<td class="nump">$ 2,057,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ChangeInFairValueOfSeriesaWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of Series A Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ChangeInFairValueOfSeriesaWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of Level 3 liability due to exchange of Series A Warrants pursuant to the 'Most favored nation' provision</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ExchangeOfSeriesaWarrantsPursuantToMostFavoredNationProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789899904">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Warrant Inputs) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">105.14%<span></span>
</td>
<td class="nump">105.14%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.99%<span></span>
</td>
<td class="nump">1.14%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightFairValue', window );">Fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Common Stock price, per share reflects the Company's management's estimation of the fair value per share of Common Stock as of December 31, 2015 and 2014. In reaching its estimation for December 31, 2015 and 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the 2014 Offering.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Due to the low trading volume of the Company's Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No. 110.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ClassOfWarrantOrRightFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Fair Value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ClassOfWarrantOrRightFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed upon price for the exchange of the underlying asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6811769920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Non-Employees) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="9">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 10, 2013</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2011</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2008</div></th>
<th class="th"><div>Dec. 31, 2006</div></th>
<th class="th"><div>Dec. 31, 2005</div></th>
<th class="th"><div>Aug. 29, 2014</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>Mar. 13, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-cash compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 630,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities', window );">Amount classified out of stockholders deficit and presented as Warrants with Down-Round Protection within long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=igap_RegulatoryServicesMember', window );">Regulatory Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued', window );">Number of securities issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=igap_InvestorFindersMember', window );">Investor Finders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued', window );">Number of securities issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,989<span></span>
</td>
<td class="nump">45,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.517<span></span>
</td>
<td class="nump">$ 4.305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=igap_InvestorFindersMember', window );">Investor Finders [Member] | Grant Date 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=igap_InvestorFindersMember', window );">Investor Finders [Member] | Grant Date 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=igap_PlacementAgentMember', window );">Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued', window );">Number of securities issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,097<span></span>
</td>
<td class="nump">84,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=igap_InvestorRelationsServicesProviderMember', window );">Investor Relations Services Provider [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued', window );">Number of securities issued</a></td>
<td class="nump">26,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-cash compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,204<span></span>
</td>
<td class="nump">$ 16,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Assumed dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.14%<span></span>
</td>
<td class="nump">105.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Assumed risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.14%<span></span>
</td>
<td class="nump">0.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Assumed exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=igap_WarrantsIssuedToPlacementAgentTrancheOneMember', window );">Warrants Issued to Placement Agent, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=igap_WarrantsIssuedToPlacementAgentTrancheTwoMember', window );">Warrants Issued to Placement Agent, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember', window );">2012 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-cash compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 562,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember', window );">2012 Offering [Member] | Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares covered by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,469<span></span>
</td>
<td class="nump">282,469<span></span>
</td>
<td class="nump">282,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Assumed dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.14%<span></span>
</td>
<td class="nump">105.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Assumed risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.99%<span></span>
</td>
<td class="nump">1.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Assumed exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.80<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember', window );">2012 Offering [Member] | Exercise Price $5.80 [Member] | Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued', window );">Number of securities issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember', window );">2012 Offering [Member] | Exercies Price $6.96 [Member] | Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued', window );">Number of securities issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember', window );">2012 Offering [Member] | Exercise Price $7.00 [Member] | Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued', window );">Number of securities issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTenOfferingMember', window );">2010 Offering [Member] | Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares covered by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,608<span></span>
</td>
<td class="nump">139,608<span></span>
</td>
<td class="nump">139,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingMember', window );">2014 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-cash compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 630,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Assumed dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Assumed risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingMember', window );">2014 Offering [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Assumed exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingMember', window );">2014 Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Assumed exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingMember', window );">2014 Offering [Member] | Exercise Price $5.80 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued', window );">Number of securities issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingMember', window );">2014 Offering [Member] | Exercise Price $10.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued', window );">Number of securities issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ClassOfWarrantOrRightTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from reclassification out of stockholders deficit to liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_AdjustmentsToAdditionalPaidInCapitalReclassificationOutOfStockholdersEquityToLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ClassOfWarrantOrRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ClassOfWarrantOrRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share price that the individual must pay to acquire shares under the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares or units of entity securities issued in the transaction in which equity securities were issued to pay for goods or nonemployee services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=igap_RegulatoryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=igap_RegulatoryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=igap_InvestorFindersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=igap_InvestorFindersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=igap_GrantDate1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=igap_GrantDate1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=igap_GrantDate2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=igap_GrantDate2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=igap_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=igap_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=igap_InvestorRelationsServicesProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=igap_InvestorRelationsServicesProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=igap_WarrantsIssuedToPlacementAgentTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=igap_WarrantsIssuedToPlacementAgentTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=igap_WarrantsIssuedToPlacementAgentTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=igap_WarrantsIssuedToPlacementAgentTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTwelveOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ClassOfWarrantOrRightExercisePriceAxis=igap_ClassOfWarrantOrRightExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ClassOfWarrantOrRightExercisePriceAxis=igap_ClassOfWarrantOrRightExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ClassOfWarrantOrRightExercisePriceAxis=igap_ClassOfWarrantOrRightExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ClassOfWarrantOrRightExercisePriceAxis=igap_ClassOfWarrantOrRightExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ClassOfWarrantOrRightExercisePriceAxis=igap_ClassOfWarrantOrRightExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ClassOfWarrantOrRightExercisePriceAxis=igap_ClassOfWarrantOrRightExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandTenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=igap_TwoThousandFourteenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ClassOfWarrantOrRightExercisePriceAxis=igap_ClassOfWarrantOrRightExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ClassOfWarrantOrRightExercisePriceAxis=igap_ClassOfWarrantOrRightExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ClassOfWarrantOrRightExercisePriceAxis=igap_ClassOfWarrantOrRightExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ClassOfWarrantOrRightExercisePriceAxis=igap_ClassOfWarrantOrRightExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6805183008">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Employees Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 12, 2012</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
<th class="th"><div>Mar. 17, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued to Employees [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted during period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued to Employees [Member] | Chief Executive Officer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted during period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">264,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued to Employees [Member] | Executive Vice President [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted during period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">79,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued to Employees [Member] | Grants To Messrs Gal And Malka [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne', window );">Unrecognized compensation costs expected to be recognized during the years ending December 31, 2015</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo', window );">Unrecognized compensation costs expected to be recognized during the years ending December 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=igap_IntegrityIsraelPlanMember', window );">Integrity Israel Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Maximum contractual term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=igap_ShareIncentivePlanMember', window );">2010 Share Incentive Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common Stock reserved for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of the awards exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,284,500<span></span>
</td>
<td class="nump">$ 23,830<span></span>
</td>
<td class="nump">$ 882,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of the awards outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,284,500<span></span>
</td>
<td class="nump">$ 23,830<span></span>
</td>
<td class="nump">$ 1,143,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=igap_ShareIncentivePlanMember', window );">2010 Share Incentive Plan [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common Stock reserved for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Common Stock price, per share for the year ended December 31, 2014 reflects the Company's management's estimation of the fair value per share of Common Stock. In reaching its estimation for December 31, 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the 2014 Offering.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of unrecognized cost of unvested share-based compensation awards expected to be recognized in year one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of unrecognized cost of unvested share-based compensation awards expected to be recognized in year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostExpectedToBeRecognizedInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share price that the individual must pay to acquire shares under the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveVicePresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveVicePresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=igap_GrantsToMessrsGalAndMalkaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=igap_GrantsToMessrsGalAndMalkaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=igap_IntegrityIsraelPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=igap_IntegrityIsraelPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=igap_ShareIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=igap_ShareIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803288416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Status of Grants to Employees) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">36,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued to Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at beginning of period</a></td>
<td class="nump">450,847<span></span>
</td>
<td class="nump">414,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(19,769)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(17,605)<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at end of the period</a></td>
<td class="nump">413,473<span></span>
</td>
<td class="nump">450,847<span></span>
</td>
<td class="nump">414,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Balance exercisable at the end of the period</a></td>
<td class="nump">293,736<span></span>
</td>
<td class="nump">302,360<span></span>
</td>
<td class="nump">298,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average exercise price (US$)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance outstanding at beginning of period</a></td>
<td class="nump">$ 5.85<span></span>
</td>
<td class="nump">$ 5.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">$ 1.82<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">6.01<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance outstanding at end of the period</a></td>
<td class="nump">6.04<span></span>
</td>
<td class="nump">5.85<span></span>
</td>
<td class="nump">$ 5.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Balance exercisable at the end of the period</a></td>
<td class="nump">$ 5.95<span></span>
</td>
<td class="nump">$ 5.58<span></span>
</td>
<td class="nump">$ 5.55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803932720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Information about Options Outstanding) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding at December 31 | shares</a></td>
<td class="nump">413,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable at December 31 | shares</a></td>
<td class="nump">293,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=igap_RangeOneMember', window );">$1.72 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Minimum exercise price</a></td>
<td class="nump">$ 1.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Maximum exercise price</a></td>
<td class="nump">$ 1.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding at December 31 | shares</a></td>
<td class="nump">21,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life years</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 1.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable at December 31 | shares</a></td>
<td class="nump">21,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life years</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=igap_RangeTwoMember', window );">$3.63 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Minimum exercise price</a></td>
<td class="nump">$ 3.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Maximum exercise price</a></td>
<td class="nump">$ 3.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding at December 31 | shares</a></td>
<td class="nump">3,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life years</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable at December 31 | shares</a></td>
<td class="nump">3,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life years</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=igap_RangeThreeMember', window );">$6.01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Minimum exercise price</a></td>
<td class="nump">$ 6.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Maximum exercise price</a></td>
<td class="nump">$ 6.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding at December 31 | shares</a></td>
<td class="nump">4,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life years</a></td>
<td class="text">2 years 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable at December 31 | shares</a></td>
<td class="nump">4,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life years</a></td>
<td class="text">2 years 15 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=igap_RangeFourMember', window );">$6.25 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Minimum exercise price</a></td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Maximum exercise price</a></td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding at December 31 | shares</a></td>
<td class="nump">351,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life years</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable at December 31 | shares</a></td>
<td class="nump">236,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life years</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=igap_RangeFiveMember', window );">$7.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Minimum exercise price</a></td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Maximum exercise price</a></td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding at December 31 | shares</a></td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life years</a></td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable at December 31 | shares</a></td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life years</a></td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=igap_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=igap_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=igap_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=igap_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=igap_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=igap_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=igap_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=igap_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=igap_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=igap_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6804131840">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Assumptions Used to Value Options) (Details) - Options Issued to Employees [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>The following are the data and assumptions used:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">105.14%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">2.31<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>The following are the data and assumptions used:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>The following are the data and assumptions used:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Due to the low trading volume of the Company's Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No. 110.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The Common Stock price, per share for the year ended December 31, 2014 reflects the Company's management's estimation of the fair value per share of Common Stock. In reaching its estimation for December 31, 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the 2014 Offering.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section D<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6804130928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Convertible Series A Preferred Stock) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of preferred shares converted</a></td>
<td class="nump">10.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.01<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=igap_ConversionOfPreferredStockIntoCommonStockMember', window );">Conversion of Preferred Stock Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock issued upon conversion</a></td>
<td class="nump">1,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Amount of stock converted</a></td>
<td class="nump">$ 5,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,888<span></span>
</td>
<td class="nump">$ 23,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=igap_ConversionOfPreferredStockIntoCommonStockMember', window );">Conversion of Preferred Stock Into Common Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of preferred shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Amount of stock converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=igap_ConversionOfPreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=igap_ConversionOfPreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790646288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and related expenses</a></td>
<td class="nump">$ 803,319<span></span>
</td>
<td class="nump">$ 651,900<span></span>
</td>
<td class="nump">$ 260,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">990,390<span></span>
</td>
<td class="nump">739,893<span></span>
</td>
<td class="nump">562,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Travel expenses</a></td>
<td class="nump">468,126<span></span>
</td>
<td class="nump">200,348<span></span>
</td>
<td class="nump">128,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfPropertyRepairsAndMaintenance', window );">Vehicle maintenance</a></td>
<td class="nump">41,180<span></span>
</td>
<td class="nump">40,087<span></span>
</td>
<td class="nump">26,529<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses, net</a></td>
<td class="nump">2,268,345<span></span>
</td>
<td class="nump">1,849,624<span></span>
</td>
<td class="nump">1,986,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and related expenses</a></td>
<td class="nump">1,303,614<span></span>
</td>
<td class="nump">1,128,672<span></span>
</td>
<td class="nump">1,293,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">525,144<span></span>
</td>
<td class="nump">377,918<span></span>
</td>
<td class="nump">247,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Materials</a></td>
<td class="nump">166,736<span></span>
</td>
<td class="nump">96,699<span></span>
</td>
<td class="nump">154,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">19,132<span></span>
</td>
<td class="nump">16,156<span></span>
</td>
<td class="nump">32,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Travel expenses</a></td>
<td class="nump">39,324<span></span>
</td>
<td class="nump">27,867<span></span>
</td>
<td class="nump">43,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfPropertyRepairsAndMaintenance', window );">Vehicle maintenance</a></td>
<td class="nump">54,936<span></span>
</td>
<td class="nump">25,888<span></span>
</td>
<td class="nump">35,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Other</a></td>
<td class="nump">159,459<span></span>
</td>
<td class="nump">176,424<span></span>
</td>
<td class="nump">179,333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses, net</a></td>
<td class="nump">$ 2,268,345<span></span>
</td>
<td class="nump">$ 1,849,624<span></span>
</td>
<td class="nump">$ 1,986,754<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfPropertyRepairsAndMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs of keeping the property in good condition but that do not appreciably prolong the life or increase the value of the property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfPropertyRepairsAndMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including equity-based compensation, and pension and other postretirement benefit expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TravelAndEntertainmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred for travel and entertainment during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TravelAndEntertainmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790644656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and related expenses</a></td>
<td class="nump">$ 803,319<span></span>
</td>
<td class="nump">$ 651,900<span></span>
</td>
<td class="nump">$ 260,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">990,390<span></span>
</td>
<td class="nump">739,893<span></span>
</td>
<td class="nump">562,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Travel &amp; expenses</a></td>
<td class="nump">468,126<span></span>
</td>
<td class="nump">200,348<span></span>
</td>
<td class="nump">128,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfPropertyRepairsAndMaintenance', window );">Vehicle maintenance</a></td>
<td class="nump">41,180<span></span>
</td>
<td class="nump">40,087<span></span>
</td>
<td class="nump">26,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other</a></td>
<td class="nump">227,160<span></span>
</td>
<td class="nump">185,282<span></span>
</td>
<td class="nump">63,805<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total selling, marketing and general and administrative expenses</a></td>
<td class="nump">$ 2,530,175<span></span>
</td>
<td class="nump">$ 1,817,510<span></span>
</td>
<td class="nump">$ 1,041,140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfPropertyRepairsAndMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs of keeping the property in good condition but that do not appreciably prolong the life or increase the value of the property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfPropertyRepairsAndMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including equity-based compensation, and pension and other postretirement benefit expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of expenses not otherwise specified in the taxonomy for managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51677171&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TravelAndEntertainmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred for travel and entertainment during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TravelAndEntertainmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789066976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING (INCOME) EXPENSES, NET (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders', window );">Israeli CPI linkage difference on principal of loans from stockholders</a></td>
<td class="num">$ (2,521)<span></span>
</td>
<td class="num">$ (556)<span></span>
</td>
<td class="nump">$ 14,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Exchange rate differences</a></td>
<td class="nump">38,873<span></span>
</td>
<td class="num">(25,282)<span></span>
</td>
<td class="nump">94,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Warrants with down-round protection</a></td>
<td class="num">$ (149,092)<span></span>
</td>
<td class="num">$ (6,559,758)<span></span>
</td>
<td class="nump">6,251,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecapitalizationCosts', window );">Issuance cost allocated to warrants with down-round protection</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">390,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expenses on credit from banks and other</a></td>
<td class="nump">$ 15,205<span></span>
</td>
<td class="num">$ (2,189)<span></span>
</td>
<td class="nump">$ 17,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_GainLossOnUnitConversion', window );">Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants</a></td>
<td class="nump">1,284,354<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_FinancingIncomeExpensesNet', window );">Financing expenses, net</a></td>
<td class="nump">$ 1,186,819<span></span>
</td>
<td class="num">$ (6,587,785)<span></span>
</td>
<td class="nump">$ 6,768,959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_FinancingIncomeExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Income (Expenses), Net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_FinancingIncomeExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_GainLossOnUnitConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) resulting from a unit conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_GainLossOnUnitConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Linkage difference on principal of loans from stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_LinkageDifferenceOnPrincipalOfLoansFromStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recapitalization costs for professional fees associated with restructuring debt and equity mixture that do not qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6787837504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAX (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=us-gaap_ParentCompanyMember', window );">Parent Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Loss carry forward balances</a></td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=igap_AdIntegrityApplicationsLtdMember', window );">Ad Integrity Applications Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Loss carry forward balances</a></td>
<td class="nump">$ 20.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=us-gaap_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=us-gaap_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=igap_AdIntegrityApplicationsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=igap_AdIntegrityApplicationsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6811852416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX (Reconciliation of Statutory Tax Rate to the Effective Income Tax Rate) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pretax income (loss)</a></td>
<td class="num">$ (5,842,172)<span></span>
</td>
<td class="nump">$ 2,980,426<span></span>
</td>
<td class="num">$ (9,796,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Tax expense reported in the financial statements:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax expenses (benefit) computed at the ordinary tax rate</a></td>
<td class="num">$ (1,986,338)<span></span>
</td>
<td class="nump">$ 1,043,149<span></span>
</td>
<td class="num">$ (3,428,899)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">31,050<span></span>
</td>
<td class="nump">27,250<span></span>
</td>
<td class="nump">21,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">4,503<span></span>
</td>
<td class="nump">14,415<span></span>
</td>
<td class="nump">10,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Amortization of warrants with down round protection</a></td>
<td class="num">(50,691)<span></span>
</td>
<td class="num">$ (2,295,915)<span></span>
</td>
<td class="nump">$ 2,324,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants', window );">Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants</a></td>
<td class="nump">436,680<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Tax in respect of differences in corporate tax rates</a></td>
<td class="nump">340,263<span></span>
</td>
<td class="nump">$ 278,466<span></span>
</td>
<td class="nump">$ 253,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Losses and timing differences in respect of which no deferred taxes assets were recognized</a></td>
<td class="nump">$ 1,224,533<span></span>
</td>
<td class="nump">$ 932,635<span></span>
</td>
<td class="nump">$ 818,377<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax expense reported in the financial statements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax effect of loss on partial extinguishment of Series A Preferred Stock and Series A Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_IncomeTaxReconciliationLossOnPartialExtinguishmentOfPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51673353&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 10<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Subparagraph 1<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Subparagraph 2<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6792766752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAX (Deferred Taxes) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAbstract', window );"><strong>Composition of deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Provision for employee-related obligation</a></td>
<td class="nump">$ 23,494<span></span>
</td>
<td class="nump">$ 20,220<span></span>
</td>
<td class="nump">$ 33,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Non-capital loss carry forwards</a></td>
<td class="nump">6,233,314<span></span>
</td>
<td class="nump">4,810,780<span></span>
</td>
<td class="nump">4,364,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (6,256,808)<span></span>
</td>
<td class="num">$ (4,831,000)<span></span>
</td>
<td class="num">$ (4,398,095)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790256736">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>INCOME (LOSS) PER SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Income (loss) for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5,842,172)<span></span>
</td>
<td class="nump">$ 2,980,426<span></span>
</td>
<td class="num">$ (9,796,853)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPreferredStockDividendsAndAdjustments', window );">Stock dividend to certain Common Stockholder</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (278,263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Income attributable to participating securities (Preferred Stock)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (596,472)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Income (loss) for the period attributable to common stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (6,289,452)<span></span>
</td>
<td class="nump">$ 1,969,655<span></span>
</td>
<td class="num">$ (10,363,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Number of shares:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Common shares used in computing Basic income (loss) per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,476,870<span></span>
</td>
<td class="nump">5,304,500<span></span>
</td>
<td class="nump">5,325,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Common shares used in computing Diluted income (loss) per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,476,870<span></span>
</td>
<td class="nump">5,349,242<span></span>
</td>
<td class="nump">5,325,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total weighted average number of Common shares related to outstanding convertible Preferred Stock, options and warrants excluded from the calculations of diluted income (loss) per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">9,431,728<span></span>
</td>
<td class="nump">4,557,612<span></span>
</td>
<td class="nump">2,813,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Dividend on Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (57,061)<span></span>
</td>
<td class="num">$ (370,441)<span></span>
</td>
<td class="num">$ (288,247)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Dividend on Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (390,219)<span></span>
</td>
<td class="num">$ (43,858)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In applying the treasury method, the average market price of Common Stock was based on management estimate. For December 31, 2015 and 2014, management estimation considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series B Units (See Note 10C). The fair value per share of the Company's Common Stock as of December 31, 2013 was based on the management's estimate which was based among other factors on the closing price per share of the Company's Common Stock on December 27, 2013, as reported on the OTCQB, which was the last reported sale of Common Stock in 2013.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The Company excludes from the calculation of diluted income (loss) per share, shares that will be issued upon the exercise of options and warrants with exercise prices, that are greater than the estimated average market value of the Company's Common Stock and shares issuable upon conversion of Preferred Stock because their effect would be anti-dilutive. Outstanding shares that will be issued upon conversion or exercise, as applicable, of all convertible Preferred Stock, stock options and warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was anti-dilutive.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPreferredStockDividendsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other preferred stock dividends and adjustments, not otherwise defined in the taxonomy, that are necessary to adjust net income to obtain net income applicable to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section Q<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPreferredStockDividendsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6792783552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Revenues based on the customer's location) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 143,167<span></span>
</td>
<td class="nump">$ 59,775<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 13,420<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_AsiaPacificMember', window );">Asia and Pacific [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 129,747<span></span>
</td>
<td class="nump">$ 27,775<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790234176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES (Details)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=igap_AvnerGalMember', window );">Avner Gal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_RelatedPartyTransactionOwnershipInterestInEntity', window );">Ownership percentage</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount of related party transaction relating to annual salary</a></td>
<td class="nump">$ 123,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,769<span></span>
</td>
<td class="nump">$ 134,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PortionOfRelatedPartySalaryRelatingToBonusesPaid', window );">Bonuses paid to related party</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">61,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=igap_AvnerGalMember', window );">Avner Gal [Member] | ILS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount of related party transaction relating to annual salary | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=igap_DavidMalkaMember', window );">David Malka [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_RelatedPartyTransactionOwnershipInterestInEntity', window );">Ownership percentage</a></td>
<td class="nump">3.07%<span></span>
</td>
<td class="nump">3.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount of related party transaction relating to annual salary</a></td>
<td class="nump">$ 61,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,302<span></span>
</td>
<td class="nump">66,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_PortionOfRelatedPartySalaryRelatingToBonusesPaid', window );">Bonuses paid to related party</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 30,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=igap_DavidMalkaMember', window );">David Malka [Member] | ILS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount of related party transaction relating to annual salary | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_PortionOfRelatedPartySalaryRelatingToBonusesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bonuses paid to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_PortionOfRelatedPartySalaryRelatingToBonusesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_RelatedPartyTransactionOwnershipInterestInEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_RelatedPartyTransactionOwnershipInterestInEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=igap_AvnerGalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=igap_AvnerGalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=igap_DavidMalkaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=igap_DavidMalkaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789178240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 17, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors', window );">Amount of annual cash payment owed to each director</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AmountOfQuarterlyCompensationOwedToEachDirector', window );">Amount of quarterly compensation owed to each director</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AnnualCompensationOwedToChairperson', window );">Annual compensation owed to the chairperson of the Nominating and Corporate Governance Committee</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_AmountOfQuarterlyCompensationOwedChairperson', window );">Amount of quarterly compensation owed to the chairperson of the Nominating and Corporate Governance Committee</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant', window );">Total number of common shares allowed for purchase through one-time grant of options to each non-employee director</a></td>
<td class="nump">26,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_ExercisePriceOfOptionsGranted', window );">Exercise price of options granted</a></td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_igap_NumberOfSharesVestingInEachIncrement', window );">Number of shares vesting</a></td>
<td class="nump">3,333.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=igap_ShareIncentivePlanMember', window );">2010 Share Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common Stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=igap_ShareIncentivePlanMember', window );">2010 Share Incentive Plan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common Stock reserved for issuance</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of annual cash payment owed to each director.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_AmountOfAnnualCashPaymentOwedToEachBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_AmountOfQuarterlyCompensationOwedChairperson">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of quarterly compensation owed to the chairperson of the Nominating and Corporate Governance Committee payable in four equal quarterly installments, on the last day of each calendar quarter commencing with the second quarter of 2016, subject to the chairperson&#8217;s continued service as of each such date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_AmountOfQuarterlyCompensationOwedChairperson</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_AmountOfQuarterlyCompensationOwedToEachDirector">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of quarterly compensation owed to each director paid each on the last day of each calendar quarter commencing with the second quarter of 2016, subject to the director&#8217;s continued service as of each such date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_AmountOfQuarterlyCompensationOwedToEachDirector</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_AnnualCompensationOwedToChairperson">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual compensation owed to the chairperson of the Nominating and Corporate Governance Committee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_AnnualCompensationOwedToChairperson</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_ExercisePriceOfOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_ExercisePriceOfOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_NumberOfSharesVestingInEachIncrement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares vesting in eight equal quarterly increments (subject to the director's continued service as of each such date) commencing with the second quarter of 2016.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_NumberOfSharesVestingInEachIncrement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igap_TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares allowed for purchase through one-time grant of options to each non-employee director.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igap_TotalNumberOfCommonSharesAllowedForPurchaseThroughOneTimeGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=igap_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=igap_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=igap_ShareIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=igap_ShareIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M5H,B:X4B:X4B:X4B:X4B:_5+5C;_U_?Z)U!+ P04    " "W;7Y(2'4%[L4
M   K @  "P   %]R96QS+RYR96QSK9++;L) #$5_)9I]<4HE%A%AQ88=0OR
M.^,\E,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL#C2B]AQ2U\=43'X,J<K]VG2J
ML0)(MB./:<&10IXV+!XUE])"1#M@2[ LRQ7(K8[9K.?:Q<[51G;NTQ1'E):T
M-M,(9Y;AFWE89.D\^(GT%V-NFM[2ENW)4] '_K,- \]YEE<>QW8OG*\M"_V/
MZ'D4X$G1H>)%]2-F Q+M*;V"^GH A3&^.R6:E((C-Z."N[_8_ )02P,$%
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MU#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ
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M5^%OB* U:W\U.WE4M,CW=G1/SJU\8\,W.LXAT0&WK!7FW]N>A63=U>)['?F
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MIY/"[+K^K^RK!'LN..GJX[B%G/:QR_\ 4$L#!!0    ( +=M?DCJ$;,OX 8
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M5_>!Q"<SGSW7U</URZ%^["X?L_[S>7Q/;OS2-2_^M;_KNX?K_P%02P,$%
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MI8U?4H_6H5HHE"C^EE:AXSJE/]MBIMTFY#,A7PF?LF@\-8HVOW#'J]+@1.S
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M[OULB836^O"KBW6\4C&Q.*X/9'NEU3]02P,$%     @ MVU^2#>]XR6C 0
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M8 _:_VG0*.Y\:EIF>P.\CB0E69YEMTQQH6E9Q-J3*0L<G!0:G@RQ@U+<O!]
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M?%FD\HI40( "(A83\5747I$:"(J B,64RR*-5Z31!#=)_J_1@$:UK+'R:JR
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M[&:6&RD_ZI%5)#MVF:09Y=RJ&XL?L)X%/^!=>R9'^H/P8S^)Y(5)-5'JP>_
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MQ@/H$!UX^^SNGI+!OY\UD="Y$#[XV*0KE1*'X_) UE=:_P=02P,$%     @
MMVU^2,M2F[6E 0  L0,  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
MA5/;;J,P$/T5RQ]0 Z%M%!&DIJNJ?:A4]6'WV8$!K-H,M4WH_OWZ C191>H+
MGAG.9<:78D+]83H 2[Z4[,V>=M8..\9,U8'BY@8'Z-V?!K7BUJ6Z96;0P.M
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M[UVLXY6*B<5A>2#K*RW_ 5!+ P04    " "W;7Y(4"*"Y:8!  "Q P  &0
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M$B]"8A^PN@&9--_H9+L(V?J ]0W(I-G<AR2+D,0'Q#<@DV9['Y(N0E(?D-R
M3)KT"P1?_.<,1&V/LT0%'SKE?O-Y=[XQ'B-[3C[E>=:3&GX14;>=1">N]&FS
MAZ+B7('&AP]Q@!I]I\T+"I4RTT3/A3OF;J%X/UU:\\V9_P=02P,$%     @
MMVU^2!38U!FG 0  L0,  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
MA5/;;J,P$/T5RQ]0$T*Z;420FJY6NP^5JC[L/CLP@%7;P]HFM']?7P)-JDA]
MP3/#.6?.^%).:%YM#^#(FY+:[FCOW+!ES-8]*&YO< #M_[1H%'<^-1VS@P'>
M1)*2+,^R6Z:XT+0J8^W95"6.3@H-SX;842ENWO<@<=K1%9T++Z+K72BPJF0+
MKQ$*M!6HB8%V1Q]6VWT1$!'P5\!DSV(2O!\07T/RI]G1+%@ ";4+"MPO1W@$
M*8.0;_S_I/G9,A#/XUG]5YS6NS]P"X\H_XG&]=YL1DD#+1^E>\'I-YQ&V 3!
M&J6-7U*/UJ&:*90H_I96H>,ZI3_%[8EVG9"?"/E"N,NB\=0HVOS)':]*@Q.Q
M P]GM]IZN DB7IEX;]:/'35-'+PJCU5^?U^R8Q"ZP"3B/F%6"X)Y]:LM<GJ-
MGJ<6W]/7E_1U<KA.]&SSO4!Q*5 D@2(*K+/LVH@)LY\Q7X=D9WNJP'3QZEA2
MXZA=VM*ENMS.ASR>R2>\*@?>P1,WG="6'-#YDXT'T"(Z\.VSFPTEO7\_2R*A
M=2'\X6.3KE1*' [S UE>:?4!4$L#!!0    ( +=M?D@=A:\PI@$  +$#   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;(53RVZD,!#\%<L?$//*)AHQ
M2)FL5IM#I"B'Y.R!!JS8-&N;(?OWZP>0F=5(N>#NIJJZVH]R1OUA>@!+/I4<
MS)[VUHX[QDS=@^+F!D<8W)\6M>+6I;IC9M3 FT!2DF5)\H,I+@9:E:'VHJL2
M)RO% "^:F$DIKO\>0.*\IRE="Z^BZZTOL*ID&Z\1"@8C<" :VCU]2'>'PB,"
MX$W ;,YBXKT?$3]\\M3L:>(M@(3:>@7NEA,\@I1>R#7^LVA^M?3$\WA5_Q6F
M=>Z/W, CRG?1V-Z932AIH.63M*\X_X9EA%LO6*,TX4OJR5A4*X42Q3_C*H:P
MSO'/7;K0KA.RA9!MA/LD&(^-@LV?W/*JU#@3,W)_=NG.P;47<<K$>3-N[*"I
MP^!5>:KR)"O9R0M=8"+Q$#'IAF!._6J+C%ZC9X&>?4_/+^EY=)A'>G+_O4!Q
M*5!$@6(9,;\V8L0<5DSQ7Q-VMJ<*=!>NCB$U3H.-6[I5M]OYD(4S^8)7Y<@[
M>.:Z$X,A1[3N9,,!M(@67/ODYI:2WKV?+9'06A_>N5C'*Q43B^/Z0+976OT#
M4$L#!!0    ( +=M?D@*I(^&I@$  +$#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;(U3RV[;,!#\%8(?$$JRG!2&+"!.$;2' D$.[9F65A(1DJN0
ME)7^??FP%+LPT%[$W=7,["P?U8SFS0X CGPHJ>V>#LZ-.\9L,X#B]@Y'T/Y/
MAT9QYU/3,SL:X&TD*<F*++MGB@M-ZRK67DQ=X>2DT/!BB)V4XN;W 23.>YK3
MI? J^L&% JLKMO):H4!;@9H8Z/;T,=\=RH"(@)\"9GL1D^#]B/@6DN_MGF;!
M DAH7%#@?CG!$T@9A'SC][/F9\M O(P7]><XK7=_Y!:>4/X2K1N\V8R2%CH^
M2?>*\S<XC[ -@@U*&[^DF:Q#M5 H4?PCK4+'=4Y_RH5VFU"<"<5*^))%XZE1
MM/F5.UY7!F=B1Q[.+M]YN DB7IEX;]:/'35-'+RN3O4FVU;L%(2N,(EX2)A\
M13"O?K-%06_1BT@O_DW?7-,WR>$FT?/_Z%]>"Y1)H#R/>']KQ(0Y+)B'OYJP
MBSU58/IX=2QI<-(N;>E:76_G8Q'/Y!->5R/OX0<WO="6'-'YDXT'T"$Z\.VS
MNRTE@W\_:R*A<R%\\+%)5RHE#L?E@:ROM/X#4$L#!!0    ( +=M?D@5HQMK
MM0$  !8$   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;(54VVZ<,!#]
M%<L?$ .[VZ0K%BF;J&H?*D5Y:)^],( 5FR&V6=*_KR] =BO4?<'CX9PS9QB;
M?$3]9EH 2SZ4[,R!MM;V>\9,V8+BY@Y[Z-R;&K7BUFUUPTRO@5>!I"3+DN0+
M4UQTM,A#[D47.0Y6B@Y>-#&#4ES_.8+$\4!3.B=>1=-:GV!%SA9>)11T1F!'
M--0'^ICNCSN/"(!? D9S$1/O_83XYC<_J@--O 604%JOP-URAB>0T@NYPN^3
MYF=)3[R,9_5OH5OG_L0-/*'\+2K;.K,))174?)#V%<?O,+40')8H37B2<C 6
MU4RA1/&/N(HNK&-\<Y],M'5"-A&RA? 0""P6"C:?N>5%KG$DIN=^=NG>P;47
M<<K$>3.N[:"I0^-%?BXVR4/.SE[H"A.)QXA)%P1SZJLE,KI&SP(]NTW?7-,W
MT>$FTM/M;8'MM< V"FRG%K^NM1@QQPF3)K>+[%:+[":!]#]%9LR_GX)=#$Z!
M;L+Y-*3$H;-Q;DMVN0*/61C\)[S(>][ 3ZX;T1ER0NN.3YARC6C!E4_N=I2T
M[I(N&PFU]>&]BW4\MW%CL9]OX?(K*/X"4$L#!!0    ( +=M?DB= '<DI0$
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M@E?ER#OXS74G!D,.:-W)A@-H$2VX]LG-AI+>O9\UD=!:']ZY6,<K%1.+X_)
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M.%<1I,U65?M0:;4/[;-#3@):&U/;"=N_KV^P264I]"6^,#-GAN#C<A#R734
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M,UIWLN$ &D0+KGWRL*6D<^]G320TUH=[%^MXI6)B<5@>R/I*RW]02P,$%
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MZA@^$,*QL.:_B$90BE^!85+C Y?#1(RI;HYZPDG7]_KAAZ/X#U!+ P04
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MT.(!5CP<;?"&($$?Z[B'!.A^,+1N@-4-E_PCR$__@98-L++ADN89Y+-!M&8
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MG\9YTNRLJMFTG=NRV[;3R=M4:CT9O[6>/F%XA[D*&-./N0X8VX^9!8SKQ]P
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MW W= H@4!N>D!$Y:=(8(8:!+,M54DD(IV7-7#+2TZ(UZN'X>9*PRC")8$N^
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MLML5K0KGE,[@[(GC+KU&I3/*[Y1D,8DZQIDWCSOMTONOL'G"BPM),=^;1B7
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M+P  &0   'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6R5FMUVVC@4A5^%Q0.
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M(;@!"\'#&#SUH-%D;2>.CI'":LZ2#7"<0$)-K))/8= J$1D<J/US,R/#Z4/
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M0(EHL"\91OVS-(SZ)P=0(AI<_QA&_;.,$'XS':-Y720EHL%>:5CU3Z22DN!
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MN97=NKRA^-+_? Q_0-E_4$L#!!0    ( +=M?DC*%A"&A (  " )   9
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MAN()&A:=>D6G3O2(M&?>M&7CTY9[%>1.0>8+-+59LQB8(6]N+6@Q!K2T( P
M&-8[]>J=GMWXO&16K\4D>9X_!BW&@)935V$T1C $7L5F6:<X'V$">JL,X?@R
M0^17@9[]'ZD[K)#;^&.B]9\#,![>4','4E7$(WX=B/V>\/!6F#N0*C.\SUUT
MU19:RG>F(8M@S0Z=M,=QO]HW_5>DV\K=^EQ?!DR[N9@IBSW9T=^$[^I.!"LF
M5=,RO67+F*1*&9BHX"IU7>DG#=U*_9KIJ&T#MQ/)]N?[2'\I*O\#4$L#!!0
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M>R.E$18-W15ILK.G^[G3BXUQS<JV%1QXT#%R?SJ^S_\AVO]02P,$%     @
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MF=-,GP^N&W072NY/S>VYPZ[^ U!+ P04    " "W;7Y(U%05D1H"  !,!@
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MR*48(S4P^W8D"X-+:V*<([-[90KK/*4K;9$?"YKB'!RMT16#'+/R#+I-E)[
M\#92>61&SP@P&2>#HNN@V =%(2AY;("O#?SD,PX&Z77(WC$SOU//($SFY#95
M!@HB!&]3E:<PIFC^.#*9C$Q"9#JU#/61 X,PQLED:,^5GB-9 F?99&S/58'#
ME!#ZB8>53@9/0_#9G5I[Y@M%*<U@=J?< 2093B"\5_$3B.<9G*>/L]/)[#1D
MSZ9>9L^L/(/GMY'R,5+]A_BDX.(['MB>_V!RW_0J6@MMC@3WY>Z$T-Q8P*<T
MCFISM)\'+=]IVYV9OO2GG1]H,9S.[O,/I/@+4$L#!!0    ( +=M?DA_LN"U
M0@,  -,,   9    >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;)5779.:,!3]
M*PSON^0[X"@S7:73/G1FIP_M,ZM1F05B =?MOV]" JMNC/1%)#GGY-R;K\O\
M))O7=B]$%[Q79=TNPGW7'691U*[WHLK;1WD0M>K9RJ;*._7:[*+VT(A\TY.J
M,D( L*C*BSI,YWW;<Y/.Y;$KBUH\-T%[K*J\^?LD2GE:A# <&GX6NWVG&Z)T
M'HV\35&)NBUD'31BNPB_P%D&N8;TB%^%.+5G_P-M_D7*5_WR?;,(@?8@2K'N
MM$2N'F]B*<I2*ZF1_UC1CS$U\?S_H/ZU#U?9?\E;L93E[V+3[95;$ 8;L<V/
M9?=3GKX)&P/5@FM9MOUOL#ZVG:P&2AA4^;MY%G7_/)F>&%B:FX L 4TE8$O
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M=09-S6U>.GD8/B'&[YCT'U!+ P04    " "W;7Y(3P1MMDL"  ".!P  &0
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M!M,+KE31:;WNM-YF^ :Z+N(\!5XBGK'-<^LF00T#U^JVQ!Z-(;Q%LH#I;'"
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MMG;4.PY:V"@T$;O52Y47S;!>' ._LLMWY?(;M4<'7EQ%3RC!9,4\E-%2\UB
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MI"TIJ#"N_894)#"5(,?S51^CQZB5$@%*:$?1;5ZO;#36-ME-=W-QMY:NIU6
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M]KN8#'[!T&/.8,(C9$%5]X_-'I=AH7:I$[SABF@,5.U>79H9*Y6R"!&]UD0
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M41]RW6%].%6?T6 \Q<1LF"<@/;6NA!;0:?4[K6MC)NH)OVI]1P5:6]1U@\$
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MO/3)[UU".=8BH&$"NM/]0X4IZ1&XR-VF7TB^+;E"^'#P)WF,G)8KHND8\$?
M05+S(]+WG5]4]S+%BV]Z<U&.UK-9O3\-])FR%H)N^W(G4=LK"7YD6A9K>U%_
MU44?JE\A#)SC+;4:P8.O(P@+OK03IWNA<+H-'ZJH>WCM][RS_PDV A^B_%[T
M$%<(Q "91(Z=0+K.68C V@Q]X^;D3$0KV_FWAF#P@2OV)IJH$Q75WE##PZ2P
M'IG_K[UO6VX;2=.\YU,@'.XUM0%R2(#@P1W;$;1$VYK1J22Y:C8Z]H*2((E=
M%.$F2+LT,1<3^PH[3S&7^PC[*/TD^Q_RB,P$05M5.]W;%^6R)2"1AS__\__]
MIXQ!+6*RW&4QQBKF.Z:4$Q+P!*[ZZOP0P["XZ>8B9670%PXX_(FL\"J:ERC#
M)P@V]H"IO9'FK78 4ZA XG/RUC@'63R#A?+<N8&-Q\M%].F<WBF<GO?!P(_U
MYL)2*;5@:Z;JKD/GK)9=D0(F[_(%O$W=E#3<!]V&Q@G(\+8HWL58W&2?!^?%
M\13NDJO!'X.//S0E/P5,J>A-0Y#T>@-;,$_2..WU J"/%B*FC+K438[Q,:W/
M=5O-&J8H]\,:$RG71 $+S@241VXE\G)"[IB@!K@B.QY-TAVJA,AJ<O)USKHM
M^2O#%Z)J[N91,F#C0(LN\L49-49(3JN"#M4P[XUT+$TEY.<6=H&B&"-90'U#
MXDX1,2$WMA4YJ949&T)T*J)Y!GFO_8I0@[8\:BZ:(]#55^J\L\?O',RT ,",
M@\O>;35^MU4/=45>=.'5NWEFB#%5X% +\:65%/R-BX962LMX-YQ<48'J,6ME
MC=/F+Z/+6,&4*0+10&9DT$BHM%+G#UM?:(M @DQ^#(')' B_IXHSB)O%>Z;R
MBV[,/=:;J]VD6'9!/BH9 (\^LF>)FEE) [RX5W Q,1-H$)]-6C(J5T@![D9&
M 2V-8;QU5^B^P52.37%M3,,TL!*1B7,_+Y%JZ.0TBWXY$N^L0H%&?CKO2RX1
M"XV6-?@?)>XP=Q4Q23YFT+6HB"Y2/8CHF#E#E'3_>E2E8NW40L&/I.JG#P5L
M#@4[QCH='PXF[U$ 3'ZD'A))#_AJ<=\1Q)2KSLGDCZ:I*IP?KC01QZ,]@B9@
M#V9DA*!Z+FIZ_FI^*CS!I6**Q,E*1;ZJ/$<F;<DR'<Z2$H,K<QQ+()3;P/1R
M( R4#F2H,%@XY-(?D[EW:,RAPSMI_@ASK#@+OCH3G:TA9&EQ7X5\<HS8FNQ%
MX0/0H$-R/RQ7CMW=@60) 3M7LGQH1@Y2FS-!28L+?_N@=TLPQ#I7MW"3<UF=
MT4%+A%)4T#HS!2?J'V+.%:1?D=XB4BJ,4^(VP5OJH6O!\&'2^U($7S$X2!\4
MB'PJ?8)R4-#OI:HX),;T6C]$'<2QA5?E&5*3Y_@OS,87[2Y67.$G$N$%[@!_
M7GC'JO%>4"9N1 ,_<03^$274V)Q!Z>^Z+2]-T6'F$@@!<PVY9X?5-9N%@0A!
MR%2 N@!/ULLZ&0889WREWM%'+XPKA1"TRL_[RDV@MFC(RRFJK_S0;35XJZ4G
M.4XR"M>\>J\>/-8/OA+%TV6 3S%S$94/=K#)O3;^(2CA0.@*1-$F<6L3.A".
MOPUE <8Z0L>:N0"0X^1.<LK*$@GC45'H%JLGI,-<YHUP0[E 6QF=%R9?-]V1
M,I9*/@H#A4)P49-WWFT5<CHE+7)2C)UU&)8>O($N?G9-\YAU+MKLP=TDGQ';
M6%J%%O%ED'V%D-\J?X)";:I)G[+YS(@&W%$S0\*E/KCL<^[AP2>M2TD-$H(K
MO$:CZEG'3+DAA91KBQ6H)'8FN ;@9#Y6+(N'!4LG7H#]C;>M$S36HG[4B7[8
M%A1'(B3&J+U=28WE@*\][1!G4\I"'N8/V"Z*_%',F<R8+ D*DK0<?Z8* $4B
MCN10*XX>R(U'^AVHTQCA%(M_1D*1D^8-Z(I%)+"(\QMDP!S[X86HF2H!)[8-
M5<,_\YJ+ZOI E]NB"K8&OENHY!R12@J+FLMOIO#-3ZM"?U4,KC)(2 # <C=+
MRK)?%>8H!.V'90R<JB2'-,8P9(#$_@1-VMP.G=W@VTC1_:"V#,?0'LTVE]C<
M@2=D<B@9N%5%.GYU83?S,%MF8'T;1P[+V\?\;@M[)=T,S_F&TZ5U_HDC-PX+
M*APT4'I$[R?L)>CXH#"J5/-\Z[V7;1,9*5T=^SK*PD^U-2Q-PR/S8?+9 1$L
MEL^U'%WF4%:9>C<*IH*+1!T9IB,&^#3_$_9 I098"BU1Y<_897XPG>D3L,/;
M.>)GJ'3>FWR)VH38! \C!N5*JZ+J5[A)Q'C)43TWW<;80^\):TN,W>' A1/[
MYNAA@/$WZAZLDGHXT;:ZGP39Q& B(A I-UY,EU>LBYH*X?^2(L3H]VD30.7\
MK6M4Y*5AG*Z>K5J]XOZ^([[788E2-VXL\P15?9,JOI V;RD!L/5/5%ZO>@MN
M'F$T$CMX$&DOGKO&!9>WGDS]*[I;^O>&?:;\5.C(D_V1N V!^4:E FHY7SQA
M<CJ("V&N:YT#:&M]*SW1K#';:K+I$F-0('S0],0:>9"P[R+U20; E %!YU;F
M>NJ6.<^*OD#TF)=66R!Q"C:JQX(*<V7C&?0A5(3  ]&1Y3;VH)AX]R[7II$9
MHG"SW2V;OOKK:TQAMY[ K/9KU9"#]?OH4,@*AHM%=R[EE-UOEY0JP>E=-'>!
MZCWM)K'\^[M8_Y1[9$GH;_(1<8&[ZI_EN,54AJ#H^^[':AEXFQ@W:</B=!JH
M-J:6&AGCX<Q%#8W"1Y>IZL2E57>2NYQK1V7$33H9!328%)Y5EY;C@I&>&A$9
M%F%@^1VC)IJSK(%!%!R'U>FMR'NPVF+Y+$&$C9U2Z 7K8ED)^%$S[8VI;_MV
MT7C [=G *8Q&EVO=ZH6=,92)?XQ10;@)1B_"UJ?/I+[Q+ZQ$P-H9*82@!RY&
M8<,@WX"53-S"T[W2UH/\1L(!N[QU8K7I07E%$(+H:R33!S[%R0+TBEZ]<%:0
M4X5K:Q1$@G*L&SWAS2:9\,Y3-VJT)>X9>+>$DWRJV_(NN"U\6K7;P)F(7RP5
M432E?OG-:*7=E@'395+.^8K=D&[FF0N>82 :,#,7E@A+%U5&8%QG,>G*)E,Y
M-;E"OU!2/COOU=A*H2WYEAOC<<*#DF;S4F9YU)4XV[R./$&PAS)3E-B%$6B0
M[_NGKG+UYL*&JZ0*:3 &590C&3+K(BQ4E8Q5Z##&(A7.B^_[VI&%J(Y(;J(/
MG%U41(6MV@NG9 /H,2L#7NE.59$L-DKFNCZUP"3(S8\3SY]4*D;.NRC=\M@H
MD3J5Z^515F-K0!J1=*>_S^>4_S4%/> 9+H&5N_(XM\H2>>^U8T15\6-& F:A
M@Z*T6=P*GQ2H@65@+^.J_UH6V:_9:XG1%*G!?LF-_ISW/%L0'XI!UDM(LK)1
M/MA6*VD%\Y\71->B*)GR+N_RFTU%O"P80;6Z#SLW@'B-N0FH!]S=D8M81S/4
M[;(A:>G]H@P2(S*7,E^B!40I%6\>,3U):M)O1-1LR8T,2>*#<I83P-N2%<BI
M[F<0!Z<G]EO9([+X4;"#F\4]*+QBO&59Q,*$GDLH%54_I[BF!7KRS0); AY4
M\9DJL2(Y_;9=]:%Z<AJ/RIKP[],C" C /,D#VCIR&'D;A[ANBC H50TAUAR9
M1DCNMK)NZQ0, ZD?D\$E.VZ7E5]MBI@Q&&0QG"RO].E.MDN>./.3,5K$0, V
M+DHWNB*^O#+L$XJZ8>XSN;9T\2YC"B((UF(S%_"P!?T $U_D3RKQHEOAL+!+
M^&3TSRB!!^(UQZ[,QP D0K4):(T;\HAD([D]A$CJTH/T#+ EM!!F(D5J5T(K
M(/!J!****+_2L+IC7>:*[8[,Y0)3Y+)QPL(E*8RW\$H%H:41: 69C9*_D)05
MBKA ;.4C]W[8VA?BV3I^9GKW.%KVR><3I-]5,_:PNE'ZH)W;X6RP"4,K/./H
M*KG?B*]5R5#2,Q4SVM\H]QN!BZ>UHV6IVT)NXOHW%Z7GQE3OAW'XPI>PXY:Y
MJ&/^^,,1QA\NR0UVH>(/#MP8)E<W?]U2&\RJT$=1&U9*[R-A\O2SSH#K<X^4
M%<.7]2-[?-Y&A\HK!%)ZAN3'//'\ZTI8^YR;[/KF3(-!35TKZ38XJX7*%%T(
MC A$Y216ZWH,CF(K;5ER84][(%B=#O5@2H,1[>'I4#X%NVWH#9V7H^:M8:)\
MLDX]9K$^?@0_H,IHY=&4RA99"N=#J7* I/--I!\(7"2OFU.D5,QE2[B%6;M"
M>KW$Z:B?M_ 3JF4 TQ,%T[:^AMV4?]&'9H#Z?Q40,YXD8$VV;@ZI/\*V<0*!
MD=^4)3M*[Z7,'ZI\EU//UP)=2@19E%EK%)D;W[.GJ5&19$Z$+JM5B5 &A$P@
MPX+=O-]@P'JO$CW9R*EW235<2TS4I#MG%", ZU@56 CHC:'_B-G2#=]%1Z#Q
MRRO9KOW39[*QT.?6Z4VL @?RY&H&0T=R*!I.(7(89E>=SI\-?]W[Z=4[R3F:
M?*S1EZ(VAV"'O>%!U'XUO?HD!WAU &O2_T0S>4EF^1PU[(=E7@%'XH(!+$HL
M53F1F**9VFY[LNU9W:I94<W8%@L[\CNJ-$/+0D33?4GRLD;6A'%9B SP#C)F
M:L$EG\+8LUX8:2\J?8'2F$4FK4AE0!%+ $Z,]:#\U,+M9VDF<T8GE7H<1?ES
M+DS@-/_"CVC)U9SHW]PH> ]2HF/A-8AE4VI*2I/5J]+GHAL\&^I5HZV&0U[Q
MHI\QRX"D 28#B2B PH^GJPX\%G>.E2SJTG9?"=1CCB/'V,NW41\KM#;KPFBH
M($%T&7V[B@AI>+T8GA,+6LN%X(WX+B4(2I?N9P+DN246_QET,!8+6/V=N%_6
M3$]GC^ML/,%@A29)Z24FC;AY\#+92W)FX802G/E>U$_CM&G.LD/EAE0ZU/L7
M1CX"&59$A^((7$1Y%2C1^34EI6!6,X_FLFS5@K,U%H-W9$-IV!R_]_"2TF F
M60?+"U\UXR8= 1R Y@23QDQ9ND<PX*M8M,KXO+U9$O8B;E'L(3;KAJY-BYDK
MI%:,&UI!%#6<7*P]J]B'J+@;V1P"W25/ZF7E\I]O7-(D'\?] BZH"3\LJKRI
MT@^&'ZO@A= /#A!J&=U@:Y-"*"J'NMN&\RPX1E;<?_NZAKYUN</4K="N&?."
MW[-56H-];PD,+D'?B2]'<8T=1#CHX#H)2X<8A KXZK2$*S7@7_[MWS\4W&*)
MX$F%-!4QL<8"U?W^MWP\:E]M;S8D8Y,>FAP';Z,C*T7NDV+F%*V\P58D<\O>
MF&H&>"@[-)&R7_F2%M_]S!+?_4Q79R@XB6)5;?6+-@SJO+KRU>AV(#'+\(]<
M9N'<+9031P;5W#QYY><6C6S7\T5IF:W170%[))9.EH9>^URO_=9:NXU *PA;
M]4[1MK/V<O,%#N%M,AVTB_7WCZ7BUK)&D\?FK%<5K*@<D-TL3YV2T=6;_9G"
M^VF(@:KA5VW@K++?^(8'^"Q.P>&S='S,DP0;%"[^(!>276RLMTI1W6ZSVXW1
MWV;&7N( BWQ1U@0+;<J:"#1!'( E=]/=^CYN!CD7V$C'YW[25RCZB"JME*.D
M+T<?GV_6B[O(EX(K+1"Q[O<%=U.92XCX,CI%K]%4A!..\ALJ98>_*C\%LL S
M!%SC4K-OL2IP20%GB;0CQOT,&=Q_BD5;#''XZJ">_(>85[/&H.!C\549&PK>
M76IF5(1&N#BY0,VJ=(1I%I&:1U:TA/?BD??"Y^X0<3I5RR+VY%[M"7E0NM&5
ML'50E774*KE ]A95U7[)N*G^0^,T>P)?6M.P@C:&0T-& &YR<AP(X$OF##)B
M0Q:4NW]L]NBD#V.7NM%[KK?'V%G]ZE:%M%*Y\]!:!R5HL1(;:D%).<*/MF=$
ML3*WRSE.+=ZU",Q$I*(T7;[4^(MX8 A0&Z83T;M-[PJ)%7-KZO>\0I>Q2R;,
M:.DU(<*U3ZV&:J+VHIMW#71,)!.8=;YZV#QJ+)6;#6%"D4(A?8 _^\*OE M=
M&V8Y8($KR1K7BC<;<6:Q&%$$-]V1Q1;J (R8W%ZK%9N%?C+9;6>NIF)UEZ\>
MNOBQ9TP=</T]OVD%E3CC6;M;ZY@)!N9T4=S\EG6*WRM/KZZ^ XV,\P(D*8='
M=5I $KC7XK$H[C1XBSOR+JXLO!$%EZ4I[XS,7Z=EK#DT6*P%G"&WP8SK9EL=
M(LA2=TW/T9F$:7N#7A*\*6K.^$O#7E28/P$CM* $7_/Q749@%K4UZM@P8(J"
MEG7'(7^3D<N?">@W>U*QK8Q5W!MZS-)CQWL&(W@3 [!=2U:-2FN@8NFT%>%L
M,DQNEHH2-4G\R_P:'Y^!IV@X>FC)LN8M>,!Z=C+&2*T .>J58^&3X6?2/0$I
M;YMX3AT-UI)>TTW <];WWN3])FU6/&)A=X2X:HJ[L:M.MFQI!3/@?7$VO8V4
M-43%RJ2:,P.S4F6=U >S"4DUB0Q3B.K55?9;(<P0Y?/<J_+&4[O60P*G2QT9
M>R9+B*;KJH(,"T*T(C5\T[&E>IRF/</-CF,8=CK^4[O9!3'+ 8QTU/*V^)Q+
MV!IE*-Z8Q5@^U'?"RLDE+C29IZ(22T]3C< N7NS6UD%&2GZO#IKG[9/C]^<'
M.KN(4"J->0J,T_;E\>F!+E"G,\\U3E[^U7#&7Q"!"0-7A88T_?!6&ULQ+W<L
M50/<M[^2NT(&OHP^L'/T=WQ6?3$9>%QX4&]S[J$B:O&K.\9B>5D4Z^ 3#,8-
MBU\_*0PWG 5<8SCP]WOY0(DNK+L<L[WPV;C.8/2O4/O\+N^HUXOX<M[1T4Z1
M9'.B /\S1$IXL2_H,N![V=2;^3U]UZZ1@DJG[]J5+/^".:E6(C)I"NV.*CA(
M],O3\FT)Z\G_VZO/ OO_U1]^DV8E4=WDK18 ,]TA0.'+F[C^3B3W/R$(_1GV
M+CZ_;'IXBM$ZJ2ZJV4XK<#279L\-="7'PT$695F<9:/63Y7&&5G6C_M M'"A
M!]D$:_?L'AI1-HD'PU$$?'68CEIC>"Y)TFB<QL,L=8!FKC_.+J/#3Y>7V*UY
M>G4UNVY(JN3W.12>E*D7EW_WPB^P#')A=)3+1G'2&T:#8=R;#%H&<MBQKKF+
MVO_U($KZB)<XC(:C>#08MY+A.!Y-$EAT&H\'20L>:5W*<K52P0+-[[Z@_/$C
M1E509 E#>@L"3Q9DKS6ZT%=6I9PAA B40_Q(XF)*#I1K>SBW0.GR_&)V>?W?
MH^G9433[X=/QQ2D<21R=S:X;'8C_^NU_)/K")8->W!L.HWXRB/O#_J[;E_1Z
M<3881_WQ($Y'D\!%C-(D'D_&49+$DTG2&HS2..LG<+GA.-,$7@(*_\N__:]P
M)XUVDJ5Q;S")0-=*>A/X:S\Z:"5)#X@^A;DF\6#2KR?SD^/IN^.3X^O&;-FB
M]1-=S=V(,^_><@,'F, 6EJ)#DE%EBF>19K!MO0%L7P_58P('T\!]JDBP/Q[%
M60*/IED\'@U:@V04C^&F#&"(T7#@\/##\]/3\[/HZOK\\)_BZ.)R]GX&VW3$
M/R!J_&EZ>0EB[2KZZ?CZ8^?H_*>SZ!+DVQ$\?'X].[P^AM>;[..ASD@B!(L?
M9>:EK )7F-.--O;:3G+:>!,ZY=!&%A8;7Z(!4M2&5_41';QUTQ)#Q_:.ZTGB
MZ%W5@&.=*.X!-QOVQ]$X3H )CWI9RZX?])2(R_J.3C2 ZS0<]5M*%8"QW8S)
M*@0VF$2GJ"3?S[\4J$&O)-2.MMZB-G'.>)S"Q8DZK4.1,[JJ[)ZG1*P_@/L&
M7!:NWA!DTR0> 4D>Z(V8$5_@Y:<)R)])9FQ#'6D8]# U^G1^*O,[IU03EOES
M_NR#@C 6(&'":1C./3.:7CGET\Y/!JTC@3 6/2\0OZ3].]@LV*Z9A&C]4N#P
M1%+X.Q1*_5[6[0_$_UJ76.)]O\Y%4(&*95#9PJ=[W<DDZN-3:CSV96N0JS9I
M)3@PBKMNTHM2^ .>MQ(>VP;M1EEWW*,_& /']PB,1L/!X>,?)I2,]5RO.Q[@
M!%,2I4>Z*&>);M;UG*P(V(+M4X/* G)O>_8-338KL_1Q@?X]ROHQ'I,^6F--
MN$_$[82=Q5WHE/-0M/=4P%!SRF?DE#&$2]MP?K,QZVX+]]E<Z#U[,H0-JN!V
MK2IV(W?,F+K*247 B\KJZ90K919V%67);@=T/PF ,1\&41A]F1"7^SU:$*Q(
M6$JZ]H<V,#:@VH1CKG0.L1IKYJH2PYMCW#<]7%'!^IOO "R@7-<U)HZ18;JQ
M/H0V91U<IE'$H7,3**T.N;&(32(T'=8W:*08;B^=BXY'\,3ZKH-(?,_&,V#P
M/IG);X\<*$4CC0(.KC%H\#->NH#)G:(5[THUXF3&!TB RBPY]!-NGYY$;P(B
M8C!#M\IH%LAH)FA;+'2RM>PWH?J@[SB!MZTS2@QO_50%<LP=9O/Z(-07D_GH
M.UED:11>SC>VC4_R89#U0%,?(;O*6A\$7!HS6/XFL-P^2)@A:GK][CA!QPJ"
MFM$O0*+T,OC%L-OKA[Z9K^XL@3P VP#T37Q'"6^YPKF!YE-]+YFD\2@=PDPG
MV8OMU&"/G0)"YYT";4[NU&! _>!'W5[/V#'</V.;QO0,[E(2/!EGE\QSV6.7
MTEX2IT,4/YG3U#1T,V*\?TJ@7=#.7:(VTEC_<ZX/7QKLKF*"3G#VD8*/M'?
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M#!"&O1+X9C.RLJ5(Z+!>B.W_M+O2Q98(KZ-_")D/VP>PBIA!.PX.E?LC4UV
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M365$[O *+ N5MAG:[DJCS,+I-[I+0XXP)=$*OO]#66[^\'\!4$L! A0#%
M  @ MVU^2*8%%-8Q @  \RL  !,              ( !     %M#;VYT96YT
M7U1Y<&5S72YX;6Q02P$"% ,4    " "W;7Y(2'4%[L4    K @  "P
M        @ %B @  7W)E;',O+G)E;'-02P$"% ,4    " "W;7Y(8=AS8F "
M  ![+   &@              @ %0 P  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " "W;7Y(B!H@WNH#  "#$0  $
M@ 'H!0  9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +=M?DB<CA%-/@$
M &D#   1              "  0 *  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( +=M?DB97)PC$ 8  )PG   3              "  6T+  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ MVU^2%ESK &" @  #@X   T
M             ( !KA$  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "W;7Y(
MJMZE9:H%   Q%P  #P              @ %;%   >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ MVU^2.B%'5N* @  ?PD  !@              ( !,AH
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( +=M?D@JM!Q"
M<@0  !@5   8              "  ?(<  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " "W;7Y(ORZVU'P"  !%"@  &
M@ &:(0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ MVU^
M2-U6*3ZJ P  TPX  !@              ( !3"0  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( +=M?DCJ$;,OX 8  (<H   8
M      "  2PH  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" "W;7Y(KU[W4&,%  #[&0  &               @ %"+P  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ MVU^2#@*65(T P  7@\  !@
M             ( !VS0  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( +=M?DB" % 9H0$  +$#   8              "  44X  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "W;7Y(^%E0H:0!  "Q
M P  &               @ $<.@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ MVU^2!D\4/RB 0  L0,  !D              ( !]CL
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "W;7Y(POR)
MO:,!  "Q P  &0              @ '//0  >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( +=M?D@+2 /8HP$  +$#   9
M  "  :D_  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
MMVU^2.QTM>RD 0  L0,  !D              ( !@T$  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " "W;7Y(%$5L>Z(!  "Q P  &0
M            @ %>0P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( +=M?DCW*<PHI $  +$#   9              "  3=%  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ MVU^2/G(1J6E 0
ML0,  !D              ( !$D<  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " "W;7Y(5;' C:(!  "Q P  &0              @ 'N
M2   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( +=M?DA#
MU XFHP$  +$#   9              "  <=*  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ MVU^2.ZWE=^D 0  L0,  !D
M     ( !H4P  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +=M?DCKM!)<HP$  +$#   9              "
M >)5  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ MVU^
M2#Q+;1&D 0  L0,  !D              ( !O%<  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    " "W;7Y(4(468<H"   J#   &0
M        @ &760  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( +=M?DB3E6$?L $  !8$   9              "  9A<  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ MVU^2#;HSD^F 0  L0,
M !D              ( !?UX  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    " "W;7Y(S@.?(*8!  "Q P  &0              @ %<8
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( +=M?DC+4INU
MI0$  +$#   9              "  3EB  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ MVU^2% B@N6F 0  L0,  !D
M ( !%60  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "W
M;7Y(]!V9:]T!  !%!0  &0              @ 'R90  >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( +=M?D@4V-09IP$  +$#   9
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M  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ MVU^2)T
M=R2E 0  L0,  !D              ( !BF\  'AL+W=O<FMS:&5E=',O<VAE
M970S-RYX;6Q02P$"% ,4    " "W;7Y(BH<(4*8!  "Q P  &0
M    @ %F<0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M +=M?D@A.>3B'0,   <-   9              "  4-S  !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ MVU^2$9Y L+> 0  P@0  !D
M             ( !EW8  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    " "W;7Y(BE FA @"  "U!@  &0              @ &L>   >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( +=M?DBT;?+;Y $
M ,$$   9              "  >MZ  !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ MVU^2*7E;W;V 0  -04  !D              ( !
M!GT  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " "W;7Y(
M2DQ0@/$!  !<!0  &0              @ $S?P  >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( +=M?DCA_3ZG*0(  "0&   9
M      "  5N!  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ MVU^2!QB%=K) @  :@H  !D              ( !NX,  'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " "W;7Y( KST+=8!  #3!
M&0              @ &[A@  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    ( +=M?DA$C3@^O $  'L$   9              "  <B(  !X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ MVU^2'2-352G
M 0  L0,  !D              ( !NXH  'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    " "W;7Y(V\B6"6L"  !\"   &0
M@ &9C   >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( +=M
M?DBZ)Q81J0(  !@+   9              "  3N/  !X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ MVU^2+V4^:?W @  LPP  !D
M         ( !&Y(  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
M    " "W;7Y(+KA6_CH"  "5!P  &0              @ %)E0  >&PO=V]R
M:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( +=M?DA8",:(C0,  &00
M   9              "  ;J7  !X;"]W;W)K<VAE971S+W-H965T-30N>&UL
M4$L! A0#%     @ MVU^2*YWBRC6!0  K2(  !D              ( !?IL
M 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " "W;7Y(NX(8
M!*("  !!"@  &0              @ &+H0  >&PO=V]R:W-H965T<R]S:&5E
M=#4V+GAM;%!+ 0(4 Q0    ( +=M?DA58;6G)@(  #<&   9
M  "  62D  !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @
MMVU^2#3LCB2_ @  O H  !D              ( !P:8  'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6Q02P$"% ,4    " "W;7Y(TBP16O4&   5+P  &0
M            @ &WJ0  >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4
M Q0    ( +=M?DB'?SG?E@,  (T0   9              "  >.P  !X;"]W
M;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ MVU^2"/@J/82 P
MJ@P  !D              ( !L+0  'AL+W=O<FMS:&5E=',O<VAE970V,2YX
M;6Q02P$"% ,4    " "W;7Y(N)@L>:X#   #%0  &0              @ 'Y
MMP  >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( +=M?DC'
M$QS^#0,   T-   9              "  =Z[  !X;"]W;W)K<VAE971S+W-H
M965T-C,N>&UL4$L! A0#%     @ MVU^2,H6$(:$ @  ( D  !D
M     ( !(K\  'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +=M?D@#3IKP"P,  &T+   9              "
M ?',  !X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ MVU^
M2-14%9$: @  3 8  !D              ( !,]   'AL+W=O<FMS:&5E=',O
M<VAE970W,"YX;6Q02P$"% ,4    " "W;7Y(?[+@M4(#  #3#   &0
M        @ &$T@  >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0
M   ( +=M?DA/!&VV2P(  (X'   9              "  ?W5  !X;"]W;W)K
M<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ MVU^2!65CS7  @  \ H
M !D              ( !?]@  'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q0
M2P$"% ,4    " "W;7Y(;XTI0D8"   ?"   &0              @ %VVP
M>&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( +=M?D@"!2Z'
M<9\  #]\ @ 4              "  ?/=  !X;"]S:&%R9613=')I;F=S+GAM
7;%!+!08     4P!3 +<6  "6?0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.1.900</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>212</ContextCount>
  <ElementCount>326</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-daei1</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cbs</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cbsp</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/Statement-CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/StatementsOfChangesInStockholdersDeficit</Role>
      <ShortName>STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-csocf</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-csocfp</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-g</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-sosap</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-i</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-oca</Role>
      <ShortName>OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-paen</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-ocl</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - LINE OF CREDIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-loc</Role>
      <ShortName>LINE OF CREDIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - LONG-TERM LOANS FROM STOCKHOLDERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-llfs</Role>
      <ShortName>LONG-TERM LOANS FROM STOCKHOLDERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cacl</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cspsawwrp</Role>
      <ShortName>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-rade</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-smagaae</Role>
      <ShortName>SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - FINANCING (INCOME) EXPENSES, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-fien</Role>
      <ShortName>FINANCING (INCOME) EXPENSES, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - INCOME TAX</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-it</Role>
      <ShortName>INCOME TAX</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - INCOME (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-ilps</Role>
      <ShortName>INCOME (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-si</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-rp</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-se</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-sosapp</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-sosapt</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-sosap</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-it1</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-i</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-ocat</Role>
      <ShortName>OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-oca</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-paent</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-paen</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-oclt</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-ocl</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cspsawwdpt</Role>
      <ShortName>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cspsawwrp</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-radet</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-rade</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-smagaaet</Role>
      <ShortName>SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-smagaae</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - FINANCING (INCOME) EXPENSES, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-fient</Role>
      <ShortName>FINANCING (INCOME) EXPENSES, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-fien</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - INCOME TAX (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-itt</Role>
      <ShortName>INCOME TAX (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-it</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - INCOME (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-ilpst</Role>
      <ShortName>INCOME (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-it</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-sit</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-si</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - GENERAL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-gd</Role>
      <ShortName>GENERAL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-g</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Functional Currency) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-sosapd</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Functional Currency) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-sosapt</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property and equipment, net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property and equipment, net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-sosapt</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Liability for employee rights upon retirement) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesLiabilityForEmployeeRightsUponRetirementDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Liability for employee rights upon retirement) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-sosapt</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Royalty-bearing grants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesRoyalty-bearingGrantsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Royalty-bearing grants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-sosapt</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-id</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-it1</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-ocad1</Role>
      <ShortName>OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-ocat</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-paend</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-paent</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-ocld</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-oclt</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - LINE OF CREDIT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-locd</Role>
      <ShortName>LINE OF CREDIT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-loc</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - LONG-TERM LOANS FROM STOCKHOLDERS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-llfsd</Role>
      <ShortName>LONG-TERM LOANS FROM STOCKHOLDERS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-llfs</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Grants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cacld</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES (Grants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cacl</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLeasesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES (Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cacl</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Offering) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesOfferingDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES (Offering) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cacl</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesLitigationDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES (Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cacl</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Description of Rights Attached to Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cspsawwrpdoratsd</Role>
      <ShortName>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Description of Rights Attached to Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cspsawwdpt</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Offering) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cspsawwrpod</Role>
      <ShortName>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Offering) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cspsawwdpt</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Warrants with down round protection) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cspsawwrpwwdrpd</Role>
      <ShortName>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Warrants with down round protection) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cspsawwdpt</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Changes in Fair Value of Level 3 Liability) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/CommonStockPreferredStockAndWarrantsWith-downRoundProtectionChangesInFairValueOfLevel3LiabilityDetails</Role>
      <ShortName>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Changes in Fair Value of Level 3 Liability) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cspsawwdpt</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Warrant Inputs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cspsawwrpsowid</Role>
      <ShortName>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Warrant Inputs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cspsawwdpt</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Non-Employees) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cspsawwrpgtnd</Role>
      <ShortName>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Non-Employees) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cspsawwdpt</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Employees Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cspsawwrpgtend</Role>
      <ShortName>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Employees Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cspsawwdpt</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Status of Grants to Employees) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cspsawwrpsosogted</Role>
      <ShortName>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Status of Grants to Employees) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cspsawwdpt</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Information about Options Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cspsawwrpsoiaood</Role>
      <ShortName>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Information about Options Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cspsawwdpt</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Assumptions Used to Value Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cspsawwrpsoautvod</Role>
      <ShortName>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Assumptions Used to Value Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cspsawwdpt</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Convertible Series A Preferred Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-cspsawwrpcsapsd</Role>
      <ShortName>COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Convertible Series A Preferred Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-cspsawwdpt</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-raded</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-radet</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-smagaaed</Role>
      <ShortName>SELLING, MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-smagaaet</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - FINANCING (INCOME) EXPENSES, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-fiend</Role>
      <ShortName>FINANCING (INCOME) EXPENSES, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-fient</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - INCOME TAX (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-itdtd</Role>
      <ShortName>INCOME TAX (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-itt</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>00000069 - Disclosure - INCOME TAX (Reconciliation of Statutory Tax Rate to the Effective Income Tax Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-itrostrteitrd</Role>
      <ShortName>INCOME TAX (Reconciliation of Statutory Tax Rate to the Effective Income Tax Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-itt</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>00000070 - Disclosure - INCOME TAX (Deferred Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/IncomeTaxDeferredTaxesDetails</Role>
      <ShortName>INCOME TAX (Deferred Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-itt</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>00000071 - Disclosure - INCOME (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-ilpsd1</Role>
      <ShortName>INCOME (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-itt</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>00000072 - Disclosure - SEGMENT INFORMATION (Revenues based on the customer's location) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/igap-sirbotcld</Role>
      <ShortName>SEGMENT INFORMATION (Revenues based on the customer's location) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-sit</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>00000073 - Disclosure - RELATED PARTIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/RelatedPartiesDetails</Role>
      <ShortName>RELATED PARTIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-rp</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="igap-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>00000074 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/SubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/igap-se</ParentRole>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>igap-20151231.xml</File>
    <File>igap-20151231.xsd</File>
    <File>igap-20151231_cal.xml</File>
    <File>igap-20151231_def.xml</File>
    <File>igap-20151231_lab.xml</File>
    <File>igap-20151231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>95
<FILENAME>0001178913-16-004924-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-16-004924-xbrl.zip
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M0QGZ6)7ZCD2[^7HDUT/O;R>LEXZ*]EW1+HP^-8XR]-&)=L*9RNC+A@R:,]=
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M1U(FZQKA%IT;(V83YAJZ_G)0IP9R&=\SY9TA\$[/%Q ;2AB.\3Y98 OQ=\L
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MX9Y_:HI"*E7X:'"O:[ )HM8Y*V1,4)N7>4T3A;3=M7?PP^ HU,; ]DU>U[8
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M%VL-+[.X]GIKPX>'5DO#1T*03PA!/FV"WUGZC,073Y_AG\C.CGY[?',>7YS
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MK%DY+,)Q.[]W5KJ%&>G1N9UY:Y[&Y0EGJW]>73\DH#8M;PMJ. +94K0+FWR
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MX=#&!5"BI;]'I+$5_HCSQCVL^'=6>(8[Y3(Q*0%C"0RO@1R7J-,R.EHN.A%
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MUEI)[-ZUVC PCQFX**LE=Y*]I8*2DW [N[69?;*M?L27)&3OWRZQ5I"_09)
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M\A,'[R<KOK8 5-=X]R@[M_('CH"8I<3F=@;(4>!=0F0>*=Z%XI+<6V2ZHSK
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M32N1?T5>@?,$A]J\(EQ8K6P/'XG7)*FP!MX!T/="'J*@<4H1>3;\$SQYZ*\
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MBV4 YRA-:AD0&P\@)X 7V0DKTZP6RL%CY6".%R><?.0=/&C3GXJ=#@+7-OW
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MC=(\/$<;RB0V=_I>2X\J)\9V&#;/MB;<!)%$0&$8<$X)(FXL@)#,A!<=9O-
MP2*NJ8VECLD978R$,> &OCKS"#RO:%.T,;R:"T5V:&1C\4SH@SM%$AB\#:2)
M!)AT9\TXS%T\92+?:+0/R)J%PB[D:KSD> N$RCZU%*FE6%[/2N5D[?I>B#*"
M-Q!\A\^IZ,P*KQ?C>\RT'VK_X;FKPB5=-+%@#74M \UA.X0&X,[F#W4C%T5Q
M"T3MP4-8<$9:H>*##[0_3/QG=+"F;RNW%+?H&;*M[3BE8T8 P][0\-C T1$X
M+,UUB ,YME5C%VSDR5R % L'W0)ZDKBT7_MLD^E/)#8/T EGBV$)L<'WV+ (
M)X9ID3+IL0MR4^XAZ]@),?KJQAE49$PX*O,P*T?:YI:R!B4/RI.IE@*SG4!S
MCSR$I7 B1).,LE@& .N#,_??8%7'EDL3?SS4#4'K2I24QYN\C"RA3!)FN(R>
M\:/-F-E_+ \W8R8+YON+AXOI_=F_DW29\XO?+JYO[W#^#'/Q7W<7-P_O(%DF
MB\Q--?!M-;=NST8IJ(PHBYT4>'X'W0PYMFQ]4T$LK.M<0:8-KO$;[>#;1OLW
MV*A#WI/CVGYCWEY_9'M2>MYK(]Y6]/RC?4]I-U_:S9=R->WF2[GZO7&U0+DZ
M2YN*)VV_V:M<5AT?7C^[!QVL7!.E>[W&]Z2'>#=IE\RCZY+)3016F,A9I^A0
M[++>6^0,EBV&1=D>>9CCU8FL\)2'*0^/EH=Y39BP<D;+FF/BX5[Z%8]8E;O;
M#I2CZMMPF'D 8D/BI0DG4N6-<O!8.5A0E(G&==S^FG(PY>#FFE*+N/'LD7,P
M]<)5)>[7J.0]5=D&Q,8#$!><+$\4H>,^U?3 HQS<& =K\D36,AH+4 :F##P*
M!N8D<2+Q1^XNIJZV:J0]1TL7S4R2Z415MN'P\1#DA3;AA",7%Y2!>P>V39MC
MPDG4Y* ,/%8&%OB)*E$7&W6QI8C[Z.JOR**A;0-DYB'(#&TB\/1JE#+P6!F8
M5R;JL0<$40;N'=CV&%@4P&[.J*=Q3 Q,W6S52/L;>C%G%DJU.Z)ZVV#8>0!2
M0Q(G&KT?I0P\6@;FI>./!Z(,W#NP+5K.TD23,JH%'!,#]^=MRTFM'9\Z=XM+
M37:LP'51&:59F9*?JM[_9J@D<ZH@TV3,AC81I8ZCC@;&:72OT+U2:J\H\D3L
MVO4],$ZC>X7NE7)[19L(0D:YE:/?*TUX+NMHNV*O9>P:D0O-H]"!7 "@&<,)
MGBQT#()A'S8-NG$FO*Q.!+%C0WA@W$;W"]TO94M8J*(VD?O7.^E^H?ME%/M%
M4^6)(NW?+VDE+=&F(.EB2WS>=%NIW2\E;KQB/L,H#V$WKB]A]RT88)KJO741
MQMVMWZ6]5FBOE6J]5C)R*FBOE0VFN5A%B]]XKY6'B^OKJYLO$^;K]/X?%X_P
MD71=^7)Q<W$_O2:?I^=?KVZN'A[OIX]7OUW0)BRT"0LM0I];V)@V8:%-6$JY
MX6IOU"'OR7%MOS%O+]J$I>%M1<\_6MB?-F&A[2HH5],F+)2KWQM7TR8LU$AI
M\8:BUI;K <[Q!GG3]:?K3]?__:X_+:E2E;BT=]A(6'L :6(J*TP$CA:"I1P\
M5@Z6)6ZBL2SE8,K!(^5@7F8GO'+DU1)HC95JI*5=PP;,S ,0&IK&3@2-'GN4
M@\?*P8J@352MXZP]RL&4@YNK<B7S$U&@15:H_RVKI'%(8T']F?K>!LC6 Q ?
MHJQ../[([3[*P;T#VZ+G@@4C1*1E\B@'CY6#.5Z=L!I5X:COC=8W'@L[#T!L
MB-R$4ZGSC3+P:!F8G; J[4M!&7BL#,S+$XD_\K@56M^X$8K3^L:T#F4G=2AY
M7ID +MT*I8%Q&MTK=*^4<KRHTH17.V[(/#!.HWN%[I52(:["1&5[+V%*RQO3
M\L:T_&0%N=!%>6-)8"><TKMLH.5:Z7X9P7[A)BJG3"2N=Q.-[A>Z7T:Q7UA\
MTR7NWR]I):U,>>,Z58E3%8TO37PC"V]'3WDWR,^H@DPK&=-*QM4J&=<K%;-%
M;UK)N-%*QI=7-].;,US ^,>KF[/;KQ<_K4L53YB;B\?JB-!ZQ;1>\7NHUTCK
M%=-ZQ:7\:K4WZI#WY+BVWYBW%ZU7W/"VHN<?K8%)ZQ73RJZ4JVF]8LK5[XVK
M:;UB:J30>J4C#MJFZT_7GZ[_^UW_P==+T0I5'ZW+[(PKS]6193)G=U<,O/"G
M_HP NOD<N<B>(<:QF:5KVC-SJ5N,,V<L1[<]9@[OPX0 ^@NH&ZBF:[=^/,2
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M9R_,5_=T,R&@&(Y'.NQA3<:T X0_>\A]11A0D@'[8J(Y@[ZC6>"#9@?  SF
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M(4)GDP!QBD#0L28Z,GPQORL-8PCC8>C8C@SFUP([:F%F?C R%Z7A,111FP_
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M8](2!KDN=DDD.XZ!3UG7*R[K/9OOH 8WNO)Q1=J V00]>E+C 'M*Z BF?/J
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M=*/Y6_1E,@IB%'06*.CW&J$@S7]70V!IU%A)Z6/HP]"'H<^.T*>4L3)$ O@
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M%0]I6T2M5/NN?^]H XM>0/$9O_!QP\<-'S<[3?<#9LV)IK@2?X]]:C>#]:%
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M9,">^N-14^^ZT3QO:N*C^^23/6!O'*O5?S;0DZFUYM3:NFZ<><\W)M:S(59
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M2+E8(U,UER!EJGYN5,TE2%E)X1*$-8[#Y/?/[Y_?__-]_Y4O@7#S4^AS<\R
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M(7WO_H/SH&S]D)?S=\J_![J9(*W<!DK6O7J4)N0G/K[?*GW^WHAEE_N_3I3
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M"4"STL>5S3!(:BW@1>K'3'DA_&'' >YV=A/M/: PWPZOQ>THBN$1L&.Q"Z/
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MX8=0QU9EMI&DX9$($3=%D\"/[R=+9JC\""1T=)ZUZV+FN'>E?NA4="WF\)M
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MA9)S41G,,)C9H]';5,<.4ZLSF8K#5&E*F"XQ".L,2=<5ZM^Q@]$_Q)YI91L
M-ED%GGSI+2?(-U%(.S>N;O?0'!0R5%_EYG*E44?^JQQP 7T3 =?BS+3BE0M4
M0O2AM5<#HI;S<G$3LJKBA+?R8=58[%!_ :,F^U.H-Y8M-&UC"3@MC6JB_I3P
M \UH99!1<9#BG!.(AY%0Z?9F<.RE*T&$WHU Q42ED&ZZPBPPO( RXU8^59,'
MA@Z9E16%L/8Z6*3_(I[+WJT?C)6#E8^PCMILYL[39ALC$!RF\2AV!Z,Y$$*T
MA)^4$ ^0KK"$&ZC! >7F&?L%D%UZD3-%6X83+5Y#4=T2_X)93(F@ (S:.O],
MFG8=.(!YO"GTMMC8=!;X0]UH(^D,6S[BHP-\,,2%31SUP-TD^&3BDVG7Z9;*
M;A*:6FU&-HW=B"3X):75)L>--OV9]@=)K^EUS2:ZC>Y5%YL*O=%'V4MZZ.?<
M4?81QD\KZ5X<-W&UE"^8'UG3K(NF^??Z:)IO"PBKU!S%1SN+$C[:=PM]3D_>
M0:M+?9 NWJ:L]CYCM0ML[ 8#ABL,PUI3A3,;U=9B-Z=EG:M\B(ERT^+[I.CD
M8[BR0A>Z9'00D JCPZYP3*HBC;.@#S@3>)RBK).T!9;.M="U/GPJ4D2!7]B#
MBAK5Y2X%F&-*'YDKDCK[\"@W;5ON^M)+BI[DG;8XC^(#\F5BDPZ 5$F$LG!^
MD)YF5/*\(F['*@DK#R<P T&/A8L39^1:<_U*/?(.5#.X^5;\D3@H=+$4_Q$$
ME8_)0;EZ)('"GE^T2[KHB\ZMR6+@3._$0(U]XU,Q!@P=-F?NSA3P8F\$T.:R
M%5^+98($M1!>A0-7ZY<_]K%S(;[]'%6!LA=@YLP\ZU/F^+A'B=W$\68Q]J$(
M,RO"0]H+46N\ONO?.]KZH1=0?,8O?-SP<</'S4[3_8 Y;:(IKL3?8Y]ZNF#U
M(] :8R_QP[[0"B+)&"#F[RJ)UC6:I I#"C(Q5J!\)T$RW9$M5/<=Q8X F=S5
MQTF9S!#W5,F*XCZ ;[ /GQ$?<Y2^R:2U"&&#$HL!%@/[$ ,M$ .?AF@NUIV,
MM"A(>3TUVINC&X.N_JVEAK\H(2PQC#$T(PA\(!QI O'TCR@6)',M<RUS[3ZX
MM@U<^\WS,[XU[*EC-95Q^,"1&\%O< )[?IX/T:LC'Z3CXJW7(ADR-T;.YV-"
M2P'M%X[DK/]ZV6'.G,Z<SIR^>RA"CK?R&-L8='*1C4D7:T=SK*M9.F^\29I$
M)P[I%6[XG]M5TOAL!\N9&E>4"$<39<= HDE-C3D(FZ&BZMBZBG45W< <K<@^
MI%KZD+[4QX?TRO>0F)/P(#03 ZYP(A$XX??*203&";40(HP3,A]MJ2.'-/@T
M?<*=BS >_BM)J]"(0 >-K.9-K05HT \L "]TK8^'OBQQ\Y0Z0%ZM'B7(=RLE
ME\A4_@MTF*'TOI-?P!3O,AX/T(/HRKN(J@O #&^G*@!JNA:_2T_>:\0T5"Y&
MHIE]*?'6.%&<!3NF/^&^D2N&:L[+? 5X0#2P*VYAPW0WCZ6^VKJ):KEWZ.>5
M!W+>&KJT9(L!"6K0E?9C3=Z%F:Y><3J*R9[+G$I ')BG2)DV!9I8((D"H/15
MF$O"\^ A0-L 04>2(.KXRCSO2ON8UHUKD@0E%<E7,(Q(F@*DN7W_/WMOVMRX
MD2R*?C\1YS\@=.VP= *BN2_V>"+4FZ?/&W?W:<EGWOWTH@@6)4R#  >+U)I?
M_S*SJH ""%#<"5+E\'@H$DM65F96[HF=Z^8RP5)^0ZF/%.%3=X$.>D\A252,
MQ=;7T%=LM$ZC=9ZDUGE[4EHG)C+C^%S3:-]HF4;+W($W2IS[:0<F[+W(/#'7
M!JOKZ6!.>0[.8)?*+<B#Y'C,G<$1CE%@69V?Y>> BA6B6D).:U%TD*\TT)L]
MH7^)_$JY;K59^R?0*'VL/="&HZ4U&*2^1#P#/5=[+&HED$)HH!H%L*-(J--2
M&<&P]D04.9 >1[4/M)HQQX+G@E_]GM2I7&M=E_077Z;UD*98BCN>59?DYA34
M39(97<;H,B>IR]R=CBY3Z"I@9("1 =:HW^B>A QH#8\I U989*M.@F I>[QX
M_[7H4"7DB9!R?#8/0A8^6Z*6RWHKXX1.1<> .LD58R6=A"AJM?K&3,JZV,\P
M 7^:H!$QX9$3NF.A]M,,Y%;SIM&VU><W=O9MA^P8^>=;ZJ;V!XVA:#=;XK>%
M!G)@=,1/: K=)/>P!@N'77L+KN1N?EJI[(*45A\46Q;1#&WQXYOBC_EV^5F6
M/[4')BL-A,Q$&$1SNI6&7I.?'\B*N5C(, &1)&H:Q/A5U8YOS'T^==/DAF+S
MMX762JH#DQRX+:=KJ_>D]E1L8<]?=!]'@1AO+:!6?>>BP(.UD"4F2Q(DIE3G
MA-;@5V&>A4%Y4X#<8-AQ(+OT+46P=L$"D@FRK%X#\Z]2(2YZ2]3/"C22^B0D
MM5$:=V"-92MMUTES7 [T1YPUS3SKCRR+S @1(T2,NK<=N'_.J31"\)8VT]U>
MK@)('2P.[CDYP$7A)X^9\T TM%@:>IG/[RPO KT2,PG2PL]<QZ4+T"C<"7;(
MI6I7>-4%J2)T2Z9NR+9%U(3)#3&! 8&E4M%T\@'YY.D^Y@'C,MFX$^Z9-:R5
M4+*H])2BA*!80,N;2K0(]6@I&FBL+6)-2WT5H_#V@(P#B-BR_QS#>V>$I]'
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M)EV-9J\V96U)T9S.)^3'KT(<%LL*JSE@1V5 )3.CJLJ E!FWUU(@&IAU:J5
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M'L46]I U-E_-R+H&TJ/9&(W.6W88^CT^L'L\_<S99RR_$LN/!C(%4RN8BPR
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M!)$MGHD:P3VH@#$I6$P^4*H;DZ(B*/2?%34(!$&"3_H6<C_!+*(-D41!(=X
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M61B5S+JA1'?Z;U>ENV/N=,B7QQA6S @X8V5UY;4N%G'E?4UF_-TQ^M?79U:
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MYQ)AUL_>!N9L*$_H"Z4<Q,[4%[O#OSG.:N9M UO1+=+2Z0Z.JDC/C D++G%
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M#/V0;KX1D'=.3N/4[+_&7__6I12&M+=F.N7E),L'=] 7C_TM;K?3[%@?P3U
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MQ-QKT1CQ2+I/(!I3#BE)O1;(X_AARL/9!([Y7*^,?/F NA/9:ID JG)[+?-
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MWS:A)L@-B*-:CTO7-,-5&-6-B$(EA.RUAY;T.M8SBJN!W&/?'Z)@-)\9K\R
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MM5\3*G,M$,^5H2@1*;%^WH8>,7S'R+-QG$O3PT2-/>IZ'<WCGP/[R4'II'A
M(XX>5V_HY; '85RUXD0YC.,=I@:02PS<2I3+\L<*I2KU3_.7+]X^OW?YEAQ*
M7]R/XDA3Q_:M_6Q;R+5\3IFG=#OM,2H@%P2@JLNFRI(:7R_;$E=EZ4P-H"\,
M%?@ \5'KU=EK4GKU%ITN!;WT14V4>! JM>Z;-+F')8#C(V!VTQXL/O4@6FH]
M.H"6E9Y3VB/$HAO$1FV".W_I'D5W;/S^*_),VV<9@.7'TA[1BBR!8*M-F8_(
MOC$(E=1SCUS?B*7LT2SDZ'V*S:')V(B>K.B^&)ZU9?)3] C"P(V%P% $J=_1
M7TGDLPLJD-JRHRR/1[$42J\6C+'T5X1J+(%@)UQ BHKH^=B<[PE,743X5?SJ
M1:\[_=RYNQ]]F]9\M>) ,U#Z[T,5HC4J IAT-T7*EM/(HNP,N(_25),,69S+
M%5![;2Y9\+')99ZP)-"R2Q?M+AK(@>)<//!</% ?0%IQN^(DBP=*KU2G*)%?
M2J4ZC7/XI5>JT[WD(X]V<!U4G6Z<V79O-E]<^\\0W2+?].SH=,PV)L1':(=M
M458BNJ4EY^@?&BO$W>)8G=08'Z5QX,"8%X-^1HEDZ'0V4^J#MQ[S!0A )^E(
MK_T#-\ BET#I,"5'474+2F1.X>.X G%3?4/JI"H;5#MLEZMPH#:3X%SA0.>-
M[ESA0!!!G8_BDF[T*BI!+N%&K\8%R.\,VXMB7C>;74+[)CK*LO<K3K=V[%="
MO.MV&VY/=.+^P0,R:!%5:^1.D!EZ-)IY8_BV_\7%3S[RGJD,!NXZ#,B?L6N2
M7E% ,\LV;W5MX--J]E$Q10"4IVX<M-N33UD#=;85M-12G>V.;;H_S]Q(-5.5
MM]+<<H(YS$-@_JI%8'1+[\B;V(MEP'$XPUW:8:!P>=;M/G@AP8)1T^).BES*
M7,$+ *7Y-BX;*YVW3HEX-NHTWL8*+WD[672QIZBMJB>-128$%J$=DO2'JKL1
M6])7)22=;OOX6YLD74 [).G?-(L[)R_S!LBZ+!'PRG8E<UF3^,A]V?S#8E8@
M##6+5B9?+2B/W[9?Z\%+\0$AI]GDZZYPZ :5)E^V:XOQ*V8%M/,D5XJ)/DXH
M*<KWZK^:T3,%UAWV"A.-@"WMN$%; *4L)F4',0&0=\]G;;=I?T\=@!_8OB70
M<.B7[8H'I#YP30\9/KI%\?\/W#CX<QNB&=Z1=" 2P*+D*"U!J!)7LKT4T&S!
MKFGXRQ[95A>(.L/(5ZP9OK-=PS51_Y5>X4)=?X)\<HC<T[@C&II21PW:$E1E
M, DZ#/6XR)XL&BMXE3W;I05@BK$ GJ957U[<5RQ.WP'\K7/1.3P227[YU!_V
M)]W[)NXF^M@W@*N)'[-D3;\\/'0G_Z1W$:>#3\/!W:#7'<XZW5YO]&4X&PP_
M=<:C^T%OT&_D5J5=2/7EVRS5@^'7_G VFC1$%IGKQ81=9@D;S3[W)YW>E\FD
M3Z4XG?9GC5"X-I!;3.)5EL3QA#Y2-OMG]$!9_^]?!F-Z&_7GSK _:T:63C&A
MUVQ9W@^Z-X/[P:PAR,G*5$SFNRR9]X-A/[K*.^G?#AH1H>/,_6+BWN>(&PT_
M7<SZDP?R4W<X[=Q-1@^I1]L:N2MM0)C_FJ6W-WIX&,SBZ]'Q WK1(J1  4Q_
M[1LO+U[Q0GKYH8CRT?9!O)_)).O?]8GBWL;_$/'RK3N9="ECWP:SSQ>WHV_#
MSH0LLK=T1L[Z/?IJ8!.,>8:%BGG*[5F3_K3?G?0^1^3?]K_V[T?18M'I_V/<
M'TZ; <)?&<0^ $C.[V?]>S(A/_W<(;O:W_K1!D:)W^Z^T<_=VX?!<#"=T8<:
MO_8;Y65N \OT56Z+NQL,N\,>I?_'^-W(G_:4-K96 \]#7N6VO>W+EK/N/QHA
MRUD7KW]7N<TN]>1FA^Q[G>GG[J3?B-X6&S-7N7UNVO\43:K!\&XT>>@VM@X4
MKVQ7N0UNTK^/*E>,NY.F%E^_>+I?Y?:WZ9>;*;%AHC6)FH3-4$?M:T!ZN1U-
MW,#N_#C&CFUNZGX:]L #,+US>UL9'J*L$+\1'NS@LIB!W$:6."\T2B%U$A23
MF-NXBDX.C=)*CQ#%Q%[G-B?&&:)A^3H R9R36<*8;)3@K55I 5/O.K>!23$K
M&V61VI< =[FMCVM@-DKYUM($B,_MB]5-S4:YHC8GP%)N.^49G0TO[P#9N3WV
M8'XV2R"Q0P$2<ULH8(@VJ]^ /7^=VR\+3-)&*5U8Q83F=LW=9/OQEMY?<GRE
M9=,2=33N!2JF%3=7>0/87"(K=-#^MGI$(N\Y>E8G?<JFL;#)7@;FBZ%E9=.F
M)G(-S\:"-[G3S94EG(O@ %SC+F)8MPRE'8U?7'^-3)MLTQ8OAYG11?$U[D*!
M9Z<5AU_M\LQE(J1SCKD4%'6^3M6CV5/(6QM>L*'U/'C5GHI:MV@99+&K6RFG
M"5J'GKDT?-1=>"@NZI<AGS?G2@RAJLP3 X_L-?R2XM!NT6P24)T7U3I UWF-
M/9$:O4<8G>*%>M76#3H7ZM5LR3P7ZFUSH5Z)!6 5W>"74@#V? %?OZVIPBU\
MM26"SK?PS[?P==S'OM];^,KN#\BXAL^^G_I6NXOXEVHKP!]W$_^250+^4G$-
M^&QYPZYIAJO0(=:I=4OD:QXBH_RBCOF^CY>**CR6"6N)L@%!J-J]0%A<8H>0
MXL?7]UA^A6S;5@ $D2T[? 4L7V,/FPA9_AWA@5[PI]?HZ'/S^]M80Q2,YKN_
M]+ /7B.M,)+> !W%E)Y^]R0[!__C:#Y!%D(K>J80?4:W[$AZ0WT44WKZ^XI?
M=)Z0A7],SI[$[#4*;Q+O)<'OW1)(11G1\VR<IG]L>",O<J_%#W\2'J+:+*)
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M<(%%7 !%$<T-&:U=#QFC>:P\T[4!OD.>:Z>M8&%J&PJU/9!-:NELHJ\?',N
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MFW6,+HJO3A8*//L<)8=?[59&F0CIO"I*0;$5ZV%R(1%<$_-=6KPN0OSK]KA
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M&IM&'<-1)O_ -0D']C.BA##]FE!S1<YB0*FQ&,%ZKCS9A91\CY-8#'5HPU[
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MZB3P#O+VW^E_:.4L\B__'U!+ P04    " "W;7Y(__3O;_Z$  ">$ < %0
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MI)6F6K4\E>)'-/W?U*C9]_QW5-/*1^=SMQ^HTUCU S+U:GZ@2H &!S*M6GY
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MFI1<)(W(XNKQU'.N)"R%##(_@8M@2[;<5D/(F-4:F'H:4\+*D \'P/HI:[2
M./ 3$# !YBIKEH].Z(A_W=)^Z.L2,B4.S0S4(5(O 2TVC=3NO<P]B"),UK2
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M$,PF!H8:S"8:*7@&P%#5I8'YFR>@YAE/!?FY7?[X?H(;!S>A-FS5:/D%7_U
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M+J;I<:V[*Z3G0([:CMM"<I"^5M^ .R=$]BFQ:L W%2Z-"ZAV,J%$9Y_RJ"5
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M>W4UY:]HYK7X^.4-MQ2#%'"S+=P*[^_XVGR3PDYEAA9Y32:\X%-HVBHKS\G
M\8D#M-&\G>+*G/@>TY'G]LSJ613%_IMW&\6"X%*;1#.*1&M7YL8QO;PR=YRX
MR8$[G@WJN5Q9WR^?VHNM6H]7$U<]7SS2<U&* 2&T/21IE%;+VDM#; W&G0J7
M"%52X@!?EWIJ7)4U=$L 6;M@+%Z=N\[H*BKT5:9>#1,QX15B(^,T=X:U_#A
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M:3#<R,.S!OUE3([H(Q77@;1VM^GF<+>)RP:"JG1LLTUYLU ,VKX31Q?[-'.
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M)QJ$]E)7NK7(=V:H=R$"M%/=/*D\&U(/$6:;3<SW2T5>4'Z#+!$FP4/9A^A
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M*'SC.LDS0^MV1\-$K*KH9_@WEDT \*27L%C\$$5>PLQD2K.P/(CVE!9F\I)
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M:R=.?Z$TOFX/_Y2&-@?DI1/ 'LL%N:0;/X0[0$5M5G@-\KP'I*(Y/CA^"!7
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M9XH_1X%'X]K.YU 9>":+HRUHHF">Q X-?'+U,">!D$N\4C")0CC$$:+AE#
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M(\'W+;\>!0O[Z??#YGE!A>O\]OH\[..?6[UYG#A<G3V*+9(WZT65@*\+L=_
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M[FHDO;B1]>X U5L]7,K(*Y'D4HKJ$6CJD"SAM0U-K?+&[[AZ2JY<RX?R!T6
M#$%+JXN$-W['V-*=I;Y%2S.RZ5M:79V[_C/"=NZLL<V;F5%-W\J/4,I,U\X5
M H0MW=9N4+7CF'=( L+(EDN;9,86)OF?M?U1_(RQ-QJZR7'/J*;'O:X<?),
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M;ZK4V(_; "C@7-?^6\S3CY+$.,WJ=^-= +2DHB>UM7IYJ@#;HX&#)UD*$-R
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M_LKDXY[F>18];'/E#X/0Y("&J$,%M5[<Z8*AN2C:26U9*<J]B<T],:F:ZO_
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M.2?(E9T3Q&!@)0HR3(27NDF>9@W>N%8 TFQST=F37Q8H&3XI,UA[SYNO8?K
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M][3CTK9MK.KHL#/>) OP=&ZA1*?UA-89ZG<T-D)JR0B#J(40&O>PC9-92/%
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MD9,.PPB03?2F"4:<3K93$FEB)"0=!D:51?IF?^^3WQ,\Q)$3DO1I0KP/J8\
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M'_/#YU/#3W%\6#WK5^M*"G:=U?KXP1[RW1X^?O+//1_'UU6[ZSM4I414M0R
M:H2(; 08?ADMRJ7)" 02$,*=9N5,J5'G8@(W5$1-<E6K7DS !9%PIWJS7]%O
MBUW:E#J_;D3SE,*(/>'31[\L\WU3Z@P#40W)52Y*DR,2A"MP%MR/P],,96[
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M&HYAO#FSP\EL/:"L)_$M<M+80_EV)^YETZA7,S')T[*@"XR'#16(RO8\/DU
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M"L$ON1!F.QPB-L\4#S=+'*2<FD74&\A]M8,'"#5ZH;Q'U$VQLIS5/$I(^L&
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MS2XB$Y(N>0Y#BMC"AWQ6B+5<I/$V"(\<FH4##Q%1F*SF,)=FHY')12,NPA
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M5]VGVW\/ALR=1Z.5-N?V+ 424]0Q)R6%YTQ\["J;W?(3<NA40[5K%CG5\F-
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MW[K\O*0K8DU;&/A(9:Z\\M50 L(!+[N%]8M*+_,-$W:R[6/!%["RJLA)A['
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MB>^+</@+^P]+F4)_\_\!4$L! A0#%     @ MVU^2#J)A6O*2P$ PET5 !$
M             ( !     &EG87 M,C Q-3$R,S$N>&UL4$L! A0#%     @
MMVU^2'2BRYIW%P  L?$  !$              ( !^4L! &EG87 M,C Q-3$R
M,S$N>'-D4$L! A0#%     @ MVU^2&8\FL6'&   T2D! !4
M ( !GV,! &EG87 M,C Q-3$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( +=M?DB)
MMKOK*D4  &O!!  5              "  5E\ 0!I9V%P+3(P,34Q,C,Q7V1E
M9BYX;6Q02P$"% ,4    " "W;7Y(__3O;_Z$  ">$ < %0
M@ &VP0$ :6=A<"TR,#$U,3(S,5]L86(N>&UL4$L! A0#%     @ MVU^2)&O
MT4JL60  SO4% !4              ( !YT8" &EG87 M,C Q-3$R,S%?<')E
:+GAM;%!+!08     !@ & (H!  #&H (    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
